1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O

1	A	O
2	new	O
3	Onchocerca	O
4	species	O
5	,	O
6	a	O
7	parasite	O
8	of	O
9	domestic	O
10	cattle	O
11	,	O
12	in	O
13	Senegal	O

1	Induction	O
2	of	O
3	correctly	O
4	spliced	O
5	germline	O
6	transcripts	O
7	is	O
8	necessary	O
9	to	O
10	target	O
11	a	O
12	switch	O
13	region	O
14	for	O
15	recombination	O
16	and	O
17	switching	O
18	.	O

1	The	O
2	human	O
3	immunodeficiency	O
4	virus	O
5	type	O
6	1	O
7	(	O
8	HIV	O
9	-	O
10	1	O
11	)	O
12	preferentially	O
13	infects	O
14	CD4	B
15	+	I
16	T	O
17	lymphocytes	O
18	and	O
19	may	O
20	exist	O
21	as	O
22	a	O
23	latent	O
24	provirus	O
25	within	O
26	these	O
27	cells	O
28	for	O
29	extended	O
30	periods	O
31	.	O

1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	B
50	)--	I
51	6	I
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O

1	BACKGROUND	O
2	:	O
3	Hepatic	O
4	encephalopathy	O
5	is	O
6	a	O
7	neuropsychiatric	O
8	syndrome	O
9	associated	O
10	with	O
11	acute	O
12	liver	O
13	failure	O
14	,	O
15	chronic	O
16	parenchymal	O
17	liver	O
18	disease	O
19	or	O
20	portal	O
21	systemic	O
22	anastomosis	O
23	.	O

1	A	O
2	prospective	O
3	trial	O
4	was	O
5	carried	O
6	out	O
7	in	O
8	156	O
9	unselected	O
10	patients	O
11	(	O
12	41	O
13	men	O
14	,	O
15	mean	O
16	age	O
17	67	O
18	.	O
19	5	O
20	years	O
21	,	O
22	115	O
23	women	O
24	,	O
25	mean	O
26	age	O
27	71	O
28	.	O
29	4	O
30	years	O
31	)	O
32	who	O
33	had	O
34	undergone	O
35	total	O
36	hip	O
37	joint	O
38	replacement	O
39	because	O
40	of	O
41	degenerative	O
42	or	O
43	inflammatory	O
44	arthritis	O
45	or	O
46	fracture	O
47	of	O
48	the	O
49	neck	O
50	of	O
51	the	O
52	femur	O
53	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	VP1	B
6	was	O
7	efficiently	O
8	transported	O
9	to	O
10	the	O
11	nucleus	O
12	and	O
13	localized	O
14	in	O
15	the	O
16	discrete	O
17	subnuclear	O
18	regions	O
19	,	O
20	possibly	O
21	with	O
22	VP2	B
23	and	O
24	VP3	O
25	.	O

1	Results	O
2	of	O
3	the	O
4	long	O
5	-	O
6	term	O
7	observation	O
8	and	O
9	treatment	O
10	of	O
11	patients	O
12	with	O
13	arterial	O
14	hypertension	O

1	When	O
2	data	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	cumulative	O
8	manner	O
9	,	O
10	the	O
11	response	O
12	to	O
13	intravenous	O
14	adenosine	O
15	3	O
16	mg	O
17	,	O
18	6	O
19	mg	O
20	,	O
21	9	O
22	mg	O
23	and	O
24	12	O
25	mg	O
26	in	O
27	the	O
28	24	O
29	episodes	O
30	of	O
31	PSVT	O
32	were	O
33	5	O
34	episodes	O
35	(	O
36	21	O
37	%),	O
38	16	O
39	episodes	O
40	(	O
41	67	O
42	%),	O
43	20	O
44	episodes	O
45	(	O
46	83	O
47	%)	O
48	and	O
49	20	O
50	episodes	O
51	(	O
52	83	O
53	%)	O
54	respectively	O
55	.	O

1	We	O
2	previously	O
3	delineated	O
4	a	O
5	region	O
6	in	O
7	the	O
8	fatty	B
9	-	I
10	acid	I
11	synthase	I
12	promoter	I
13	,	O
14	which	O
15	was	O
16	responsible	O
17	for	O
18	obesity	O
19	-	O
20	related	O
21	overexpression	O
22	of	O
23	the	O
24	fatty	B
25	-	I
26	acid	I
27	synthase	I
28	(	O
29	FAS	B
30	)	I
31	gene	I
32	,	O
33	by	O
34	negatively	O
35	regulating	O
36	the	O
37	activity	O
38	of	O
39	the	O
40	downstream	O
41	promoter	O
42	in	O
43	lean	O
44	but	O
45	not	O
46	obese	O
47	rat	O
48	fat	O
49	cells	O
50	.	O

1	Univariate	O
2	statistical	O
3	analysis	O
4	based	O
5	on	O
6	Kaplan	O
7	-	O
8	Meier	O
9	-	O
10	estimates	O
11	and	O
12	Log	O
13	-	O
14	Rank	O
15	-	O
16	Test	O
17	showed	O
18	the	O
19	following	O
20	prognostically	O
21	beneficial	O
22	factors	O
23	:	O
24	Limited	O
25	disease	O
26	stage	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	009	O
33	),	O
34	NSE	O
35	serum	O
36	level	O
37	less	O
38	than	O
39	25	O
40	micrograms	O
41	/	O
42	l	O
43	(	O
44	p	O
45	=	O
46	0	O
47	.	O
48	016	O
49	),	O
50	serum	B
51	alkaline	I
52	phosphatase	I
53	less	O
54	than	O
55	200	O
56	U	O
57	/	O
58	l	O
59	(	O
60	p	O
61	=	O
62	0	O
63	.	O
64	035	O
65	),	O
66	normal	O
67	serum	B
68	albumin	I
69	(	O
70	p	O
71	=	O
72	0	O
73	.	O
74	003	O
75	)	O
76	and	O
77	activity	O
78	index	O
79	of	O
80	minimum	O
81	of	O
82	70	O
83	(	O
84	p	O
85	<	O
86	0	O
87	.	O
88	001	O
89	).	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	of	O
6	2862	O
7	bp	O
8	encoding	O
9	a	O
10	954	O
11	amino	O
12	acid	O
13	protein	O
14	was	O
15	identified	O
16	.	O

1	We	O
2	conclude	O
3	that	O
4	cAMP	O
5	,	O
6	acting	O
7	through	O
8	PKA	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	regulator	O
14	of	O
15	basal	O
16	CFTR	B
17	gene	I
18	expression	O
19	and	O
20	may	O
21	mediate	O
22	an	O
23	induction	O
24	of	O
25	CFTR	B
26	in	O
27	responsive	O
28	cell	O
29	types	O
30	.	O

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O

1	Their	O
2	use	O
3	resulted	O
4	in	O
5	a	O
6	sensitivity	O
7	of	O
8	73	O
9	%	O
10	and	O
11	a	O
12	specificity	O
13	of	O
14	74	O
15	%	O
16	with	O
17	regard	O
18	to	O
19	predictability	O
20	of	O
21	ALT	B
22	levels	O
23	increasing	O
24	during	O
25	the	O
26	trial	O
27	.	O

1	Data	O
2	collection	O
3	was	O
4	made	O
5	with	O
6	a	O
7	query	O
8	language	O
9	,	O
10	and	O
11	data	O
12	analysis	O
13	performed	O
14	with	O
15	an	O
16	interactive	O
17	knowledge	O
18	-	O
19	based	O
20	statistical	O
21	tool	O
22	,	O
23	MAXITAB	O
24	,	O
25	employing	O
26	a	O
27	multivariate	O
28	tabular	O
29	analysis	O
30	technique	O
31	.	O

1	NE	O
2	and	O
3	PR3	O
4	assist	O
5	in	O
6	the	O
7	destruction	O
8	of	O
9	phagocytosed	O
10	microorganisms	O
11	,	O
12	cleave	O
13	the	O
14	important	O
15	connective	O
16	-	O
17	tissue	B
18	protein	I
19	elastin	I
20	,	O
21	and	O
22	generate	O
23	chemotactic	O
24	activities	O
25	by	O
26	forming	O
27	alpha	B
28	1	I
29	-	I
30	proteinase	I
31	inhibitor	O
32	complexes	O
33	and	O
34	elastin	B
35	peptides	I
36	.	O

1	Phylogenetic	O
2	analyses	O
3	of	O
4	19	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	6	O
10	related	O
11	protein	O
12	types	O
13	indicate	O
14	that	O
15	actin	B
16	-	I
17	associated	I
18	proteins	I
19	related	O
20	to	O
21	gelsolin	B
22	are	O
23	monophyletic	O
24	to	O
25	a	O
26	common	O
27	ancestor	O
28	and	O
29	include	O
30	flightless	O
31	proteins	O
32	.	O

1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	O
6	-	O
7	E	O
8	-	O
9	specific	O
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	O
24	AMPD3	O
25	cDNA	O
26	.	O

1	Adapromine	O
2	was	O
3	established	O
4	to	O
5	evoke	O
6	a	O
7	decrease	O
8	of	O
9	the	O
10	amplitude	O
11	of	O
12	the	O
13	dominant	O
14	peak	O
15	and	O
16	dominant	O
17	theta	O
18	-	O
19	activity	O
20	in	O
21	power	O
22	spectra	O
23	of	O
24	the	O
25	EEG	O
26	in	O
27	the	O
28	cortex	O
29	and	O
30	hippocamp	O
31	,	O
32	with	O
33	an	O
34	increase	O
35	of	O
36	rapid	O
37	wave	O
38	activity	O
39	in	O
40	the	O
41	beta	O
42	2	O
43	range	O
44	in	O
45	the	O
46	right	O
47	cortex	O
48	and	O
49	hippocamp	O
50	.	O

1	The	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	I
6	peroxidase	I
7	(	O
8	ABC	B
9	-	I
10	P	I
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	O
30	Ziehl	B
31	-	I
32	Neelsen	I
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O

1	Eight	O
2	highly	O
3	trained	O
4	male	O
5	kayakers	O
6	were	O
7	studied	O
8	to	O
9	determine	O
10	the	O
11	relationship	O
12	between	O
13	critical	O
14	power	O
15	(	O
16	CP	O
17	)	O
18	and	O
19	the	O
20	onset	O
21	of	O
22	blood	O
23	lactate	O
24	accumulation	O
25	(	O
26	OBLA	O
27	).	O

1	Also	O
2	,	O
3	the	O
4	anti	O
5	-	O
6	inflammatory	O
7	activities	O
8	of	O
9	an	O
10	aqueous	O
11	extract	O
12	of	O
13	Buddleia	O
14	cordata	O
15	and	O
16	its	O
17	principal	O
18	glycoside	O
19	linarin	O
20	were	O
21	evaluated	O
22	.	O

1	Gel	O
2	-	O
3	mobility	O
4	shift	O
5	analysis	O
6	was	O
7	also	O
8	performed	O
9	for	O
10	the	O
11	CCAAT	O
12	motif	O
13	at	O
14	-	O
15	67	O
16	.	O

1	The	O
2	tissue	O
3	-	O
4	specific	O
5	expression	O
6	of	O
7	DP	B
8	family	I
9	members	I
10	suggests	O
11	that	O
12	the	O
13	combination	O
14	of	O
15	DP	B
16	/	O
17	E2F	B
18	heterodimers	O
19	that	O
20	constitute	O
21	DRTF1	B
22	/	O
23	E2F	B
24	is	O
25	influenced	O
26	by	O
27	the	O
28	phenotype	O
29	of	O
30	the	O
31	cell	O
32	.	O

1	The	O
2	3	O
3	'	O
4	fragment	O
5	was	O
6	shown	O
7	to	O
8	accumulate	O
9	as	O
10	full	O
11	-	O
12	length	O
13	mRNA	O
14	disappeared	O
15	in	O
16	actinomycin	O
17	D	O
18	-	O
19	treated	O
20	cells	O
21	,	O
22	indicating	O
23	a	O
24	precursor	O
25	-	O
26	product	O
27	relationship	O
28	.	O

1	Both	O
2	reduced	O
3	spontaneous	O
4	locomotor	O
5	activity	O
6	in	O
7	mice	O
8	,	O
9	protected	O
10	them	O
11	from	O
12	death	O
13	from	O
14	amphetamine	O
15	induced	O
16	toxicity	O
17	,	O
18	prolonged	O
19	hexobarbitone	O
20	sleeping	O
21	time	O
22	and	O
23	caused	O
24	a	O
25	depletion	O
26	of	O
27	catecholamines	O
28	from	O
29	various	O
30	organs	O
31	of	O
32	the	O
33	rat	O
34	.	O

1	The	O
2	differentiation	O
3	and	O
4	maintenance	O
5	of	O
6	a	O
7	neurotransmitter	O
8	phenotype	O
9	is	O
10	guided	O
11	by	O
12	the	O
13	interaction	O
14	of	O
15	exogenous	O
16	cues	O
17	with	O
18	intrinsic	O
19	genetic	O
20	machinery	O
21	.	O

1	These	O
2	REPs	O
3	,	O
4	or	O
5	clusters	O
6	of	O
7	paralogous	O
8	loci	O
9	,	O
10	are	O
11	15	O
12	-	O
13	100	O
14	kb	O
15	and	O
16	harbor	O
17	at	O
18	least	O
19	four	O
20	ESTs	O
21	and	O
22	an	O
23	expressed	O
24	SH3GL	B
25	pseudogene	I
26	.	O

1	The	O
2	intracellular	O
3	basic	O
4	region	O
5	/	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	(	I
12	bHLH	I
13	)	I
14	dioxin	I
15	receptor	I
16	mediates	O
17	signal	O
18	transduction	O
19	by	O
20	dioxin	O
21	(	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	)	O
36	and	O
37	functions	O
38	as	O
39	a	O
40	ligand	O
41	-	O
42	activated	O
43	DNA	O
44	binding	O
45	protein	O
46	directly	O
47	interacting	O
48	with	O
49	target	O
50	genes	O
51	by	O
52	binding	O
53	to	O
54	dioxin	O
55	response	O
56	elements	O
57	.	O

1	To	O
2	identify	O
3	structural	O
4	features	O
5	of	O
6	residues	O
7	flanking	O
8	the	O
9	c	B
10	-	I
11	region	I
12	that	O
13	influence	O
14	the	O
15	fidelity	O
16	and	O
17	efficiency	O
18	of	O
19	signal	B
20	peptidase	I
21	cleavage	O
22	as	O
23	well	O
24	as	O
25	co	O
26	-	O
27	translational	O
28	translocation	O
29	,	O
30	we	O
31	introduced	O
32	six	O
33	amino	O
34	acid	O
35	substitutions	O
36	into	O
37	the	O
38	COOH	O
39	terminus	O
40	of	O
41	the	O
42	hydrophobic	O
43	core	O
44	and	O
45	seven	O
46	substitutions	O
47	at	O
48	the	O
49	NH2	O
50	terminus	O
51	of	O
52	the	O
53	mature	O
54	region	O
55	(	O
56	the	O
57	+	O
58	1	O
59	position	O
60	)	O
61	of	O
62	a	O
63	model	O
64	eukaryotic	O
65	preprotein	B
66	-	I
67	human	I
68	pre	I
69	(	I
70	delta	I
71	pro	I
72	)	O
73	apoA	B
74	-	I
75	II	I
76	.	O

1	Upstream	O
2	of	O
3	the	O
4	dra	O
5	gene	O
6	an	O
7	open	O
8	reading	O
9	frame	O
10	of	O
11	313	O
12	amino	O
13	acids	O
14	was	O
15	identified	O
16	.	O

1	Overexpression	O
2	of	O
3	EFG1	O
4	in	O
5	C	O
6	.	O
7	albicans	O
8	leads	O
9	to	O
10	enhanced	O
11	filamentous	O
12	growth	O
13	in	O
14	the	O
15	form	O
16	of	O
17	extended	O
18	pseudohyphae	O
19	in	O
20	liquid	O
21	and	O
22	on	O
23	solid	O
24	media	O
25	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	B
25	II	I
26	region	I
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	Penicillinase	B
2	production	O
3	in	O
4	Staphylococcus	O
5	aureus	O
6	strains	O
7	of	O
8	clinical	O
9	importance	O
10	.	O

1	With	O
2	steady	O
3	illumination	O
4	,	O
5	outer	O
6	retinal	O
7	(	O
8	photoreceptor	O
9	)	O
10	QO2	O
11	decreased	O
12	to	O
13	1	O
14	.	O
15	4	O
16	+/-	O
17	0	O
18	.	O
19	9	O
20	ml	O
21	O2	O
22	/(	O
23	100	O
24	g	O
25	.	O
26	min	O
27	),	O
28	but	O
29	inner	O
30	retinal	O
31	QO2	O
32	remained	O
33	unchanged	O
34	at	O
35	3	O
36	.	O
37	7	O
38	+/-	O
39	1	O
40	.	O
41	5	O
42	ml	O
43	O2	O
44	/(	O
45	100	O
46	g	O
47	.	O
48	min	O
49	)	O
50	(	O
51	5	O
52	cats	O
53	).	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	is	O
7	twofold	O
8	:	O
9	(	O
10	1	O
11	)	O
12	to	O
13	present	O
14	a	O
15	parallel	O
16	form	O
17	of	O
18	the	O
19	Gudjonsson	O
20	Suggestibility	O
21	Scale	O
22	(	O
23	GSS	O
24	,	O
25	Form	O
26	1	O
27	);	O
28	(	O
29	2	O
30	)	O
31	to	O
32	study	O
33	test	O
34	-	O
35	retest	O
36	reliabilities	O
37	of	O
38	interrogative	O
39	suggestibility	O
40	.	O

1	The	O
2	results	O
3	confirm	O
4	that	O
5	a	O
6	single	O
7	base	O
8	change	O
9	in	O
10	the	O
11	branchpoint	O
12	consensus	O
13	sequence	O
14	of	O
15	an	O
16	intron	O
17	can	O
18	cause	O
19	human	O
20	disease	O
21	although	O
22	this	O
23	sequence	O
24	is	O
25	poorly	O
26	conserved	O
27	in	O
28	mammals	O
29	.	O

1	The	O
2	arrangement	O
3	of	O
4	these	O
5	cutoff	O
6	-	O
7	levels	O
8	leads	O
9	to	O
10	a	O
11	sensitivity	O
12	of	O
13	85	O
14	%	O
15	at	O
16	a	O
17	specificity	O
18	of	O
19	55	O
20	%	O
21	for	O
22	Protein	B
23	S100	I
24	when	O
25	measured	O
26	by	O
27	RIA	O
28	,	O
29	and	O
30	to	O
31	a	O
32	sensitivity	O
33	of	O
34	77	O
35	%	O
36	at	O
37	a	O
38	specificity	O
39	of	O
40	61	O
41	%	O
42	when	O
43	measured	O
44	by	O
45	LIA	O
46	.	O

1	A	O
2	single	O
3	N	O
4	-	O
5	glycosylation	O
6	site	O
7	present	O
8	in	O
9	chicken	O
10	gp42	O
11	is	O
12	conserved	O
13	among	O
14	all	O
15	five	O
16	of	O
17	these	O
18	proteins	O
19	:	O
20	carbohydrate	O
21	analysis	O
22	of	O
23	gp42	O
24	revealed	O
25	the	O
26	presence	O
27	of	O
28	a	O
29	complex	O
30	type	O
31	glycan	O
32	chain	O
33	at	O
34	this	O
35	site	O
36	.	O

1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O

1	The	O
2	POEMS	O
3	syndrome	O
4	(	O
5	Polyneuropathy	O
6	,	O
7	Organomegaly	O
8	,	O
9	Endocrinopathy	O
10	,	O
11	Monoclonal	O
12	component	O
13	,	O
14	Skin	O
15	).	O

1	A	O
2	cDNA	O
3	for	O
4	a	O
5	newly	O
6	discovered	O
7	pseudogene	O
8	,	O
9	closely	O
10	related	O
11	to	O
12	the	O
13	mouse	O
14	mast	O
15	cell	O
16	chymases	O
17	was	O
18	isolated	O
19	by	O
20	polymerase	O
21	chain	O
22	reaction	O
23	amplification	O
24	from	O
25	a	O
26	mouse	O
27	connective	O
28	tissue	O
29	-	O
30	like	O
31	mast	O
32	cell	O
33	line	O
34	.	O

1	The	O
2	rats	O
3	were	O
4	used	O
5	for	O
6	the	O
7	study	O
8	of	O
9	the	O
10	effects	O
11	of	O
12	sepsis	O
13	on	O
14	the	O
15	utilization	O
16	of	O
17	exogenous	O
18	fat	O
19	emulsion	O
20	.	O

1	We	O
2	propose	O
3	that	O
4	Mnt	O
5	:	O
6	Max	B
7	:	O
8	Sin3	O
9	complexes	O
10	normally	O
11	function	O
12	to	O
13	restrict	O
14	Myc	O
15	:	O
16	Max	B
17	activities	O
18	associated	O
19	with	O
20	cell	O
21	proliferation	O
22	.	O

1	4	O
2	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	CSF1R	B
5	/	O
6	IRDelta960	B
7	was	O
8	as	O
9	effective	O
10	as	O
11	the	O
12	CSF1R	B
13	/	I
14	IR	I
15	in	O
16	mediating	O
17	CSF	B
18	-	I
19	1	I
20	protection	O
21	of	O
22	cells	O
23	from	O
24	staurosporine	O
25	-	O
26	induced	O
27	apoptosis	O
28	.	O

1	Natural	O
2	Haemophilus	O
3	influenzae	O
4	type	O
5	b	O
6	capsular	O
7	polysaccharide	O
8	antibodies	O
9	in	O
10	412	O
11	infants	O
12	and	O
13	children	O
14	from	O
15	West	O
16	Africa	O
17	(	O
18	Burkina	O
19	-	O
20	Faso	O
21	)	O
22	and	O
23	France	O
24	:	O
25	a	O
26	cross	O
27	-	O
28	sectional	O
29	serosurvey	O
30	.	O

1	The	O
2	terminator	O
3	region	O
4	supported	O
5	termination	O
6	of	O
7	transcripts	O
8	initiated	O
9	by	O
10	RNA	B
11	polymerase	I
12	I	I
13	in	O
14	vivo	O
15	.	O

1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	B
6	tyrosine	I
7	kinases	I
8	(	O
9	RTKs	B
10	)	O
11	for	O
12	which	O
13	EPH	B
14	is	O
15	the	O
16	prototype	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	intercellular	O
22	communication	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	utilised	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	characterised	O
40	.	O

1	Ulcer	O
2	appeared	O
3	on	O
4	the	O
5	angulus	O
6	of	O
7	the	O
8	stomach	O
9	at	O
10	the	O
11	28th	O
12	week	O
13	and	O
14	resulted	O
15	in	O
16	ulcer	O
17	scar	O
18	at	O
19	the	O
20	42nd	O
21	week	O
22	.	O

1	Although	O
2	no	O
3	Rh	O
4	-	O
5	antibodies	O
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O

1	Moxidectin	B
2	(	O
3	at	O
4	3	O
5	times	O
6	the	O
7	therapeutic	O
8	dose	O
9	)	O
10	did	O
11	not	O
12	have	O
13	deleterious	O
14	effects	O
15	on	O
16	cow	O
17	reproductive	O
18	performance	O
19	as	O
20	examined	O
21	(	O
22	eg	O
23	,	O
24	at	O
25	folliculogenesis	O
26	,	O
27	ovulation	O
28	,	O
29	and	O
30	the	O
31	early	O
32	embryonic	O
33	phase	O
34	of	O
35	development	O
36	).	O

1	Alternatively	O
2	,	O
3	loss	O
4	-	O
5	of	O
6	-	O
7	function	O
8	alleles	O
9	of	O
10	genes	O
11	that	O
12	inhibit	O
13	cAPK	B
14	lead	O
15	to	O
16	the	O
17	inability	O
18	to	O
19	undergo	O
20	sexual	O
21	differentiation	O
22	.	O

1	The	O
2	fracture	O
3	groups	O
4	were	O
5	significantly	O
6	older	O
7	and	O
8	had	O
9	more	O
10	years	O
11	since	O
12	menopause	O
13	than	O
14	the	O
15	control	O
16	groups	O
17	.	O

1	Significant	O
2	alterations	O
3	in	O
4	CBC	O
5	results	O
6	and	O
7	serum	B
8	CRP	I
9	concentration	O
10	,	O
11	compared	O
12	with	O
13	baseline	O
14	values	O
15	,	O
16	were	O
17	lacking	O
18	in	O
19	dogs	O
20	of	O
21	the	O
22	control	O
23	group	O
24	.	O

1	The	O
2	second	O
3	transcriptional	O
4	unit	O
5	,	O
6	designated	O
7	UL26	B
8	.	I
9	5	I
10	,	O
11	predicted	O
12	to	O
13	specify	O
14	a	O
15	protein	O
16	of	O
17	329	O
18	amino	O
19	acids	O
20	,	O
21	encodes	O
22	the	O
23	family	O
24	35	O
25	proteins	O
26	;	O
27	it	O
28	is	O
29	transcribed	O
30	by	O
31	an	O
32	mRNA	O
33	which	O
34	initiates	O
35	at	O
36	approximately	O
37	nucleotide	O
38	+	O
39	1000	O
40	of	O
41	the	O
42	UL26	B
43	transcription	I
44	initiation	I
45	site	I
46	and	O
47	is	O
48	translated	O
49	from	O
50	the	O
51	methionine	O
52	initiation	O
53	codon	O
54	located	O
55	at	O
56	position	O
57	+	O
58	1099	O
59	of	O
60	the	O
61	UL26	B
62	transcriptional	O
63	unit	O
64	.	O

1	Radiation	O
2	-	O
3	induced	O
4	changes	O
5	in	O
6	the	O
7	area	O
8	of	O
9	alveoli	O
10	and	O
11	septa	O
12	as	O
13	well	O
14	as	O
15	collagen	B
16	content	O
17	were	O
18	seen	O
19	11	O
20	weeks	O
21	after	O
22	irradiation	O
23	.	O

1	Apropos	O
2	of	O
3	a	O
4	case	O

1	The	O
2	Trk	B
3	/	O
4	Nerve	B
5	Growth	I
6	Factor	I
7	receptor	I
8	mediates	O
9	the	O
10	rapid	O
11	activation	O
12	of	O
13	a	O
14	number	O
15	of	O
16	intracellular	O
17	signaling	O
18	proteins	O
19	,	O
20	including	O
21	phosphatidylinositol	B
22	3	I
23	-	I
24	kinase	I
25	(	O
26	PI	B
27	3	I
28	-	I
29	kinase	I
30	).	O

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	O
8	-	O
9	Spectrum	B
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	O
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O

1	Using	O
2	GST	B
3	-	O
4	PKR	B
5	fusion	O
6	chromatography	O
7	,	O
8	direct	O
9	physical	O
10	interaction	O
11	between	O
12	the	O
13	mouse	O
14	and	O
15	human	O
16	PKR	B
17	homologs	I
18	was	O
19	established	O
20	.	O

1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O

1	Bacterial	O
2	metabolism	O
3	of	O
4	4	O
5	-	O
6	chlorophenoxyacetate	O
7	.	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	O
35	transposon	O
36	-	O
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	Mutations	O
2	at	O
3	the	O
4	extreme	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	EIAV	B
10	Tat	I
11	impaired	O
12	both	O
13	RNA	O
14	binding	O
15	and	O
16	activation	O
17	domain	O
18	functions	O
19	,	O
20	suggesting	O
21	effects	O
22	on	O
23	secondary	O
24	or	O
25	tertiary	O
26	structure	O
27	.	O

1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O

1	In	O
2	contrast	O
3	,	O
4	COUP	B
5	-	I
6	TF	I
7	alone	O
8	had	O
9	no	O
10	effect	O
11	on	O
12	repCRS2	O
13	-	O
14	dependent	O
15	reporter	O
16	gene	O
17	activity	O
18	.	O

1	We	O
2	obtained	O
3	quantitative	O
4	evidence	O
5	on	O
6	the	O
7	coding	O
8	of	O
9	interaural	O
10	time	O
11	differences	O
12	(	O
13	ITDs	O
14	)	O
15	of	O
16	click	O
17	stimuli	O
18	by	O
19	40	O
20	single	O
21	neurons	O
22	in	O
23	the	O
24	auditory	O
25	cortex	O
26	of	O
27	anesthetized	O
28	albino	O
29	rats	O
30	.	O

1	Copyright	O
2	1999	O
3	Academic	O
4	Press	O
5	.	O

1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O

1	Genomic	O
2	DNA	O
3	sequencing	O
4	in	O
5	the	O
6	vicinity	O
7	of	O
8	methylmalonyl	B
9	-	I
10	CoA	I
11	mutase	I
12	gene	I
13	(	O
14	mutAB	O
15	)	O
16	from	O
17	a	O
18	rifamycin	O
19	SV	O
20	-	O
21	producing	O
22	Amycolatopsis	O
23	mediterranei	O
24	U32	O
25	allowed	O
26	us	O
27	to	O
28	clone	O
29	,	O
30	sequence	O
31	,	O
32	and	O
33	identify	O
34	a	O
35	gene	O
36	encoding	O
37	a	O
38	novel	O
39	serine	B
40	/	I
41	threonine	I
42	protein	I
43	kinase	I
44	(	O
45	amk	O
46	).	O

1	Using	O
2	16	O
3	strains	O
4	of	O
5	C	O
6	.	O
7	trachomatis	O
8	in	O
9	triplicate	O
10	assays	O
11	,	O
12	we	O
13	found	O
14	the	O
15	RT	O
16	-	O
17	PCR	O
18	method	O
19	consistently	O
20	more	O
21	sensitive	O
22	than	O
23	the	O
24	conventional	O
25	technique	O
26	for	O
27	all	O
28	eight	O
29	antimicrobials	O
30	tested	O
31	,	O
32	with	O
33	resultant	O
34	MICs	O
35	determined	O
36	by	O
37	RT	O
38	-	O
39	PCR	O
40	ranging	O
41	from	O
42	1	O
43	.	O
44	6	O
45	-	O
46	fold	O
47	higher	O
48	(	O
49	erythromycin	O
50	)	O
51	to	O
52	>/=	O
53	195	O
54	-	O
55	fold	O
56	higher	O
57	(	O
58	amoxicillin	O
59	).	O

1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	29	O
6	patients	O
7	who	O
8	received	O
9	concurrent	O
10	chemotherapy	O
11	and	O
12	G	B
13	-	I
14	CSF	I
15	,	O
16	ten	O
17	(	O
18	34	O
19	%;	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	[	O
25	CI	O
26	],	O
27	17	O
28	.	O
29	9	O
30	to	O
31	54	O
32	.	O
33	3	O
34	%)	O
35	were	O
36	believed	O
37	to	O
38	have	O
39	clinically	O
40	significant	O
41	bleomycin	O
42	toxicity	O
43	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	B
8	protein	I
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	Thus	O
2	,	O
3	cibenzoline	O
4	is	O
5	an	O
6	effective	O
7	antiarrhythmic	O
8	agent	O
9	with	O
10	a	O
11	favourable	O
12	pharmacokinetic	O
13	profile	O
14	that	O
15	may	O
16	be	O
17	considered	O
18	with	O
19	other	O
20	class	O
21	I	O
22	drugs	O
23	in	O
24	patients	O
25	requiring	O
26	therapy	O
27	for	O
28	high	O
29	risk	O
30	arrhythmias	O
31	.	O

1	Effect	O
2	of	O
3	biliary	O
4	obstruction	O
5	and	O
6	cholangitis	O
7	on	O
8	serum	O
9	SPan	B
10	-	I
11	1	I
12	level	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	wild	O
6	-	O
7	type	O
8	strain	O
9	containing	O
10	a	O
11	temperature	O
12	-	O
13	sensitive	O
14	threonyl	B
15	-	I
16	tRNA	I
17	synthetase	I
18	mutation	O
19	showed	O
20	increased	O
21	thr	O
22	operon	O
23	expression	O
24	at	O
25	the	O
26	non	O
27	-	O
28	permissive	O
29	temperature	O
30	,	O
31	whereas	O
32	none	O
33	of	O
34	the	O
35	mutants	O
36	showed	O
37	any	O
38	change	O
39	.	O

1	Theories	O
2	proffered	O
3	to	O
4	account	O
5	for	O
6	the	O
7	modality	O
8	shift	O
9	effect	O
10	are	O
11	critically	O
12	evaluated	O
13	.	O

1	The	O
2	other	O
3	model	O
4	was	O
5	a	O
6	continuous	O
7	exponential	O
8	plus	O
9	constant	O
10	of	O
11	the	O
12	form	O
13	La	O
14	-	O
15	=	O
16	a	O
17	+	O
18	b	O
19	[	O
20	exp	O
21	(	O
22	cVO2	O
23	)].	O

1	Mutations	O
2	that	O
3	alter	O
4	photoreceptor	O
5	cell	O
6	structure	O
7	and	O
8	development	O
9	were	O
10	isolated	O
11	that	O
12	fail	O
13	to	O
14	complement	O
15	these	O
16	deletions	O
17	.	O

1	Promoter	O
2	activities	O
3	were	O
4	estimated	O
5	using	O
6	beta	B
7	-	I
8	glucuronidase	I
9	and	I
10	neomycin	I
11	phosphotransferase	I
12	II	I
13	reporter	I
14	gene	I
15	systems	O
16	.	O

1	Removal	O
2	of	O
3	all	O
4	core	B
5	histone	I
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	trypsin	O
11	proteolysis	O
12	or	O
13	acetylation	O
14	of	O
15	the	O
16	core	O
17	histone	O
18	tails	O
19	significantly	O
20	relieves	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	TFIIIA	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	nucleosomal	O
34	DNA	O
35	.	O

1	The	O
2	two	O
3	IL6	B
4	mRNA	I
5	species	O
6	are	O
7	generated	O
8	by	O
9	alternative	O
10	polyadenylation	O
11	at	O
12	sites	O
13	separated	O
14	by	O
15	a	O
16	distance	O
17	of	O
18	1	O
19	.	O
20	2	O
21	kilobases	O
22	.	O

1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	B
9	EGF	I
10	receptor	I
11	DER	I
12	/	O
13	Egfr	B
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	O
23	for	O
24	Vein	O
25	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	B
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	B
24	/	O
25	U6	B
26	helix	O
27	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	O
8	-	O
9	dependent	O
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	B
17	SF	I
18	-	I
19	1	I
20	vs	O
21	.	O
22	the	O
23	repressor	O
24	COUP	B
25	-	I
26	TF	I
27	could	O
28	influence	O
29	CRS2	O
30	-	O
31	dependent	O
32	transcription	O
33	.	O

1	In	O
2	vitro	O
3	expression	O
4	levels	O
5	of	O
6	the	O
7	different	O
8	plasmids	O
9	differed	O
10	by	O
11	as	O
12	much	O
13	as	O
14	tenfold	O
15	.	O

1	The	O
2	eating	O
3	and	O
4	drinking	O
5	patterns	O
6	of	O
7	pygmy	O
8	goats	O
9	fed	O
10	ad	O
11	lib	O
12	and	O
13	kept	O
14	on	O
15	a	O
16	12	O
17	h	O
18	light	O
19	/	O
20	12	O
21	h	O
22	dark	O
23	cycle	O
24	were	O
25	recorded	O
26	and	O
27	analyzed	O
28	.	O

1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	B
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	O
18	BALB	O
19	/	O
20	c	B
21	-	I
22	specific	I
23	variants	I
24	of	O
25	p16	B
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	O
39	CDK4	B
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	B
72	(	O
73	INK4a	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O

1	Basic	B
2	fibroblast	I
3	growth	I
4	factor	I
5	(	O
6	bFGF	B
7	)	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	induce	O
13	angiogenesis	O
14	in	O
15	various	O
16	animal	O
17	models	O
18	,	O
19	but	O
20	the	O
21	methods	O
22	of	O
23	administration	O
24	used	O
25	experimentally	O
26	are	O
27	not	O
28	clinically	O
29	feasible	O
30	.	O

1	Although	O
2	the	O
3	molecular	O
4	mechanisms	O
5	involved	O
6	in	O
7	this	O
8	regulation	O
9	are	O
10	currently	O
11	being	O
12	elucidated	O
13	,	O
14	very	O
15	little	O
16	is	O
17	known	O
18	about	O
19	the	O
20	trans	O
21	-	O
22	acting	O
23	factors	O
24	that	O
25	allow	O
26	expression	O
27	of	O
28	the	O
29	nitrate	O
30	and	O
31	nitrite	B
32	reductase	I
33	genes	I
34	which	O
35	code	O
36	for	O
37	the	O
38	first	O
39	enzymes	O
40	in	O
41	the	O
42	pathway	O
43	.	O

1	Incorporation	O
2	of	O
3	the	O
4	polyene	O
5	antibiotic	O
6	amphotericin	O
7	B	O
8	(	O
9	AMB	O
10	)	O
11	in	O
12	liposomes	O
13	results	O
14	in	O
15	a	O
16	marked	O
17	reduction	O
18	in	O
19	drug	O
20	toxicity	O
21	with	O
22	no	O
23	loss	O
24	of	O
25	antifungal	O
26	potency	O
27	.	O

1	The	O
2	effectiveness	O
3	of	O
4	alpha	B
5	-	I
6	mercapto	I
7	-	I
8	beta	I
9	-(	I
10	2	I
11	-	I
12	furyl	I
13	)	O
14	acrylic	O
15	acid	O
16	(	O
17	MFA	O
18	)	O
19	and	O
20	N	O
21	-	O
22	benzyl	O
23	-	O
24	N	O
25	-	O
26	dithiocarboxy	O
27	-	O
28	D	O
29	-	O
30	glucamine	O
31	(	O
32	NaB	B
33	),	O
34	used	O
35	in	O
36	combination	O
37	,	O
38	in	O
39	the	O
40	mobilization	O
41	and	O
42	excretion	O
43	of	O
44	lead	O
45	was	O
46	investigated	O
47	in	O
48	rats	O
49	.	O

1	I	O
2	.	O

1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	B
8	-	I
9	I	I
10	promoter	I
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O

1	Each	O
2	expressed	O
3	domain	O
4	,	O
5	as	O
6	well	O
7	as	O
8	FKBP	B
9	-	I
10	33	I
11	itself	O
12	,	O
13	possesses	O
14	peptidyl	B
15	-	I
16	prolyl	I
17	cis	I
18	-	I
19	trans	I
20	isomerase	I
21	activity	O
22	,	O
23	though	O
24	with	O
25	much	O
26	lower	O
27	specific	O
28	activities	O
29	than	O
30	FKBP	O
31	-	O
32	12	O
33	.	O

1	Tranilast	O
2	in	O
3	the	O
4	Therapy	O
5	of	O
6	Coronary	O
7	Artery	O
8	Disease	O
9	.	O

1	The	O
2	side	O
3	-	O
4	to	O
5	-	O
6	side	O
7	difference	O
8	was	O
9	statistically	O
10	significant	O
11	at	O
12	EXT	O
13	30	O
14	degrees	O
15	/	O
16	s	O
17	and	O
18	60	O
19	degrees	O
20	/	O
21	s	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	Neuronal	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	associations	O
13	in	O
14	S	O
15	-	O
16	R	O
17	compatibility	O
18	tasks	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O

1	The	O
2	EPO	B
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	a	O
6	study	O
7	of	O
8	low	O
9	dose	O
10	X	O
11	-	O
12	rays	O
13	effects	O
14	,	O
15	we	O
16	found	O
17	that	O
18	male	O
19	ICR	O
20	white	O
21	Swiss	O
22	mice	O
23	showed	O
24	remarkable	O
25	suppression	O
26	of	O
27	mounting	O
28	behavior	O
29	after	O
30	whole	O
31	body	O
32	irradiation	O
33	by	O
34	5	O
35	to	O
36	15	O
37	cGy	O
38	X	O
39	-	O
40	rays	O
41	.	O

1	Northern	O
2	blotting	O
3	with	O
4	a	O
5	unique	O
6	17	O
7	-	O
8	mer	O
9	oligonucleotide	O
10	demonstrated	O
11	the	O
12	absence	O
13	of	O
14	the	O
15	mutant	O
16	sequence	O
17	in	O
18	the	O
19	mRNA	O
20	from	O
21	which	O
22	the	O
23	cDNA	O
24	library	O
25	giving	O
26	rise	O
27	to	O
28	the	O
29	mutant	O
30	cDNA	O
31	was	O
32	constructed	O
33	.	O

1	Serum	O
2	levels	O
3	of	O
4	testosterone	O
5	also	O
6	showed	O
7	no	O
8	significant	O
9	changes	O
10	by	O
11	exposure	O
12	to	O
13	p	O
14	,	O
15	p	O
16	'-	O
17	DDE	O
18	under	O
19	the	O
20	conditions	O
21	of	O
22	this	O
23	study	O
24	.	O

1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	O
13	subtilis	O
14	,	O
15	ArgR	B
16	and	O
17	AhrC	B
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	O
30	-	O
31	dependent	O
32	DNA	O
33	-	O
34	binding	O
35	complexes	O
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	O
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O

1	Deletion	O
2	of	O
3	the	O
4	proximal	O
5	octanucleotide	O
6	motif	O
7	from	O
8	the	O
9	plasmid	O
10	containing	O
11	the	O
12	-	O
13	461	O
14	fragment	O
15	of	O
16	the	O
17	LPL	B
18	promoter	I
19	,	O
20	resulted	O
21	in	O
22	a	O
23	79	O
24	and	O
25	76	O
26	%	O
27	decrease	O
28	in	O
29	the	O
30	level	O
31	of	O
32	expression	O
33	in	O
34	transfected	O
35	3T3	O
36	-	O
37	L1	O
38	adipocytes	O
39	and	O
40	HepG2	O
41	hepatocytes	O
42	,	O
43	respectively	O
44	.	O

1	The	O
2	extent	O
3	of	O
4	the	O
5	fbpA	B
6	operator	I
7	sequence	I
8	(	O
9	42	O
10	bp	O
11	),	O
12	as	O
13	defined	O
14	by	O
15	our	O
16	footprinting	O
17	analysis	O
18	,	O
19	would	O
20	suggest	O
21	the	O
22	binding	O
23	of	O
24	two	O
25	Fur	B
26	repressor	I
27	dimers	O
28	.	O

1	Campomelic	O
2	dysplasia	O
3	translocation	O
4	breakpoints	O
5	are	O
6	scattered	O
7	over	O
8	1	O
9	Mb	O
10	proximal	O
11	to	O
12	SOX9	O
13	:	O
14	evidence	O
15	for	O
16	an	O
17	extended	O
18	control	O
19	region	O
20	.	O

1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	O
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O

1	In	O
2	Experiment	O
3	2	O
4	scopolamine	O
5	hydrobromide	O
6	,	O
7	0	O
8	.	O
9	5	O
10	and	O
11	1	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	i	O
18	.	O
19	p	O
20	.,	O
21	was	O
22	administered	O
23	1	O
24	h	O
25	before	O
26	each	O
27	electrical	O
28	stimulation	O
29	until	O
30	each	O
31	rat	O
32	showed	O
33	the	O
34	stage	O
35	-	O
36	3	O
37	seizure	O
38	.	O

1	Conclusion	O
2	:	O
3	inlet	O
4	type	O
5	VSD	O
6	and	O
7	perimembranous	O
8	type	O
9	TOF	O
10	have	O
11	anatomic	O
12	features	O
13	in	O
14	which	O
15	the	O
16	proximal	O
17	His	O
18	bundle	O
19	tends	O
20	to	O
21	be	O
22	jeopardized	O
23	by	O
24	suturing	O
25	for	O
26	VSD	O
27	closure	O
28	.	O

1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O

1	Human	O
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	O
11	-	O
12	75	O
13	cobalt	O
14	-	O
15	based	O
16	alloy	O
17	.	O

1	Tele	O
2	-	O
3	Talk	O
4	has	O
5	the	O
6	extra	O
7	capability	O
8	of	O
9	operating	O
10	in	O
11	live	O
12	conference	O
13	situations	O
14	using	O
15	microphone	O
16	input	O
17	.	O

1	Furthermore	O
2	,	O
3	direct	O
4	association	O
5	with	O
6	D3	O
7	phosphatidylinositides	O
8	seems	O
9	to	O
10	be	O
11	essential	O
12	for	O
13	activation	O
14	of	O
15	PKB	B
16	/	O
17	Akt	B
18	.	O

1	Genes	O
2	for	O
3	ocs	O
4	element	O
5	binding	O
6	factors	O
7	(	O
8	OBFs	O
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	O
16	basic	B
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	I
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	SV	O
2	increased	O
3	less	O
4	in	O
5	SHR	O
6	,	O
7	mainly	O
8	reflecting	O
9	the	O
10	reduced	O
11	diastolic	O
12	compliance	O
13	of	O
14	the	O
15	hypertrophied	O
16	SHR	O
17	left	O
18	ventricle	O
19	and	O
20	the	O
21	consequent	O
22	rightward	O
23	shift	O
24	of	O
25	its	O
26	Frank	O
27	-	O
28	Starling	O
29	curve	O
30	.	O

1	Such	O
2	a	O
3	concept	O
4	is	O
5	crucial	O
6	to	O
7	our	O
8	understanding	O
9	of	O
10	the	O
11	pathology	O
12	of	O
13	ageing	O
14	in	O
15	general	O
16	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	O
16	ADR	O
17	and	O
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	O
29	therapeutic	O
30	index	O
31	of	O
32	this	O
33	combined	O
34	therapeutic	O
35	modality	O
36	treatment	O
37	.	O

1	Another	O
2	element	O
3	necessary	O
4	for	O
5	augmenting	O
6	the	O
7	amplitude	O
8	of	O
9	the	O
10	oscillation	O
11	lies	O
12	between	O
13	-	O
14	178	O
15	and	O
16	-	O
17	264	O
18	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	B
13	.	O

1	Stress	O
2	-	O
3	inducible	O
4	protein	O
5	kinases	O
6	capable	O
7	of	O
8	activating	O
9	c	B
10	-	I
11	jun	I
12	expression	O
13	include	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	/	O
20	c	B
21	-	I
22	Jun	I
23	N	I
24	-	I
25	terminal	I
26	protein	I
27	kinase	I
28	(	O
29	SAPK	B
30	/	O
31	JNK	B
32	)	O
33	and	O
34	p38	B
35	members	O
36	of	O
37	the	O
38	mitogen	B
39	-	I
40	activated	I
41	protein	I
42	kinase	I
43	(	O
44	MAPK	B
45	)	O
46	superfamily	O
47	of	O
48	signaling	O
49	molecules	O
50	.	O

1	Endocardial	O
2	fibro	O
3	-	O
4	elastosis	O
5	,	O
6	mitral	O
7	incompetence	O
8	,	O
9	and	O
10	coarctation	O
11	of	O
12	abdominal	O
13	aorta	O
14	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	O
8	IVS2C	B
9	beta	I
10	1	I
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O

1	Metabolism	O
2	of	O
3	calcium	O
4	and	O
5	vitamin	O
6	D3	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	tubulointerstitial	O
12	nephritis	O
13	:	O
14	a	O
15	study	O
16	of	O
17	41	O
18	patients	O
19	with	O
20	nephropathia	O
21	epidemica	O
22	.	O

1	It	O
2	is	O
3	related	O
4	to	O
5	a	O
6	variety	O
7	of	O
8	mammalian	B
9	Golgi	I
10	-	I
11	associated	I
12	proteins	I
13	and	O
14	to	O
15	the	O
16	yeast	O
17	Uso1p	O
18	,	O
19	an	O
20	essential	O
21	protein	O
22	involved	O
23	in	O
24	docking	O
25	of	O
26	endoplasmic	O
27	reticulum	O
28	-	O
29	derived	O
30	vesicles	O
31	to	O
32	the	O
33	cis	O
34	-	O
35	Golgi	O
36	.	O

1	Mean	O
2	corpuscular	O
3	hemoglobin	B
4	concentrations	O
5	remained	O
6	normal	O
7	for	O
8	48	O
9	h	O
10	and	O
11	then	O
12	decreased	O
13	in	O
14	both	O
15	groups	O
16	,	O
17	the	O
18	CO2	O
19	group	O
20	showing	O
21	the	O
22	larger	O
23	decrease	O
24	.	O

1	Transcription	O
2	initiation	O
3	sites	O
4	of	O
5	the	O
6	rat	B
7	II	I
8	beta	I
9	-,	I
10	III	I
11	beta	I
12	,	O
13	and	O
14	O	B
15	beta	I
16	-	I
17	globin	I
18	genes	I
19	were	O
20	determined	O
21	to	O
22	be	O
23	52	O
24	base	O
25	pairs	O
26	(	O
27	bp	O
28	)	O
29	5	O
30	'-	O
31	upstream	O
32	of	O
33	the	O
34	translation	O
35	initiation	O
36	codon	O
37	(	O
38	ATG	O
39	),	O
40	in	O
41	each	O
42	gene	O
43	by	O
44	primer	O
45	extension	O
46	analysis	O
47	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	define	O
7	the	O
8	mechanism	O
9	for	O
10	the	O
11	respiratory	O
12	inhibition	O
13	observed	O
14	during	O
15	high	O
16	-	O
17	frequency	O
18	oscillatory	O
19	ventilation	O
20	(	O
21	HFOV	O
22	).	O

1	Northern	O
2	blot	O
3	analysis	O
4	,	O
5	using	O
6	the	O
7	Ltp4	O
8	-	O
9	specific	O
10	probe	O
11	,	O
12	indicated	O
13	that	O
14	Xanthomonas	O
15	campestris	O
16	pv	O
17	.	O
18	translucens	O
19	induced	O
20	an	O
21	increase	O
22	over	O
23	basal	O
24	levels	O
25	of	O
26	Ltp4	B
27	mRNA	I
28	,	O
29	while	O
30	Pseudomonas	O
31	syringae	O
32	pv	O
33	.	O
34	japonica	O
35	caused	O
36	a	O
37	decrease	O
38	.	O

1	Two	O
2	points	O
3	are	O
4	indicated	O
5	:	O
6	first	O
7	,	O
8	the	O
9	photosensitized	O
10	damage	O
11	of	O
12	YHPD	O
13	is	O
14	interrelated	O
15	to	O
16	not	O
17	only	O
18	1O2	O
19	,	O
20	but	O
21	also	O
22	free	O
23	radicals	O
24	(	O
25	O2	O
26	-.	O
27	.	O
28	OH	O
29	and	O
30	YHPD	O
31	-.);	O
32	second	O
33	,	O
34	although	O
35	the	O
36	photosensitized	O
37	damage	O
38	of	O
39	YHPD	O
40	is	O
41	stronger	O
42	than	O
43	that	O
44	of	O
45	BHPD	O
46	,	O
47	yet	O
48	the	O
49	photosensitized	O
50	damage	O
51	is	O
52	negatively	O
53	correlated	O
54	to	O
55	the	O
56	yield	O
57	of	O
58	1O2	O
59	but	O
60	positively	O
61	correlated	O
62	to	O
63	those	O
64	of	O
65	O2	O
66	-.	O
67	and	O
68	OH	O
69	.	O

1	In	O
2	vitro	O
3	interaction	O
4	studies	O
5	,	O
6	using	O
7	proteins	O
8	fused	O
9	to	O
10	glutathione	B
11	-	I
12	S	I
13	-	I
14	transferase	I
15	,	O
16	showed	O
17	that	O
18	RBP	B
19	-	I
20	J	I
21	kappa	I
22	and	I
23	Su	I
24	(	O
25	H	O
26	)	O
27	bind	O
28	directly	O
29	to	O
30	the	O
31	RAM23	O
32	regions	O
33	of	O
34	mouse	B
35	Notch1	I
36	and	O
37	Drosophila	O
38	Notch	B
39	,	O
40	respectively	O
41	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	the	O
7	STORP	B
8	gene	I
9	has	O
10	a	O
11	ubiquitous	O
12	pattern	O
13	of	O
14	expression	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	PML	B
21	gene	I
22	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	Maf	B
6	-	I
7	related	I
8	protein	I
9	,	I
10	Nrl	I
11	,	O
12	completely	O
13	mimicked	O
14	c	B
15	-	I
16	Maf	I
17	actions	O
18	.	O

1	Cotransfection	O
2	analyses	O
3	of	O
4	the	O
5	T	B
6	/	I
7	EBP	I
8	promoter	I
9	-	O
10	reporter	O
11	constructs	O
12	with	O
13	a	O
14	T	B
15	/	I
16	EBP	I
17	expression	O
18	vector	O
19	into	O
20	human	O
21	HepG2	O
22	cells	O
23	,	O
24	which	O
25	do	O
26	not	O
27	express	O
28	T	B
29	/	I
30	EBP	I
31	,	O
32	suggested	O
33	that	O
34	autoregulation	O
35	may	O
36	be	O
37	involved	O
38	in	O
39	controlling	O
40	both	O
41	rat	O
42	and	O
43	human	B
44	T	I
45	/	I
46	EBP	I
47	gene	I
48	expression	O
49	.	O

1	HS	O
2	inducibility	O
3	required	O
4	the	O
5	HSE	O
6	which	O
7	was	O
8	bound	O
9	by	O
10	HS	B
11	transcription	I
12	factor	I
13	-	I
14	1	I
15	(	O
16	HSF	B
17	-	I
18	1	I
19	)	O
20	present	O
21	in	O
22	extracts	O
23	prepared	O
24	from	O
25	cells	O
26	exposed	O
27	to	O
28	HS	O
29	.	O

1	Defects	O
2	of	O
3	fibrillin	B
4	(	O
5	FBN1	O
6	),	O
7	a	O
8	glycoprotein	O
9	component	O
10	of	O
11	the	O
12	extracellular	O
13	microfibril	O
14	,	O
15	cause	O
16	Marfan	O
17	syndrome	O
18	.	O

1	Enzyme	O
2	I	O
3	of	O
4	the	O
5	phosphoenolpyruvate	O
6	:	O
7	sugar	B
8	phosphotransferase	I
9	system	O
10	.	O

1	TEMTU	O
2	and	O
3	DPTU	O
4	were	O
5	the	O
6	most	O
7	potent	O
8	teratogens	O
9	.	O

1	Multistep	O
2	transformation	O
3	by	O
4	defined	O
5	fragments	O
6	of	O
7	herpes	O
8	simplex	O
9	virus	O
10	type	O
11	2	O
12	DNA	O
13	:	O
14	oncogenic	O
15	region	O
16	and	O
17	its	O
18	gene	O
19	product	O
20	.	O

1	This	O
2	study	O
3	represents	O
4	the	O
5	first	O
6	published	O
7	long	O
8	-	O
9	term	O
10	follow	O
11	-	O
12	up	O
13	regarding	O
14	this	O
15	mode	O
16	of	O
17	treatment	O
18	in	O
19	patients	O
20	with	O
21	alveolar	O
22	hypoventilation	O
23	.	O

1	Twenty	O
2	-	O
3	eight	O
4	were	O
5	excluded	O
6	as	O
7	gallstones	O
8	were	O
9	not	O
10	proved	O
11	:	O
12	of	O
13	the	O
14	remainder	O
15	,	O
16	21	O
17	patients	O
18	received	O
19	glucagon	B
20	and	O
21	22	O
22	placebo	O
23	.	O

1	National	O
2	Institutes	O
3	of	O
4	Health	O
5	Consensus	O
6	Development	O
7	Conference	O
8	Statement	O
9	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	O
10	human	B
11	TrxR2	I
12	gene	I
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O

1	To	O
2	facilitate	O
3	the	O
4	availability	O
5	of	O
6	important	O
7	new	O
8	therapeutic	O
9	agents	O
10	,	O
11	the	O
12	Food	O
13	and	O
14	Drug	O
15	Administration	O
16	(	O
17	FDA	O
18	)	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	1970s	O
24	began	O
25	assigning	O
26	therapeutic	O
27	ratings	O
28	to	O
29	investigational	O
30	new	O
31	drugs	O
32	and	O
33	holding	O
34	end	O
35	-	O
36	of	O
37	-	O
38	phase	O
39	II	O
40	conferences	O
41	with	O
42	drug	O
43	sponsors	O
44	.	O

1	The	O
2	addition	O
3	of	O
4	an	O
5	equimolar	O
6	complex	O
7	of	O
8	the	O
9	fourth	O
10	and	O
11	seventh	O
12	largest	O
13	subunits	O
14	,	O
15	purified	O
16	from	O
17	pol	B
18	II	I
19	holoenzyme	I
20	by	O
21	ion	O
22	-	O
23	exchange	O
24	chromatography	O
25	in	O
26	the	O
27	presence	O
28	of	O
29	urea	O
30	,	O
31	restored	O
32	promoter	O
33	-	O
34	directed	O
35	initiation	O
36	activity	O
37	to	O
38	pol	B
39	II	I
40	delta	I
41	4	I
42	/	O
43	7	O
44	.	O

1	Specialized	O
2	actin	B
3	tails	O
4	that	O
5	propel	O
6	IEV	O
7	particles	O
8	to	O
9	the	O
10	periphery	O
11	and	O
12	virus	O
13	-	O
14	tipped	O
15	microvilli	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	vA33delta	B
34	.	O

1	As	O
2	shown	O
3	previously	O
4	,	O
5	EBNA2	B
6	transactivates	O
7	the	O
8	promoters	O
9	of	O
10	the	O
11	viral	O
12	latent	O
13	membrane	O
14	proteins	O
15	.	O

1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	O
11	.	O
12	pneumoniae	O
13	nifH	B
14	promoter	I
15	showed	I
16	sigma	I
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	B
7	-	I
8	2	I
9	gene	I
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	Eight	O
2	hr	O
3	of	O
4	acidosis	O
5	caused	O
6	a	O
7	significant	O
8	(	O
9	P	O
10	less	O
11	than	O
12	0	O
13	.	O
14	01	O
15	)	O
16	decrease	O
17	in	O
18	P50	O
19	in	O
20	vitro	O
21	which	O
22	fell	O
23	from	O
24	29	O
25	.	O
26	0	O
27	to	O
28	24	O
29	.	O
30	4	O
31	torr	O
32	.	O

1	Furthermore	O
2	,	O
3	early	O
4	-	O
5	and	O
6	late	O
7	-	O
8	firing	O
9	origins	O
10	differ	O
11	not	O
12	in	O
13	the	O
14	timing	O
15	of	O
16	their	O
17	recruitment	O
18	of	O
19	an	O
20	Mcm	B
21	protein	I
22	,	O
23	but	O
24	in	O
25	the	O
26	timing	O
27	of	O
28	RPA	B
29	'	O
30	s	O
31	recruitment	O
32	.	O

1	16	O
2	women	O
3	were	O
4	treated	O
5	with	O
6	methadone	O
7	to	O
8	prevent	O
9	withdrawal	O
10	symptoms	O
11	.	O

1	We	O
2	propose	O
3	that	O
4	epigenetic	O
5	features	O
6	of	O
7	tissue	O
8	-	O
9	specific	O
10	control	O
11	and	O
12	of	O
13	the	O
14	control	O
15	of	O
16	allelic	O
17	expression	O
18	are	O
19	intricately	O
20	linked	O
21	.	O

1	Expression	O
2	of	O
3	six	O
4	genes	O
5	,	O
6	ipaB	B
7	,	O
8	ipaC	B
9	,	O
10	invE	B
11	,	O
12	invG	B
13	,	O
14	invJ	B
15	,	O
16	and	O
17	invK	B
18	,	O
19	was	O
20	apparently	O
21	regulated	O
22	by	O
23	the	O
24	positive	O
25	regulator	O
26	virF	B
27	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	gene	O
8	was	O
9	525	O
10	bp	O
11	long	O
12	and	O
13	encoded	O
14	a	O
15	175	O
16	-	O
17	amino	O
18	-	O
19	acid	O
20	protein	O
21	with	O
22	a	O
23	molecular	O
24	weight	O
25	of	O
26	19	O
27	,	O
28	094	O
29	containing	O
30	a	O
31	21	O
32	-	O
33	residue	O
34	typical	O
35	lipoprotein	O
36	signal	O
37	peptide	O
38	and	O
39	consensus	O
40	prolipoprotein	O
41	processing	O
42	site	O
43	.	O

1	The	O
2	development	O
3	and	O
4	histostructural	O
5	organization	O
6	of	O
7	intrahepatic	O
8	biliary	O
9	ducts	O
10	were	O
11	studied	O
12	on	O
13	a	O
14	human	O
15	embryofetal	O
16	material	O
17	6	O
18	to	O
19	32	O
20	weeks	O
21	old	O
22	.	O

1	Clinical	O
2	and	O
3	haematological	O
4	signs	O
5	are	O
6	not	O
7	specific	O
8	in	O
9	this	O
10	setting	O
11	,	O
12	and	O
13	the	O
14	diagnosis	O
15	relies	O
16	on	O
17	histological	O
18	features	O
19	,	O
20	mainly	O
21	bone	O
22	marrow	O
23	examination	O
24	.	O

1	These	O
2	lesions	O
3	were	O
4	asymptomatic	O
5	,	O
6	but	O
7	both	O
8	were	O
9	characterized	O
10	clinically	O
11	by	O
12	central	O
13	ulceration	O
14	.	O

1	Encapsidation	O
2	of	O
3	poliovirus	O
4	replicons	O
5	encoding	O
6	the	O
7	complete	O
8	human	B
9	immunodeficiency	I
10	virus	I
11	type	I
12	1	I
13	gag	I
14	gene	O
15	by	O
16	using	O
17	a	O
18	complementation	O
19	system	O
20	which	O
21	provides	O
22	the	O
23	P1	B
24	capsid	I
25	protein	I
26	in	O
27	trans	O
28	.	O

1	Scintigraphic	O
2	visualisation	O
3	of	O
4	Walker	O
5	carcinoma	O
6	-	O
7	256	O
8	in	O
9	Sprague	O
10	-	O
11	Dawley	O
12	rats	O
13	by	O
14	means	O
15	of	O
16	99mTc	O
17	-	O
18	labelled	O
19	monocytes	O
20	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAC1	B
6	may	O
7	also	O
8	be	O
9	one	O
10	of	O
11	the	O
12	meiotic	O
13	genes	O
14	.	O

1	The	O
2	correlation	O
3	between	O
4	PaCO2	O
5	and	O
6	PtcO2	B
7	in	O
8	RDS	O
9	was	O
10	insufficient	O
11	to	O
12	make	O
13	clinical	O
14	judgement	O
15	.	O

1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O

1	Once	O
2	NGF	O
3	administration	O
4	is	O
5	proven	O
6	effective	O
7	it	O
8	will	O
9	be	O
10	possible	O
11	to	O
12	develop	O
13	alternative	O
14	ways	O
15	of	O
16	NGF	B
17	administration	O
18	.	O

1	The	O
2	mean	O
3	weight	O
4	and	O
5	height	O
6	velocities	O
7	were	O
8	148	O
9	%	O
10	and	O
11	122	O
12	%	O
13	of	O
14	the	O
15	standard	O
16	,	O
17	respectively	O
18	.	O

1	To	O
2	those	O
3	of	O
4	us	O
5	who	O
6	are	O
7	not	O
8	satisfied	O
9	with	O
10	the	O
11	present	O
12	outlook	O
13	there	O
14	is	O
15	much	O
16	to	O
17	be	O
18	investigated	O
19	and	O
20	much	O
21	to	O
22	be	O
23	contributed	O
24	.	O

1	Reverse	B
2	transcriptase	I
3	and	O
4	protease	O
5	activities	O
6	of	O
7	avian	O
8	leukosis	O
9	virus	O
10	Gag	B
11	-	O
12	Pol	B
13	fusion	O
14	proteins	O
15	expressed	O
16	in	O
17	insect	O
18	cells	O
19	.	O

1	Circulating	O
2	platelets	O
3	may	O
4	be	O
5	activated	O
6	by	O
7	exposed	O
8	triple	O
9	-	O
10	helical	O
11	collagen	B
12	in	O
13	atherosclerotic	O
14	lesions	O
15	in	O
16	Mg	O
17	-	O
18	deficient	O
19	ruminants	O
20	.	O

1	VP	O
2	-	O
3	16	O
4	,	O
5	ifosfamide	O
6	and	O
7	cisplatin	O
8	(	O
9	VIP	O
10	)	O
11	for	O
12	extensive	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	.	O

1	Ventilatory	O
2	management	O
3	casebook	O
4	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	we	O
6	concluded	O
7	that	O
8	this	O
9	ORF	O
10	is	O
11	the	O
12	FRDS	O
13	gene	O
14	.	O

1	Carbonic	B
2	anhydrase	I
3	V	I
4	(	O
5	CA	B
6	V	I
7	)	I
8	is	O
9	expressed	O
10	in	O
11	mitochondrial	O
12	matrix	O
13	in	O
14	liver	O
15	and	O
16	several	O
17	other	O
18	tissues	O
19	.	O

1	PSI	B
2	-	I
3	G	I
4	and	O
5	PSI	B
6	-	I
7	K	I
8	probably	O
9	have	O
10	evolved	O
11	from	O
12	a	O
13	gene	O
14	duplication	O
15	of	O
16	an	O
17	ancestral	O
18	gene	O
19	.	O

1	Areas	O
2	with	O
3	significantly	O
4	greater	O
5	rCBF	O
6	for	O
7	targeting	O
8	were	O
9	the	O
10	left	O
11	motor	O
12	cortex	O
13	,	O
14	left	O
15	intraparietal	O
16	sulcus	O
17	,	O
18	and	O
19	left	O
20	caudate	O
21	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	O
22	Rel	B
23	and	O
24	PI	B
25	-	I
26	3K	I
27	are	O
28	crucial	O
29	for	O
30	CD40	B
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	effects	O
6	of	O
7	hypovolemia	O
8	on	O
9	the	O
10	extracellular	O
11	ptO2	O
12	and	O
13	ptH	O
14	distributions	O
15	at	O
16	multiple	O
17	tissue	O
18	sites	O
19	using	O
20	a	O
21	recently	O
22	developed	O
23	multipoint	O
24	microelectrode	O
25	,	O
26	that	O
27	provides	O
28	simultaneous	O
29	measurements	O
30	of	O
31	ptO2	B
32	and	O
33	ptH	B
34	.	O

1	Nipponbare	O
2	as	O
3	well	O
4	as	O
5	O	O
6	.	O
7	australiensis	O
8	.	O

1	The	O
2	decrease	O
3	in	O
4	HDL	B
5	-	I
6	cholesterol	I
7	with	O
8	increasing	O
9	VLDL	O
10	-	O
11	triglycerides	O
12	was	O
13	relatively	O
14	much	O
15	larger	O
16	than	O
17	the	O
18	concomitant	O
19	decrease	O
20	in	O
21	apo	B
22	A	I
23	-	I
24	I	I
25	.	O

1	The	O
2	rear	O
3	silver	O
4	liquid	O
5	chamber	O
6	was	O
7	threefold	O
8	thick	O
9	to	O
10	17	O
11	MeV	O
12	protons	O
13	in	O
14	water	O
15	and	O
16	it	O
17	efficiently	O
18	produced	O
19	either	O
20	13N	O
21	by	O
22	the	O
23	16O	O
24	(	O
25	p	O
26	,	O
27	alpha	O
28	)	O
29	13N	O
30	reaction	O
31	or	O
32	[	O
33	18F	O
34	]	O
35	fluoride	O
36	ion	O
37	by	O
38	the	O
39	18O	O
40	(	O
41	p	O
42	,	O
43	n	O
44	)	O
45	18F	O
46	reaction	O
47	.	O

1	Removal	O
2	of	O
3	PDMP	O
4	from	O
5	the	O
6	cell	O
7	medium	O
8	resulted	O
9	in	O
10	reversal	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	changes	O
16	,	O
17	with	O
18	cells	O
19	re	O
20	-	O
21	entering	O
22	the	O
23	S	O
24	phase	O
25	.	O

1	Acad	O
2	.	O

1	Group	O
2	6	O
3	was	O
4	given	O
5	physostigmine	O
6	,	O
7	0	O
8	.	O
9	1	O
10	mg	O
11	/	O
12	kg	O
13	i	O
14	.	O
15	v	O
16	.,	O
17	known	O
18	to	O
19	inhibit	O
20	cholinesterase	B
21	degradation	O
22	,	O
23	5	O
24	min	O
25	before	O
26	bupivacaine	O
27	administration	O
28	,	O
29	and	O
30	Group	O
31	7	O
32	received	O
33	a	O
34	combination	O
35	of	O
36	physostigmine	O
37	pretreatment	O
38	and	O
39	electrical	O
40	vagal	O
41	stimulation	O
42	.	O

1	The	O
2	roll	O
3	-	O
4	over	O
5	test	O
6	to	O
7	predict	O
8	toxemia	O
9	in	O
10	pregnancy	O
11	.	O

1	Pure	O
2	T1	O
3	and	O
4	dual	O
5	-	O
6	T1	O
7	images	O
8	were	O
9	visually	O
10	evaluated	O
11	for	O
12	image	O
13	quality	O
14	(	O
15	IQ	O
16	)	O
17	on	O
18	a	O
19	five	O
20	-	O
21	point	O
22	scale	O
23	(	O
24	0	O
25	=	O
26	unacceptable	O
27	to	O
28	4	O
29	=	O
30	excellent	O
31	).	O

1	Primary	O
2	infection	O
3	is	O
4	usually	O
5	managed	O
6	conservatively	O
7	.	O

1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	consist	O
9	of	O
10	a	O
11	focal	O
12	abnormality	O
13	characterized	O
14	by	O
15	a	O
16	slight	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O

1	Relationship	O
2	of	O
3	CDK	B
4	-	I
5	activating	I
6	kinase	I
7	and	O
8	RNA	B
9	polymerase	I
10	II	I
11	CTD	I
12	kinase	I
13	TFIIH	I
14	/	O
15	TFIIK	O
16	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	O
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	O
8	-	O
9	type	O
10	Fus3	O
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	O
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	The	O
2	calculated	O
3	values	O
4	of	O
5	lambda	O
6	tb	O
7	at	O
8	37	O
9	degrees	O
10	C	O
11	and	O
12	50	O
13	per	O
14	cent	O
15	haematocrit	O
16	were	O
17	0	O
18	.	O
19	650	O
20	for	O
21	the	O
22	pulp	O
23	,	O
24	0	O
25	.	O
26	674	O
27	for	O
28	the	O
29	tongue	O
30	,	O
31	0	O
32	.	O
33	828	O
34	for	O
35	the	O
36	submandibular	O
37	gland	O
38	and	O
39	0	O
40	.	O
41	881	O
42	for	O
43	the	O
44	gingiva	O
45	of	O
46	the	O
47	dog	O
48	.	O
49	lambda	O
50	cp	O
51	increased	O
52	and	O
53	lambda	O
54	tp	O
55	decreased	O
56	as	O
57	the	O
58	temperature	O
59	was	O
60	reduced	O
61	from	O
62	37	O
63	to	O
64	4	O
65	degrees	O
66	C	O
67	.	O

1	Here	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	an	O
7	antagonistic	O
8	,	O
9	BMP	B
10	/	O
11	ALK2	B
12	/	O
13	Smad	B
14	-	O
15	mediated	O
16	signaling	O
17	pathway	O
18	is	O
19	active	O
20	on	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	Xenopus	O
27	embryo	O
28	.	O

1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O

1	RNP1	O
2	,	O
3	a	O
4	new	O
5	ribonucleoprotein	O
6	gene	O
7	of	O
8	the	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	.	O

1	Sex	O
2	selection	O
3	via	O
4	albumin	B
5	columns	O
6	:	O
7	20	O
8	years	O
9	of	O
10	results	O
11	.	O

1	Patient	O
2	characteristics	O
3	associated	O
4	with	O
5	deep	O
6	wounds	O
7	as	O
8	well	O
9	as	O
10	patient	O
11	and	O
12	wound	O
13	characteristics	O
14	predictive	O
15	of	O
16	the	O
17	extent	O
18	of	O
19	healing	O
20	and	O
21	time	O
22	required	O
23	for	O
24	healing	O
25	were	O
26	identified	O
27	.	O

1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	type	O
7	II	O
8	hyperbetalipoproteinemia	O
9	in	O
10	a	O
11	patient	O
12	whose	O
13	diagnosis	O
14	had	O
15	been	O
16	previously	O
17	unrecognized	O
18	,	O
19	and	O
20	who	O
21	had	O
22	previously	O
23	been	O
24	misdiagnosed	O
25	with	O
26	rheumatoid	O
27	arthritis	O
28	and	O
29	later	O
30	gout	O
31	.	O

1	METHODS	O
2	:	O
3	The	O
4	responses	O
5	of	O
6	a	O
7	31	O
8	-	O
9	year	O
10	-	O
11	old	O
12	woman	O
13	with	O
14	complex	O
15	regional	O
16	pain	O
17	syndrome	O
18	type	O
19	I	O
20	(	O
21	reflex	O
22	sympathetic	O
23	dystrophy	O
24	)	O
25	to	O
26	a	O
27	thermal	O
28	grill	O
29	were	O
30	evaluated	O
31	before	O
32	and	O
33	after	O
34	stellate	O
35	ganglion	O
36	block	O
37	.	O

1	In	O
2	the	O
3	latter	O
4	category	O
5	particular	O
6	emphasis	O
7	is	O
8	being	O
9	placed	O
10	on	O
11	new	O
12	anthracycline	O
13	analogues	O
14	of	O
15	doxorubicin	O
16	and	O
17	analogues	O
18	of	O
19	cisplatinum	O
20	diammine	O
21	dichloride	O
22	.	O

1	X	O
2	-	O
3	ray	O
4	crystallographic	O
5	data	O
6	show	O
7	that	O
8	the	O
9	PLZF	B
10	BTB	I
11	/	O
12	POZ	O
13	domain	O
14	forms	O
15	an	O
16	obligate	O
17	homodimer	O
18	via	O
19	an	O
20	extensive	O
21	interface	O
22	.	O

1	On	O
2	the	O
3	other	O
4	hand	B
5	factor	I
6	IX	I
7	activity	O
8	is	O
9	decreased	O
10	in	O
11	coumarin	O
12	treatment	O
13	with	O
14	factor	B
15	IX	I
16	antigen	I
17	remaining	O
18	normal	O
19	.	O

1	Leads	O
2	from	O
3	the	O
4	MMWR	O
5	.	O

1	In	O
2	vitro	O
3	,	O
4	Arix	B
5	and	O
6	NBPhox	B
7	form	O
8	DNA	O
9	-	O
10	independent	O
11	multimers	O
12	and	O
13	exhibit	O
14	cooperative	O
15	binding	O
16	to	O
17	the	O
18	DB1	B
19	regulatory	I
20	element	I
21	,	O
22	which	O
23	contains	O
24	two	O
25	homeodomain	B
26	recognition	I
27	sites	I
28	.	O

1	In	O
2	adherent	O
3	macrophages	O
4	,	O
5	absence	O
6	of	O
7	CD45	B
8	led	I
9	to	O
10	the	O
11	hyperphosphorylation	O
12	and	O
13	hyperactivation	O
14	of	O
15	p56	B
16	/	O
17	59	O
18	(	O
19	hck	O
20	)	O
21	and	O
22	p53	B
23	/	O
24	56	O
25	(	O
26	lyn	O
27	),	O
28	but	O
29	not	O
30	of	O
31	p58	B
32	(	O
33	c	O
34	-	O
35	fgr	O
36	).	O

1	Consistent	O
2	with	O
3	this	O
4	model	O
5	,	O
6	a	O
7	synthetic	O
8	construct	O
9	containing	O
10	three	O
11	tandem	O
12	copies	O
13	of	O
14	the	O
15	native	O
16	LDL	B
17	receptor	I
18	SREBP	I
19	site	I
20	linked	O
21	to	O
22	a	O
23	single	O
24	Sp1	B
25	site	I
26	was	O
27	also	O
28	significantly	O
29	activated	O
30	in	O
31	a	O
32	buttonhead	O
33	-	O
34	independent	O
35	fashion	O
36	.	O

1	The	O
2	CD4	B
3	count	O
4	at	O
5	which	O
6	remission	O
7	occurs	O
8	may	O
9	reflect	O
10	severe	O
11	immunodeficiency	O
12	such	O
13	that	O
14	risk	O
15	for	O
16	AIDS	O
17	-	O
18	related	O
19	infection	O
20	is	O
21	high	O
22	.	O

1	Conversely	O
2	,	O
3	the	O
4	central	O
5	regions	O
6	are	O
7	highly	O
8	variable	O
9	.	O

1	The	O
2	class	B
3	II	I
4	Escherichia	I
5	coli	I
6	alanine	I
7	tRNA	I
8	synthetase	I
9	aminoacylates	O
10	RNA	O
11	miniduplexes	O
12	,	O
13	which	O
14	reconstruct	O
15	the	O
16	acceptor	O
17	end	O
18	of	O
19	alanine	O
20	tRNA	O
21	with	O
22	the	O
23	critical	O
24	G3	O
25	:	O
26	U70	O
27	base	O
28	pair	O
29	.	O

1	Here	O
2	,	O
3	we	O
4	have	O
5	used	O
6	specific	O
7	antibody	O
8	to	O
9	identify	O
10	and	O
11	characterize	O
12	the	O
13	SSN6	B
14	protein	I
15	.	O

1	Together	O
2	,	O
3	our	O
4	results	O
5	show	O
6	that	O
7	tinman	B
8	is	O
9	controlled	O
10	by	O
11	an	O
12	array	O
13	of	O
14	discrete	O
15	enhancer	O
16	elements	O
17	that	O
18	are	O
19	activated	O
20	successively	O
21	by	O
22	differential	O
23	genetic	O
24	inputs	O
25	,	O
26	as	O
27	well	O
28	as	O
29	by	O
30	closely	O
31	linked	O
32	activator	O
33	and	O
34	repressor	O
35	binding	O
36	sites	O
37	within	O
38	an	O
39	early	O
40	-	O
41	acting	O
42	enhancer	O
43	,	O
44	which	O
45	restrict	O
46	twist	O
47	activity	O
48	to	O
49	specific	O
50	areas	O
51	within	O
52	the	O
53	twist	O
54	expression	O
55	domain	O
56	.	O

1	In	O
2	transient	O
3	assays	O
4	,	O
5	using	O
6	rice	O
7	suspension	O
8	-	O
9	cultured	O
10	cells	O
11	transformed	O
12	by	O
13	particle	O
14	bombardment	O
15	,	O
16	we	O
17	showed	O
18	previously	O
19	that	O
20	Oshox1	O
21	can	O
22	transcriptionally	O
23	repress	O
24	the	O
25	activity	O
26	of	O
27	reporter	O
28	gene	O
29	constructs	O
30	with	O
31	upstream	O
32	HD	B
33	-	I
34	Zip	I
35	binding	I
36	sites	I
37	.	O

1	Glomerular	O
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O

1	The	O
2	results	O
3	presented	O
4	suggest	O
5	that	O
6	TIQ	O
7	reduces	O
8	the	O
9	turnover	O
10	rate	O
11	of	O
12	the	O
13	nigrostriatal	O
14	dopamine	O
15	neurons	O
16	after	O
17	repeated	O
18	administration	O
19	for	O
20	a	O
21	long	O
22	period	O
23	in	O
24	mice	O
25	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	B
21	1	I
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	Isolation	O
2	by	O
3	PCR	O
4	of	O
5	a	O
6	cDNA	O
7	clone	O
8	from	O
9	pea	O
10	petals	O
11	with	O
12	similarity	O
13	to	O
14	petunia	O
15	and	O
16	wheat	B
17	zinc	I
18	finger	I
19	proteins	I
20	.	O

1	A	O
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	O
7	-	O
8	36	O
9	survey	O
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	Isolation	O
2	of	O
3	Proteus	O
4	vulgaris	O
5	MC	O
6	-	O
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	The	O
2	murine	O
3	int	B
4	-	I
5	6	I
6	locus	I
7	,	O
8	identified	O
9	as	O
10	a	O
11	frequent	O
12	integration	O
13	site	O
14	of	O
15	mouse	O
16	mammary	O
17	tumor	O
18	viruses	O
19	,	O
20	encodes	O
21	the	O
22	48	O
23	-	O
24	kDa	O
25	eIF3e	O
26	subunit	O
27	of	O
28	translation	B
29	initiation	I
30	factor	I
31	eIF3	I
32	.	O

1	In	O
2	the	O
3	icosahaedral	O
4	MVMi	O
5	capsid	O
6	,	O
7	this	O
8	sequence	O
9	forms	O
10	the	O
11	carboxy	O
12	end	O
13	of	O
14	the	O
15	amphipathic	O
16	beta	O
17	-	O
18	strand	O
19	I	O
20	(	O
21	betaI	B
22	),	O
23	and	O
24	all	O
25	its	O
26	basic	O
27	residues	O
28	are	O
29	contiguously	O
30	positioned	O
31	at	O
32	the	O
33	face	O
34	that	O
35	in	O
36	the	O
37	unassembled	O
38	subunit	O
39	would	O
40	be	O
41	exposed	O
42	to	O
43	solvent	O
44	.	O

1	The	O
2	transverse	O
3	magnetization	O
4	decays	O
5	mentioned	O
6	above	O
7	exhibited	O
8	two	O
9	components	O
10	,	O
11	a	O
12	T2	O
13	fast	O
14	(	O
15	T2f	O
16	)	O
17	and	O
18	a	O
19	T2	O
20	slow	O
21	(	O
22	T2s	O
23	)	O
24	component	O
25	.	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	B
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O

1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	B
9	was	O
10	coinjected	O
11	with	O
12	plakoglobin	B
13	RNA	I
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	B
24	were	O
25	suppressed	O
26	.	O

1	The	O
2	ARX2	O
3	procedure	O
4	models	O
5	the	O
6	recorded	O
7	signal	O
8	as	O
9	the	O
10	sum	O
11	of	O
12	three	O
13	signals	O
14	:	O
15	(	O
16	a	O
17	)	O
18	the	O
19	background	O
20	EEG	O
21	activity	O
22	,	O
23	modelled	O
24	as	O
25	an	O
26	autoregressive	O
27	process	O
28	driven	O
29	by	O
30	a	O
31	white	O
32	noise	O
33	;	O
34	(	O
35	b	O
36	)	O
37	a	O
38	filtered	O
39	version	O
40	of	O
41	a	O
42	reference	O
43	signal	O
44	carrying	O
45	the	O
46	average	O
47	information	O
48	contained	O
49	in	O
50	each	O
51	sweep	O
52	;	O
53	(	O
54	c	O
55	)	O
56	a	O
57	signal	O
58	due	O
59	to	O
60	the	O
61	ocular	O
62	artefact	O
63	propagation	O
64	.	O

1	The	O
2	three	O
3	-	O
4	dimensional	O
5	structure	O
6	of	O
7	RT	B
8	shows	O
9	that	O
10	it	O
11	is	O
12	a	O
13	strikingly	O
14	asymmetric	O
15	heterodimer	O
16	consisting	O
17	of	O
18	two	O
19	differently	O
20	folded	O
21	subunits	O
22	(	O
23	molecular	O
24	weights	O
25	66	O
26	kDa	O
27	and	O
28	51	O
29	kDa	O
30	)	O
31	with	O
32	identical	O
33	amino	O
34	-	O
35	terminal	O
36	amino	O
37	acid	O
38	sequences	O
39	(	O
40	residues	O
41	1	O
42	-	O
43	428	O
44	).	O

1	Obesity	O
2	was	O
3	strongly	O
4	associated	O
5	with	O
6	the	O
7	proportions	O
8	of	O
9	nonprotein	O
10	-	O
11	bound	O
12	and	O
13	albumin	B
14	-	O
15	bound	O
16	estradiol	O
17	,	O
18	and	O
19	inversely	O
20	associated	O
21	with	O
22	sex	B
23	hormone	I
24	binding	I
25	globulin	I
26	(	O
27	SHBG	B
28	)	O
29	levels	O
30	and	O
31	the	O
32	proportion	O
33	of	O
34	SHBG	B
35	-	O
36	bound	O
37	estradiol	O
38	.	O

1	Greater	O
2	attenuation	O
3	of	O
4	the	O
5	N1	O
6	-	O
7	P2	O
8	and	O
9	baseline	O
10	-	O
11	P2	O
12	amplitude	O
13	of	O
14	the	O
15	probe	O
16	EPs	O
17	was	O
18	observed	O
19	when	O
20	the	O
21	probe	O
22	stimulus	O
23	was	O
24	presented	O
25	to	O
26	the	O
27	right	O
28	ear	O
29	and	O
30	the	O
31	verbal	O
32	material	O
33	presented	O
34	to	O
35	the	O
36	left	O
37	ear	O
38	than	O
39	when	O
40	the	O
41	opposite	O
42	stimulation	O
43	arrangement	O
44	was	O
45	used	O
46	.	O

1	I	O
2	.	O

1	S1	B
2	nuclease	I
3	analysis	O
4	of	O
5	RNA	O
6	prepared	O
7	after	O
8	transfection	O
9	of	O
10	these	O
11	HIV	O
12	constructs	O
13	into	O
14	HeLa	O
15	cells	O
16	infected	O
17	with	O
18	wild	O
19	-	O
20	type	O
21	adenovirus	O
22	indicated	O
23	that	O
24	the	O
25	enhancer	O
26	,	O
27	SP1	B
28	,	O
29	TATA	O
30	,	O
31	and	O
32	a	O
33	portion	O
34	of	O
35	the	O
36	transactivation	O
37	-	O
38	responsive	O
39	element	O
40	were	O
41	each	O
42	required	O
43	for	O
44	complete	O
45	E1A	B
46	/	O
47	E1B	O
48	-	O
49	mediated	O
50	activation	O
51	of	O
52	the	O
53	HIV	B
54	LTR	I
55	.	O

1	Acta	O
2	572	O
3	,	O
4	113	O
5	-	O
6	120	O
7	].	O

1	An	O
2	11	O
3	-	O
4	month	O
5	-	O
6	old	O
7	girl	O
8	suffering	O
9	from	O
10	Dandy	O
11	-	O
12	Walker	O
13	malformation	O
14	(	O
15	DWM	O
16	)	O
17	associated	O
18	with	O
19	tetralogy	O
20	of	O
21	Fallot	O
22	(	O
23	TOF	O
24	)	O
25	is	O
26	presented	O
27	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	O
28	mRNA	O
29	levels	O
30	.	O

1	Biol	O
2	.	O

1	However	O
2	,	O
3	mutations	O
4	in	O
5	the	O
6	HNF	B
7	-	I
8	4	I
9	binding	I
10	site	I
11	on	O
12	element	O
13	CIIB	O
14	and	O
15	inhibition	O
16	of	O
17	HNF	B
18	-	I
19	4	I
20	synthesis	O
21	in	O
22	HepG2	O
23	cells	O
24	by	O
25	antisense	O
26	HNF	B
27	-	I
28	4	I
29	constructs	O
30	decreased	O
31	the	O
32	apoCII	B
33	promoter	I
34	activity	O
35	to	O
36	25	O
37	-	O
38	40	O
39	%	O
40	of	O
41	the	O
42	control	O
43	,	O
44	indicating	O
45	that	O
46	HNF	B
47	-	I
48	4	I
49	is	O
50	a	O
51	positive	O
52	regulator	O
53	of	O
54	the	O
55	apoCII	B
56	gene	I
57	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	B
16	-	I
17	myc	I
18	deregulation	O
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	I
40	myc	I
41	alleles	I
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O

1	The	O
2	SR	B
3	protein	I
4	family	I
5	is	O
6	involved	O
7	in	O
8	constitutive	O
9	and	O
10	regulated	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	and	O
16	has	O
17	been	O
18	found	O
19	to	O
20	be	O
21	evolutionarily	O
22	conserved	O
23	in	O
24	metazoan	O
25	organisms	O
26	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O

1	Biol	O
2	.	O

1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O

1	Therefore	O
2	,	O
3	it	O
4	was	O
5	concluded	O
6	that	O
7	thrombotic	O
8	tendency	O
9	certainly	O
10	existed	O
11	in	O
12	patients	O
13	with	O
14	MS	O
15	compared	O
16	to	O
17	those	O
18	with	O
19	non	O
20	RHD	O
21	and	O
22	that	O
23	it	O
24	was	O
25	one	O
26	of	O
27	the	O
28	causes	O
29	of	O
30	the	O
31	significantly	O
32	high	O
33	incidence	O
34	of	O
35	thromboembolism	O
36	in	O
37	comparison	O
38	with	O
39	non	O
40	RHD	O
41	.	O

1	METHODS	O
2	:	O
3	We	O
4	retrospectively	O
5	reviewed	O
6	242	O
7	adult	O
8	cadaveric	O
9	renal	O
10	transplant	O
11	recipients	O
12	treated	O
13	between	O
14	11	O
15	/	O
16	91	O
17	and	O
18	5	O
19	/	O
20	97	O
21	.	O

1	Ume6p	O
2	,	O
3	which	O
4	also	O
5	controls	O
6	the	O
7	expression	O
8	of	O
9	early	O
10	meiotic	O
11	genes	O
12	,	O
13	represses	O
14	CAR1	O
15	expression	O
16	through	O
17	a	O
18	sequence	O
19	called	O
20	URS	B
21	,	O
22	as	O
23	a	O
24	function	O
25	of	O
26	nitrogen	O
27	availability	O
28	.	O

1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	O
14	-	O
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	O
25	-	O
26	therapy	O
27	plus	O
28	iliac	O
29	lymphadenectomy	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	megavolt	O
43	bremsstrahlung	O
44	beam	O
45	from	O
46	the	O
47	luc	O
48	type	O
49	installation	O
50	and	O
51	iliac	O
52	lymphadenectomy	O
53	(	O
54	50	O
55	cases	O
56	).	O

1	Sixty	O
2	months	O
3	after	O
4	the	O
5	initial	O
6	vaccination	O
7	,	O
8	all	O
9	vaccinees	O
10	who	O
11	received	O
12	annual	O
13	follow	O
14	-	O
15	up	O
16	still	O
17	had	O
18	protective	O
19	levels	O
20	of	O
21	anti	B
22	-	I
23	HAV	I
24	.	O

1	Magnetic	O
2	storm	O
3	indicators	O
4	could	O
5	be	O
6	used	O
7	in	O
8	medicine	O
9	,	O
10	in	O
11	geophysics	O
12	and	O
13	for	O
14	special	O
15	purposes	O
16	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	in	O
7	this	O
8	experimental	O
9	model	O
10	,	O
11	ACE	B
12	inhibitors	O
13	limit	O
14	the	O
15	arrhythmias	O
16	following	O
17	ischemia	O
18	-	O
19	reperfusion	O
20	and	O
21	free	O
22	radical	O
23	scavenging	O
24	action	O
25	of	O
26	these	O
27	drugs	O
28	does	O
29	not	O
30	have	O
31	a	O
32	major	O
33	contributory	O
34	role	O
35	in	O
36	their	O
37	protective	O
38	effect	O
39	.	O

1	Schizosaccharomyces	O
2	pombe	O
3	cells	O
4	respond	O
5	to	O
6	nutrient	O
7	deprivation	O
8	by	O
9	altering	O
10	G2	O
11	/	O
12	M	O
13	cell	O
14	size	O
15	control	O
16	.	O

1	Since	O
2	considerable	O
3	variations	O
4	in	O
5	length	O
6	and	O
7	primary	O
8	sequence	O
9	in	O
10	the	O
11	CDR3	B
12	(	O
13	complementarity	O
14	determining	O
15	region	O
16	)	O
17	peptides	O
18	of	O
19	all	O
20	the	O
21	H	B
22	-	I
23	chains	I
24	are	O
25	evident	O
26	,	O
27	conservation	O
28	of	O
29	the	O
30	D	O
31	-	O
32	region	O
33	structure	O
34	does	O
35	not	O
36	appear	O
37	to	O
38	be	O
39	necessary	O
40	for	O
41	effective	O
42	hapten	O
43	binding	O
44	.	O

1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	B
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O

1	The	O
2	UAS	O
3	of	O
4	the	O
5	AAC2	B
6	gene	I
7	contains	O
8	at	O
9	least	O
10	two	O
11	distinct	O
12	motifs	O
13	for	O
14	DNA	O
15	-	O
16	binding	O
17	transcriptional	O
18	activators	O
19	,	O
20	including	O
21	one	O
22	which	O
23	is	O
24	identical	O
25	with	O
26	the	O
27	core	O
28	HAP2	B
29	/	O
30	3	O
31	/	O
32	4	O
33	binding	O
34	motif	O
35	,	O
36	and	O
37	a	O
38	second	O
39	one	O
40	with	O
41	the	O
42	ABF1	B
43	consensus	I
44	binding	I
45	sequence	I
46	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	TCR	B
2	alpha	I
3	(	O
4	TCRA	O
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	B
19	+,	O
20	CD8	O
21	+,	O
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O

1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	O
8	sequence	O
9	stabilizes	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O

1	EMBO	O
2	J	O
3	.	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	B
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	B
23	GR	I
24	.	O

1	Sulfuric	O
2	acid	O
3	concentration	O
4	in	O
5	the	O
6	catalyzed	O
7	breathalyzer	O
8	ampules	O
9	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	mouse	B
7	growth	I
8	hormone	I
9	receptor	I
10	/	I
11	growth	I
12	hormone	I
13	binding	I
14	protein	I
15	gene	I
16	.	O

1	Alanine	B
2	aminotransferase	I
3	(	O
4	ALT	B
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O

1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	ARNO	B
7	localizes	O
8	to	O
9	the	O
10	plasma	O
11	membrane	O
12	in	O
13	vivo	O
14	and	O
15	efficiently	O
16	catalyzes	O
17	ARF6	B
18	nucleotide	O
19	exchange	O
20	in	O
21	vitro	O
22	.	O

1	Only	O
2	one	O
3	of	O
4	these	O
5	bands	O
6	was	O
7	supershifted	O
8	by	O
9	antibody	O
10	to	O
11	p50	B
12	,	O
13	whereas	O
14	antibodies	O
15	to	O
16	p65	B
17	or	O
18	other	O
19	NF	B
20	-	I
21	kappaB	I
22	proteins	I
23	had	O
24	no	O
25	effect	O
26	.	O

1	The	O
2	preferences	O
3	were	O
4	for	O
5	intact	O
6	vis	O
7	-	O
8	a	O
9	-	O
10	vis	O
11	castrated	O
12	males	O
13	,	O
14	though	O
15	injections	O
16	of	O
17	TP	B
18	restored	O
19	the	O
20	castrates	O
21	'	O
22	attractiveness	O
23	to	O
24	the	O
25	females	O
26	.	O

1	Snail	O
2	mortality	O
3	did	O
4	not	O
5	differ	O
6	among	O
7	the	O
8	various	O
9	treatment	O
10	conditions	O
11	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O

1	Sodium	O
2	polystyrene	O
3	sulfonate	O
4	treatment	O
5	for	O
6	lithium	O
7	toxicity	O
8	:	O
9	effects	O
10	on	O
11	serum	O
12	potassium	O
13	concentrations	O
14	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	O
8	surgery	O
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	Occupational	O
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O

1	Two	O
2	distinct	O
3	Salmonella	O
4	fimbrins	O
5	,	O
6	AgfA	B
7	and	O
8	SefA	B
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	O
15	and	O
16	SEF14	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	O
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	B
45	gp63	I
46	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	distribution	O
6	of	O
7	endocytic	O
8	markers	O
9	is	O
10	not	O
11	affected	O
12	.	O

1	Enhancer	O
2	activity	O
3	requires	O
4	both	O
5	the	O
6	AP	B
7	-	I
8	1	I
9	site	I
10	and	O
11	these	O
12	adjacent	O
13	sequences	O
14	.	O

1	The	O
2	10	O
3	kDa	O
4	polypeptide	O
5	was	O
6	phosphorylated	O
7	in	O
8	vitro	O
9	by	O
10	incubating	O
11	wheat	O
12	etioplast	O
13	membranes	O
14	with	O
15	[	O
16	gamma	O
17	32P	O
18	]	O
19	ATP	O
20	.	O

1	The	O
2	importance	O
3	of	O
4	these	O
5	sites	O
6	for	O
7	transcriptional	O
8	activation	O
9	was	O
10	studied	O
11	by	O
12	site	O
13	-	O
14	directed	O
15	mutagenesis	O
16	followed	O
17	by	O
18	promoter	O
19	function	O
20	analysis	O
21	of	O
22	the	O
23	mutants	O
24	with	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	system	O
30	.	O

1	The	O
2	nm23	B
3	-	I
4	H1	I
5	/	I
6	nm23	I
7	-	I
8	H2	I
9	gene	I
10	transcriptional	O
11	activity	O
12	ratio	O
13	varied	O
14	depending	O
15	on	O
16	the	O
17	cell	O
18	line	O
19	.	O

1	Therefore	O
2	,	O
3	the	O
4	rbcL	B
5	-	I
6	rbcS	I
7	locus	I
8	seems	O
9	to	O
10	be	O
11	barely	O
12	expressed	O
13	under	O
14	a	O
15	standard	O
16	condition	O
17	for	O
18	photoautotrophic	O
19	growth	O
20	.	O

1	Rss1p	B
2	encodes	O
3	a	O
4	novel	O
5	essential	O
6	protein	O
7	of	O
8	538	O
9	amino	O
10	acids	O
11	,	O
12	which	O
13	contains	O
14	an	O
15	extended	O
16	predicted	O
17	coiled	O
18	-	O
19	coil	O
20	domain	O
21	and	O
22	is	O
23	located	O
24	both	O
25	at	O
26	nuclear	O
27	pore	O
28	complexes	O
29	(	O
30	NPCs	O
31	)	O
32	and	O
33	in	O
34	the	O
35	cytoplasm	O
36	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	One	O
2	of	O
3	these	O
4	is	O
5	located	O
6	in	O
7	the	O
8	5	O
9	'-	O
10	untranslated	O
11	region	O
12	,	O
13	and	O
14	may	O
15	encode	O
16	regulatory	O
17	sequences	O
18	.	O

1	In	O
2	contrast	O
3	,	O
4	capsid	B
5	proteins	I
6	derived	O
7	from	O
8	the	O
9	P1	O
10	precursor	O
11	with	O
12	a	O
13	valine	O
14	substitution	O
15	at	O
16	the	O
17	amino	O
18	terminus	O
19	of	O
20	VP1	B
21	(	O
22	VP1	B
23	-	I
24	G001V	I
25	)	O
26	assembled	O
27	empty	O
28	capsid	B
29	particles	I
30	but	O
31	were	O
32	deficient	O
33	in	O
34	assembling	O
35	RNA	O
36	-	O
37	containing	O
38	virions	O
39	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	The	O
2	examination	O
3	was	O
4	focused	O
5	on	O
6	assessment	O
7	of	O
8	different	O
9	types	O
10	of	O
11	drusen	O
12	,	O
13	on	O
14	evaluation	O
15	of	O
16	the	O
17	development	O
18	and	O
19	incidence	O
20	of	O
21	risk	O
22	factors	O
23	leading	O
24	to	O
25	complications	O
26	and	O
27	loss	O
28	of	O
29	central	O
30	vision	O
31	.	O

1	SEA	B
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	Using	O
2	autoantibodies	O
3	from	O
4	a	O
5	Sjogren	O
6	'	O
7	s	O
8	syndrome	O
9	patient	O
10	,	O
11	we	O
12	have	O
13	previously	O
14	identified	O
15	a	O
16	230	O
17	-	O
18	kDa	O
19	peripheral	O
20	membrane	O
21	protein	O
22	associated	O
23	with	O
24	the	O
25	cytosolic	O
26	face	O
27	of	O
28	the	O
29	trans	O
30	-	O
31	Golgi	O
32	(	O
33	Kooy	O
34	,	O
35	J	O
36	.,	O
37	Toh	O
38	,	O
39	B	O
40	.	O

1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	B
16	/	I
17	B	I
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O

1	The	O
2	CAPLC1	B
3	protein	I
4	also	O
5	exhibited	O
6	several	O
7	unique	O
8	features	O
9	,	O
10	including	O
11	a	O
12	novel	O
13	stretch	O
14	of	O
15	18	O
16	-	O
17	19	O
18	amino	O
19	acid	O
20	residues	O
21	within	O
22	the	O
23	X	O
24	domain	O
25	and	O
26	an	O
27	unusually	O
28	long	O
29	N	O
30	-	O
31	terminus	O
32	which	O
33	did	O
34	not	O
35	contain	O
36	a	O
37	recognizable	O
38	EF	B
39	-	I
40	hand	I
41	Ca	I
42	(	I
43	2	I
44	+)-	I
45	binding	I
46	domain	I
47	.	O

1	Infants	O
2	of	O
3	this	O
4	sample	O
5	had	O
6	monocular	O
7	PL	O
8	visual	O
9	acuities	O
10	similar	O
11	to	O
12	those	O
13	established	O
14	by	O
15	McDonald	O
16	et	O
17	al	O
18	.	O
19	in	O
20	a	O
21	laboratory	O
22	setting	O
23	.	O

1	The	O
2	glucose	O
3	areas	O
4	following	O
5	the	O
6	ingestion	O
7	of	O
8	the	O
9	foods	O
10	were	O
11	:	O
12	Study	O
13	1	O
14	:	O
15	glucose	O
16	11	O
17	.	O
18	7	O
19	,	O
20	orange	O
21	juice	O
22	7	O
23	.	O
24	3	O
25	,	O
26	sucrose	O
27	5	O
28	.	O
29	2	O
30	,	O
31	glucose	O
32	+	O
33	fructose	O
34	6	O
35	.	O
36	3	O
37	,	O
38	and	O
39	fructose	O
40	0	O
41	.	O
42	7	O
43	mmol	O
44	X	O
45	h	O
46	/	O
47	l	O
48	;	O
49	Study	O
50	2	O
51	:	O
52	glucose	O
53	14	O
54	.	O
55	6	O
56	,	O
57	orange	O
58	juice	O
59	7	O
60	.	O
61	3	O
62	,	O
63	apples	O
64	5	O
65	.	O
66	5	O
67	,	O
68	and	O
69	apple	O
70	juice	O
71	4	O
72	.	O
73	7	O
74	mmol	O
75	X	O
76	h	O
77	/	O
78	l	O
79	;	O
80	Study	O
81	3	O
82	:	O
83	glucose	O
84	12	O
85	.	O
86	6	O
87	,	O
88	ice	O
89	cream	O
90	8	O
91	.	O
92	1	O
93	,	O
94	milk	O
95	3	O
96	.	O
97	7	O
98	,	O
99	and	O
100	lactose	O
101	4	O
102	.	O
103	1	O
104	mmol	O
105	X	O
106	h	O
107	/	O
108	l	O
109	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	O
32	-	O
33	and	O
34	beta	B
35	-	I
36	adrenoceptors	I
37	.	O

1	Two	O
2	members	O
3	of	O
4	the	O
5	Cbl	B
6	family	I
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	O
14	c	B
15	-	I
16	Cbl	I
17	and	O
18	Cbl	B
19	-	I
20	b	I
21	),	O
22	one	O
23	in	O
24	C	O
25	.	O
26	elegans	O
27	(	O
28	Sli	B
29	-	I
30	1	I
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	O
36	(	O
37	D	B
38	-	I
39	Cbl	I
40	).	O

1	Acute	O
2	idiopathic	O
3	thrombocytopenic	O
4	purpura	O
5	presenting	O
6	a	O
7	high	O
8	serum	O
9	level	O
10	of	O
11	immunoglobulin	B
12	E	I
13	and	O
14	eosinophilia	O
15	in	O
16	an	O
17	elderly	O
18	patient	O
19	.	O

1	Our	O
2	results	O
3	also	O
4	indicate	O
5	the	O
6	existence	O
7	of	O
8	sequences	O
9	downstream	O
10	of	O
11	-	O
12	0	O
13	.	O
14	11	O
15	kb	O
16	which	O
17	can	O
18	influence	O
19	the	O
20	pattern	O
21	of	O
22	tissue	O
23	-	O
24	specific	O
25	expression	O
26	of	O
27	the	O
28	HLA	B
29	-	I
30	B7	I
31	gene	I
32	and	O
33	the	O
34	ability	O
35	of	O
36	this	O
37	gene	O
38	to	O
39	respond	O
40	to	O
41	gamma	B
42	interferon	I
43	.	O

1	The	O
2	intrapancreatic	O
3	spread	O
4	of	O
5	the	O
6	carcinoma	O
7	correlated	O
8	with	O
9	portal	O
10	invasion	O
11	of	O
12	carcinoma	O
13	,	O
14	hardness	O
15	of	O
16	the	O
17	body	O
18	and	O
19	tail	O
20	,	O
21	obstruction	O
22	of	O
23	main	O
24	pancreatic	O
25	duct	O
26	and	O
27	irregular	O
28	pancreaticogram	O
29	.	O

1	Class	O
2	I	O
3	alpha1	O
4	,	O
5	2	O
6	-	O
7	mannosidases	O
8	play	O
9	an	O
10	essential	O
11	role	O
12	in	O
13	the	O
14	elaboration	O
15	of	O
16	complex	O
17	and	O
18	hybrid	O
19	N	O
20	-	O
21	glycans	O
22	in	O
23	mammalian	O
24	cells	O
25	.	O

1	The	O
2	term	O
3	osteomesopycnosis	O
4	is	O
5	proposed	O
6	for	O
7	a	O
8	sclerosing	O
9	bone	O
10	disease	O
11	with	O
12	dominant	O
13	inheritance	O
14	that	O
15	has	O
16	been	O
17	discovered	O
18	in	O
19	five	O
20	members	O
21	of	O
22	four	O
23	different	O
24	families	O
25	.	O

1	Regulation	O
2	of	O
3	yeast	B
4	LEU2	I
5	.	O

1	The	O
2	responses	O
3	of	O
4	the	O
5	"	O
6	stress	O
7	hormones	O
8	"	O
9	cortisol	O
10	,	O
11	11	O
12	-	O
13	deoxycortisol	O
14	,	O
15	ACTH	B
16	,	O
17	vasopressin	B
18	(	O
19	AVP	B
20	),	O
21	and	O
22	corticotropin	B
23	releasing	I
24	factor	I
25	(	O
26	CRF	O
27	)	O
28	were	O
29	studied	O
30	in	O
31	6	O
32	normal	O
33	males	O
34	in	O
35	response	O
36	to	O
37	acute	O
38	cortisol	O
39	deficiency	O
40	induced	O
41	by	O
42	the	O
43	11	O
44	-	O
45	beta	B
46	-	I
47	hydroxylase	I
48	inhibitor	O
49	,	O
50	metyrapone	O
51	.	O

1	Somatostatin	B
2	gene	I
3	expression	O
4	in	O
5	pancreatic	O
6	islet	O
7	cells	O
8	is	O
9	directed	O
10	by	O
11	cell	O
12	-	O
13	specific	O
14	DNA	O
15	control	O
16	elements	O
17	and	O
18	DNA	O
19	-	O
20	binding	O
21	proteins	O
22	.	O

1	We	O
2	thus	O
3	conclude	O
4	that	O
5	the	O
6	NFAT	B
7	RIR	I
8	plays	O
9	an	O
10	essential	O
11	dual	O
12	role	O
13	in	O
14	DNA	O
15	recognition	O
16	and	O
17	cooperative	O
18	binding	O
19	to	O
20	AP	B
21	-	I
22	1	I
23	family	I
24	transcription	I
25	factors	I
26	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Associations	O
6	of	O
7	factor	O
8	analysis	O
9	-	O
10	derived	O
11	syndromes	O
12	with	O
13	risk	O
14	factors	O
15	for	O
16	chemical	O
17	interactions	O
18	that	O
19	inhibit	O
20	butyrylcholinesterase	B
21	and	O
22	neuropathy	B
23	target	I
24	esterase	I
25	.	O

1	Plasma	O
2	lipid	O
3	and	O
4	lipoprotein	O
5	profiles	O
6	were	O
7	compared	O
8	in	O
9	elderly	O
10	female	O
11	runners	O
12	(	O
13	RU	O
14	:	O
15	n	O
16	=	O
17	15	O
18	,	O
19	aged	O
20	66	O
21	+/-	O
22	5	O
23	years	O
24	,	O
25	body	O
26	fat	O
27	20	O
28	+/-	O
29	4	O
30	%,	O
31	training	O
32	distance	O
33	35	O
34	+/-	O
35	15	O
36	km	O
37	week	O
38	-	O
39	1	O
40	,	O
41	VO2max	O
42	36	O
43	+/-	O
44	4	O
45	ml	O
46	kg	O
47	-	O
48	1	O
49	min	O
50	-	O
51	1	O
52	,	O
53	mean	O
54	+/-	O
55	SD	O
56	)	O
57	and	O
58	age	O
59	-	O
60	matched	O
61	untrained	O
62	women	O
63	(	O
64	UT	O
65	:	O
66	n	O
67	=	O
68	28	O
69	,	O
70	66	O
71	+/-	O
72	4	O
73	years	O
74	,	O
75	body	O
76	fat	O
77	26	O
78	+/-	O
79	6	O
80	%,	O
81	VO2max	O
82	26	O
83	+/-	O
84	3	O
85	ml	O
86	kg	O
87	-	O
88	1	O
89	min	O
90	-	O
91	1	O
92	).	O

1	SCFFWD1	O
2	may	O
3	be	O
4	critical	O
5	for	O
6	tumor	O
7	development	O
8	and	O
9	suppression	O
10	through	O
11	regulation	O
12	of	O
13	beta	B
14	-	I
15	catenin	I
16	protein	I
17	stability	O
18	.	O

1	In	O
2	part	O
3	as	O
4	a	O
5	result	O
6	of	O
7	its	O
8	inability	O
9	to	O
10	sustain	O
11	radiative	O
12	loses	O
13	,	O
14	the	O
15	BB	O
16	resonator	O
17	has	O
18	extremely	O
19	low	O
20	RF	O
21	power	O
22	requirements	O
23	.	O

1	In	O
2	some	O
3	of	O
4	the	O
5	cases	O
6	of	O
7	solitary	O
8	lesion	O
9	,	O
10	serum	B
11	TSH	I
12	levels	O
13	,	O
14	serum	O
15	thyroglobulin	B
16	values	O
17	,	O
18	and	O
19	131I	O
20	protein	O
21	bounded	O
22	iodine	O
23	(	O
24	131I	O
25	-	O
26	PBI	O
27	)	O
28	were	O
29	measured	O
30	,	O
31	but	O
32	there	O
33	were	O
34	no	O
35	significant	O
36	differences	O
37	between	O
38	successful	O
39	and	O
40	unsuccessful	O
41	therapy	O
42	.	O

1	Only	O
2	two	O
3	of	O
4	27	O
5	participants	O
6	(	O
7	7	O
8	.	O
9	4	O
10	%)	O
11	with	O
12	definite	O
13	POAG	O
14	had	O
15	been	O
16	previously	O
17	diagnosed	O
18	and	O
19	treated	O
20	,	O
21	and	O
22	66	O
23	.	O
24	7	O
25	%	O
26	of	O
27	the	O
28	previously	O
29	undiagnosed	O
30	had	O
31	IOP	O
32	less	O
33	than	O
34	22	O
35	mmHg	O
36	.	O

1	However	O
2	,	O
3	parallax	O
4	measurements	O
5	showed	O
6	that	O
7	at	O
8	150K	O
9	,	O
10	collapse	O
11	of	O
12	Epon	O
13	sections	O
14	does	O
15	not	O
16	take	O
17	place	O
18	.	O

1	Promoter	O
2	elements	O
3	include	O
4	an	O
5	atypical	O
6	TATA	O
7	box	O
8	(	O
9	GTTA	O
10	),	O
11	one	O
12	CCAAT	O
13	box	O
14	much	O
15	further	O
16	from	O
17	the	O
18	initiation	O
19	site	O
20	,	O
21	three	O
22	reverse	O
23	compliments	O
24	of	O
25	CCAAT	O
26	(	O
27	ATTGG	O
28	),	O
29	and	O
30	two	O
31	pyrimidine	O
32	-	O
33	rich	O
34	nucleotide	O
35	stretches	O
36	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O

1	The	O
2	clinical	O
3	picture	O
4	and	O
5	laboratory	O
6	parameters	O
7	were	O
8	consistent	O
9	with	O
10	a	O
11	serum	O
12	sickness	O
13	reaction	O
14	.	O

1	Relative	O
2	to	O
3	coherent	O
4	control	O
5	words	O
6	(	O
7	e	O
8	.	O
9	g	O
10	.,	O
11	quick	O
12	),	O
13	these	O
14	discourse	O
15	-	O
16	dependent	O
17	semantic	O
18	anomalies	O
19	elicited	O
20	a	O
21	large	O
22	N400	O
23	effect	O
24	that	O
25	began	O
26	at	O
27	about	O
28	200	O
29	to	O
30	250	O
31	msec	O
32	after	O
33	word	O
34	onset	O
35	.	O

1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	O
7	N2417	O
8	and	O
9	N2403	O
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	B
22	maltosa	I
23	cycloheximide	I
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	B
30	interleukin	I
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	O
36	ILF	B
37	-	I
38	2	I
39	).	O

1	We	O
2	find	O
3	that	O
4	beta	B
5	II	I
6	PKC	I
7	phosphorylates	I
8	nuclear	I
9	envelope	I
10	lamin	I
11	B	I
12	at	O
13	10	O
14	-	O
15	20	O
16	times	O
17	the	O
18	rate	O
19	of	O
20	alpha	B
21	PKC	I
22	,	O
23	whereas	O
24	both	O
25	kinases	O
26	phosphorylate	O
27	soluble	O
28	lamin	B
29	B	I
30	at	O
31	similar	O
32	rates	O
33	.	O

1	Chemotherapy	O
2	was	O
3	administered	O
4	without	O
5	altering	O
6	the	O
7	course	O
8	of	O
9	the	O
10	disorder	O
11	.	O

1	Six	O
2	patients	O
3	with	O
4	human	B
5	T	I
6	-	I
7	cell	I
8	lymphotropic	I
9	virus	I
10	type	I
11	I	I
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	myelopathy	O
19	(	O
20	HAM	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	electrophysiologic	O
26	methods	O
27	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	administration	O
7	of	O
8	misoprostol	O
9	prevents	O
10	gastric	O
11	hemorrhage	O
12	in	O
13	healthy	O
14	dogs	O
15	treated	O
16	with	O
17	high	O
18	doses	O
19	of	O
20	methylprednisolone	O
21	sodium	O
22	succinate	O
23	(	O
24	MPSS	O
25	).	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	Significance	O
2	of	O
3	delta	O
4	-	O
5	aminolevulinic	O
6	acid	O
7	analysis	O
8	in	O
9	clinical	O
10	tests	O

1	Pao2	O
2	increased	O
3	from	O
4	15	O
5	.	O
6	5	O
7	+/-	O
8	5	O
9	.	O
10	6	O
11	kPa	O
12	(	O
13	116	O
14	+/-	O
15	42	O
16	mm	O
17	Hg	O
18	)	O
19	to	O
20	17	O
21	.	O
22	3	O
23	+/-	O
24	6	O
25	.	O
26	3	O
27	kPa	O
28	(	O
29	130	O
30	+/-	O
31	47	O
32	mm	O
33	Hg	O
34	)	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	05	O
41	).	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	assess	O
7	and	O
8	compare	O
9	the	O
10	ability	O
11	of	O
12	three	O
13	different	O
14	forms	O
15	of	O
16	DSG	B
17	to	O
18	block	O
19	EIB	O
20	.	O

1	To	O
2	analyze	O
3	the	O
4	VH	O
5	regions	O
6	of	O
7	polyreactive	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	somatically	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	B
23	(	O
24	three	O
25	IgG1	B
26	and	O
27	two	O
28	IgG3	B
29	)	I
30	mAb	I
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	SLE	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	efficiencies	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	foreign	O
66	Ag	O
67	.	O

1	Large	O
2	scale	O
3	electronic	O
4	structure	O
5	calculations	O
6	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	Rb	B
6	protein	I
7	is	O
8	interacting	O
9	with	O
10	some	O
11	component	O
12	(	O
13	s	O
14	)	O
15	of	O
16	the	O
17	cell	O
18	cycle	O
19	-	O
20	regulatory	O
21	machinery	O
22	during	O
23	G2	O
24	phase	O
25	.	O

1	The	O
2	physical	O
3	linkage	O
4	of	O
5	the	O
6	FHR2	O
7	and	O
8	the	O
9	factor	O
10	H	O
11	genes	O
12	provides	O
13	additional	O
14	evidence	O
15	for	O
16	a	O
17	close	O
18	relatedness	O
19	of	O
20	complement	B
21	factor	I
22	H	I
23	and	O
24	the	O
25	factor	B
26	H	I
27	-	I
28	related	I
29	proteins	I
30	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	Subcloning	O
2	of	O
3	DNA	O
4	fragments	O
5	from	O
6	the	O
7	8	O
8	.	O
9	5	O
10	-	O
11	kilobase	O
12	(	O
13	kb	O
14	)	O
15	insert	O
16	of	O
17	pAVO4	O
18	defined	O
19	a	O
20	4	O
21	-	O
22	kb	O
23	DNA	O
24	fragment	O
25	which	O
26	contained	O
27	the	O
28	functional	O
29	FBP	O
30	+	O
31	gene	O
32	and	O
33	its	O
34	regulatory	O
35	region	O
36	.	O

1	Most	O
2	pituitary	B
3	hormone	I
4	-	I
5	coding	I
6	gene	I
7	promoters	I
8	are	O
9	activated	O
10	by	O
11	Ptx1	O
12	.	O

1	A	O
2	1	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	HindIII	B
8	genomic	O
9	fragment	O
10	carrying	O
11	the	O
12	vspA	B
13	gene	I
14	from	O
15	M	O
16	.	O
17	bovis	O
18	PG45	O
19	was	O
20	cloned	O
21	and	O
22	sequenced	O
23	.	O

1	Plate	O
2	luting	O
3	,	O
4	a	O
5	technique	O
6	that	O
7	uses	O
8	polymethylmethacrylate	O
9	(	O
10	PMMA	O
11	)	O
12	interposed	O
13	between	O
14	the	O
15	plate	O
16	and	O
17	the	O
18	bone	O
19	,	O
20	as	O
21	well	O
22	as	O
23	between	O
24	the	O
25	screw	O
26	heads	O
27	and	O
28	the	O
29	plate	O
30	,	O
31	to	O
32	improve	O
33	the	O
34	stability	O
35	of	O
36	internal	O
37	fixation	O
38	was	O
39	tested	O
40	in	O
41	vitro	O
42	using	O
43	20	O
44	paired	O
45	equine	O
46	third	O
47	metacarpal	O
48	bones	O
49	with	O
50	mid	O
51	-	O
52	diaphyseal	O
53	osteotomies	O
54	plated	O
55	with	O
56	six	O
57	-	O
58	hole	O
59	broad	O
60	ASIF	O
61	compression	O
62	plates	O
63	.	O

1	Summers	O
2	,	O
3	Virology	O
4	89	O
5	:	O
6	517	O
7	-	O
8	527	O
9	,	O
10	1978	O
11	).	O

1	Fifty	O
2	-	O
3	four	O
4	patients	O
5	were	O
6	divided	O
7	into	O
8	groups	O
9	according	O
10	to	O
11	their	O
12	clinical	O
13	presentation	O
14	;	O
15	seven	O
16	asymptomatic	O
17	volunteers	O
18	,	O
19	20	O
20	patients	O
21	with	O
22	duodenal	O
23	-	O
24	gastric	O
25	reflux	O
26	gastropathy	O
27	(	O
28	DRG	O
29	),	O
30	16	O
31	patients	O
32	with	O
33	recurrent	O
34	ulcers	O
35	of	O
36	the	O
37	duodenal	O
38	bulb	O
39	(	O
40	RUD	O
41	),	O
42	and	O
43	11	O
44	patients	O
45	with	O
46	Moynihan	O
47	'	O
48	s	O
49	disease	O
50	.	O

1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	salmonicida	O
13	infections	O
14	,	O
15	specifically	O
16	furunculosis	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	fish	O
22	in	O
23	this	O
24	loch	O
25	.	O

1	Temporal	O
2	control	O
3	of	O
4	GUS	B
5	expression	O
6	was	O
7	found	O
8	to	O
9	involve	O
10	two	O
11	negative	O
12	regulatory	O
13	sequences	O
14	,	O
15	NRS1	O
16	(-	O
17	391	O
18	to	O
19	-	O
20	295	O
21	)	O
22	and	O
23	NRS2	O
24	(-	O
25	518	O
26	to	O
27	-	O
28	418	O
29	),	O
30	as	O
31	well	O
32	as	O
33	the	O
34	positive	O
35	domain	O
36	UAS1	O
37	.	O

1	The	O
2	expression	O
3	pattern	O
4	of	O
5	GL2	B
6	,	O
7	as	O
8	demonstrated	O
9	by	O
10	in	O
11	situ	O
12	hybridization	O
13	,	O
14	indicated	O
15	that	O
16	the	O
17	gene	O
18	is	O
19	expressed	O
20	in	O
21	trichome	O
22	progenitor	O
23	cells	O
24	and	O
25	at	O
26	stages	O
27	associated	O
28	with	O
29	trichome	O
30	development	O
31	.	O

1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O

1	Advanced	O
2	adenoma	O
3	was	O
4	defined	O
5	as	O
6	an	O
7	adenoma	O
8	larger	O
9	than	O
10	10	O
11	mm	O
12	or	O
13	an	O
14	adenoma	O
15	of	O
16	any	O
17	size	O
18	with	O
19	villous	O
20	component	O
21	,	O
22	high	O
23	-	O
24	grade	O
25	dysplasia	O
26	or	O
27	invasive	O
28	carcinoma	O
29	.	O

1	Retreatment	O
2	of	O
3	these	O
4	2	O
5	dogs	O
6	resulted	O
7	in	O
8	a	O
9	similar	O
10	,	O
11	but	O
12	blunted	O
13	,	O
14	response	O
15	to	O
16	human	B
17	immunoglobulin	I
18	.	O

1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	O
14	cdc2	B
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	I
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	The	O
2	patient	O
3	initially	O
4	attained	O
5	complete	O
6	remission	O
7	(	O
8	CR1	B
9	)	O
10	with	O
11	conventional	O
12	chemotherapy	O
13	and	O
14	then	O
15	relapsed	O
16	14	O
17	months	O
18	later	O
19	.	O

1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	O
9	response	O
10	factor	O
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O

1	The	O
2	activity	O
3	of	O
4	serum	B
5	lipase	I
6	and	I
7	amylase	I
8	distinctly	O
9	increased	O
10	at	O
11	3	O
12	h	O
13	and	O
14	went	O
15	up	O
16	to	O
17	the	O
18	maximum	O
19	at	O
20	12	O
21	h	O
22	after	O
23	injection	O
24	of	O
25	Na	O
26	-	O
27	Tc	O
28	.	O

1	Similar	O
2	experiments	O
3	with	O
4	TR	O
5	support	O
6	the	O
7	high	O
8	affinity	O
9	of	O
10	RIP140	B
11	to	O
12	the	O
13	RXR	B
14	subunit	I
15	and	O
16	also	O
17	suggest	O
18	that	O
19	either	O
20	partner	O
21	in	O
22	the	O
23	TR	B
24	/	O
25	RXR	B
26	heterodimer	O
27	can	O
28	independently	O
29	respond	O
30	to	O
31	ligand	O
32	.	O

1	Repression	O
2	of	O
3	glucocorticoid	B
4	receptor	I
5	-	O
6	mediated	O
7	transcriptional	O
8	activation	O
9	by	O
10	unliganded	B
11	thyroid	I
12	hormone	I
13	receptor	I
14	(	O
15	TR	B
16	)	O
17	is	O
18	TR	O
19	isoform	O
20	-	O
21	specific	O
22	.	O

1	On	O
2	-	O
3	line	O
4	angioscopic	O
5	images	O
6	of	O
7	tissue	O
8	flaps	O
9	floating	O
10	in	O
11	the	O
12	lumen	O
13	,	O
14	recent	O
15	or	O
16	structured	O
17	thrombi	O
18	,	O
19	artery	O
20	wall	O
21	dissections	O
22	,	O
23	plaque	O
24	ruptures	O
25	,	O
26	deep	O
27	fissurations	O
28	and	O
29	sub	O
30	-	O
31	intimal	O
32	haemorrhages	O
33	demonstrate	O
34	,	O
35	in	O
36	live	O
37	colour	O
38	,	O
39	the	O
40	pathophysiological	O
41	mechanisms	O
42	of	O
43	coronary	O
44	artery	O
45	stenosis	O
46	.	O

1	T	O
2	-	O
3	cell	O
4	hybridomas	O
5	,	O
6	thymocytes	O
7	,	O
8	and	O
9	T	O
10	cells	O
11	can	O
12	be	O
13	induced	O
14	to	O
15	undergo	O
16	apoptotic	O
17	cell	O
18	death	O
19	by	O
20	activation	O
21	through	O
22	the	O
23	T	B
24	-	I
25	cell	I
26	receptor	I
27	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	O
17	domain	O
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	O
16	is	O
17	most	O
18	pronounced	O
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	protein	O
7	product	O
8	of	O
9	the	O
10	ref	B
11	-	I
12	1	I
13	gene	I
14	stimulates	O
15	the	O
16	DNA	O
17	binding	O
18	activity	O
19	of	O
20	Fos	B
21	-	I
22	Jun	I
23	heterodimers	O
24	,	O
25	Jun	B
26	-	I
27	Jun	I
28	homodimers	I
29	and	O
30	Hela	O
31	cell	O
32	AP	B
33	-	I
34	1	I
35	proteins	I
36	as	O
37	well	O
38	as	O
39	that	O
40	of	O
41	several	O
42	other	O
43	transcription	O
44	factors	O
45	including	O
46	NF	B
47	-	I
48	kappa	I
49	B	I
50	,	I
51	Myb	I
52	and	O
53	members	O
54	of	O
55	the	O
56	ATF	B
57	/	O
58	CREB	B
59	family	I
60	.	O

1	Previous	O
2	analysis	O
3	of	O
4	the	O
5	98	O
6	-	O
7	bp	O
8	sequence	O
9	has	O
10	delineated	O
11	several	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	that	O
17	are	O
18	recognized	O
19	by	O
20	nuclear	O
21	factors	O
22	present	O
23	in	O
24	human	O
25	brain	O
26	cells	O
27	.	O

1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	O
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	DNA	O
5	using	O
6	flow	O
7	cytometry	O
8	and	O
9	immunocytochemical	O
10	findings	O
11	in	O
12	16	O
13	cases	O
14	of	O
15	cardiac	O
16	myxomas	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	spontaneous	O
6	recovery	O
7	of	O
8	central	O
9	respiratory	O
10	function	O
11	after	O
12	intoxication	O
13	with	O
14	Soman	O
15	or	O
16	Sarin	B
17	may	O
18	not	O
19	be	O
20	related	O
21	to	O
22	the	O
23	return	O
24	of	O
25	AChE	B
26	activity	O
27	.	O

1	Protein	B
2	C	I
3	deficiency	O
4	or	O
5	protein	B
6	S	I
7	deficiency	O
8	was	O
9	the	O
10	only	O
11	identified	O
12	risk	O
13	factor	O
14	for	O
15	5	O
16	.	O
17	4	O
18	%	O
19	(	O
20	2	O
21	patients	O
22	)	O
23	and	O
24	13	O
25	.	O
26	5	O
27	%	O
28	(	O
29	5	O
30	patients	O
31	),	O
32	respectively	O
33	,	O
34	of	O
35	these	O
36	37	O
37	children	O
38	.	O

1	On	O
2	line	O
3	calculation	O
4	of	O
5	steroid	O
6	concentrations	O
7	by	O
8	radioimmunoassay	O

1	Horvath	O
2	,	O
3	I	O
4	.	O

1	We	O
2	studied	O
3	GSH	B
4	-	I
5	Px	I
6	enzyme	I
7	activity	O
8	in	O
9	serum	O
10	after	O
11	acute	O
12	myocardial	O
13	infarction	O
14	(	O
15	AMI	O
16	)	O
17	and	O
18	unstable	O
19	angina	O
20	pectoris	O
21	(	O
22	UAP	O
23	).	O

1	The	O
2	products	O
3	of	O
4	genes	O
5	ura10	O
6	and	O
7	ura3	O
8	are	O
9	proposed	O
10	to	O
11	participate	O
12	in	O
13	the	O
14	channeling	O
15	of	O
16	orotidine	O
17	monophosphate	O
18	.	O

1	Structural	O
2	basis	O
3	for	O
4	activation	O
5	of	O
6	human	O
7	lymphocyte	O
8	kinase	O
9	Lck	O
10	upon	O
11	tyrosine	O
12	phosphorylation	O
13	.	O

1	The	O
2	most	O
3	common	O
4	risk	O
5	factor	O
6	reported	O
7	for	O
8	both	O
9	recent	O
10	and	O
11	all	O
12	other	O
13	hepatitis	O
14	C	O
15	cases	O
16	was	O
17	a	O
18	history	O
19	of	O
20	injecting	O
21	drug	O
22	use	O
23	,	O
24	although	O
25	the	O
26	proportion	O
27	of	O
28	cases	O
29	with	O
30	that	O
31	history	O
32	was	O
33	different	O
34	in	O
35	NT	O
36	from	O
37	ACT	O
38	and	O
39	Queensland	O
40	.	O

1	Prostacyclin	O
2	formation	O
3	,	O
4	reflected	O
5	by	O
6	the	O
7	excretion	O
8	rate	O
9	of	O
10	its	O
11	stable	O
12	metabolite	O
13	6	O
14	-	O
15	keto	O
16	-	O
17	prostaglandin	O
18	F1	O
19	alpha	O
20	,	O
21	was	O
22	measured	O
23	by	O
24	means	O
25	of	O
26	radioimmunoassay	O
27	in	O
28	4	O
29	-	O
30	hour	O
31	urine	O
32	specimens	O
33	obtained	O
34	during	O
35	a	O
36	smoking	O
37	-	O
38	free	O
39	period	O
40	and	O
41	after	O
42	participants	O
43	had	O
44	inhaled	O
45	smoke	O
46	from	O
47	four	O
48	high	O
49	-	O
50	nicotine	O
51	cigarettes	O
52	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	trans	O
6	-	O
7	activation	O
8	from	O
9	the	O
10	prothymosin	B
11	intron	I
12	enhancer	I
13	is	O
14	a	O
15	faithful	O
16	reflection	O
17	of	O
18	the	O
19	transforming	O
20	properties	O
21	of	O
22	the	O
23	Myc	B
24	protein	I
25	.	O

1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	soybean	B
9	actin	I
10	genes	I
11	contain	O
12	many	O
13	unusual	O
14	features	O
15	including	O
16	(	O
17	CT	O
18	)	O
19	repeats	O
20	and	O
21	long	O
22	stretches	O
23	of	O
24	pyrimidine	O
25	-	O
26	rich	O
27	DNA	O
28	.	O

1	The	O
2	examination	O
3	must	O
4	include	O
5	T1	O
6	and	O
7	T2	O
8	sequences	O
9	and	O
10	scans	O
11	in	O
12	three	O
13	planes	O
14	.	O

1	Further	O
2	,	O
3	we	O
4	show	O
5	that	O
6	this	O
7	EIA	O
8	-	O
9	inducible	O
10	CBF	B
11	/	O
12	cdc2	B
13	is	O
14	related	O
15	to	O
16	the	O
17	CBF	O
18	which	O
19	was	O
20	shown	O
21	to	O
22	activate	O
23	the	O
24	heat	B
25	shock	I
26	protein	I
27	70	I
28	promoter	I
29	.	O

1	This	O
2	intracellular	O
3	signaling	O
4	,	O
5	known	O
6	as	O
7	the	O
8	unfolded	O
9	protein	O
10	response	O
11	(	O
12	UPR	O
13	),	O
14	is	O
15	mediated	O
16	by	O
17	the	O
18	cis	O
19	-	O
20	acting	O
21	ER	O
22	stress	O
23	response	O
24	element	O
25	(	O
26	ERSE	O
27	)	O
28	in	O
29	mammals	O
30	.	O

1	IgM	B
2	and	O
3	IgG	B
4	anti	I
5	A	I
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	coactivator	O
5	CREB	B
6	-	I
7	binding	I
8	protein	I
9	relieved	O
10	the	O
11	transcriptional	O
12	repression	O
13	of	O
14	PPARalphawt	B
15	by	O
16	PPARalphatr	B
17	,	O
18	suggesting	O
19	that	O
20	the	O
21	dominant	O
22	negative	O
23	effect	O
24	of	O
25	PPARalphatr	B
26	might	O
27	occur	O
28	through	O
29	competition	O
30	for	O
31	essential	O
32	coactivators	O
33	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	O
27	/	O
28	gp46	B
29	complex	I
30	.	O

1	Accumulated	O
2	evidence	O
3	indicates	O
4	that	O
5	,	O
6	upon	O
7	stimulation	O
8	with	O
9	interferon	B
10	-	I
11	gamma	I
12	(	O
13	IFN	B
14	-	I
15	gamma	I
16	),	O
17	three	O
18	beta	O
19	-	O
20	type	O
21	subunits	O
22	,	O
23	designated	O
24	LMP2	B
25	,	O
26	LMP7	B
27	,	O
28	and	O
29	PSMB10	B
30	,	O
31	are	O
32	incorporated	O
33	into	O
34	the	O
35	20S	B
36	proteasome	I
37	by	O
38	displacing	O
39	the	O
40	housekeeping	O
41	beta	O
42	-	O
43	type	O
44	subunits	O
45	designated	O
46	PSMB6	B
47	,	O
48	PSMB5	B
49	,	O
50	and	O
51	PSMB7	B
52	,	O
53	respectively	O
54	.	O

1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	B
19	Rf3	I
20	allele	I
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	O
35	and	O
36	urf209	O
37	processing	O
38	activities	O
39	.	O

1	They	O
2	are	O
3	subdivided	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O

1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	O
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	O
25	-	O
26	coding	O
27	sequence	O
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O

1	In	O
2	44	O
3	evaluable	O
4	patients	O
5	the	O
6	response	O
7	rate	O
8	was	O
9	50	O
10	%,	O
11	with	O
12	one	O
13	complete	O
14	response	O
15	.	O

1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O

1	Resultant	O
2	activation	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	N	I
8	-	I
9	terminal	I
10	kinase	I
11	/	O
12	stress	B
13	-	I
14	activated	I
15	protein	I
16	kinase	I
17	(	O
18	JNK	B
19	/	O
20	SAPK	B
21	).	O

1	The	O
2	mutants	O
3	were	O
4	obtained	O
5	by	O
6	substitution	O
7	into	O
8	a	O
9	molecular	O
10	clone	O
11	of	O
12	M	O
13	-	O
14	MuLV	O
15	DNA	O
16	by	O
17	DNA	O
18	from	O
19	two	O
20	acutely	O
21	transforming	O
22	viruses	O
23	,	O
24	Ableson	O
25	MuLV	O
26	(	O
27	Ab	O
28	-	O
29	MuLV	O
30	)	O
31	and	O
32	Moloney	O
33	murine	O
34	sarcoma	O
35	virus	O
36	(	O
37	M	O
38	-	O
39	MSV	O
40	).	O

1	The	O
2	importance	O
3	of	O
4	posttranslational	O
5	regulation	O
6	of	O
7	p15INK4B	B
8	by	O
9	TGF	B
10	-	I
11	beta	I
12	is	O
13	underlined	O
14	by	O
15	the	O
16	observation	O
17	that	O
18	in	O
19	TGF	B
20	-	I
21	beta	I
22	-	O
23	resistant	O
24	184A1L5R	O
25	,	O
26	although	O
27	the	O
28	p15	B
29	transcript	I
30	increased	O
31	,	O
32	p15INK4B	B
33	protein	I
34	was	O
35	not	O
36	stabilized	O
37	and	O
38	did	O
39	not	O
40	accumulate	O
41	,	O
42	and	O
43	cyclin	B
44	D1	I
45	-	O
46	cdk	O
47	association	O
48	and	O
49	kinase	O
50	activation	O
51	were	O
52	not	O
53	inhibited	O
54	.	O

1	As	O
2	the	O
3	components	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	at	O
9	least	O
10	five	O
11	TRBPs	B
12	(	O
13	p30	O
14	,	O
15	p37	O
16	,	O
17	p46	B
18	,	O
19	p50	B
20	,	O
21	and	O
22	p56	B
23	)	O
24	showing	O
25	specific	O
26	binding	O
27	to	O
28	the	O
29	TAR	O
30	RNA	O
31	were	O
32	detected	O
33	in	O
34	the	O
35	uv	O
36	cross	O
37	-	O
38	linking	O
39	assay	O
40	.	O

1	During	O
2	the	O
3	dose	O
4	-	O
5	finding	O
6	,	O
7	two	O
8	patients	O
9	were	O
10	temporarily	O
11	withdrawn	O
12	from	O
13	medication	O
14	and	O
15	one	O
16	patient	O
17	was	O
18	excluded	O
19	because	O
20	of	O
21	elevated	O
22	levels	O
23	of	O
24	liver	O
25	enzymes	O
26	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	identified	O
6	four	O
7	open	O
8	reading	O
9	frames	O
10	(	O
11	ORFs	O
12	)	O
13	which	O
14	are	O
15	designated	O
16	UL1	B
17	,	O
18	UL2	B
19	,	O
20	UL3	B
21	,	O
22	and	O
23	UL3	O
24	.	O
25	5	O
26	based	O
27	on	O
28	their	O
29	homology	O
30	with	O
31	proteins	O
32	of	O
33	herpes	B
34	simplex	I
35	virus	I
36	-	I
37	1	I
38	(	I
39	HSV	I
40	-	I
41	1	I
42	),	O
43	pseudorabies	O
44	virus	O
45	(	O
46	PRV	O
47	),	O
48	equine	O
49	herpesvirus	O
50	-	O
51	1	O
52	,	O
53	and	O
54	varicella	O
55	-	O
56	zoster	O
57	virus	O
58	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	O
17	resistance	O
18	gene	O
19	region	O
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	This	O
2	transition	O
3	is	O
4	regulated	O
5	positively	O
6	by	O
7	G1	O
8	-	O
9	specific	O
10	cyclin	B
11	-	I
12	dependent	I
13	kinases	I
14	(	O
15	cdks	B
16	)	O
17	and	O
18	negatively	O
19	by	O
20	the	O
21	product	O
22	of	O
23	the	O
24	retinoblastoma	B
25	tumour	I
26	suppressor	I
27	gene	I
28	,	O
29	pRb	B
30	.	O

1	Leukocyte	O
2	cultures	O
3	,	O
4	prepared	O
5	from	O
6	blood	O
7	drawn	O
8	from	O
9	these	O
10	18	O
11	children	O
12	at	O
13	6	O
14	months	O
15	of	O
16	age	O
17	,	O
18	produced	O
19	lower	O
20	yields	O
21	of	O
22	IFN	B
23	than	O
24	those	O
25	of	O
26	the	O
27	remaining	O
28	53	O
29	children	O
30	,	O
31	when	O
32	stimulated	O
33	with	O
34	adenovirus	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	coronavirus	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	001	O
49	)	O
50	or	O
51	rhinovirus	O
52	(	O
53	P	O
54	=	O
55	0	O
56	.	O
57	002	O
58	).	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	myocardial	O
5	uptake	O
6	of	O
7	99mTc	O
8	sestamibi	O
9	in	O
10	normal	O
11	subjects	O
12	and	O
13	patients	O
14	with	O
15	coronary	O
16	artery	O
17	disease	O
18	is	O
19	comparable	O
20	after	O
21	exercise	O
22	,	O
23	dipyridamole	O
24	,	O
25	and	O
26	adenosine	O
27	stress	O
28	.	O

1	1	O
2	,	O
3	among	O
4	which	O
5	nine	O
6	have	O
7	been	O
8	cloned	O
9	and	O
10	two	O
11	(	O
12	potentially	O
13	functional	O
14	)	O
15	sequenced	O
16	.	O

1	In	O
2	rubella	O
3	patients	O
4	with	O
5	serologic	O
6	confirmation	O
7	by	O
8	HI	B
9	,	O
10	the	O
11	IF	O
12	test	O
13	detected	O
14	significant	O
15	rises	O
16	in	O
17	219	O
18	(	O
19	99	O
20	.	O
21	1	O
22	%)	O
23	of	O
24	221	O
25	patients	O
26	and	O
27	the	O
28	PHA	B
29	test	O
30	detected	O
31	antibody	O
32	conversion	O
33	in	O
34	68	O
35	(	O
36	93	O
37	%)	O
38	of	O
39	73	O
40	patients	O
41	.	O

1	The	O
2	results	O
3	of	O
4	induced	O
5	coexpression	O
6	were	O
7	also	O
8	supported	O
9	by	O
10	rapid	O
11	generation	O
12	of	O
13	FeLV	B
14	recombinants	I
15	when	O
16	FeLV	B
17	-	I
18	C	I
19	was	O
20	used	O
21	to	O
22	infect	O
23	the	O
24	feline	O
25	3201B	O
26	cell	O
27	line	O
28	that	O
29	constitutively	O
30	expresses	O
31	high	O
32	levels	O
33	of	O
34	endogenous	O
35	FeLV	B
36	-	I
37	specific	I
38	mRNAs	I
39	.	O

1	Patients	O
2	with	O
3	detectable	O
4	serum	O
5	TNF	B
6	levels	O
7	had	O
8	significantly	O
9	lower	O
10	serum	O
11	T3	O
12	concentrations	O
13	compared	O
14	to	O
15	those	O
16	with	O
17	undetectable	O
18	levels	O
19	[	O
20	1	O
21	.	O
22	072	O
23	+/-	O
24	0	O
25	.	O
26	588	O
27	vs	O
28	.	O

1	The	O
2	mouse	B
3	beta	I
4	2	I
5	-	I
6	syntrophin	I
7	gene	I
8	(	O
9	>	O
10	33	O
11	kilobases	O
12	)	O
13	contains	O
14	seven	O
15	exons	O
16	,	O
17	all	O
18	of	O
19	which	O
20	have	O
21	homologues	O
22	at	O
23	the	O
24	corresponding	O
25	position	O
26	in	O
27	the	O
28	alpha	B
29	1	I
30	-	I
31	syntrophin	I
32	gene	I
33	.	O

1	In	O
2	the	O
3	point	O
4	mutant	O
5	we	O
6	observed	O
7	normal	O
8	repair	O
9	of	O
10	endonuclease	B
11	III	I
12	site	I
13	(	O
14	i	O
15	.	O
16	e	O
17	.	O
18	as	O
19	wild	O
20	type	O
21	),	O
22	but	O
23	no	O
24	removal	O
25	of	O
26	CPDs	O
27	at	O
28	the	O
29	MAT	B
30	alpha	I
31	and	O
32	HML	B
33	alpha	I
34	loci	I
35	.	O

1	Survey	O
2	on	O
3	antibody	O
4	against	O
5	egg	O
6	drop	O
7	syndrome	O
8	-	O
9	1976	O
10	virus	O
11	among	O
12	chicken	O
13	flocks	O
14	in	O
15	Japan	O
16	.	O

1	Homozygous	O
2	mutation	O
3	in	O
4	two	O
5	children	O
6	led	O
7	to	O
8	amputation	O
9	of	O
10	legs	O
11	due	O
12	to	O
13	purpura	O
14	fulminans	O
15	.	O

1	Thus	O
2	,	O
3	these	O
4	studies	O
5	on	O
6	rat	B
7	Std	I
8	promoter	I
9	function	O
10	indicate	O
11	that	O
12	(	O
13	i	O
14	)	O
15	HNF1	B
16	and	O
17	C	B
18	/	I
19	EBP	I
20	are	O
21	responsible	O
22	for	O
23	liver	O
24	specificity	O
25	of	O
26	the	O
27	rat	B
28	Std	I
29	gene	I
30	;	O
31	(	O
32	ii	O
33	)	O
34	androgenic	O
35	repression	O
36	of	O
37	the	O
38	gene	O
39	requires	O
40	the	O
41	presence	O
42	of	O
43	all	O
44	of	O
45	the	O
46	OCT	B
47	-	I
48	1	I
49	and	O
50	C	B
51	/	I
52	EBP	I
53	elements	I
54	between	O
55	positions	O
56	-	O
57	231	O
58	and	O
59	-	O
60	292	O
61	;	O
62	and	O
63	(	O
64	iii	O
65	)	O
66	AR	O
67	may	O
68	exert	O
69	its	O
70	negative	O
71	regulatory	O
72	effect	O
73	indirectly	O
74	through	O
75	transcriptional	O
76	interference	O
77	of	O
78	OCT	B
79	-	I
80	1	I
81	and	O
82	C	B
83	/	I
84	EBP	I
85	rather	O
86	than	O
87	through	O
88	a	O
89	direct	O
90	DNA	O
91	-	O
92	AR	B
93	interaction	O
94	.	O

1	Mortality	O
2	on	O
3	the	O
4	last	O
5	ranch	O
6	was	O
7	particularly	O
8	severe	O
9	among	O
10	certain	O
11	segregated	O
12	groups	O
13	of	O
14	turkeys	O
15	that	O
16	included	O
17	toms	O
18	,	O
19	heavier	O
20	birds	O
21	,	O
22	and	O
23	birds	O
24	undergoing	O
25	a	O
26	stressful	O
27	event	O
28	such	O
29	as	O
30	artificial	O
31	insemination	O
32	.	O

1	METHODS	O
2	:	O
3	We	O
4	studied	O
5	20	O
6	symptomatic	O
7	patients	O
8	with	O
9	HOCM	O
10	(	O
11	12	O
12	men	O
13	),	O
14	mean	O
15	age	O
16	52	O
17	+/-	O
18	17	O
19	years	O
20	,	O
21	before	O
22	and	O
23	after	O
24	septal	O
25	reduction	O
26	using	O
27	echocardiography	O
28	and	O
29	electrocardiogram	O
30	(	O
31	ECG	O
32	).	O

1	The	O
2	transposon	O
3	-	O
4	inactivated	O
5	gene	O
6	,	O
7	designated	O
8	pilP	B
9	,	O
10	is	O
11	525	O
12	bp	O
13	long	O
14	,	O
15	potentially	O
16	encoding	O
17	a	O
18	19	O
19	.	O
20	1	O
21	-	O
22	kDa	O
23	protein	O
24	precursor	O
25	that	O
26	contains	O
27	a	O
28	typical	O
29	membrane	O
30	lipoprotein	O
31	leader	O
32	sequence	O
33	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	an	O
6	AACA	O
7	motif	O
8	,	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	be	O
14	a	O
15	negative	O
16	regulator	O
17	in	O
18	non	O
19	-	O
20	seed	O
21	tissues	O
22	and	O
23	has	O
24	a	O
25	similarity	O
26	to	O
27	the	O
28	barley	O
29	gibberellin	O
30	responsive	O
31	element	O
32	recognized	O
33	by	O
34	MYB	B
35	-	I
36	like	I
37	DNA	I
38	binding	I
39	proteins	I
40	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterized	O
6	the	O
7	GCD6	B
8	and	O
9	GCD7	B
10	genes	I
11	and	O
12	shown	O
13	that	O
14	their	O
15	products	O
16	are	O
17	required	O
18	to	O
19	repress	O
20	GCN4	B
21	translation	O
22	under	O
23	nonstarvation	O
24	conditions	O
25	.	O

1	Acute	O
2	type	O
3	A	O
4	hepatitis	O
5	in	O
6	three	O
7	patients	O
8	with	O
9	chronic	O
10	HBV	O
11	infection	O
12	.	O

1	135	O
2	students	O
3	had	O
4	a	O
5	count	O
6	of	O
7	less	O
8	than	O
9	50	O
10	eggs	O
11	/	O
12	10	O
13	ml	O
14	.	O
15	urine	O
16	and	O
17	56	O
18	had	O
19	more	O
20	than	O
21	50	O
22	eggs	O
23	/	O
24	10ml	O
25	.	O

1	The	O
2	final	O
3	predicted	O
4	structure	O
5	has	O
6	an	O
7	overall	O
8	backbone	O
9	deviation	O
10	of	O
11	0	O
12	.	O
13	7	O
14	A	O
15	from	O
16	that	O
17	of	O
18	ras	B
19	-	O
20	p21	B
21	.	O

1	The	O
2	individual	O
3	subunits	O
4	of	O
5	Ku	B
6	have	O
7	been	O
8	difficult	O
9	to	O
10	isolate	O
11	from	O
12	human	O
13	cells	O
14	without	O
15	denaturation	O
16	and	O
17	attempts	O
18	to	O
19	produce	O
20	functional	O
21	recombinant	O
22	Ku	O
23	have	O
24	been	O
25	largely	O
26	unsuccessful	O
27	.	O

1	Aryl	B
2	hydrocarbon	I
3	receptor	I
4	nuclear	I
5	translocator	I
6	(	O
7	ARNT	B
8	)	O
9	is	O
10	a	O
11	component	O
12	of	O
13	the	O
14	transcription	O
15	factors	O
16	,	O
17	aryl	B
18	hydrocarbon	I
19	receptor	I
20	(	O
21	AhR	B
22	)	O
23	and	O
24	hypoxia	B
25	-	I
26	inducible	I
27	factor	I
28	1	I
29	,	O
30	which	O
31	transactivate	O
32	their	O
33	target	O
34	genes	O
35	,	O
36	such	O
37	as	O
38	CYP1A1	B
39	and	O
40	erythropoietin	B
41	,	O
42	in	O
43	response	O
44	to	O
45	xenobiotic	O
46	aromatic	O
47	hydrocarbons	O
48	and	O
49	to	O
50	low	O
51	O2	O
52	concentration	O
53	,	O
54	respectively	O
55	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	gp54	O
6	structural	O
7	gene	O
8	is	O
9	required	O
10	for	O
11	initiation	O
12	or	O
13	amplification	O
14	of	O
15	the	O
16	splenic	O
17	erythroblast	O
18	hyperplasia	O
19	which	O
20	characterizes	O
21	the	O
22	preleukemic	O
23	phase	O
24	of	O
25	Rauscher	O
26	disease	O
27	.	O

1	The	O
2	concentrations	O
3	of	O
4	C4	O
5	and	O
6	C1	B
7	-	I
8	INH	I
9	increased	O
10	with	O
11	advancing	O
12	stage	O
13	of	O
14	disease	O
15	and	O
16	were	O
17	above	O
18	normal	O
19	mean	O
20	values	O
21	in	O
22	all	O
23	stages	O
24	.	O

1	Using	O
2	a	O
3	degenerate	O
4	oligodeoxyribonucleotide	O
5	(	O
6	oligo	O
7	)	O
8	based	O
9	on	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	aa	O
15	sequence	O
16	,	O
17	plus	O
18	an	O
19	internal	O
20	oligo	O
21	homologous	O
22	to	O
23	a	O
24	conserved	O
25	region	O
26	within	O
27	the	O
28	portion	O
29	of	O
30	CYP1	B
31	and	O
32	CYP2	O
33	that	O
34	had	O
35	been	O
36	deleted	O
37	in	O
38	the	O
39	genome	O
40	,	O
41	a	O
42	CYP3	O
43	-	O
44	specific	O
45	DNA	O
46	fragment	O
47	was	O
48	generated	O
49	by	O
50	the	O
51	polymerase	O
52	chain	O
53	reaction	O
54	(	O
55	PCR	O
56	)	O
57	using	O
58	GL81	O
59	genomic	O
60	DNA	O
61	as	O
62	a	O
63	substrate	O
64	.	O

1	AIDS	O
2	-	O
3	related	O
4	disseminated	O
5	histoplasmosis	O
6	in	O
7	San	O
8	Francisco	O
9	,	O
10	California	O
11	.	O

1	The	O
2	hemodynamics	O
3	of	O
4	isoproterenol	O
5	-	O
6	induced	O
7	cardiac	O
8	failure	O
9	in	O
10	the	O
11	rat	O
12	.	O

1	Moreover	O
2	,	O
3	we	O
4	found	O
5	that	O
6	cyclin	B
7	E	I
8	,	O
9	in	O
10	contrast	O
11	to	O
12	cyclin	B
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	O
24	in	O
25	cells	O
26	lacking	O
27	retinoblastoma	B
28	protein	I
29	function	O
30	.	O

1	The	O
2	junctions	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	O
8	were	O
9	determined	O
10	by	O
11	DNA	O
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	517	O
17	nucleotides	O
18	into	O
19	the	O
20	p30	O
21	sequence	O
22	and	O
23	1	O
24	,	O
25	920	O
26	nucleotides	O
27	into	O
28	the	O
29	polymerase	O
30	sequence	O
31	.	O

1	Role	O
2	of	O
3	the	O
4	infectious	O
5	-	O
6	disease	O
7	specialist	O
8	of	O
9	a	O
10	polyclinic	O
11	in	O
12	reducing	O
13	the	O
14	incidence	O
15	of	O
16	communicable	O
17	diseases	O

1	Adding	O
2	phytase	O
3	and	O
4	nP	O
5	improved	O
6	the	O
7	orderliness	O
8	of	O
9	development	O
10	,	O
11	mineralization	O
12	and	O
13	arrangement	O
14	of	O
15	cartilage	O
16	and	O
17	bone	O
18	cells	O
19	,	O
20	and	O
21	alleviated	O
22	the	O
23	effects	O
24	of	O
25	P	O
26	deficiency	O
27	on	O
28	the	O
29	histological	O
30	and	O
31	gross	O
32	structure	O
33	of	O
34	the	O
35	tibias	O
36	.	O

1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	concurrently	O
12	with	O
13	SSc	O
14	that	O
15	subsequently	O
16	progressed	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	just	O
25	1	O
26	month	O
27	.	O

1	Direct	O
2	and	O
3	inverted	O
4	repeat	O
5	elements	O
6	of	O
7	10	O
8	,	O
9	11	O
10	,	O
11	16	O
12	,	O
13	19	O
14	,	O
15	and	O
16	22	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	flank	O
22	the	O
23	promoter	O
24	site	O
25	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	tip	O
6	acts	O
7	at	O
8	an	O
9	early	O
10	stage	O
11	of	O
12	the	O
13	T	O
14	-	O
15	cell	O
16	signal	O
17	transduction	O
18	cascade	O
19	by	O
20	associating	O
21	with	O
22	Lck	B
23	and	O
24	downregulating	O
25	Lck	B
26	-	O
27	mediated	O
28	activation	O
29	.	O

1	Endothelium	O
2	of	O
3	the	O
4	central	O
5	ear	O
6	artery	O
7	of	O
8	an	O
9	anesthetized	O
10	rabbit	O
11	is	O
12	damaged	O
13	by	O
14	placing	O
15	artery	O
16	forceps	O
17	on	O
18	the	O
19	ear	O
20	directly	O
21	over	O
22	the	O
23	vessel	O
24	.	O

1	ZIOS	O
2	was	O
3	significantly	O
4	more	O
5	sensitive	O
6	than	O
7	all	O
8	subsequent	O
9	methods	O
10	,	O
11	and	O
12	Ptc	B
13	,	O
14	O2	O
15	was	O
16	significantly	O
17	more	O
18	sensitive	O
19	than	O
20	FEV1	O
21	.	O

1	The	O
2	non	O
3	-	O
4	homologous	O
5	sequences	O
6	in	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	regions	O
12	might	O
13	be	O
14	acquired	O
15	at	O
16	or	O
17	after	O
18	transcription	O
19	during	O
20	retrotransposition	O
21	of	O
22	the	O
23	ATLN	O
24	elements	O
25	.	O

1	Breitbart	O
2	,	O
3	L	O
4	.	O

1	However	O
2	,	O
3	alterations	O
4	in	O
5	electrostatic	O
6	and	O
7	hydrophobic	O
8	interactions	O
9	created	O
10	by	O
11	the	O
12	three	O
13	amino	O
14	acid	O
15	substitutions	O
16	prevent	O
17	the	O
18	conformational	O
19	change	O
20	in	O
21	the	O
22	enzyme	O
23	usually	O
24	produced	O
25	by	O
26	calmodulin	B
27	binding	O
28	.	O

1	No	O
2	significant	O
3	differences	O
4	existed	O
5	between	O
6	the	O
7	two	O
8	age	O
9	groups	O
10	in	O
11	baseline	O
12	characteristics	O
13	,	O
14	including	O
15	treatment	O
16	protocol	O
17	,	O
18	performance	O
19	status	O
20	,	O
21	and	O
22	serum	O
23	lactate	B
24	dehydrogenase	I
25	(	O
26	LDH	B
27	)	O
28	level	O
29	.	O

1	In	O
2	addition	O
3	,	O
4	both	O
5	the	O
6	exon	O
7	1	O
8	-	O
9	and	O
10	exon	O
11	2	O
12	-	O
13	initiated	O
14	forms	O
15	of	O
16	the	O
17	c	B
18	-	I
19	Myc	I
20	protein	I
21	stimulated	O
22	transcription	O
23	of	O
24	a	O
25	Myc	B
26	/	O
27	Max	B
28	-	O
29	responsive	O
30	reporter	O
31	construct	O
32	to	O
33	a	O
34	similar	O
35	level	O
36	.	O

1	A	O
2	proportion	O
3	of	O
4	APC	B
5	wild	O
6	-	O
7	type	O
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	I
20	beta	I
21	-	I
22	catenin	I
23	complexes	I
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	B
29	mutations	I
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	B
52	/	I
53	Conductin	I
54	.	O

1	A	O
2	limited	O
3	sampling	O
4	strategy	O
5	was	O
6	used	O
7	based	O
8	on	O
9	a	O
10	bayesian	O
11	parameter	O
12	estimation	O
13	algorithm	O
14	that	O
15	is	O
16	part	O
17	of	O
18	the	O
19	ADAPT	B
20	II	I
21	software	O
22	package	O
23	.	O

1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O

1	Resistance	O
2	pattern	O
3	of	O
4	Mycobacterium	O
5	tuberculosis	O
6	(	O
7	H	O
8	37	O
9	Rv	O
10	)	O
11	to	O
12	a	O
13	new	O
14	antibiotic	O
15	,	O
16	lividomycin	O

1	Myocardial	O
2	infarction	O
3	in	O
4	patients	O
5	with	O
6	previous	O
7	bypass	O
8	surgery	O
9	.	O

1	Mutation	O
2	analysis	O
3	implicated	O
4	multiple	O
5	segments	O
6	of	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	region	O
12	as	O
13	contributing	O
14	to	O
15	the	O
16	inhibitory	O
17	effect	O
18	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	influence	O
6	of	O
7	NaFe3	O
8	+	O
9	EDTA	O
10	,	O
11	and	O
12	of	O
13	increasing	O
14	dietary	O
15	levels	O
16	of	O
17	Na2EDTA	O
18	,	O
19	on	O
20	Zn	O
21	,	O
22	Cu	O
23	and	O
24	Ca	O
25	metabolism	O
26	in	O
27	rats	O
28	fed	O
29	on	O
30	Zn	O
31	-	O
32	sufficient	O
33	and	O
34	Zn	O
35	-	O
36	deficient	O
37	soya	O
38	-	O
39	bean	O
40	-	O
41	isolate	O
42	-	O
43	based	O
44	diets	O
45	.	O

1	The	O
2	experiment	O
3	included	O
4	6	O
5	male	O
6	and	O
7	4	O
8	female	O
9	healthy	O
10	subjects	O
11	who	O
12	,	O
13	during	O
14	a	O
15	24	O
16	-	O
17	hour	O
18	stay	O
19	in	O
20	the	O
21	respiration	O
22	chambers	O
23	,	O
24	performed	O
25	,	O
26	in	O
27	the	O
28	morning	O
29	and	O
30	afternoon	O
31	,	O
32	15	O
33	min	O
34	cycling	O
35	with	O
36	the	O
37	total	O
38	work	O
39	of	O
40	6	O
41	,	O
42	750	O
43	kg	O
44	m	O
45	.	O

1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	Ca2	O
10	+-	O
11	bound	O
12	rat	B
13	S100B	I
14	(	I
15	beta	I
16	beta	I
17	)	O
18	upon	O
19	binding	O
20	to	O
21	a	O
22	peptide	O
23	derived	O
24	from	O
25	the	O
26	C	O
27	-	O
28	terminal	O
29	regulatory	O
30	domain	O
31	of	O
32	p53	B
33	.	O

1	The	O
2	growth	O
3	of	O
4	Aer	O
5	.	O
6	hydrophila	O
7	in	O
8	filter	O
9	-	O
10	sterilized	O
11	lettuce	O
12	extract	O
13	was	O
14	completely	O
15	inhibited	O
16	by	O
17	0	O
18	.	O
19	1	O
20	%	O
21	(	O
22	v	O
23	/	O
24	v	O
25	)	O
26	BMC	O
27	whereas	O
28	that	O
29	of	O
30	Ps	O
31	.	O
32	fluorescens	O
33	was	O
34	not	O
35	significantly	O
36	affected	O
37	by	O
38	1	O
39	%	O
40	(	O
41	v	O
42	/	O
43	v	O
44	)	O
45	BMC	O
46	.	O

1	W	O
2	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	demonstrated	O
7	a	O
8	unique	O
9	mechanism	O
10	of	O
11	action	O
12	of	O
13	8	O
14	-	O
15	Cl	O
16	-	O
17	cAMP	O
18	in	O
19	the	O
20	regulation	O
21	of	O
22	these	O
23	kinase	O
24	isozymes	O
25	in	O
26	HL	O
27	-	O
28	60	O
29	human	O
30	promyelocytic	O
31	leukemia	O
32	cells	O
33	.	O

1	The	O
2	bZP2	B
3	cDNA	I
4	(	O
5	115	O
6	-	O
7	1914	O
8	nt	O
9	,	O
10	1	O
11	.	O
12	8	O
13	kb	O
14	),	O
15	excluding	O
16	sequences	O
17	coding	O
18	for	O
19	N	O
20	-	O
21	terminal	O
22	signal	O
23	sequence	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	transmembranelike	O
29	domain	O
30	,	O
31	was	O
32	PCR	O
33	amplified	O
34	and	O
35	Sac1	B
36	-	O
37	Sal1	O
38	restricted	O
39	fragment	O
40	cloned	O
41	in	O
42	frame	O
43	downstream	O
44	of	O
45	the	O
46	T5	B
47	promoter	I
48	under	O
49	the	O
50	lac	B
51	operator	I
52	control	O
53	in	O
54	a	O
55	pQE	O
56	-	O
57	30	O
58	vector	O
59	.	O

1	Serum	O
2	IgE	B
3	levels	O
4	in	O
5	Tauranga	O
6	children	O
7	.	O

1	MOP5	O
2	contained	O
3	the	O
4	characteristic	O
5	PAS	O
6	domain	O
7	and	O
8	a	O
9	variable	O
10	C	O
11	terminus	O
12	;	O
13	it	O
14	is	O
15	possible	O
16	that	O
17	the	O
18	cDNA	O
19	contains	O
20	a	O
21	bHLH	B
22	domain	I
23	,	O
24	but	O
25	the	O
26	entire	O
27	open	O
28	reading	O
29	frame	O
30	has	O
31	yet	O
32	to	O
33	be	O
34	completed	O
35	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	B
14	protein	I
15	molecule	I
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O

1	Whole	O
2	bowel	O
3	irrigation	O
4	is	O
5	a	O
6	recently	O
7	described	O
8	technique	O
9	to	O
10	enhance	O
11	the	O
12	passage	O
13	of	O
14	drugs	O
15	already	O
16	beyond	O
17	the	O
18	pylorus	O
19	.	O

1	Fentanyl	O
2	,	O
3	a	O
4	prototypic	O
5	mu	B
6	-	I
7	opiate	I
8	receptor	I
9	agonist	O
10	,	O
11	has	O
12	been	O
13	previously	O
14	shown	O
15	to	O
16	produce	O
17	a	O
18	syndrome	O
19	characterized	O
20	by	O
21	marked	O
22	analgesia	O
23	and	O
24	locomotor	O
25	stimulation	O
26	as	O
27	well	O
28	as	O
29	tachycardia	O
30	,	O
31	tachypnoea	O
32	and	O
33	behavioural	O
34	arousal	O
35	.	O

1	The	O
2	evaluation	O
3	of	O
4	amniotic	B
5	fluid	I
6	delta	I
7	OD450	I
8	is	O
9	considered	O
10	to	O
11	be	O
12	the	O
13	cornerstone	O
14	of	O
15	clinical	O
16	management	O
17	.	O

1	Protein	B
2	phosphatase	I
3	2A	I
4	is	O
5	a	O
6	critical	O
7	regulator	O
8	of	O
9	protein	B
10	kinase	I
11	C	I
12	zeta	I
13	signaling	O
14	targeted	O
15	by	O
16	SV40	O
17	small	O
18	t	O
19	to	O
20	promote	O
21	cell	O
22	growth	O
23	and	O
24	NF	B
25	-	I
26	kappaB	I
27	activation	O
28	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	B
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	B
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	O
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	B
21	-	I
22	type	I
23	activator	I
24	.	O

1	Transfection	O
2	analyses	O
3	indicate	O
4	that	O
5	mutation	O
6	of	O
7	any	O
8	one	O
9	of	O
10	these	O
11	TGACCT	O
12	motifs	O
13	or	O
14	truncation	O
15	of	O
16	the	O
17	entire	O
18	HD	O
19	PPRE	O
20	into	O
21	a	O
22	separate	O
23	DR1	B
24	and	O
25	DR2	O
26	element	O
27	significantly	O
28	reduced	O
29	the	O
30	transcriptional	O
31	response	O
32	of	O
33	HD	O
34	PPRE	O
35	to	O
36	peroxisome	O
37	proliferators	O
38	.	O

1	Tumours	O
2	of	O
3	the	O
4	cavum	O
5	oris	O
6	and	O
7	oropharynx	O
8	of	O
9	T1	O
10	-	O
11	stage	O
12	are	O
13	possible	O
14	only	O
15	in	O
16	1	O
17	of	O
18	3	O
19	cases	O
20	.	O

1	DATA	O
2	SOURCES	O
3	:	O
4	Epidemiologic	O
5	studies	O
6	,	O
7	research	O
8	studies	O
9	,	O
10	review	O
11	articles	O
12	,	O
13	and	O
14	government	O
15	reports	O
16	pertaining	O
17	to	O
18	epidemiology	O
19	of	O
20	lung	O
21	cancer	O
22	.	O

1	The	O
2	p36	B
3	gene	I
4	is	O
5	at	O
6	least	O
7	22	O
8	kb	O
9	in	O
10	length	O
11	and	O
12	has	O
13	a	O
14	coding	O
15	sequence	O
16	of	O
17	approximately	O
18	1	O
19	kb	O
20	,	O
21	representing	O
22	only	O
23	4	O
24	.	O
25	5	O
26	%	O
27	of	O
28	the	O
29	gene	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	Perceptions	O
2	of	O
3	illness	O
4	intrusiveness	O
5	were	O
6	significantly	O
7	higher	O
8	when	O
9	both	O
10	muscle	O
11	cramp	O
12	and	O
13	headache	O
14	symptoms	O
15	occurred	O
16	during	O
17	one	O
18	or	O
19	more	O
20	assessment	O
21	intervals	O
22	as	O
23	compared	O
24	to	O
25	when	O
26	muscle	O
27	cramps	O
28	or	O
29	headaches	O
30	,	O
31	only	O
32	,	O
33	occurred	O
34	.	O

1	The	O
2	significance	O
3	of	O
4	structural	O
5	integrity	O
6	of	O
7	lymphoid	O
8	tissue	O
9	for	O
10	antibody	O
11	production	O
12	in	O
13	culture	O
14	in	O
15	vivo	O

1	Naphthalene	O
2	and	O
3	paradichlorobenzene	O
4	in	O
5	clinical	O
6	toxicology	O

1	Using	O
2	purified	O
3	recombinant	O
4	HMG	B
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	O
20	factor	O
21	binding	O
22	sites	O
23	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	I
39	SFGR	I
40	)	I
41	antibody	I
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	O
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	O
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	Although	O
2	ANP	B
3	induced	O
4	systemic	O
5	capillary	O
6	filtration	O
7	,	O
8	in	O
9	the	O
10	calf	O
11	,	O
12	filtration	O
13	was	O
14	reduced	O
15	with	O
16	ANP	B
17	.	O

1	Despite	O
2	the	O
3	activation	O
4	of	O
5	these	O
6	intracellular	O
7	signaling	O
8	molecules	O
9	,	O
10	PDGF	B
11	beta	I
12	receptor	I
13	activation	O
14	elicited	O
15	no	O
16	detectable	O
17	effect	O
18	on	O
19	cell	O
20	proliferation	O
21	or	O
22	differentiation	O
23	.	O

1	A	O
2	DNA	O
3	fragment	O
4	encoding	O
5	the	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	(	O
11	amino	O
12	acids	O
13	1	O
14	-	O
15	60	O
16	)	O
17	of	O
18	the	O
19	Escherichia	O
20	coli	O
21	fru	O
22	transcriptional	O
23	regulator	O
24	was	O
25	cloned	O
26	into	O
27	the	O
28	pGEX	O
29	-	O
30	KT	O
31	vector	O
32	and	O
33	expressed	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	fused	O
39	gene	O
40	encoding	O
41	glutathione	B
42	S	I
43	-	I
44	transferase	I
45	.	O

1	While	O
2	the	O
3	examiner	O
4	observed	O
5	the	O
6	interior	O
7	of	O
8	the	O
9	eye	O
10	with	O
11	indirect	O
12	ophthalmoscopy	O
13	,	O
14	the	O
15	point	O
16	source	O
17	of	O
18	light	O
19	from	O
20	the	O
21	fiberoptic	O
22	light	O
23	pipe	O
24	was	O
25	moved	O
26	along	O
27	the	O
28	margins	O
29	of	O
30	the	O
31	episcleral	O
32	plaque	O
33	.	O

1	Luteinizing	B
2	hormone	I
3	-	I
4	releasing	I
5	hormone	I
6	analog	O
7	therapy	O
8	of	O
9	uterine	O
10	fibroid	O
11	:	O
12	analysis	O
13	of	O
14	results	O
15	obtained	O
16	with	O
17	buserelin	O
18	administered	O
19	intranasally	O
20	and	O
21	goserelin	O
22	administered	O
23	subcutaneously	O
24	as	O
25	a	O
26	monthly	O
27	depot	O
28	.	O

1	The	O
2	sequences	O
3	following	O
4	the	O
5	X	O
6	.	O
7	borealis	O
8	oocyte	O
9	and	O
10	somatic	B
11	5S	I
12	genes	I
13	are	O
14	identical	O
15	in	O
16	12	O
17	of	O
18	the	O
19	first	O
20	14	O
21	residues	O
22	and	O
23	contain	O
24	two	O
25	or	O
26	more	O
27	T	O
28	clusters	O
29	,	O
30	as	O
31	does	O
32	the	O
33	corresponding	O
34	region	O
35	of	O
36	X	O
37	.	O
38	laevis	O
39	oocyte	B
40	5S	I
41	DNA	I
42	.	O

1	In	O
2	mice	O
3	,	O
4	three	O
5	major	O
6	families	O
7	of	O
8	L1	O
9	elements	O
10	,	O
11	termed	O
12	"	B
13	A	I
14	,"	I
15	"	I
16	F	I
17	,"	I
18	and	O
19	"	B
20	V	I
21	,"	I
22	have	O
23	been	O
24	defined	O
25	on	O
26	the	O
27	basis	O
28	of	O
29	the	O
30	sequence	O
31	found	O
32	at	O
33	the	O
34	5	O
35	'	O
36	terminus	O
37	.	O

1	Each	O
2	binding	O
3	site	O
4	,	O
5	however	O
6	,	O
7	was	O
8	different	O
9	in	O
10	its	O
11	preference	O
12	for	O
13	binding	O
14	partners	O
15	.	O

1	In	O
2	the	O
3	37	O
4	patients	O
5	without	O
6	lung	O
7	disease	O
8	respiratory	O
9	muscle	O
10	weakness	O
11	was	O
12	accompanied	O
13	by	O
14	significant	O
15	decreases	O
16	in	O
17	vital	O
18	capacity	O
19	,	O
20	total	O
21	lung	O
22	capacity	O
23	,	O
24	and	O
25	maximum	O
26	voluntary	O
27	ventilation	O
28	;	O
29	by	O
30	significant	O
31	increases	O
32	in	O
33	residual	O
34	volume	O
35	and	O
36	arterial	O
37	carbon	O
38	dioxide	O
39	tension	O
40	(	O
41	PaCO2	O
42	);	O
43	and	O
44	greater	O
45	likelihood	O
46	of	O
47	dependence	O
48	on	O
49	ventilators	O
50	,	O
51	atelectasis	O
52	,	O
53	and	O
54	pneumonia	O
55	.	O

1	Out	O
2	of	O
3	these	O
4	families	O
5	74	O
6	,	O
7	3	O
8	%	O
9	planned	O
10	next	O
11	pregnancy	O
12	(	O
13	table	O
14	IX	O
15	),	O
16	57	O
17	,	O
18	6	O
19	%	O
20	wanted	O
21	to	O
22	have	O
23	prenatal	O
24	diagnosis	O
25	(	O
26	table	O
27	VI	O
28	).	O

1	The	O
2	LTR	O
3	-	O
4	binding	O
5	activities	O
6	of	O
7	VBP	B
8	,	O
9	a1	B
10	/	I
11	EBP	I
12	,	O
13	and	O
14	B	O
15	-	O
16	cell	O
17	nuclear	O
18	extract	O
19	protein	O
20	were	O
21	compared	O
22	and	O
23	mapped	O
24	by	O
25	gel	O
26	shift	O
27	,	O
28	DNase	B
29	I	I
30	footprinting	O
31	,	O
32	and	O
33	methylation	O
34	interference	O
35	assays	O
36	.	O

1	The	O
2	molecular	O
3	basis	O
4	for	O
5	commitment	O
6	of	O
7	progenitors	O
8	to	O
9	the	O
10	eosinophil	O
11	lineage	O
12	and	O
13	mechanisms	O
14	by	O
15	which	O
16	eosinophil	O
17	-	O
18	specific	O
19	genes	O
20	are	O
21	expressed	O
22	and	O
23	regulated	O
24	during	O
25	differentiation	O
26	is	O
27	unknown	O
28	.	O

1	Critical	O
2	evaluation	O
3	of	O
4	various	O
5	methods	O
6	of	O
7	determining	O
8	markers	O
9	of	O
10	fetal	O
11	maturity	O
12	in	O
13	amniotic	O
14	fluid	O

1	In	O
2	Group	O
3	IV	O
4	dogs	O
5	that	O
6	received	B
7	alpha	I
8	-	I
9	MSH	I
10	only	O
11	during	O
12	reperfusion	O
13	,	O
14	BAEPs	O
15	were	O
16	increased	O
17	approximately	O
18	10	O
19	to	O
20	14	O
21	%	O
22	more	O
23	than	O
24	in	O
25	Group	O
26	II	O
27	during	O
28	the	O
29	late	O
30	reperfusion	O
31	period	O
32	.	O

1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	O
18	(	O
19	70	O
20	%,	O
21	P	O
22	<	O
23	0	O
24	.	O
25	001	O
26	)	O
27	in	O
28	the	O
29	70	O
30	patients	O
31	with	O
32	CVD	O
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	B
41	,	O
42	plasma	O
43	IGF	B
44	-	I
45	1	I
46	,	O
47	serum	O
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	O
54	hemoglobin	B
55	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O

1	447	O
2	microns	O
3	for	O
4	A	O
5	.	O
6	microcephalum	O
7	and	O
8	350	O
9	microns	O
10	for	O
11	A	O
12	.	O
13	wedli	O
14	),	O
15	and	O
16	fewer	O
17	testes	O
18	per	O
19	proglottis	O
20	(	O
21	44	O
22	-	O
23	73	O
24	vs	O
25	.	O

1	It	O
2	also	O
3	contains	O
4	a	O
5	picornaviral	O
6	3C	B
7	-	I
8	like	I
9	protease	I
10	domain	I
11	and	O
12	two	O
13	papain	B
14	-	I
15	like	I
16	protease	I
17	domains	I
18	.	O

1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	The	O
6	authors	O
7	analyzed	O
8	41	O
9	persons	O
10	formerly	O
11	submitted	O
12	to	O
13	surgery	O
14	(	O
15	after	O
16	8	O
17	years	O
18	and	O
19	4	O
20	months	O
21	,	O
22	as	O
23	a	O
24	mean	O
25	),	O
26	31	O
27	to	O
28	highly	O
29	selective	O
30	vagotomy	O
31	,	O
32	and	O
33	10	O
34	to	O
35	truncal	O
36	or	O
37	selective	O
38	vagotomy	O
39	plus	O
40	gastroduodenal	O
41	drainage	O
42	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	full	O
5	-	O
6	deletion	O
7	mutant	O
8	showed	O
9	a	O
10	strong	O
11	block	O
12	in	O
13	virus	O
14	release	O
15	,	O
16	suggesting	O
17	that	O
18	NC	B
19	is	O
20	involved	O
21	in	O
22	virus	O
23	assembly	O
24	.	O

1	Nuclease	O
2	probing	O
3	and	O
4	structure	O
5	-	O
6	directed	O
7	mutagenesis	O
8	revealed	O
9	that	O
10	the	O
11	105	O
12	-	O
13	nt	O
14	TE	O
15	(	O
16	TE105	B
17	)	O
18	forms	O
19	a	O
20	cruciform	O
21	secondary	O
22	structure	O
23	containing	O
24	four	O
25	helices	O
26	connected	O
27	by	O
28	single	O
29	-	O
30	stranded	O
31	regions	O
32	.	O

1	Hypoglycemic	O
2	and	O
3	antidiabetic	O
4	properties	O

1	Cryopreservation	O
2	straws	O
3	filled	O
4	with	O
5	media	O
6	plus	O
7	additive	O
8	are	O
9	emersed	O
10	below	O
11	the	O
12	surface	O
13	of	O
14	an	O
15	unprocessed	O
16	donor	O
17	ejaculate	O
18	.	O

1	A	O
2	medical	O
3	-	O
4	geographical	O
5	review	O

1	Among	O
2	the	O
3	patients	O
4	grades	O
5	1	O
6	-	O
7	2	O
8	-	O
9	3	O
10	,	O
11	81	O
12	%	O
13	had	O
14	a	O
15	good	O
16	out	O
17	come	O
18	without	O
19	any	O
20	neurological	O
21	abnormality	O
22	,	O
23	among	O
24	the	O
25	patients	O
26	graded	O
27	4	O
28	-	O
29	5	O
30	,	O
31	only	O
32	27	O
33	%	O
34	had	O
35	a	O
36	fair	O
37	out	O
38	come	O
39	.	O

1	Cramps	O
2	in	O
3	extrapyramidal	O
4	disorders	O
5	.	O

1	An	O
2	intravenous	O
3	preparation	O
4	of	O
5	doxycycline	O
6	(	O
7	DOTC	O
8	,	O
9	Vibramycin	O
10	'	O
11	Pfizer	O
12	'),	O
13	a	O
14	long	O
15	-	O
16	lasting	O
17	tetracycline	O
18	,	O
19	was	O
20	administered	O
21	mainly	O
22	by	O
23	drip	O
24	infusion	O
25	for	O
26	a	O
27	series	O
28	of	O
29	study	O
30	in	O
31	the	O
32	pediatrics	O
33	field	O
34	,	O
35	and	O
36	the	O
37	results	O
38	were	O
39	as	O
40	follows	O
41	:	O
42	1	O
43	)	O
44	DOTC	O
45	(	O
46	100	O
47	mg	O
48	)	O
49	was	O
50	dissolved	O
51	in	O
52	a	O
53	100	O
54	ml	O
55	of	O
56	glucose	O
57	solution	O
58	and	O
59	2	O
60	--	O
61	3	O
62	mg	O
63	/	O
64	kg	O
65	was	O
66	administered	O
67	intravenously	O
68	.	O

1	Although	O
2	the	O
3	effects	O
4	of	O
5	the	O
6	calcium	O
7	supplement	O
8	or	O
9	calcium	O
10	antagonist	O
11	alone	O
12	were	O
13	significant	O
14	,	O
15	such	O
16	hypotensive	O
17	responses	O
18	were	O
19	not	O
20	optimal	O
21	or	O
22	predictable	O
23	or	O
24	clearly	O
25	dose	O
26	-	O
27	dependent	O
28	.	O

1	Thus	O
2	,	O
3	unlike	O
4	other	O
5	proteins	O
6	reported	O
7	to	O
8	inhibit	O
9	SRF	B
10	activity	O
11	,	O
12	the	O
13	repressor	O
14	activity	O
15	associated	O
16	with	O
17	the	O
18	GC	O
19	-	O
20	rich	O
21	element	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	function	O
27	through	O
28	direct	O
29	inhibition	O
30	of	O
31	SRF	B
32	binding	O
33	.	O

1	Cardiac	O
2	disease	O
3	was	O
4	not	O
5	detected	O
6	with	O
7	M	O
8	-	O
9	mode	O
10	,	O
11	2	O
12	-	O
13	dimensional	O
14	real	O
15	-	O
16	time	O
17	or	O
18	pulsed	O
19	-	O
20	wave	O
21	Doppler	O
22	echocardiography	O
23	.	O

1	Thus	O
2	,	O
3	the	O
4	association	O
5	of	O
6	PS1	B
7	fragments	I
8	may	O
9	be	O
10	maintained	O
11	during	O
12	cycles	O
13	of	O
14	phosphorylation	O
15	/	O
16	dephosphorylation	O
17	of	O
18	the	O
19	PS1	B
20	CTF	I
21	.	O

1	Many	O
2	cytokine	O
3	receptors	O
4	employ	O
5	Janus	B
6	protein	I
7	tyrosine	I
8	kinases	I
9	(	O
10	Jaks	O
11	)	O
12	and	O
13	signal	O
14	transducers	O
15	and	O
16	activators	O
17	of	O
18	transcription	O
19	(	O
20	Stats	B
21	)	O
22	for	O
23	nuclear	O
24	signaling	O
25	.	O

1	Carcinoembryonic	B
2	antigen	I
3	(	O
4	CEA	O
5	)	O
6	procedures	O
7	and	O
8	clinical	O
9	evaluation	O
10	.	O

1	Various	O
2	assays	O
3	demonstrate	O
4	promoter	O
5	activity	O
6	in	O
7	this	O
8	sequence	O
9	that	O
10	reproduces	O
11	the	O
12	normal	O
13	control	O
14	of	O
15	E2F2	O
16	expression	O
17	during	O
18	a	O
19	growth	O
20	stimulation	O
21	.	O

1	Renin	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O

1	Effects	O
2	of	O
3	methiothepin	O
4	and	O
5	lysergic	O
6	acid	O
7	diethylamide	O
8	on	O
9	serotonin	O
10	release	O
11	in	O
12	vitro	O
13	and	O
14	serotonin	O
15	synthesis	O
16	in	O
17	vivo	O
18	:	O
19	possible	O
20	relation	O
21	to	O
22	serotonin	O
23	autoreceptor	O
24	function	O
25	.	O

1	Some	O
2	of	O
3	the	O
4	PCR	O
5	products	O
6	contained	O
7	mutations	O
8	in	O
9	ATG1	O
10	and	O
11	/	O
12	or	O
13	ATG2	O
14	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O

1	Colorectal	O
2	carcinoma	O
3	:	O
4	therapeutic	O
5	approach	O
6	in	O
7	patients	O
8	already	O
9	treated	O
10	with	O
11	metastasis	O
12	resection	O

1	Later	O
2	in	O
3	development	O
4	,	O
5	Tbx6	B
6	expression	O
7	is	O
8	restricted	O
9	to	O
10	presomitic	O
11	,	O
12	paraxial	O
13	mesoderm	O
14	and	O
15	to	O
16	the	O
17	tail	O
18	bud	O
19	,	O
20	which	O
21	replaces	O
22	the	O
23	streak	O
24	as	O
25	the	O
26	source	O
27	of	O
28	mesoderm	O
29	.	O

1	By	O
2	comparing	O
3	the	O
4	abundances	O
5	of	O
6	many	O
7	yeast	O
8	transcripts	O
9	in	O
10	isogenic	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	paf1	O
16	mutant	O
17	strains	O
18	,	O
19	we	O
20	have	O
21	identified	O
22	genes	O
23	whose	O
24	expression	O
25	is	O
26	affected	O
27	by	O
28	PAF1	B
29	.	O

1	When	O
2	pollen	O
3	allergen	O
4	from	O
5	three	O
6	grass	O
7	species	O
8	were	O
9	used	O
10	,	O
11	The	O
12	RAST	O
13	-	O
14	test	O
15	results	O
16	did	O
17	not	O
18	differ	O
19	from	O
20	duplicate	O
21	values	O
22	either	O
23	.	O

1	The	O
2	gene	O
3	is	O
4	separated	O
5	into	O
6	four	O
7	exons	O
8	by	O
9	three	O
10	short	O
11	introns	O
12	,	O
13	and	O
14	the	O
15	open	O
16	reading	O
17	frame	O
18	consists	O
19	of	O
20	6660	O
21	base	O
22	pairs	O
23	(	O
24	bp	O
25	)	O
26	capable	O
27	of	O
28	encoding	O
29	a	O
30	polypeptide	O
31	of	O
32	2220	O
33	amino	O
34	acid	O
35	residues	O
36	.	O

1	The	O
2	recovery	O
3	rates	O
4	for	O
5	the	O
6	MB	B
7	/	O
8	BacT	B
9	,	O
10	MGIT	O
11	960	O
12	,	O
13	and	O
14	solid	O
15	media	O
16	were	O
17	91	O
18	.	O
19	6	O
20	,	O
21	87	O
22	.	O
23	4	O
24	,	O
25	and	O
26	54	O
27	.	O
28	7	O
29	%,	O
30	respectively	O
31	,	O
32	for	O
33	all	O
34	mycobacteria	O
35	;	O
36	the	O
37	recovery	O
38	rates	O
39	were	O
40	93	O
41	.	O
42	6	O
43	,	O
44	88	O
45	.	O
46	9	O
47	,	O
48	and	O
49	63	O
50	.	O
51	4	O
52	%,	O
53	respectively	O
54	,	O
55	for	O
56	M	O
57	.	O
58	tuberculosis	O
59	complex	O
60	alone	O
61	,	O
62	and	O
63	87	O
64	.	O
65	5	O
66	,	O
67	84	O
68	.	O
69	4	O
70	,	O
71	and	O
72	37	O
73	.	O
74	5	O
75	%,	O
76	respectively	O
77	,	O
78	for	O
79	all	O
80	nontuberculous	O
81	mycobacteria	O
82	.	O

1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	modular	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	I
12	gene	I
13	generates	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	effectors	O
21	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	Dbp5p	B
6	and	O
7	Rat7p	B
8	interact	O
9	through	O
10	their	O
11	Nterminal	O
12	domains	O
13	.	O

1	Effects	O
2	of	O
3	estradiol	O
4	on	O
5	worm	O
6	burden	O
7	and	O
8	peripheral	O
9	leukocytes	O
10	in	O
11	Parastrongylus	O
12	malaysiensis	O
13	-	O
14	infected	O
15	rats	O
16	.	O

1	This	O
2	approach	O
3	enables	O
4	the	O
5	sources	O
6	of	O
7	error	O
8	in	O
9	the	O
10	calculation	O
11	of	O
12	nutrient	O
13	utilization	O
14	to	O
15	be	O
16	readily	O
17	identified	O
18	,	O
19	and	O
20	their	O
21	effect	O
22	on	O
23	precision	O
24	to	O
25	be	O
26	assessed	O
27	in	O
28	different	O
29	nutritional	O
30	and	O
31	metabolic	O
32	states	O
33	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	protein	I
9	,	O
10	expression	O
11	of	O
12	p45	B
13	NF	I
14	-	I
15	E2	I
16	lacking	O
17	this	O
18	activation	O
19	domain	O
20	in	O
21	an	O
22	NF	B
23	-	I
24	E2	I
25	null	O
26	cell	O
27	line	O
28	fails	O
29	to	O
30	support	O
31	enhancer	O
32	-	O
33	dependent	O
34	transcription	O
35	in	O
36	transient	O
37	assays	O
38	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	suppression	O
6	of	O
7	elevated	O
8	prolactin	B
9	levels	O
10	in	O
11	progressive	O
12	metastatic	O
13	breast	O
14	cancer	O
15	patients	O
16	is	O
17	not	O
18	effective	O
19	in	O
20	restoring	O
21	tumor	O
22	sensitivity	O
23	to	O
24	chemotherapy	O
25	.	O

1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O

1	The	O
2	data	O
3	presented	O
4	in	O
5	this	O
6	work	O
7	indicate	O
8	that	O
9	thi1	O
10	may	O
11	also	O
12	be	O
13	involved	O
14	in	O
15	DNA	O
16	damage	O
17	tolerance	O
18	in	O
19	plant	O
20	cells	O
21	.	O

1	In	O
2	vivo	O
3	dimethyl	O
4	sulfate	O
5	footprinting	O
6	of	O
7	the	O
8	cyclin	B
9	E	I
10	promoter	I
11	revealed	O
12	several	O
13	regions	O
14	of	O
15	protection	O
16	and	O
17	hypersensitivity	O
18	that	O
19	were	O
20	unique	O
21	to	O
22	infected	O
23	cells	O
24	.	O

1	The	O
2	progression	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	hepatitis	O
12	to	O
13	chronic	O
14	diseases	O
15	,	O
16	and	O
17	the	O
18	transformation	O
19	to	O
20	hepatocellular	O
21	carcinoma	O

1	Therefore	O
2	,	O
3	it	O
4	would	O
5	be	O
6	advantageous	O
7	to	O
8	identify	O
9	such	O
10	persons	O
11	and	O
12	treat	O
13	them	O
14	preferentially	O
15	.	O

1	Since	O
2	1967	O
3	at	O
4	the	O
5	times	O
6	of	O
7	their	O
8	biennial	O
9	ABCC	B
10	/	O
11	RERF	O
12	radiological	O
13	examinations	O
14	,	O
15	all	O
16	Adult	O
17	Health	O
18	Study	O
19	(	O
20	AHS	O
21	)	O
22	subjects	O
23	have	O
24	been	O
25	interviewed	O
26	to	O
27	determine	O
28	the	O
29	exposures	O
30	to	O
31	medical	O
32	x	O
33	-	O
34	rays	O
35	they	O
36	experienced	O
37	in	O
38	institutions	O
39	other	O
40	than	O
41	RERF	O
42	in	O
43	order	O
44	to	O
45	estimate	O
46	the	O
47	numbers	O
48	of	O
49	examinations	O
50	and	O
51	corresponding	O
52	doses	O
53	which	O
54	they	O
55	received	O
56	.	O

1	An	O
2	AP	B
3	-	I
4	1	I
5	binding	I
6	sequence	I
7	is	O
8	essential	O
9	for	O
10	regulation	O
11	of	O
12	the	O
13	human	B
14	alpha2	I
15	(	I
16	I	I
17	)	I
18	collagen	I
19	(	O
20	COL1A2	O
21	)	O
22	promoter	O
23	activity	O
24	by	O
25	transforming	B
26	growth	I
27	factor	I
28	-	I
29	beta	I
30	.	O

1	The	O
2	RMR	O
3	was	O
4	measured	O
5	twice	O
6	in	O
7	each	O
8	phase	O
9	and	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	(	O
15	F	O
16	(	O
17	1	O
18	,	O
19	18	O
20	)	O
21	=	O
22	0	O
23	.	O
24	863	O
25	)	O
26	across	O
27	the	O
28	follicular	O
29	(	O
30	5018	O
31	kJ	O
32	/	O
33	24	O
34	h	O
35	)	O
36	and	O
37	the	O
38	luteal	O
39	(	O
40	5098	O
41	kJ	O
42	/	O
43	24	O
44	h	O
45	)	O
46	phases	O
47	.	O

1	However	O
2	,	O
3	inclusion	O
4	of	O
5	the	O
6	neighboring	O
7	CGGAAR	O
8	motifs	O
9	from	O
10	the	O
11	ICP4	B
12	promoter	I
13	,	O
14	which	O
15	bind	O
16	factors	O
17	GABP	B
18	alpha	I
19	and	O
20	beta	O
21	,	O
22	results	O
23	in	O
24	a	O
25	strong	O
26	synergistic	O
27	activation	O
28	.	O

1	We	O
2	have	O
3	recently	O
4	identified	O
5	a	O
6	mouse	O
7	enzyme	O
8	termed	O
9	gamma	B
10	-	I
11	glutamyl	I
12	leukotrienase	I
13	(	O
14	GGL	B
15	)	O
16	that	O
17	converts	O
18	leukotriene	O
19	C4	O
20	(	O
21	LTC4	O
22	)	O
23	to	O
24	leukotriene	O
25	D4	O
26	(	O
27	LTD4	O
28	).	O

1	The	O
2	mapping	O
3	was	O
4	completed	O
5	with	O
6	Southern	O
7	blotting	O
8	and	O
9	restriction	O
10	analysis	O
11	.	O

1	All	O
2	four	O
3	doubly	O
4	tyrosine	O
5	phosphorylated	O
6	TAM	O
7	peptides	O
8	cross	O
9	-	O
10	compete	O
11	with	O
12	each	O
13	other	O
14	for	O
15	binding	O
16	to	O
17	the	O
18	tandem	O
19	SH2	B
20	domains	I
21	of	O
22	ZAP	B
23	-	I
24	70	I
25	.	O

1	However	O
2	,	O
3	a	O
4	similar	O
5	mutation	O
6	of	O
7	a	O
8	leucine	O
9	residue	O
10	to	O
11	arginine	O
12	at	O
13	position	O
14	422	O
15	showed	O
16	no	O
17	alteration	O
18	of	O
19	heterodimerization	O
20	,	O
21	DNA	O
22	binding	O
23	,	O
24	or	O
25	transcriptional	O
26	activation	O
27	.	O

1	In	O
2	spite	O
3	of	O
4	much	O
5	effort	O
6	,	O
7	no	O
8	one	O
9	has	O
10	succeeded	O
11	in	O
12	isolating	O
13	and	O
14	characterizing	O
15	the	O
16	enzyme	O
17	(	O
18	s	O
19	)	O
20	responsible	O
21	for	O
22	synthesis	O
23	of	O
24	cellulose	O
25	,	O
26	the	O
27	major	O
28	cell	O
29	wall	O
30	polymer	O
31	of	O
32	plants	O
33	.	O

1	Chem	O
2	.	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Femoral	O
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	O
14	porous	O
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	Activation	O
2	of	O
3	ERK1	B
4	/	I
5	2	I
6	is	O
7	correlated	O
8	with	O
9	induction	O
10	of	O
11	the	O
12	immediate	B
13	-	I
14	early	I
15	response	I
16	genes	I
17	.	O

1	Strategies	O
2	for	O
3	blood	O
4	screening	O
5	for	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	and	O
11	for	O
12	the	O
13	human	O
14	immunodeficiency	O
15	virus	O
16	in	O
17	high	O
18	risk	O
19	groups	O
20	.	O

1	The	O
2	salient	O
3	clinical	O
4	features	O
5	,	O
6	the	O
7	problems	O
8	of	O
9	management	O
10	and	O
11	the	O
12	modern	O
13	approaches	O
14	to	O
15	the	O
16	reconstruction	O
17	of	O
18	facial	O
19	deformities	O
20	seen	O
21	in	O
22	this	O
23	disease	O
24	are	O
25	described	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	Translocation	O
4	of	O
5	bacteria	O
6	or	O
7	endotoxin	O
8	from	O
9	the	O
10	gastrointestinal	O
11	tract	O
12	into	O
13	the	O
14	bloodstream	O
15	has	O
16	been	O
17	noted	O
18	in	O
19	animal	O
20	experiments	O
21	;	O
22	however	O
23	,	O
24	translocation	O
25	was	O
26	not	O
27	detected	O
28	in	O
29	our	O
30	patients	O
31	with	O
32	hemorrhagic	O
33	shock	O
34	.	O

1	These	O
2	data	O
3	indicate	O
4	a	O
5	functional	O
6	role	O
7	for	O
8	U1	B
9	in	O
10	NRS	O
11	-	O
12	mediated	O
13	splicing	O
14	inhibition	O
15	.	O

1	Increase	O
2	in	O
3	blood	O
4	NEFA	O
5	was	O
6	further	O
7	augmented	O
8	by	O
9	fat	O
10	plus	O
11	AA	O
12	supplementation	O
13	,	O
14	but	O
15	no	O
16	changes	O
17	in	O
18	concentrations	O
19	of	O
20	Lys	O
21	or	O
22	Met	O
23	in	O
24	blood	O
25	were	O
26	found	O
27	.	O

1	Entry	O
2	of	O
3	yeast	O
4	cells	O
5	into	O
6	the	O
7	mitotic	O
8	cell	O
9	cycle	O
10	(	O
11	Start	O
12	)	O
13	involves	O
14	a	O
15	form	O
16	of	O
17	the	O
18	CDC28	B
19	kinase	O
20	that	O
21	associates	O
22	with	O
23	G1	B
24	-	I
25	specific	I
26	cyclins	I
27	encoded	O
28	by	O
29	CLN1	B
30	and	O
31	CLN2	B
32	(	O
33	ref	O
34	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	residues	O
7	in	O
8	this	O
9	domain	O
10	(	O
11	R82A	O
12	,	O
13	K85A	O
14	,	O
15	K88A	O
16	,	O
17	and	O
18	V89A	O
19	)	O
20	resulted	O
21	in	O
22	proteins	O
23	which	O
24	failed	O
25	to	O
26	transactivate	O
27	from	O
28	the	O
29	HTLV	B
30	-	I
31	1	I
32	LTR	I
33	in	O
34	vivo	O
35	.	O

1	Furthermore	O
2	the	O
3	median	O
4	increase	O
5	in	O
6	cyclosporine	O
7	DR	O
8	/	O
9	C	O
10	(	O
11	SS	O
12	trough	O
13	)	O
14	was	O
15	18	O
16	l	O
17	h	O
18	-	O
19	1	O
20	(-	O
21	3	O
22	.	O
23	1	O
24	to	O
25	42	O
26	.	O
27	1	O
28	l	O
29	h	O
30	-	O
31	1	O
32	,	O
33	interquartile	O
34	range	O
35	).	O

1	Possibilities	O
2	and	O
3	outlook	O
4	for	O
5	wrist	O
6	joint	O
7	endoprosthesis	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	Ariga	O
2	,	O
3	Biochem	O
4	.	O

1	HIV	O
2	infectiousness	O
3	and	O
4	the	O
5	AIDS	O
6	epidemic	O
7	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	O
12	and	O
13	hepatic	O
14	leukemia	O
15	factor	O
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	O
28	DBP	B
29	fusion	I
30	proteins	I
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	CBT	O
2	is	O
3	discussed	O
4	in	O
5	comparison	O
6	with	O
7	the	O
8	Wisconsin	O
9	Card	O
10	Sorting	O
11	Test	O
12	as	O
13	a	O
14	potential	O
15	cognitive	O
16	activation	O
17	task	O
18	for	O
19	functional	O
20	neuroimaging	O
21	of	O
22	the	O
23	frontal	O
24	lobes	O
25	.	O

1	In	O
2	throttling	O
3	valves	O
4	,	O
5	the	O
6	aim	O
7	is	O
8	to	O
9	correlate	O
10	the	O
11	effect	O
12	of	O
13	shear	O
14	to	O
15	a	O
16	parameter	O
17	related	O
18	to	O
19	the	O
20	inner	O
21	geometry	O
22	of	O
23	the	O
24	valve	O
25	and	O
26	to	O
27	operating	O
28	conditions	O
29	.	O

1	The	O
2	84	O
3	.	O
4	1C	O
5	mAb	O
6	recognizes	O
7	a	O
8	site	O
9	on	O
10	IgE	B
11	which	O
12	is	O
13	identical	O
14	or	O
15	very	O
16	close	O
17	to	O
18	the	O
19	Fc	B
20	epsilon	I
21	R	I
22	binding	I
23	site	I
24	,	O
25	and	O
26	95	O
27	.	O
28	3	O
29	recognizes	O
30	a	O
31	site	O
32	on	O
33	IgE	B
34	which	O
35	is	O
36	related	O
37	,	O
38	but	O
39	not	O
40	identical	O
41	to	O
42	the	O
43	Fc	B
44	epsilon	I
45	R	I
46	binding	I
47	site	I
48	.	O

1	Expression	O
2	of	O
3	a	O
4	hybrid	O
5	protein	O
6	containing	O
7	the	O
8	cytoplasmic	O
9	C	O
10	-	O
11	terminal	O
12	half	O
13	of	O
14	UhpB	B
15	fused	O
16	to	O
17	glutathione	B
18	S	I
19	-	I
20	transferase	I
21	(	O
22	GST	B
23	)	O
24	also	O
25	interfered	O
26	with	O
27	Uhp	B
28	signaling	O
29	.	O

1	Furthermore	O
2	,	O
3	expression	O
4	of	O
5	the	O
6	promoter	O
7	in	O
8	embryonic	O
9	Drosophila	O
10	melanogaster	O
11	cells	O
12	that	O
13	lack	O
14	MyoD1	B
15	and	O
16	Sp1	B
17	is	O
18	strictly	O
19	dependent	O
20	on	O
21	all	O
22	three	O
23	sites	O
24	remaining	O
25	intact	O
26	and	O
27	on	O
28	the	O
29	presence	O
30	of	O
31	exogenously	O
32	supplied	O
33	Sp1	B
34	and	O
35	MyoD1	B
36	.	O

1	Bioplastique	O
2	granuloma	O
3	presents	O
4	with	O
5	irregularly	O
6	shaped	O
7	cystic	O
8	spaces	O
9	of	O
10	varying	O
11	size	O
12	containing	O
13	jagged	O
14	,	O
15	translucent	O
16	,	O
17	nonbirefringent	O
18	foreign	O
19	bodies	O
20	whereas	O
21	Artecoll	O
22	granuloma	O
23	shows	O
24	numerous	O
25	round	O
26	vacuoles	O
27	nearly	O
28	identical	O
29	in	O
30	size	O
31	and	O
32	shape	O
33	enclosing	O
34	round	O
35	and	O
36	sharply	O
37	circumscribed	O
38	,	O
39	translucent	O
40	,	O
41	nonbirefringent	O
42	foreign	O
43	bodies	O
44	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	B
22	kinase	I
23	C	I
24	beta	I
25	.	O

1	A	O
2	3	O
3	-	O
4	week	O
5	regimen	O
6	of	O
7	erythropoietin	B
8	may	O
9	help	O
10	prevent	O
11	the	O
12	donor	O
13	'	O
14	s	O
15	need	O
16	to	O
17	receive	O
18	allogeneic	O
19	blood	O
20	transfusion	O
21	,	O
22	when	O
23	the	O
24	initial	O
25	Hb	B
26	levels	O
27	were	O
28	below	O
29	130	O
30	milligrams	O
31	.	O

1	W	O
2	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	By	O
2	stepwise	O
3	linear	O
4	multiple	O
5	regression	O
6	analysis	O
7	,	O
8	ionized	O
9	magnesium	O
10	was	O
11	significantly	O
12	related	O
13	to	O
14	cyclosporin	O
15	trough	O
16	level	O
17	and	O
18	total	O
19	cholesterol	O
20	but	O
21	not	O
22	to	O
23	serum	O
24	creatinine	O
25	,	O
26	time	O
27	after	O
28	transplant	O
29	or	O
30	the	O
31	dose	O
32	of	O
33	cyclosporin	O
34	.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	CDE	O
5	/	O
6	CHR	O
7	elements	O
8	and	O
9	Sp1	B
10	sites	I
11	in	O
12	this	O
13	region	O
14	,	O
15	alone	O
16	or	O
17	in	O
18	combination	O
19	,	O
20	reduced	O
21	transcriptional	O
22	activity	O
23	by	O
24	40	O
25	-	O
26	60	O
27	%	O
28	in	O
29	asynchronously	O
30	growing	O
31	cells	O
32	and	O
33	abolished	O
34	cell	O
35	cycle	O
36	periodicity	O
37	in	O
38	G2	O
39	-	O
40	M	O
41	-	O
42	synchronized	O
43	cells	O
44	.	O

1	A	O
2	new	O
3	instrument	O
4	has	O
5	been	O
6	designed	O
7	for	O
8	freeze	O
9	-	O
10	fracturing	O
11	of	O
12	biological	O
13	material	O
14	in	O
15	ultra	O
16	high	O
17	vacuum	O
18	.	O

1	IMPLICATIONS	O
2	:	O
3	Given	O
4	the	O
5	small	O
6	size	O
7	of	O
8	this	O
9	study	O
10	and	O
11	the	O
12	inconsistency	O
13	of	O
14	results	O
15	among	O
16	the	O
17	few	O
18	prospective	O
19	studies	O
20	of	O
21	ovarian	O
22	cancer	O
23	conducted	O
24	to	O
25	test	O
26	these	O
27	associations	O
28	,	O
29	replications	O
30	of	O
31	these	O
32	findings	O
33	are	O
34	highly	O
35	desirable	O
36	.	O

1	In	O
2	NASCIS	O
3	III	O
4	,	O
5	a	O
6	randomization	O
7	imbalance	O
8	occurred	O
9	that	O
10	allocated	O
11	a	O
12	disproportionate	O
13	number	O
14	of	O
15	patients	O
16	with	O
17	no	O
18	motor	O
19	deficit	O
20	(	O
21	and	O
22	therefore	O
23	no	O
24	chance	O
25	for	O
26	recovery	O
27	)	O
28	to	O
29	the	O
30	lower	O
31	dose	O
32	control	O
33	group	O
34	.	O

1	Taken	O
2	together	O
3	,	O
4	they	O
5	uphold	O
6	the	O
7	emerging	O
8	concern	O
9	that	O
10	women	O
11	with	O
12	ER	B
13	(+)	O
14	cancers	O
15	may	O
16	not	O
17	benefit	O
18	significantly	O
19	from	O
20	endocrine	O
21	treatment	O
22	if	O
23	the	O
24	tumors	O
25	also	O
26	overexpress	O
27	HER	B
28	-	I
29	2	I
30	.	O

1	1	O
2	.	O

1	Epitope	O
2	mapping	O
3	revealed	O
4	that	O
5	these	O
6	three	O
7	clones	O
8	appear	O
9	to	O
10	recognize	O
11	an	O
12	identical	O
13	epitope	O
14	domain	O
15	present	O
16	on	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	RNP	O
22	motif	O
23	of	O
24	the	O
25	U1A	B
26	protein	I
27	.	O

1	A	O
2	-	O
3	tracts	O
4	functioned	O
5	best	O
6	when	O
7	positioned	O
8	close	O
9	to	O
10	the	O
11	-	O
12	35	O
13	hexamer	O
14	rather	O
15	than	O
16	one	O
17	helical	O
18	turn	O
19	farther	O
20	upstream	O
21	,	O
22	similar	O
23	to	O
24	the	O
25	positioning	O
26	optimal	O
27	for	O
28	UP	O
29	element	O
30	function	O
31	.	O

1	Its	O
2	hydropathy	O
3	profile	O
4	predicts	O
5	seven	O
6	transmembrane	O
7	spans	O
8	and	O
9	a	O
10	hydrophilic	O
11	amino	O
12	terminus	O
13	of	O
14	approximately	O
15	100	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	suggests	O
21	the	O
22	presence	O
23	of	O
24	an	O
25	amphiphilic	O
26	alpha	O
27	-	O
28	helix	O
29	(	O
30	L	O
31	-	O
32	61	O
33	to	O
34	F	B
35	-	I
36	97	I
37	)	O
38	in	O
39	close	O
40	proximity	O
41	to	O
42	the	O
43	first	O
44	strongly	O
45	hydrophobic	O
46	segment	O
47	of	O
48	ProW	B
49	.	O

1	100	O
2	more	O
3	than	O
4	in	O
5	the	O
6	summer	O
7	coat	O
8	).	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	role	O
6	of	O
7	cellular	O
8	p21ras	B
9	protein	I
10	in	O
11	insulin	B
12	and	O
13	insulin	B
14	-	I
15	like	I
16	growth	I
17	factor	I
18	-	I
19	I	I
20	(	O
21	IGF	B
22	-	I
23	I	I
24	)	O
25	signaling	O
26	pathways	O
27	.	O

1	The	O
2	Drosophila	B
3	insulin	I
4	receptor	I
5	homolog	I
6	:	O
7	a	O
8	gene	O
9	essential	O
10	for	O
11	embryonic	O
12	development	O
13	encodes	O
14	two	O
15	receptor	O
16	isoforms	O
17	with	O
18	different	O
19	signaling	O
20	potential	O
21	.	O

1	The	O
2	pre	O
3	-	O
4	and	O
5	postoperative	B
6	haemoglobin	I
7	concentrations	O
8	in	O
9	the	O
10	autologous	O
11	group	O
12	were	O
13	lower	O
14	by	O
15	15	O
16	and	O
17	10	O
18	g	O
19	/	O
20	L	O
21	,	O
22	respectively	O
23	,	O
24	after	O
25	primary	O
26	THR	O
27	and	O
28	by	O
29	10	O
30	g	O
31	/	O
32	L	O
33	in	O
34	both	O
35	instances	O
36	after	O
37	revision	O
38	THR	O
39	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	Specific	O
2	binding	O
3	was	O
4	not	O
5	observed	O
6	with	O
7	either	O
8	the	O
9	orthologous	O
10	rat	O
11	or	O
12	mouse	O
13	fragments	O
14	using	O
15	human	O
16	or	O
17	rodent	O
18	extracts	O
19	.	O

1	Genomic	O
2	locus	O
3	of	O
4	chCTCF	B
5	contains	O
6	a	O
7	GC	O
8	-	O
9	rich	O
10	untranslated	O
11	exon	O
12	separated	O
13	from	O
14	seven	O
15	coding	O
16	exons	O
17	by	O
18	a	O
19	long	O
20	intron	O
21	.	O

1	ANIMALS	O
2	:	O
3	Fifty	O
4	dogs	O
5	with	O
6	naturally	O
7	developing	O
8	DM	O
9	.	O

1	This	O
2	laser	O
3	provided	O
4	sufficient	O
5	power	O
6	in	O
7	an	O
8	amniotic	O
9	fluid	O
10	medium	O
11	to	O
12	occlude	O
13	placental	O
14	vessels	O
15	as	O
16	large	O
17	as	O
18	7	O
19	mm	O
20	in	O
21	diameter	O
22	within	O
23	6	O
24	seconds	O
25	at	O
26	a	O
27	power	O
28	density	O
29	of	O
30	2000	O
31	W	O
32	/	O
33	cm2	O
34	.	O

1	The	O
2	mRNA	O
3	identified	O
4	in	O
5	both	O
6	human	O
7	and	O
8	rat	O
9	cells	O
10	with	O
11	the	O
12	human	B
13	clathrin	I
14	clone	I
15	revealed	O
16	transcripts	O
17	of	O
18	approximately	O
19	6	O
20	.	O
21	5	O
22	kb	O
23	,	O
24	which	O
25	is	O
26	consistent	O
27	with	O
28	the	O
29	predicted	O
30	180	O
31	kDa	O
32	molecular	O
33	weight	O
34	of	O
35	the	O
36	clathrin	B
37	heavy	I
38	chain	I
39	.	O

1	Trials	O
2	of	O
3	sevine	O
4	activity	O
5	against	O
6	mosquito	O
7	larvae	O

1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O

1	At	O
2	the	O
3	MTD	O
4	(	O
5	8	O
6	mg	O
7	/	O
8	m2	O
9	/	O
10	day	O
11	),	O
12	the	O
13	dose	O
14	-	O
15	limiting	O
16	toxicity	O
17	of	O
18	this	O
19	agent	O
20	is	O
21	myelosuppression	O
22	.	O

1	The	O
2	murine	O
3	chromosomal	O
4	locations	O
5	of	O
6	the	O
7	five	O
8	NMDA	B
9	receptor	I
10	channel	I
11	subunits	I
12	,	O
13	the	O
14	epsilon	O
15	1	O
16	(	O
17	Grin2a	O
18	),	O
19	epsilon	O
20	2	O
21	(	O
22	Grin2b	O
23	),	O
24	epsilon	O
25	3	O
26	(	O
27	Grin2c	O
28	),	O
29	epsilon	O
30	4	O
31	(	O
32	Grin2d	O
33	)	O
34	and	O
35	zeta	B
36	1	I
37	(	O
38	Grinl	O
39	)	O
40	subunits	O
41	,	O
42	were	O
43	determined	O
44	using	O
45	an	O
46	interspecific	O
47	backcross	O
48	mapping	O
49	panel	O
50	derived	O
51	from	O
52	crosses	O
53	of	O
54	[(	O
55	C57BL	O
56	/	O
57	6JxM	B
58	.	O
59	spretus	O
60	)	O
61	F1xC57BL	O
62	/	O
63	6J	O
64	]	O
65	mice	O
66	.	O

1	Pyk2	O
2	phosphorylation	O
3	increased	O
4	upon	O
5	adherence	O
6	of	O
7	FLG	O
8	29	O
9	.	O
10	1	O
11	cells	O
12	to	O
13	fibronectin	B
14	and	O
15	to	O
16	ST2	O
17	stromal	O
18	cells	O
19	.	O

1	Troubled	O
2	CareNetwork	O
3	gets	O
4	pact	O
5	from	O
6	largest	O
7	teacher	O
8	union	O
9	in	O
10	Wis	O
11	.	O

1	Linearized	O
2	overall	O
3	infection	O
4	rates	O
5	(	O
6	events	O
7	/	O
8	100	O
9	patient	O
10	-	O
11	days	O
12	)	O
13	were	O
14	2	O
15	.	O
16	05	O
17	+/-	O
18	0	O
19	.	O
20	33	O
21	(	O
22	heart	O
23	-	O
24	lung	O
25	)	O
26	and	O
27	2	O
28	.	O
29	34	O
30	+/-	O
31	0	O
32	.	O
33	34	O
34	(	O
35	double	O
36	-	O
37	lung	O
38	;	O
39	P	O
40	=	O
41	NS	O
42	)	O
43	at	O
44	3	O
45	months	O
46	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	sought	O
8	to	O
9	investigate	O
10	whether	O
11	constitutive	O
12	NF	B
13	-	I
14	kappaB	I
15	activity	O
16	in	O
17	chronically	O
18	HIV	O
19	-	O
20	1	O
21	-	O
22	infected	O
23	promonocytic	O
24	U937	O
25	(	O
26	U9	O
27	-	O
28	IIIB	O
29	)	O
30	and	O
31	myeloblastic	O
32	PLB	O
33	-	O
34	985	O
35	(	O
36	PLB	B
37	-	I
38	IIIB	I
39	)	O
40	cells	O
41	affects	O
42	apoptotic	O
43	signaling	O
44	.	O

1	An	O
2	experiment	O
3	examined	O
4	the	O
5	effects	O
6	of	O
7	treatment	O
8	with	O
9	gonadotrophin	B
10	releasing	I
11	hormone	I
12	(	O
13	100	O
14	micrograms	O
15	GnRH	B
16	injected	O
17	24	O
18	h	O
19	after	O
20	progestagen	O
21	sponge	O
22	removal	O
23	),	O
24	season	O
25	of	O
26	treatment	O
27	(	O
28	autumn	O
29	v	O
30	.	O
31	spring	O
32	),	O
33	the	O
34	effect	O
35	of	O
36	supplementary	O
37	feeding	O
38	with	O
39	lupin	O
40	grain	O
41	(	O
42	in	O
43	autumn	O
44	only	O
45	,	O
46	from	O
47	12	O
48	days	O
49	before	O
50	until	O
51	8	O
52	days	O
53	after	O
54	sponge	O
55	removal	O
56	)	O
57	on	O
58	the	O
59	time	O
60	of	O
61	ovulation	O
62	in	O
63	182	O
64	mature	O
65	Merino	O
66	ewes	O
67	superovulated	O
68	with	O
69	a	O
70	combination	O
71	of	O
72	400	O
73	I	O
74	.	O
75	U	O
76	.	O
77	pregnant	O
78	mare	O
79	serum	O
80	gonadotrophin	B
81	(	O
82	PMSG	O
83	)	O
84	and	O
85	12	O
86	mg	O
87	follicle	O
88	stimulating	O
89	hormone	O
90	(	O
91	FSH	B
92	-	O
93	P	O
94	).	O

1	The	O
2	protein	O
3	encoded	O
4	is	O
5	114	O
6	kDa	O
7	and	O
8	contains	O
9	eight	O
10	zinc	O
11	finger	O
12	motifs	O
13	,	O
14	seven	O
15	of	O
16	which	O
17	are	O
18	present	O
19	in	O
20	two	O
21	clusters	O
22	at	O
23	opposite	O
24	ends	O
25	of	O
26	the	O
27	molecule	O
28	.	O

1	We	O
2	cloned	O
3	a	O
4	complete	O
5	cDNA	O
6	(	O
7	2	O
8	.	O
9	9	O
10	kb	O
11	)	O
12	for	O
13	HET	O
14	from	O
15	an	O
16	MCF	O
17	-	O
18	7	O
19	cDNA	O
20	library	O
21	.	O

1	Toxicity	O
2	during	O
3	the	O
4	therapeutic	O
5	period	O
6	was	O
7	not	O
8	significant	O
9	in	O
10	the	O
11	study	O
12	group	O
13	compared	O
14	with	O
15	the	O
16	historical	O
17	control	O
18	,	O
19	treated	O
20	with	O
21	the	O
22	same	O
23	regimen	O
24	without	O
25	G	B
26	-	I
27	CSF	I
28	.	O

1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	O
16	.	O

1	Intravesical	O
2	chemotherapy	O
3	.	O

1	Effect	O
2	of	O
3	immune	O
4	lymphocytes	O
5	and	O
6	of	O
7	rabbit	B
8	-	I
9	anti	I
10	-	I
11	lymphocyte	I
12	globulin	I
13	(	O
14	RAMLG	O
15	)	O
16	on	O
17	infected	O
18	macrophages	O
19	exposed	O
20	to	O
21	increased	O
22	incubation	O
23	temperature	O
24	in	O
25	vitro	O
26	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	B
7	proteins	I
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	B
15	NHP6A	I
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	The	O
2	Myc	B
3	LZ	I
4	was	O
5	found	O
6	to	O
7	prevent	O
8	homodimeric	O
9	interactions	O
10	,	O
11	thus	O
12	explaining	O
13	Myc	O
14	inability	O
15	to	O
16	homodimerize	O
17	efficiently	O
18	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	In	O
2	transient	O
3	analysis	O
4	using	O
5	particle	O
6	bombardment	O
7	of	O
8	tobacco	O
9	leaf	O
10	sections	O
11	,	O
12	a	O
13	tetramer	O
14	of	O
15	the	O
16	distB	B
17	ABRE	I
18	(	O
19	abscisic	O
20	acid	O
21	-	O
22	responsive	O
23	element	O
24	)	O
25	mediated	O
26	transactivation	O
27	by	O
28	ABI3	B
29	and	O
30	ABI3	O
31	-	O
32	dependent	O
33	response	O
34	to	O
35	ABA	O
36	,	O
37	whereas	O
38	a	O
39	tetramer	O
40	of	O
41	the	O
42	composite	O
43	RY	O
44	/	O
45	G	B
46	complex	I
47	,	O
48	containing	O
49	RY	O
50	repeats	O
51	and	O
52	a	O
53	G	O
54	-	O
55	box	O
56	,	O
57	mediated	O
58	only	O
59	ABA	O
60	-	O
61	independent	O
62	transactivation	O
63	by	O
64	ABI3	O
65	.	O

1	No	O
2	case	O
3	of	O
4	SMF	O
5	demonstrated	O
6	expansive	O
7	tumorous	O
8	growth	O
9	.	O

1	Subsets	O
2	of	O
3	patients	O
4	were	O
5	performed	O
6	according	O
7	to	O
8	the	O
9	severity	O
10	of	O
11	trauma	O
12	(	O
13	ISS	O
14	<	O
15	9	O
16	;	O
17	9	O
18	-	O
19	17	O
20	;	O
21	18	O
22	-	O
23	31	O
24	;	O
25	>	O
26	32	O
27	),	O
28	based	O
29	on	O
30	the	O
31	different	O
32	injury	O
33	pattern	O
34	,	O
35	and	O
36	survivors	O
37	versus	O
38	nonsurvivors	O
39	as	O
40	well	O
41	.	O

1	In	O
2	addition	O
3	a	O
4	significant	O
5	Treatment	O
6	X	O
7	Strain	O
8	interaction	O
9	was	O
10	due	O
11	to	O
12	the	O
13	larger	O
14	defecation	O
15	numbers	O
16	displayed	O
17	by	O
18	the	O
19	taurine	O
20	-	O
21	injected	O
22	MR	O
23	rats	O
24	relative	O
25	to	O
26	the	O
27	saline	O
28	-	O
29	injected	O
30	MR	O
31	rats	O
32	.	O

1	Competition	O
2	EMSA	O
3	established	O
4	that	O
5	constitutively	O
6	expressed	O
7	nuclear	O
8	proteins	O
9	bound	O
10	the	O
11	KCS	O
12	element	O
13	selectively	O
14	;	O
15	KCS	B
16	protein	I
17	binding	O
18	activity	O
19	correlated	O
20	with	O
21	promoter	O
22	activity	O
23	in	O
24	the	O
25	transient	O
26	transfection	O
27	reporter	O
28	assay	O
29	.	O

1	The	O
2	polyubiquitin	B
3	gene	I
4	was	O
5	transcribed	O
6	throughout	O
7	the	O
8	Volvox	O
9	life	O
10	cycle	O
11	with	O
12	peaks	O
13	in	O
14	the	O
15	1	O
16	.	O
17	6	O
18	-	O
19	kb	O
20	mRNA	O
21	levels	O
22	during	O
23	pre	O
24	-	O
25	cleavage	O
26	,	O
27	cleavage	O
28	,	O
29	and	O
30	post	O
31	-	O
32	inversion	O
33	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	follow	O
5	-	O
6	up	O
7	prospectively	O
8	patients	O
9	with	O
10	arthritis	O
11	after	O
12	infection	O
13	with	O
14	beta	O
15	-	O
16	haemolytic	O
17	streptococci	O
18	of	O
19	Lancefield	O
20	group	O
21	A	O
22	(	O
23	beta	O
24	HSA	O
25	),	O
26	with	O
27	emphasis	O
28	on	O
29	clinical	O
30	characteristics	O
31	and	O
32	serological	O
33	features	O
34	.	O

1	The	O
2	initial	O
3	inpatient	O
4	experience	O
5	for	O
6	individuals	O
7	with	O
8	HIV	O
9	-	O
10	related	O
11	TB	O
12	may	O
13	be	O
14	pivotal	O
15	to	O
16	the	O
17	acceptance	O
18	of	O
19	and	O
20	participation	O
21	in	O
22	ongoing	O
23	TB	O
24	care	O
25	.	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	O
21	-	O
22	protein	O
23	interactions	O
24	.	O

1	Ex	O
2	vivo	O
3	MAO	O
4	inhibition	O
5	data	O
6	indicated	O
7	DPGPEA	O
8	to	O
9	be	O
10	an	O
11	inhibitor	O
12	of	O
13	MAO	B
14	-	I
15	B	I
16	,	O
17	although	O
18	the	O
19	effect	O
20	was	O
21	much	O
22	weaker	O
23	than	O
24	seen	O
25	with	O
26	tranylcypromine	O
27	or	O
28	pargyline	O
29	.	O

1	Cytogenetic	O
2	studies	O
3	were	O
4	performed	O
5	in	O
6	lymphocytes	O
7	from	O
8	hospital	O
9	workers	O
10	exposed	O
11	to	O
12	low	O
13	doses	O
14	of	O
15	radiation	O
16	(	O
17	1	O
18	.	O
19	6	O
20	-	O
21	42	O
22	.	O
23	71	O
24	mSv	O
25	).	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	protein	O
7	from	O
8	Drosophila	O
9	nuclear	O
10	extracts	O
11	which	O
12	binds	O
13	specifically	O
14	to	O
15	a	O
16	site	O
17	in	O
18	this	O
19	second	O
20	region	O
21	.	O

1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	indicate	O
7	that	O
8	MAP	B
9	kinase	I
10	stimulates	O
11	the	O
12	hPL	B
13	-	I
14	B	I
15	enhancer	I
16	by	O
17	an	O
18	NF	B
19	-	I
20	IL	I
21	-	I
22	6	I
23	-	O
24	dependent	O
25	pathway	O
26	.	O

1	The	O
2	two	O
3	ParA	B
4	proteins	I
5	that	O
6	are	O
7	produced	O
8	as	O
9	a	O
10	result	O
11	of	O
12	independent	O
13	translation	O
14	initiation	O
15	at	O
16	two	O
17	different	O
18	start	O
19	codons	O
20	within	O
21	the	O
22	same	O
23	open	O
24	reading	O
25	frame	O
26	were	O
27	overexpressed	O
28	in	O
29	Escherichia	O
30	coli	O
31	and	O
32	partially	O
33	purified	O
34	.	O

1	Drag	O
2	reduction	O
3	in	O
4	turbulent	O
5	flows	O
6	by	O
7	polymers	O
8	.	O

1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	I
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O

1	It	O
2	contains	O
3	a	O
4	5	O
5	'-	O
6	noncoding	O
7	region	O
8	(	O
9	NCR	O
10	)	O
11	of	O
12	73	O
13	nucleotides	O
14	,	O
15	five	O
16	open	O
17	reading	O
18	frames	O
19	(	O
20	ORFs	O
21	1	O
22	to	O
23	5	O
24	)	O
25	which	O
26	encode	O
27	proteins	O
28	with	O
29	M	B
30	(	I
31	r	I
32	)	I
33	160	I
34	kDa	I
35	RNA	I
36	-	I
37	dependent	I
38	RNA	I
39	polymerase	I
40	(	O
41	ORF1	O
42	),	O
43	26	B
44	kDa	I
45	movement	I
46	protein	I
47	1	I
48	(	O
49	ORF2	O
50	),	O
51	13	O
52	kDa	O
53	movement	O
54	protein	O
55	2	O
56	(	O
57	ORF3	O
58	),	O
59	10	O
60	kDa	O
61	movement	O
62	protein	O
63	3	O
64	(	O
65	ORF4	O
66	),	O
67	24	B
68	kDa	I
69	coat	I
70	protein	I
71	(	O
72	OFR5	O
73	),	O
74	and	O
75	a	O
76	3	O
77	'	O
78	NCR	O
79	of	O
80	76	O
81	nucleotides	O
82	.	O

1	This	O
2	computation	O
3	is	O
4	performed	O
5	by	O
6	a	O
7	parallel	O
8	network	O
9	of	O
10	locally	O
11	connected	O
12	neuron	O
13	-	O
14	like	O
15	elements	O
16	.	O

1	Characterization	O
2	of	O
3	the	O
4	regulatory	O
5	regions	O
6	of	O
7	the	O
8	human	B
9	aromatase	I
10	(	O
11	P450arom	O
12	)	O
13	gene	O
14	involved	O
15	in	O
16	placenta	O
17	-	O
18	specific	O
19	expression	O
20	.	O

1	Protein	B
2	S	I
3	levels	O
4	were	O
5	virtually	O
6	undetectable	O
7	at	O
8	the	O
9	time	O
10	of	O
11	admission	O
12	and	O
13	failed	O
14	to	O
15	respond	O
16	to	O
17	infusions	O
18	of	O
19	fresh	O
20	frozen	O
21	plasma	O
22	,	O
23	despite	O
24	correction	O
25	of	O
26	other	O
27	procoagulant	O
28	and	O
29	anticoagulant	O
30	factors	O
31	.	O

1	The	O
2	baroreflex	O
3	latency	O
4	(	O
5	from	O
6	the	O
7	ECG	O
8	R	O
9	-	O
10	wave	O
11	to	O
12	the	O
13	integrated	O
14	MSNA	O
15	burst	O
16	peak	O
17	)	O
18	was	O
19	constant	O
20	at	O
21	approximately	O
22	1	O
23	.	O
24	20	O
25	s	O
26	during	O
27	sleep	O
28	,	O
29	suggesting	O
30	that	O
31	pulse	O
32	-	O
33	synchronicity	O
34	was	O
35	maintained	O
36	.	O

1	In	O
2	consequence	O
3	,	O
4	the	O
5	gpI	O
6	derived	O
7	from	O
8	cells	O
9	infected	O
10	with	O
11	mO74	O
12	showed	O
13	antigenic	O
14	characteristics	O
15	similar	O
16	to	O
17	those	O
18	of	O
19	gpI	O
20	from	O
21	VZV	O
22	-	O
23	infected	O
24	cells	O
25	as	O
26	determined	O
27	from	O
28	the	O
29	immunoprecipitation	O
30	pattern	O
31	,	O
32	although	O
33	the	O
34	molecular	O
35	weight	O
36	of	O
37	each	O
38	polypeptide	O
39	was	O
40	different	O
41	,	O
42	and	O
43	antibody	O
44	produced	O
45	in	O
46	rabbits	O
47	infected	O
48	with	O
49	recombinant	O
50	virus	O
51	had	O
52	a	O
53	high	O
54	neutralizing	O
55	activity	O
56	,	O
57	when	O
58	the	O
59	reaction	O
60	was	O
61	performed	O
62	with	O
63	complement	O
64	.	O

1	Examination	O
2	of	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	Punta	B
8	Toro	I
9	M	I
10	gene	I
11	product	I
12	reveals	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	hydrophobic	O
18	sequences	O
19	including	O
20	a	O
21	19	O
22	-	O
23	amino	O
24	acid	O
25	,	O
26	carboxy	O
27	-	O
28	proximal	O
29	,	O
30	hydrophobic	O
31	region	O
32	(	O
33	G2	O
34	).	O

1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	O
6	EGFR	B
7	/	O
8	ErbB	B
9	-	I
10	3	I
11	receptor	I
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	I
26	3	I
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	The	O
2	rate	O
3	of	O
4	decrement	O
5	in	O
6	DPOAE	O
7	amplitude	O
8	over	O
9	a	O
10	prescribed	O
11	time	O
12	period	O
13	was	O
14	utilized	O
15	as	O
16	a	O
17	measure	O
18	of	O
19	susceptibility	O
20	to	O
21	the	O
22	acoustic	O
23	trauma	O
24	.	O

1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	O
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	B
23	.	O

1	Electrophoretic	O
2	characteriaztion	O
3	of	O
4	virus	O
5	-	O
6	induced	O
7	interferon	B
8	of	O
9	the	O
10	blood	O
11	and	O
12	urine	O
13	in	O
14	rabbits	O

1	Blood	O
2	eosinophils	O
3	in	O
4	patients	O
5	with	O
6	Taenia	O
7	saginata	O
8	taeniasis	O
9	.	O

1	To	O
2	derive	O
3	quantitative	O
4	concentration	O
5	changes	O
6	from	O
7	measurements	O
8	of	O
9	light	O
10	attenuation	O
11	,	O
12	the	O
13	optical	O
14	path	O
15	length	O
16	must	O
17	be	O
18	known	O
19	.	O

1	Stimulation	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	killed	O
7	Bordetella	O
8	pertussis	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	beneficial	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O

1	Previous	O
2	genetic	O
3	studies	O
4	led	O
5	to	O
6	the	O
7	conclusion	O
8	that	O
9	nitrate	O
10	and	O
11	nitrite	O
12	induction	O
13	of	O
14	nasF	B
15	operon	I
16	expression	O
17	is	O
18	determined	O
19	by	O
20	a	O
21	transcriptional	O
22	antitermination	O
23	mechanism	O
24	.	O

1	BCL	B
2	-	I
3	2	I
4	,	O
5	an	O
6	inhibitor	O
7	of	O
8	apoptosis	O
9	in	O
10	a	O
11	wide	O
12	variety	O
13	of	O
14	cell	O
15	types	O
16	,	O
17	has	O
18	been	O
19	reported	O
20	to	O
21	prevent	O
22	oxidative	O
23	stress	O
24	-	O
25	induced	O
26	cell	O
27	death	O
28	.	O

1	Efficacy	O
2	and	O
3	field	O
4	evaluation	O
5	of	O
6	Bacillus	O
7	thuringiensis	O
8	(	O
9	H	O
10	-	O
11	14	O
12	)	O
13	and	O
14	B	O
15	.	O
16	sphaericus	O
17	against	O
18	floodwater	O
19	mosquitoes	O
20	in	O
21	California	O
22	.	O

1	Refractory	O
2	periods	O
3	of	O
4	the	O
5	AV	O
6	junction	O
7	were	O
8	altered	O
9	in	O
10	a	O
11	comparable	O
12	fashion	O
13	to	O
14	conduction	O
15	through	O
16	the	O
17	AV	O
18	node	O
19	.	O

1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	B
40	formula	O
41	,	O
42	soy	B
43	/	I
44	pork	I
45	collagen	I
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	plus	O
14	c	B
15	-	I
16	Fos	I
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	B
22	-	O
23	CAT	B
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	B
29	-	I
30	1	I
31	,	O
32	GATA	B
33	-	I
34	2	I
35	or	O
36	GATA	B
37	-	I
38	3	I
39	did	O
40	not	O
41	.	O

1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	B
9	A	I
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O

1	Analysis	O
2	of	O
3	functional	O
4	domains	O
5	of	O
6	Arix	B
7	reveals	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	activation	O
13	domain	O
14	and	O
15	a	O
16	C	O
17	-	O
18	terminal	O
19	repression	O
20	domain	O
21	.	O

1	RNase	B
2	protection	O
3	experiments	O
4	confirmed	O
5	the	O
6	presence	O
7	of	O
8	the	O
9	GHR1	O
10	-	O
11	279	O
12	variant	O
13	in	O
14	IM	O
15	-	O
16	9	O
17	cells	O
18	and	O
19	human	O
20	liver	O
21	.	O

1	The	O
2	Aie1	B
3	locus	I
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	O
10	-	O
11	A3	O
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	A	O
2	13	O
3	-	O
4	bp	O
5	cis	O
6	-	O
7	regulatory	O
8	element	O
9	in	O
10	the	O
11	LTR	O
12	promoter	O
13	of	O
14	the	O
15	tobacco	O
16	retrotransposon	O
17	Tto1	O
18	is	O
19	involved	O
20	in	O
21	responsiveness	O
22	to	O
23	tissue	O
24	culture	O
25	,	O
26	wounding	O
27	,	O
28	methyl	O
29	jasmonate	O
30	and	O
31	fungal	O
32	elicitors	O
33	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	B
14	fluid	I
15	gamma	I
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	Human	O
2	ESP1	O
3	/	O
4	CRP2	B
5	protein	I
6	has	O
7	two	O
8	LIM	B
9	domains	I
10	,	O
11	and	O
12	each	O
13	shares	O
14	35	O
15	.	O
16	1	O
17	%	O
18	and	O
19	77	O
20	or	O
21	79	O
22	%	O
23	identical	O
24	residues	O
25	with	O
26	human	O
27	cysteine	O
28	-	O
29	rich	O
30	protein	O
31	(	O
32	CRP	B
33	)	O
34	and	O
35	rat	B
36	CRIP	I
37	,	O
38	respectively	O
39	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	cytochromes	O
5	bd	O
6	and	O
7	their	O
8	homologs	O
9	from	O
10	various	O
11	organisms	O
12	demonstrates	O
13	that	O
14	the	O
15	proteins	O
16	can	O
17	be	O
18	classified	O
19	into	O
20	two	O
21	subfamilies	O
22	,	O
23	a	O
24	proteobacterial	O
25	type	O
26	including	O
27	E	O
28	.	O
29	coli	O
30	bd	O
31	and	O
32	a	O
33	more	O
34	widely	O
35	distributed	O
36	type	O
37	including	O
38	the	O
39	B	O
40	.	O
41	stearothermophilus	O
42	enzyme	O
43	,	O
44	suggesting	O
45	that	O
46	the	O
47	latter	O
48	type	O
49	is	O
50	evolutionarily	O
51	older	O
52	.	O

1	The	O
2	syncytial	O
3	microvillous	O
4	projections	O
5	seemed	O
6	to	O
7	be	O
8	more	O
9	numerous	O
10	and	O
11	longer	O
12	in	O
13	CNF	O
14	,	O
15	otherwise	O
16	the	O
17	structure	O
18	of	O
19	the	O
20	trophoblastic	O
21	layer	O
22	of	O
23	the	O
24	villi	O
25	and	O
26	the	O
27	lining	O
28	of	O
29	the	O
30	subtrophoblastic	O
31	vessels	O
32	were	O
33	identical	O
34	in	O
35	CNF	O
36	and	O
37	controls	O
38	.	O

1	The	O
2	C	O
3	-	O
4	LIP	O
5	also	O
6	was	O
7	compared	O
8	with	O
9	transcather	O
10	arterial	O
11	embolization	O
12	(	O
13	TAE	O
14	;	O
15	C	O
16	-	O
17	LIP	O
18	followed	O
19	by	O
20	gelatin	O
21	sponge	O
22	)	O
23	and	O
24	percutaneous	O
25	ethanol	O
26	injection	O
27	therapy	O
28	(	O
29	PEIT	O
30	).	O

1	The	O
2	gene	O
3	for	O
4	the	O
5	RNA	O
6	-	O
7	dependent	O
8	eIF	B
9	-	I
10	2	I
11	alpha	I
12	protein	I
13	kinase	I
14	(	O
15	PKR	B
16	)	O
17	was	O
18	isolated	O
19	from	O
20	mouse	O
21	genomic	O
22	DNA	O
23	and	O
24	characterized	O
25	.	O

1	CONTEXT	O
2	:	O
3	ThinPrep	O
4	,	O
5	AutoPap	O
6	,	O
7	and	O
8	Papnet	O
9	are	O
10	3	O
11	new	O
12	technologies	O
13	that	O
14	increase	O
15	the	O
16	sensitivity	O
17	and	O
18	cost	O
19	of	O
20	cervical	O
21	cancer	O
22	screening	O
23	.	O

1	The	O
2	diagnosis	O
3	of	O
4	metachromatic	O
5	leukodystrophy	O
6	(	O
7	MLD	O
8	)	O
9	was	O
10	confirmed	O
11	by	O
12	the	O
13	finding	O
14	of	O
15	low	B
16	arylsulfatase	I
17	A	I
18	(	O
19	ASA	O
20	)	O
21	levels	O
22	in	O
23	cultured	O
24	fibroblasts	O
25	in	O
26	both	O
27	sisters	O
28	.	O

1	Consistent	O
2	with	O
3	our	O
4	model	O
5	,	O
6	CTCF	B
7	binding	O
8	is	O
9	abolished	O
10	by	O
11	DNA	O
12	methylation	O
13	.	O

1	Rep	B
2	-	I
3	Rep	I
4	protein	I
5	interaction	O
6	was	O
7	confirmed	O
8	in	O
9	vitro	O
10	through	O
11	coimmunoprecipitation	O
12	experiments	O
13	with	O
14	a	O
15	bacterially	O
16	expressed	O
17	maltose	O
18	-	O
19	binding	O
20	protein	O
21	-	O
22	Rep78	B
23	fusion	O
24	protein	O
25	in	O
26	combination	O
27	with	O
28	[	O
29	35S	O
30	]	O
31	methionine	O
32	-	O
33	labeled	O
34	Rep78	B
35	synthesized	O
36	in	O
37	a	O
38	coupled	O
39	in	O
40	vitro	O
41	transcription	O
42	-	O
43	translation	O
44	system	O
45	.	O

1	The	O
2	gene	O
3	contains	O
4	six	O
5	exons	O
6	separated	O
7	by	O
8	1	O
9	.	O
10	1	O
11	-	O
12	5	O
13	.	O
14	8	O
15	kb	O
16	introns	O
17	and	O
18	has	O
19	been	O
20	localized	O
21	to	O
22	the	O
23	murine	O
24	chromosome	O
25	2	O
26	by	O
27	linkage	O
28	analysis	O
29	.	O

1	The	O
2	resulting	O
3	integrated	O
4	physical	O
5	,	O
6	genetic	O
7	,	O
8	and	O
9	cytogenetic	O
10	map	O
11	constitutes	O
12	a	O
13	resource	O
14	for	O
15	the	O
16	characterization	O
17	of	O
18	genes	O
19	that	O
20	may	O
21	be	O
22	involved	O
23	in	O
24	the	O
25	WAGR	O
26	syndrome	O
27	.	O

1	Syndecan	O
2	-	O
3	4	O
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	localize	O
16	PKC	B
17	and	O
18	amplify	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	adhesions	O
26	.	O

1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O

1	Alternative	O
2	processing	O
3	of	O
4	the	O
5	tryptophanyl	B
6	-	I
7	tRNA	I
8	synthetase	I
9	mRNA	I
10	from	O
11	interferon	B
12	-	O
13	treated	O
14	human	O
15	cells	O
16	.	O

1	The	O
2	hydrophobicity	O
3	plot	O
4	of	O
5	NHE	B
6	-	I
7	3	I
8	is	O
9	very	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	NHE	B
15	-	I
16	1	I
17	and	O
18	NHE	B
19	-	I
20	2	I
21	.	O

1	This	O
2	dimer	O
3	interface	O
4	is	O
5	likely	O
6	important	O
7	for	O
8	increasing	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	affinity	O
16	of	O
17	the	O
18	trimeric	O
19	form	O
20	of	O
21	HSF	B
22	,	O
23	as	O
24	well	O
25	as	O
26	for	O
27	increasing	O
28	cooperativity	O
29	between	O
30	adjacent	O
31	trimers	O
32	.	O

1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	looks	O
6	at	O
7	the	O
8	impact	O
9	of	O
10	synthesis	O
11	conditions	O
12	on	O
13	block	O
14	length	O
15	and	O
16	crystallinity	O
17	,	O
18	and	O
19	the	O
20	impact	O
21	of	O
22	the	O
23	blocking	O
24	on	O
25	both	O
26	,	O
27	crystallinity	O
28	and	O
29	solubility	O
30	of	O
31	the	O
32	polymers	O
33	.	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	O
19	C	O
20	-	O
21	terminal	O
22	399	O
23	amino	O
24	acids	O
25	)	O
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O

1	In	O
2	the	O
3	ileum	O
4	,	O
5	enterotoxin	O
6	increased	O
7	the	O
8	luminal	O
9	disappearance	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	)	O
18	and	O
19	peripheral	O
20	blood	O
21	appearance	O
22	(	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	001	O
29	)	O
30	of	O
31	chloroquine	O
32	.	O

1	The	O
2	subjects	O
3	from	O
4	the	O
5	two	O
6	regions	O
7	with	O
8	a	O
9	higher	O
10	pollution	O
11	level	O
12	had	O
13	lower	O
14	FVC	O
15	and	O
16	FEV1	O
17	values	O
18	than	O
19	those	O
20	from	O
21	the	O
22	Viskovo	O
23	region	O
24	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	prostate	O
9	carcinomas	O
10	with	O
11	the	O
12	Ras	B
13	/	O
14	MAPK	B
15	pathway	O
16	activation	O
17	might	O
18	have	O
19	a	O
20	selective	O
21	growth	O
22	advantage	O
23	by	O
24	autocrine	O
25	TGF	B
26	-	I
27	beta1	I
28	production	O
29	.	O

1	Spatial	O
2	accuracy	O
3	of	O
4	primary	O
5	and	O
6	secondary	O
7	memory	O
8	-	O
9	guided	O
10	saccades	O
11	in	O
12	schizophrenic	O
13	patients	O
14	.	O

1	Demographic	O
2	characteristics	O
3	and	O
4	risk	O
5	factor	O
6	data	O
7	for	O
8	76	O
9	,	O
10	672	O
11	clients	O
12	were	O
13	studied	O
14	to	O
15	characterize	O
16	the	O
17	distribution	O
18	of	O
19	infection	O
20	with	O
21	human	O
22	immunodeficiency	O
23	virus	O
24	(	O
25	HIV	O
26	)	O
27	and	O
28	the	O
29	use	O
30	of	O
31	counseling	O
32	and	O
33	testing	O
34	facilities	O
35	in	O
36	Houston	O
37	,	O
38	Tex	O
39	.	O

1	Overexpression	O
2	of	O
3	the	O
4	bZip	B
5	interaction	I
6	domain	I
7	of	O
8	CBP	B
9	specifically	O
10	abolishes	O
11	the	O
12	positive	O
13	cross	O
14	talk	O
15	between	O
16	TR	B
17	and	O
18	p45	B
19	/	O
20	NF	B
21	-	I
22	E2	I
23	.	O

1	In	O
2	an	O
3	ongoing	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	SMSP	B
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	Mini	O
18	Speech	O
19	Processor	O
20	(	O
21	MSP	B
22	).	O

1	Effect	O
2	of	O
3	indomethacin	O
4	on	O
5	coronary	O
6	circulation	O
7	:	O
8	effect	O
9	on	O
10	ECG	O
11	tracing	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	O
11	knuckle	O
12	9G8	O
13	variant	O
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	B
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	O
30	and	O
31	SRp20	B
32	are	O
33	similar	O
34	.	O

1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	O
37	ORF2b	B
38	transframe	I
39	protein	I
40	.	O

1	A	O
2	safe	O
3	and	O
4	simple	O
5	system	O
6	for	O
7	the	O
8	detection	O
9	of	O
10	sudden	O
11	infant	O
12	death	O
13	syndrome	O
14	(	O
15	SIDS	O
16	)	O
17	is	O
18	proposed	O
19	.	O

1	In	O
2	vitro	O
3	transcription	O
4	results	O
5	indicate	O
6	that	O
7	this	O
8	5	O
9	'	O
10	structure	O
11	functions	O
12	in	O
13	the	O
14	attenuation	O
15	mechanism	O
16	,	O
17	since	O
18	deletion	O
19	of	O
20	the	O
21	stem	O
22	-	O
23	loop	O
24	caused	O
25	an	O
26	increase	O
27	in	O
28	transcription	O
29	readthrough	O
30	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	B
6	-	O
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O

1	The	O
2	extents	O
3	of	O
4	phosphorylation	O
5	of	O
6	Ser44	O
7	and	O
8	Ser64	O
9	were	O
10	1	O
11	:	O
12	1	O
13	,	O
14	whereas	O
15	those	O
16	of	O
17	the	O
18	four	O
19	minor	O
20	sites	O
21	all	O
22	together	O
23	were	O
24	<	O
25	30	O
26	%	O
27	of	O
28	the	O
29	major	O
30	one	O
31	.	O

1	Changing	O
2	and	O
3	predicting	O
4	doses	O
5	of	O
6	Cs137	O
7	irradiation	O

1	The	O
2	region	O
3	that	O
4	imparts	O
5	inducibility	O
6	by	O
7	IL	B
8	-	I
9	1	I
10	or	O
11	TNF	B
12	(	O
13	positions	O
14	-	O
15	165	O
16	to	O
17	-	O
18	58	O
19	)	O
20	contains	O
21	potential	O
22	binding	O
23	sites	O
24	for	O
25	IRF	B
26	-	I
27	1	I
28	and	O
29	-	O
30	2	O
31	,	O
32	AP	B
33	-	I
34	1	I
35	,	O
36	and	O
37	NF	B
38	-	I
39	IL	I
40	-	I
41	6	I
42	.	O

1	Twenty	O
2	patients	O
3	aged	O
4	45	O
5	or	O
6	older	O
7	with	O
8	the	O
9	diagnosis	O
10	of	O
11	endogenous	O
12	depression	O
13	were	O
14	evaluated	O
15	in	O
16	terms	O
17	of	O
18	safety	O
19	and	O
20	efficacy	O
21	in	O
22	their	O
23	response	O
24	to	O
25	multiple	O
26	monitored	O
27	electroconvulsive	O
28	therapy	O
29	(	O
30	MMECT	O
31	)	O
32	versus	O
33	single	O
34	electroconvulsive	O
35	therapy	O
36	(	O
37	SECT	O
38	).	O

1	Cutaneous	O
2	necrosis	O
3	associated	O
4	with	O
5	protein	B
6	S	I
7	deficiency	O
8	.	O

1	Transabdominal	O
2	repair	O
3	of	O
4	type	O
5	IV	O
6	thoraco	O
7	-	O
8	abdominal	O
9	aortic	O
10	aneurysms	O
11	.	O

1	The	O
2	purpose	O
3	of	O
4	the	O
5	study	O
6	reported	O
7	here	O
8	was	O
9	to	O
10	investigate	O
11	whether	O
12	differences	O
13	in	O
14	T1	O
15	and	O
16	T2	O
17	between	O
18	tumors	O
19	are	O
20	mainly	O
21	a	O
22	consequence	O
23	of	O
24	differences	O
25	in	O
26	the	O
27	fractional	O
28	volume	O
29	of	O
30	the	O
31	extracellular	O
32	compartment	O
33	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	B
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	O
26	group	O
27	of	O
28	the	O
29	esterase	B
30	/	I
31	lipase	I
32	family	I
33	.	O

1	Type	B
2	2	I
3	deiodinase	I
4	(	O
5	D2	O
6	)	O
7	catalyzes	O
8	the	O
9	5	O
10	'-	O
11	deiodination	O
12	of	O
13	thyroxine	O
14	to	O
15	form	O
16	3	O
17	,	O
18	5	O
19	,	O
20	3	O
21	'-	O
22	triiodothyronine	O
23	.	O

1	NH2	O
2	-	O
3	terminal	O
4	trimming	O
5	of	O
6	Xenopus	O
7	and	O
8	mammalian	O
9	FGF3s	O
10	may	O
11	therefore	O
12	be	O
13	a	O
14	prerequisite	O
15	of	O
16	optimal	O
17	biological	O
18	activity	O
19	.	O

1	FK	O
2	33	O
3	-	O
4	824	O
5	,	O
6	a	O
7	methionine	O
8	-	O
9	enkephalin	O
10	analogue	O
11	,	O
12	suppressed	O
13	plasma	O
14	ACTH	B
15	to	O
16	85	O
17	%	O
18	of	O
19	basal	O
20	level	O
21	,	O
22	while	O
23	bromocriptine	O
24	(	O
25	CB	O
26	-	O
27	154	O
28	)	O
29	caused	O
30	no	O
31	significant	O
32	change	O
33	.	O

1	The	O
2	level	O
3	of	O
4	carboxyl	O
5	-	O
6	terminal	O
7	parathyroid	O
8	hormone	O
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O

1	Cell	O
2	lines	O
3	are	O
4	checked	O
5	to	O
6	find	O
7	out	O
8	whether	O
9	they	O
10	develop	O
11	tumors	O
12	in	O
13	nude	O
14	mice	O
15	followed	O
16	by	O
17	an	O
18	analysis	O
19	of	O
20	the	O
21	karyotype	O
22	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	Tax	B
10	activation	O
11	of	O
12	NF	B
13	-	I
14	kappa	I
15	B	I
16	/	O
17	Rel	B
18	involves	O
19	phosphorylation	O
20	and	O
21	degradation	O
22	of	O
23	I	B
24	kappa	I
25	B	I
26	alpha	I
27	and	O
28	RelA	B
29	(	O
30	p65	B
31	)-	O
32	mediated	O
33	induction	O
34	of	O
35	the	O
36	c	O
37	-	O
38	rel	B
39	gene	I
40	.	O

1	Its	O
2	transcription	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	be	O
8	induced	O
9	40	O
10	-	O
11	50	O
12	-	O
13	fold	O
14	in	O
15	response	O
16	to	O
17	oxygen	O
18	or	O
19	heme	O
20	deficiency	O
21	,	O
22	in	O
23	part	O
24	through	O
25	relief	O
26	of	O
27	repression	O
28	exerted	O
29	by	O
30	Rox1p	B
31	and	O
32	in	O
33	part	O
34	by	O
35	activation	O
36	mediated	O
37	by	O
38	an	O
39	upstream	O
40	activation	O
41	sequence	O
42	(	O
43	UAS	O
44	).	O

1	In	O
2	Experiment	O
3	II	O
4	,	O
5	as	O
6	performing	O
7	moderate	O
8	supine	O
9	cycling	O
10	(	O
11	55	O
12	%	O
13	VO2	O
14	max	O
15	)	O
16	for	O
17	50	O
18	minutes	O
19	under	O
20	several	O
21	LBNP	O
22	conditions	O
23	in	O
24	5	O
25	sedentary	O
26	women	O
27	,	O
28	there	O
29	were	O
30	correspondingly	O
31	similar	O
32	changing	O
33	manners	O
34	of	O
35	the	O
36	cardiovascular	O
37	adjustments	O
38	to	O
39	each	O
40	of	O
41	the	O
42	phases	O
43	given	O
44	in	O
45	Experiment	O
46	I	O
47	.	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	O
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	O
18	factor	O
19	binding	O
20	sites	O
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	O
26	-	O
27	responsive	O
28	element	O
29	)	O
30	were	O
31	found	O
32	.	O

1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	B
7	and	O
8	KlaB	B
9	polypeptides	I
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	B
19	polypeptide	I
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O

1	Two	O
2	new	O
3	flavone	O
4	glucosides	O
5	,	O
6	nevadensin	B
7	5	I
8	-	I
9	O	I
10	-	I
11	beta	I
12	-	I
13	D	I
14	-	I
15	glucoside	I
16	and	I
17	nevadensin	I
18	5	I
19	-	I
20	O	I
21	-	I
22	beta	I
23	-	I
24	D	I
25	-	I
26	glucosyl	I
27	(	I
28	1	I
29	-->	I
30	6	I
31	)	I
32	beta	I
33	-	I
34	D	I
35	-	I
36	glucoside	I
37	,	O
38	have	O
39	been	O
40	isolated	O
41	from	O
42	the	O
43	aerial	O
44	parts	O
45	of	O
46	Lysionotus	O
47	pauciflorus	O
48	.	O

1	Antipyretic	O
2	therapy	O
3	:	O
4	physiologic	O
5	rationale	O
6	,	O
7	diagnostic	O
8	implications	O
9	,	O
10	and	O
11	clinical	O
12	consequences	O
13	.	O

1	The	O
2	centromedial	O
3	amygdala	O
4	and	O
5	gastric	O
6	pathology	O
7	in	O
8	rats	O
9	.	O

1	This	O
2	generally	O
3	means	O
4	an	O
5	energy	O
6	intake	O
7	of	O
8	1	O
9	.	O
10	4	O
11	to	O
12	1	O
13	.	O
14	6	O
15	times	O
16	the	O
17	energy	O
18	expenditure	O
19	,	O
20	with	O
21	a	O
22	N	O
23	intake	O
24	of	O
25	250	O
26	to	O
27	400	O
28	mg	O
29	/	O
30	kg	O
31	/	O
32	day	O
33	.	O

1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O

1	Recombinant	B
2	Leishmania	I
3	surface	I
4	glycoprotein	I
5	GP63	I
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	B
16	metalloproteinase	I
17	.	O

1	The	O
2	interaction	O
3	of	O
4	zf4	O
5	-	O
6	6	O
7	with	O
8	full	B
9	-	I
10	length	I
11	5	I
12	S	I
13	RNA	I
14	was	O
15	far	O
16	more	O
17	sensitive	O
18	to	O
19	non	O
20	-	O
21	specific	O
22	competitor	O
23	concentration	O
24	than	O
25	was	O
26	the	O
27	zf4	O
28	-	O
29	7	O
30	:	O
31	5	O
32	S	O
33	RNA	O
34	interaction	O
35	,	O
36	suggesting	O
37	that	O
38	finger	O
39	seven	O
40	contributes	O
41	to	O
42	both	O
43	affinity	O
44	and	O
45	specificity	O
46	in	O
47	this	O
48	protein	O
49	:	O
50	RNA	O
51	interaction	O
52	.	O

1	The	O
2	protein	O
3	expressed	O
4	from	O
5	the	O
6	cloned	O
7	cDNA	O
8	is	O
9	secreted	O
10	into	O
11	the	O
12	culture	O
13	medium	O
14	and	O
15	yields	O
16	of	O
17	up	O
18	to	O
19	40	O
20	mg	O
21	per	O
22	litre	O
23	have	O
24	been	O
25	obtained	O
26	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	O
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	the	O
6	mechanism	O
7	of	O
8	action	O
9	,	O
10	two	O
11	groups	O
12	of	O
13	inodilators	O
14	are	O
15	distinguished	O
16	,	O
17	the	O
18	phosphodiesterase	B
19	inhibitors	O
20	and	O
21	the	O
22	dopaminergic	O
23	agents	O
24	.	O

1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	gagging	O
7	induced	O
8	by	O
9	oropharyngeal	O
10	irritation	O
11	is	O
12	unclear	O
13	.	O

1	In	O
2	vitro	O
3	binding	O
4	studies	O
5	using	O
6	GST	B
7	fusion	O
8	proteins	O
9	and	O
10	yeast	O
11	extracts	O
12	defined	O
13	distinct	O
14	binding	O
15	sites	O
16	on	O
17	yAP180A	O
18	for	O
19	Pan1p	B
20	and	O
21	clathrin	B
22	.	I
23	yAP180	I
24	proteins	I
25	and	O
26	Pan1p	B
27	,	O
28	like	O
29	actin	B
30	,	O
31	localize	O
32	to	O
33	peripheral	O
34	patches	O
35	along	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O

1	We	O
2	have	O
3	visualized	O
4	DNA	O
5	-	O
6	protein	O
7	complexes	O
8	by	O
9	electron	O
10	microscopy	O
11	and	O
12	a	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	site	O
18	of	O
19	WDV	B
20	Rep	I
21	protein	I
22	within	O
23	the	O
24	core	O
25	element	O
26	has	O
27	been	O
28	mapped	O
29	to	O
30	approximately	O
31	144	O
32	+/-	O
33	18	O
34	bp	O
35	upstream	O
36	from	O
37	the	O
38	initiation	O
39	site	O
40	,	O
41	between	O
42	the	O
43	start	O
44	site	O
45	for	O
46	complementary	O
47	-	O
48	sense	O
49	transcription	O
50	and	O
51	the	O
52	TATA	O
53	box	O
54	.	O

1	Mapping	O
2	of	O
3	the	O
4	DNA	O
5	binding	O
6	domain	O
7	of	O
8	the	O
9	copper	B
10	-	I
11	responsive	I
12	transcription	I
13	factor	I
14	Mac1	I
15	from	O
16	Saccharomyces	O
17	cerevisiae	O
18	.	O

1	Significant	O
2	clinical	O
3	differences	O
4	between	O
5	the	O
6	patients	O
7	treated	O
8	with	O
9	and	O
10	without	O
11	AMB	O
12	were	O
13	longer	O
14	survival	O
15	time	O
16	following	O
17	diagnosis	O
18	of	O
19	illness	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	and	O
29	more	O
30	frequent	O
31	cranial	O
32	nerve	O
33	signs	O
34	in	O
35	the	O
36	treated	O
37	patients	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	089	O
44	).	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	However	O
2	,	O
3	ICK1	B
4	was	O
5	induced	O
6	by	O
7	ABA	O
8	,	O
9	and	O
10	along	O
11	with	O
12	ICK1	B
13	induction	O
14	there	O
15	was	O
16	a	O
17	decrease	O
18	in	O
19	Cdc2	B
20	-	I
21	like	I
22	histone	I
23	H1	I
24	kinase	I
25	activity	O
26	.	O

1	The	O
2	effect	O
3	of	O
4	water	O
5	deprivation	O
6	for	O
7	19	O
8	h	O
9	on	O
10	renal	O
11	Na	O
12	excretion	O
13	of	O
14	conscious	O
15	adrenalectomized	O
16	(	O
17	ADX	O
18	)	O
19	sheep	O
20	maintained	O
21	on	O
22	a	O
23	constant	O
24	intravenous	O
25	infusion	O
26	of	O
27	aldosterone	O
28	and	O
29	cortisol	O
30	(	O
31	ADX	O
32	-	O
33	constant	O
34	steroid	O
35	sheep	O
36	)	O
37	was	O
38	investigated	O
39	.	O

1	Two	O
2	domains	O
3	of	O
4	EBNA2	B
5	defined	O
6	by	O
7	deletion	O
8	of	O
9	amino	O
10	acids	O
11	247	O
12	-	O
13	337	O
14	and	O
15	437	O
16	-	O
17	476	O
18	were	O
19	found	O
20	to	O
21	be	O
22	important	O
23	for	O
24	the	O
25	activation	O
26	of	O
27	both	O
28	promoters	O
29	,	O
30	while	O
31	two	O
32	different	O
33	domains	O
34	corresponding	O
35	to	O
36	residues	O
37	4	O
38	-	O
39	18	O
40	and	O
41	118	O
42	-	O
43	198	O
44	were	O
45	required	O
46	solely	O
47	for	O
48	the	O
49	LMP1	B
50	promoter	I
51	.	O

1	However	O
2	,	O
3	the	O
4	ratio	O
5	M	O
6	/	O
7	Pc	O
8	provides	O
9	a	O
10	useful	O
11	index	O
12	that	O
13	seems	O
14	to	O
15	be	O
16	independent	O
17	of	O
18	the	O
19	metabolic	O
20	demand	O
21	.	O

1	In	O
2	agreement	O
3	with	O
4	these	O
5	data	O
6	,	O
7	western	O
8	blot	O
9	experiments	O
10	using	O
11	an	O
12	antibody	O
13	directed	O
14	against	O
15	the	O
16	carboxy	O
17	-	O
18	terminal	O
19	portion	O
20	of	O
21	the	O
22	mouse	B
23	c	I
24	-	I
25	kit	I
26	protein	I
27	showed	O
28	that	O
29	a	O
30	polypeptide	O
31	,	O
32	of	O
33	the	O
34	size	O
35	predicted	O
36	by	O
37	the	O
38	open	O
39	reading	O
40	frame	O
41	of	O
42	the	O
43	spermatid	O
44	-	O
45	specific	O
46	c	B
47	-	I
48	kit	I
49	cDNA	I
50	,	O
51	accumulates	O
52	in	O
53	the	O
54	latest	O
55	stages	O
56	of	O
57	spermatogenesis	O
58	and	O
59	in	O
60	epididymal	O
61	spermatozoa	O
62	.	O

1	A	O
2	previous	O
3	report	O
4	described	O
5	that	O
6	a	O
7	548	O
8	-	O
9	bp	O
10	BglII	B
11	-	I
12	SmaI	I
13	fragment	I
14	has	O
15	an	O
16	SSO	O
17	activity	O
18	(	O
19	ori2	O
20	;	O
21	Kataoka	O
22	et	O
23	al	O
24	.,	O
25	Mol	O
26	.	O

1	Furthermore	O
2	,	O
3	the	O
4	potency	O
5	of	O
6	Dacarbacine	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	carcinoid	O
12	tumors	O
13	seems	O
14	to	O
15	be	O
16	underestimated	O
17	up	O
18	to	O
19	now	O
20	.	O

1	In	O
2	contrast	O
3	to	O
4	this	O
5	mRNA	O
6	,	O
7	90	O
8	%	O
9	of	O
10	alpha	O
11	and	O
12	beta	B
13	actin	I
14	mRNAs	I
15	were	O
16	translated	O
17	in	O
18	both	O
19	myoblasts	O
20	and	O
21	myotubes	O
22	.	O

1	The	O
2	rate	O
3	-	O
4	limiting	O
5	step	O
6	for	O
7	telomerase	B
8	activity	O
9	seems	O
10	to	O
11	be	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	catalytic	O
17	subunit	O
18	of	O
19	the	O
20	enzyme	O
21	,	O
22	encoded	O
23	by	O
24	the	O
25	human	B
26	telomerase	I
27	reverse	I
28	transcriptase	I
29	(	O
30	hTERT	O
31	)	O
32	gene	O
33	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	neuroinfection	O
8	,	O
9	Lyme	O
10	disease	O
11	,	O
12	Guillain	O
13	Barre	O
14	syndrome	O
15	,	O
16	demyelinization	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	antiphospholipid	O
28	antibodies	O
29	of	O
30	IgG	B
31	and	O
32	IgM	B
33	subtypes	O
34	,	O
35	together	O
36	with	O
37	anticoagulant	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	thrombocytes	O
43	,	O
44	sedimentation	O
45	rate	O
46	of	O
47	erythrocytes	O
48	.	O

1	Workers	O
2	with	O
3	"	O
4	sensitivity	O
5	"	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O

1	In	O
2	contrast	O
3	to	O
4	some	O
5	results	O
6	previously	O
7	published	O
8	for	O
9	a	O
10	very	O
11	close	O
12	sequence	O
13	variant	O
14	(	O
15	see	O
16	ref	O
17	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	O
31	(	O
32	Suvar3	O
33	-	O
34	9	O
35	,	O
36	Enhancer	O
37	-	O
38	of	O
39	-	O
40	zeste	O
41	,	O
42	Trithorax	B
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	B
51	.	O

1	Like	O
2	humans	O
3	,	O
4	the	O
5	PITSLRE	B
6	PK	I
7	genes	I
8	in	O
9	chickens	O
10	must	O
11	be	O
12	closely	O
13	linked	O
14	,	O
15	based	O
16	on	O
17	fluorescent	O
18	in	O
19	situ	O
20	hybridization	O
21	(	O
22	FISH	O
23	)	O
24	localization	O
25	of	O
26	these	O
27	genes	O
28	to	O
29	a	O
30	single	O
31	chicken	O
32	microchromosome	O
33	.	O

1	Point	O
2	mutations	O
3	that	O
4	suppressed	O
5	the	O
6	in	O
7	vitro	O
8	binding	O
9	of	O
10	NF	B
11	-	I
12	Y	I
13	to	O
14	the	O
15	internal	O
16	palindromic	O
17	arm	O
18	reduced	O
19	the	O
20	activity	O
21	of	O
22	the	O
23	resident	O
24	P4	B
25	promoter	I
26	,	O
27	while	O
28	those	O
29	preventing	O
30	complex	O
31	formation	O
32	with	O
33	USF	B
34	did	O
35	not	O
36	,	O
37	as	O
38	determined	O
39	by	O
40	transient	O
41	expression	O
42	assays	O
43	using	O
44	the	O
45	luciferase	B
46	reporter	I
47	gene	I
48	.	O

1	Removal	O
2	of	O
3	the	O
4	GST	B
5	domain	O
6	from	O
7	GST	B
8	-	O
9	Tax	B
10	by	O
11	thrombin	B
12	restores	O
13	Tax	B
14	'	O
15	s	O
16	ability	O
17	to	O
18	assemble	O
19	a	O
20	ternary	O
21	Tax	B
22	-	O
23	CREB	B
24	-	O
25	21	O
26	-	O
27	bp	O
28	-	O
29	repeat	O
30	complex	O
31	.(	O
32	ABSTRACT	O
33	TRUNCATED	O
34	AT	O
35	400	O
36	WORDS	O
37	)	O

1	A	O
2	recombinant	O
3	derivative	O
4	harboring	O
5	the	O
6	pMJ101	O
7	replication	O
8	region	O
9	proved	O
10	to	O
11	be	O
12	compatible	O
13	with	O
14	pJM1	B
15	,	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	iron	O
21	acquisition	O
22	system	O
23	required	O
24	for	O
25	the	O
26	virulence	O
27	of	O
28	V	O
29	.	O
30	anguillarum	O
31	775	O
32	,	O
33	another	O
34	important	O
35	pathogen	O
36	that	O
37	causes	O
38	vibriosis	O
39	.	O

1	These	O
2	mutations	O
3	create	O
4	stop	O
5	codons	O
6	in	O
7	exon	O
8	7	O
9	and	O
10	8	O
11	,	O
12	respectively	O
13	,	O
14	and	O
15	probably	O
16	result	O
17	in	O
18	truncated	O
19	proteins	O
20	lacking	O
21	HLH	O
22	-	O
23	Zip	O
24	or	O
25	Zip	O
26	structure	O
27	.	O

1	This	O
2	dependence	O
3	,	O
4	however	O
5	,	O
6	can	O
7	be	O
8	overcome	O
9	to	O
10	a	O
11	large	O
12	extent	O
13	by	O
14	dividing	O
15	min	O
16	LVdP	O
17	/	O
18	dt	O
19	by	O
20	mean	O
21	aortic	O
22	pressure	O
23	.	O

1	CodY	O
2	does	O
3	not	O
4	have	O
5	any	O
6	homologues	O
7	in	O
8	the	O
9	data	O
10	-	O
11	bases	O
12	.	O

1	Histopathologically	O
2	,	O
3	a	O
4	cystic	O
5	lymphangioma	O
6	was	O
7	diagnosed	O
8	because	O
9	of	O
10	the	O
11	morphological	O
12	features	O
13	and	O
14	the	O
15	immunohistochemical	O
16	stainings	O
17	of	O
18	CD34	B
19	and	O
20	Factor	B
21	VIII	I
22	related	I
23	antigen	I
24	which	O
25	were	O
26	observed	O
27	positive	O
28	reactions	O
29	in	O
30	endothelial	O
31	cells	O
32	of	O
33	the	O
34	cysts	O
35	.	O

1	A	O
2	strong	O
3	correlation	O
4	exists	O
5	between	O
6	the	O
7	numbers	O
8	of	O
9	CFU	O
10	-	O
11	GM	O
12	transfused	O
13	and	O
14	the	O
15	rate	O
16	of	O
17	granulocytes	O
18	and	O
19	platelets	O
20	recovery	O
21	.	O

1	Validity	O
2	of	O
3	NIR	O
4	spectroscopy	O
5	for	O
6	quantitatively	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O

1	N	O
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O

1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	ERP	O
6	effects	O
7	of	O
8	distinct	O
9	memory	O
10	processes	O
11	are	O
12	differentially	O
13	influenced	O
14	by	O
15	the	O
16	encoding	O
17	instructions	O
18	.	O

1	Fluorescence	O
2	in	O
3	situ	O
4	hybridization	O
5	of	O
6	metaphase	B
7	spreads	O
8	of	O
9	chromosome	O
10	8	O
11	,	O
12	containing	O
13	hybrid	O
14	cell	O
15	line	O
16	706	O
17	-	O
18	B6	O
19	clone	O
20	17	O
21	(	O
22	CL	O
23	-	O
24	17	O
25	)	O
26	with	O
27	cosmid	O
28	c101F1	O
29	,	O
30	placed	O
31	the	O
32	9804	O
33	gene	O
34	close	O
35	to	O
36	the	O
37	telomere	O
38	at	O
39	8q24	O
40	.	O
41	3	O
42	.	O

1	We	O
2	have	O
3	carried	O
4	out	O
5	a	O
6	comprehensive	O
7	and	O
8	systematic	O
9	mutagenesis	O
10	of	O
11	the	O
12	Cse4p	B
13	N	I
14	terminus	I
15	to	O
16	analyze	O
17	its	O
18	function	O
19	.	O

1	During	O
2	this	O
3	time	O
4	,	O
5	the	O
6	patients	O
7	all	O
8	had	O
9	the	O
10	characteristic	O
11	plasma	O
12	thyroid	O
13	hormone	O
14	changes	O
15	associated	O
16	with	O
17	amiodarone	O
18	therapy	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	increased	O
25	T4	O
26	,	O
27	free	O
28	T4	O
29	,	O
30	and	O
31	rT3	B
32	and	O
33	decreased	O
34	T3	O
35	,	O
36	while	O
37	remaining	O
38	clinically	O
39	euthyroid	O
40	.	O

1	This	O
2	report	O
3	focused	O
4	on	O
5	the	O
6	relationship	O
7	between	O
8	Type	O
9	A	O
10	behavior	O
11	and	O
12	eight	O
13	basic	O
14	emotion	O
15	dimensions	O
16	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	clarify	O
7	the	O
8	location	O
9	of	O
10	a	O
11	transesophageal	O
12	echocardiographic	O
13	(	O
14	TEE	O
15	)	O
16	transducer	O
17	when	O
18	obtaining	O
19	the	O
20	short	O
21	-	O
22	axis	O
23	view	O
24	of	O
25	the	O
26	left	O
27	ventricle	O
28	(	O
29	S	O
30	-	O
31	LV	O
32	).	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	B
6	PGS	I
7	-	I
8	2	I
9	gene	I
10	contains	O
11	a	O
12	CAAT	B
13	enhancer	I
14	-	I
15	binding	I
16	protein	I
17	consensus	I
18	site	I
19	(	O
20	CAAT	O
21	box	O
22	)	O
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	PGS	B
31	-	I
32	2	I
33	.	O
34	CAT	B
35	reporter	I
36	gene	I
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	O
44	-	O
45	box	O
46	region	O
47	.	O

1	During	O
2	this	O
3	period	O
4	,	O
5	administration	O
6	of	O
7	additional	O
8	exogenous	O
9	PRL	B
10	did	O
11	not	O
12	stimulate	O
13	further	O
14	activation	O
15	(	O
16	binding	O
17	)	O
18	of	O
19	the	O
20	Stat	B
21	factors	I
22	.	O

1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	I
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	complexed	O
17	with	O
18	a	O
19	doubly	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	polyomavirus	B
25	middle	I
26	T	I
27	antigen	I
28	(	O
29	MT	O
30	).	O

1	By	O
2	Felix	O
3	Lagrange	O
4	,	O
5	1918	O
6	.	O

1	The	O
2	nonconsensus	O
3	TATA	O
4	box	O
5	in	O
6	promoter	O
7	B	O
8	plays	O
9	a	O
10	more	O
11	important	O
12	role	O
13	in	O
14	promoter	O
15	activity	O
16	than	O
17	the	O
18	TATA	O
19	box	O
20	in	O
21	promoter	O
22	A	O
23	.	O

1	Prazosin	O
2	alone	O
3	was	O
4	effective	O
5	in	O
6	volume	O
7	responsive	O
8	patients	O
9	at	O
10	a	O
11	dose	O
12	of	O
13	5	O
14	+/-	O
15	1	O
16	.	O
17	0	O
18	mg	O
19	daily	O
20	.	O

1	The	O
2	results	O
3	supported	O
4	the	O
5	therapeutic	O
6	principle	O
7	of	O
8	TCM	O
9	:	O
10	Treating	O
11	patients	O
12	according	O
13	to	O
14	their	O
15	pathophysiological	O
16	patterns	O
17	.	O

1	In	O
2	the	O
3	present	O
4	article	O
5	,	O
6	the	O
7	causes	O
8	of	O
9	death	O
10	or	O
11	ill	O
12	-	O
13	being	O
14	as	O
15	found	O
16	in	O
17	10	O
18	consecutive	O
19	carcinogenicity	O
20	studies	O
21	--	O
22	5	O
23	studies	O
24	with	O
25	2400	O
26	OFA	O
27	(	O
28	Sprague	O
29	-	O
30	Dawley	O
31	-	O
32	derived	O
33	)	O
34	and	O
35	Wistar	O
36	rats	O
37	and	O
38	5	O
39	studies	O
40	with	O
41	2400	O
42	OF1	O
43	and	O
44	NMRI	O
45	mice	O
46	--	O
47	were	O
48	re	O
49	-	O
50	examined	O
51	.	O

1	Dopamine	B
2	receptor	I
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	O
7	,	O
8	a	O
9	crystallographic	O
10	study	O
11	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	G	B
6	beta	I
7	gamma	I
8	-	O
9	stimulated	O
10	Shc	B
11	phosphorylation	O
12	represents	O
13	an	O
14	early	O
15	step	O
16	in	O
17	the	O
18	pathway	O
19	leading	O
20	to	O
21	p21ras	B
22	activation	O
23	,	O
24	similar	O
25	to	O
26	the	O
27	mechanism	O
28	utilized	O
29	by	O
30	growth	B
31	factor	I
32	tyrosine	I
33	kinase	I
34	receptors	I
35	.	O

1	All	O
2	33	O
3	subjects	O
4	were	O
5	given	O
6	psychometric	O
7	instruments	O
8	for	O
9	measuring	O
10	various	O
11	components	O
12	of	O
13	anger	O
14	and	O
15	anxiety	O
16	:	O
17	Spielberger	O
18	'	O
19	s	O
20	State	O
21	-	O
22	Trait	O
23	Personality	O
24	Inventory	O
25	,	O
26	the	O
27	Anger	O
28	Expression	O
29	Scale	O
30	,	O
31	and	O
32	the	O
33	State	O
34	Anger	O
35	Reaction	O
36	Scale	O
37	.	O

1	Flap	O
2	survival	O
3	depends	O
4	on	O
5	the	O
6	development	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	vascular	O
13	connections	O
14	between	O
15	vessels	O
16	arising	O
17	from	O
18	the	O
19	pedicle	O
20	and	O
21	preexisting	O
22	dermal	O
23	vessels	O
24	.	O

1	A	O
2	phylogenetic	O
3	tree	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	B
9	/	I
10	S	I
11	-	I
12	RNase	I
13	superfamily	I
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O

1	Comparison	O
2	of	O
3	the	O
4	p50	B
5	sequence	I
6	to	O
7	other	O
8	cloned	O
9	proteins	O
10	revealed	O
11	89	O
12	%	O
13	homology	O
14	with	O
15	a	O
16	glycosaminoglycan	B
17	-	I
18	binding	I
19	protein	I
20	and	O
21	54	O
22	%	O
23	homology	O
24	with	O
25	Drosophila	O
26	cell	O
27	cycle	O
28	control	O
29	protein	O
30	(	O
31	cdc	O
32	)	O
33	37	O
34	.	O

1	Studies	O
2	in	O
3	mammalian	O
4	cells	O
5	have	O
6	correlated	O
7	induction	O
8	of	O
9	inhibitory	B
10	tyrosine	I
11	15	I
12	(	O
13	Y15	O
14	)	O
15	phosphorylation	O
16	on	O
17	p34cdc2	B
18	with	O
19	the	O
20	response	O
21	to	O
22	DNA	O
23	damage	O
24	.	O

1	Exposure	O
2	to	O
3	hepatitis	O
4	B	O
5	virus	O
6	in	O
7	the	O
8	general	O
9	population	O
10	of	O
11	Hisayama	O
12	,	O
13	Japan	O
14	:	O
15	significance	O
16	of	O
17	isolated	O
18	antibody	O
19	to	O
20	hepatitis	B
21	B	I
22	surface	I
23	antigen	I
24	in	O
25	general	O
26	population	O
27	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	O
16	isozymes	O
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	latest	O
8	BPVs	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O

1	The	O
2	addition	O
3	of	O
4	culture	O
5	to	O
6	the	O
7	CC	O
8	and	O
9	CC	O
10	:	O
11	SW	O
12	by	O
13	-	O
14	products	O
15	resulted	O
16	in	O
17	pH	O
18	values	O
19	lower	O
20	(	O
21	P	O
22	<	O
23	0	O
24	.	O
25	05	O
26	)	O
27	than	O
28	those	O
29	without	O
30	culture	O
31	on	O
32	Day	O
33	21	O
34	,	O
35	and	O
36	the	O
37	15	O
38	%	O
39	carbohydrate	O
40	treatment	O
41	significantly	O
42	reduced	O
43	pH	O
44	beyond	O
45	the	O
46	5	O
47	%	O
48	carbohydrate	O
49	.	O

1	We	O
2	have	O
3	identified	O
4	in	O
5	the	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	of	O
11	the	O
12	Drosophila	O
13	copia	O
14	retrotransposon	O
15	,	O
16	3	O
17	'	O
18	to	O
19	the	O
20	left	B
21	LTR	I
22	,	O
23	a	O
24	sequence	O
25	for	O
26	transcriptional	O
27	regulation	O
28	by	O
29	homeoproteins	O
30	.	O

1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	High	O
2	-	O
3	resolution	O
4	structure	O
5	of	O
6	the	O
7	diphtheria	B
8	toxin	I
9	repressor	I
10	complexed	O
11	with	O
12	cobalt	O
13	and	O
14	manganese	O
15	reveals	O
16	an	O
17	SH3	B
18	-	O
19	like	O
20	third	O
21	domain	O
22	and	O
23	suggests	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	phosphate	O
29	as	O
30	co	O
31	-	O
32	corepressor	O
33	.	O

1	Lead	O
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O

1	The	O
2	concentration	O
3	of	O
4	mite	O
5	allergen	O
6	was	O
7	very	O
8	low	O
9	(	O
10	mean	O
11	0	O
12	.	O
13	18	O
14	micrograms	O
15	Der	O
16	p	O
17	milligrams	O
18	sieved	O
19	house	O
20	dust	O
21	),	O
22	whereas	O
23	that	O
24	of	O
25	cat	O
26	allergen	O
27	was	O
28	high	O
29	in	O
30	homes	O
31	with	O
32	a	O
33	cat	O
34	(	O
35	80	O
36	.	O
37	8	O
38	micrograms	O
39	Fel	O
40	d	O
41	milligrams	O
42	)	O
43	but	O
44	also	O
45	in	O
46	homes	O
47	with	O
48	no	O
49	cat	O
50	(	O
51	3	O
52	.	O
53	2	O
54	micrograms	O
55	Fel	O
56	d	O
57	milligrams	O
58	).	O

1	The	O
2	DNase	B
3	I	I
4	footprint	O
5	extended	O
6	5	O
7	'	O
8	in	O
9	the	O
10	silencer	O
11	region	O
12	to	O
13	include	O
14	an	O
15	inverted	O
16	repeat	O
17	of	O
18	a	O
19	six	O
20	-	O
21	nucleotide	O
22	motif	O
23	(	O
24	epsilon	O
25	-	O
26	267	O
27	to	O
28	-	O
29	278	O
30	bp	O
31	)	O
32	which	O
33	shares	O
34	5	O
35	of	O
36	6	O
37	bases	O
38	with	O
39	the	O
40	GATA	B
41	-	I
42	1	I
43	consensus	I
44	sequence	I
45	.	O

1	When	O
2	ligated	O
3	to	O
4	the	O
5	proIL	B
6	-	I
7	1	I
8	beta	I
9	cap	I
10	site	I
11	-	I
12	proximal	I
13	region	I
14	(	O
15	located	O
16	between	O
17	-	O
18	131	O
19	to	O
20	+	O
21	12	O
22	),	O
23	both	O
24	the	O
25	proIL	B
26	-	I
27	1	I
28	beta	I
29	and	I
30	the	I
31	simian	I
32	virus	I
33	40	I
34	enhancer	I
35	elements	I
36	functioned	O
37	more	O
38	efficiently	O
39	in	O
40	monocytes	O
41	than	O
42	in	O
43	HeLa	O
44	cells	O
45	,	O
46	which	O
47	are	O
48	not	O
49	normally	O
50	competent	O
51	for	O
52	IL	B
53	-	I
54	1	I
55	beta	I
56	expression	O
57	.	O

1	Determination	O
2	of	O
3	lead	O
4	in	O
5	blood	O
6	.	O

1	After	O
2	selection	O
3	and	O
4	conversion	O
5	to	O
6	adipocytes	O
7	,	O
8	the	O
9	level	O
10	of	O
11	EGFR	B
12	expression	O
13	was	O
14	retained	O
15	in	O
16	infectant	O
17	adipocytes	O
18	(	O
19	150	O
20	,	O
21	000	O
22	and	O
23	250	O
24	,	O
25	000	O
26	/	O
27	cell	O
28	,	O
29	respectively	O
30	),	O
31	but	O
32	not	O
33	in	O
34	the	O
35	parental	O
36	3T3	O
37	-	O
38	L1	O
39	adipocytes	O
40	(<	O
41	5000	O
42	/	O
43	cell	O
44	).	O

1	Crohn	O
2	'	O
3	s	O
4	disease	O
5	in	O
6	prolonged	O
7	remission	O
8	:	O
9	should	O
10	one	O
11	augment	O
12	protein	O
13	-	O
14	calorie	O
15	intake	O
16	as	O
17	compared	O
18	to	O
19	healthy	O
20	subjects	O
21	?]	O
22	The	O
23	aim	O
24	of	O
25	our	O
26	two	O
27	year	O
28	prospective	O
29	study	O
30	was	O
31	to	O
32	evaluate	O
33	whether	O
34	adult	O
35	Crohn	O
36	'	O
37	s	O
38	disease	O
39	patients	O
40	in	O
41	prolonged	O
42	remission	O
43	(	O
44	CDAI	O
45	<	O
46	150	O
47	),	O
48	in	O
49	order	O
50	to	O
51	maintain	O
52	their	O
53	body	O
54	weight	O
55	as	O
56	close	O
57	as	O
58	possible	O
59	to	O
60	the	O
61	ideal	O
62	one	O
63	,	O
64	need	O
65	a	O
66	protein	O
67	-	O
68	calorie	O
69	intake	O
70	higher	O
71	than	O
72	the	O
73	predicted	O
74	one	O
75	and	O
76	that	O
77	of	O
78	healthy	O
79	controls	O
80	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	O
17	Pkr	B
18	gene	I
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	O
28	Pkr	B
29	promoter	I
30	region	O
31	required	O
32	for	O
33	IFN	B
34	-	O
35	inducible	O
36	transcription	O
37	.	O

1	After	O
2	2	O
3	min	O
4	of	O
5	dobutamine	O
6	injection	O
7	,	O
8	or	O
9	after	O
10	20	O
11	min	O
12	of	O
13	pimobendan	O
14	injection	O
15	,	O
16	the	O
17	myocardium	O
18	was	O
19	removed	O
20	,	O
21	and	O
22	used	O
23	for	O
24	determination	O
25	of	O
26	the	O
27	tissue	O
28	levels	O
29	of	O
30	metabolites	O
31	of	O
32	energy	O
33	and	O
34	carbohydrate	O
35	metabolism	O
36	.	O

1	It	O
2	has	O
3	been	O
4	reported	O
5	that	O
6	rat	O
7	blood	O
8	chloroform	O
9	levels	O
10	were	O
11	significantly	O
12	decreased	O
13	after	O
14	treatment	O
15	with	O
16	ClO2	O
17	.	O

1	Such	O
2	multisensory	O
3	interactions	O
4	can	O
5	be	O
6	significant	O
7	for	O
8	behavior	O
9	.	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	Second	O
2	,	O
3	nitrate	O
4	induction	O
5	of	O
6	aeg	B
7	-	I
8	46	I
9	.	I
10	5	I
11	operon	I
12	expression	O
13	is	O
14	substantially	O
15	enhanced	O
16	in	O
17	narL	B
18	null	O
19	strains	O
20	(	O
21	M	O
22	.	O
23	H	O
24	.	O

1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	ROSP	O
7	undergoes	O
8	a	O
9	number	O
10	of	O
11	fluctuations	O
12	in	O
13	the	O
14	negative	O
15	and	O
16	positive	O
17	directions	O
18	with	O
19	a	O
20	gradually	O
21	decreasing	O
22	amplitude	O
23	in	O
24	the	O
25	course	O
26	of	O
27	5	O
28	-	O
29	25	O
30	days	O
31	following	O
32	the	O
33	operation	O
34	,	O
35	after	O
36	which	O
37	relatively	O
38	stable	O
39	negative	O
40	values	O
41	of	O
42	the	O
43	ROSP	B
44	are	O
45	established	O
46	on	O
47	the	O
48	average	O
49	in	O
50	electrodes	O
51	implanted	O
52	to	O
53	the	O
54	level	O
55	of	O
56	the	O
57	dura	O
58	mater	O
59	,	O
60	and	O
61	positive	O
62	values	O
63	in	O
64	electrodes	O
65	implanted	O
66	to	O
67	the	O
68	level	O
69	of	O
70	the	O
71	pia	O
72	mater	O
73	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	a	O
7	mutant	O
8	form	O
9	of	O
10	XRN1	B
11	,	O
12	which	O
13	encodes	O
14	a	O
15	5	B
16	'-	I
17	3	I
18	'	I
19	exonuclease	I
20	,	O
21	was	O
22	identified	O
23	as	O
24	an	O
25	extragenic	O
26	suppressor	O
27	that	O
28	increases	O
29	the	O
30	half	O
31	-	O
32	life	O
33	of	O
34	rhis4	B
35	mRNA	I
36	,	O
37	leading	O
38	to	O
39	a	O
40	10	O
41	-	O
42	fold	O
43	increase	O
44	in	O
45	steady	O
46	-	O
47	state	O
48	mRNA	O
49	levels	O
50	compared	O
51	to	O
52	the	O
53	wild	B
54	-	I
55	type	I
56	HIS4	I
57	mRNA	I
58	level	O
59	.	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	the	O
6	JNKK2	O
7	-	O
8	JNK1	B
9	fusion	O
10	protein	O
11	showed	O
12	significant	O
13	JNK	B
14	activity	O
15	,	O
16	which	O
17	was	O
18	comparable	O
19	with	O
20	that	O
21	of	O
22	JNK1	B
23	activated	O
24	by	O
25	many	O
26	stimuli	O
27	and	O
28	activators	O
29	,	O
30	including	O
31	EGF	B
32	,	O
33	TNF	B
34	-	I
35	alpha	I
36	,	O
37	anisomycin	O
38	,	O
39	UV	O
40	irradiation	O
41	,	O
42	MEKK1	B
43	,	O
44	and	O
45	small	B
46	GTP	I
47	binding	I
48	proteins	I
49	Rac1	I
50	and	O
51	Cdc42Hs	B
52	.	O

1	Antithrombin	B
2	III	I
3	(	O
4	AT	O
5	III	O
6	)	O
7	is	O
8	a	O
9	plasma	O
10	protein	O
11	which	O
12	acts	O
13	as	O
14	the	O
15	principal	O
16	inhibitor	O
17	of	O
18	thrombin	B
19	and	O
20	is	O
21	a	O
22	major	O
23	modulator	O
24	of	O
25	intravascular	O
26	coagulation	O
27	.	O

1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	sequences	O
6	in	O
7	the	O
8	SH2	B
9	/	O
10	SH3	B
11	/	O
12	SH2	B
13	region	I
14	of	O
15	p120	B
16	GAP	I
17	are	O
18	required	O
19	for	O
20	full	O
21	catalytic	O
22	activity	O
23	toward	O
24	Ras	B
25	.	O

1	One	O
2	complex	O
3	containing	O
4	a	O
5	70	O
6	D	O
7	protein	O
8	was	O
9	found	O
10	to	O
11	be	O
12	associated	O
13	specifically	O
14	with	O
15	transcriptionally	O
16	active	O
17	leukemia	O
18	cells	O
19	.	O

1	The	O
2	present	O
3	study	O
4	investigated	O
5	dose	O
6	dependence	O
7	and	O
8	time	O
9	course	O
10	effects	O
11	of	O
12	the	O
13	benzodiazepine	O
14	(	O
15	BDZ	O
16	)	O
17	partial	O
18	inverse	O
19	agonist	O
20	,	O
21	RO19	B
22	-	I
23	4603	I
24	(	O
25	0	O
26	.	O
27	005	O
28	-	O
29	0	O
30	.	O
31	30	O
32	mg	O
33	/	O
34	kg	O
35	)	O
36	alone	O
37	,	O
38	and	O
39	in	O
40	combination	O
41	with	O
42	the	O
43	BDZ	B
44	receptor	I
45	antagonists	O
46	flumazenil	O
47	,	O
48	ZK	O
49	93426	O
50	,	O
51	and	O
52	CGS	O
53	8216	O
54	(	O
55	20	O
56	mg	O
57	/	O
58	kg	O
59	)	O
60	in	O
61	selectively	O
62	bred	O
63	alcohol	O
64	-	O
65	preferring	O
66	(	O
67	P	O
68	)	O
69	rats	O
70	provided	O
71	a	O
72	two	O
73	-	O
74	bottle	O
75	choice	O
76	test	O
77	between	O
78	ethanol	O
79	(	O
80	EtOH	O
81	)	O
82	(	O
83	10	O
84	%	O
85	v	O
86	/	O
87	v	O
88	),	O
89	and	O
90	a	O
91	palatable	O
92	saccharin	O
93	(	O
94	0	O
95	.	O
96	0125	O
97	%	O
98	g	O
99	/	O
100	v	O
101	)	O
102	solution	O
103	.	O

1	Gap	O
2	b3	O
3	consists	O
4	of	O
5	two	O
6	polypeptide	O
7	chains	O
8	(	O
9	Mr	O
10	=	O
11	110	O
12	,	O
13	000	O
14	and	O
15	30	O
16	,	O
17	000	O
18	),	O
19	which	O
20	seem	O
21	to	O
22	be	O
23	proteolytic	O
24	cleavage	O
25	products	O
26	connected	O
27	by	O
28	disulfide	O
29	bonds	O
30	from	O
31	a	O
32	precursor	O
33	protein	O
34	.	O

1	The	O
2	use	O
3	of	O
4	antibodies	O
5	to	O
6	the	O
7	polypyrimidine	B
8	tract	I
9	binding	I
10	protein	I
11	(	O
12	PTB	B
13	)	O
14	to	O
15	analyze	O
16	the	O
17	protein	O
18	components	O
19	that	O
20	assemble	O
21	on	O
22	alternatively	O
23	spliced	O
24	pre	O
25	-	O
26	mRNAs	O
27	that	O
28	use	O
29	distant	O
30	branch	O
31	points	O
32	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	gene	I
6	is	O
7	overexpressed	O
8	in	O
9	a	O
10	variety	O
11	of	O
12	tumor	O
13	types	O
14	and	O
15	appears	O
16	to	O
17	play	O
18	an	O
19	important	O
20	role	O
21	in	O
22	the	O
23	abnormal	O
24	growth	O
25	of	O
26	a	O
27	number	O
28	of	O
29	cell	O
30	types	O
31	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	accepted	O
6	that	O
7	the	O
8	p53	B
9	C	I
10	-	O
11	terminus	O
12	plays	O
13	a	O
14	central	O
15	role	O
16	in	O
17	controlling	O
18	the	O
19	activity	O
20	of	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	molecule	O
26	.	O

1	The	O
2	nature	O
3	of	O
4	the	O
5	process	O
6	formed	O
7	by	O
8	the	O
9	successive	O
10	occurrences	O
11	of	O
12	this	O
13	arrhythmia	O
14	was	O
15	studied	O
16	in	O
17	8	O
18	patients	O
19	with	O
20	a	O
21	history	O
22	of	O
23	symptomatic	O
24	paroxysmal	O
25	AF	O
26	.	O

1	Against	O
2	200	O
3	strains	O
4	of	O
5	methicillin	O
6	-	O
7	resistant	O
8	Staphylococcus	O
9	aureus	O
10	(	O
11	MRSA	O
12	)	O
13	isolated	O
14	from	O
15	1990	O
16	to	O
17	1991	O
18	,	O
19	minimum	O
20	inhibitory	O
21	concentrations	O
22	(	O
23	MICs	O
24	)	O
25	of	O
26	a	O
27	total	O
28	of	O
29	15	O
30	antibacterial	O
31	agents	O
32	including	O
33	arbekacin	O
34	(	O
35	ABK	O
36	)	O
37	were	O
38	determined	O
39	.	O

1	A	O
2	database	O
3	search	O
4	has	O
5	revealed	O
6	as	O
7	the	O
8	most	O
9	significative	O
10	homology	O
11	a	O
12	match	O
13	with	O
14	the	O
15	human	B
16	mitochondrial	I
17	transcription	I
18	termination	I
19	factor	I
20	(	O
21	mTERF	O
22	),	O
23	a	O
24	protein	O
25	that	O
26	also	O
27	binds	O
28	DNA	O
29	as	O
30	a	O
31	monomer	O
32	and	O
33	contains	O
34	three	O
35	leucine	O
36	zippers	O
37	forming	O
38	intramolecular	O
39	interactions	O
40	.	O

1	Modification	O
2	of	O
3	the	O
4	growth	O
5	of	O
6	Tetrahymena	O
7	by	O
8	compounds	O
9	which	O
10	affect	O
11	the	O
12	adrenergic	O
13	mechanism	O
14	.	O

1	Nuclear	O
2	localization	O
3	and	O
4	protein	O
5	sequence	O
6	similarities	O
7	suggested	O
8	that	O
9	the	O
10	SPT2	B
11	/	I
12	SIN1	I
13	protein	I
14	may	O
15	be	O
16	related	O
17	to	O
18	the	O
19	nonhistone	O
20	chromosomal	O
21	protein	O
22	HMG1	O
23	.	O

1	Human	O
2	expressed	O
3	sequence	O
4	tag	O
5	clones	O
6	were	O
7	identified	O
8	by	O
9	sequence	O
10	similarity	O
11	to	O
12	mammalian	O
13	and	O
14	yeast	O
15	oligosaccharide	O
16	-	O
17	processing	O
18	mannosidases	O
19	,	O
20	and	O
21	the	O
22	full	O
23	-	O
24	length	O
25	coding	O
26	region	O
27	of	O
28	the	O
29	putative	O
30	mannosidase	B
31	homolog	I
32	was	O
33	isolated	O
34	by	O
35	a	O
36	combination	O
37	of	O
38	5	O
39	'-	O
40	rapid	O
41	amplification	O
42	of	O
43	cDNA	O
44	ends	O
45	and	O
46	direct	O
47	polymerase	O
48	chain	O
49	reaction	O
50	from	O
51	human	O
52	placental	O
53	cDNA	O
54	.	O

1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O

1	ROCK	O
2	-	O
3	I	O
4	,	O
5	Kinectin	B
6	,	O
7	and	O
8	mDia2	B
9	can	O
10	bind	O
11	the	O
12	wild	O
13	type	O
14	forms	O
15	of	O
16	both	O
17	RhoA	B
18	and	O
19	Cdc42	B
20	in	O
21	a	O
22	GTP	O
23	-	O
24	dependent	O
25	manner	O
26	in	O
27	vitro	O
28	.	O

1	Unilateral	O
2	naris	O
3	occlusion	O
4	and	O
5	the	O
6	rat	O
7	accessory	O
8	olfactory	O
9	bulb	O
10	.	O

1	Experience	O
2	with	O
3	the	O
4	restoration	O
5	of	O
6	agglutination	O
7	properties	O
8	of	O
9	non	O
10	-	O
11	agglutinating	O
12	dysenterial	O
13	cultures	O
14	with	O
15	the	O
16	use	O
17	of	O
18	Rzhaninov	O
19	'	O
20	s	O
21	method	O

1	The	O
2	role	O
3	of	O
4	HIV	B
5	tat	I
6	,	O
7	which	O
8	is	O
9	the	O
10	main	O
11	enhancing	O
12	factor	O
13	for	O
14	viral	B
15	LTR	I
16	,	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	IL	B
22	-	I
23	2	I
24	gene	I
25	transcription	O
26	has	O
27	been	O
28	studied	O
29	following	O
30	transient	O
31	expression	O
32	of	O
33	the	O
34	tat	B
35	gene	I
36	in	O
37	phorbol	O
38	ester	O
39	and	O
40	calcium	O
41	ionophore	O
42	-	O
43	activated	O
44	Jurkat	O
45	cells	O
46	transfected	O
47	with	O
48	IL	B
49	-	I
50	2	I
51	promoter	I
52	-	I
53	chloramphenicol	I
54	acetyltransferase	I
55	reporter	I
56	constructs	I
57	.	O

1	Within	O
2	Stage	O
3	IA	O
4	,	O
5	141	O
6	patients	O
7	had	O
8	well	O
9	differentiated	O
10	tumor	O
11	(	O
12	G1	O
13	),	O
14	20	O
15	had	O
16	moderately	O
17	well	O
18	differentiated	O
19	tumor	O
20	(	O
21	G2	O
22	),	O
23	and	O
24	12	O
25	patients	O
26	had	O
27	poorly	O
28	differentiated	O
29	(	O
30	G3	O
31	).	O

1	The	O
2	cysteine	O
3	-	O
4	rich	O
5	region	O
6	of	O
7	raf	B
8	-	I
9	1	I
10	kinase	I
11	contains	O
12	zinc	O
13	,	O
14	translocates	O
15	to	O
16	liposomes	O
17	,	O
18	and	O
19	is	O
20	adjacent	O
21	to	O
22	a	O
23	segment	O
24	that	O
25	binds	O
26	GTP	B
27	-	I
28	ras	I
29	.	O

1	TNF	B
2	-	I
3	alpha	I
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	cyclooxygenase	B
15	-	I
16	2	I
17	(	O
18	COX	B
19	-	I
20	2	I
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	NCI	O
29	-	O
30	H292	O
31	epithelial	O
32	cells	O
33	.	O

1	Basal	O
2	components	O
3	of	O
4	the	O
5	transcription	O
6	apparatus	O
7	(	O
8	RNA	B
9	polymerase	I
10	II	I
11	,	O
12	TATA	B
13	-	I
14	binding	I
15	protein	I
16	)	O
17	contain	O
18	activation	O
19	domains	O
20	:	O
21	is	O
22	the	O
23	repetitive	O
24	C	O
25	-	O
26	terminal	O
27	domain	O
28	(	O
29	CTD	O
30	)	O
31	of	O
32	RNA	B
33	polymerase	I
34	II	I
35	a	I
36	"	I
37	portable	I
38	enhancer	I
39	domain	I
40	"?	I
41	Regions	I
42	rich	O
43	in	O
44	serine	O
45	,	O
46	threonine	O
47	,	O
48	and	O
49	proline	O
50	residues	O
51	can	O
52	be	O
53	found	O
54	in	O
55	transcriptional	O
56	activation	O
57	domains	O
58	,	O
59	as	O
60	well	O
61	as	O
62	in	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	parts	O
68	of	O
69	mammalian	B
70	TATA	I
71	-	I
72	binding	I
73	proteins	I
74	,	O
75	where	O
76	they	O
77	are	O
78	interrupted	O
79	by	O
80	polyglutamine	O
81	stretches	O
82	.	O

1	Lack	O
2	of	O
3	effect	O
4	of	O
5	the	O
6	appetite	O
7	stimulant	O
8	pizotifen	O
9	(	O
10	BC	B
11	105	I
12	)	O
13	on	O
14	the	O
15	absorption	O
16	of	O
17	isonicotinylhydrazine	O
18	.	O

1	Nucleotide	O
2	sequencing	O
3	indicates	O
4	that	O
5	this	O
6	E1	B
7	alpha	I
8	cDNA	I
9	clone	I
10	is	O
11	1821	O
12	base	O
13	pairs	O
14	(	O
15	bp	O
16	)	O
17	in	O
18	length	O
19	with	O
20	an	O
21	open	O
22	reading	O
23	frame	O
24	of	O
25	1365	O
26	bp	O
27	and	O
28	a	O
29	3	O
30	'-	O
31	untranslated	O
32	region	O
33	of	O
34	356	O
35	bp	O
36	.	O

1	Further	O
2	outbreaks	O
3	of	O
4	ocular	O
5	disease	O
6	in	O
7	farmed	O
8	red	O
9	deer	O
10	calves	O
11	caused	O
12	by	O
13	HVC	B
14	-	I
15	1	I
16	were	O
17	investigated	O
18	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	O
24	transcriptosomal	O
25	component	O
26	scaffold	O
27	attachment	O
28	factor	O
29	B	O
30	,	O
31	and	O
32	the	O
33	68	B
34	-	I
35	kDa	I
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O

1	The	O
2	maps	O
3	of	O
4	Case	B
5	2	I
6	showed	O
7	that	O
8	a	O
9	maximum	O
10	first	O
11	appeared	O
12	on	O
13	the	O
14	upper	O
15	right	O
16	back	O
17	and	O
18	then	O
19	moved	O
20	down	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	posterior	O
27	thorax	O
28	.	O

1	Anti	B
2	-	I
3	PTB	I
4	antibodies	I
5	did	O
6	not	O
7	inhibit	O
8	the	O
9	binding	O
10	of	O
11	PTB	B
12	to	O
13	RNA	O
14	because	O
15	they	O
16	were	O
17	able	O
18	to	O
19	supershift	O
20	RNA	O
21	-	O
22	PTB	B
23	complexes	O
24	.	O

1	It	O
2	is	O
3	the	O
4	human	O
5	homolog	O
6	of	O
7	the	O
8	mouse	B
9	Mx	I
10	protein	I
11	involved	O
12	in	O
13	resistance	O
14	to	O
15	influenza	O
16	virus	O
17	.	O

1	The	O
2	human	O
3	cDNA	O
4	was	O
5	used	O
6	to	O
7	demonstrate	O
8	that	O
9	tumor	B
10	necrosis	I
11	factor	I
12	-	I
13	alpha	I
14	could	O
15	rapidly	O
16	stimulate	O
17	MARCKS	B
18	gene	I
19	transcription	O
20	in	O
21	the	O
22	human	O
23	promyelocytic	O
24	leukemia	O
25	cell	O
26	line	O
27	HL60	O
28	.	O

1	We	O
2	have	O
3	also	O
4	found	O
5	that	O
6	the	O
7	in	O
8	vitro	O
9	interaction	O
10	between	O
11	the	O
12	SV40	O
13	octamer	O
14	motif	O
15	and	O
16	the	O
17	lymphoid	B
18	cell	I
19	-	I
20	specific	I
21	protein	I
22	oct	I
23	-	I
24	B2	I
25	was	O
26	negatively	O
27	modulated	O
28	by	O
29	a	O
30	component	O
31	present	O
32	in	O
33	the	O
34	nuclear	O
35	extracts	O
36	from	O
37	several	O
38	lymphoid	O
39	cell	O
40	lines	O
41	.	O

1	Sensitive	O
2	fluorometric	O
3	method	O
4	of	O
5	determining	O
6	SH	O
7	-	O
8	and	O
9	S	O
10	-	O
11	S	O
12	-	O
13	groups	O
14	when	O
15	jointly	O
16	present	O

1	When	O
2	the	O
3	coding	O
4	segments	O
5	,	O
6	including	O
7	both	O
8	framework	O
9	and	O
10	complementarity	O
11	-	O
12	determining	O
13	regions	O
14	,	O
15	of	O
16	these	O
17	genes	O
18	and	O
19	the	O
20	murine	O
21	probe	O
22	sequences	O
23	are	O
24	compared	O
25	by	O
26	metric	O
27	analysis	O
28	,	O
29	it	O
30	is	O
31	apparent	O
32	that	O
33	the	O
34	caiman	O
35	genes	O
36	are	O
37	only	O
38	slightly	O
39	more	O
40	related	O
41	to	O
42	each	O
43	other	O
44	than	O
45	to	O
46	the	O
47	mammalian	O
48	sequence	O
49	,	O
50	consistent	O
51	with	O
52	significant	O
53	preservation	O
54	of	O
55	nucleotide	O
56	sequence	O
57	over	O
58	an	O
59	extended	O
60	period	O
61	of	O
62	phylogenetic	O
63	time	O
64	.	O

1	At	O
2	all	O
3	time	O
4	-	O
5	points	O
6	,	O
7	most	O
8	patients	O
9	(>/=	O
10	87	O
11	%)	O
12	were	O
13	receiving	O
14	irbesartan	O
15	/	O
16	HCTZ	O
17	alone	O
18	.	O

1	These	O
2	results	O
3	demonstrate	O
4	the	O
5	existence	O
6	of	O
7	different	O
8	PI	B
9	3	I
10	-	I
11	kinase	I
12	isoforms	I
13	and	O
14	define	O
15	a	O
16	family	O
17	of	O
18	genes	O
19	encoding	O
20	distinct	O
21	PI	B
22	3	I
23	-	I
24	kinase	I
25	catalytic	O
26	subunits	O
27	that	O
28	can	O
29	associate	O
30	with	O
31	p85	B
32	.	O

1	Clinical	O
2	accuracy	O
3	of	O
4	updated	O
5	version	O
6	of	O
7	the	O
8	Phadebas	O
9	RAST	O
10	test	O
11	.	O

1	Control	O
2	intact	O
3	rats	O
4	were	O
5	age	O
6	-	O
7	matched	O
8	to	O
9	the	O
10	different	O
11	treated	O
12	groups	O
13	.	O

1	NiCl	O
2	(	O
3	2	O
4	)-	O
5	induced	O
6	MCP	B
7	-	I
8	1	I
9	synthesis	O
10	required	O
11	activation	O
12	of	O
13	NF	B
14	-	I
15	kappaB	I
16	since	I
17	mutation	I
18	of	O
19	NF	B
20	-	I
21	kappaB	I
22	-	I
23	binding	I
24	sites	I
25	in	O
26	the	O
27	promoter	O
28	resulted	O
29	in	O
30	complete	O
31	loss	O
32	of	O
33	inducible	O
34	promoter	O
35	activity	O
36	.	O

1	Two	O
2	transcripts	O
3	of	O
4	1	O
5	.	O
6	6	O
7	kb	O
8	and	O
9	5	O
10	.	O
11	8	O
12	kb	O
13	are	O
14	5	O
15	'	O
16	coterminal	O
17	and	O
18	may	O
19	both	O
20	encode	O
21	the	O
22	novel	O
23	glycoprotein	B
24	gene	I
25	EUS4	I
26	.	O

1	Hoeben	O
2	,	O
3	F	O
4	.	O
5	J	O
6	.	O

1	Plasma	B
2	renin	I
3	concentration	O
4	is	O
5	significantly	O
6	higher	O
7	in	O
8	the	O
9	subcapsular	O
10	venous	O
11	outflow	O
12	,	O
13	which	O
14	drains	O
15	the	O
16	superficial	O
17	cortex	O
18	,	O
19	than	O
20	in	O
21	the	O
22	deep	O
23	venous	O
24	outflow	O
25	,	O
26	which	O
27	drains	O
28	the	O
29	inner	O
30	half	O
31	of	O
32	the	O
33	cortex	O
34	and	O
35	medulla	O
36	of	O
37	the	O
38	cat	O
39	kidney	O
40	.	O

1	Overexpression	O
2	of	O
3	ICBP90	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	O

1	Pacing	O
2	the	O
3	Roux	O
4	limb	O
5	abolished	O
6	the	O
7	ectopic	O
8	pacemakers	O
9	,	O
10	restored	O
11	the	O
12	slow	O
13	emptying	O
14	of	O
15	liquids	O
16	to	O
17	the	O
18	more	O
19	rapid	O
20	rate	O
21	found	O
22	in	O
23	the	O
24	Billroth	O
25	dogs	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	:	O
31	paced	O
32	Roux	O
33	,	O
34	72	O
35	+/-	O
36	15	O
37	minutes	O
38	;	O
39	Billroth	O
40	,	O
41	43	O
42	+/-	O
43	9	O
44	minutes	O
45	;	O
46	p	O
47	greater	O
48	than	O
49	0	O
50	.	O
51	05	O
52	)	O
53	and	O
54	did	O
55	not	O
56	change	O
57	emptying	O
58	of	O
59	solids	O
60	.	O

1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	O
22	),	O
23	whereas	O
24	bFcgamma2R	B
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O

1	Low	O
2	-	O
3	dose	O
4	D	O
5	(	O
6	0	O
7	.	O
8	4	O
9	-	O
10	0	O
11	.	O
12	8	O
13	mg	O
14	)	O
15	and	O
16	DB	O
17	(	O
18	1	O
19	.	O
20	0	O
21	-	O
22	5	O
23	.	O
24	0	O
25	mg	O
26	)	O
27	did	O
28	not	O
29	significantly	O
30	alter	O
31	any	O
32	parameter	O
33	from	O
34	control	O
35	.	O

1	In	O
2	one	O
3	glioblastoma	O
4	cell	O
5	line	O
6	,	O
7	a	O
8	Shc	B
9	-	I
10	associated	I
11	p190	I
12	was	O
13	identified	O
14	as	O
15	the	O
16	activated	O
17	PDGFR	B
18	.	O

1	A	O
2	prostaglandin	O
3	analogue	O
4	given	O
5	in	O
6	early	O
7	pregnancy	O
8	and	O
9	human	B
10	chorionic	I
11	gonadotropin	I
12	given	O
13	near	O
14	the	O
15	end	O
16	of	O
17	the	O
18	ensuing	O
19	follicular	O
20	phase	O
21	were	O
22	used	O
23	for	O
24	controlling	O
25	the	O
26	reproductive	O
27	cycle	O
28	,	O
29	timing	O
30	oocyte	O
31	collection	O
32	,	O
33	and	O
34	synchronizing	O
35	the	O
36	cycles	O
37	of	O
38	oocyte	O
39	donors	O
40	and	O
41	embryo	O
42	recipients	O
43	.	O

1	Apo	B
2	A	I
3	-	I
4	I	I
5	level	O
6	was	O
7	unrelated	O
8	to	O
9	age	O
10	,	O
11	but	O
12	increased	O
13	with	O
14	ethanol	O
15	consumption	O
16	and	O
17	decreased	O
18	with	O
19	adiposity	O
20	.	O

1	Studies	O
2	of	O
3	lipoprotein	B
4	-	I
5	X	I
6	(	O
7	LP	B
8	-	I
9	X	I
10	)	O
11	and	O
12	bile	O
13	acids	O
14	in	O
15	familial	O
16	LCAT	B
17	deficiency	O
18	.	O

1	Another	O
2	long	O
3	insertion	O
4	in	O
5	the	O
6	cathepsin	B
7	X	I
8	amino	I
9	acid	I
10	sequence	I
11	forms	O
12	a	O
13	beta	O
14	-	O
15	hairpin	O
16	pointing	O
17	away	O
18	from	O
19	the	O
20	active	O
21	site	O
22	.	O

1	Conjugated	O
2	estrogens	O
3	shorten	O
4	bleeding	O
5	time	O
6	in	O
7	uraemia	O
8	:	O
9	a	O
10	possible	O
11	role	O
12	of	O
13	serotonin	O
14	?	O

1	In	O
2	contrast	O
3	,	O
4	extracts	O
5	of	O
6	the	O
7	mutant	O
8	virions	O
9	catalyze	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	level	O
15	of	O
16	transcription	O
17	from	O
18	an	O
19	exogenous	O
20	template	O
21	containing	O
22	an	O
23	early	O
24	promoter	O
25	.	O

1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	O
10	mutants	O
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	O
20	plate	O
21	inducer	O
22	shh	O
23	.	O

1	The	O
2	chick	B
3	axon	I
4	-	I
5	associated	I
6	surface	I
7	glycoprotein	I
8	neurofascin	I
9	is	O
10	implicated	O
11	in	O
12	axonal	O
13	growth	O
14	and	O
15	fasciculation	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	perturbation	O
21	experiments	O
22	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	during	O
6	pregnancy	O
7	there	O
8	are	O
9	increases	O
10	in	O
11	bone	O
12	formation	O
13	rates	O
14	contributing	O
15	to	O
16	the	O
17	increases	O
18	in	O
19	skeletal	O
20	mass	O
21	.	O

1	Kss1	O
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	O
8	Dig1	B
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O

1	Interestingly	O
2	,	O
3	one	O
4	IRF	B
5	binding	I
6	site	I
7	was	O
8	found	O
9	within	O
10	the	O
11	IRF	B
12	-	I
13	2	I
14	promoter	I
15	,	O
16	and	O
17	expression	O
18	of	O
19	the	O
20	IRF	B
21	-	I
22	2	I
23	gene	I
24	was	O
25	affected	O
26	by	O
27	both	O
28	transient	O
29	and	O
30	stable	O
31	IRF	B
32	-	I
33	1	I
34	expression	O
35	.	O

1	Finally	O
2	,	O
3	using	O
4	in	O
5	vitro	O
6	binding	O
7	studies	O
8	,	O
9	we	O
10	showed	O
11	that	O
12	SREBP2	B
13	was	O
14	able	O
15	to	O
16	displace	O
17	ADD1	O
18	/	O
19	SREBP1	B
20	binding	O
21	from	O
22	the	O
23	sterol	B
24	regulatory	I
25	element	I
26	(	O
27	SRE	O
28	)	O
29	site	O
30	.	O

1	When	O
2	Hy	O
3	-	O
4	Vac	O
5	SPF	O
6	type	O
7	V	O
8	embryos	O
9	were	O
10	exposed	O
11	to	O
12	either	O
13	0	O
14	.	O
15	20	O
16	ml	O
17	50	O
18	%	O
19	ethanol	O
20	in	O
21	CRS	O
22	or	O
23	to	O
24	0	O
25	.	O
26	20	O
27	ml	O
28	CRS	O
29	(	O
30	controls	O
31	),	O
32	ethanol	O
33	-	O
34	treated	O
35	embryos	O
36	showed	O
37	a	O
38	VSD	O
39	incidence	O
40	of	O
41	34	O
42	.	O
43	1	O
44	%	O
45	compared	O
46	with	O
47	a	O
48	3	O
49	.	O
50	6	O
51	%	O
52	incidence	O
53	in	O
54	the	O
55	controls	O
56	(	O
57	P	O
58	=	O
59	0	O
60	.	O
61	0017	O
62	).	O

1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	O
6	reporter	O
7	construct	O
8	,	O
9	(	O
10	PRDII	B
11	)(	I
12	4	I
13	)-	O
14	CAT	B
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	O
27	by	O
28	Tat	B
29	.	O

1	These	O
2	observations	O
3	link	O
4	actin	B
5	plaque	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	Spleen	O
2	weight	O
3	in	O
4	rats	O
5	during	O
6	tumour	O
7	growth	O
8	and	O
9	in	O
10	homograft	O
11	rejection	O
12	.	O

1	Maize	B
2	rbcS	I
3	promoter	I
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	O
13	rbcS	O
14	promoters	O
15	.	O

1	These	O
2	exons	O
3	were	O
4	identified	O
5	by	O
6	cloning	O
7	and	O
8	sequencing	O
9	cDNAs	O
10	obtained	O
11	by	O
12	polymerase	O
13	chain	O
14	reaction	O
15	amplification	O
16	of	O
17	a	O
18	fibroblast	O
19	cDNA	O
20	library	O
21	.	O

1	The	O
2	sympathetic	O
3	neuroeffector	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	ATCI	B
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	neurotransmitter	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	cardiomyocyte	O
26	adrenoreceptors	O
27	.	O

1	In	O
2	untransformed	O
3	cells	O
4	,	O
5	three	O
6	major	O
7	proteins	O
8	coprecipitated	O
9	with	O
10	CRKL	B
11	,	O
12	identified	O
13	as	O
14	C3G	B
15	,	O
16	SOS	O
17	and	O
18	c	B
19	-	I
20	ABL	I
21	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	the	O
6	origin	O
7	core	O
8	,	O
9	is	O
10	required	O
11	only	O
12	for	O
13	DNA	O
14	replication	O
15	.	O

1	The	O
2	mobility	O
3	shift	O
4	of	O
5	both	O
6	of	O
7	these	O
8	proteins	O
9	is	O
10	abolished	O
11	by	O
12	treatment	O
13	with	O
14	inhibitors	O
15	of	O
16	PKC	B
17	or	O
18	mitogen	B
19	-	I
20	activated	I
21	protein	I
22	kinase	I
23	/	O
24	extracellular	B
25	signal	I
26	-	I
27	related	I
28	kinase	I
29	kinase	I
30	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	BL	O
6	cell	O
7	line	O
8	Raji	O
9	with	O
10	constructs	O
11	containing	O
12	core	B
13	promoter	I
14	mutations	O
15	confirmed	O
16	that	O
17	the	O
18	proximal	O
19	Sp1	B
20	site	I
21	and	O
22	the	O
23	TATA	O
24	box	O
25	are	O
26	essential	O
27	for	O
28	the	O
29	activation	O
30	of	O
31	promoter	O
32	P1	O
33	by	O
34	the	O
35	Ig	B
36	kappa	I
37	enhancers	I
38	.	O

1	Transplantation	O
2	of	O
3	kidneys	O
4	of	O
5	juvenile	O
6	donors	O
7	in	O
8	adult	O
9	recipients	O
10	.	O

1	In	O
2	addition	O
3	,	O
4	all	O
5	three	O
6	Opa	B
7	proteins	I
8	of	O
9	C751	O
10	bind	O
11	equally	O
12	well	O
13	to	O
14	HeLa	O
15	cells	O
16	transfected	O
17	with	O
18	cDNA	O
19	encoding	O
20	the	O
21	carcinoembryonic	B
22	antigen	I
23	[	I
24	CEA	I
25	(	O
26	CD66e	O
27	)]	O
28	subgroup	O
29	of	O
30	the	O
31	CD66	B
32	family	I
33	,	O
34	but	O
35	show	O
36	distinct	O
37	tropism	O
38	for	O
39	CGM1	O
40	-	O
41	(	O
42	CD66d	O
43	)	O
44	and	O
45	NCA	B
46	(	O
47	CD66c	O
48	)-	O
49	expressing	O
50	cells	O
51	.	O

1	Both	O
2	groups	O
3	rejected	O
4	pops	O
5	with	O
6	added	O
7	SOA	O
8	,	O
9	decreasing	O
10	mouthing	O
11	times	O
12	as	O
13	SOA	O
14	concentration	O
15	increased	O
16	.	O

1	RESULTS	O
2	:	O
3	At	O
4	the	O
5	beginning	O
6	of	O
7	the	O
8	QA	B
9	/	O
10	QI	O
11	process	O
12	,	O
13	monitoring	O
14	of	O
15	blood	O
16	administration	O
17	practices	O
18	revealed	O
19	that	O
20	a	O
21	variance	O
22	from	O
23	institutional	O
24	blood	O
25	administration	O
26	policy	O
27	occurred	O
28	during	O
29	50	O
30	percent	O
31	of	O
32	blood	O
33	and	O
34	component	O
35	transfusions	O
36	.	O

1	Urological	O
2	complications	O
3	are	O
4	frequent	O
5	during	O
6	and	O
7	after	O
8	the	O
9	treatment	O
10	of	O
11	gynecological	O
12	malignancy	O
13	.	O

1	Digitalis	O
2	glycosides	O
3	or	O
4	beta	B
5	-	I
6	receptor	I
7	antagonists	O
8	are	O
9	not	O
10	helpful	O
11	in	O
12	the	O
13	therapy	O
14	of	O
15	this	O
16	form	O
17	of	O
18	atrial	O
19	fibrillation	O
20	whereas	O
21	class	O
22	I	O
23	antiarrhythmic	O
24	drugs	O
25	have	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	more	O
31	effective	O
32	.	O

1	Deletion	O
2	of	O
3	the	O
4	apeA	B
5	gene	I
6	,	O
7	either	O
8	with	O
9	or	O
10	without	O
11	deletion	O
12	of	O
13	other	O
14	proteinases	O
15	(	O
16	protease	O
17	IV	O
18	and	O
19	aminopeptidase	B
20	N	I
21	),	O
22	did	O
23	not	O
24	have	O
25	any	O
26	effect	O
27	on	O
28	cell	O
29	growth	O
30	in	O
31	the	O
32	various	O
33	media	O
34	tested	O
35	.	O

1	The	O
2	discordant	O
3	behaviour	O
4	in	O
5	weakly	O
6	infected	O
7	mice	O
8	was	O
9	due	O
10	to	O
11	the	O
12	occurrence	O
13	in	O
14	some	O
15	animals	O
16	of	O
17	a	O
18	second	O
19	phase	O
20	of	O
21	more	O
22	rapid	O
23	increase	O
24	of	O
25	the	O
26	parasitemia	O
27	.	O

1	The	O
2	protein	O
3	kinase	O
4	domains	O
5	of	O
6	LIMK1	B
7	and	O
8	LIMK2	B
9	are	O
10	unique	O
11	in	O
12	that	O
13	they	O
14	contain	O
15	an	O
16	unusual	O
17	sequence	O
18	motif	O
19	Asp	O
20	-	O
21	Leu	O
22	-	O
23	Asn	O
24	-	O
25	Ser	O
26	-	O
27	His	O
28	-	O
29	Asn	O
30	in	O
31	subdomain	O
32	VIB	O
33	and	O
34	a	O
35	highly	O
36	basic	O
37	insert	O
38	between	O
39	subdomains	B
40	VII	I
41	and	I
42	VIII	I
43	.	O

1	Ime1	O
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	O
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	characterization	O
7	of	O
8	an	O
9	alternatively	O
10	processed	O
11	form	O
12	of	O
13	AFAP	O
14	-	O
15	110	O
16	that	O
17	encodes	O
18	an	O
19	additional	O
20	258	O
21	base	O
22	pair	O
23	(	O
24	bp	O
25	)	O
26	of	O
27	open	O
28	reading	O
29	frame	O
30	.	O

1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O

1	Weight	O
2	and	O
3	height	O
4	z	O
5	-	O
6	scores	O
7	were	O
8	significantly	O
9	associated	O
10	with	O
11	BMD	O
12	z	O
13	-	O
14	scores	O
15	.	O

1	Because	O
2	all	O
3	PDGFbetaR	O
4	fusions	O
5	described	O
6	thus	O
7	far	O
8	result	O
9	in	O
10	splicing	O
11	to	O
12	a	O
13	common	O
14	exon	O
15	of	O
16	this	O
17	gene	O
18	,	O
19	we	O
20	performed	O
21	5	O
22	'-	O
23	rapid	O
24	amplification	O
25	of	O
26	cDNA	O
27	ends	O
28	PCR	O
29	on	O
30	patient	O
31	RNA	O
32	.	O

1	The	O
2	mutations	O
3	did	O
4	not	O
5	affect	O
6	the	O
7	repression	O
8	of	O
9	CPA1	B
10	by	O
11	arginine	O
12	.	O

1	Comparison	O
2	of	O
3	promoters	O
4	repressed	O
5	by	O
6	c	B
7	-	I
8	myc	I
9	reveals	O
10	a	O
11	weak	O
12	consensus	O
13	sequence	O
14	of	O
15	the	O
16	initiator	O
17	(	O
18	Inr	O
19	)	O
20	element	O
21	:	O
22	TCA	O
23	(+	O
24	1	O
25	)	O
26	YYYNY	O
27	.	O

1	Recently	O
2	,	O
3	we	O
4	have	O
5	reported	O
6	the	O
7	cloning	O
8	of	O
9	the	O
10	germ	O
11	cell	O
12	-	O
13	specific	O
14	,	O
15	nuclear	B
16	orphan	I
17	receptor	I
18	germ	I
19	cell	I
20	nuclear	I
21	factor	I
22	(	O
23	GCNF	O
24	)/	O
25	RTR	B
26	.	O

1	Direct	O
2	approach	O
3	to	O
4	the	O
5	study	O
6	of	O
7	soliton	O
8	perturbations	O
9	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	N	O
6	-	O
7	nitroso	O
8	compounds	O
9	can	O
10	be	O
11	formed	O
12	in	O
13	vivo	O
14	in	O
15	the	O
16	infected	O
17	bladder	O
18	,	O
19	which	O
20	could	O
21	explain	O
22	the	O
23	association	O
24	between	O
25	urinary	O
26	-	O
27	tract	O
28	infections	O
29	and	O
30	increased	O
31	risk	O
32	for	O
33	bladder	O
34	cancer	O
35	.	O

1	This	O
2	motif	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	mediate	O
8	protein	O
9	interactions	O
10	in	O
11	the	O
12	case	O
13	of	O
14	ankyrin	B
15	as	O
16	well	O
17	as	O
18	several	O
19	other	O
20	repeat	O
21	-	O
22	bearing	O
23	proteins	O
24	.	O

1	These	O
2	genes	O
3	are	O
4	expressed	O
5	within	O
6	a	O
7	few	O
8	hours	O
9	of	O
10	the	O
11	initiation	O
12	of	O
13	development	O
14	;	O
15	their	O
16	mRNAs	O
17	accumulate	O
18	to	O
19	a	O
20	peak	O
21	at	O
22	12	O
23	hr	O
24	and	O
25	persist	O
26	until	O
27	culmination	O
28	.	O

1	The	O
2	median	O
3	survival	O
4	is	O
5	not	O
6	reached	O
7	with	O
8	a	O
9	median	O
10	follow	O
11	-	O
12	up	O
13	time	O
14	of	O
15	9	O
16	.	O
17	6	O
18	years	O
19	.	O

1	NF	B
2	-	I
3	HB	I
4	(	O
5	BSAP	B
6	)	O
7	is	O
8	a	O
9	repressor	O
10	of	O
11	the	O
12	murine	B
13	immunoglobulin	I
14	heavy	I
15	-	I
16	chain	I
17	3	I
18	'	I
19	alpha	I
20	enhancer	I
21	at	O
22	early	O
23	stages	O
24	of	O
25	B	O
26	-	O
27	cell	O
28	differentiation	O
29	.	O

1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	B
15	lipoxygenase	I
16	activity	O
17	.	O

1	However	O
2	,	O
3	in	O
4	the	O
5	subgroup	O
6	with	O
7	normal	O
8	Ht	O
9	(<	O
10	0	O
11	.	O
12	45	O
13	l	O
14	/	O
15	l	O
16	;	O
17	n	O
18	=	O
19	201	O
20	)	O
21	there	O
22	was	O
23	a	O
24	significant	O
25	reduction	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	05	O
32	)	O
33	of	O
34	the	O
35	mortality	O
36	after	O
37	3	O
38	months	O
39	(	O
40	27	O
41	%	O
42	and	O
43	16	O
44	%,	O
45	respectively	O
46	)	O
47	and	O
48	an	O
49	increase	O
50	of	O
51	independence	O
52	at	O
53	home	O
54	(	O
55	35	O
56	%	O
57	and	O
58	48	O
59	%,	O
60	respectively	O
61	)	O
62	due	O
63	to	O
64	a	O
65	reduction	O
66	of	O
67	the	O
68	viscosity	O
69	by	O
70	means	O
71	of	O
72	haemodilution	O
73	with	O
74	albumin	B
75	(	O
76	a	O
77	specific	O
78	viscosity	O
79	effect	O
80	in	O
81	the	O
82	normovolaemic	O
83	group	O
84	).	O

1	Finally	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	alpha	I
10	can	O
11	also	O
12	active	O
13	the	O
14	GM	B
15	-	I
16	CSF	I
17	receptor	I
18	alpha	I
19	promoter	I
20	in	O
21	nonmyeloid	O
22	cells	O
23	.	O

1	Among	O
2	953	O
3	infants	O
4	in	O
5	22	O
6	neonatal	O
7	care	O
8	units	O
9	studied	O
10	,	O
11	23	O
12	%	O
13	(	O
14	median	O
15	value	O
16	,	O
17	range	O
18	0	O
19	-	O
20	78	O
21	)	O
22	were	O
23	found	O
24	to	O
25	be	O
26	faecally	O
27	colonized	O
28	with	O
29	one	O
30	of	O
31	21	O
32	distinct	O
33	nosocomial	O
34	strains	O
35	of	O
36	Escherichia	O
37	coli	O
38	,	O
39	Klebsiella	O
40	or	O
41	Enterobacter	O
42	spp	O
43	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	O
5	human	O
6	SLF	O
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	O
19	-	O
20	kit	O
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O

1	A	O
2	brief	O
3	discussion	O
4	of	O
5	color	O
6	deficiencies	O
7	.	O

1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	moderate	O
7	cooling	O
8	increases	O
9	the	O
10	responsiveness	O
11	of	O
12	vascular	B
13	alpha2	I
14	-	I
15	adrenoceptors	I
16	.	O

1	Interestingly	O
2	,	O
3	these	O
4	response	O
5	elements	O
6	display	O
7	dramatically	O
8	reduced	O
9	affinity	O
10	for	O
11	retinoic	B
12	acid	I
13	receptor	I
14	-	I
15	retinoid	I
16	-	I
17	X	I
18	receptor	I
19	heterodimers	O
20	.	O

1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O

1	Promoter	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	dependently	O
7	inhibited	O
8	by	O
9	cotransfection	O
10	with	O
11	either	O
12	ras	B
13	or	O
14	mos	O
15	oncogenes	O
16	,	O
17	but	O
18	oncogene	O
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	O
25	activity	O
26	increased	O
27	when	O
28	cells	O
29	were	O
30	treated	O
31	with	O
32	the	O
33	MAP	B
34	kinase	I
35	kinase	I
36	(	O
37	MKK	B
38	)	O
39	inhibitor	O
40	PD98059	O
41	.	O

1	Continued	O
2	development	O
3	of	O
4	the	O
5	rat	O
6	conditioning	O
7	paradigm	O
8	is	O
9	especially	O
10	warranted	O
11	because	O
12	of	O
13	the	O
14	ability	O
15	to	O
16	record	O
17	sympathetic	O
18	nerve	O
19	activity	O
20	in	O
21	intact	O
22	,	O
23	awake	O
24	subjects	O
25	and	O
26	the	O
27	large	O
28	number	O
29	of	O
30	readily	O
31	available	O
32	genetic	O
33	strains	O
34	,	O
35	which	O
36	model	O
37	human	O
38	pathological	O
39	states	O
40	.	O

1	Bacterial	O
2	meningitis	O
3	secondary	O
4	to	O
5	abscess	O
6	of	O
7	the	O
8	nasal	O
9	septum	O
10	.	O

1	Brain	O
2	pH	O
3	following	O
4	3	O
5	h	O
6	of	O
7	cerebral	O
8	focal	O
9	ischemia	O
10	changed	O
11	from	O
12	a	O
13	normal	O
14	value	O
15	of	O
16	7	O
17	.	O
18	0	O
19	to	O
20	6	O
21	.	O
22	5	O
23	and	O
24	6	O
25	.	O
26	2	O
27	in	O
28	animals	O
29	studied	O
30	under	O
31	barbiturate	O
32	and	O
33	halothane	O
34	anesthesia	O
35	,	O
36	respectively	O
37	.	O

1	These	O
2	results	O
3	indicate	O
4	a	O
5	possible	O
6	involvement	O
7	of	O
8	endogenous	O
9	opioid	O
10	peptides	O
11	in	O
12	the	O
13	cardiac	O
14	effects	O
15	due	O
16	to	O
17	myocardial	O
18	ischaemia	O
19	and	O
20	reperfusion	O
21	,	O
22	mediated	O
23	by	O
24	opiate	B
25	receptors	I
26	through	O
27	opiate	O
28	antagonism	O
29	.	O

1	The	O
2	rCBF	O
3	and	O
4	vasomotion	O
5	were	O
6	recorded	O
7	by	O
8	laser	O
9	-	O
10	doppler	O
11	fluxmetry	O
12	.	O

1	Activity	O
2	of	O
3	acid	O
4	hydrolases	O
5	of	O
6	peripheral	O
7	blood	O
8	leukocytes	O
9	in	O
10	focal	O
11	and	O
12	segmental	O
13	pneumonia	O
14	in	O
15	children	O

1	Notably	O
2	,	O
3	these	O
4	residues	O
5	are	O
6	located	O
7	in	O
8	different	O
9	domains	O
10	.	O

1	The	O
2	effect	O
3	of	O
4	L	O
5	-	O
6	methionine	O
7	supplementation	O
8	on	O
9	the	O
10	utilization	O
11	of	O
12	a	O
13	soy	O
14	protein	O
15	isolate	O
16	(	O
17	SPI	O
18	)	O
19	was	O
20	evaluated	O
21	by	O
22	short	O
23	-	O
24	term	O
25	nitrogen	O
26	balance	O
27	studies	O
28	in	O
29	young	O
30	women	O
31	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	saccharin	O
6	in	O
7	the	O
8	diet	O
9	on	O
10	caecal	O
11	microflora	O
12	.	O

1	It	O
2	has	O
3	been	O
4	previously	O
5	shown	O
6	that	O
7	genes	O
8	transcribed	O
9	by	O
10	RNA	B
11	polymerase	I
12	II	I
13	(	O
14	RNAP	B
15	II	I
16	)	O
17	are	O
18	subject	O
19	to	O
20	position	O
21	effect	O
22	variegation	O
23	when	O
24	located	O
25	near	O
26	yeast	O
27	telomeres	O
28	.	O

1	The	O
2	exploratory	O
3	behaviour	O
4	in	O
5	normal	O
6	and	O
7	aggressive	O
8	mice	O
9	.	O

1	Under	O
2	resting	O
3	conditions	O
4	,	O
5	activity	O
6	levels	O
7	of	O
8	cardiac	O
9	vagal	O
10	and	O
11	sympathetic	O
12	outflows	O
13	are	O
14	not	O
15	related	O
16	across	O
17	young	O
18	,	O
19	healthy	O
20	human	O
21	subjects	O
22	and	O
23	peripheral	O
24	interaction	O
25	is	O
26	not	O
27	manifest	O
28	between	O
29	the	O
30	autonomic	O
31	divisions	O
32	.	O

1	The	O
2	sequenced	O
3	cDNA	O
4	predicts	O
5	a	O
6	704	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	80	O
12	%	O
13	identical	O
14	to	O
15	human	B
16	progelatinase	I
17	B	I
18	.	O

1	The	O
2	smallest	O
3	of	O
4	the	O
5	mini	O
6	-	O
7	Mu	O
8	elements	O
9	is	O
10	only	O
11	7	O
12	.	O
13	9	O
14	kilobase	O
15	pairs	O
16	long	O
17	,	O
18	allowing	O
19	the	O
20	cloning	O
21	of	O
22	DNA	O
23	fragments	O
24	of	O
25	up	O
26	to	O
27	31	O
28	.	O
29	1	O
30	kilobase	O
31	pairs	O
32	,	O
33	and	O
34	the	O
35	largest	O
36	of	O
37	them	O
38	is	O
39	21	O
40	.	O
41	7	O
42	kilobase	O
43	pairs	O
44	,	O
45	requiring	O
46	that	O
47	clones	O
48	carry	O
49	insertions	O
50	of	O
51	less	O
52	than	O
53	17	O
54	.	O
55	3	O
56	kilobase	O
57	pairs	O
58	.	O

1	Interestingly	O
2	,	O
3	segment	O
4	nesting	O
5	differentially	O
6	increases	O
7	the	O
8	copy	O
9	number	O
10	of	O
11	genes	O
12	encoded	O
13	by	O
14	segment	O
15	W	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	unusual	O
21	genomic	O
22	organization	O
23	of	O
24	PDVs	B
25	may	O
26	be	O
27	directly	O
28	linked	O
29	to	O
30	the	O
31	unique	O
32	functions	O
33	of	O
34	this	O
35	virus	O
36	in	O
37	its	O
38	obligate	O
39	mutualistic	O
40	association	O
41	with	O
42	parasitic	O
43	wasps	O
44	.	O

1	Courses	O
2	were	O
3	repeated	O
4	monthly	O
5	upon	O
6	recovery	O
7	of	O
8	myelosuppression	O
9	.	O

1	All	O
2	groups	O
3	were	O
4	challenged	O
5	subsequently	O
6	with	O
7	naloxone	O
8	(	O
9	0	O
10	.	O
11	4	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	in	O
17	the	O
18	distinctive	O
19	environment	O
20	and	O
21	then	O
22	observed	O
23	for	O
24	signs	O
25	of	O
26	opiate	O
27	withdrawal	O
28	.	O

1	Mechanism	O
2	of	O
3	activation	O
4	of	O
5	the	O
6	vav	B
7	protooncogene	I
8	.	O
9	vav	O
10	is	O
11	a	O
12	human	B
13	locus	I
14	that	O
15	appears	O
16	to	O
17	be	O
18	specifically	O
19	expressed	O
20	in	O
21	cells	O
22	of	O
23	hematopoietic	O
24	origin	O
25	regardless	O
26	of	O
27	their	O
28	differentiation	O
29	lineage	O
30	.	O

1	Altogether	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	,	O
7	in	O
8	KG1a	O
9	cells	O
10	,	O
11	TNFalpha	B
12	can	O
13	stimulate	O
14	in	O
15	parallel	O
16	PC	B
17	-	I
18	PLC	I
19	and	O
20	PLD	O
21	,	O
22	whose	O
23	lipid	O
24	products	O
25	activate	O
26	in	O
27	turn	O
28	mitogen	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	(	O
34	MAP	B
35	kinase	I
36	)	O
37	and	O
38	NF	B
39	-	I
40	kappaB	I
41	signalling	O
42	respectively	O
43	.	O

1	HYPOTHESIS	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	apolipoprotein	B
16	B	I
17	-	I
18	containing	I
19	lipoproteins	I
20	and	O
21	antioxidant	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	syndromes	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	pectoris	O
34	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	significant	O
6	pulmonary	O
7	metabolism	O
8	of	O
9	5	O
10	-	O
11	HT	O
12	followed	O
13	by	O
14	efflux	O
15	of	O
16	5	O
17	-	O
18	HIAA	O
19	into	O
20	venous	O
21	output	O
22	occurs	O
23	during	O
24	single	O
25	-	O
26	pass	O
27	circulation	O
28	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	are	O
5	being	O
6	used	O
7	to	O
8	accelerate	O
9	the	O
10	recovery	O
11	of	O
12	myelopoiesis	O
13	following	O
14	high	O
15	-	O
16	dose	O
17	chemotherapy	O
18	in	O
19	cancer	O
20	patients	O
21	.	O

1	Nucleoprotein	O
2	(	O
3	N	O
4	)	O
5	expressed	O
6	by	O
7	both	O
8	recombinant	O
9	vaccinia	O
10	virus	O
11	and	O
12	TGEV	O
13	had	O
14	a	O
15	relative	O
16	molecular	O
17	mass	O
18	(	O
19	Mr	O
20	)	O
21	of	O
22	47	O
23	,	O
24	000	O
25	and	O
26	was	O
27	susceptible	O
28	to	O
29	degradation	O
30	at	O
31	the	O
32	C	O
33	-	O
34	terminus	O
35	yielding	O
36	discrete	O
37	breakdown	O
38	products	O
39	.	O

1	The	O
2	multidomain	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	motif	O
10	resembling	O
11	those	O
12	of	O
13	protein	B
14	kinase	I
15	C	I
16	and	O
17	n	O
18	-	O
19	chimaerin	O
20	and	O
21	a	O
22	putative	O
23	pleckstrin	B
24	homology	I
25	domain	I
26	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mature	O
6	region	O
7	is	O
8	highly	O
9	conserved	O
10	in	O
11	other	O
12	serine	O
13	carboxypeptidases	O
14	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	B
8	ORL1	I
9	and	O
10	GAIP	B
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	O
12	factors	O
13	NF	B
14	-	I
15	kappaB	I
16	and	O
17	AP	B
18	-	I
19	1	I
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	I
27	8	I
28	gene	I
29	by	O
30	HTLV	B
31	-	I
32	I	I
33	Tax	I
34	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	By	O
2	sequence	O
3	comparison	O
4	,	O
5	42	O
6	blocks	O
7	of	O
8	homology	O
9	are	O
10	defined	O
11	in	O
12	the	O
13	5	O
14	'-	O
15	terminal	O
16	region	O
17	,	O
18	of	O
19	which	O
20	36	O
21	appear	O
22	in	O
23	the	O
24	CpG	O
25	island	O
26	and	O
27	contain	O
28	numerous	O
29	conserved	O
30	CpG	O
31	dinucleotides	O
32	.	O

1	In	O
2	the	O
3	artificial	O
4	lung	O
5	,	O
6	like	O
7	in	O
8	the	O
9	natural	O
10	lung	O
11	and	O
12	peripheral	O
13	tissues	O
14	,	O
15	gas	O
16	exchanges	O
17	depend	O
18	on	O
19	several	O
20	parameters	O
21	:	O
22	blood	O
23	inlet	O
24	conditions	O
25	,	O
26	blood	O
27	flow	O
28	rate	O
29	,	O
30	temperature	O
31	,	O
32	composition	O
33	of	O
34	the	O
35	gas	O
36	mixture	O
37	used	O
38	for	O
39	ventilation	O
40	,	O
41	blood	O
42	tissue	O
43	perfusion	O
44	,	O
45	O2	O
46	consumption	O
47	,	O
48	etc	O
49	.	O

1	The	O
2	usefulness	O
3	of	O
4	the	O
5	lambda	B
6	PG15	I
7	and	O
8	the	O
9	lambda	B
10	AD5	I
11	cloning	O
12	vectors	O
13	was	O
14	demonstrated	O
15	by	O
16	constructing	O
17	large	O
18	Neurospora	O
19	crassa	O
20	cDNA	O
21	libraries	O
22	.	O

1	Factor	B
2	V	I
3	Leiden	I
4	is	O
5	a	O
6	genetic	O
7	disorder	O
8	associated	O
9	with	O
10	an	O
11	increased	O
12	risk	O
13	of	O
14	venous	O
15	thrombosis	O
16	.	O

1	The	O
2	recruitment	O
3	of	O
4	constitutively	O
5	phosphorylated	O
6	p185	O
7	(	O
8	neu	B
9	)	O
10	and	O
11	the	O
12	activated	O
13	mitogenic	O
14	pathway	O
15	proteins	O
16	to	O
17	this	O
18	membrane	O
19	-	O
20	microfilament	O
21	interaction	O
22	site	O
23	provides	O
24	a	O
25	physical	O
26	model	O
27	for	O
28	integrating	O
29	the	O
30	assembly	O
31	of	O
32	the	O
33	mitogenic	O
34	pathway	O
35	with	O
36	the	O
37	transmission	O
38	of	O
39	growth	O
40	factor	O
41	signal	O
42	to	O
43	the	O
44	cytoskeleton	O
45	.	O

1	Germ	O
2	-	O
3	free	O
4	rabbits	O
5	given	O
6	mouse	B
7	CRF	I
8	-	I
9	flora	I
10	showed	O
11	values	O
12	quite	O
13	different	O
14	from	O
15	control	O
16	animals	O
17	for	O
18	most	O
19	parameters	O
20	,	O
21	indicating	O
22	unsuitability	O
23	of	O
24	mouse	B
25	CRF	I
26	flora	I
27	to	O
28	'	O
29	normalize	O
30	'	O
31	rabbits	O
32	.	O

1	Patients	O
2	and	O
3	their	O
4	relatives	O
5	must	O
6	be	O
7	informed	O
8	about	O
9	the	O
10	available	O
11	effective	O
12	treatment	O
13	possibilities	O
14	and	O
15	about	O
16	the	O
17	right	O
18	moment	O
19	for	O
20	their	O
21	application	O
22	in	O
23	an	O
24	individual	O
25	patient	O
26	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	B
32	I	I
33	digestion	O
34	in	O
35	vivo	O
36	.	O

1	Recent	O
2	developments	O
3	in	O
4	drugs	O
5	antagonistic	O
6	to	O
7	factors	O
8	causing	O
9	peptic	O
10	ulcer	O
11	--	O
12	clinical	O
13	efficacy	O
14	and	O
15	problems	O
16	;	O
17	gastrin	B
18	receptor	I
19	blockaders	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	periseizure	O
6	lipid	O
7	accumulation	O
8	is	O
9	related	O
10	to	O
11	cortical	O
12	oxygenation	O
13	.	O

1	EEG	O
2	theta	O
3	waves	O
4	and	O
5	psychological	O
6	phenomena	O
7	:	O
8	a	O
9	review	O
10	and	O
11	analysis	O
12	.	O

1	Comparisons	O
2	with	O
3	the	O
4	available	O
5	amino	O
6	acid	O
7	residue	O
8	(	O
9	aa	O
10	)	O
11	sequence	O
12	information	O
13	from	O
14	the	O
15	complete	O
16	CPMV	B
17	RNA	I
18	1	I
19	sequence	I
20	and	O
21	the	O
22	partial	O
23	sequence	O
24	of	O
25	red	O
26	clover	O
27	mottle	O
28	virus	O
29	RNA	O
30	1	O
31	suggest	O
32	that	O
33	CPSMV	B
34	RNA	I
35	1	I
36	specifies	O
37	the	O
38	expected	O
39	set	O
40	of	O
41	five	O
42	mature	O
43	proteins	O
44	:	O
45	32K	B
46	proteinase	I
47	cofactor	I
48	,	O
49	58K	O
50	presumed	O
51	helicase	B
52	,	O
53	VPg	B
54	5	I
55	'-	I
56	linked	I
57	protein	I
58	of	O
59	the	O
60	genomic	O
61	RNAs	O
62	,	O
63	24K	B
64	proteinase	I
65	,	O
66	and	O
67	87K	O
68	presumed	O
69	polymerase	O
70	,	O
71	separated	O
72	by	O
73	four	O
74	cleavage	O
75	sites	O
76	.	O

1	Information	O
2	about	O
3	immunologic	O
4	drug	O
5	interactions	O
6	is	O
7	needed	O
8	by	O
9	pharmacists	O
10	to	O
11	make	O
12	rational	O
13	drug	O
14	-	O
15	use	O
16	decisions	O
17	.	O

1	Assay	O
2	of	O
3	urea	O
4	by	O
5	immobilized	O
6	urease	B
7	coupled	O
8	to	O
9	a	O
10	differential	O
11	pH	O
12	-	O
13	meter	O
14	.	O

1	Cell	O
2	.	O

1	Selective	O
2	activation	O
3	of	O
4	adrenaline	O
5	secretion	O
6	by	O
7	the	O
8	rat	O
9	adrenal	O
10	in	O
11	neuroglycopenia	O
12	detected	O
13	via	O
14	microdialysis	O

1	Altogether	O
2	our	O
3	data	O
4	indicate	O
5	that	O
6	PEDF	B
7	belongs	O
8	to	O
9	the	O
10	subgroup	O
11	of	O
12	noninhibitory	O
13	serpins	O
14	and	O
15	that	O
16	its	O
17	N	O
18	-	O
19	terminal	O
20	region	O
21	confers	O
22	a	O
23	neurite	O
24	-	O
25	promoting	O
26	activity	O
27	to	O
28	the	O
29	protein	O
30	.	O

1	Mean	O
2	rCBF	O
3	increased	O
4	in	O
5	some	O
6	patients	O
7	4	O
8	-	O
9	8	O
10	weeks	O
11	after	O
12	surgery	O
13	on	O
14	the	O
15	ipsilateral	O
16	side	O
17	.	O

1	Six	O
2	(	O
3	four	O
4	FAP	O
5	;	O
6	two	O
7	primary	O
8	amyloidosis	O
9	)	O
10	also	O
11	had	O
12	diffusely	O
13	positive	O
14	myocardial	O
15	uptakes	O
16	,	O
17	but	O
18	the	O
19	intensity	O
20	was	O
21	less	O
22	than	O
23	that	O
24	of	O
25	the	O
26	sternum	O
27	.	O

1	The	O
2	short	O
3	-	O
4	term	O
5	synthesis	O
6	and	O
7	infant	O
8	-	O
9	regulated	O
10	removal	O
11	of	O
12	milk	O
13	in	O
14	lactating	O
15	women	O
16	.	O

1	Circulatory	O
2	arrest	O
3	in	O
4	the	O
5	operating	O
6	room	O
7	.	O

1	The	O
2	relation	O
3	between	O
4	VE	O
5	/	O
6	VO2	O
7	and	O
8	Q	O
9	/	O
10	VO2	O
11	showed	O
12	a	O
13	significant	O
14	negative	O
15	correlation	O
16	(	O
17	r	O
18	=	O
19	-	O
20	0	O
21	.	O
22	93	O
23	,	O
24	p	O
25	less	O
26	than	O
27	0	O
28	.	O
29	01	O
30	).	O

1	In	O
2	vitro	O
3	metabolism	O
4	of	O
5	progesterone	O
6	by	O
7	the	O
8	human	O
9	undescended	O
10	testis	O
11	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	identification	O
6	and	O
7	characterization	O
8	of	O
9	several	O
10	Sp100	B
11	splice	I
12	variant	I
13	proteins	I
14	and	O
15	support	O
16	their	O
17	existence	O
18	by	O
19	elucidation	O
20	of	O
21	the	O
22	3	O
23	'-	O
24	end	O
25	of	O
26	the	O
27	Sp100	B
28	gene	I
29	.	O

1	Changes	O
2	in	O
3	xanthine	B
4	oxidase	I
5	activity	O
6	in	O
7	patients	O
8	with	O
9	circulatory	O
10	failure	O

1	One	O
2	antibody	O
3	,	O
4	mAb1C2	B
5	,	O
6	and	O
7	a	O
8	synthetic	O
9	peptide	O
10	comprising	O
11	its	O
12	epitope	O
13	selectively	O
14	inhibited	O
15	in	O
16	vitro	O
17	transcription	O
18	from	O
19	TATA	O
20	-	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	from	O
26	TATA	O
27	-	O
28	less	O
29	promoters	O
30	,	O
31	irrespective	O
32	of	O
33	whether	O
34	they	O
35	were	O
36	transcribed	O
37	by	O
38	Pol	B
39	II	I
40	or	O
41	Pol	B
42	III	I
43	.	O

1	Previous	O
2	studies	O
3	characterized	O
4	a	O
5	cytokine	O
6	-	O
7	inducible	O
8	,	O
9	functional	O
10	nuclear	B
11	factor	I
12	(	I
13	NF	I
14	)-	I
15	kappaB	I
16	consensus	O
17	element	O
18	in	O
19	the	O
20	immediate	O
21	5	O
22	'	O
23	regulatory	O
24	region	O
25	of	O
26	the	O
27	MGSA	B
28	/	O
29	GRO	B
30	-	I
31	alpha	I
32	gene	I
33	at	O
34	-	O
35	78	O
36	bp	O
37	.	O

1	Five	O
2	of	O
3	the	O
4	Aeromonas	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	cholerae	O
11	non	O
12	-	O
13	O1	O
14	were	O
15	positive	O
16	for	O
17	enterotoxin	O
18	activity	O
19	.	O

1	Induction	O
2	of	O
3	B	O
4	cell	O
5	apoptosis	O
6	by	O
7	co	O
8	-	O
9	cross	O
10	-	O
11	linking	O
12	CD23	B
13	and	O
14	sIg	O
15	involves	O
16	aberrant	O
17	regulation	O
18	of	O
19	c	B
20	-	I
21	myc	I
22	and	O
23	is	O
24	inhibited	O
25	by	O
26	bcl	B
27	-	I
28	2	I
29	.	O

1	Antibodies	O
2	against	O
3	this	O
4	purified	O
5	protein	O
6	localize	O
7	RIM1	O
8	to	O
9	mitochondria	O
10	.	O

1	Comparison	O
2	of	O
3	immunoassay	O
4	kits	O
5	for	O
6	detection	O
7	of	O
8	staphylococcal	O
9	enterotoxins	O
10	produced	O
11	by	O
12	Staphylococcus	O
13	aureus	O

1	Oligonucleotides	O
2	,	O
3	designed	O
4	on	O
5	the	O
6	basis	O
7	of	O
8	conserved	O
9	flanking	O
10	amino	O
11	acid	O
12	sequence	O
13	segments	O
14	within	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	eukaryotic	B
20	protein	I
21	kinase	I
22	C	I
23	(	I
24	PKC	I
25	)	I
26	proteins	I
27	,	O
28	were	O
29	used	O
30	as	O
31	primers	O
32	for	O
33	polymerase	O
34	chain	O
35	reactions	O
36	to	O
37	amplify	O
38	a	O
39	427	O
40	-	O
41	bp	O
42	chromosomal	O
43	DNA	O
44	fragment	O
45	from	O
46	the	O
47	filamentous	O
48	fungus	O
49	Trichoderma	O
50	reesei	O
51	.	O

1	Recently	O
2	,	O
3	identical	O
4	RBE	O
5	sequences	O
6	have	O
7	been	O
8	identified	O
9	at	O
10	other	O
11	locations	O
12	in	O
13	the	O
14	human	O
15	genome	O
16	.	O

1	In	O
2	these	O
3	constructs	O
4	,	O
5	GUS	B
6	expression	O
7	was	O
8	driven	O
9	by	O
10	promoter	O
11	regions	O
12	derived	O
13	from	O
14	the	O
15	Arabidopsis	B
16	alcohol	I
17	dehydrogenase	I
18	(	O
19	Adh1	O
20	),	O
21	maize	B
22	ubiquitin	I
23	(	O
24	Ubi1	O
25	),	O
26	rice	B
27	actin	I
28	(	O
29	Act1	B
30	)	O
31	and	O
32	CaMV	B
33	35S	I
34	genes	O
35	.	O

1	No	O
2	difference	O
3	in	O
4	telomere	O
5	length	O
6	was	O
7	seen	O
8	in	O
9	mutants	O
10	affected	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	Cdc2	B
16	,	O
17	whereas	O
18	some	O
19	of	O
20	the	O
21	DNA	O
22	repair	O
23	mutants	O
24	examined	O
25	had	O
26	slightly	O
27	longer	O
28	telomeres	O
29	than	O
30	did	O
31	the	O
32	wild	O
33	type	O
34	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	total	O
7	protein	O
8	profiles	O
9	of	O
10	wild	O
11	-	O
12	type	O
13	S	O
14	.	O
15	entomophila	O
16	UC9	O
17	and	O
18	mutant	O
19	UC21	O
20	revealed	O
21	that	O
22	the	O
23	mutant	O
24	lacked	O
25	an	O
26	approximately	O
27	44	B
28	-	I
29	kDa	I
30	protein	I
31	and	O
32	overexpressed	O
33	an	O
34	approximately	O
35	20	B
36	-	I
37	kDa	I
38	protein	I
39	.	O

1	A	O
2	novel	O
3	,	O
4	testis	O
5	-	O
6	specific	O
7	mRNA	O
8	transcript	O
9	encoding	O
10	an	O
11	NH2	B
12	-	I
13	terminal	I
14	truncated	I
15	nitric	I
16	-	I
17	oxide	I
18	synthase	I
19	.	O
20	mRNA	O
21	diversity	O
22	represents	O
23	a	O
24	major	O
25	theme	O
26	of	O
27	neuronal	O
28	nitric	B
29	-	I
30	oxide	I
31	synthase	I
32	(	O
33	nNOS	B
34	)	O
35	gene	O
36	expression	O
37	in	O
38	somatic	O
39	cells	O
40	/	O
41	tissues	O
42	.	O

1	The	O
2	lysozyme	B
3	FEF	I
4	site	I
5	is	O
6	immediately	O
7	5	O
8	'	O
9	to	O
10	a	O
11	PU	B
12	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	One	O
2	complex	O
3	appears	O
4	to	O
5	be	O
6	ubiquitous	O
7	but	O
8	enriched	O
9	in	O
10	lymphoid	O
11	cells	O
12	and	O
13	represents	O
14	the	O
15	binding	O
16	of	O
17	a	O
18	potentially	O
19	novel	O
20	factor	O
21	with	O
22	an	O
23	apparent	O
24	molecular	O
25	mass	O
26	of	O
27	approximately	O
28	50	O
29	kDa	O
30	.	O

1	Thus	O
2	,	O
3	the	O
4	P	O
5	.	O
6	aeruginosa	O
7	orfX	O
8	and	O
9	vfr	O
10	promoters	O
11	are	O
12	arranged	O
13	in	O
14	a	O
15	back	O
16	-	O
17	to	O
18	-	O
19	back	O
20	orientation	O
21	rather	O
22	than	O
23	the	O
24	face	O
25	-	O
26	to	O
27	-	O
28	face	O
29	orientation	O
30	of	O
31	the	O
32	dorf	O
33	and	O
34	crp	B
35	promoters	I
36	.	O

1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O

1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O

1	The	O
2	mysteries	O
3	of	O
4	geographic	O
5	variability	O
6	in	O
7	nonmelanoma	O
8	skin	O
9	cancer	O
10	incidence	O
11	.	O

1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O

1	The	O
2	fatigue	O
3	exercise	O
4	showed	O
5	relatively	O
6	high	O
7	blood	O
8	lactate	O
9	concentration	O
10	[	O
11	12	O
12	.	O
13	5	O
14	(	O
15	SD	O
16	2	O
17	.	O
18	6	O
19	)	O
20	mmol	O
21	x	O
22	l	O
23	(-	O
24	1	O
25	)]	O
26	and	O
27	an	O
28	increase	O
29	of	O
30	serum	B
31	creatine	I
32	kinase	I
33	(	O
34	CK	B
35	)	O
36	activity	O
37	delayed	O
38	by	O
39	2	O
40	days	O
41	[	O
42	540	O
43	(	O
44	SD	O
45	407	O
46	)	O
47	U	O
48	x	O
49	l	O
50	(-	O
51	1	O
52	)].	O

1	The	O
2	mortality	O
3	rate	O
4	and	O
5	histopathological	O
6	features	O
7	of	O
8	Nocardia	O
9	asteroides	O
10	and	O
11	Nocardia	O
12	brasiliensis	O
13	infections	O
14	in	O
15	congenitally	O
16	athymic	O
17	(	O
18	nude	O
19	)	O
20	mice	O
21	of	O
22	ICR	B
23	and	O
24	C3H	O
25	/	O
26	eB	B
27	origins	I
28	were	O
29	quite	O
30	different	O
31	from	O
32	what	O
33	we	O
34	found	O
35	for	O
36	Swiss	O
37	white	O
38	mice	O
39	and	O
40	other	O
41	inbred	O
42	mouse	O
43	strains	O
44	(	O
45	namely	O
46	,	O
47	C57	O
48	/	O
49	BL	B
50	/	O
51	6J	O
52	,	O
53	New	O
54	Zealand	O
55	Black	O
56	,	O
57	BALB	O
58	/	O
59	c	B
60	,	O
61	CBA	B
62	/	O
63	LAC	B
64	,	O
65	and	O
66	C3H	O
67	/	O
68	eB	B
69	).	O

1	Study	O
2	of	O
3	the	O
4	physico	O
5	-	O
6	chemical	O
7	state	O
8	of	O
9	plutonium	O
10	-	O
11	239	O
12	in	O
13	a	O
14	citrate	O
15	solution	O
16	-	O
17	blood	O
18	system	O

1	The	O
2	NR2	B
3	hybrid	O
4	is	O
5	a	O
6	powerful	O
7	tool	O
8	for	O
9	the	O
10	mapping	O
11	of	O
12	new	O
13	probes	O
14	of	O
15	this	O
16	region	O
17	,	O
18	as	O
19	well	O
20	as	O
21	for	O
22	obtaining	O
23	new	O
24	informative	O
25	probes	O
26	specific	O
27	for	O
28	the	O
29	deletion	O
30	by	O
31	subtractive	O
32	cloning	O
33	of	O
34	the	O
35	region	O
36	.	O

1	In	O
2	this	O
3	case	O
4	the	O
5	degree	O
6	of	O
7	promoter	O
8	methylation	O
9	,	O
10	which	O
11	could	O
12	extend	O
13	beyond	O
14	the	O
15	T	O
16	-	O
17	DNA	O
18	borders	O
19	,	O
20	was	O
21	not	O
22	correlated	O
23	with	O
24	the	O
25	reduction	O
26	in	O
27	steady	O
28	-	O
29	state	O
30	poly	O
31	(	O
32	A	O
33	)+	B
34	mRNA	I
35	levels	O
36	,	O
37	the	O
38	silenced	O
39	state	O
40	was	O
41	transmitted	O
42	through	O
43	meiosis	O
44	and	O
45	reactivation	O
46	lasted	O
47	several	O
48	generations	O
49	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	O
8	IGF	B
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	The	O
2	XS2	B
3	gene	I
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	B
14	genes	I
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	B
22	.	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	B
7	,	O
8	attB	B
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	O
15	and	O
16	attR	B
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	B
38	gene	I
39	.	O

1	The	O
2	CPK	B
3	-	I
4	MB	I
5	isoenzyme	I
6	showed	O
7	no	O
8	percentage	O
9	increase	O
10	of	O
11	total	O
12	CPK	O
13	higher	O
14	than	O
15	5	O
16	%,	O
17	measured	O
18	at	O
19	6	O
20	,	O
21	12	O
22	,	O
23	and	O
24	24	O
25	h	O
26	after	O
27	the	O
28	shock	O
29	,	O
30	independent	O
31	of	O
32	the	O
33	number	O
34	of	O
35	attempts	O
36	of	O
37	cardioversion	O
38	.	O

1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O

1	This	O
2	region	O
3	is	O
4	required	O
5	for	O
6	activation	O
7	of	O
8	DNA	O
9	binding	O
10	of	O
11	MyoD	B
12	and	O
13	E12	B
14	homodimers	I
15	and	O
16	E12	B
17	/	O
18	MyoD	B
19	heterodimers	O
20	.	O

1	Diminished	O
2	forearm	O
3	arteriolar	O
4	dilator	O
5	capacity	O
6	produced	O
7	by	O
8	mineralocorticoid	O
9	-	O
10	induced	O
11	salt	O
12	retention	O
13	in	O
14	man	O
15	.	O

1	A	O
2	cDNA	O
3	clone	O
4	corresponding	O
5	to	O
6	the	O
7	putative	O
8	GA	B
9	20	I
10	-	I
11	oxidase	I
12	genomic	I
13	sequence	I
14	was	O
15	constructed	O
16	with	O
17	the	O
18	reverse	O
19	transcription	O
20	-	O
21	PCR	O
22	method	O
23	,	O
24	and	O
25	the	O
26	identity	O
27	of	O
28	the	O
29	cDNA	O
30	clone	O
31	was	O
32	confirmed	O
33	by	O
34	analyzing	O
35	the	O
36	capability	O
37	of	O
38	the	O
39	fusion	O
40	protein	O
41	expressed	O
42	in	O
43	Escherichia	O
44	coli	O
45	to	O
46	convert	O
47	GA53	O
48	to	O
49	GA44	O
50	and	O
51	GA19	O
52	to	O
53	GA20	O
54	.	O

1	The	O
2	trk	B
3	-	I
4	2h	I
5	oncogene	I
6	,	O
7	isolated	O
8	from	O
9	the	O
10	human	O
11	breast	O
12	carcinoma	O
13	cell	O
14	line	O
15	MDA	O
16	-	O
17	MB	O
18	231	O
19	by	O
20	genomic	O
21	DNA	O
22	-	O
23	transfection	O
24	into	O
25	NIH3T3	O
26	cells	O
27	,	O
28	consists	O
29	of	O
30	the	O
31	trk	B
32	proto	I
33	-	I
34	oncogene	I
35	receptor	I
36	kinase	I
37	domain	I
38	fused	O
39	to	O
40	a	O
41	N	B
42	-	I
43	terminal	I
44	41	I
45	amino	I
46	acid	I
47	activating	I
48	sequence	I
49	(	O
50	Kozma	O
51	,	O
52	S	O
53	.	O
54	C	O
55	.,	O
56	Redmond	O
57	,	O
58	S	O
59	.	O
60	M	O
61	.	O
62	S	O
63	.,	O
64	Xiao	O
65	-	O
66	Chang	O
67	,	O
68	F	O
69	.,	O
70	Saurer	O
71	,	O
72	S	O
73	.	O
74	M	O
75	.,	O
76	Groner	O
77	,	O
78	B	O
79	.	O
80	and	O
81	Hynes	O
82	,	O
83	N	O
84	.	O
85	E	O
86	.	O

1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	I
6	5	I
7	-	I
8	nucleotidase	I
9	.	O

1	Polarised	O
2	expression	O
3	of	O
4	human	B
5	intestinal	I
6	N	I
7	-	I
8	benzoyl	I
9	-	I
10	L	I
11	-	I
12	tyrosyl	I
13	-	I
14	p	I
15	-	I
16	aminobenzoic	I
17	acid	I
18	hydrolase	I
19	(	I
20	human	I
21	meprin	I
22	)	I
23	alpha	I
24	and	O
25	beta	O
26	subunits	O
27	in	O
28	Madin	O
29	-	O
30	Darby	O
31	canine	O
32	kidney	O
33	cells	O
34	.	O

1	To	O
2	investigate	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	this	O
8	Tax	B
9	-	O
10	mediated	O
11	inhibition	O
12	,	O
13	we	O
14	analyzed	O
15	its	O
16	effect	O
17	on	O
18	the	O
19	transcriptional	O
20	activity	O
21	of	O
22	the	O
23	myogenic	O
24	MyoD	B
25	protein	I
26	,	O
27	which	O
28	was	O
29	used	O
30	as	O
31	a	O
32	paradigm	O
33	of	O
34	bHLH	B
35	factors	I
36	.	O

1	Since	O
2	September	O
3	1980	O
4	to	O
5	June	O
6	1983	O
7	we	O
8	have	O
9	treated	O
10	32	O
11	patients	O
12	with	O
13	ovarian	O
14	cancer	O
15	.	O

1	Another	O
2	sequence	O
3	,	O
4	GGGXGGAG	O
5	,	O
6	which	O
7	is	O
8	repeated	O
9	several	O
10	times	O
11	in	O
12	many	O
13	polyomaviruses	O
14	and	O
15	adenoviruses	O
16	,	O
17	and	O
18	which	O
19	is	O
20	thought	O
21	to	O
22	play	O
23	a	O
24	role	O
25	in	O
26	DNA	O
27	replication	O
28	and	O
29	/	O
30	or	O
31	transcription	O
32	,	O
33	is	O
34	not	O
35	found	O
36	in	O
37	the	O
38	JCV	O
39	sequence	O
40	presented	O
41	.	O

1	Cost	O
2	-	O
3	effectiveness	O
4	analysis	O
5	provides	O
6	a	O
7	rational	O
8	means	O
9	of	O
10	allocating	O
11	limited	O
12	health	O
13	care	O
14	resources	O
15	by	O
16	allowing	O
17	the	O
18	comparison	O
19	of	O
20	the	O
21	costs	O
22	of	O
23	lipid	O
24	-	O
25	lowering	O
26	therapy	O
27	,	O
28	in	O
29	particular	O
30	,	O
31	therapy	O
32	with	O
33	beta	B
34	-	I
35	hydroxy	I
36	-	I
37	beta	I
38	-	I
39	methylglutaryl	I
40	-	I
41	CoA	I
42	(	I
43	coenzyme	I
44	A	I
45	)	I
46	reductase	I
47	inhibitors	O
48	(	O
49	statins	O
50	),	O
51	with	O
52	the	O
53	costs	O
54	of	O
55	atherosclerosis	O
56	that	O
57	could	O
58	be	O
59	prevented	O
60	by	O
61	lowering	O
62	cholesterol	O
63	.	O

1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O

1	Sudomoina	O
2	,	O
3	A	O
4	.	O

1	However	O
2	,	O
3	cotransfection	O
4	studies	O
5	indicate	O
6	that	O
7	RVR	B
8	does	O
9	not	O
10	activate	O
11	transcription	O
12	when	O
13	this	O
14	hormone	O
15	response	O
16	element	O
17	is	O
18	linked	O
19	to	O
20	a	O
21	reporter	O
22	gene	O
23	but	O
24	rather	O
25	acts	O
26	as	O
27	a	O
28	potent	O
29	competitive	O
30	repressor	O
31	of	O
32	ROR	B
33	alpha	I
34	function	O
35	.	O

1	When	O
2	10	O
3	fields	O
4	were	O
5	analysed	O
6	,	O
7	a	O
8	strong	O
9	relationship	O
10	was	O
11	found	O
12	between	O
13	the	O
14	presence	O
15	of	O
16	bacteria	O
17	on	O
18	Gram	O
19	staining	O
20	and	O
21	the	O
22	final	O
23	diagnosis	O
24	of	O
25	VAP	B
26	(	O
27	for	O
28	PSB	B
29	and	O
30	PTC	O
31	respectively	O
32	:	O
33	sensitivity	O
34	74	O
35	and	O
36	81	O
37	%,	O
38	specificity	O
39	94	O
40	and	O
41	100	O
42	%,	O
43	positive	O
44	predictive	O
45	value	O
46	91	O
47	and	O
48	100	O
49	%,	O
50	negative	O
51	predictive	O
52	value	O
53	82	O
54	and	O
55	88	O
56	%).	O

1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O

1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	I
10	beta	I
11	1	I
12	is	O
13	the	O
14	major	O
15	laminin	B
16	receptor	I
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O

1	New	O
2	alkaloids	O
3	from	O
4	bark	O
5	of	O
6	Erythrophleum	O
7	ivorense	O
8	.	O

1	Predictors	O
2	of	O
3	success	O
4	in	O
5	pharmacy	O
6	school	O
7	:	O
8	PCAT	O
9	vs	O
10	.	O
11	other	O
12	admission	O
13	criteria	O
14	.	O

1	This	O
2	study	O
3	provides	O
4	a	O
5	direct	O
6	demonstration	O
7	of	O
8	a	O
9	role	O
10	for	O
11	G	O
12	betagamma	O
13	in	O
14	mediating	O
15	the	O
16	agonist	O
17	-	O
18	stimulated	O
19	translocation	O
20	of	O
21	GRK2	B
22	and	O
23	GRK3	O
24	in	O
25	an	O
26	intact	O
27	cellular	O
28	system	O
29	and	O
30	demonstrates	O
31	isoform	O
32	specificity	O
33	in	O
34	the	O
35	interaction	O
36	of	O
37	these	O
38	components	O
39	.	O

1	We	O
2	show	O
3	also	O
4	that	O
5	RA	O
6	represses	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	a	O
12	reporter	O
13	gene	O
14	containing	O
15	a	O
16	TPA	O
17	responding	O
18	AP1	B
19	binding	O
20	site	O
21	driving	O
22	the	O
23	HSV	B
24	tk	I
25	promoter	I
26	.	O

1	In	O
2	experiments	O
3	with	O
4	the	O
5	D1	O
6	antagonist	O
7	SCH	O
8	23390	O
9	,	O
10	buprenorphine	O
11	-	O
12	induced	O
13	depression	O
14	was	O
15	consistently	O
16	blocked	O
17	,	O
18	but	O
19	facilitation	O
20	was	O
21	unaffected	O
22	.	O

1	We	O
2	were	O
3	interested	O
4	in	O
5	studying	O
6	the	O
7	relationship	O
8	between	O
9	the	O
10	circadian	O
11	rhythm	O
12	in	O
13	body	O
14	temperature	O
15	and	O
16	24	O
17	-	O
18	h	O
19	variations	O
20	in	O
21	plasma	O
22	concentrations	O
23	of	O
24	iron	O
25	,	O
26	zinc	O
27	,	O
28	circulating	O
29	leukocyte	O
30	counts	O
31	,	O
32	and	O
33	plasma	B
34	interleukin	I
35	1	I
36	(	O
37	IL	B
38	-	I
39	1	I
40	)	O
41	activity	O
42	.	O

1	Liquid	O
2	chromatography	O
3	with	O
4	amperometric	O
5	detection	O
6	(	O
7	LC	O
8	/	O
9	AD	O
10	)	O
11	is	O
12	used	O
13	to	O
14	determine	O
15	fluazifop	O
16	acid	O
17	produced	O
18	from	O
19	the	O
20	metabolism	O
21	or	O
22	base	O
23	hydrolysis	O
24	of	O
25	fluazifop	O
26	-	O
27	butyl	O
28	in	O
29	soybeans	O
30	and	O
31	soybean	O
32	oil	O
33	.	O

1	Dynamics	O
2	of	O
3	hospital	O
4	stay	O
5	in	O
6	peptic	O
7	ulcer	O
8	patients	O

1	LMP	B
2	-	I
3	1	I
4	is	O
5	targeted	O
6	to	O
7	the	O
8	plasma	O
9	membrane	O
10	,	O
11	where	O
12	it	O
13	binds	O
14	TRAF	O
15	,	O
16	TRADD	B
17	,	O
18	and	O
19	JAK	B
20	molecules	O
21	to	O
22	activate	O
23	NF	B
24	-	I
25	kappaB	I
26	-,	I
27	AP	I
28	-	I
29	1	I
30	-,	O
31	and	O
32	STAT	B
33	-	O
34	dependent	O
35	pathways	O
36	as	O
37	does	O
38	CD40	B
39	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	B
14	and	O
15	Triton	B
16	X	I
17	-	I
18	100	I
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	The	O
2	UV	O
3	induction	O
4	of	O
5	c	B
6	-	I
7	jun	I
8	is	O
9	mediated	O
10	by	O
11	two	O
12	UV	O
13	response	O
14	elements	O
15	consisting	O
16	of	O
17	AP	B
18	-	I
19	1	I
20	-	I
21	like	I
22	sequences	I
23	within	O
24	its	O
25	5	O
26	'	O
27	control	O
28	region	O
29	.	O

1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	In	O
2	this	O
3	way	O
4	it	O
5	is	O
6	possible	O
7	to	O
8	simulate	O
9	the	O
10	growth	O
11	function	O
12	of	O
13	the	O
14	embryofetal	O
15	curve	O
16	of	O
17	the	O
18	length	O
19	'	O
20	increase	O
21	of	O
22	man	O
23	and	O
24	the	O
25	curve	O
26	of	O
27	the	O
28	mass	O
29	'	O
30	increase	O
31	of	O
32	rat	O
33	.	O

1	The	O
2	27	O
3	-	O
4	base	O
5	element	O
6	interacts	O
7	with	O
8	a	O
9	PDGF	B
10	-	I
11	activated	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	that	O
17	is	O
18	detected	O
19	only	O
20	within	O
21	the	O
22	nucleus	O
23	of	O
24	PDGF	B
25	-	O
26	treated	O
27	3T3	O
28	cells	O
29	.	O

1	GAP	B
2	-	O
3	N	O
4	bound	O
5	constitutively	O
6	to	O
7	p190	B
8	in	O
9	both	O
10	serum	O
11	-	O
12	deprived	O
13	and	O
14	growth	O
15	factor	O
16	-	O
17	stimulated	O
18	cells	O
19	.	O

1	Expression	O
2	of	O
3	class	B
4	IV	I
5	ADH	I
6	mRNA	I
7	was	O
8	detected	O
9	in	O
10	human	O
11	stomach	O
12	but	O
13	not	O
14	liver	O
15	.	O

1	Fregnac	O
2	,	O
3	M	O
4	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	S1	B
6	nuclease	I
7	protection	O
8	analysis	O
9	of	O
10	RNA	O
11	preparations	O
12	from	O
13	several	O
14	mouse	O
15	tissues	O
16	,	O
17	both	O
18	dhfr	B
19	and	O
20	divergent	O
21	genes	O
22	showed	O
23	similar	O
24	levels	O
25	of	O
26	expression	O
27	but	O
28	did	O
29	show	O
30	some	O
31	specificity	O
32	in	O
33	start	O
34	site	O
35	utilization	O
36	.	O

1	In	O
2	a	O
3	previous	O
4	interim	O
5	report	O
6	we	O
7	noted	O
8	more	O
9	prompt	O
10	resolution	O
11	of	O
12	dermatomal	O
13	signs	O
14	and	O
15	symptoms	O
16	with	O
17	acyclovir	O
18	treatment	O
19	.	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	the	O
5	NF	B
6	-	I
7	4FB	I
8	enhancer	I
9	binding	I
10	protein	I
11	has	O
12	been	O
13	cloned	O
14	by	O
15	screening	O
16	a	O
17	lambda	O
18	gt11	O
19	cDNA	O
20	library	O
21	with	O
22	a	O
23	rabiolabelled	O
24	oligonucleotide	O
25	corresponding	O
26	to	O
27	the	O
28	NF	B
29	-	I
30	4FB	I
31	recognition	I
32	sequence	I
33	.	O

1	The	O
2	distribution	O
3	phase	O
4	is	O
5	followed	O
6	by	O
7	an	O
8	elimination	O
9	phase	O
10	with	O
11	a	O
12	much	O
13	longer	O
14	half	O
15	-	O
16	life	O
17	(	O
18	mean	O
19	value	O
20	375	O
21	min	O
22	)	O
23	and	O
24	a	O
25	volume	O
26	of	O
27	distribution	O
28	of	O
29	approximately	O
30	200	O
31	-	O
32	400	O
33	l	O
34	.	O

1	We	O
2	have	O
3	used	O
4	the	O
5	hydrophobic	O
6	repeats	O
7	of	O
8	the	O
9	HSF1	B
10	trimerization	O
11	domain	O
12	in	O
13	the	O
14	yeast	O
15	two	O
16	-	O
17	hybrid	O
18	protein	O
19	interaction	O
20	assay	O
21	to	O
22	identify	B
23	heat	I
24	shock	I
25	factor	I
26	binding	I
27	protein	I
28	1	I
29	(	O
30	HSBP1	B
31	),	O
32	a	O
33	novel	O
34	,	O
35	conserved	O
36	,	O
37	76	O
38	-	O
39	amino	O
40	-	O
41	acid	O
42	protein	O
43	that	O
44	contains	O
45	two	O
46	extended	O
47	arrays	O
48	of	O
49	hydrophobic	O
50	repeats	O
51	that	O
52	interact	O
53	with	O
54	the	O
55	HSF1	B
56	heptad	O
57	repeats	O
58	.	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	DNase	B
2	I	I
3	and	I
4	1	I
5	,	O
6	10	O
7	-	O
8	phenanthroline	O
9	-	O
10	copper	O
11	footprinting	O
12	of	O
13	MURA	B
14	-	I
15	Mu1	I
16	TIR	I
17	complexes	O
18	indicate	O
19	that	O
20	MURA	B
21	binds	O
22	to	O
23	a	O
24	conserved	O
25	approximately	O
26	32	O
27	-	O
28	bp	O
29	region	O
30	in	O
31	the	O
32	TIR	O
33	of	O
34	Mu1	B
35	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	O
9	/	O
10	Smarcal1	O
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O

1	They	O
2	were	O
3	checked	O
4	for	O
5	anti	B
6	-	I
7	HCV	I
8	(	O
9	anti	B
10	-	I
11	C100	I
12	-	I
13	3	I
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	B
27	).	O

1	Pre	B
2	-	I
3	beta	I
4	-	I
5	1	I
6	lipoprotein	I
7	and	O
8	early	O
9	detection	O
10	of	O
11	risk	O
12	factors	O
13	for	O
14	coronary	O
15	heart	O
16	disease	O
17	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O

1	Furthermore	O
2	,	O
3	microinjection	O
4	of	O
5	dominant	O
6	negative	O
7	forms	O
8	of	O
9	Rac	B
10	and	O
11	Cdc42	B
12	or	O
13	of	O
14	the	O
15	Rho	B
16	inhibitor	O
17	C3	B
18	transferase	I
19	blocked	O
20	serum	O
21	-	O
22	induced	O
23	DNA	O
24	synthesis	O
25	.	O

1	Control	O
2	subjects	O
3	'	O
4	evoked	O
5	potentials	O
6	(	O
7	EPs	O
8	)	O
9	were	O
10	characterized	O
11	by	O
12	an	O
13	initial	O
14	positivity	O
15	in	O
16	the	O
17	90	O
18	-	O
19	140	O
20	ms	O
21	range	O
22	(	O
23	P1	O
24	)	O
25	at	O
26	the	O
27	temporo	O
28	-	O
29	occipital	O
30	site	O
31	.	O

1	The	O
2	interferon	B
3	-	O
4	induced	O
5	RNA	B
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	(	O
11	PKR	B
12	)	O
13	is	O
14	considered	O
15	to	O
16	play	O
17	an	O
18	important	O
19	role	O
20	in	O
21	the	O
22	cellular	O
23	defense	O
24	against	O
25	viral	O
26	infection	O
27	and	O
28	,	O
29	in	O
30	addition	O
31	,	O
32	has	O
33	been	O
34	suggested	O
35	to	O
36	be	O
37	a	O
38	tumor	O
39	suppressor	O
40	gene	O
41	because	O
42	of	O
43	its	O
44	growth	O
45	-	O
46	suppressive	O
47	properties	O
48	.	O

1	Creatine	B
2	kinase	I
3	release	O
4	after	O
5	hepatic	O
6	artery	O
7	embolization	O
8	in	O
9	patients	O
10	with	O
11	carcinoid	O
12	tumors	O
13	.	O

1	Study	O
2	on	O
3	micromelias	O
4	in	O
5	the	O
6	mouse	O
7	fetus	O
8	caused	O
9	by	O
10	x	O
11	-	O
12	radiation	O
13	,	O
14	hypoxia	O
15	,	O
16	trypan	O
17	blue	O
18	injection	O
19	of	O
20	hypervitaminosis	O
21	-	O
22	A	O
23	upon	O
24	mother	O
25	animals	O
26	during	O
27	pregnancy	O
28	.	O

1	Immunity	O
2	acquired	O
3	by	O
4	mice	O
5	during	O
6	I	O
7	.	O
8	scapularis	O
9	nymphal	O
10	activity	O
11	in	O
12	early	O
13	summer	O
14	may	O
15	exclude	O
16	a	O
17	large	O
18	proportion	O
19	of	O
20	the	O
21	mouse	O
22	population	O
23	from	O
24	maintaining	O
25	E	O
26	.	O
27	phagocytophila	O
28	during	O
29	the	O
30	period	O
31	of	O
32	larval	O
33	activity	O
34	later	O
35	in	O
36	the	O
37	season	O
38	.	O

1	Nhp2p	O
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	B
15	-	I
16	binding	I
17	proteins	I
18	.	O

1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	O
7	1	O
8	insulin	B
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	O
14	IGF	B
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O

1	A	O
2	-	O
3	69	O
4	-	O
5	year	O
6	-	O
7	old	O
8	patient	O
9	with	O
10	postoperative	O
11	small	O
12	-	O
13	bowel	O
14	obstruction	O
15	underwent	O
16	laparotomy	O
17	three	O
18	times	O
19	.	O

1	Nonreturn	O
2	rates	O
3	can	O
4	be	O
5	used	O
6	to	O
7	derive	O
8	more	O
9	elementary	O
10	biological	O
11	measures	O
12	for	O
13	reproductive	O
14	efficiency	O
15	,	O
16	such	O
17	as	O
18	conception	O
19	rate	O
20	and	O
21	calving	O
22	rate	O
23	,	O
24	which	O
25	separately	O
26	might	O
27	be	O
28	more	O
29	reliable	O
30	than	O
31	nonreturn	O
32	rate	O
33	itself	O
34	to	O
35	evaluate	O
36	the	O
37	fertility	O
38	of	O
39	a	O
40	bull	O
41	or	O
42	the	O
43	performance	O
44	of	O
45	an	O
46	AI	O
47	technician	O
48	.	O

1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O

1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	B
25	AML	I
26	10	I
27	trial	O
28	.	O

1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O

1	With	O
2	both	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	the	O
8	mutant	O
9	enzymes	O
10	,	O
11	ATP	O
12	activates	O
13	both	O
14	[	O
15	14C	O
16	]	O
17	Asp	O
18	in	O
19	equilibrium	O
20	N	O
21	-	O
22	carbamyl	B
23	-	I
24	L	I
25	-	I
26	aspartate	I
27	(	I
28	C	I
29	-	I
30	Asp	I
31	)	O
32	and	O
33	the	O
34	[	O
35	32P	O
36	]	O
37	carbamyl	O
38	phosphate	O
39	(	O
40	C	O
41	-	O
42	P	O
43	)	O
44	in	O
45	equilibrium	O
46	Pi	O
47	exchanges	O
48	.	O

1	Patients	O
2	with	O
3	low	O
4	probability	O
5	of	O
6	having	O
7	aluminum	O
8	overload	O
9	(	O
10	serum	O
11	iron	O
12	levels	O
13	<	O
14	40	O
15	micrograms	O
16	/	O
17	L	O
18	and	O
19	DAI	O
20	<	O
21	150	O
22	micrograms	O
23	/	O
24	L	O
25	)	O
26	had	O
27	significantly	O
28	higher	O
29	values	O
30	of	O
31	serum	O
32	iron	O
33	,	O
34	iron	O
35	transferrin	B
36	saturation	O
37	,	O
38	and	O
39	serum	O
40	ferritin	B
41	levels	O
42	compared	O
43	with	O
44	those	O
45	patients	O
46	with	O
47	a	O
48	high	O
49	probability	O
50	of	O
51	having	O
52	aluminum	O
53	overload	O
54	(	O
55	serum	O
56	aluminum	O
57	levels	O
58	>	O
59	40	O
60	micrograms	O
61	/	O
62	L	O
63	and	O
64	DAI	O
65	>	O
66	150	O
67	micrograms	O
68	/	O
69	L	O
70	).	O

1	Despite	O
2	continuous	O
3	compliance	O
4	,	O
5	unexplained	O
6	resurgence	O
7	of	O
8	serum	O
9	ferritin	B
10	levels	O
11	occurred	O
12	in	O
13	4	O
14	/	O
15	7	O
16	patients	O
17	of	O
18	the	O
19	'	O
20	veteran	O
21	'	O
22	group	O
23	after	O
24	4	O
25	-	O
26	5	O
27	years	O
28	on	O
29	L1	O
30	.	O

1	We	O
2	have	O
3	utilized	O
4	the	O
5	human	B
6	4F2	I
7	heavy	I
8	chain	I
9	(	O
10	4F2HC	O
11	)	O
12	gene	O
13	as	O
14	a	O
15	model	O
16	system	O
17	in	O
18	studies	O
19	designed	O
20	to	O
21	elucidate	O
22	the	O
23	molecular	O
24	events	O
25	involved	O
26	in	O
27	regulating	O
28	inducible	O
29	gene	O
30	expression	O
31	during	O
32	normal	O
33	human	O
34	T	O
35	-	O
36	cell	O
37	activation	O
38	.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	B
6	T	I
7	antigens	I
8	expressed	O
9	by	O
10	recombinant	O
11	baculoviruses	O
12	in	O
13	Sf9	O
14	cells	O
15	,	O
16	we	O
17	find	O
18	that	O
19	the	O
20	origin	O
21	unwinding	O
22	activities	O
23	of	O
24	both	O
25	TS677	O
26	-->	O
27	A	O
28	and	O
29	TS677	B
30	,	O
31	679	O
32	-->	O
33	A	O
34	are	O
35	inhibited	O
36	by	O
37	the	O
38	T	B
39	-	I
40	antigen	I
41	kinase	I
42	,	O
43	as	O
44	is	O
45	wild	B
46	-	I
47	type	I
48	T	I
49	antigen	I
50	.	O

1	The	O
2	virus	O
3	encodes	O
4	a	O
5	40	O
6	-	O
7	kDa	O
8	protein	O
9	,	O
10	tax	B
11	,	O
12	that	O
13	is	O
14	important	O
15	for	O
16	the	O
17	immortalization	O
18	of	O
19	T	O
20	cells	O
21	.	O

1	Neomycin	O
2	is	O
3	fairly	O
4	effective	O
5	against	O
6	staphylococci	O
7	,	O
8	less	O
9	effective	O
10	against	O
11	streptococci	O
12	,	O
13	and	O
14	fairly	O
15	effective	O
16	against	O
17	gram	O
18	-	O
19	negative	O
20	intestinal	O
21	organisms	O
22	.	O

1	DNA	O
2	sequencing	O
3	and	O
4	Southern	O
5	blot	O
6	analyses	O
7	established	O
8	that	O
9	the	O
10	cDNA	O
11	clones	O
12	are	O
13	derived	O
14	from	O
15	two	O
16	different	O
17	genes	O
18	.	O

1	Most	O
2	likely	O
3	they	O
4	might	O
5	represent	O
6	regulatory	O
7	RNAs	O
8	or	O
9	transcribed	O
10	transposable	O
11	elements	O
12	.	O

1	Combined	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	and	O
8	p65	B
9	induced	O
10	vigorous	O
11	transcription	O
12	of	O
13	IL	B
14	-	I
15	2	I
16	promoter	I
17	-	O
18	and	O
19	CD28RE	O
20	-	O
21	driven	O
22	reporter	O
23	constructs	O
24	in	O
25	both	O
26	LFA	O
27	-	O
28	3	O
29	-	O
30	and	O
31	B7	B
32	-	I
33	1	I
34	-	O
35	costimulated	O
36	Jurkat	O
37	cells	O
38	.	O

1	Based	O
2	on	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	conRTRE	O
8	,	O
9	we	O
10	located	O
11	a	O
12	putative	O
13	RTRE	O
14	,	O
15	referred	O
16	to	O
17	as	O
18	P2	O
19	-	O
20	RE	O
21	,	O
22	in	O
23	the	O
24	5	O
25	'	O
26	promoter	O
27	-	O
28	flanking	O
29	region	O
30	of	O
31	the	O
32	mouse	B
33	protamine	I
34	2	I
35	gene	I
36	,	O
37	which	O
38	is	O
39	induced	O
40	during	O
41	the	O
42	same	O
43	stage	O
44	of	O
45	spermatogenesis	O
46	as	O
47	RTR	O
48	.	O

1	Non	O
2	-	O
3	complement	O
4	-	O
5	dependent	O
6	sperm	O
7	-	O
8	immobilizing	O
9	activity	O
10	was	O
11	also	O
12	detected	O
13	in	O
14	the	O
15	cervical	O
16	mucus	O
17	of	O
18	several	O
19	patients	O
20	.	O

1	The	O
2	results	O
3	demonstrate	O
4	(	O
5	i	O
6	)	O
7	that	O
8	the	O
9	selenocysteine	O
10	-	O
11	specific	O
12	UGA	O
13	codon	O
14	is	O
15	readily	O
16	suppressed	O
17	under	O
18	conditions	O
19	where	O
20	the	O
21	homologous	O
22	SelB	B
23	protein	I
24	is	O
25	absent	O
26	and	O
27	(	O
28	ii	O
29	)	O
30	that	O
31	apart	O
32	from	O
33	the	O
34	specificity	O
35	of	O
36	the	O
37	SelB	B
38	-	I
39	mRNA	I
40	interaction	O
41	,	O
42	a	O
43	structural	O
44	compatibility	O
45	of	O
46	the	O
47	quaternary	O
48	complex	O
49	with	O
50	the	O
51	ribosome	O
52	is	O
53	required	O
54	.	O

1	For	O
2	higher	O
3	expression	O
4	of	O
5	lipA	B
6	in	O
7	S	O
8	.	O
9	lividans	O
10	,	O
11	the	O
12	gene	O
13	was	O
14	cloned	O
15	next	O
16	to	O
17	the	O
18	strong	O
19	aphII	B
20	promoter	I
21	.	O

1	25	O
2	-	O
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	Total	O
2	body	O
3	irradiation	O
4	was	O
5	delivered	O
6	according	O
7	to	O
8	a	O
9	hyperfractionated	O
10	scheme	O
11	of	O
12	12	O
13	fractions	O
14	given	O
15	three	O
16	per	O
17	day	O
18	5	O
19	hr	O
20	apart	O
21	for	O
22	4	O
23	days	O
24	.	O

1	Intracellular	O
2	activity	O
3	studies	O
4	indicated	O
5	that	O
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	B
16	X	I
17	collagen	I
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O

1	He	O
2	was	O
3	administered	O
4	recombinant	O
5	IFN	B
6	alpha	I
7	-	I
8	2b	I
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	I
19	Epstein	I
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O

1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	O
41	acid	O
42	decarboxylase	O
43	.	O

1	This	O
2	study	O
3	shows	O
4	that	O
5	C	B
6	/	I
7	EBPbeta	I
8	is	O
9	the	O
10	predominant	B
11	C	I
12	/	I
13	EBP	I
14	isoform	I
15	found	O
16	in	O
17	activated	O
18	stellate	O
19	cells	O
20	and	O
21	that	O
22	increased	O
23	C	B
24	/	I
25	EBPbeta	I
26	protein	I
27	and	O
28	C	B
29	/	I
30	EBPbeta	I
31	binding	O
32	to	O
33	a	O
34	proximal	B
35	C	I
36	/	I
37	EBP	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	promoter	O
43	mediates	O
44	the	O
45	activating	O
46	effect	O
47	of	O
48	acetaldehyde	O
49	.	O

1	The	O
2	significance	O
3	of	O
4	the	O
5	phenolphthalein	B
6	sulphatase	I
7	test	O
8	for	O
9	the	O
10	differentiation	O
11	and	O
12	identification	O
13	of	O
14	Nocardia	O
15	species	O
16	.	O

1	The	O
2	spectrum	O
3	of	O
4	phenotypes	O
5	caused	O
6	by	O
7	these	O
8	mutations	O
9	was	O
10	strikingly	O
11	different	O
12	than	O
13	mutations	O
14	in	O
15	the	O
16	adaptor	O
17	for	O
18	the	O
19	VP16	B
20	activation	O
21	domain	O
22	.	O

1	Primers	O
2	for	O
3	subsequent	O
4	rounds	O
5	of	O
6	RACE	O
7	were	O
8	designed	O
9	from	O
10	the	O
11	5	O
12	'-	O
13	ends	O
14	of	O
15	amplified	O
16	RACE	O
17	products	O
18	.	O

1	Jkappa	O
2	DNA	O
3	-	O
4	binding	O
5	sites	O
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	B
16	EBNA	I
17	-	I
18	3C	I
19	protein	I
20	unable	O
21	to	O
22	bind	O
23	Jkappa	O
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	B
30	-	I
31	type	I
32	EBNA	I
33	-	I
34	3C	I
35	,	O
36	indicating	O
37	that	O
38	EBNA	B
39	-	I
40	3C	I
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	O
52	.	O

1	The	O
2	transforming	O
3	gene	O
4	of	O
5	the	O
6	avian	O
7	sarcoma	O
8	virus	O
9	CT10	O
10	encodes	O
11	a	O
12	fusion	O
13	protein	O
14	(	O
15	p47gag	B
16	-	I
17	crk	I
18	or	O
19	v	B
20	-	I
21	Crk	I
22	)	O
23	containing	O
24	viral	O
25	Gag	O
26	sequences	O
27	fused	O
28	to	O
29	cellular	O
30	sequences	O
31	consisting	O
32	primarily	O
33	of	O
34	Src	B
35	homology	I
36	regions	I
37	2	I
38	and	O
39	3	O
40	(	O
41	SH2	B
42	and	O
43	SH3	B
44	sequences	I
45	).	O

1	Radioimmunoassay	O
2	of	O
3	serum	B
4	creatine	I
5	kinase	I
6	B	I
7	isoenzyme	I
8	in	O
9	the	O
10	diagnosis	O
11	of	O
12	acute	O
13	myocardial	O
14	infarction	O
15	.	O

1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O

1	Rad6	O
2	mutants	O
3	display	O
4	a	O
5	remarkably	O
6	pleiotropic	O
7	phenotype	O
8	,	O
9	implicating	O
10	the	O
11	protein	O
12	in	O
13	DNA	O
14	damage	O
15	-	O
16	induced	O
17	mutagenesis	O
18	,	O
19	postreplication	O
20	repair	O
21	,	O
22	repression	O
23	of	O
24	retrotransposition	O
25	,	O
26	and	O
27	sporulation	O
28	.	O

1	The	O
2	effects	O
3	of	O
4	a	O
5	1	O
6	-	O
7	or	O
8	24	O
9	-	O
10	hour	O
11	pretreatment	O
12	regimen	O
13	with	O
14	monophosphoryl	O
15	lipid	O
16	A	O
17	(	O
18	MLA	O
19	,	O
20	35	O
21	micrograms	O
22	/	O
23	kg	O
24	i	O
25	.	O
26	v	O
27	.)	O
28	on	O
29	myocardial	O
30	stunning	O
31	produced	O
32	by	O
33	repetitive	O
34	coronary	O
35	occlusions	O
36	were	O
37	studied	O
38	in	O
39	barbital	O
40	-	O
41	anesthetized	O
42	dogs	O
43	.	O

1	Paradoxically	O
2	,	O
3	however	O
4	,	O
5	the	O
6	GH	B
7	receptor	I
8	cloned	O
9	from	O
10	liver	O
11	exhibits	O
12	no	O
13	sequence	O
14	similarity	O
15	to	O
16	receptors	O
17	with	O
18	known	O
19	signal	O
20	transduction	O
21	mechanisms	O
22	,	O
23	including	O
24	those	O
25	exhibiting	O
26	ligand	O
27	-	O
28	activated	O
29	tyrosine	B
30	kinase	I
31	activity	O
32	.	O

1	Our	O
2	results	O
3	showed	O
4	that	O
5	compared	O
6	to	O
7	the	O
8	primary	O
9	photon	O
10	fluence	O
11	,	O
12	the	O
13	extra	O
14	-	O
15	focal	O
16	photon	O
17	fluence	O
18	from	O
19	the	O
20	primary	O
21	collimator	O
22	and	O
23	the	O
24	flattening	O
25	filter	O
26	was	O
27	11	O
28	%-	O
29	16	O
30	%	O
31	at	O
32	the	O
33	isocenter	O
34	,	O
35	among	O
36	which	O
37	70	O
38	%	O
39	was	O
40	contributed	O
41	by	O
42	the	O
43	flattening	O
44	filter	O
45	.	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	Mucosal	O
2	application	O
3	of	O
4	NCX	B
5	-	I
6	4016	I
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	PD	O
14	reduction	O
15	and	O
16	luminal	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	hyperemia	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	STZ	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O

1	Randomly	O
2	selected	O
3	300	O
4	children	O
5	aged	O
6	3	O
7	months	O
8	-	O
9	3	O
10	yr	O
11	were	O
12	analysed	O
13	over	O
14	a	O
15	period	O
16	of	O
17	one	O
18	year	O
19	for	O
20	estimating	O
21	prevalence	O
22	of	O
23	nutritional	O
24	anaemia	O
25	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	LvUSF2	B
8	is	O
9	nearly	O
10	identical	O
11	to	O
12	LvUSF1	B
13	except	O
14	at	O
15	the	O
16	amino	O
17	end	O
18	,	O
19	where	O
20	they	O
21	are	O
22	sharply	O
23	divergent	O
24	.	O

1	Mean	O
2	fluorosis	O
3	scores	O
4	,	O
5	however	O
6	,	O
7	were	O
8	similar	O
9	.	O

1	A	O
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	B
9	lymphocyte	I
10	early	I
11	-	I
12	activation	I
13	gene	I
14	(	I
15	Tea	I
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	ecotropic	O
27	retrovirus	O
28	receptor	O
29	/	O
30	cationic	O
31	amino	O
32	acid	O
33	transporter	O
34	(	O
35	ecoR	B
36	/	O
37	CAT1	B
38	),	O
39	and	O
40	RNA	O
41	blots	O
42	suggested	O
43	highest	O
44	Tea	O
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	MacLeod	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	Finley	O
59	,	O
60	K	O
61	.,	O
62	Kakuda	O
63	,	O
64	D	O
65	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	Echosismography	O
2	enables	O
3	to	O
4	improve	O
5	the	O
6	diagnosis	O
7	when	O
8	compared	O
9	with	O
10	classical	O
11	sonography	O
12	in	O
13	about	O
14	20	O
15	%	O
16	of	O
17	cases	O
18	.	O

1	(	O
2	ii	O
3	)	O
4	opening	O
5	of	O
6	KATP	O
7	attenuates	O
8	,	O
9	inhibition	O
10	of	O
11	the	O
12	channel	O
13	exacerbates	O
14	functional	O
15	consequences	O
16	of	O
17	coronary	O
18	occlusion	O
19	,	O
20	and	O
21	(	O
22	iii	O
23	)	O
24	KATP	O
25	opening	O
26	attenuates	O
27	reperfusion	O
28	-	O
29	induced	O
30	VF	O
31	,	O
32	but	O
33	it	O
34	triggers	O
35	ischemia	O
36	-	O
37	induced	O
38	VF	O
39	.	O

1	Surprisingly	O
2	,	O
3	calf	O
4	thymus	O
5	CstF	O
6	contained	O
7	an	O
8	additional	O
9	,	O
10	novel	O
11	form	O
12	of	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	with	O
19	a	O
20	molecular	O
21	mass	O
22	of	O
23	70	O
24	kDa	O
25	.	O

1	4	O
2	.	O

1	Regulation	O
2	of	O
3	ASN1	B
4	and	O
5	ASN2	B
6	expression	O
7	was	O
8	studied	O
9	using	O
10	lacZ	B
11	fusions	O
12	and	O
13	both	O
14	genes	O
15	were	O
16	found	O
17	to	O
18	be	O
19	several	O
20	times	O
21	less	O
22	expressed	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	the	O
28	transcription	O
29	activator	O
30	Gcn4p	B
31	.	O

1	Functional	B
2	rearranged	I
3	antibody	I
4	genes	I
5	were	O
6	detected	O
7	with	O
8	JH	B
9	and	O
10	VH	B
11	heavy	I
12	chain	I
13	probes	I
14	and	O
15	with	O
16	Jk	O
17	and	O
18	Vk	B
19	light	I
20	chain	I
21	probes	O
22	.	O

1	The	O
2	regurgitation	O
3	of	O
4	large	O
5	vitreous	O
6	injections	O
7	.	O

1	The	O
2	cDNA	O
3	corresponding	O
4	to	O
5	the	O
6	FPS1	B
7	gene	I
8	was	O
9	isolated	O
10	by	O
11	functional	O
12	complementation	O
13	of	O
14	a	O
15	mutant	O
16	yeast	O
17	strain	O
18	defective	O
19	in	O
20	FPS	B
21	activity	O
22	(	O
23	Delourme	O
24	,	O
25	D	O
26	.,	O
27	Lacroute	O
28	,	O
29	F	O
30	.,	O
31	and	O
32	Karst	O
33	,	O
34	F	O
35	.	O

1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O

1	These	O
2	data	O
3	should	O
4	be	O
5	useful	O
6	in	O
7	developing	O
8	reagents	O
9	for	O
10	heterozygote	O
11	detection	O
12	and	O
13	prenatal	O
14	diagnosis	O
15	of	O
16	11	O
17	beta	B
18	-	I
19	hydroxylase	I
20	deficiency	O
21	,	O
22	the	O
23	second	O
24	most	O
25	frequent	O
26	cause	O
27	of	O
28	congenital	O
29	adrenal	O
30	hyperplasia	O
31	.	O

1	The	O
2	Mean	O
3	was	O
4	74	O
5	,	O
6	3	O
7	+/-	O
8	53	O
9	,	O
10	6	O
11	micrograms	O
12	J	O
13	/	O
14	g	O
15	Cr	O
16	,	O
17	the	O
18	Median	O
19	61	O
20	micrograms	O
21	J	O
22	/	O
23	g	O
24	Cr	O
25	.	O

1	Vertebrate	O
2	synapsins	O
3	constitute	O
4	a	O
5	family	O
6	of	O
7	synaptic	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	neurotransmitter	O
16	release	O
17	.	O

1	The	O
2	protein	O
3	expressed	O
4	by	O
5	F2771	O
6	cDNA	O
7	in	O
8	transfected	O
9	COS	O
10	cells	O
11	is	O
12	localized	O
13	in	O
14	the	O
15	cytoplasm	O
16	.	O

1	For	O
2	SMX	O
3	at	O
4	pH	O
5	7	O
6	.	O
7	0	O
8	,	O
9	a	O
10	1	O
11	:	O
12	1	O
13	complex	O
14	is	O
15	formed	O
16	,	O
17	but	O
18	at	O
19	pH	O
20	7	O
21	.	O
22	5	O
23	HPCD	O
24	has	O
25	little	O
26	effect	O
27	on	O
28	the	O
29	solubility	O
30	of	O
31	the	O
32	highly	O
33	ionized	O
34	SMX	O
35	,	O
36	presumably	O
37	since	O
38	only	O
39	un	O
40	-	O
41	ionized	O
42	molecules	O
43	can	O
44	form	O
45	inclusion	O
46	complexes	O
47	with	O
48	the	O
49	HPCD	O
50	.	O

1	CYC2	O
2	encodes	O
3	a	O
4	24	O
5	-	O
6	kDa	O
7	protein	O
8	that	O
9	has	O
10	sequence	O
11	identity	O
12	to	O
13	the	O
14	Neurospora	O
15	crassa	O
16	PREG1	O
17	and	O
18	the	O
19	S	B
20	.	I
21	cerevisiae	I
22	PHO80	I
23	cyclin	I
24	.	O

1	Hailey	O
2	-	O
3	Hailey	O
4	disease	O
5	is	O
6	caused	O
7	by	O
8	mutations	O
9	in	O
10	ATP2C1	O
11	encoding	O
12	a	O
13	novel	O
14	Ca	O
15	(	O
16	2	O
17	+)	O
18	pump	O
19	.	O

1	We	O
2	argue	O
3	that	O
4	the	O
5	primary	O
6	role	O
7	of	O
8	hh	B
9	in	O
10	controlling	O
11	polarity	O
12	is	O
13	to	O
14	cause	O
15	anterior	O
16	compartment	O
17	cells	O
18	to	O
19	reverse	O
20	their	O
21	interpretation	O
22	of	O
23	an	O
24	underlying	O
25	symmetric	O
26	polarization	O
27	.	O

1	From	O
2	March	O
3	5	O
4	through	O
5	October	O
6	26	O
7	,	O
8	1991	O
9	,	O
10	eight	O
11	persons	O
12	were	O
13	diagnosed	O
14	with	O
15	elevated	O
16	blood	O
17	lead	O
18	levels	O
19	(	O
20	BLLs	O
21	)	O
22	at	O
23	a	O
24	local	O
25	hospital	O
26	and	O
27	were	O
28	reported	O
29	to	O
30	the	O
31	notifiable	O
32	disease	O
33	surveillance	O
34	system	O
35	maintained	O
36	by	O
37	the	O
38	Alabama	O
39	Department	O
40	of	O
41	Public	O
42	Health	O
43	(	O
44	ADPH	O
45	).	O

1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	A	O
2	narrow	O
3	zone	O
4	of	O
5	myelin	O
6	-	O
7	axonal	O
8	dissociation	O
9	was	O
10	also	O
11	observed	O
12	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	HSF	B
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	.	O

1	No	O
2	UOxase	B
3	mRNA	I
4	was	O
5	detected	O
6	in	O
7	11	O
8	nonhepatic	O
9	tissues	O
10	of	O
11	rat	O
12	,	O
13	suggesting	O
14	tissue	O
15	specificity	O
16	of	O
17	expression	O
18	of	O
19	this	O
20	UOxase	B
21	gene	I
22	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	Maximum	O
2	number	O
3	of	O
4	strains	O
5	(	O
6	39	O
7	.	O
8	1	O
9	%)	O
10	were	O
11	resistant	O
12	in	O
13	S	O
14	.	O
15	bareilly	O
16	serotype	O
17	,	O
18	followed	O
19	by	O
20	S	O
21	.	O
22	typhimurium	O
23	(	O
24	21	O
25	.	O
26	7	O
27	%)	O
28	and	O
29	least	O
30	in	O
31	S	O
32	.	O
33	typhi	O
34	(	O
35	17	O
36	.	O
37	4	O
38	%).	O

1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O

1	Biol	O
2	.	O

1	Furthermore	O
2	,	O
3	we	O
4	notice	O
5	two	O
6	potential	O
7	consensus	O
8	motifs	O
9	which	O
10	are	O
11	also	O
12	found	O
13	in	O
14	corresponding	O
15	positions	O
16	in	O
17	the	O
18	genes	O
19	for	O
20	the	O
21	nerve	B
22	growth	I
23	factor	I
24	receptor	I
25	and	O
26	the	O
27	68	O
28	-	O
29	kDa	O
30	neurofilament	O
31	protein	O
32	.	O

1	Neither	O
2	the	O
3	p42	B
4	/	I
5	44	I
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O

1	The	O
2	sequence	O
3	and	O
4	isolated	O
5	cDNAs	O
6	will	O
7	provide	O
8	useful	O
9	reagents	O
10	for	O
11	studying	O
12	the	O
13	expression	O
14	of	O
15	Brca1	B
16	in	O
17	the	O
18	mouse	O
19	,	O
20	and	O
21	for	O
22	testing	O
23	the	O
24	importance	O
25	of	O
26	the	O
27	evolutionarily	O
28	conserved	O
29	domains	O
30	.	O

1	Overexpression	O
2	of	O
3	mcl	B
4	-	I
5	1	I
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	O
13	while	O
14	transfection	O
15	of	O
16	a	O
17	mcl	B
18	-	I
19	1	I
20	antisense	I
21	plasmid	I
22	causes	O
23	cell	O
24	death	O
25	.	O

1	(	O
2	2	O
3	)	O
4	Diffusion	O
5	limitation	O
6	in	O
7	the	O
8	heterogeneous	O
9	model	O
10	sets	O
11	in	O
12	at	O
13	a	O
14	lower	O
15	O2	O
16	requirement	O
17	value	O
18	,	O
19	and	O
20	increases	O
21	more	O
22	gradually	O
23	with	O
24	increasing	O
25	O2	O
26	requirement	O
27	,	O
28	than	O
29	in	O
30	the	O
31	corresponding	O
32	homogeneous	O
33	models	O
34	with	O
35	the	O
36	same	O
37	average	O
38	cylinder	O
39	diameter	O
40	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O

1	The	O
2	fourth	O
3	dose	O
4	produced	O
5	favorable	O
6	results	O
7	(	O
8	66	O
9	.	O
10	7	O
11	%)	O
12	in	O
13	individuals	O
14	with	O
15	HB	O
16	antibodies	O
17	between	O
18	10	O
19	and	O
20	100	O
21	IU	O
22	/	O
23	ml	O
24	and	O
25	unfavorable	O
26	ones	O
27	(	O
28	3	O
29	.	O
30	8	O
31	%)	O
32	where	O
33	the	O
34	HB	O
35	antibodies	O
36	were	O
37	below	O
38	10	O
39	IU	O
40	/	O
41	ml	O
42	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPAR	O
8	)	O
9	modulate	O
10	transcription	O
11	by	O
12	binding	O
13	to	O
14	specific	O
15	peroxisome	O
16	proliferator	O
17	-	O
18	response	O
19	elements	O
20	(	O
21	PPRE	O
22	)	O
23	through	O
24	heterodimerization	O
25	with	O
26	the	O
27	9	O
28	-	O
29	cis	O
30	retinoic	B
31	acid	I
32	receptor	I
33	(	O
34	RXR	B
35	).	O

1	Dosimetric	O
2	estimates	O
3	for	O
4	these	O
5	organs	O
6	were	O
7	2	O
8	.	O
9	3	O
10	+/-	O
11	1	O
12	.	O
13	1	O
14	and	O
15	2	O
16	.	O
17	3	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	rad	O
23	(.	O
24	02	O
25	+/-	O
26	.	O
27	01	O
28	Gy	O
29	),	O
30	respectively	O
31	,	O
32	with	O
33	a	O
34	whole	O
35	-	O
36	body	O
37	estimate	O
38	of	O
39	0	O
40	.	O
41	28	O
42	rad	O
43	(.	O
44	003	O
45	Gy	O
46	).	O

1	The	O
2	negative	O
3	predictive	O
4	value	O
5	is	O
6	92	O
7	%,	O
8	vs	O
9	80	O
10	%	O
11	for	O
12	the	O
13	NCEP	B
14	I	I
15	.	O

1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O

1	The	O
2	effects	O
3	on	O
4	reflex	O
5	latencies	O
6	but	O
7	not	O
8	on	O
9	paCO2	O
10	or	O
11	pHa	O
12	were	O
13	blocked	O
14	by	O
15	naloxone	O
16	(	O
17	2	O
18	mg	O
19	/	O
20	kg	O
21	),	O
22	and	O
23	were	O
24	not	O
25	present	O
26	in	O
27	morphine	O
28	-	O
29	tolerant	O
30	animals	O
31	.	O

1	L	O
2	-	O
3	735	O
4	,	O
5	524	O
6	free	O
7	base	O
8	or	O
9	sulfate	O
10	salt	O
11	was	O
12	administered	O
13	orally	O
14	as	O
15	suspension	O
16	,	O
17	solution	O
18	or	O
19	in	O
20	solid	O
21	dosage	O
22	forms	O
23	to	O
24	fasted	O
25	or	O
26	fed	O
27	Beagle	O
28	dogs	O
29	.	O

1	Hence	O
2	temperature	O
3	and	O
4	virF	B
5	are	O
6	both	O
7	required	O
8	for	O
9	the	O
10	induction	O
11	of	O
12	the	O
13	yop	O
14	regulon	O
15	.	O

1	The	O
2	antinociceptive	O
3	properties	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	tail	O
10	-	O
11	flick	O
12	and	O
13	hot	O
14	-	O
15	plate	O
16	tests	O
17	,	O
18	and	O
19	the	O
20	motor	O
21	effects	O
22	of	O
23	an	O
24	intrathecally	O
25	-	O
26	administered	O
27	benzodiazepine	O
28	agonist	O
29	midazolam	O
30	,	O
31	alone	O
32	,	O
33	and	O
34	in	O
35	combination	O
36	with	O
37	morphine	O
38	,	O
39	was	O
40	examined	O
41	in	O
42	rats	O
43	.	O

1	Consistent	O
2	with	O
3	these	O
4	findings	O
5	,	O
6	relatively	O
7	weak	O
8	transcriptional	O
9	silencing	O
10	by	O
11	the	O
12	native	O
13	VDR	B
14	was	O
15	observed	O
16	using	O
17	the	O
18	osteopontin	B
19	VDRE	I
20	.	O

1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	O
7	-	O
8	binding	O
9	motif	O
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	O
23	.	O

1	The	O
2	319	O
3	base	O
4	pair	O
5	region	O
6	immediately	O
7	upstream	O
8	of	O
9	the	O
10	CAP	B
11	site	I
12	is	O
13	characterized	O
14	by	O
15	the	O
16	lack	O
17	of	O
18	a	O
19	proximal	O
20	TATA	O
21	box	O
22	and	O
23	the	O
24	presence	O
25	of	O
26	sequences	O
27	similar	O
28	to	O
29	GC	O
30	boxes	O
31	,	O
32	CACCC	O
33	boxes	O
34	,	O
35	CCAAT	O
36	boxes	O
37	,	O
38	activator	B
39	protein	I
40	2	I
41	(	O
42	Ap	B
43	-	I
44	2	I
45	)	O
46	sites	O
47	,	O
48	partial	O
49	glucocorticoid	O
50	response	O
51	elements	O
52	(	O
53	GREs	O
54	),	O
55	and	O
56	partial	O
57	cyclic	O
58	AMP	O
59	response	O
60	elements	O
61	(	O
62	CREs	O
63	).	O

1	The	O
2	U17	O
3	/	O
4	U16	O
5	and	O
6	the	O
7	U16	O
8	+	O
9	gene	O
10	products	O
11	transactivated	O
12	the	O
13	HIV	B
14	LTR	I
15	.	O

1	These	O
2	rearrangements	O
3	result	O
4	in	O
5	the	O
6	formation	O
7	of	O
8	chimeric	O
9	genes	O
10	showing	O
11	the	O
12	tyrosine	B
13	kinase	I
14	domain	I
15	of	O
16	ret	O
17	fused	O
18	with	O
19	the	O
20	5	O
21	'	O
22	end	O
23	sequences	O
24	of	O
25	different	O
26	genes	O
27	.	O

1	A	O
2	polymorphic	O
3	bipartite	O
4	motif	O
5	signals	O
6	nuclear	O
7	targeting	O
8	of	O
9	early	O
10	auxin	O
11	-	O
12	inducible	O
13	proteins	O
14	related	O
15	to	O
16	PS	O
17	-	O
18	IAA4	O
19	from	O
20	pea	O
21	(	O
22	Pisum	O
23	sativum	O
24	).	O

1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O

1	A	O
2	new	O
3	UASH	O
4	consensus	O
5	sequence	O
6	derived	O
7	from	O
8	this	O
9	mutational	O
10	analysis	O
11	closely	O
12	matches	O
13	a	O
14	consensus	O
15	Abf1	O
16	binding	O
17	site	O
18	.	O

1	The	O
2	maximum	O
3	period	O
4	of	O
5	treatment	O
6	was	O
7	73	O
8	(	O
9	oral	O
10	),	O
11	73	O
12	(	O
13	intraperitoneal	O
14	)	O
15	or	O
16	75	O
17	(	O
18	dermal	O
19	)	O
20	weeks	O
21	.	O

1	Analysis	O
2	of	O
3	one	O
4	cDNA	O
5	revealed	O
6	an	O
7	unusual	O
8	splicing	O
9	event	O
10	involving	O
11	EZH1	B
12	and	O
13	a	O
14	tandemly	O
15	linked	O
16	gene	O
17	GPR2	O
18	and	O
19	suggests	O
20	a	O
21	potential	O
22	mechanism	O
23	for	O
24	modifying	O
25	the	O
26	EZH1	B
27	protein	I
28	in	O
29	the	O
30	conserved	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	.	O

1	In	O
2	the	O
3	DNAs	O
4	of	O
5	all	O
6	Ph1	O
7	-	O
8	positive	O
9	chronic	O
10	myelocytic	O
11	leukemia	O
12	patients	O
13	studied	O
14	to	O
15	date	O
16	,	O
17	a	O
18	breakpoint	O
19	on	O
20	chromosome	O
21	22	O
22	(	O
23	the	O
24	Ph1	O
25	chromosome	O
26	)	O
27	can	O
28	be	O
29	demonstrated	O
30	with	O
31	a	O
32	probe	O
33	from	O
34	the	O
35	bcr	B
36	(	O
37	breakpoint	O
38	cluster	O
39	region	O
40	).	O

1	During	O
2	the	O
3	CR	O
4	/	O
5	PP	O
6	diet	O
7	only	O
8	the	O
9	HS	O
10	subjects	O
11	did	O
12	not	O
13	show	O
14	the	O
15	stress	O
16	-	O
17	induced	O
18	rise	O
19	in	O
20	depression	O
21	,	O
22	decline	O
23	in	O
24	vigour	O
25	and	O
26	cortisol	O
27	elevation	O
28	that	O
29	they	O
30	showed	O
31	after	O
32	the	O
33	PR	B
34	/	O
35	CP	O
36	diet	O
37	.	O

1	The	O
2	incidence	O
3	of	O
4	cryptosporidiosis	O
5	in	O
6	young	O
7	children	O
8	was	O
9	determined	O
10	by	O
11	staining	O
12	of	O
13	faecal	O
14	specimens	O
15	with	O
16	a	O
17	modified	O
18	Kinyoun	O
19	stain	O
20	.	O

1	The	O
2	infected	O
3	cell	O
4	protein	O
5	no	O
6	.	O
7	0	O
8	(	O
9	ICP0	O
10	)	O
11	of	O
12	herpes	B
13	simplex	I
14	virus	I
15	1	I
16	is	O
17	a	O
18	promiscuous	O
19	transactivator	O
20	shown	O
21	to	O
22	enhance	O
23	the	O
24	expression	O
25	of	O
26	genes	O
27	introducted	O
28	into	O
29	cells	O
30	by	O
31	infection	O
32	or	O
33	transfection	O
34	.	O

1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	Synchronous	O
2	extracts	O
3	showed	O
4	no	O
5	significant	O
6	migration	O
7	inhibition	O
8	in	O
9	allogeneic	O
10	assays	O
11	.	O

1	Deletions	O
2	in	O
3	each	O
4	of	O
5	these	O
6	regions	O
7	abolish	O
8	membrane	O
9	localization	O
10	of	O
11	Tiam1	O
12	and	O
13	membrane	O
14	ruffling	O
15	,	O
16	suggesting	O
17	that	O
18	they	O
19	function	O
20	cooperatively	O
21	.	O

1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	O
25	promoter	O
26	.	O

1	Wild	O
2	type	O
3	HA	O
4	-	O
5	p190	O
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O

1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	B
12	nucleotide	I
13	exchange	I
14	factors	I
15	or	O
16	GTPase	B
17	-	I
18	activating	I
19	proteins	I
20	in	O
21	the	O
22	c	B
23	-	I
24	cbl	I
25	gene	I
26	.	O

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	B
14	protein	I
15	genes	I
16	.	O

1	A	O
2	9	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	KpnI	B
8	-	I
9	SalI	I
10	fragment	I
11	,	O
12	where	O
13	all	O
14	the	O
15	DNA	O
16	changes	O
17	associated	O
18	with	O
19	su	O
20	(	O
21	Hw	O
22	)	O
23	mutations	O
24	were	O
25	mapped	O
26	,	O
27	was	O
28	able	O
29	to	O
30	rescue	O
31	the	O
32	su	O
33	(	O
34	Hw	O
35	)	O
36	mutant	O
37	phenotype	O
38	after	O
39	P	O
40	-	O
41	element	O
42	-	O
43	mediated	O
44	germ	O
45	-	O
46	line	O
47	transformation	O
48	.	O

1	Piperacillin	B
2	-	O
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	Contrary	O
2	to	O
3	expectations	O
4	,	O
5	we	O
6	find	O
7	a	O
8	relatively	O
9	high	O
10	level	O
11	of	O
12	variation	O
13	in	O
14	the	O
15	stripe	B
16	2	I
17	enhancer	I
18	region	I
19	,	O
20	including	O
21	point	O
22	substitutions	O
23	and	O
24	insertion	O
25	/	O
26	deletions	O
27	in	O
28	binding	O
29	sites	O
30	,	O
31	and	O
32	a	O
33	comparable	O
34	level	O
35	of	O
36	variation	O
37	in	O
38	the	O
39	other	O
40	noncoding	O
41	regions	O
42	.	O

1	Mycoplasma	O
2	hominis	O
3	infections	O
4	are	O
5	easily	O
6	missed	O
7	because	O
8	conventional	O
9	methods	O
10	for	O
11	bacterial	O
12	detection	O
13	may	O
14	fail	O
15	.	O

1	155	O
2	aa	O
3	,	O
4	shares	O
5	78	O
6	%	O
7	identity	O
8	with	O
9	the	O
10	analogous	O
11	region	O
12	of	O
13	Xenopus	B
14	laevis	I
15	FGF3	I
16	and	O
17	72	O
18	%	O
19	identity	O
20	with	O
21	the	O
22	product	O
23	of	O
24	the	O
25	more	O
26	distantly	O
27	related	O
28	human	O
29	gene	O
30	.	O

1	Felodipine	O
2	did	O
3	not	O
4	alter	O
5	the	O
6	baseline	O
7	FEV1	O
8	,	O
9	but	O
10	showed	O
11	a	O
12	small	O
13	significant	O
14	inhibitory	O
15	effect	O
16	upon	O
17	histamine	O
18	and	O
19	AMP	O
20	induced	O
21	bronchoconstriction	O
22	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	for	O
7	a	O
8	model	O
9	in	O
10	which	O
11	mRNA	O
12	sequences	O
13	up	O
14	to	O
15	around	O
16	100	O
17	nucleotides	O
18	downstream	O
19	from	O
20	the	O
21	start	O
22	codon	O
23	of	O
24	21K	O
25	fold	O
26	back	O
27	and	O
28	base	O
29	-	O
30	pair	O
31	to	O
32	the	O
33	21K	O
34	translation	O
35	initiation	O
36	region	O
37	,	O
38	thereby	O
39	decreasing	O
40	the	O
41	translation	O
42	initiation	O
43	frequency	O
44	.	O

1	3	O
2	activities	O
3	of	O
4	the	O
5	factor	B
6	II	I
7	molecule	I
8	in	O
9	the	O
10	newborn	O
11	infant	O
12	at	O
13	term	O

1	No	O
2	local	O
3	destruction	O
4	by	O
5	tumor	O
6	or	O
7	infection	O
8	could	O
9	be	O
10	demonstrated	O
11	apart	O
12	from	O
13	HIV	O
14	infection	O
15	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	pregnant	O
6	group	O
7	,	O
8	serum	O
9	PP14	O
10	concentrations	O
11	were	O
12	markedly	O
13	increased	O
14	after	O
15	ET	O
16	,	O
17	and	O
18	a	O
19	significant	O
20	difference	O
21	between	O
22	the	O
23	pregnant	O
24	group	O
25	and	O
26	the	O
27	nonpregnant	O
28	group	O
29	was	O
30	observed	O
31	8	O
32	days	O
33	following	O
34	ET	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	01	O
41	).	O

1	Functional	O
2	analysis	O
3	of	O
4	promoter	O
5	activity	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	cyclin	B
14	D2	I
15	suggested	O
16	that	O
17	the	O
18	region	O
19	-	O
20	1	O
21	,	O
22	100	O
23	to	O
24	-	O
25	805	O
26	including	O
27	C	B
28	/	I
29	EBP	I
30	,	O
31	PEA3	B
32	,	O
33	AP2	B
34	,	O
35	NF	B
36	-	I
37	Y	I
38	,	O
39	c	B
40	-	I
41	Myc	I
42	,	O
43	and	O
44	Sp1	B
45	may	O
46	have	O
47	a	O
48	major	O
49	positive	O
50	regulatory	O
51	activity	O
52	for	O
53	expression	O
54	of	O
55	cyclin	B
56	D2	I
57	.	O

1	Overall	O
2	,	O
3	lesions	O
4	infiltrating	O
5	the	O
6	deep	O
7	lamina	O
8	propria	O
9	do	O
10	not	O
11	exhibit	O
12	a	O
13	reduced	O
14	frequency	O
15	of	O
16	occurrence	O
17	compared	O
18	to	O
19	lesions	O
20	infiltrating	O
21	the	O
22	skeletal	O
23	muscle	O
24	;	O
25	however	O
26	,	O
27	carcinomas	O
28	affecting	O
29	other	O
30	oral	O
31	sites	O
32	showed	O
33	a	O
34	reduced	O
35	frequency	O
36	of	O
37	deeply	O
38	infiltrating	O
39	lesions	O
40	in	O
41	comparison	O
42	to	O
43	more	O
44	superficial	O
45	lesions	O
46	.	O

1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O

1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O

1	In	O
2	marked	O
3	contrast	O
4	to	O
5	AgfA	B
6	,	O
7	none	O
8	of	O
9	the	O
10	chimeric	O
11	SefA	B
12	proteins	I
13	were	O
14	expressed	O
15	or	O
16	assembled	O
17	into	O
18	fimbriae	O
19	.	O

1	Trial	O
2	3	O
3	broiler	O
4	chickens	O
5	were	O
6	maintained	O
7	on	O
8	control	O
9	feed	O
10	until	O
11	they	O
12	reached	O
13	3	O
14	weeks	O
15	of	O
16	age	O
17	at	O
18	which	O
19	time	O
20	they	O
21	were	O
22	taken	O
23	off	O
24	of	O
25	feed	O
26	for	O
27	2	O
28	.	O
29	5	O
30	hr	O
31	and	O
32	then	O
33	placed	O
34	on	O
35	either	O
36	control	O
37	feed	O
38	or	O
39	feed	O
40	containing	O
41	4	O
42	.	O
43	0	O
44	ppm	O
45	ochratoxin	O
46	A	O
47	,	O
48	and	O
49	heart	O
50	rate	O
51	and	O
52	blood	O
53	pressure	O
54	were	O
55	measured	O
56	every	O
57	half	O
58	hour	O
59	through	O
60	7	O
61	hr	O
62	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	Transfection	O
2	of	O
3	increasing	O
4	amounts	O
5	of	O
6	delta5ERalpha	B
7	expression	O
8	vector	O
9	into	O
10	[	O
11	ERalpha	B
12	+]	O
13	OS	O
14	cells	O
15	resulted	O
16	in	O
17	potentiation	O
18	of	O
19	E2	B
20	-	O
21	stimulated	O
22	ERELuc	B
23	activity	O
24	in	O
25	a	O
26	synergistic	O
27	,	O
28	dose	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	Biometric	O
2	analysis	O
3	of	O
4	intraocular	O
5	lens	O
6	power	O
7	required	O
8	to	O
9	produce	O
10	emmetropia	O
11	:	O
12	results	O
13	of	O
14	450	O
15	implants	O
16	.	O

1	At	O
2	the	O
3	genomic	O
4	level	O
5	,	O
6	the	O
7	sequences	O
8	of	O
9	two	O
10	members	O
11	of	O
12	this	O
13	family	O
14	are	O
15	known	O
16	in	O
17	the	O
18	rat	O
19	Rattus	O
20	norvegicus	O
21	:	O
22	the	O
23	VCSA1	B
24	gene	I
25	,	O
26	encoding	O
27	the	O
28	prohormone	O
29	-	O
30	like	O
31	polypeptide	O
32	SMR1	O
33	,	O
34	and	O
35	the	O
36	VCSB1	B
37	gene	I
38	,	O
39	encoding	O
40	a	O
41	salivary	O
42	Pro	O
43	-	O
44	rich	O
45	polypeptide	O
46	.	O

1	In	O
2	calves	O
3	receiving	O
4	milk	O
5	-	O
6	substitute	O
7	diets	O
8	containing	O
9	80	O
10	-	O
11	260	O
12	g	O
13	DM	O
14	/	O
15	kg	O
16	,	O
17	milk	O
18	intakes	O
19	were	O
20	reduced	O
21	by	O
22	up	O
23	to	O
24	30	O
25	%	O
26	on	O
27	the	O
28	1st	O
29	day	O
30	that	O
31	calves	O
32	were	O
33	fed	O
34	once	O
35	daily	O
36	instead	O
37	of	O
38	twice	O
39	daily	O
40	.	O

1	We	O
2	observed	O
3	abundant	O
4	levels	O
5	of	O
6	Rev	B
7	-	I
8	erbA	I
9	alpha	I
10	mRNA	I
11	in	O
12	dividing	O
13	C2C12	O
14	myoblasts	O
15	,	O
16	which	O
17	were	O
18	suppressed	O
19	when	O
20	the	O
21	cells	O
22	differentiated	O
23	into	O
24	postmitotic	O
25	multinucleated	O
26	myotubes	O
27	.	O

1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	impact	O
7	of	O
8	the	O
9	introduction	O
10	of	O
11	clarithromycin	O
12	and	O
13	azithromycin	O
14	on	O
15	the	O
16	treatment	O
17	and	O
18	survival	O
19	of	O
20	patients	O
21	with	O
22	AIDS	O
23	and	O
24	disseminated	O
25	Mycobacterium	O
26	avium	O
27	complex	O
28	(	O
29	DMAC	O
30	).	O

1	Potential	O
2	consensus	O
3	sequences	O
4	for	O
5	early	O
6	and	O
7	late	O
8	regulatory	O
9	elements	O
10	were	O
11	identified	O
12	.	O

1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O

1	Two	O
2	Lab	O
3	8	O
4	computer	O
5	programmes	O
6	for	O
7	use	O
8	in	O
9	the	O
10	study	O
11	of	O
12	the	O
13	isometric	O
14	and	O
15	isotonic	O
16	contractile	O
17	characteristics	O
18	of	O
19	skeletal	O
20	muscle	O
21	.	O

1	Full	O
2	-	O
3	length	O
4	FLAP	O
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O

1	The	O
2	O2	O
3	deficit	O
4	was	O
5	not	O
6	related	O
7	to	O
8	blood	O
9	lactate	O
10	during	O
11	submaximal	O
12	exercise	O
13	,	O
14	muscle	O
15	enzyme	O
16	activity	O
17	(	O
18	citrate	B
19	synthase	I
20	,	I
21	3	I
22	-	I
23	hydroxyacyl	I
24	-	I
25	CoA	I
26	-	I
27	dehydrogenase	I
28	,	O
29	lactate	B
30	dehydrogenase	I
31	),	O
32	number	O
33	of	O
34	muscle	O
35	capillaries	O
36	,	O
37	%	O
38	ST	O
39	fibres	O
40	or	O
41	muscle	O
42	buffer	O
43	capacity	O
44	.	O

1	Keeping	O
2	in	O
3	mind	O
4	the	O
5	limited	O
6	range	O
7	of	O
8	age	O
9	and	O
10	dosages	O
11	,	O
12	advantages	O
13	and	O
14	disadvantages	O
15	of	O
16	the	O
17	drug	O
18	are	O
19	discussed	O
20	,	O
21	comparing	O
22	the	O
23	experimental	O
24	results	O
25	with	O
26	those	O
27	derived	O
28	from	O
29	the	O
30	literature	O
31	.	O

1	We	O
2	show	O
3	that	O
4	stabilization	O
5	of	O
6	the	O
7	hairpin	O
8	reduced	O
9	the	O
10	amount	O
11	of	O
12	tRNA	O
13	primer	O
14	that	O
15	is	O
16	annealed	O
17	to	O
18	the	O
19	PBS	O
20	.	O

1	No	O
2	such	O
3	benefits	O
4	were	O
5	seen	O
6	for	O
7	children	O
8	with	O
9	CD4	B
10	+	I
11	counts	O
12	below	O
13	0	O
14	.	O
15	2	O
16	x	O
17	10	O
18	(	O
19	9	O
20	)	O
21	per	O
22	liter	O
23	at	O
24	entry	O
25	.	O

1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	distinct	O
6	cytoplasmic	O
7	domains	O
8	of	O
9	these	O
10	cytokine	O
11	receptors	O
12	elicit	O
13	convergent	O
14	signaling	O
15	pathways	O
16	and	O
17	provide	O
18	evidence	O
19	that	O
20	beta	B
21	c	I
22	and	O
23	IL	B
24	-	I
25	2R	I
26	beta	I
27	function	O
28	as	O
29	a	O
30	complete	O
31	signal	O
32	transducer	O
33	.	O

1	The	O
2	corresponding	O
3	gene	O
4	was	O
5	identified	O
6	in	O
7	the	O
8	GenBankTM	O
9	data	O
10	base	O
11	by	O
12	sequence	O
13	alignment	O
14	and	O
15	termed	O
16	RPS30A	B
17	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	presented	O
6	with	O
7	Transient	O
8	Ischemic	O
9	Attacks	O
10	(	O
11	64	O
12	%)	O
13	or	O
14	Reversible	O
15	Ischemic	O
16	Neurologic	O
17	Deficits	O
18	(	O
19	19	O
20	%).	O

1	Judicious	O
2	use	O
3	of	O
4	laboratory	O
5	testing	O
6	,	O
7	including	O
8	monitoring	O
9	of	O
10	CD4	B
11	cell	O
12	counts	O
13	,	O
14	is	O
15	recommended	O
16	.	O

1	An	O
2	N	O
3	-	O
4	terminal	O
5	arm	O
6	from	O
7	each	O
8	subunit	O
9	wraps	O
10	around	O
11	the	O
12	dinucleotide	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	an	O
18	adjacent	O
19	subunit	O
20	,	O
21	covering	O
22	the	O
23	adenine	O
24	ring	O
25	of	O
26	NADP	O
27	.	O

1	The	O
2	DNA	O
3	binding	O
4	domain	O
5	of	O
6	NirA	B
7	was	O
8	expressed	O
9	as	O
10	a	O
11	fusion	O
12	protein	O
13	with	O
14	the	O
15	glutathione	B
16	S	I
17	-	I
18	transferase	I
19	of	O
20	Schistosoma	O
21	japonicum	O
22	.	O

1	Molecular	O
2	neurochemistry	O
3	of	O
4	addictive	O
5	drugs	O
6	.	O

1	Maternal	O
2	lactation	O

1	Previously	O
2	,	O
3	we	O
4	characterized	O
5	a	O
6	DNA	O
7	-	O
8	binding	O
9	protein	O
10	,	O
11	HS2NF5	B
12	,	O
13	that	O
14	bound	O
15	tightly	O
16	to	O
17	a	O
18	conserved	O
19	region	O
20	within	O
21	hypersensitive	O
22	site	O
23	2	O
24	(	O
25	HS2	O
26	)	O
27	of	O
28	the	O
29	human	B
30	beta	I
31	-	I
32	globin	I
33	locus	I
34	control	I
35	region	I
36	(	O
37	LCR	O
38	)	O
39	(	O
40	Lam	O
41	,	O
42	L	O
43	.	O

1	The	O
2	effect	O
3	of	O
4	salmon	O
5	calcitonin	B
6	nasal	O
7	spray	O
8	in	O
9	women	O
10	with	O
11	established	O
12	osteoporosis	O
13	has	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O

1	We	O
2	conclude	O
3	that	O
4	CPET	O
5	is	O
6	a	O
7	useful	O
8	investigation	O
9	in	O
10	the	O
11	management	O
12	of	O
13	patients	O
14	with	O
15	cardiopulmonary	O
16	disease	O
17	and	O
18	complements	O
19	the	O
20	various	O
21	other	O
22	investigations	O
23	offered	O
24	by	O
25	a	O
26	pulmonary	O
27	function	O
28	laboratory	O
29	.	O

1	Assembly	O
2	of	O
3	a	O
4	complex	O
5	between	O
6	FAK	B
7	and	O
8	Src	B
9	kinases	I
10	may	O
11	serve	O
12	to	O
13	regulate	O
14	the	O
15	subcellular	O
16	localization	O
17	and	O
18	the	O
19	enzymatic	O
20	activity	O
21	of	O
22	members	O
23	of	O
24	the	O
25	Src	B
26	family	I
27	of	I
28	kinases	I
29	.	O

1	The	O
2	Ntl1	B
3	gene	I
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	diploid	O
13	N	O
14	.	O
15	plumbaginifolia	O
16	species	O
17	.	O

1	When	O
2	used	O
3	subcutaneously	O
4	or	O
5	intravenously	O
6	in	O
7	maximum	O
8	tolerated	O
9	doses	O
10	the	O
11	antibiotic	O
12	inhibited	O
13	the	O
14	development	O
15	of	O
16	lymphadenosis	O
17	NK	O
18	/	O
19	Li	O
20	by	O
21	90	O
22	and	O
23	70	O
24	per	O
25	cent	O
26	respectively	O
27	.	O

1	Since	O
2	the	O
3	RINX	B
4	gene	I
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	O
12	Vsx1	O
13	gene	O
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	B
20	by	O
21	the	O
22	Human	O
23	Gene	O
24	Nomenclature	O
25	Committee	O
26	.	O

1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	I
9	cholesterol	I
10	concentrations	O
11	and	O
12	the	O
13	HDL2	B
14	-	I
15	cholesterol	I
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	O
22	triglyceride	B
23	lipase	I
24	activity	O
25	.	O

1	The	O
2	authors	O
3	concluded	O
4	that	O
5	ultrasonic	O
6	Doppler	O
7	-	O
8	cardiography	O
9	can	O
10	be	O
11	used	O
12	for	O
13	measuring	O
14	the	O
15	relative	O
16	changes	O
17	in	O
18	the	O
19	stroke	O
20	volume	O
21	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	for	O
6	expression	O
7	of	O
8	snRNA	B
9	genes	I
10	in	O
11	maize	O
12	,	O
13	a	O
14	monocotyledonous	O
15	plant	O
16	,	O
17	the	O
18	USE	O
19	and	O
20	TATA	O
21	elements	O
22	are	O
23	essential	O
24	,	O
25	but	O
26	not	O
27	sufficient	O
28	,	O
29	for	O
30	transcription	O
31	.	O

1	The	O
2	effectiveness	O
3	of	O
4	NRT	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	smoker	O
20	.	O

1	Prevention	O
2	of	O
3	maternal	O
4	Rh	O
5	sensitization	O
6	:	O
7	anti	B
8	-	I
9	Rh	I
10	immune	I
11	globulin	I
12	.	O

1	Comprising	O
2	a	O
3	126	O
4	-	O
5	nucleotide	O
6	5	O
7	'	O
8	untranscribed	O
9	genomic	O
10	sequence	O
11	and	O
12	a	O
13	466	O
14	-	O
15	nucleotide	O
16	5	O
17	'	O
18	noncoding	O
19	cDNA	O
20	sequence	O
21	,	O
22	the	O
23	592	O
24	-	O
25	nucleotide	O
26	5	O
27	'	O
28	CpG	O
29	island	O
30	lacked	O
31	TATA	O
32	and	O
33	CAAT	O
34	boxes	O
35	but	O
36	displayed	O
37	a	O
38	high	O
39	G	O
40	+	O
41	C	O
42	content	O
43	,	O
44	was	O
45	enriched	O
46	for	O
47	CpG	O
48	dinucleotides	O
49	,	O
50	and	O
51	contained	O
52	a	O
53	potential	O
54	Sp1	B
55	-	I
56	binding	I
57	site	I
58	,	O
59	i	O
60	.	O
61	e	O
62	.,	O
63	features	O
64	compatible	O
65	with	O
66	a	O
67	housekeeping	O
68	gene	O
69	.	O

1	Effect	O
2	of	O
3	thrombotic	O
4	and	O
5	antithrombotic	O
6	drugs	O
7	on	O
8	the	O
9	surface	O
10	charge	O
11	characteristics	O
12	of	O
13	canine	O
14	blood	O
15	vessels	O
16	:	O
17	in	O
18	vivo	O
19	and	O
20	in	O
21	vitro	O
22	studies	O
23	.	O

1	In	O
2	a	O
3	maxicell	O
4	system	O
5	a	O
6	protein	O
7	with	O
8	an	O
9	approximate	O
10	molecular	O
11	weight	O
12	of	O
13	36	O
14	,	O
15	000	O
16	was	O
17	synthesized	O
18	.	O

1	The	O
2	cop	O
3	region	O
4	also	O
5	harbors	O
6	a	O
7	region	O
8	of	O
9	plasmid	O
10	incompatibility	O
11	,	O
12	inc	O
13	,	O
14	encompassing	O
15	a	O
16	stem	O
17	-	O
18	loop	O
19	structure	O
20	,	O
21	the	O
22	repA	B
23	promoter	I
24	,	O
25	Prep	O
26	,	O
27	as	O
28	well	O
29	as	O
30	two	O
31	distinct	O
32	RepA	B
33	binding	I
34	sites	I
35	,	O
36	BD	B
37	-	I
38	1	I
39	and	O
40	BD	B
41	-	I
42	2	I
43	.	O

1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	RNU2	O
6	fragility	O
7	can	O
8	be	O
9	induced	O
10	by	O
11	transfection	O
12	with	O
13	an	O
14	expression	O
15	vector	O
16	encoding	O
17	Ad12	O
18	E1B	O
19	55	O
20	kDa	O
21	alone	O
22	but	O
23	not	O
24	by	O
25	an	O
26	E1	O
27	vector	O
28	encoding	O
29	all	O
30	E1	B
31	products	I
32	(	I
33	3	I
34	E1A	I
35	proteins	I
36	,	O
37	as	O
38	well	O
39	as	O
40	the	O
41	E1B	B
42	19	I
43	kDa	I
44	and	I
45	55	I
46	kDa	I
47	proteins	I
48	).	O

1	We	O
2	also	O
3	report	O
4	that	O
5	AHR	B
6	interacts	O
7	with	O
8	COUP	B
9	-	I
10	TF	I
11	in	O
12	transfected	O
13	CV	O
14	-	O
15	1	O
16	cells	O
17	.	O

1	METHODS	O
2	:	O
3	Von	B
4	Willebrand	I
5	factor	I
6	(	O
7	vWF	B
8	)	O
9	and	O
10	the	O
11	fibrinolytic	O
12	factors	O
13	tissue	B
14	plasminogen	I
15	activator	I
16	(	O
17	tPA	O
18	),	O
19	measured	O
20	as	O
21	tPA	O
22	capacity	O
23	,	O
24	and	O
25	plasminogen	B
26	activator	I
27	inhibitor	I
28	1	I
29	(	O
30	PAI	B
31	-	I
32	1	I
33	),	O
34	platelets	O
35	,	O
36	fibrinogen	B
37	,	O
38	and	O
39	inflammatory	O
40	markers	O
41	were	O
42	measured	O
43	in	O
44	74	O
45	patients	O
46	with	O
47	active	O
48	seropositive	O
49	RA	O
50	.	O

1	Acad	O
2	.	O

1	Overexpression	O
2	of	O
3	c	B
4	-	I
5	Myc	I
6	in	O
7	serum	O
8	-	O
9	starved	O
10	human	O
11	or	O
12	mouse	O
13	embryonic	O
14	cells	O
15	leads	O
16	to	O
17	apoptosis	O
18	which	O
19	is	O
20	significantly	O
21	reduced	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	growth	O
27	factor	O
28	-	O
29	containing	O
30	serum	O
31	.	O
32	c	B
33	-	I
34	Myc	I
35	-	O
36	induced	O
37	apoptosis	O
38	appears	O
39	to	O
40	be	O
41	deficient	O
42	in	O
43	bax	O
44	-	O
45	null	O
46	as	O
47	compared	O
48	with	O
49	bax	O
50	-	O
51	wild	O
52	-	O
53	type	O
54	mouse	O
55	embryonic	O
56	fibroblasts	O
57	.	O

1	Family	O
2	visits	O
3	and	O
4	involvement	O
5	in	O
6	treatment	O
7	of	O
8	patients	O
9	at	O
10	a	O
11	state	O
12	hospital	O
13	.	O

1	It	O
2	could	O
3	also	O
4	inhibit	O
5	C1q	O
6	-	O
7	dependent	O
8	haemolysis	O
9	of	O
10	both	O
11	IgG	B
12	-	O
13	and	O
14	IgM	B
15	-	O
16	sensitized	O
17	erythrocytes	O
18	.	O

1	Thus	O
2	,	O
3	VF	O
4	resistant	O
5	to	O
6	defibrillation	O
7	is	O
8	not	O
9	necessarily	O
10	associated	O
11	with	O
12	both	O
13	toxic	O
14	plasma	O
15	drug	O
16	level	O
17	and	O
18	remarkably	O
19	decreased	O
20	conduction	O
21	.	O

1	This	O
2	philosophy	O
3	was	O
4	instituted	O
5	for	O
6	the	O
7	compound	O
8	RP	O
9	73401	O
10	,	O
11	a	O
12	specific	O
13	phosphodiesterase	B
14	IV	I
15	inhibitor	O
16	,	O
17	that	O
18	was	O
19	being	O
20	developed	O
21	simultaneously	O
22	for	O
23	delivery	O
24	by	O
25	both	O
26	oral	O
27	and	O
28	pulmonary	O
29	routes	O
30	of	O
31	administration	O
32	.	O

1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O

1	SIM1	O
2	and	O
3	SIM2	O
4	do	O
5	not	O
6	form	O
7	homodimers	O
8	,	O
9	and	O
10	they	O
11	do	O
12	not	O
13	interact	O
14	with	O
15	AHR	O
16	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	Letter	O
2	:	O
3	Perspectives	O
4	in	O
5	bone	O
6	marrow	O
7	transplantation	O
8	.	O

1	Transcription	O
2	readthrough	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O

1	Uroflowmetry	O
2	can	O
3	detect	O
4	dysuria	O
5	,	O
6	which	O
7	may	O
8	be	O
9	poorly	O
10	perceived	O
11	or	O
12	even	O
13	unknown	O
14	to	O
15	the	O
16	subjects	O
17	themselves	O
18	.	O

1	A	O
2	model	O
3	with	O
4	age	O
5	and	O
6	weight	O
7	described	O
8	the	O
9	best	O
10	fit	O
11	for	O
12	TBBMD	O
13	,	O
14	whereas	O
15	age	O
16	,	O
17	weight	O
18	,	O
19	and	O
20	height	O
21	described	O
22	the	O
23	best	O
24	fit	O
25	for	O
26	total	O
27	body	O
28	TBBMC	O
29	.	O

1	She	O
2	also	O
3	had	O
4	slight	O
5	weakness	O
6	of	O
7	the	O
8	upper	O
9	extremities	O
10	.	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	Genomic	O
2	organization	O
3	of	O
4	the	O
5	human	B
6	beta	I
7	-	I
8	catenin	I
9	gene	I
10	(	O
11	CTNNB1	O
12	).	O

1	A	O
2	prospective	O
3	trail	O
4	comparing	O
5	hysterectomy	O
6	,	O
7	hysterectomy	O
8	plus	O
9	vaginal	O
10	radium	O
11	,	O
12	and	O
13	uterine	O
14	radium	O
15	plus	O
16	hysterectomy	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O

1	While	O
2	this	O
3	Saccharomyces	B
4	cerevisiae	I
5	SIN4	I
6	gene	I
7	product	I
8	is	O
9	a	O
10	component	O
11	of	O
12	a	O
13	mediator	O
14	complex	O
15	associated	O
16	with	O
17	RNA	B
18	polymerase	I
19	II	I
20	,	O
21	various	O
22	studies	O
23	suggest	O
24	the	O
25	involvement	O
26	of	O
27	Sin4	O
28	in	O
29	the	O
30	alteration	O
31	of	O
32	higher	O
33	-	O
34	order	O
35	chromatin	O
36	structure	O
37	.	O

1	Data	O
2	from	O
3	119	O
4	men	O
5	and	O
6	40	O
7	women	O
8	undergoing	O
9	coronary	O
10	angiography	O
11	provide	O
12	an	O
13	opportunity	O
14	to	O
15	compare	O
16	these	O
17	associations	O
18	in	O
19	relation	O
20	to	O
21	a	O
22	direct	O
23	and	O
24	continuous	O
25	measure	O
26	of	O
27	atherosclerosis	O
28	while	O
29	controlling	O
30	for	O
31	age	O
32	,	O
33	sex	O
34	,	O
35	income	O
36	,	O
37	hypertension	O
38	,	O
39	serum	O
40	cholesterol	O
41	,	O
42	smoking	O
43	,	O
44	angina	O
45	,	O
46	diabetes	O
47	,	O
48	family	O
49	history	O
50	of	O
51	heart	O
52	disease	O
53	,	O
54	Type	O
55	A	O
56	behavior	O
57	pattern	O
58	,	O
59	and	O
60	hostility	O
61	.	O

1	When	O
2	expressed	O
3	in	O
4	and	O
5	purified	O
6	from	O
7	Escherichia	O
8	coli	O
9	,	O
10	both	O
11	full	O
12	-	O
13	length	O
14	Fpr3	O
15	and	O
16	its	O
17	isolated	O
18	COOH	O
19	-	O
20	terminal	O
21	domain	O
22	exhibit	O
23	readily	O
24	detectable	O
25	PPIase	B
26	activity	O
27	.	O

1	Unlike	O
2	P135gag	B
3	-	I
4	myb	I
5	-	I
6	ets	I
7	and	O
8	the	O
9	Mr	O
10	75	O
11	,	O
12	000	O
13	translation	O
14	product	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	(	O
20	P75c	B
21	-	I
22	myb	I
23	),	O
24	which	O
25	are	O
26	nuclear	O
27	proteins	O
28	,	O
29	P54c	B
30	-	I
31	ets	I
32	was	O
33	found	O
34	to	O
35	be	O
36	predominantly	O
37	cytoplasmic	O
38	.	O

1	This	O
2	mutation	O
3	also	O
4	results	O
5	in	O
6	markedly	O
7	decreased	O
8	levels	O
9	of	O
10	CAD	B
11	mRNA	I
12	and	O
13	protein	O
14	in	O
15	the	O
16	mutant	O
17	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	binding	I
8	protein	I
9	-	I
10	2	I
11	(	O
12	IGF	B
13	-	I
14	BP	I
15	-	I
16	2	I
17	)	O
18	transcription	O
19	in	O
20	rat	O
21	liver	O
22	varies	O
23	with	O
24	developmental	O
25	age	O
26	and	O
27	fasting	O
28	.	O

1	Endotoxemia	O
2	induced	O
3	by	O
4	gram	O
5	-	O
6	negative	O
7	bacteria	O
8	leads	O
9	to	O
10	endotoxic	O
11	shock	O
12	pathogenetically	O
13	stemming	O
14	from	O
15	the	O
16	integral	O
17	component	O
18	of	O
19	the	O
20	bacterial	O
21	wall	O
22	--	O
23	lipid	O
24	A	O
25	.	O

1	In	O
2	assays	O
3	with	O
4	purified	O
5	enzymes	O
6	,	O
7	wild	O
8	-	O
9	type	O
10	but	O
11	not	O
12	PTPS	O
13	-	O
14	S19A	O
15	was	O
16	a	O
17	specific	O
18	substrate	O
19	for	O
20	the	O
21	cGMP	B
22	-	I
23	dependent	I
24	protein	I
25	kinase	I
26	(	O
27	cGK	O
28	)	O
29	type	O
30	I	O
31	and	O
32	II	O
33	.	O

1	The	O
2	protooncogene	O
3	c	B
4	-	I
5	myb	I
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O

1	Role	O
2	of	O
3	g2	O
4	in	O
5	relating	O
6	the	O
7	Schwinger	O
8	and	O
9	Gerasimov	O
10	-	O
11	Drell	O
12	-	O
13	Hearn	O
14	sum	O
15	rules	O
16	.	O

1	In	O
2	10	O
3	patients	O
4	with	O
5	subacute	O
6	cardiac	O
7	tamponade	O
8	,	O
9	pulmonary	O
10	wedge	O
11	pressure	O
12	(	O
13	PWP	O
14	),	O
15	RAP	B
16	,	O
17	and	O
18	IPP	O
19	were	O
20	measured	O
21	along	O
22	with	O
23	indexes	O
24	of	O
25	systolic	O
26	function	O
27	.	O

1	Thus	O
2	,	O
3	the	O
4	pol	B
5	alpha	I
6	-	I
7	primase	I
8	complex	O
9	appears	O
10	to	O
11	act	O
12	processively	O
13	for	O
14	only	O
15	a	O
16	short	O
17	distance	O
18	.	O

1	Additional	O
2	exonuclease	O
3	III	O
4	protection	O
5	was	O
6	observed	O
7	beyond	O
8	the	O
9	core	O
10	region	O
11	on	O
12	both	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	sides	O
20	,	O
21	suggesting	O
22	that	O
23	E1	O
24	interacted	O
25	with	O
26	more	O
27	distal	O
28	sequences	O
29	as	O
30	well	O
31	.	O

1	We	O
2	conclude	O
3	that	O
4	class	O
5	I	O
6	cytologic	O
7	smears	O
8	with	O
9	moderate	O
10	to	O
11	severe	O
12	inflammation	O
13	may	O
14	be	O
15	associated	O
16	with	O
17	findings	O
18	of	O
19	condylomata	O
20	and	O
21	cervical	O
22	dysplasia	O
23	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	II	I
7	(	O
8	IGFII	O
9	)	O
10	is	O
11	a	O
12	mitogenic	O
13	polypeptide	O
14	,	O
15	the	O
16	mRNAs	O
17	of	O
18	which	O
19	are	O
20	present	O
21	in	O
22	multiple	O
23	forms	O
24	,	O
25	despite	O
26	derivation	O
27	from	O
28	a	O
29	single	O
30	gene	O
31	.	O

1	An	O
2	evolutionary	O
3	comparison	O
4	of	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	34	O
10	HSP70	B
11	proteins	I
12	from	O
13	17	O
14	species	O
15	suggests	O
16	that	O
17	BiP	B
18	genes	I
19	share	O
20	a	O
21	common	O
22	ancestor	O
23	,	O
24	which	O
25	diverged	O
26	from	O
27	other	O
28	HSP70	B
29	genes	I
30	near	O
31	the	O
32	time	O
33	when	O
34	eukaryotes	O
35	first	O
36	appeared	O
37	.	O

1	Systemic	O
2	lupus	O
3	erythematosus	O
4	was	O
5	diagnosed	O
6	.	O

1	Finally	O
2	,	O
3	the	O
4	pathophysiological	O
5	aspects	O
6	of	O
7	urinary	O
8	acidification	O
9	are	O
10	discussed	O
11	,	O
12	focusing	O
13	on	O
14	renal	O
15	tubular	O
16	acidosis	O
17	models	O
18	(	O
19	induced	O
20	by	O
21	maleate	O
22	and	O
23	amphotericin	O
24	B	O
25	treatment	O
26	)	O
27	and	O
28	their	O
29	cellular	O
30	mechanisms	O
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	role	O
37	of	O
38	adrenal	O
39	steroids	O
40	in	O
41	urinary	O
42	acidification	O
43	.	O

1	IE2	B
2	-	O
3	IE2	B
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	O
18	motif	O
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	402	O
6	consecutive	O
7	autopsies	O
8	,	O
9	parietal	O
10	pleural	O
11	plaques	O
12	(	O
13	PP	O
14	)	O
15	were	O
16	found	O
17	in	O
18	68	O
19	individuals	O
20	above	O
21	40	O
22	years	O
23	of	O
24	age	O
25	.	O

1	The	O
2	cost	O
3	per	O
4	test	O
5	is	O
6	less	O
7	than	O
8	those	O
9	for	O
10	CC	O
11	,	O
12	kEIA	B
13	and	O
14	PACE2	O
15	.	O

1	First	O
2	,	O
3	each	O
4	lung	O
5	was	O
6	cut	O
7	into	O
8	slices	O
9	,	O
10	from	O
11	which	O
12	primary	O
13	disectors	O
14	were	O
15	sampled	O
16	systematically	O
17	with	O
18	a	O
19	known	O
20	sampling	O
21	fraction	O
22	.	O

1	The	O
2	gene	O
3	structure	O
4	of	O
5	Elk1	B
6	spans	I
7	15	I
8	.	I
9	2	I
10	kb	I
11	and	O
12	consists	O
13	of	O
14	seven	O
15	exons	O
16	and	O
17	six	O
18	introns	O
19	.	O

1	Articles	O
2	addressing	O
3	valvular	O
4	heart	O
5	disease	O
6	or	O
7	heart	O
8	failure	O
9	secondary	O
10	to	O
11	acute	O
12	myocardial	O
13	infarction	O
14	or	O
15	Chagas	O
16	'	O
17	disease	O
18	were	O
19	excluded	O
20	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	purified	O
7	and	O
8	characterized	O
9	the	O
10	recombinant	B
11	furin	I
12	from	O
13	the	O
14	conditioned	O
15	medium	O
16	of	O
17	these	O
18	cells	O
19	.	O

1	An	O
2	activation	O
3	-	O
4	responsive	O
5	element	O
6	in	O
7	single	O
8	C	B
9	motif	I
10	-	I
11	1	I
12	/	I
13	lymphotactin	I
14	promoter	I
15	is	O
16	a	O
17	site	O
18	of	O
19	constitutive	O
20	and	O
21	inducible	O
22	DNA	O
23	-	O
24	protein	O
25	interactions	O
26	involving	O
27	nuclear	O
28	factor	O
29	of	O
30	activated	O
31	T	O
32	cell	O
33	.	O

1	Furthermore	O
2	,	O
3	as	O
4	in	O
5	the	O
6	human	B
7	gene	I
8	,	O
9	the	O
10	3	O
11	'	O
12	end	O
13	of	O
14	the	O
15	Cacna1f	B
16	gene	I
17	maps	O
18	within	O
19	5	O
20	kb	O
21	of	O
22	the	O
23	5	O
24	'	O
25	end	O
26	of	O
27	the	O
28	mouse	B
29	synaptophysin	I
30	gene	I
31	in	O
32	a	O
33	region	O
34	orthologous	O
35	to	O
36	Xp11	O
37	.	O
38	23	O
39	.	O

1	ACE	B
2	-	I
3	2	I
4	has	O
5	a	O
6	hydrophobic	O
7	C	O
8	terminus	O
9	of	O
10	H	O
11	type	O
12	.	O

1	The	O
2	presence	O
3	of	O
4	type	O
5	I	O
6	hypersensitivity	O
7	in	O
8	a	O
9	subgroup	O
10	of	O
11	aspergillomas	O
12	suggests	O
13	an	O
14	immunoallergic	O
15	component	O
16	to	O
17	this	O
18	disease	O
19	which	O
20	could	O
21	contribute	O
22	to	O
23	a	O
24	chronic	O
25	inflammatory	O
26	response	O
27	to	O
28	Aspergillus	O
29	in	O
30	some	O
31	aspergillomas	O
32	.	O

1	By	O
2	DNase	B
3	I	I
4	footprint	O
5	analysis	O
6	of	O
7	the	O
8	PNR	O
9	element	O
10	,	O
11	a	O
12	palindrome	O
13	of	O
14	two	O
15	high	O
16	-	O
17	affinity	O
18	Ets	B
19	-	I
20	binding	I
21	sites	I
22	(	O
23	CTTCCCTGGAAG	O
24	)	O
25	was	O
26	identified	O
27	.	O

1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	B
16	,	O
17	existed	O
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	the	O
7	gene	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	rat	B
15	CRP1	I
16	.	O

1	Tissues	O
2	and	O
3	exudates	O
4	contain	O
5	sufficient	O
6	thymidine	O
7	for	O
8	growth	O
9	of	O
10	anaerobic	O
11	bacteria	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	inhibitory	O
17	levels	O
18	of	O
19	trimethoprim	O
20	-	O
21	sulfamethoxazole	O
22	.	O

1	DNA	O
2	from	O
3	PCR	O
4	was	O
5	labeled	O
6	and	O
7	used	O
8	to	O
9	isolate	O
10	several	O
11	lambda	O
12	gt11	O
13	cDNA	O
14	clones	O
15	,	O
16	including	O
17	one	O
18	full	O
19	-	O
20	length	O
21	one	O
22	(	O
23	Dd	B
24	kinase	I
25	-	I
26	2	I
27	).	O

1	Biol	O
2	.	O

1	The	O
2	histological	O
3	grading	O
4	was	O
5	certified	O
6	in	O
7	68	O
8	cases	O
9	:	O
10	12	O
11	G1	O
12	,	O
13	39	O
14	G2	O
15	,	O
16	17	O
17	G3	O
18	;	O
19	extracapsular	O
20	spread	O
21	was	O
22	found	O
23	in	O
24	20	O
25	/	O
26	54	O
27	cases	O
28	(	O
29	37	O
30	%).	O

1	Neonatal	O
2	lupus	O
3	erythematosus	O
4	is	O
5	most	O
6	often	O
7	associated	O
8	with	O
9	autoantibodies	O
10	against	O
11	Ro	O
12	and	O
13	La	B
14	antigens	I
15	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	contains	O
7	the	O
8	PTP	B
9	-	I
10	like	I
11	domain	I
12	,	O
13	whereas	O
14	the	O
15	N	O
16	-	O
17	terminal	O
18	region	O
19	shows	O
20	no	O
21	homology	O
22	to	O
23	any	O
24	known	O
25	mammalian	O
26	protein	O
27	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	showed	O
6	that	O
7	two	O
8	adjacent	O
9	SP1	B
10	sites	I
11	proximal	O
12	to	O
13	exon	O
14	1	O
15	were	O
16	equally	O
17	important	O
18	in	O
19	sustaining	O
20	basal	O
21	promoter	O
22	activity	O
23	.	O

1	SCA	O
2	was	O
3	resistant	O
4	to	O
5	inhibitors	O
6	of	O
7	serine	O
8	,	O
9	aspartyl	O
10	,	O
11	and	O
12	metalloproteases	O
13	,	O
14	but	O
15	it	O
16	was	O
17	sensitive	O
18	to	O
19	N	O
20	-	O
21	ethylmaleimide	O
22	.	O

1	Excision	O
2	repair	O
3	at	O
4	the	O
5	level	O
6	of	O
7	the	O
8	nucleotide	O
9	in	O
10	the	O
11	Saccharomyces	B
12	cerevisiae	I
13	MFA2	I
14	gene	I
15	:	O
16	mapping	O
17	of	O
18	where	O
19	enhanced	O
20	repair	O
21	in	O
22	the	O
23	transcribed	O
24	strand	O
25	begins	O
26	or	O
27	ends	O
28	and	O
29	identification	O
30	of	O
31	only	O
32	a	O
33	partial	O
34	rad16	O
35	requisite	O
36	for	O
37	repairing	O
38	upstream	O
39	control	O
40	sequences	O
41	.	O

1	It	O
2	consists	O
3	of	O
4	2185	O
5	amino	O
6	acid	O
7	residues	O
8	encoded	O
9	by	O
10	a	O
11	9	O
12	-	O
13	kilobase	O
14	pair	O
15	mRNA	O
16	;	O
17	several	O
18	splice	O
19	variants	O
20	have	O
21	been	O
22	detected	O
23	in	O
24	human	O
25	and	O
26	rat	O
27	cDNA	O
28	libraries	O
29	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O

1	In	O
2	contrast	O
3	to	O
4	hemodynamic	O
5	and	O
6	histopathological	O
7	predictors	O
8	of	O
9	survival	O
10	,	O
11	vWF	B
12	:	I
13	Ag	I
14	does	O
15	not	O
16	require	O
17	invasive	O
18	techniques	O
19	to	O
20	be	O
21	determined	O
22	.	O

1	Clb2	O
2	/	O
3	Cdc28	B
4	kinase	I
5	is	O
6	not	O
7	required	O
8	for	O
9	the	O
10	repression	O
11	of	O
12	MCB	B
13	-	I
14	binding	I
15	factor	I
16	transcriptional	O
17	activity	O
18	in	O
19	G2	O
20	and	O
21	M	O
22	phase	O
23	.	O

1	Measurement	O
2	of	O
3	open	O
4	-	O
5	loop	O
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	O
15	.	O

1	Glycemic	O
2	response	O
3	to	O
4	malted	O
5	,	O
6	popped	O
7	and	O
8	roller	O
9	dried	O
10	wheat	O
11	-	O
12	legume	O
13	based	O
14	foods	O
15	in	O
16	normal	O
17	subjects	O
18	.	O

1	Rapid	O
2	detection	O
3	of	O
4	radioisotopically	O
5	contaminated	O
6	test	O
7	serum	O
8	before	O
9	radioassay	O
10	of	O
11	vitamin	O
12	B12	O
13	.	O

1	X2	O
2	test	O
3	,	O
4	with	O
5	Yates	O
6	correction	O
7	if	O
8	need	O
9	,	O
10	was	O
11	used	O
12	as	O
13	statistical	O
14	.	O
15	method	O
16	.	O

1	The	O
2	MPS1	B
3	open	O
4	reading	O
5	frame	O
6	has	O
7	been	O
8	fused	O
9	to	O
10	those	O
11	that	O
12	encode	O
13	the	O
14	LexA	B
15	protein	I
16	or	O
17	the	O
18	GST	B
19	protein	O
20	and	O
21	both	O
22	of	O
23	these	O
24	constructs	O
25	function	O
26	in	O
27	yeast	O
28	.	O

1	However	O
2	,	O
3	the	O
4	BCH	O
5	group	O
6	showed	O
7	inferior	O
8	gross	O
9	motor	O
10	performance	O
11	on	O
12	the	O
13	Bruininks	O
14	-	O
15	Oseretsky	O
16	Test	O
17	of	O
18	Motor	O
19	Proficiency	O
20	(	O
21	Bruininks	O
22	1978	O
23	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	O
6	genes	O
7	are	O
8	derepressed	O
9	upon	O
10	binding	O
11	of	O
12	Cat8p	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	B
22	(	I
23	Mig1p	I
24	)	O
25	from	O
26	the	O
27	CAT8	B
28	promoter	I
29	.	O

1	In	O
2	patients	O
3	with	O
4	complete	O
5	or	O
6	partial	O
7	remission	O
8	of	O
9	the	O
10	tumor	O
11	,	O
12	the	O
13	neopterine	O
14	excretion	O
15	dropped	O
16	to	O
17	normal	O
18	values	O
19	.	O

1	Fermentation	O
2	process	O
3	after	O
4	supplementation	O
5	of	O
6	nitrate	O
7	,	O
8	nitrite	O
9	,	O
10	lactic	O
11	acid	O
12	bacteria	O
13	and	O
14	formic	O
15	acid	O

1	Distant	O
2	spread	O
3	was	O
4	found	O
5	in	O
6	46	O
7	patients	O
8	(	O
9	34	O
10	%),	O
11	42	O
12	of	O
13	whom	O
14	had	O
15	serum	O
16	Tg	O
17	greater	O
18	than	O
19	10	O
20	micrograms	O
21	/	O
22	l	O
23	.	O

1	Visual	O
2	averaged	O
3	evoked	O
4	responses	O
5	and	O
6	platelet	B
7	monoamine	I
8	oxidase	I
9	in	O
10	patients	O
11	suffering	O
12	from	O
13	alcoholism	O
14	.	O

1	The	O
2	requirement	O
3	of	O
4	PilE	B
5	in	O
6	pilus	O
7	biogenesis	O
8	was	O
9	confirmed	O
10	by	O
11	demonstrating	O
12	that	O
13	chromosomal	O
14	pilE	O
15	insertion	O
16	mutants	O
17	were	O
18	pilus	O
19	-	O
20	and	O
21	twitching	O
22	-	O
23	motility	O
24	deficient	O
25	.	O

1	Although	O
2	the	O
3	terminase	B
4	apparently	O
5	interacts	O
6	with	O
7	this	O
8	gp20	O
9	portal	O
10	peptide	O
11	,	O
12	polyclonal	O
13	antibody	O
14	against	O
15	the	O
16	portal	O
17	peptide	O
18	appears	O
19	unable	O
20	to	O
21	access	O
22	it	O
23	in	O
24	the	O
25	native	O
26	structure	O
27	,	O
28	suggesting	O
29	intimate	O
30	association	O
31	of	O
32	gp20	B
33	and	I
34	gp17	I
35	possibly	I
36	internalizes	I
37	terminase	I
38	regions	I
39	within	O
40	the	O
41	portal	O
42	in	O
43	the	O
44	packasome	O
45	complex	O
46	.	O

1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O

1	Large	O
2	differences	O
3	between	O
4	the	O
5	groups	O
6	were	O
7	not	O
8	observed	O
9	in	O
10	HA	O
11	-	O
12	synthesizing	O
13	enzyme	O
14	activity	O
15	,	O
16	but	O
17	degradative	O
18	enzyme	O
19	activity	O
20	was	O
21	much	O
22	higher	O
23	in	O
24	aspirin	O
25	-	O
26	induced	O
27	asthma	O
28	-	O
29	related	O
30	polyps	O
31	than	O
32	in	O
33	other	O
34	types	O
35	of	O
36	nasal	O
37	polyps	O
38	tested	O
39	.	O

1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	B
9	,	O
10	but	O
11	not	O
12	HNF4	O
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	B
22	gene	I
23	expression	O
24	.	O

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	B
17	-	I
18	R	I
19	gene	I
20	.	O

1	Among	O
2	them	O
3	,	O
4	26	O
5	cases	O
6	were	O
7	benign	O
8	and	O
9	34	O
10	malignant	O
11	.	O

1	Activation	O
2	of	O
3	a	O
4	CRE	O
5	-	O
6	dependent	O
7	junB	B
8	promoter	I
9	/	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	by	O
18	the	O
19	BCR	B
20	was	O
21	also	O
22	blocked	O
23	by	O
24	SB203580	O
25	.	O

1	However	O
2	,	O
3	division	O
4	of	O
5	the	O
6	chest	O
7	wall	O
8	muscles	O
9	,	O
10	usually	O
11	with	O
12	diathermy	O
13	,	O
14	contributes	O
15	to	O
16	prolonged	O
17	pain	O
18	and	O
19	morbidity	O
20	.	O

1	Comparative	O
2	study	O
3	on	O
4	acute	O
5	oral	O
6	overload	O
7	using	O
8	tolbutamide	O
9	and	O
10	tolazamide	O
11	in	O
12	normal	O
13	and	O
14	diabetic	O
15	subjects	O
16	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	does	O
5	not	O
6	predict	O
7	the	O
8	antihypertensive	O
9	efficacy	O
10	of	O
11	chlorthalidone	O
12	.	O

1	To	O
2	analyze	O
3	the	O
4	regulatory	O
5	activity	O
6	of	O
7	Gtx	B
8	,	O
9	we	O
10	first	O
11	identified	O
12	the	O
13	optimal	O
14	Gtx	O
15	-	O
16	binding	O
17	sequence	O
18	using	O
19	an	O
20	in	O
21	vitro	O
22	DNA	O
23	-	O
24	binding	O
25	assay	O
26	.	O

1	Immuno	O
2	-	O
3	cytochemistry	O
4	,	O
5	using	O
6	antisera	O
7	against	O
8	Campylobacter	O
9	jejuni	O
10	,	O
11	showed	O
12	that	O
13	the	O
14	positive	O
15	staining	O
16	in	O
17	altered	O
18	epithelial	O
19	cells	O
20	were	O
21	restricted	O
22	to	O
23	intracellular	O
24	organisms	O
25	having	O
26	a	O
27	structure	O
28	resembling	O
29	Campylobacter	O
30	spp	O
31	.	O

1	Parkinsonian	O
2	patients	O
3	had	O
4	a	O
5	significantly	O
6	lower	O
7	prevalence	O
8	of	O
9	alcohol	O
10	use	O
11	.	O

1	Acquired	O
2	factor	B
3	VIII	I
4	inhibitor	O
5	in	O
6	non	O
7	-	O
8	hemophilic	O
9	patients	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	O
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O

1	Viral	O
2	infections	O
3	have	O
4	long	O
5	been	O
6	suspected	O
7	to	O
8	be	O
9	causative	O
10	agents	O
11	in	O
12	a	O
13	number	O
14	of	O
15	inner	O
16	ear	O
17	dysfunctions	O
18	.	O

1	Blood	O
2	serum	O
3	erythropoietin	B
4	level	O
5	and	O
6	basic	O
7	hematological	O
8	indices	O
9	during	O
10	the	O
11	adaptation	O
12	of	O
13	healthy	O
14	newborn	O
15	infants	O

1	Two	O
2	-	O
3	Channel	O
4	Kondo	O
5	Lattice	O
6	:	O
7	An	O
8	Incoherent	O
9	Metal	O
10	.	O

1	Because	O
2	of	O
3	the	O
4	probable	O
5	causal	O
6	relationship	O
7	between	O
8	constitutive	O
9	p210	O
10	(	O
11	bcr	B
12	/	O
13	abl	B
14	)	I
15	protein	I
16	tyrosine	I
17	kinase	I
18	activity	O
19	and	O
20	manifestations	O
21	of	O
22	chronic	O
23	-	O
24	phase	O
25	chronic	O
26	myelogenous	O
27	leukemia	O
28	(	O
29	CML	O
30	;	O
31	myeloid	O
32	expansion	O
33	),	O
34	a	O
35	key	O
36	goal	O
37	is	O
38	to	O
39	identify	O
40	relevant	O
41	p210	O
42	substrates	O
43	in	O
44	primary	O
45	chronic	O
46	-	O
47	phase	O
48	CML	O
49	hematopoietic	O
50	progenitor	O
51	cells	O
52	.	O

1	Although	O
2	it	O
3	has	O
4	two	O
5	potential	O
6	binding	O
7	sites	O
8	,	O
9	the	O
10	purified	O
11	MerR	B
12	homodimer	I
13	binds	O
14	only	O
15	one	O
16	Hg	O
17	(	O
18	II	O
19	)	O
20	ion	O
21	,	O
22	employing	O
23	Cys82	O
24	from	O
25	one	O
26	monomer	O
27	and	O
28	Cys117	O
29	and	O
30	Cys126	O
31	from	O
32	the	O
33	other	O
34	.	O

1	By	O
2	deletion	O
3	analysis	O
4	of	O
5	the	O
6	MLS1	B
7	control	I
8	region	I
9	,	O
10	we	O
11	identified	O
12	two	O
13	sites	O
14	,	O
15	UAS1	O
16	and	O
17	UAS2	O
18	,	O
19	as	O
20	important	O
21	for	O
22	efficient	O
23	derepression	O
24	of	O
25	the	O
26	gene	O
27	.	O

1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O

1	We	O
2	further	O
3	found	O
4	that	O
5	KmMig1p	B
6	is	O
7	fully	O
8	functional	O
9	when	O
10	expressed	O
11	in	O
12	S	O
13	.	O
14	cerevisiae	O
15	.	O

1	In	O
2	general	O
3	lookback	O
4	,	O
5	all	O
6	patients	O
7	who	O
8	received	O
9	blood	O
10	before	O
11	being	O
12	tested	O
13	for	O
14	hepatitis	O
15	C	O
16	are	O
17	advised	O
18	to	O
19	undergo	O
20	testing	O
21	.	O

1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	O
7	virulence	O
8	genes	O
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	O
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	O
30	mutants	O
31	.	O

1	Its	O
2	organization	O
3	and	O
4	regulation	O
5	indicate	O
6	that	O
7	the	O
8	S	O
9	.	O
10	pombe	O
11	URA1	B
12	gene	I
13	product	I
14	appears	O
15	very	O
16	similar	O
17	to	O
18	the	O
19	S	O
20	.	O
21	cerevisiae	O
22	URA2	B
23	gene	I
24	product	I
25	.	O

1	Northern	O
2	blot	O
3	and	O
4	in	O
5	situ	O
6	hybridization	O
7	analyses	O
8	revealed	O
9	GPR34	B
10	mRNA	I
11	transcripts	I
12	in	O
13	several	O
14	human	O
15	and	O
16	rat	O
17	brain	O
18	regions	O
19	.	O

1	The	O
2	systolic	O
3	pressure	O
4	gradient	O
5	(	O
6	SPG	O
7	)	O
8	between	O
9	the	O
10	left	O
11	ventricle	O
12	(	O
13	LV	O
14	)	O
15	and	O
16	left	O
17	atrium	O
18	(	O
19	LA	O
20	)	O
21	was	O
22	obtained	O
23	from	O
24	high	O
25	-	O
26	fidelity	O
27	pressure	O
28	transducers	O
29	.	O

1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	I
5	vs	I
6	HHV	I
7	-	I
8	6	I
9	(	O
10	anti	B
11	-	I
12	HHV	I
13	-	I
14	6	I
15	-	I
16	IgG	I
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	IVDA	O
26	(	O
27	29	O
28	seronegative	O
29	and	O
30	71	O
31	seropositive	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	CDC	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O

1	A	O
2	novel	O
3	Drosophila	B
4	A	I
5	kinase	I
6	anchor	I
7	protein	I
8	,	O
9	Drosophila	B
10	A	I
11	kinase	I
12	anchor	I
13	protein	I
14	200	I
15	(	O
16	DAKAP200	O
17	),	O
18	is	O
19	predicted	O
20	to	O
21	be	O
22	involved	O
23	in	O
24	routing	O
25	,	O
26	mediating	O
27	,	O
28	and	O
29	integrating	O
30	signals	O
31	carried	O
32	by	O
33	cAMP	O
34	,	O
35	Ca	O
36	(	O
37	2	O
38	+),	O
39	and	O
40	diacylglycerol	O
41	(	O
42	Li	O
43	,	O
44	Z	O
45	.,	O
46	Rossi	O
47	,	O
48	E	O
49	.	O

1	Since	O
2	myoglobin	B
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	Homozygous	O
2	null	O
3	embryos	O
4	also	O
5	displayed	O
6	abnormalities	O
7	in	O
8	heart	O
9	development	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	conclusion	O
15	that	O
16	Tek	B
17	is	O
18	necessary	O
19	for	O
20	endocardial	O
21	/	O
22	myocardial	O
23	interactions	O
24	during	O
25	development	O
26	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	O
15	-	O
16	and	O
17	RNA	B
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O

1	Eight	O
2	-	O
3	four	O
4	ACOAs	O
5	were	O
6	tested	O
7	in	O
8	order	O
9	to	O
10	examine	O
11	the	O
12	fit	O
13	of	O
14	the	O
15	model	O
16	to	O
17	the	O
18	data	O
19	by	O
20	path	O
21	analysis	O
22	with	O
23	LISREL	B
24	VII	I
25	.	O

1	Vancomycin	O
2	data	O
3	were	O
4	analyzed	O
5	according	O
6	to	O
7	a	O
8	one	O
9	-	O
10	compartment	O
11	open	O
12	model	O
13	with	O
14	use	O
15	of	O
16	NONMEM	O
17	population	O
18	pharmacokinetic	O
19	software	O
20	.	O

1	A	O
2	736	O
3	-	O
4	bp	O
5	sequence	O
6	of	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	adjacent	O
13	to	O
14	the	O
15	cap	O
16	site	O
17	of	O
18	the	O
19	human	B
20	AFP	I
21	gene	I
22	shows	O
23	a	O
24	61	O
25	%	O
26	similarity	O
27	with	O
28	the	O
29	corresponding	O
30	region	O
31	of	O
32	the	O
33	mouse	B
34	AFP	I
35	gene	I
36	.	O

1	M	O
2	-	O
3	Ras	B
4	interacted	O
5	poorly	O
6	in	O
7	a	O
8	yeast	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	with	O
14	multiple	O
15	Ras	B
16	effectors	I
17	,	O
18	including	O
19	c	B
20	-	I
21	Raf	I
22	-	I
23	1	I
24	,	I
25	A	I
26	-	I
27	Raf	I
28	,	O
29	B	B
30	-	I
31	Raf	I
32	,	O
33	phosphoinositol	B
34	-	I
35	3	I
36	kinase	I
37	delta	I
38	,	O
39	RalGDS	B
40	,	O
41	and	O
42	Rin1	B
43	.	O

1	Abrogation	O
2	of	O
3	p53	B
4	function	O
5	by	O
6	E6	B
7	resulted	O
8	in	O
9	an	O
10	increase	O
11	in	O
12	the	O
13	spontaneous	O
14	mutation	O
15	frequencies	O
16	at	O
17	the	O
18	heterozygous	O
19	thymidine	B
20	kinase	I
21	(	O
22	TK	B
23	)	O
24	locus	O
25	but	O
26	not	O
27	at	O
28	the	O
29	hemizygous	O
30	hypoxanthine	O
31	phosphoribosyl	B
32	transferase	I
33	(	O
34	HPRT	B
35	)	I
36	locus	I
37	.	O

1	No	O
2	therapy	O
3	exists	O
4	for	O
5	halting	O
6	the	O
7	progression	O
8	of	O
9	the	O
10	disease	O
11	with	O
12	the	O
13	possible	O
14	exception	O
15	of	O
16	laser	O
17	photocoagulation	O
18	treatment	O
19	used	O
20	to	O
21	ablate	O
22	subretinal	O
23	neovascular	O
24	membranes	O
25	in	O
26	an	O
27	attempt	O
28	to	O
29	avoid	O
30	complications	O
31	of	O
32	subretinal	O
33	hemorrhages	O
34	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	I
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	I
28	C	I
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	O
14	and	O
15	15	O
16	min	O
17	after	O
18	exposure	O
19	to	O
20	NOC	B
21	-	I
22	5	I
23	,	O
24	but	O
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	O
36	controls	O
37	.	O

1	Computer	O
2	assisted	O
3	mapping	O
4	in	O
5	quantitative	O
6	analysis	O
7	of	O
8	cerebral	O
9	positron	O
10	emission	O
11	tomograms	O
12	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O

1	Genetic	O
2	and	O
3	biochemical	O
4	evidence	O
5	suggests	O
6	that	O
7	v	B
8	-	I
9	Crk	I
10	can	O
11	induce	O
12	transformation	O
13	of	O
14	chicken	O
15	embryo	O
16	fibroblasts	O
17	by	O
18	influencing	O
19	the	O
20	activity	O
21	of	O
22	cellular	O
23	proteins	O
24	involved	O
25	in	O
26	growth	O
27	regulation	O
28	.	O

1	Treatment	O
2	of	O
3	recurrent	O
4	FSGS	O
5	has	O
6	included	O
7	high	O
8	-	O
9	dose	O
10	steroids	O
11	,	O
12	high	O
13	-	O
14	dose	O
15	cyclosporine	O
16	(	O
17	CSA	O
18	),	O
19	plasmapheresis	O
20	,	O
21	and	O
22	ACE	B
23	inhibitors	O
24	with	O
25	mixed	O
26	results	O
27	.	O

1	Cell	O
2	viability	O
3	and	O
4	lysosomal	O
5	enzymes	O

1	We	O
2	exploit	O
3	the	O
4	properties	O
5	of	O
6	LexA	B
7	fusion	O
8	proteins	O
9	to	O
10	study	O
11	the	O
12	dimerization	O
13	and	O
14	DNA	O
15	-	O
16	contacting	O
17	domains	O
18	of	O
19	cRel	O
20	.	O

1	Sequence	O
2	analyses	O
3	of	O
4	sos2	B
5	mutant	I
6	alleles	I
7	reveal	O
8	that	O
9	both	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	catalytic	O
15	domain	O
16	and	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	regulatory	O
22	domain	O
23	of	O
24	SOS2	B
25	are	O
26	functionally	O
27	essential	O
28	.	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	O
15	of	O
16	1	O
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	direct	O
6	cDNA	O
7	mapping	O
8	using	O
9	fluorescence	O
10	in	O
11	situ	O
12	hybridization	O
13	provides	O
14	an	O
15	accurate	O
16	and	O
17	rapid	O
18	approach	O
19	to	O
20	the	O
21	definition	O
22	of	O
23	a	O
24	transcribed	O
25	map	O
26	of	O
27	the	O
28	human	O
29	genome	O
30	.	O

1	Using	O
2	anchored	O
3	PCR	O
4	,	O
5	a	O
6	VL	B
7	element	I
8	rearranged	I
9	to	O
10	CL2	B
11	was	O
12	isolated	O
13	.	O

1	Importance	O
2	of	O
3	determining	O
4	the	O
5	blood	O
6	sulfhydryl	O
7	groups	O
8	in	O
9	fractures	O
10	of	O
11	the	O
12	long	O
13	tubular	O
14	bones	O
15	complicated	O
16	by	O
17	infection	O

1	From	O
2	two	O
3	inhibitor	O
4	scaffolds	O
5	,	O
6	we	O
7	have	O
8	identified	O
9	potent	O
10	and	O
11	selective	O
12	inhibitors	O
13	for	O
14	sensitized	O
15	kinases	O
16	from	O
17	five	O
18	distinct	O
19	subfamilies	O
20	.	O

1	The	O
2	physical	O
3	and	O
4	chemical	O
5	stability	O
6	of	O
7	a	O
8	combination	O
9	of	O
10	drugs	O
11	commonly	O
12	administered	O
13	into	O
14	the	O
15	epidural	O
16	or	O
17	intrathecal	O
18	space	O
19	for	O
20	the	O
21	treatment	O
22	of	O
23	chronic	O
24	pain	O
25	was	O
26	investigated	O
27	.	O

1	The	O
2	structural	O
3	gene	O
4	for	O
5	hydrogenase	B
6	encodes	O
7	a	O
8	protein	O
9	product	O
10	of	O
11	molecular	O
12	mass	O
13	45820	O
14	Da	O
15	.	O

1	Schooling	O
2	is	O
3	found	O
4	to	O
5	be	O
6	related	O
7	to	O
8	good	O
9	health	O
10	even	O
11	after	O
12	controlling	O
13	for	O
14	differences	O
15	in	O
16	observable	O
17	health	O
18	inputs	O
19	.	O

1	Psychiatric	O
2	disorders	O
3	in	O
4	children	O
5	and	O
6	adolescents	O
7	carry	O
8	considerable	O
9	morbidity	O
10	,	O
11	impede	O
12	development	O
13	,	O
14	and	O
15	carry	O
16	a	O
17	significant	O
18	mortality	O
19	by	O
20	suicide	O
21	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	B
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	B
19	.	O

1	The	O
2	same	O
3	ligands	O
4	also	O
5	exhibit	O
6	a	O
7	similar	O
8	inhibitory	O
9	effect	O
10	on	O
11	PDGF	B
12	-	I
13	BB	I
14	-	O
15	dependent	O
16	[	O
17	3H	O
18	]	O
19	thymidine	O
20	incorporation	O
21	in	O
22	PAE	O
23	cells	O
24	expressing	O
25	the	O
26	PDGF	B
27	beta	I
28	-	I
29	receptors	I
30	.	O

1	The	O
2	active	O
3	derivatives	O
4	of	O
5	the	O
6	present	O
7	series	O
8	were	O
9	also	O
10	tested	O
11	for	O
12	their	O
13	analgesic	O
14	activity	O
15	against	O
16	aconitine	O
17	-	O
18	induced	O
19	writhing	O
20	in	O
21	albino	O
22	mice	O
23	and	O
24	ulcerogenic	O
25	activity	O
26	in	O
27	albino	O
28	rats	O
29	.	O

1	Despite	O
2	the	O
3	existence	O
4	of	O
5	30	O
6	cysteine	O
7	residues	O
8	,	O
9	carboxymethylation	O
10	prevented	O
11	the	O
12	formation	O
13	of	O
14	most	O
15	if	O
16	not	O
17	all	O
18	disulfide	O
19	bonds	O
20	that	O
21	otherwise	O
22	occurred	O
23	when	O
24	the	O
25	cells	O
26	were	O
27	sonicated	O
28	.	O

1	The	O
2	ATR	O
3	-	O
4	X	O
5	syndrome	O
6	results	O
7	from	O
8	mutations	O
9	of	O
10	the	O
11	XH2	B
12	gene	I
13	,	O
14	located	O
15	on	O
16	the	O
17	X	O
18	chromosome	O
19	(	O
20	Xq13	O
21	.	O
22	3	O
23	)	O
24	and	O
25	coding	O
26	for	O
27	a	O
28	transacting	O
29	factor	O
30	which	O
31	regulates	O
32	gene	O
33	expression	O
34	.	O

1	We	O
2	have	O
3	tested	O
4	the	O
5	function	O
6	of	O
7	two	O
8	potential	O
9	NF	B
10	-	I
11	kappaB	I
12	-	I
13	like	I
14	sites	I
15	present	O
16	in	O
17	the	O
18	PAI	B
19	-	I
20	2	I
21	proximal	I
22	promoter	I
23	for	O
24	responsiveness	O
25	to	O
26	TNFalpha	B
27	using	I
28	chloramphenicol	I
29	acetyl	I
30	transferase	I
31	reporter	I
32	gene	I
33	deletion	I
34	and	O
35	mutation	O
36	analyses	O
37	.	O

1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	B
16	operons	I
17	.	O

1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	O
37	deoxynucleotidyltransferase	O
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O

1	Internal	O
2	biliary	O
3	drainage	O
4	,	O
5	unlike	O
6	external	O
7	drainage	O
8	,	O
9	does	O
10	not	O
11	suppress	O
12	the	O
13	regeneration	O
14	of	O
15	cholestatic	O
16	rat	O
17	liver	O
18	after	O
19	partial	O
20	hepatectomy	O
21	.	O

1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O

1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	B
7	toxin	I
8	deactivates	O
9	CC	O
10	chemokine	O
11	receptor	O
12	5	O
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	tropic	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O

1	The	O
2	coding	O
3	sequence	O
4	for	O
5	a	O
6	260	O
7	-	O
8	amino	O
9	-	O
10	acid	O
11	residue	O
12	polypeptide	O
13	was	O
14	interrupted	O
15	by	O
16	a	O
17	single	O
18	short	O
19	intron	O
20	of	O
21	60	O
22	base	O
23	pairs	O
24	(	O
25	bp	O
26	),	O
27	and	O
28	about	O
29	70	O
30	%	O
31	of	O
32	the	O
33	deduced	O
34	amino	O
35	acid	O
36	sequence	O
37	of	O
38	the	O
39	Drosophila	O
40	PCNA	B
41	was	O
42	identical	O
43	to	O
44	the	O
45	rat	O
46	and	O
47	human	O
48	PCNA	B
49	polypeptides	I
50	,	O
51	with	O
52	conserved	O
53	unique	O
54	repeats	O
55	of	O
56	leucine	O
57	in	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	region	O
63	.	O

1	Human	B
2	LAF	I
3	-	I
4	4	I
5	readily	O
6	hybridized	O
7	with	O
8	genes	O
9	in	O
10	mouse	O
11	and	O
12	chicken	O
13	,	O
14	thus	O
15	showing	O
16	that	O
17	this	O
18	gene	O
19	family	O
20	has	O
21	been	O
22	highly	O
23	conserved	O
24	during	O
25	vertebrate	O
26	evolution	O
27	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	collagen	B
7	binding	O
8	has	O
9	not	O
10	been	O
11	shown	O
12	.	O

1	HL	O
2	-	O
3	A	O
4	antibodies	O
5	in	O
6	polytransfused	O
7	patients	O

1	Sucrose	O
2	-	O
3	specific	O
4	regulation	O
5	of	O
6	scrB	B
7	was	O
8	also	O
9	lost	O
10	upon	O
11	deletion	O
12	of	O
13	4	O
14	bp	O
15	of	O
16	a	O
17	palindromic	O
18	sequence	O
19	(	O
20	OB	O
21	)	O
22	covering	O
23	positions	O
24	+	O
25	6	O
26	to	O
27	+	O
28	21	O
29	downstream	O
30	of	O
31	the	O
32	scrB	B
33	transcriptional	O
34	start	O
35	site	O
36	.	O

1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	B
15	/	O
16	abl	B
17	gene	I
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	O
25	/	O
26	abl	B
27	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	cortical	O
7	end	O
8	of	O
9	the	O
10	auditory	O
11	analyzer	O
12	during	O
13	postnatal	O
14	ontogenesis	O
15	in	O
16	lower	O
17	monkeys	O
18	and	O
19	man	O

1	These	O
2	data	O
3	strongly	O
4	implicate	O
5	the	O
6	normal	O
7	product	O
8	of	O
9	the	O
10	int	B
11	-	I
12	2	I
13	gene	I
14	,	O
15	which	O
16	is	O
17	related	O
18	to	O
19	the	O
20	fibroblast	B
21	growth	I
22	factor	I
23	family	I
24	,	O
25	as	O
26	a	O
27	contributory	O
28	factor	O
29	in	O
30	virally	O
31	induced	O
32	mammary	O
33	tumors	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	O
12	-	O
13	bp	O
14	BAL	O
15	cDNA	O
16	structure	O
17	.	O

1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O

1	Data	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	semi	O
7	-	O
8	automatic	O
9	computer	O
10	program	O
11	which	O
12	develops	O
13	an	O
14	averaged	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O

1	To	O
2	determine	O
3	the	O
4	function	O
5	of	O
6	VZV	B
7	gK	I
8	in	O
9	virus	O
10	growth	O
11	,	O
12	a	O
13	series	O
14	of	O
15	gK	B
16	deletion	I
17	mutants	I
18	were	O
19	constructed	O
20	with	O
21	VZV	O
22	cosmid	O
23	DNA	O
24	derived	O
25	from	O
26	the	O
27	Oka	O
28	strain	O
29	.	O

1	Among	O
2	six	O
3	different	O
4	library	O
5	isolates	O
6	containing	O
7	6	O
8	.	O
9	5	O
10	-	O
11	to	O
12	7	O
13	-	O
14	kb	O
15	IAP	O
16	units	O
17	,	O
18	some	O
19	restriction	O
20	sites	O
21	were	O
22	highly	O
23	conserved	O
24	whereas	O
25	others	O
26	varied	O
27	in	O
28	both	O
29	occurrence	O
30	and	O
31	position	O
32	.	O

1	Because	O
2	of	O
3	the	O
4	increased	O
5	CPK	B
6	activity	O
7	found	O
8	in	O
9	normal	O
10	newborns	O
11	,	O
12	screening	O
13	for	O
14	Duchenne	O
15	-	O
16	type	O
17	muscular	O
18	dystrophy	O
19	should	O
20	be	O
21	postponed	O
22	for	O
23	a	O
24	few	O
25	weeks	O
26	after	O
27	delivery	O
28	.	O

1	Cystatin	B
2	A	I
3	,	O
4	a	O
5	cysteine	B
6	proteinase	I
7	inhibitor	O
8	,	O
9	is	O
10	one	O
11	of	O
12	the	O
13	precursor	O
14	proteins	O
15	of	O
16	cornified	O
17	cell	O
18	envelope	O
19	of	O
20	keratinocytes	O
21	and	O
22	is	O
23	expressed	O
24	during	O
25	the	O
26	late	O
27	stage	O
28	of	O
29	keratinocyte	O
30	differentiation	O
31	.	O

1	Mechanism	O
2	of	O
3	enhancement	O
4	of	O
5	DNA	O
6	expression	O
7	consequent	O
8	to	O
9	cointernalization	O
10	of	O
11	a	O
12	replication	O
13	-	O
14	deficient	O
15	adenovirus	O
16	and	O
17	unmodified	O
18	plasmid	O
19	DNA	O
20	.	O

1	Although	O
2	antisperm	O
3	antibodies	O
4	are	O
5	associated	O
6	with	O
7	infertility	O
8	,	O
9	many	O
10	hospital	O
11	laboratories	O
12	do	O
13	not	O
14	test	O
15	for	O
16	these	O
17	antibodies	O
18	.	O

1	Thus	O
2	,	O
3	hGRbeta	B
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	B
13	activity	O
14	.	O

1	The	O
2	RAP74	O
3	subunit	O
4	of	O
5	TFIIF	B
6	alone	O
7	contained	O
8	the	O
9	stimulatory	O
10	activity	O
11	and	O
12	the	O
13	minimal	O
14	region	O
15	sufficient	O
16	for	O
17	stimulation	O
18	corresponds	O
19	to	O
20	COOH	O
21	-	O
22	terminal	O
23	residues	O
24	358	O
25	-	O
26	517	O
27	.	O

1	Here	O
2	the	O
3	conventional	O
4	tests	O
5	clearly	O
6	pointed	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	retrocochlear	O
12	disease	O
13	.	O

1	How	O
2	does	O
3	a	O
4	nurse	O
5	go	O
6	about	O
7	maintaining	O
8	her	O
9	level	O
10	of	O
11	competence	O
12	when	O
13	she	O
14	is	O
15	one	O
16	of	O
17	the	O
18	few	O
19	local	O
20	practitioners	O
21	in	O
22	her	O
23	field	O
24	?	O
25	Vancouver	O
26	sex	O
27	therapist	O
28	Bianca	O
29	Rucker	O
30	is	O
31	doing	O
32	it	O
33	by	O
34	cultivating	O
35	a	O
36	network	O
37	of	O
38	colleagues	O
39	and	O
40	mentors	O
41	in	O
42	related	O
43	fields	O
44	both	O
45	at	O
46	home	O
47	and	O
48	across	O
49	the	O
50	continent	O
51	.	O

1	The	O
2	greatest	O
3	difference	O
4	between	O
5	the	O
6	Ad7	O
7	and	O
8	Ad5	B
9	DBPs	I
10	is	O
11	the	O
12	absence	O
13	,	O
14	in	O
15	the	O
16	Ad7	B
17	protein	I
18	,	O
19	of	O
20	12	O
21	amino	O
22	acids	O
23	located	O
24	between	O
25	the	O
26	two	O
27	functional	O
28	domains	O
29	in	O
30	the	O
31	Ad5	B
32	protein	I
33	(	O
34	amino	O
35	acids	O
36	151	O
37	-	O
38	162	O
39	).	O

1	In	O
2	contrast	O
3	,	O
4	transiently	O
5	transfected	O
6	cells	O
7	expressing	O
8	EBNA	B
9	-	I
10	3	I
11	revealed	O
12	a	O
13	sixfold	O
14	increase	O
15	in	O
16	EBNA	B
17	-	I
18	3	I
19	protein	I
20	expression	O
21	from	O
22	the	O
23	genomic	O
24	EBNA	B
25	-	I
26	3	I
27	gene	I
28	compared	O
29	to	O
30	EBNA	B
31	-	I
32	3	I
33	cDNA	I
34	.	O

1	Heterogeneity	O
2	of	O
3	human	B
4	serum	I
5	albumin	I
6	.	O

1	Chordoma	O
2	of	O
3	the	O
4	spinal	O
5	cord	O
6	in	O
7	a	O
8	F344	O
9	rat	O
10	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	and	O
5	genomic	O
6	sequences	O
7	shows	O
8	that	O
9	the	O
10	ZNF189	B
11	gene	I
12	spans	I
13	approximately	I
14	11	I
15	kb	I
16	and	O
17	is	O
18	organized	O
19	into	O
20	at	O
21	least	O
22	four	O
23	exons	O
24	,	O
25	the	O
26	large	O
27	3	O
28	'-	O
29	end	O
30	exon	O
31	coding	O
32	for	O
33	the	O
34	complete	O
35	zinc	O
36	finger	O
37	domain	O
38	and	O
39	the	O
40	3	O
41	'	O
42	untranslated	O
43	region	O
44	.	O

1	The	O
2	apparent	O
3	Kd	O
4	of	O
5	the	O
6	MetRS	B
7	/	O
8	CAU	B
9	operator	I
10	complex	I
11	is	O
12	one	O
13	order	O
14	magnitude	O
15	higher	O
16	than	O
17	that	O
18	of	O
19	the	O
20	ThrRS	B
21	/	O
22	CGU	B
23	operator	I
24	complex	I
25	.	O

1	Improved	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	breeding	O
10	the	O
11	neotropical	O
12	short	O
13	-	O
14	tailed	O
15	fruit	O
16	bat	O
17	,	O
18	Carollia	O
19	perspicillata	O
20	,	O
21	in	O
22	an	O
23	easily	O
24	-	O
25	reproduced	O
26	,	O
27	laboratory	O
28	setting	O
29	.	O

1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	A	O
2	cluster	O
3	of	O
4	basic	O
5	amino	O
6	acids	O
7	,	O
8	KKKR	B
9	,	O
10	generated	O
11	by	O
12	joining	O
13	of	O
14	the	O
15	sequences	O
16	encoded	O
17	by	O
18	the	O
19	constitutive	O
20	exon	O
21	13	O
22	and	O
23	the	O
24	alternative	O
25	exon	O
26	16	O
27	,	O
28	is	O
29	necessary	O
30	for	O
31	the	O
32	nuclear	O
33	targeting	O
34	of	O
35	4	O
36	.	O
37	1H	O
38	,	O
39	as	O
40	demonstrated	O
41	by	O
42	site	O
43	-	O
44	directed	O
45	mutagenesis	O
46	analysis	O
47	.	O

1	Human	B
2	bcl3	I
3	protein	I
4	specifically	O
5	displaces	O
6	(	O
7	p50	B
8	)	O
9	2	O
10	-	O
11	DNA	O
12	complexes	O
13	.	O

1	UDP	B
2	-	I
3	Gal	I
4	:	I
5	Gal	I
6	beta	I
7	1	I
8	----	I
9	4GlcNAc	I
10	alpha	I
11	1	I
12	----	I
13	3	I
14	-	I
15	galactosyltransferase	I
16	is	O
17	a	O
18	terminal	O
19	glycosyltransferase	O
20	that	O
21	is	O
22	widely	O
23	expressed	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	mammalian	O
29	species	O
30	,	O
31	with	O
32	the	O
33	notable	O
34	exception	O
35	of	O
36	man	O
37	,	O
38	apes	O
39	,	O
40	and	O
41	Old	O
42	World	O
43	monkeys	O
44	.	O

1	Large	O
2	ones	O
3	were	O
4	similar	O
5	in	O
6	size	O
7	to	O
8	the	O
9	main	O
10	lobe	O
11	and	O
12	small	O
13	ones	O
14	were	O
15	approximately	O
16	1	O
17	/	O
18	4	O
19	of	O
20	the	O
21	length	O
22	of	O
23	the	O
24	main	O
25	lobe	O
26	.	O

1	During	O
2	sub	O
3	-	O
4	maximal	O
5	exercise	O
6	,	O
7	DCR	O
8	in	O
9	the	O
10	UT	O
11	dogs	O
12	decreased	O
13	from	O
14	a	O
15	resting	O
16	value	O
17	of	O
18	4	O
19	.	O
20	08	O
21	+/-	O
22	0	O
23	.	O
24	18	O
25	mm	O
26	Hg	O
27	X	O
28	ml	O
29	-	O
30	1	O
31	X	O
32	min	O
33	-	O
34	1	O
35	to	O
36	1	O
37	.	O
38	91	O
39	+/-	O
40	0	O
41	.	O
42	17	O
43	mm	O
44	Hg	O
45	X	O
46	ml	O
47	-	O
48	1	O
49	X	O
50	min	O
51	-	O
52	1	O
53	at	O
54	a	O
55	workload	O
56	of	O
57	6	O
58	.	O
59	4	O
60	kph	O
61	(	O
62	speed	O
63	)/	O
64	16	O
65	%	O
66	(	O
67	grade	O
68	).	O

1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	disodium	O
8	cromoglycate	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	bronchospasm	O
17	:	O
18	a	O
19	double	O
20	-	O
21	blind	O
22	study	O
23	.	O

1	We	O
2	linked	O
3	a	O
4	4	O
5	.	O
6	1	O
7	-	O
8	kilobase	O
9	pair	O
10	HindIII	B
11	DNA	O
12	fragment	O
13	from	O
14	the	O
15	region	O
16	upstream	O
17	of	O
18	the	O
19	human	B
20	AP	I
21	endonuclease	I
22	gene	I
23	(	O
24	APE	O
25	)	O
26	to	O
27	the	O
28	chloramphenicol	B
29	acetyltransferase	I
30	(	O
31	CAT	B
32	)	O
33	gene	O
34	.	O

1	Vascular	O
2	responses	O
3	to	O
4	reactive	O
5	hyperemia	O
6	(	O
7	with	O
8	flow	O
9	increase	O
10	leading	O
11	to	O
12	endothelium	O
13	-	O
14	dependent	O
15	dilation	O
16	)	O
17	and	O
18	to	O
19	sublingual	O
20	glyceryl	O
21	trinitrate	O
22	(	O
23	GTN	O
24	;	O
25	endothelium	O
26	-	O
27	independent	O
28	dilation	O
29	)	O
30	were	O
31	recorded	O
32	.	O

1	The	O
2	selenium	O
3	level	O
4	and	O
5	glutathione	B
6	peroxidase	I
7	activity	O
8	in	O
9	the	O
10	blood	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	stomach	O
16	mucosa	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	high	O
23	-	O
24	selenium	O
25	diet	O
26	group	O
27	than	O
28	in	O
29	the	O
30	low	O
31	-	O
32	selenium	O
33	diet	O
34	group	O
35	.	O

1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	156	O
7	women	O
8	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	B
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	Nine	O
2	new	O
3	naphthalene	O
4	related	O
5	compounds	O
6	(	O
7	I	O
8	,	O
9	IV	O
10	,	O
11	V	O
12	,	O
13	VII	B
14	-	I
15	XII	I
16	)	O
17	together	O
18	with	O
19	four	O
20	known	O
21	compounds	O
22	(	O
23	II	O
24	,	O
25	III	O
26	,	O
27	VI	O
28	,	O
29	XIII	B
30	)	O
31	were	O
32	isolated	O
33	from	O
34	the	O
35	root	O
36	bark	O
37	of	O
38	Oroxylum	O
39	indicum	O
40	Vent	O
41	.	O

1	It	O
2	bound	O
3	to	O
4	vitamin	B
5	D	I
6	receptor	I
7	(	O
8	VDR	B
9	)	O
10	but	O
11	not	O
12	retinoic	B
13	acid	I
14	Xalpha	I
15	receptor	I
16	(	O
17	RXRalpha	B
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O

1	The	O
2	PC2	B
3	protein	I
4	also	O
5	shows	O
6	great	O
7	similarity	O
8	to	O
9	the	O
10	incomplete	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	of	O
16	the	O
17	human	B
18	furin	I
19	gene	I
20	product	I
21	,	O
22	a	O
23	putative	O
24	membrane	O
25	-	O
26	inserted	O
27	receptor	O
28	-	O
29	like	O
30	molecule	O
31	.	O

1	Hemodynamic	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	digoxin	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	cis	O
7	-	O
8	regulatory	O
9	elements	O
10	required	O
11	for	O
12	developmental	O
13	control	O
14	of	O
15	the	O
16	HaG3	B
17	-	I
18	A	I
19	helianthinin	I
20	gene	I
21	are	O
22	located	O
23	in	O
24	a	O
25	2	O
26	.	O
27	4	O
28	kb	O
29	upstream	O
30	region	O
31	of	O
32	this	O
33	gene	O
34	.	O

1	CONCLUSION	O
2	:	O
3	We	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	features	O
9	of	O
10	disease	O
11	likely	O
12	to	O
13	be	O
14	associated	O
15	with	O
16	a	O
17	clinically	O
18	useful	O
19	response	O
20	to	O
21	inhaled	O
22	NO	O
23	therapy	O
24	using	O
25	the	O
26	parameters	O
27	studied	O
28	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	B
10	RNA	I
11	,	O
12	Lyp2	O
13	.	O

1	Ischaemia	O
2	was	O
3	induced	O
4	by	O
5	a	O
6	low	O
7	flow	O
8	rate	O
9	of	O
10	0	O
11	.	O
12	8	O
13	mL	O
14	min	O
15	-	O
16	1	O
17	for	O
18	30	O
19	min	O
20	,	O
21	and	O
22	was	O
23	followed	O
24	by	O
25	a	O
26	40	O
27	-	O
28	minute	O
29	reperfusion	O
30	.	O

1	Carnitine	B
2	palmitoyltransferase	I
3	(	I
4	CPT	I
5	)	I
6	II	I
7	deficiency	O
8	is	O
9	the	O
10	most	O
11	common	O
12	inherited	O
13	disorder	O
14	of	O
15	lipid	O
16	metabolism	O
17	affecting	O
18	skeletal	O
19	muscle	O
20	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	[	O
6	Hisanaga	O
7	,	O
8	S	O
9	.,	O
10	Kusubata	O
11	,	O
12	M	O
13	.,	O
14	Okumura	O
15	,	O
16	E	O
17	.	O
18	&	O
19	Kishimoto	O
20	,	O
21	T	O
22	.	O

1	No	O
2	causal	O
3	relations	O
4	may	O
5	be	O
6	inferred	O
7	from	O
8	the	O
9	correlation	O
10	between	O
11	the	O
12	level	O
13	of	O
14	trapezius	O
15	activity	O
16	and	O
17	complaints	O
18	,	O
19	though	O
20	it	O
21	indicates	O
22	that	O
23	individual	O
24	,	O
25	inexpedient	O
26	muscle	O
27	activity	O
28	patterns	O
29	may	O
30	constitute	O
31	an	O
32	important	O
33	risk	O
34	factor	O
35	for	O
36	development	O
37	of	O
38	musculo	O
39	-	O
40	skeletal	O
41	complaints	O
42	.	O

1	A	O
2	complementary	O
3	DNA	O
4	was	O
5	isolated	O
6	from	O
7	Caenorhabditis	O
8	elegans	O
9	that	O
10	encoded	O
11	a	O
12	polypeptide	O
13	of	O
14	1438	O
15	amino	O
16	acid	O
17	residues	O
18	,	O
19	CeGAP	B
20	,	O
21	which	O
22	contains	O
23	a	O
24	domain	O
25	with	O
26	sequence	O
27	similarity	O
28	to	O
29	the	O
30	COOH	O
31	-	O
32	terminal	O
33	segment	O
34	(	O
35	GTPase	B
36	-	I
37	activating	I
38	protein	I
39	region	I
40	)	O
41	of	O
42	Bcr	B
43	and	O
44	other	O
45	known	O
46	GTPase	B
47	-	I
48	activating	I
49	proteins	I
50	of	O
51	the	O
52	Rho	B
53	subfamily	I
54	.	O

1	After	O
2	surgery	O
3	,	O
4	patients	O
5	self	O
6	administered	O
7	one	O
8	of	O
9	three	O
10	possible	O
11	postsurgical	O
12	medications	O
13	,	O
14	which	O
15	included	O
16	placebo	O
17	,	O
18	codeine	O
19	60	O
20	mg	O
21	,	O
22	and	O
23	ibuprofen	O
24	400	O
25	mg	O
26	,	O
27	when	O
28	their	O
29	pain	O
30	reached	O
31	a	O
32	moderate	O
33	or	O
34	severe	O
35	intensity	O
36	.	O

1	Methoxyflurane	O
2	and	O
3	renal	O
4	function	O

1	A	O
2	larger	O
3	region	O
4	upstream	O
5	of	O
6	human	O
7	CMV	O
8	dbp	O
9	also	O
10	mediated	O
11	replication	O
12	in	O
13	transient	O
14	assays	O
15	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	Intravenous	O
2	antibiotic	O
3	therapy	O
4	in	O
5	cystic	O
6	fibrosis	O
7	:	O
8	in	O
9	hospital	O
10	or	O
11	at	O
12	home	O
13	?	O

1	Complexes	O
2	of	O
3	qTBP42	O
4	with	O
5	each	O
6	complementary	O
7	strand	O
8	of	O
9	telomeric	O
10	DNA	O
11	and	O
12	with	O
13	quadruplex	O
14	forms	O
15	of	O
16	the	O
17	guanine	O
18	-	O
19	rich	O
20	strand	O
21	had	O
22	3	O
23	.	O
24	7	O
25	-	O
26	14	O
27	.	O
28	6	O
29	nM	O
30	dissociation	O
31	constants	O
32	,	O
33	Kd	O
34	,	O
35	whereas	O
36	complexes	O
37	with	O
38	double	O
39	-	O
40	stranded	O
41	telomeric	O
42	DNA	O
43	had	O
44	up	O
45	to	O
46	100	O
47	-	O
48	fold	O
49	higher	O
50	Kd	O
51	values	O
52	.	O

1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	O
13	(	O
14	Zea	O
15	mays	O
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O

1	In	O
2	a	O
3	randomized	O
4	study	O
5	on	O
6	150	O
7	patients	O
8	(	O
9	ASA	B
10	1	I
11	)	O
12	undergoing	O
13	induction	O
14	of	O
15	anaesthesia	O
16	,	O
17	the	O
18	effects	O
19	of	O
20	Fentanyl	O
21	(	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	),	O
27	the	O
28	combination	O
29	of	O
30	Fentanyl	O
31	(	O
32	0	O
33	.	O
34	1	O
35	mg	O
36	)	O
37	and	O
38	Droperidol	O
39	(	O
40	5	O
41	mg	O
42	)	O
43	(	O
44	Innovar	O
45	,	O
46	Thalamonal	O
47	)	O
48	and	O
49	Atropine	O
50	(	O
51	0	O
52	.	O
53	01	O
54	mg	O
55	/	O
56	kg	O
57	b	O
58	.	O
59	w	O
60	.)	O
61	alone	O
62	on	O
63	cardiocirculatory	O
64	parameters	O
65	were	O
66	studied	O
67	.	O

1	As	O
2	PP2A	B
3	exerts	O
4	a	O
5	range	O
6	of	O
7	cellular	O
8	functions	O
9	including	O
10	cell	O
11	cycle	O
12	regulation	O
13	and	O
14	cell	O
15	fate	O
16	determination	O
17	,	O
18	we	O
19	were	O
20	surprised	O
21	to	O
22	find	O
23	that	O
24	these	O
25	embryos	O
26	develop	O
27	normally	O
28	until	O
29	postimplantation	O
30	,	O
31	around	O
32	embryonic	O
33	day	O
34	5	O
35	.	O
36	5	O
37	/	O
38	6	O
39	.	O
40	0	O
41	.	O

1	While	O
2	these	O
3	findings	O
4	may	O
5	reflect	O
6	the	O
7	sensitivity	O
8	of	O
9	a	O
10	thick	O
11	myocardial	O
12	wall	O
13	to	O
14	ischaemia	O
15	during	O
16	surgery	O
17	,	O
18	the	O
19	postoperative	O
20	recovery	O
21	was	O
22	not	O
23	related	O
24	to	O
25	the	O
26	serum	O
27	CK	B
28	-	I
29	MB	I
30	level	O
31	.	O

1	Deletion	O
2	of	O
3	the	O
4	last	O
5	two	O
6	Ser	O
7	residues	O
8	,	O
9	including	O
10	one	O
11	PKC	B
12	consensus	I
13	site	I
14	in	O
15	the	O
16	receptor	O
17	tail	O
18	,	O
19	prevented	O
20	only	O
21	phorbol	O
22	12	O
23	-	O
24	myristate	O
25	13	O
26	-	O
27	acetate	O
28	-	O
29	induced	O
30	desensitization	O
31	by	O
32	30	O
33	%.	O

1	In	O
2	a	O
3	randomised	O
4	double	O
5	-	O
6	blind	O
7	study	O
8	,	O
9	46	O
10	first	O
11	episode	O
12	schizophrenics	O
13	were	O
14	given	O
15	pimozide	O
16	or	O
17	flupenthixol	O
18	for	O
19	up	O
20	to	O
21	5	O
22	weeks	O
23	;	O
24	the	O
25	mean	O
26	daily	O
27	dose	O
28	at	O
29	the	O
30	end	O
31	was	O
32	18	O
33	.	O
34	8	O
35	mg	O
36	pimozide	O
37	and	O
38	20	O
39	mg	O
40	flupenthixol	O
41	.	O

1	In	O
2	treated	O
3	herds	O
4	,	O
5	cows	O
6	more	O
7	than	O
8	40	O
9	d	O
10	postpartum	O
11	with	O
12	a	O
13	corpus	O
14	luteum	O
15	received	O
16	prostaglandin	O
17	F2	O
18	alpha	O
19	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	similar	O
6	fragment	O
7	lacking	O
8	the	O
9	38	O
10	-	O
11	base	O
12	-	O
13	pair	O
14	region	O
15	had	O
16	no	O
17	such	O
18	stabilizing	O
19	effect	O
20	.	O

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	B
11	oxidase	I
12	inhibitors	O
13	.	O

1	Losartan	O
2	Intervention	O
3	For	O
4	Endpoint	O
5	.	O

1	Insulin	B
2	-	O
3	regulated	O
4	events	O
5	,	O
6	however	O
7	,	O
8	occur	O
9	in	O
10	all	O
11	cells	O
12	.	O

1	ACTH	B
2	release	O
3	is	O
4	transiently	O
5	suppressed	O
6	in	O
7	some	O
8	children	O
9	after	O
10	exogenous	O
11	ACTH	B
12	treatment	O
13	.	O

1	73	O
2	:	O
3	658	O
4	-	O
5	666	O
6	,	O
7	1999	O
8	).	O

1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O

1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	B
8	-	I
9	BP1	I
10	and	O
11	AT	O
12	-	O
13	BP2	B
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O

1	Detailed	O
2	molecular	O
3	organization	O
4	of	O
5	the	O
6	coding	O
7	and	O
8	upstream	O
9	regulatory	O
10	regions	O
11	of	O
12	the	O
13	murine	B
14	homeodomain	I
15	-	I
16	containing	I
17	gene	I
18	,	O
19	Msx	B
20	-	I
21	1	I
22	,	O
23	is	O
24	reported	O
25	.	O

1	The	O
2	nucleosomal	O
3	response	O
4	associated	O
5	with	O
6	immediate	B
7	-	I
8	early	I
9	gene	I
10	induction	O
11	is	O
12	mediated	O
13	via	O
14	alternative	O
15	MAP	B
16	kinase	I
17	cascades	O
18	:	O
19	MSK1	O
20	as	O
21	a	O
22	potential	O
23	histone	B
24	H3	I
25	/	O
26	HMG	B
27	-	I
28	14	I
29	kinase	I
30	.	O

1	Elimination	O
2	of	O
3	the	O
4	inducible	O
5	response	O
6	requires	O
7	simultaneous	O
8	mutation	O
9	of	O
10	both	O
11	sequences	O
12	,	O
13	however	O
14	,	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	an	O
20	intact	O
21	EpRE	O
22	the	O
23	upstream	O
24	AP	B
25	-	I
26	1	I
27	site	I
28	is	O
29	irrelevant	O
30	to	O
31	induction	O
32	.	O

1	E1	O
2	,	O
3	a	O
4	DNA	B
5	helicase	I
6	,	O
7	collaborates	O
8	with	O
9	the	O
10	HPV	B
11	E2	I
12	protein	I
13	in	O
14	ori	O
15	-	O
16	dependent	O
17	replication	O
18	.	O

1	The	O
2	Lp	B
3	mouse	I
4	mutant	I
5	provides	O
6	a	O
7	model	O
8	for	O
9	the	O
10	severe	O
11	human	O
12	neural	O
13	tube	O
14	defect	O
15	(	O
16	NTD	O
17	),	O
18	cranio	O
19	-	O
20	rachischisis	O
21	.	O

1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O

1	The	O
2	genome	O
3	organization	O
4	of	O
5	the	O
6	mite	O
7	-	O
8	transmitted	O
9	wheat	O
10	streak	O
11	mosaic	O
12	virus	O
13	(	O
14	WSMV	O
15	)	O
16	appears	O
17	to	O
18	parallel	O
19	that	O
20	of	O
21	members	O
22	of	O
23	the	O
24	Potyviridae	O
25	with	O
26	monopartite	O
27	genomes	O
28	,	O
29	but	O
30	there	O
31	are	O
32	substantial	O
33	amino	O
34	acid	O
35	dissimilarities	O
36	with	O
37	other	O
38	potyviral	O
39	polyproteins	O
40	.	O

1	SRC	B
2	-	I
3	1	I
4	can	O
5	relieve	O
6	the	O
7	NF	B
8	-	I
9	kappaB	I
10	-	O
11	mediated	O
12	repression	O
13	of	O
14	GR	B
15	activity	O
16	.	O

1	Unlike	O
2	the	O
3	typical	O
4	enhancer	O
5	element	O
6	,	O
7	this	O
8	region	O
9	functions	O
10	in	O
11	an	O
12	orientation	O
13	-	O
14	dependent	O
15	manner	O
16	.	O

1	Glutamyl	B
2	-	I
3	tRNA	I
4	synthetase	I
5	and	O
6	prolyl	B
7	-	I
8	tRNA	I
9	synthetase	I
10	belong	O
11	to	O
12	different	O
13	classes	O
14	of	O
15	aminoacyl	B
16	-	I
17	tRNA	I
18	synthetases	I
19	that	O
20	are	O
21	thought	O
22	to	O
23	have	O
24	evolved	O
25	along	O
26	independent	O
27	evolutionary	O
28	pathways	O
29	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	transcription	O
6	factor	O
7	CREB	B
8	is	O
9	regulated	O
10	by	O
11	extracellular	O
12	stimuli	O
13	that	O
14	result	O
15	in	O
16	its	O
17	phosphorylation	O
18	at	O
19	a	O
20	critical	O
21	serine	O
22	residue	O
23	,	O
24	Ser133	O
25	.	O

1	Serum	B
2	response	I
3	factor	I
4	(	O
5	SRF	B
6	),	O
7	a	O
8	member	O
9	of	O
10	an	O
11	ancient	O
12	family	O
13	of	O
14	DNA	O
15	-	O
16	binding	O
17	proteins	O
18	,	O
19	is	O
20	generally	O
21	assumed	O
22	to	O
23	be	O
24	a	O
25	ubiquitous	O
26	transcription	O
27	factor	O
28	involved	O
29	in	O
30	regulating	O
31	growth	B
32	factor	I
33	-	I
34	responsive	I
35	genes	I
36	.	O

1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	B
22	homolog	I
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	B
37	enhancer	I
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O

1	However	O
2	,	O
3	conversions	O
4	of	O
5	12	O
6	mm	O
7	or	O
8	more	O
9	from	O
10	a	O
11	documented	O
12	negative	O
13	result	O
14	indicated	O
15	spread	O
16	of	O
17	infection	O
18	.	O

1	This	O
2	study	O
3	evaluates	O
4	the	O
5	feasibility	O
6	of	O
7	indirect	O
8	mesenteric	O
9	lymphangiography	O
10	as	O
11	a	O
12	colonoscopic	O
13	technique	O
14	in	O
15	a	O
16	canine	O
17	model	O
18	.	O

1	Serum	B
2	insulin	I
3	-	I
4	like	I
5	growth	I
6	factor	I
7	I	I
8	(	O
9	IGF	B
10	-	I
11	I	I
12	)	O
13	SD	O
14	score	O
15	increased	O
16	from	O
17	-	O
18	2	O
19	.	O
20	2	O
21	and	O
22	-	O
23	4	O
24	.	O
25	2	O
26	in	O
27	men	O
28	and	O
29	women	O
30	,	O
31	respectively	O
32	,	O
33	to	O
34	1	O
35	.	O
36	8	O
37	and	O
38	-	O
39	0	O
40	.	O
41	9	O
42	at	O
43	6	O
44	months	O
45	and	O
46	0	O
47	.	O
48	8	O
49	and	O
50	-	O
51	0	O
52	.	O
53	7	O
54	at	O
55	12	O
56	months	O
57	.	O

1	In	O
2	conclusion	O
3	,	O
4	the	O
5	disposition	O
6	of	O
7	venlafaxine	O
8	and	O
9	O	O
10	-	O
11	desmethylvenlafaxine	O
12	is	O
13	markedly	O
14	altered	O
15	in	O
16	renal	O
17	disease	O
18	;	O
19	therefore	O
20	dosage	O
21	adjustment	O
22	is	O
23	warranted	O
24	for	O
25	patients	O
26	with	O
27	creatinine	O
28	clearance	O
29	values	O
30	below	O
31	30	O
32	ml	O
33	/	O
34	min	O
35	.	O

1	We	O
2	have	O
3	demonstrated	O
4	previously	O
5	that	O
6	two	O
7	binding	O
8	sites	O
9	in	O
10	the	O
11	-	O
12	184	O
13	HNF	B
14	-	I
15	3	I
16	beta	I
17	promoter	I
18	are	O
19	recognized	O
20	by	O
21	widely	O
22	distributed	O
23	factors	O
24	and	O
25	that	O
26	there	O
27	is	O
28	also	O
29	a	O
30	critical	O
31	autoregulatory	O
32	site	O
33	,	O
34	we	O
35	identified	O
36	a	O
37	binding	O
38	site	O
39	for	O
40	a	O
41	cell	O
42	-	O
43	specific	O
44	factor	O
45	,	O
46	LF	B
47	-	I
48	H3	I
49	beta	I
50	,	O
51	that	O
52	may	O
53	function	O
54	in	O
55	restricting	O
56	HNF	B
57	-	I
58	3	I
59	beta	I
60	gene	I
61	expression	O
62	to	O
63	hepatocytes	O
64	.	O

1	Biological	O
2	activities	O
3	of	O
4	hematopoietic	B
5	growth	I
6	factors	I
7	that	O
8	lead	O
9	to	O
10	future	O
11	clinical	O
12	application	O
13	.	O

1	Relations	O
2	between	O
3	adrenergic	O
4	mechanisms	O
5	and	O
6	analgesic	O
7	effects	O

1	In	O
2	a	O
3	model	O
4	of	O
5	the	O
6	ternary	O
7	complex	O
8	,	O
9	the	O
10	segment	O
11	of	O
12	NFAT	B
13	nearest	O
14	AP	B
15	-	I
16	1	I
17	is	O
18	the	O
19	Rel	B
20	insert	O
21	region	O
22	(	O
23	RIR	O
24	),	O
25	a	O
26	feature	O
27	that	O
28	is	O
29	notable	O
30	for	O
31	its	O
32	hypervariability	O
33	in	O
34	size	O
35	and	O
36	in	O
37	sequence	O
38	amongst	O
39	members	O
40	of	O
41	the	O
42	Rel	B
43	transcription	I
44	factor	I
45	family	I
46	.	O

1	Selenium	O
2	,	O
3	as	O
4	a	O
5	constituent	O
6	of	O
7	glutathione	B
8	peroxidase	I
9	,	O
10	plays	O
11	a	O
12	role	O
13	in	O
14	the	O
15	antioxidant	O
16	defense	O
17	systems	O
18	of	O
19	the	O
20	body	O
21	,	O
22	but	O
23	other	O
24	metabolic	O
25	roles	O
26	for	O
27	selenium	O
28	may	O
29	yet	O
30	be	O
31	discovered	O
32	.	O

1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	O
7	-	O
8	kDa	O
9	nuclear	O
10	pore	O
11	glycoprotein	O
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	O
31	pore	O
32	glycoproteins	O
33	.	O

1	USF	B
2	synthesized	O
3	in	O
4	an	O
5	in	O
6	vitro	O
7	transcription	O
8	and	O
9	translation	O
10	system	O
11	also	O
12	binds	O
13	to	O
14	the	O
15	ADH	B
16	promoter	I
17	as	O
18	well	O
19	as	O
20	to	O
21	the	O
22	MLP	O
23	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	rat	B
12	placental	I
13	prolactin	I
14	(	I
15	PRL	I
16	)	I
17	family	I
18	,	O
19	PRL	B
20	-	I
21	like	I
22	protein	I
23	H	I
24	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	B
12	serum	I
13	prolactin	I
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	cysteine	B
6	synthase	I
7	cDNA	I
8	from	O
9	Citrullus	O
10	vulgaris	O
11	(	O
12	watermelon	O
13	)	O
14	by	O
15	genetic	O
16	complementation	O
17	in	O
18	an	O
19	Escherichia	B
20	coli	I
21	Cys	I
22	-	I
23	auxotroph	I
24	.	O

1	For	O
2	the	O
3	5HT5A	B
4	receptor	I
5	the	O
6	addition	O
7	of	O
8	yohimbine	O
9	resulted	O
10	in	O
11	a	O
12	similar	O
13	but	O
14	smaller	O
15	effect	O
16	.	O

1	A	O
2	triple	O
3	Ser	O
4	-->	O
5	Ala	O
6	mutant	O
7	form	O
8	of	O
9	yeast	B
10	eIF	I
11	-	I
12	2	I
13	alpha	I
14	was	O
15	found	O
16	to	O
17	be	O
18	no	O
19	longer	O
20	phosphorylated	O
21	by	O
22	either	O
23	of	O
24	the	O
25	yeast	O
26	(	O
27	or	O
28	mammalian	O
29	)	O
30	casein	B
31	kinase	I
32	activities	O
33	in	O
34	vitro	O
35	.	O

1	The	O
2	proposed	O
3	mechanism	O
4	of	O
5	effect	O
6	states	O
7	that	O
8	mono	O
9	(	O
10	2	O
11	-	O
12	ethylhexyl	O
13	)	O
14	phthalate	O
15	(	O
16	MEHP	O
17	),	O
18	the	O
19	primary	O
20	hydrolysis	O
21	product	O
22	of	O
23	DEHP	B
24	,	O
25	mimics	O
26	the	O
27	inducing	O
28	prostaglandins	O
29	(	O
30	PG	O
31	)	O
32	PGD	O
33	(	O
34	2	O
35	),	O
36	9alpha	B
37	,	O
38	11betaPGF2	B
39	,	O
40	and	O
41	PGF2alpha	B
42	,	O
43	and	O
44	thromboxanes	O
45	in	O
46	the	O
47	lungs	O
48	,	O
49	thereby	O
50	increasing	O
51	the	O
52	risk	O
53	of	O
54	inducing	O
55	inflammation	O
56	in	O
57	the	O
58	airways	O
59	,	O
60	which	O
61	is	O
62	a	O
63	characteristic	O
64	of	O
65	asthma	O
66	.	O

1	Restriction	O
2	analysis	O
3	and	O
4	Southern	O
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	O
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	O
16	mediated	O
17	cadmium	O
18	-	O
19	resistant	O
20	L	O
21	.	O
22	monocytogenes	O
23	strains	O
24	tested	O
25	but	O
26	not	O
27	in	O
28	strains	O
29	encoding	O
30	cadmium	O
31	resistance	O
32	on	O
33	the	O
34	chromosome	O
35	.	O

1	Radiogallium	O
2	imaging	O
3	is	O
4	thus	O
5	of	O
6	limited	O
7	use	O
8	in	O
9	evaluation	O
10	of	O
11	suspected	O
12	giant	O
13	cell	O
14	tumors	O
15	of	O
16	bone	O
17	.	O

1	This	O
2	repression	O
3	does	O
4	not	O
5	require	O
6	the	O
7	PU	B
8	.	I
9	1	I
10	transactivation	O
11	or	O
12	PEST	O
13	domains	O
14	and	O
15	cannot	O
16	be	O
17	reversed	O
18	by	O
19	p300	B
20	expression	O
21	.	O

1	This	O
2	analysis	O
3	,	O
4	together	O
5	with	O
6	a	O
7	consideration	O
8	of	O
9	the	O
10	SCBs	O
11	found	O
12	upstream	O
13	of	O
14	known	O
15	SWI4	B
16	,	O
17	6	O
18	-	O
19	dependent	O
20	genes	O
21	,	O
22	leads	O
23	to	O
24	the	O
25	proposal	O
26	of	O
27	a	O
28	revised	O
29	consensus	O
30	sequence	O
31	for	O
32	this	O
33	important	O
34	regulatory	O
35	element	O
36	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	while	O
6	many	O
7	muscle	O
8	gene	O
9	E	O
10	-	O
11	boxes	O
12	are	O
13	capable	O
14	of	O
15	binding	O
16	the	O
17	previously	O
18	characterized	O
19	spectrum	O
20	of	O
21	MDF	B
22	/	O
23	bH	B
24	-	I
25	L	I
26	-	I
27	H	I
28	heterodimers	I
29	in	O
30	vitro	O
31	,	O
32	MCK	B
33	-	I
34	L	I
35	type	I
36	E	I
37	-	O
38	boxes	O
39	probably	O
40	bind	O
41	qualitatively	O
42	different	O
43	factors	O
44	in	O
45	vivo	O
46	.	O

1	Frequent	O
2	loss	O
3	of	O
4	heterozygosity	O
5	(	O
6	LOH	O
7	)	O
8	of	O
9	>	O
10	30	O
11	%	O
12	of	O
13	the	O
14	informative	O
15	cases	O
16	was	O
17	observed	O
18	on	O
19	chromosomes	O
20	3p	O
21	(	O
22	41	O
23	.	O
24	1	O
25	%),	O
26	5q	O
27	(	O
28	52	O
29	.	O
30	6	O
31	%),	O
32	6p	O
33	(	O
34	30	O
35	.	O
36	4	O
37	%),	O
38	8p	O
39	(	O
40	33	O
41	.	O
42	3	O
43	%),	O
44	9p	O
45	(	O
46	35	O
47	.	O
48	7	O
49	%),	O
50	9q	O
51	(	O
52	30	O
53	.	O
54	8	O
55	%),	O
56	11p	O
57	(	O
58	32	O
59	.	O
60	4	O
61	%),	O
62	13q	O
63	(	O
64	52	O
65	.	O
66	7	O
67	%),	O
68	17p	O
69	(	O
70	55	O
71	.	O
72	2	O
73	%),	O
74	17q	O
75	(	O
76	33	O
77	.	O
78	3	O
79	%),	O
80	18q	O
81	(	O
82	45	O
83	.	O
84	7	O
85	%),	O
86	and	O
87	19q	O
88	(	O
89	30	O
90	.	O
91	4	O
92	%).	O

1	Differential	O
2	signaling	O
3	and	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	activation	O
9	by	O
10	four	O
11	splice	O
12	variants	O
13	of	O
14	the	O
15	human	B
16	pituitary	I
17	adenylate	I
18	cyclase	I
19	-	I
20	activating	I
21	polypeptide	I
22	receptor	I
23	(	O
24	hPACAP	B
25	-	I
26	R	I
27	).	O

1	Chinese	O
2	Spring	O
3	(	O
4	CS	O
5	)	O
6	carrying	O
7	the	O
8	Q	O
9	gene	O
10	to	O
11	those	O
12	of	O
13	a	O
14	chromosome	O
15	deletion	O
16	line	O
17	of	O
18	CS	O
19	,	O
20	namely	O
21	,	O
22	q5	O
23	,	O
24	which	O
25	lacks	O
26	15	O
27	%	O
28	of	O
29	5AL	O
30	including	O
31	the	O
32	Q	O
33	gene	O
34	.	O

1	The	O
2	expression	O
3	of	O
4	ERV3	B
5	env	I
6	mRNA	I
7	was	O
8	found	O
9	to	O
10	be	O
11	differentiation	O
12	-	O
13	associated	O
14	,	O
15	with	O
16	high	O
17	expression	O
18	detected	O
19	in	O
20	the	O
21	late	O
22	stages	O
23	of	O
24	monocytic	O
25	development	O
26	.	O

1	Total	O
2	PGE	O
3	levels	O
4	in	O
5	synovial	O
6	fluid	O
7	remained	O
8	significantly	O
9	depressed	O
10	in	O
11	the	O
12	patient	O
13	group	O
14	for	O
15	24	O
16	hours	O
17	after	O
18	the	O
19	400	O
20	-	O
21	mg	O
22	test	O
23	dose	O
24	of	O
25	tolmetin	B
26	on	O
27	day	O
28	8	O
29	.	O

1	INF	O
2	-	O
3	alpha	O
4	therapy	O
5	has	O
6	been	O
7	a	O
8	major	O
9	development	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	CML	O
15	.	O

1	In	O
2	diethyl	O
3	ether	O
4	solution	O
5	the	O
6	main	O
7	peak	O
8	is	O
9	that	O
10	of	O
11	2	O
12	-	O
13	benzylidenamio	O
14	-	O
15	1	O
16	-	O
17	phenylpropane	O
18	,	O
19	which	O
20	has	O
21	a	O
22	retention	O
23	time	O
24	of	O
25	23	O
26	,	O
27	2	O
28	minutes	O
29	under	O
30	the	O
31	condition	O
32	delineated	O
33	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	encodes	O
15	a	O
16	40	O
17	-	O
18	kDa	O
19	nuclear	O
20	protein	O
21	,	O
22	Tax	B
23	,	O
24	which	O
25	stimulates	O
26	transcription	O
27	from	O
28	three	O
29	21	O
30	-	O
31	base	O
32	pair	O
33	(	O
34	bp	O
35	)	O
36	repeats	O
37	in	O
38	its	O
39	U3	O
40	region	O
41	.	O

1	This	O
2	mutation	O
3	no	O
4	longer	O
5	repressed	O
6	the	O
7	HPV	O
8	-	O
9	11	O
10	upstream	O
11	regulatory	O
12	region	O
13	-	O
14	controlled	O
15	reporter	O
16	expression	O
17	.	O

1	The	O
2	binding	O
3	of	O
4	NF	B
5	-	I
6	ATp	I
7	,	O
8	although	O
9	not	O
10	NF	B
11	-	I
12	AT4	I
13	,	O
14	to	O
15	this	O
16	enhancer	O
17	also	O
18	occurs	O
19	along	O
20	with	O
21	HTLV	O
22	-	O
23	I	O
24	-	O
25	mediated	O
26	infection	O
27	of	O
28	human	O
29	peripheral	O
30	blood	O
31	T	O
32	-	O
33	cells	O
34	.	O

1	From	O
2	the	O
3	Icelandic	B
4	Red	I
5	Cross	I
6	activities	O

1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	B
8	in	O
9	nmt1	B
10	-	I
11	451Dino2	I
12	Delta	I
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	myristoy	O
41	-	O
42	lation	O
43	.	O

1	The	O
2	main	O
3	causes	O
4	of	O
5	liver	O
6	disease	O
7	in	O
8	the	O
9	patients	O
10	with	O
11	HCC	O
12	were	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	(	O
20	77	O
21	%),	O
22	alcohol	O
23	abuse	O
24	(	O
25	73	O
26	%),	O
27	and	O
28	the	O
29	combination	O
30	of	O
31	HCV	O
32	and	O
33	alcohol	O
34	abuse	O
35	(	O
36	50	O
37	%).	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	appropriately	O
7	spaced	O
8	upstream	O
9	from	O
10	the	O
11	transcription	O
12	initiation	O
13	site	O
14	.	O

1	Mechanism	O
2	of	O
3	interferon	B
4	action	O
5	:	O
6	identification	O
7	of	O
8	essential	O
9	positions	O
10	within	O
11	the	O
12	novel	O
13	15	O
14	-	O
15	base	O
16	-	O
17	pair	O
18	KCS	O
19	element	O
20	required	O
21	for	O
22	transcriptional	O
23	activation	O
24	of	O
25	the	O
26	RNA	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	pkr	I
32	gene	I
33	.	O

1	G	B
2	-	I
3	CSF	I
4	activates	O
5	multiple	O
6	signaling	O
7	molecules	O
8	,	O
9	including	O
10	the	O
11	JAK1	B
12	and	O
13	JAK2	B
14	kinases	I
15	and	O
16	the	O
17	STAT	B
18	transcription	I
19	factors	I
20	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	The	O
2	absorbable	O
3	perisplenic	O
4	mesh	O
5	is	O
6	an	O
7	important	O
8	improvement	O
9	,	O
10	and	O
11	in	O
12	some	O
13	cases	O
14	it	O
15	may	O
16	replace	O
17	other	O
18	techniques	O
19	for	O
20	arresting	O
21	splenic	O
22	bleeding	O
23	.	O

1	The	O
2	gene	O
3	encoding	O
4	human	B
5	tissue	I
6	-	I
7	type	I
8	plasminogen	I
9	activator	I
10	(	I
11	t	I
12	-	I
13	PA	I
14	)	O
15	is	O
16	regulated	O
17	in	O
18	a	O
19	cell	O
20	-	O
21	type	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	Chronic	O
2	renal	O
3	failure	O
4	patients	O
5	essentially	O
6	die	O
7	from	O
8	cardiovascular	O
9	causes	O
10	,	O
11	and	O
12	the	O
13	frequency	O
14	of	O
15	malignant	O
16	disease	O
17	responsible	O
18	for	O
19	death	O
20	is	O
21	estimated	O
22	to	O
23	be	O
24	10	O
25	%.	O

1	We	O
2	identified	O
3	a	O
4	protein	O
5	,	O
6	termed	O
7	NFIL	B
8	-	I
9	1	I
10	beta	I
11	A	I
12	(	O
13	NF	B
14	beta	I
15	A	I
16	),	O
17	that	O
18	binds	O
19	to	O
20	a	O
21	highly	O
22	conserved	O
23	12	O
24	-	O
25	bp	O
26	DNA	O
27	sequence	O
28	(-	O
29	49	O
30	to	O
31	-	O
32	38	O
33	)	O
34	located	O
35	upstream	O
36	of	O
37	the	O
38	TATA	O
39	box	O
40	motif	O
41	in	O
42	both	O
43	the	O
44	human	O
45	and	O
46	murine	B
47	IL	I
48	-	I
49	1	I
50	beta	I
51	genes	I
52	.	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	O
13	TATA	O
14	motif	O
15	.	O

1	Pokeweed	B
2	antiviral	I
3	protein	I
4	(	O
5	PAP	B
6	)	O
7	from	O
8	Phytolacca	O
9	americana	O
10	is	O
11	a	O
12	highly	O
13	specific	O
14	N	B
15	-	I
16	glycosidase	I
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	B
24	rRNA	I
25	and	O
26	A2660	O
27	in	O
28	23S	B
29	rRNA	I
30	)	O
31	from	O
32	intact	O
33	ribosomes	O
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O

1	As	O
2	extensively	O
3	examined	O
4	with	O
5	the	O
6	myogenin	B
7	promoter	I
8	,	O
9	presence	O
10	of	O
11	one	O
12	or	O
13	multiple	O
14	copies	O
15	of	O
16	Me	O
17	in	O
18	the	O
19	vectors	O
20	elevated	O
21	the	O
22	expression	O
23	activity	O
24	in	O
25	myotubes	O
26	by	O
27	4	O
28	.	O
29	5	O
30	-	O
31	to	O
32	19	O
33	-	O
34	fold	O
35	over	O
36	those	O
37	without	O
38	Me	O
39	,	O
40	but	O
41	not	O
42	significantly	O
43	in	O
44	myoblasts	O
45	.	O

1	Venkatesan	O
2	,	O
3	and	O
4	D	O
5	.	O

1	Sequence	O
2	analysis	O
3	indicates	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	an	O
9	ATA	O
10	and	O
11	GC	O
12	box	O
13	,	O
14	this	O
15	region	O
16	contains	O
17	domains	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	the	O
24	regulation	O
25	of	O
26	other	O
27	muscle	O
28	-	O
29	specific	O
30	genes	O
31	:	O
32	a	O
33	CArG	O
34	box	O
35	at	O
36	-	O
37	91	O
38	bp	O
39	;	O
40	myocyte	B
41	-	I
42	specific	I
43	enhancer	I
44	-	I
45	binding	I
46	nuclear	I
47	factor	I
48	1	I
49	binding	I
50	site	I
51	homologies	O
52	at	O
53	-	O
54	58	O
55	,	O
56	-	O
57	535	O
58	,	O
59	and	O
60	-	O
61	583	O
62	bp	O
63	;	O
64	and	O
65	a	O
66	muscle	O
67	-	O
68	CAAT	O
69	consensus	O
70	sequence	O
71	at	O
72	-	O
73	394	O
74	bp	O
75	relative	O
76	to	O
77	the	O
78	cap	O
79	site	O
80	.	O

1	A	O
2	diagnosis	O
3	of	O
4	IgA	B
5	lambda	O
6	multiple	O
7	myeloma	O
8	with	O
9	peritoneal	O
10	involvement	O
11	was	O
12	made	O
13	.	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	B
18	minimal	I
19	promoter	I
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	B
25	gene	I
26	expression	O
27	.	O

1	Additionally	O
2	,	O
3	a	O
4	variety	O
5	of	O
6	regulatory	O
7	schemes	O
8	contribute	O
9	temporal	O
10	and	O
11	/	O
12	or	O
13	spatial	O
14	restriction	O
15	to	O
16	TGF	B
17	-	I
18	beta	I
19	responses	O
20	.	O

1	USA	O
2	80	O
3	,	O
4	3618	O
5	-	O
6	3622	O
7	)	O
8	The	O
9	two	O
10	proteins	O
11	show	O
12	36	O
13	%	O
14	identities	O
15	in	O
16	their	O
17	amino	O
18	acid	O
19	sequence	O
20	,	O
21	in	O
22	an	O
23	alignment	O
24	requiring	O
25	six	O
26	gaps	O
27	.	O

1	Although	O
2	Micrococcus	O
3	luteus	O
4	UV	O
5	endonuclease	O
6	has	O
7	been	O
8	reported	O
9	to	O
10	be	O
11	an	O
12	18	O
13	-	O
14	kDa	O
15	enzyme	O
16	with	O
17	possible	O
18	homology	O
19	to	O
20	the	O
21	16	O
22	-	O
23	kDa	O
24	endonuclease	O
25	V	O
26	from	O
27	bacteriophage	O
28	T4	O
29	(	O
30	Gordon	O
31	,	O
32	L	O
33	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Large	O
2	and	O
3	small	O
4	medullary	O
5	lesions	O
6	inhibited	O
7	the	O
8	occurrence	O
9	of	O
10	target	O
11	fibres	O
12	in	O
13	the	O
14	tenotomized	O
15	muscles	O
16	,	O
17	the	O
18	smallest	O
19	one	O
20	being	O
21	neurolysis	O
22	of	O
23	the	O
24	dorsal	O
25	roots	O
26	.	O

1	The	O
2	level	O
3	of	O
4	contamination	O
5	in	O
6	the	O
7	wound	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	the	O
13	rapid	O
14	biopsy	O
15	fixation	O
16	technique	O
17	.	O

1	To	O
2	determine	O
3	if	O
4	the	O
5	NF	B
6	(	I
7	H	I
8	)	I
9	promoter	I
10	can	O
11	be	O
12	activated	O
13	in	O
14	a	O
15	tissue	O
16	specific	O
17	manner	O
18	during	O
19	development	O
20	transgenic	O
21	mice	O
22	containing	O
23	the	O
24	promoter	O
25	region	O
26	linked	O
27	to	O
28	a	O
29	beta	B
30	-	I
31	galactosidase	I
32	reporter	I
33	gene	I
34	were	O
35	generated	O
36	.	O

1	Such	O
2	transgenic	O
3	plants	O
4	should	O
5	enable	O
6	not	O
7	only	O
8	the	O
9	mutational	O
10	analysis	O
11	of	O
12	sequence	O
13	elements	O
14	within	O
15	the	O
16	replication	O
17	origin	O
18	region	O
19	,	O
20	but	O
21	also	O
22	the	O
23	construction	O
24	of	O
25	a	O
26	new	O
27	generation	O
28	of	O
29	vectors	O
30	for	O
31	gene	O
32	amplification	O
33	in	O
34	plants	O
35	,	O
36	based	O
37	on	O
38	a	O
39	minimal	O
40	virus	O
41	replicon	O
42	.	O

1	1	O
2	.	O

1	To	O
2	this	O
3	end	O
4	,	O
5	we	O
6	analyzed	O
7	the	O
8	phosphorylation	O
9	status	O
10	of	O
11	a	O
12	universal	B
13	tyrosine	I
14	kinase	I
15	substrate	O
16	,	O
17	the	O
18	transforming	O
19	Shc	B
20	adapter	I
21	protein	I
22	,	O
23	in	O
24	fibroblasts	O
25	expressing	O
26	the	O
27	viral	O
28	oncogene	O
29	.	O

1	Pharmacoeconomic	O
2	assessment	O
3	of	O
4	HMG	B
5	-	I
6	CoA	I
7	reductase	I
8	inhibitor	O
9	therapy	O
10	:	O
11	an	O
12	analysis	O
13	based	O
14	on	O
15	the	O
16	CURVES	O
17	study	O
18	.	O

1	HVH2	B
2	mRNA	I
3	showed	O
4	an	O
5	expression	O
6	pattern	O
7	distinct	O
8	from	O
9	CL100	B
10	(	O
11	human	O
12	homologue	O
13	of	O
14	mouse	B
15	MKP1	I
16	)	O
17	and	O
18	PAC1	B
19	,	O
20	two	O
21	previously	O
22	identified	O
23	MAP	B
24	kinase	I
25	phosphatases	I
26	.	O

1	UDP	B
2	-	I
3	GlcNAc	I
4	:	I
5	alpha	I
6	-	I
7	6	I
8	-	I
9	D	I
10	-	I
11	mannoside	I
12	beta	I
13	-	I
14	1	I
15	,	I
16	2	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	II	I
22	(	O
23	GnT	B
24	II	I
25	;	O
26	EC	B
27	2	I
28	.	I
29	4	I
30	.	I
31	1	I
32	.	O
33	143	O
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	Selenium	O
2	status	O
3	of	O
4	thoroughbreds	O
5	in	O
6	the	O
7	United	O
8	Kingdom	O
9	.	O

1	The	O
2	records	O
3	from	O
4	1948	O
5	through	O
6	1967	O
7	of	O
8	344	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	squamous	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	oropharynx	O
22	,	O
23	supraglottic	O
24	larynx	O
25	and	O
26	hypopharynx	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	metastases	O
35	staged	O
36	N1	O
37	,	O
38	N2A	O
39	,	O
40	or	O
41	N2B	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O

1	Finding	O
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O

1	Thus	O
2	,	O
3	Sir	B
4	proteins	I
5	from	O
6	K	O
7	.	O
8	lactis	O
9	have	O
10	roles	O
11	in	O
12	both	O
13	silencing	O
14	and	O
15	telomere	O
16	length	O
17	maintenance	O
18	,	O
19	reflecting	O
20	conserved	O
21	functional	O
22	themes	O
23	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	B
22	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	activation	O
6	of	O
7	protein	B
8	kinase	I
9	A	I
10	(	O
11	PKA	B
12	)	O
13	signaling	O
14	is	O
15	sufficient	O
16	to	O
17	down	O
18	-	O
19	regulate	O
20	caveolin	B
21	-	I
22	1	I
23	protein	I
24	expression	O
25	and	O
26	promoter	O
27	activity	O
28	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	the	O
9	non	O
10	-	O
11	spliced	O
12	variant	O
13	,	O
14	multiple	O
15	mRNA	O
16	species	O
17	were	O
18	generated	O
19	by	O
20	alternative	O
21	splicing	O
22	resulting	O
23	in	O
24	the	O
25	exclusion	O
26	of	O
27	92	O
28	,	O
29	166	O
30	,	O
31	170	O
32	,	O
33	174	O
34	and	O
35	263	O
36	nucleotides	O
37	(	O
38	nt	O
39	),	O
40	respectively	O
41	,	O
42	from	O
43	exon	O
44	1	O
45	.	O

1	The	O
2	divergence	O
3	in	O
4	primary	O
5	structure	O
6	between	O
7	the	O
8	sheep	O
9	CRF1	B
10	and	O
11	the	O
12	other	O
13	mammalian	O
14	CRF1s	O
15	is	O
16	primarily	O
17	localized	O
18	to	O
19	the	O
20	extracellular	O
21	amino	O
22	terminal	O
23	domain	O
24	of	O
25	the	O
26	receptor	O
27	(	O
28	18	O
29	of	O
30	22	O
31	divergent	O
32	residues	O
33	,	O
34	ovine	O
35	vs	O
36	human	B
37	CRF1	I
38	).	O

1	The	O
2	above	O
3	results	O
4	mean	O
5	that	O
6	the	O
7	increase	O
8	in	O
9	alpha	B
10	-	I
11	adrenergic	I
12	receptors	I
13	makes	O
14	the	O
15	prostate	O
16	,	O
17	which	O
18	has	O
19	been	O
20	already	O
21	hypertrophied	O
22	,	O
23	less	O
24	elastic	O
25	,	O
26	inhibiting	O
27	external	O
28	urinary	O
29	sphincter	O
30	function	O
31	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	I
5	MB	I
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	STAT	B
8	activation	O
9	in	O
10	a	O
11	panel	O
12	of	O
13	rodent	O
14	fibroblast	O
15	cell	O
16	lines	O
17	stably	O
18	transformed	O
19	by	O
20	diverse	O
21	viral	O
22	oncoproteins	O
23	.	O

1	Structural	O
2	organization	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	human	B
9	lipocalin	I
10	tear	I
11	prealbumin	I
12	and	O
13	synthesis	O
14	of	O
15	the	O
16	recombinant	B
17	protein	I
18	in	O
19	Escherichia	O
20	coli	O
21	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	of	O
7	the	O
8	200	O
9	-	O
10	bp	O
11	proximal	O
12	region	O
13	of	O
14	the	O
15	promoter	O
16	with	O
17	a	O
18	murine	B
19	Hepa	I
20	1	I
21	-	I
22	6	I
23	cell	O
24	nuclear	O
25	extract	O
26	revealed	O
27	a	O
28	clear	O
29	footprint	O
30	of	O
31	a	O
32	region	O
33	corresponding	O
34	to	O
35	-	O
36	80	O
37	to	O
38	-	O
39	28	O
40	bp	O
41	of	O
42	the	O
43	murine	B
44	fVII	I
45	gene	I
46	,	O
47	suggesting	O
48	that	O
49	liver	O
50	factors	O
51	interact	O
52	with	O
53	this	O
54	region	O
55	of	O
56	the	O
57	DNA	O
58	.	O

1	A	O
2	constitutive	O
3	mutant	O
4	form	O
5	with	O
6	a	O
7	single	O
8	substitution	O
9	(	O
10	V88A	O
11	)	O
12	in	O
13	the	O
14	amino	O
15	-	O
16	terminal	O
17	(	O
18	response	O
19	regulator	O
20	)	O
21	region	O
22	was	O
23	used	O
24	.	O

1	A	O
2	new	O
3	DNA	O
4	repair	O
5	gene	O
6	from	O
7	Schizosaccharomyces	O
8	pombe	O
9	with	O
10	homology	O
11	to	O
12	RecA	B
13	was	O
14	identified	O
15	and	O
16	characterized	O
17	.	O

1	The	O
2	N3	O
3	wave	O
4	of	O
5	the	O
6	SSEP	O
7	'	O
8	s	O
9	,	O
10	which	O
11	has	O
12	been	O
13	found	O
14	to	O
15	correlate	O
16	best	O
17	with	O
18	neurological	O
19	recovery	O
20	,	O
21	returned	O
22	to	O
23	65	O
24	%	O
25	+/-	O
26	48	O
27	%	O
28	of	O
29	the	O
30	preischemia	O
31	amplitude	O
32	in	O
33	the	O
34	insulin	B
35	-	O
36	treated	O
37	animals	O
38	,	O
39	compared	O
40	to	O
41	40	O
42	%	O
43	+/-	O
44	34	O
45	%	O
46	in	O
47	the	O
48	fasted	O
49	group	O
50	and	O
51	26	O
52	%	O
53	+/-	O
54	24	O
55	%	O
56	in	O
57	the	O
58	control	O
59	animals	O
60	.	O

1	Validation	O
2	of	O
3	automated	O
4	systems	O
5	--	O
6	system	O
7	definition	O
8	.	O

1	The	O
2	measurement	O
3	of	O
4	NO	O
5	in	O
6	biological	O
7	systems	O
8	using	O
9	chemiluminescence	O
10	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	gene	O
10	encoding	O
11	human	B
12	K14	I
13	(	O
14	D	O
15	.	O

1	Shoulder	O
2	forearm	O
3	support	O
4	for	O
5	the	O
6	subluxed	O
7	shoulder	O
8	.	O

1	Linkage	O
2	studies	O
3	have	O
4	shown	O
5	locus	O
6	heterogeneity	O
7	with	O
8	one	O
9	TSC	B
10	gene	I
11	mapped	O
12	to	O
13	chromosome	O
14	9q34	O
15	and	O
16	a	O
17	second	O
18	to	O
19	16p13	O
20	.	O
21	3	O
22	.	O

1	Moreover	O
2	,	O
3	in	O
4	rats	O
5	allowed	O
6	to	O
7	choose	O
8	in	O
9	a	O
10	T	O
11	-	O
12	maze	O
13	between	O
14	immediate	O
15	-	O
16	but	O
17	-	O
18	small	O
19	vs	O
20	.	O
21	delayed	O
22	-	O
23	but	O
24	-	O
25	large	O
26	reward	O
27	,	O
28	BZP	O
29	significantly	O
30	decreased	O
31	the	O
32	frequency	O
33	with	O
34	which	O
35	the	O
36	delayed	O
37	reward	O
38	was	O
39	chosen	O
40	,	O
41	with	O
42	5	O
43	-	O
44	HT	O
45	uptake	O
46	blockers	O
47	producing	O
48	opposite	O
49	effects	O
50	.	O

1	Cosmid	O
2	clones	O
3	containing	O
4	both	O
5	VNTR	O
6	sequences	O
7	were	O
8	identified	O
9	,	O
10	and	O
11	restriction	O
12	mapping	O
13	showed	O
14	them	O
15	to	O
16	be	O
17	less	O
18	than	O
19	15	O
20	kb	O
21	apart	O
22	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	a	O
7	Chessmaster	O
8	gradually	O
9	increases	O
10	the	O
11	number	O
12	of	O
13	boards	O
14	he	O
15	can	O
16	reproduce	O
17	with	O
18	higher	O
19	than	O
20	70	O
21	%	O
22	average	O
23	accuracy	O
24	to	O
25	nine	O
26	,	O
27	replacing	O
28	as	O
29	many	O
30	as	O
31	160	O
32	pieces	O
33	correctly	O
34	.	O

1	Standardized	O
2	gastric	O
3	wall	O
4	specimens	O
5	from	O
6	the	O
7	area	O
8	of	O
9	grossly	O
10	healed	O
11	ulcers	O
12	were	O
13	obtained	O
14	,	O
15	processed	O
16	,	O
17	and	O
18	evaluated	O
19	by	O
20	light	O
21	microscopy	O
22	and	O
23	by	O
24	transmission	O
25	electron	O
26	microscopy	O
27	.	O

1	The	O
2	elements	O
3	responsible	O
4	for	O
5	glucocorticoid	O
6	stimulation	O
7	of	O
8	ADH	B
9	gene	I
10	transcription	O
11	appear	O
12	to	O
13	reside	O
14	outside	O
15	of	O
16	this	O
17	region	O
18	.	O

1	Effect	O
2	of	O
3	the	O
4	methods	O
5	of	O
6	cutaneous	O
7	administration	O
8	of	O
9	methyl	O
10	isobutyl	O
11	ketone	O
12	on	O
13	its	O
14	toxicity	O

1	Twenty	O
2	-	O
3	two	O
4	of	O
5	the	O
6	24	O
7	patients	O
8	had	O
9	a	O
10	rise	O
11	in	O
12	the	O
13	total	O
14	serum	B
15	amylase	I
16	following	O
17	ERCP	O
18	.	O

1	The	O
2	2	O
3	kb	O
4	of	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	and	O
10	the	O
11	1	O
12	.	O
13	1	O
14	kb	O
15	of	O
16	the	O
17	entire	O
18	sGTH	B
19	alpha	I
20	subunit	I
21	coding	O
22	region	O
23	were	O
24	sequenced	O
25	from	O
26	the	O
27	genomic	O
28	clone	O
29	,	O
30	sGTH	B
31	alpha	I
32	-	I
33	G1	I
34	.	O

1	To	O
2	test	O
3	promotor	O
4	function	O
5	,	O
6	chimeric	O
7	genes	O
8	were	O
9	constructed	O
10	linking	O
11	fragments	O
12	of	O
13	chicken	B
14	IGF	I
15	-	I
16	I	I
17	5	I
18	'-	I
19	flanking	I
20	DNA	I
21	to	O
22	a	O
23	promoterless	O
24	reporter	O
25	plasmid	O
26	.	O

1	The	O
2	oxygen	O
3	uptake	O
4	(	O
5	VO2	O
6	),	O
7	carbon	O
8	dioxide	O
9	output	O
10	(	O
11	VCO2	O
12	),	O
13	respiratory	O
14	rate	O
15	(	O
16	fR	O
17	),	O
18	minute	O
19	ventilation	O
20	(	O
21	VE	O
22	),	O
23	alveolar	O
24	ventilation	O
25	(	O
26	VA	O
27	),	O
28	alveolar	O
29	oxygen	O
30	pressure	O
31	(	O
32	PAO2	O
33	),	O
34	and	O
35	VE	O
36	/	O
37	VO2	O
38	ratio	O
39	were	O
40	higher	O
41	in	O
42	the	O
43	cows	O
44	,	O
45	while	O
46	the	O
47	tidal	O
48	volume	O
49	(	O
50	VT	O
51	)	O
52	and	O
53	physiological	O
54	dead	O
55	space	O
56	(	O
57	VD	O
58	)	O
59	were	O
60	larger	O
61	in	O
62	the	O
63	horses	O
64	.	O

1	Nuclear	B
2	protein	I
3	phosphatase	I
4	2A	I
5	dephosphorylates	I
6	protein	I
7	kinase	I
8	A	I
9	-	O
10	phosphorylated	O
11	CREB	B
12	and	O
13	regulates	O
14	CREB	B
15	transcriptional	O
16	stimulation	O
17	.	O

1	The	O
2	rational	O
3	for	O
4	the	O
5	prophylactic	O
6	treatment	O
7	,	O
8	the	O
9	therapy	O
10	of	O
11	the	O
12	meningopathy	O
13	and	O
14	AIL	O
15	-	O
16	AIEOP	O
17	protocols	O
18	are	O
19	exposed	O
20	.	O

1	Association	O
2	of	O
3	stress	O
4	during	O
5	delivery	O
6	with	O
7	increased	O
8	numbers	O
9	of	O
10	nucleated	O
11	cells	O
12	and	O
13	hematopoietic	O
14	progenitor	O
15	cells	O
16	in	O
17	umbilical	O
18	cord	O
19	blood	O
20	.	O

1	We	O
2	present	O
3	this	O
4	case	O
5	because	O
6	of	O
7	the	O
8	rarity	O
9	of	O
10	left	O
11	ventricular	O
12	involvement	O
13	associated	O
14	with	O
15	ARVD	O
16	.	O

1	C	O
2	.	O

1	The	O
2	drug	O
3	sensitivity	O
4	was	O
5	100	O
6	%	O
7	for	O
8	vancomycin	O
9	(	O
10	VCM	O
11	),	O
12	30	O
13	%	O
14	for	O
15	imipenam	O
16	(	O
17	IMP	O
18	),	O
19	31	O
20	%	O
21	for	O
22	minomycin	O
23	(	O
24	MINO	O
25	),	O
26	31	O
27	%	O
28	for	O
29	amikacin	O
30	(	O
31	AMK	O
32	),	O
33	and	O
34	7	O
35	%	O
36	for	O
37	fosfomycin	O
38	(	O
39	FOM	O
40	).	O

1	Examples	O
2	are	O
3	using	O
4	more	O
5	subjects	O
6	or	O
7	an	O
8	improved	O
9	research	O
10	design	O
11	,	O
12	developing	O
13	consensus	O
14	statements	O
15	or	O
16	using	O
17	meta	O
18	-	O
19	analysis	O
20	.	O

1	Diverse	B
2	endogenous	I
3	light	I
4	chains	I
5	contribute	O
6	to	O
7	basement	O
8	membrane	O
9	reactivity	O
10	in	O
11	nonautoimmune	O
12	mice	O
13	transgenic	O
14	for	O
15	an	O
16	anti	B
17	-	I
18	laminin	I
19	Ig	I
20	heavy	I
21	chain	I
22	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	Our	O
2	study	O
3	also	O
4	demonstrated	O
5	significant	O
6	increases	O
7	in	O
8	the	O
9	number	O
10	of	O
11	larger	O
12	myelinated	O
13	fibers	O
14	crossing	O
15	the	O
16	repair	O
17	site	O
18	in	O
19	comparison	O
20	with	O
21	the	O
22	neonatal	O
23	and	O
24	adult	O
25	groups	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	04	O
32	).	O

1	Primer	O
2	extension	O
3	and	O
4	mung	O
5	bean	O
6	and	O
7	S1	B
8	nuclease	I
9	mapping	O
10	indicated	O
11	multiple	O
12	transcription	O
13	initiation	O
14	sites	O
15	and	O
16	were	O
17	consistent	O
18	with	O
19	Northern	O
20	analyses	O
21	.	O

1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	DNA	B
9	polymerase	I
10	gene	I
11	of	I
12	Bombyx	I
13	mori	I
14	nuclear	I
15	polyhedrosis	I
16	virus	I
17	.	O

1	Eukaryotic	B
2	initiation	I
3	factor	I
4	3	I
5	(	O
6	eIF3	B
7	)	O
8	is	O
9	a	O
10	large	O
11	multisubunit	O
12	complex	O
13	that	O
14	stabilizes	O
15	the	O
16	ternary	O
17	complex	O
18	,	O
19	eIF2	B
20	x	I
21	GTP	I
22	x	I
23	tRNA	I
24	(	I
25	Met	I
26	)	I
27	i	I
28	and	O
29	promotes	O
30	mRNA	O
31	binding	O
32	to	O
33	the	O
34	40	B
35	S	I
36	ribosomal	I
37	subunit	I
38	.	I
39	eIF3	I
40	also	O
41	functions	O
42	as	O
43	a	O
44	ribosome	O
45	subunit	O
46	anti	O
47	-	O
48	association	O
49	factor	O
50	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	patients	O
6	with	O
7	IS	O
8	,	O
9	67	O
10	%	O
11	had	O
12	significantly	O
13	greater	O
14	values	O
15	of	O
16	directional	O
17	preponderance	O
18	on	O
19	the	O
20	OVAR	O
21	test	O
22	(	O
23	a	O
24	measure	O
25	of	O
26	otolith	O
27	system	O
28	imbalance	O
29	)	O
30	compared	O
31	with	O
32	control	O
33	subjects	O
34	.	O

1	A	O
2	randomised	O
3	,	O
4	controlled	O
5	trial	O
6	was	O
7	undertaken	O
8	in	O
9	40	O
10	patients	O
11	with	O
12	active	O
13	Crohn	O
14	'	O
15	s	O
16	disease	O
17	to	O
18	evaluate	O
19	clinical	O
20	and	O
21	nutritional	O
22	outcomes	O
23	after	O
24	an	O
25	amino	O
26	acid	O
27	based	O
28	diet	O
29	containing	O
30	3	O
31	%	O
32	fat	O
33	was	O
34	given	O
35	by	O
36	a	O
37	feeding	O
38	tube	O
39	compared	O
40	with	O
41	a	O
42	peptide	O
43	based	O
44	diet	O
45	containing	O
46	33	O
47	%	O
48	fat	O
49	.	O

1	Expression	O
2	of	O
3	SREBP	B
4	-	I
5	1a	I
6	stimulated	O
7	StAR	B
8	promoter	I
9	activity	O
10	in	O
11	the	O
12	context	O
13	of	O
14	COS	O
15	-	O
16	1	O
17	cells	O
18	and	O
19	human	O
20	granulosa	O
21	-	O
22	lutein	O
23	cells	O
24	.	O

1	Using	O
2	bovine	O
3	and	O
4	murine	B
5	c	I
6	-	I
7	myb	I
8	clones	O
9	,	O
10	no	O
11	change	O
12	in	O
13	the	O
14	rate	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	gene	I
20	transcription	O
21	or	O
22	mRNA	O
23	stability	O
24	was	O
25	detected	O
26	during	O
27	the	O
28	cell	O
29	cycle	O
30	.	O

1	As	O
2	an	O
3	initial	O
4	step	O
5	towards	O
6	the	O
7	characterization	O
8	of	O
9	replicative	O
10	DNA	O
11	polymerases	O
12	of	O
13	trypanosomes	O
14	,	O
15	we	O
16	have	O
17	cloned	O
18	,	O
19	sequenced	O
20	and	O
21	examined	O
22	the	O
23	expression	O
24	of	O
25	the	O
26	Trypanosoma	O
27	(	O
28	Trypanozoon	O
29	)	O
30	brucei	O
31	brucei	O
32	gene	O
33	that	O
34	encodes	O
35	the	O
36	DNA	B
37	polymerase	I
38	alpha	I
39	catalytic	I
40	core	I
41	(	O
42	pol	B
43	alpha	I
44	).	O

1	There	O
2	were	O
3	no	O
4	instances	O
5	of	O
6	major	O
7	flap	O
8	necrosis	O
9	although	O
10	two	O
11	flaps	O
12	showed	O
13	tip	O
14	ischaemia	O
15	.	O

1	Effect	O
2	of	O
3	Azadirachta	O
4	indica	O
5	hydroalcoholic	O
6	leaf	O
7	extract	O
8	on	O
9	the	O
10	cardiovascular	O
11	system	O
12	.	O

1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	O
11	magnitude	O
12	of	O
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O

1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	B
9	/	O
10	mTOR	B
11	protein	I
12	and	O
13	a	O
14	FRAP	B
15	/	O
16	mTOR	B
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	O
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	B
28	-	I
29	BP1	I
30	.	O

1	The	O
2	diagnosis	O
3	of	O
4	miliary	O
5	tuberculosis	O
6	should	O
7	be	O
8	systematically	O
9	considered	O
10	in	O
11	ARDS	O
12	of	O
13	unknown	O
14	origin	O
15	.	O

1	Marker	O
2	rescue	O
3	analysis	O
4	has	O
5	localized	O
6	ts8	O
7	to	O
8	a	O
9	910	O
10	-	O
11	bp	O
12	internal	O
13	segment	O
14	of	O
15	rpoB	B
16	that	O
17	encodes	O
18	the	O
19	Rif	O
20	domain	O
21	.	O

1	Laryngographic	O
2	changes	O
3	following	O
4	endotracheal	O
5	intubation	O
6	in	O
7	adults	O
8	.	O

1	The	O
2	interrelation	O
3	of	O
4	the	O
5	levels	O
6	of	O
7	glucocorticoids	O
8	and	O
9	insulin	B
10	in	O
11	the	O
12	blood	O
13	of	O
14	irradiated	O
15	animals	O

1	Female	O
2	but	O
3	not	O
4	male	O
5	mortalities	O
6	were	O
7	significantly	O
8	higher	O
9	for	O
10	cake	O
11	-	O
12	fed	O
13	rats	O
14	than	O
15	for	O
16	those	O
17	fed	O
18	diet	O
19	41B	O
20	.	O

1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	B
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O

1	About	O
2	20	O
3	kb	O
4	upstream	O
5	of	O
6	LAMB2	O
7	we	O
8	found	O
9	a	O
10	gene	O
11	encoding	O
12	a	O
13	transcribed	O
14	,	O
15	non	O
16	-	O
17	processed	O
18	LAMB2	B
19	-	I
20	like	I
21	pseudogene	I
22	(	O
23	LAMB2L	O
24	).	O

1	The	O
2	transcription	O
3	factor	O
4	E2F	B
5	plays	O
6	an	O
7	important	O
8	role	O
9	in	O
10	G	O
11	(	O
12	1	O
13	)	O
14	to	O
15	S	O
16	phase	O
17	transition	O
18	in	O
19	the	O
20	higher	O
21	eukaryotic	O
22	cell	O
23	cycle	O
24	.	O

1	In	O
2	protocol	O
3	2	O
4	,	O
5	eight	O
6	different	O
7	subjects	O
8	performed	O
9	Con	O
10	and	O
11	Ecc	B
12	arm	O
13	curls	O
14	to	O
15	fatigue	O
16	,	O
17	followed	O
18	by	O
19	postexercise	O
20	muscle	O
21	ischemia	O
22	,	O
23	by	O
24	using	O
25	the	O
26	same	O
27	resistance	O
28	as	O
29	in	O
30	protocol	O
31	1	O
32	.	O

1	Using	O
2	a	O
3	battery	O
4	of	O
5	I	B
6	kappa	I
7	B	I
8	alpha	I
9	mutants	I
10	,	O
11	we	O
12	show	O
13	that	O
14	(	O
15	i	O
16	)	O
17	a	O
18	dimer	O
19	binds	O
20	a	O
21	single	O
22	I	B
23	kappa	I
24	B	I
25	alpha	I
26	molecule	I
27	,	O
28	(	O
29	ii	O
30	)	O
31	the	O
32	acidic	O
33	C	O
34	-	O
35	terminal	O
36	region	O
37	of	O
38	I	B
39	kappa	I
40	B	I
41	alpha	I
42	is	O
43	not	O
44	required	O
45	for	O
46	protein	O
47	-	O
48	protein	O
49	binding	O
50	and	O
51	does	O
52	not	O
53	mask	O
54	the	O
55	nuclear	O
56	localization	O
57	signal	O
58	of	O
59	the	O
60	dimer	O
61	,	O
62	(	O
63	iii	O
64	)	O
65	the	O
66	same	O
67	C	O
68	-	O
69	terminal	O
70	region	O
71	is	O
72	required	O
73	for	O
74	inhibition	O
75	of	O
76	DNA	O
77	binding	O
78	,	O
79	and	O
80	(	O
81	iv	O
82	)	O
83	this	O
84	inhibition	O
85	may	O
86	be	O
87	accomplished	O
88	by	O
89	direct	O
90	interaction	O
91	between	O
92	the	O
93	PEST	B
94	-	I
95	like	I
96	region	I
97	and	O
98	the	O
99	DNA	O
100	-	O
101	binding	O
102	region	O
103	of	O
104	one	O
105	of	O
106	the	O
107	subunits	O
108	of	O
109	the	O
110	dimer	O
111	.	O

1	Subcellular	O
2	localizations	O
3	of	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	CBFbeta	I
9	and	O
10	the	O
11	CBFbeta	B
12	-	I
13	SMMHC	I
14	fusion	I
15	protein	I
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	O
26	wild	O
27	-	O
28	type	O
29	or	O
30	fusion	O
31	protein	O
32	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	O
11	lumbar	O
12	disc	O
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	B
20	-	I
21	1	I
22	alpha	I
23	are	O
24	produced	O
25	,	O
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	Assessment	O
2	of	O
3	the	O
4	carcinogenicity	O
5	of	O
6	non	O
7	-	O
8	nutritive	O
9	sweetners	O
10	II	O
11	:	O
12	Cyclamates	O
13	and	O
14	cyclohexylamine	O
15	.	O

1	Exchange	O
2	of	O
3	the	O
4	LPL	B
5	and	O
6	HL	O
7	lids	O
8	resulted	O
9	in	O
10	a	O
11	reversal	O
12	of	O
13	the	O
14	phospholipase	B
15	/	I
16	neutral	I
17	lipase	I
18	ratio	O
19	,	O
20	establishing	O
21	the	O
22	important	O
23	role	O
24	of	O
25	this	O
26	region	O
27	in	O
28	mediating	O
29	substrate	O
30	specificity	O
31	.	O

1	Changes	O
2	in	O
3	body	O
4	weight	O
5	and	O
6	agonistic	O
7	behavior	O
8	were	O
9	also	O
10	recorded	O
11	.	O

1	Thus	O
2	,	O
3	phosphodiesterase	B
4	inhibitors	O
5	that	O
6	produce	O
7	an	O
8	opiate	O
9	quasi	O
10	-	O
11	withdrawal	O
12	syndrome	O
13	potentiate	O
14	interoceptive	O
15	stimuli	O
16	and	O
17	weight	O
18	loss	O
19	associated	O
20	with	O
21	the	O
22	withdrawal	O
23	syndrome	O
24	precipitated	O
25	by	O
26	naltrexone	O
27	in	O
28	morphine	O
29	-	O
30	dependent	O
31	rats	O
32	.	O

1	Escalation	O
2	to	O
3	180	O
4	mg	O
5	/	O
6	m2	O
7	was	O
8	to	O
9	be	O
10	carried	O
11	out	O
12	if	O
13	white	O
14	blood	O
15	cell	O
16	nadir	O
17	count	O
18	was	O
19	>	O
20	2	O
21	.	O
22	0	O
23	x	O
24	10	O
25	(	O
26	9	O
27	)/	O
28	l	O
29	and	O
30	platelet	O
31	nadir	O
32	count	O
33	was	O
34	>	O
35	75	O
36	x	O
37	10	O
38	(	O
39	9	O
40	)/	O
41	l	O
42	.	O

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	The	O
2	network	O
3	evolution	O
4	was	O
5	interpreted	O
6	by	O
7	an	O
8	approach	O
9	based	O
10	on	O
11	the	O
12	Flory	O
13	model	O
14	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	Retroviral	B
2	nucleocapsid	I
3	proteins	I
4	(	O
5	NCPs	O
6	)	O
7	are	O
8	CCHC	B
9	-	I
10	type	I
11	zinc	I
12	finger	I
13	proteins	I
14	that	O
15	mediate	O
16	virion	O
17	RNA	O
18	binding	O
19	activities	O
20	associated	O
21	with	O
22	retrovirus	O
23	assembly	O
24	and	O
25	genomic	O
26	RNA	O
27	encapsidation	O
28	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	ClC	B
5	-	I
6	6	I
7	(	O
8	a	O
9	member	O
10	of	O
11	the	O
12	CIC	O
13	chloride	O
14	-	O
15	channel	O
16	family	O
17	)	O
18	transcripts	O
19	generates	O
20	three	O
21	truncated	O
22	isoforms	O
23	one	O
24	of	O
25	which	O
26	,	O
27	ClC	B
28	-	I
29	6c	I
30	,	O
31	is	O
32	kidney	O
33	-	O
34	specific	O
35	.	O

1	TAR	O
2	and	O
3	Sp1	B
4	-	O
5	independent	O
6	transactivation	O
7	of	O
8	HIV	O
9	long	O
10	terminal	O
11	repeat	O
12	by	O
13	the	O
14	Tat	B
15	protein	I
16	in	O
17	the	O
18	presence	O
19	of	O
20	human	O
21	cytomegalovirus	O
22	IE1	B
23	/	O
24	IE2	B
25	.	O

1	Tec	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	and	O
15	the	O
16	Tec	B
17	pleckstrin	I
18	homology	I
19	domain	I
20	.	O

1	The	O
2	pulmonary	O
3	toxic	O
4	events	O
5	induced	O
6	by	O
7	acute	O
8	nitrogen	O
9	dioxide	O
10	(	O
11	NO	O
12	)	O
13	2	O
14	exposure	O
15	were	O
16	studied	O
17	in	O
18	the	O
19	rat	O
20	to	O
21	develop	O
22	an	O
23	inhalation	O
24	model	O
25	to	O
26	investigate	O
27	therapeutic	O
28	measures	O
29	.	O

1	First	O
2	,	O
3	human	O
4	erythroid	O
5	K562	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	HS	B
12	-	I
13	40	I
14	mutants	I
15	cis	I
16	linked	O
17	to	O
18	a	O
19	human	B
20	alpha	I
21	-	I
22	globin	I
23	promoter	I
24	-	I
25	growth	I
26	hormone	I
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O

1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O

1	The	O
2	activation	O
3	and	O
4	injury	O
5	of	O
6	endothelial	O
7	cells	O
8	induced	O
9	by	O
10	TNF	B
11	and	O
12	other	O
13	proinflammatory	O
14	cytokines	O
15	may	O
16	underlie	O
17	the	O
18	local	O
19	effects	O
20	of	O
21	these	O
22	mediators	O
23	in	O
24	vivo	O
25	.	O

1	Mesial	O
2	temporal	O
3	sclerosis	O
4	was	O
5	characterized	O
6	by	O
7	severe	O
8	neuronal	O
9	loss	O
10	accompanied	O
11	by	O
12	gliosis	O
13	occurring	O
14	in	O
15	the	O
16	CA1	O
17	/	O
18	prosubiculum	O
19	(	O
20	27	O
21	patients	O
22	,	O
23	100	O
24	%),	O
25	focally	O
26	in	O
27	the	O
28	dentate	O
29	gyrus	O
30	(	O
31	12	O
32	patients	O
33	,	O
34	44	O
35	%),	O
36	and	O
37	in	O
38	the	O
39	CA4	O
40	region	O
41	(	O
42	11	O
43	patients	O
44	,	O
45	41	O
46	%).	O

1	In	O
2	this	O
3	study	O
4	26	O
5	patients	O
6	(	O
7	20	O
8	females	O
9	and	O
10	6	O
11	males	O
12	)	O
13	were	O
14	evaluated	O
15	.	O

1	On	O
2	the	O
3	trail	O
4	of	O
5	Dr	O
6	.	O

1	A	O
2	role	O
3	for	O
4	glycogen	B
5	synthase	I
6	kinase	I
7	-	I
8	3	I
9	in	O
10	the	O
11	control	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	XXI	O
2	.	O

1	This	O
2	night	O
3	-	O
4	day	O
5	oscillation	O
6	is	O
7	driven	O
8	by	O
9	the	O
10	endogenous	O
11	clock	O
12	(	O
13	located	O
14	in	O
15	the	O
16	suprachiasmatic	O
17	nucleus	O
18	,	O
19	SCN	O
20	).	O

1	Enhancer	O
2	and	O
3	promoter	O
4	elements	O
5	directing	O
6	activation	O
7	and	O
8	glucocorticoid	O
9	repression	O
10	of	O
11	the	O
12	alpha	B
13	1	I
14	-	I
15	fetoprotein	I
16	gene	I
17	in	O
18	hepatocytes	O
19	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	,	O
7	from	O
8	nucleotide	O
9	-	O
10	837	O
11	to	O
12	-	O
13	336	O
14	,	O
15	contains	O
16	TATA	O
17	and	O
18	inverted	O
19	CAAT	O
20	boxes	O
21	as	O
22	well	O
23	as	O
24	GATA	B
25	-	I
26	1	I
27	/	O
28	SP1	B
29	erythroid	O
30	-	O
31	specific	O
32	cis	O
33	-	O
34	acting	O
35	regulatory	O
36	elements	O
37	.	O

1	After	O
2	termination	O
3	of	O
4	medication	O
5	the	O
6	animals	O
7	were	O
8	kindled	O
9	electrically	O
10	in	O
11	the	O
12	nucleus	O
13	amygdala	O
14	.	O

1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O

1	An	O
2	infectious	O
3	origin	O
4	should	O
5	always	O
6	be	O
7	excluded	O
8	since	O
9	specific	O
10	etiologic	O
11	therapy	O
12	may	O
13	be	O
14	implemented	O
15	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	ORFK10	O
2	.	O
3	5	O
4	encodes	O
5	a	O
6	protein	O
7	,	O
8	latency	B
9	-	I
10	associated	I
11	nuclear	I
12	antigen	I
13	2	I
14	(	O
15	LANA2	B
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	KSHV	O
22	-	O
23	infected	O
24	hematopoietic	O
25	tissues	O
26	,	O
27	including	O
28	PEL	O
29	and	O
30	CD	O
31	but	O
32	not	O
33	KS	O
34	lesions	O
35	.	O

1	The	O
2	survival	O
3	in	O
4	the	O
5	case	O
6	of	O
7	these	O
8	patients	O
9	was	O
10	studied	O
11	five	O
12	years	O
13	later	O
14	.	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	O
7	K1F	O
8	tail	O
9	gene	O
10	encoding	O
11	endo	B
12	-	I
13	N	I
14	-	I
15	acylneuraminidase	I
16	(	O
17	endo	O
18	-	O
19	N	O
20	)	O
21	and	O
22	comparison	O
23	to	O
24	an	O
25	endo	O
26	-	O
27	N	O
28	homolog	O
29	in	O
30	bacteriophage	O
31	PK1E	O
32	.	O

1	According	O
2	to	O
3	their	O
4	staining	O
5	affinity	O
6	for	O
7	anti	B
8	-	I
9	T	I
10	antibodies	I
11	,	O
12	the	O
13	glandular	O
14	tissue	O
15	cells	O
16	were	O
17	classified	O
18	as	O
19	T	B
20	-,	I
21	T	I
22	+,	I
23	T	I
24	++,	I
25	and	O
26	T	O
27	and	O
28	the	O
29	annual	O
30	changes	O
31	in	O
32	the	O
33	numbers	O
34	of	O
35	these	O
36	cell	O
37	populations	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	volume	O
45	occupied	O
46	by	O
47	the	O
48	glandular	O
49	tissue	O
50	,	O
51	were	O
52	calculated	O
53	.	O

1	A	O
2	limiting	O
3	factor	O
4	were	O
5	disturbances	O
6	in	O
7	the	O
8	system	O
9	of	O
10	energy	O
11	transport	O
12	(	O
13	creatine	O
14	phosphate	O
15	,	O
16	creatine	B
17	phosphokinase	I
18	)	O
19	and	O
20	of	O
21	the	O
22	calcium	O
23	pump	O
24	(	O
25	Ca	B
26	++-	I
27	ATPase	I
28	of	O
29	the	O
30	sarcoplasmic	O
31	reticulum	O
32	,	O
33	SPR	O
34	),	O
35	which	O
36	evidently	O
37	led	O
38	to	O
39	a	O
40	decrease	O
41	of	O
42	the	O
43	inotropic	O
44	properties	O
45	of	O
46	the	O
47	myocardium	O
48	at	O
49	70	O
50	%	O
51	restriction	O
52	of	O
53	coronary	O
54	blood	O
55	flow	O
56	.	O

1	We	O
2	compared	O
3	the	O
4	volume	O
5	of	O
6	the	O
7	pulmonary	O
8	extravascular	O
9	,	O
10	extracellular	O
11	water	O
12	space	O
13	using	O
14	sodium	O
15	and	O
16	sucrose	O
17	indicators	O
18	in	O
19	8	O
20	normal	O
21	and	O
22	11	O
23	edematous	O
24	rabbit	O
25	lungs	O
26	by	O
27	steady	O
28	-	O
29	state	O
30	techniques	O
31	.	O

1	Possible	O
2	factors	O
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	full	O
6	-	O
7	length	O
8	coding	O
9	cDNA	O
10	sequence	O
11	of	O
12	the	O
13	mouse	O
14	homologue	O
15	of	O
16	MPP3	O
17	.	O

1	Problems	O
2	in	O
3	the	O
4	determination	O
5	of	O
6	the	O
7	antigenic	O
8	content	O
9	of	O
10	influenza	O
11	vaccines	O
12	.	O

1	The	O
2	4	O
3	days	O
4	dexamethasone	O
5	suppression	O
6	test	O
7	showed	O
8	more	O
9	than	O
10	80	O
11	%	O
12	suppression	O
13	of	O
14	dehydroepiandrosterone	O
15	-	O
16	sulphate	O
17	and	O
18	a	O
19	variable	O
20	(	O
21	40	O
22	-	O
23	60	O
24	%)	O
25	reduction	O
26	of	O
27	testosterone	O
28	and	O
29	androstenedione	O
30	levels	O
31	.	O

1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	As	O
2	it	O
3	had	O
4	been	O
5	previously	O
6	reported	O
7	that	O
8	the	O
9	18	O
10	-	O
11	bp	O
12	palindrome	O
13	contains	O
14	sufficient	O
15	nucleotide	O
16	sequence	O
17	information	O
18	for	O
19	E1	B
20	binding	O
21	,	O
22	we	O
23	speculate	O
24	that	O
25	a	O
26	minimal	O
27	E1	O
28	recognition	O
29	motif	O
30	is	O
31	presented	O
32	in	O
33	each	O
34	half	O
35	site	O
36	.	O

1	Inhibition	O
2	of	O
3	phosphatidylinositol	B
4	-	I
5	3	I
6	kinase	I
7	did	O
8	not	O
9	have	O
10	a	O
11	significant	O
12	effect	O
13	on	O
14	p53	B
15	conformation	O
16	but	O
17	did	O
18	have	O
19	a	O
20	weak	O
21	but	O
22	significant	O
23	effect	O
24	on	O
25	Tpo	B
26	-	O
27	enhanced	O
28	viability	O
29	.	O

1	J	O
2	.	O

1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	factors	I
12	bound	O
13	to	O
14	the	O
15	E1	O
16	element	O
17	.	O

1	NF	B
2	-	I
3	kappaB	I
4	,	O
5	which	O
6	is	O
7	probably	O
8	important	O
9	for	O
10	basal	O
11	activity	O
12	of	O
13	the	O
14	human	B
15	NOS	I
16	II	I
17	promoter	I
18	,	O
19	is	O
20	unlikely	O
21	to	O
22	function	O
23	as	O
24	a	O
25	major	O
26	effector	O
27	of	O
28	CM	O
29	in	O
30	DLD	O
31	-	O
32	1	O
33	cells	O
34	.	O

1	Also	O
2	,	O
3	HR21ap	B
4	as	O
5	well	O
6	as	O
7	HR21Xap	B
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	B
15	binding	O
16	.	O

1	Most	O
2	of	O
3	them	O
4	were	O
5	situated	O
6	at	O
7	Sylvius	O
8	fissure	O
9	(	O
10	13	O
11	cases	O
12	).	O

1	A	O
2	potential	O
3	TATA	O
4	box	O
5	is	O
6	located	O
7	29	O
8	base	O
9	pairs	O
10	upstream	O
11	of	O
12	the	O
13	first	O
14	transcription	O
15	initiation	O
16	site	O
17	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	B
6	glycosylasparaginase	I
7	with	O
8	a	O
9	mammalian	B
10	glycosylasparaginase	I
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O

1	Benefits	O
2	of	O
3	obtaining	O
4	board	O
5	certification	O
6	in	O
7	pharmacotherapy	O
8	.	O

1	In	O
2	addition	O
3	,	O
4	CaMig1	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	B
15	.	I
16	cerevisiae	I
17	FBP1	I
18	gene	I
19	.	O

1	The	O
2	afferents	O
3	'	O
4	phase	O
5	of	O
6	response	O
7	was	O
8	unmodified	O
9	by	O
10	electrical	O
11	EVS	O
12	stimulation	O
13	.	O

1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	B
19	.	O

1	Interestingly	O
2	,	O
3	virions	O
4	also	O
5	contained	O
6	smaller	O
7	proteins	O
8	that	O
9	reacted	O
10	with	O
11	antibodies	O
12	specific	O
13	for	O
14	the	O
15	accessory	O
16	proteins	O
17	as	O
18	well	O
19	as	O
20	SN	B
21	and	O
22	CAT	B
23	fusion	O
24	partners	O
25	.	O

1	An	O
2	expression	O
3	library	O
4	was	O
5	constructed	O
6	by	O
7	inserting	O
8	5	O
9	'	O
10	portion	O
11	-	O
12	enriched	O
13	cDNAs	O
14	from	O
15	phytohemagglutinin	B
16	-	O
17	stimulated	O
18	peripheral	O
19	blood	O
20	mononuclear	O
21	cells	O
22	into	O
23	upstream	O
24	of	O
25	signal	O
26	sequence	O
27	-	O
28	deleted	O
29	CD4	B
30	cDNA	I
31	in	O
32	an	O
33	Epstein	O
34	-	O
35	Barr	O
36	virus	O
37	shuttle	O
38	vector	O
39	.	O

1	Extracellular	O
2	fibril	O
3	formation	O
4	by	O
5	neuroglial	O
6	cells	O
7	at	O
8	the	O
9	vitreoretinal	O
10	junction	O
11	of	O
12	the	O
13	human	O
14	eye	O
15	.	O

1	Two	O
2	of	O
3	these	O
4	resulted	O
5	in	O
6	increased	O
7	levels	O
8	of	O
9	the	O
10	alpha	O
11	subunit	O
12	,	O
13	and	O
14	one	O
15	caused	O
16	a	O
17	substitution	O
18	of	O
19	glycine	O
20	for	O
21	the	O
22	aspartic	O
23	acid	O
24	residue	O
25	at	O
26	position	O
27	171	O
28	,	O
29	in	O
30	the	O
31	N	O
32	-	O
33	terminal	O
34	domain	O
35	.	O

1	The	O
2	SSB	B
3	-	I
4	poly	I
5	(	O
6	dT	O
7	)	O
8	affinity	O
9	is	O
10	too	O
11	high	O
12	to	O
13	measure	O
14	in	O
15	buffers	O
16	containing	O
17	even	O
18	5	O
19	M	O
20	NaCl	O
21	;	O
22	however	O
23	,	O
24	in	O
25	1	O
26	.	O
27	8	O
28	-	O
29	2	O
30	.	O
31	5	O
32	M	O
33	NaBr	O
34	,	O
35	we	O
36	measure	O
37	alpha	O
38	log	O
39	Kobsd	O
40	/	O
41	alpha	O
42	log	O
43	[	O
44	NaBr	O
45	]	O
46	=	O
47	-	O
48	5	O
49	.	O
50	7	O
51	+/-	O
52	0	O
53	.	O
54	7	O
55	,	O
56	with	O
57	a	O
58	lower	O
59	value	O
60	of	O
61	omega	O
62	T	O
63	/	O
64	O	O
65	=	O
66	130	O
67	+/-	O
68	70	O
69	.	O

1	The	O
2	distribution	O
3	of	O
4	cryptosporidia	O
5	in	O
6	the	O
7	intestine	O
8	and	O
9	number	O
10	of	O
11	cryptosporidia	O
12	per	O
13	ileal	O
14	villus	O
15	on	O
16	different	O
17	DPI	O
18	were	O
19	also	O
20	estimated	O
21	for	O
22	detailed	O
23	characterization	O
24	of	O
25	the	O
26	infection	O
27	in	O
28	kids	O
29	as	O
30	a	O
31	model	O
32	for	O
33	experimental	O
34	cryptosporidiosis	O
35	.	O

1	If	O
2	no	O
3	reply	O
4	was	O
5	received	O
6	,	O
7	telephone	O
8	contact	O
9	or	O
10	home	O
11	visits	O
12	were	O
13	made	O
14	.	O

1	Adjuvant	O
2	therapy	O
3	for	O
4	colon	O
5	cancer	O
6	]	O
7	Surgery	O
8	alone	O
9	may	O
10	fail	O
11	to	O
12	cure	O
13	a	O
14	considerable	O
15	number	O
16	of	O
17	locally	O
18	advanced	O
19	colon	O
20	cancers	O
21	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	optimal	O
6	development	O
7	conditions	O
8	by	O
9	summary	O
10	oxygen	O
11	consumption	O

1	Interestingly	O
2	,	O
3	the	O
4	positions	O
5	of	O
6	these	O
7	introns	O
8	have	O
9	been	O
10	conserved	O
11	in	O
12	comparison	O
13	with	O
14	the	O
15	genes	O
16	of	O
17	two	O
18	other	O
19	transglutaminase	O
20	-	O
21	like	O
22	activities	O
23	described	O
24	in	O
25	the	O
26	literature	O
27	,	O
28	but	O
29	the	O
30	TGM1	B
31	gene	I
32	is	O
33	by	O
34	far	O
35	the	O
36	smallest	O
37	characterized	O
38	to	O
39	date	O
40	because	O
41	its	O
42	introns	O
43	are	O
44	relatively	O
45	smaller	O
46	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	EGF	B
8	/	O
9	Ras	B
10	/	O
11	Raf	B
12	induces	O
13	transcription	O
14	via	O
15	combined	O
16	activation	O
17	of	O
18	ATF3	B
19	/	O
20	c	B
21	-	I
22	Jun	I
23	and	O
24	a	O
25	52	O
26	-	O
27	kDa	O
28	nuclear	O
29	factor	O
30	,	O
31	whereas	O
32	JunD	B
33	acts	O
34	as	O
35	a	O
36	repressor	O
37	of	O
38	this	O
39	response	O
40	.	O

1	The	O
2	number	O
3	of	O
4	bacteria	O
5	in	O
6	the	O
7	lung	O
8	,	O
9	peripheral	O
10	white	O
11	blood	O
12	cell	O
13	and	O
14	BAL	O
15	fluid	O
16	cell	O
17	also	O
18	decreased	O
19	by	O
20	the	O
21	administration	O
22	of	O
23	FN	B
24	.	O

1	Sequence	O
2	determination	O
3	of	O
4	isolated	O
5	peptides	O
6	suggested	O
7	that	O
8	Asn120	B
9	is	O
10	glycosylated	O
11	,	O
12	Asn65	O
13	and	O
14	Asn109	B
15	glycosylated	O
16	in	O
17	some	O
18	molecules	O
19	but	O
20	not	O
21	in	O
22	others	O
23	,	O
24	and	O
25	Asn72	O
26	not	O
27	glycosylated	O
28	.	O

1	Cleavage	O
2	by	O
3	the	O
4	intron	O
5	-	O
6	encoded	O
7	enzyme	O
8	(	O
9	I	O
10	-	O
11	CreI	O
12	)	O
13	occurs	O
14	5	O
15	bp	O
16	and	O
17	1	O
18	bp	O
19	3	O
20	'	O
21	to	O
22	the	O
23	intron	O
24	insertion	O
25	site	O
26	(	O
27	in	O
28	the	O
29	3	O
30	'-	O
31	exon	O
32	)	O
33	in	O
34	the	O
35	top	O
36	(/)	O
37	and	O
38	bottom	O
39	(,)	O
40	strands	O
41	,	O
42	respectively	O
43	,	O
44	resulting	O
45	in	O
46	4	O
47	-	O
48	nt	O
49	single	O
50	-	O
51	stranded	O
52	overhangs	O
53	with	O
54	3	O
55	'-	O
56	OH	O
57	termini	O
58	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	human	O
6	Lnk	O
7	,	O
8	an	O
9	adaptor	O
10	protein	O
11	with	O
12	pleckstrin	B
13	homology	I
14	and	O
15	Src	B
16	homology	I
17	2	I
18	domains	I
19	that	O
20	can	O
21	inhibit	O
22	T	O
23	cell	O
24	activation	O
25	.	O

1	Synthesis	O
2	of	O
3	antisense	O
4	RNA	O
5	and	O
6	S	O
7	phase	O
8	-	O
9	dependent	O
10	binding	O
11	of	O
12	E2F	B
13	complexes	I
14	in	I
15	intron	I
16	1	I
17	.	O

1	Second	O
2	,	O
3	when	O
4	the	O
5	NBF1	B
6	+	I
7	R	I
8	protein	I
9	,	O
10	the	O
11	NBF2	B
12	protein	I
13	,	O
14	and	O
15	a	O
16	mixture	O
17	of	O
18	the	O
19	two	O
20	proteins	O
21	were	O
22	folded	O
23	separately	O
24	and	O
25	analyzed	O
26	by	O
27	molecular	O
28	sieve	O
29	chomatography	O
30	,	O
31	the	O
32	mixture	O
33	was	O
34	found	O
35	to	O
36	elute	O
37	prior	O
38	to	O
39	either	O
40	NBF1	O
41	+	O
42	R	O
43	or	O
44	NBF2	B
45	.	O

1	Statins	O
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O

1	Hydrocortisone	O
2	seems	O
3	to	O
4	be	O
5	unable	O
6	to	O
7	hinder	O
8	the	O
9	postdenervation	O
10	changes	O
11	in	O
12	the	O
13	muscle	O
14	membrane	O
15	whereas	O
16	high	O
17	doses	O
18	of	O
19	the	O
20	hormone	O
21	are	O
22	able	O
23	to	O
24	induce	O
25	changes	O
26	in	O
27	the	O
28	muscle	O
29	membrane	O
30	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	I
8	4FA	I
9	,	O
10	NF	B
11	-	I
12	4FB	I
13	,	O
14	and	O
15	AP	B
16	-	I
17	1	I
18	sequences	I
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	B
16	and	I
17	serum	I
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	Platelet	O
2	number	O
3	and	O
4	life	O
5	span	O
6	were	O
7	determined	O
8	in	O
9	the	O
10	last	O
11	trimester	O
12	of	O
13	pregnancy	O
14	in	O
15	22	O
16	women	O
17	who	O
18	were	O
19	delivered	O
20	of	O
21	small	O
22	-	O
23	for	O
24	-	O
25	gestational	O
26	age	O
27	(	O
28	SGA	O
29	)	O
30	infants	O
31	and	O
32	in	O
33	21	O
34	women	O
35	with	O
36	infants	O
37	having	O
38	normal	O
39	birth	O
40	weights	O
41	.	O

1	As	O
2	expected	O
3	,	O
4	glycosylation	O
5	of	O
6	Env	B
7	produced	O
8	from	O
9	mutants	O
10	was	O
11	affected	O
12	but	O
13	,	O
14	irrespective	O
15	of	O
16	the	O
17	glycosylation	O
18	phenotype	O
19	,	O
20	(	O
21	i	O
22	)	O
23	similar	O
24	quantities	O
25	of	O
26	Env	B
27	were	O
28	synthesized	O
29	,	O
30	(	O
31	ii	O
32	)	O
33	the	O
34	immunoreactivity	O
35	of	O
36	V3	B
37	was	O
38	similar	O
39	,	O
40	(	O
41	iii	O
42	)	O
43	gp160	O
44	was	O
45	efficiently	O
46	cleaved	O
47	into	O
48	gp120	B
49	and	O
50	gp41	O
51	,	O
52	(	O
53	vi	O
54	)	O
55	Env	B
56	was	O
57	exposed	O
58	at	O
59	the	O
60	cell	O
61	membrane	O
62	,	O
63	(	O
64	v	O
65	)	O
66	secreted	O
67	gp120	B
68	bound	O
69	CD4	B
70	,	O
71	and	O
72	(	O
73	vi	O
74	)	O
75	membrane	O
76	gp41	O
77	was	O
78	able	O
79	to	O
80	induce	O
81	membrane	O
82	fusion	O
83	with	O
84	CD4	B
85	+	I
86	cells	O
87	.	O

1	[	O
2	14C	O
3	]-	O
4	beta	O
5	-	O
6	phenethylamine	O
7	,	O
8	its	O
9	distribution	O
10	after	O
11	administration	O
12	by	O
13	various	O
14	routes	O
15	to	O
16	cats	O
17	,	O
18	and	O
19	the	O
20	effects	O
21	of	O
22	monoamine	B
23	oxidase	I
24	inhibitors	O
25	.	O

1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	O
39	tsp	O
40	).	O

1	Interferon	B
2	type	I
3	I	I
4	in	O
5	protective	O
6	body	O
7	reactions	O
8	in	O
9	an	O
10	experimental	O
11	Klebsiella	O
12	infection	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	examine	O
10	the	O
11	antimicrobial	O
12	susceptibility	O
13	to	O
14	10	O
15	currently	O
16	used	O
17	antimicrobial	O
18	agents	O
19	of	O
20	50	O
21	strains	O
22	of	O
23	P	O
24	.	O
25	acnes	O
26	isolated	O
27	from	O
28	acne	O
29	lesions	O
30	and	O
31	identified	O
32	using	O
33	a	O
34	Rap	B
35	ID	I
36	ANA	I
37	II	I
38	panel	I
39	.	O

1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O

1	Combination	O
2	of	O
3	3	O
4	multiple	O
5	primary	O
6	malignant	O
7	and	O
8	benign	O
9	tumors	O
10	of	O
11	the	O
12	breasts	O
13	and	O
14	uterus	O

1	The	O
2	Fis	B
3	protein	I
4	regulates	O
5	site	O
6	-	O
7	specific	O
8	DNA	O
9	inversion	O
10	catalyzed	O
11	by	O
12	a	O
13	family	O
14	of	O
15	DNA	O
16	invertases	O
17	when	O
18	bound	O
19	to	O
20	a	O
21	cis	O
22	-	O
23	acting	O
24	recombinational	O
25	enhancer	O
26	.	O

1	In	O
2	conclusion	O
3	,	O
4	marmoset	O
5	monkey	O
6	LHR	O
7	seems	O
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	O
18	LHR	B
19	gene	I
20	in	O
21	other	O
22	mammalian	O
23	species	O
24	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	promoters	O
6	for	O
7	muMIP	B
8	-	I
9	1	I
10	beta	I
11	and	O
12	muMIP	B
13	-	I
14	1	I
15	alpha	I
16	reveals	O
17	a	O
18	conserved	O
19	CK	B
20	-	I
21	1	I
22	element	I
23	,	O
24	but	O
25	transient	O
26	expression	O
27	studies	O
28	in	O
29	RAW	O
30	264	O
31	.	O
32	7	O
33	macrophages	O
34	with	O
35	proximal	O
36	fragments	O
37	of	O
38	either	O
39	the	O
40	muMIP	B
41	-	I
42	1	I
43	beta	I
44	or	O
45	the	O
46	muMIP	B
47	-	I
48	1	I
49	alpha	I
50	5	I
51	'	I
52	promoter	I
53	fused	O
54	to	O
55	a	O
56	human	B
57	growth	I
58	hormone	I
59	reporter	I
60	gene	I
61	link	I
62	LPS	I
63	-	I
64	inducibility	I
65	in	O
66	both	O
67	to	O
68	promoter	O
69	segments	O
70	near	O
71	to	O
72	,	O
73	but	O
74	not	O
75	identical	O
76	with	O
77	,	O
78	the	O
79	consensus	O
80	CK	B
81	-	I
82	1	I
83	sequence	I
84	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	negative	O
6	Smad2	O
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	B
13	reporter	I
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	B
26	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	investigate	O
6	whether	O
7	the	O
8	intergenic	O
9	region	O
10	between	O
11	the	O
12	oleosin	B
13	and	O
14	a	O
15	second	O
16	open	O
17	reading	O
18	frame	O
19	(	O
20	ORFII	O
21	)	O
22	in	O
23	Brassica	O
24	napus	O
25	(	O
26	L	O
27	.)	O
28	is	O
29	a	O
30	divergent	O
31	promoter	O
32	,	O
33	and	O
34	also	O
35	to	O
36	characterize	O
37	the	O
38	ORFII	O
39	,	O
40	cDNA	O
41	clones	O
42	homologous	O
43	to	O
44	ORFII	O
45	were	O
46	isolated	O
47	from	O
48	a	O
49	leaf	O
50	cDNA	O
51	library	O
52	.	O

1	INTERVENTIONS	O
2	:	O
3	Study	O
4	patients	O
5	were	O
6	randomly	O
7	divided	O
8	into	O
9	four	O
10	parallel	O
11	groups	O
12	to	O
13	receive	O
14	either	O
15	terbinafine	O
16	250	O
17	mg	O
18	a	O
19	day	O
20	for	O
21	12	O
22	or	O
23	16	O
24	weeks	O
25	(	O
26	groups	O
27	T12	O
28	and	O
29	T16	O
30	)	O
31	or	O
32	itraconazole	O
33	400	O
34	mg	O
35	a	O
36	day	O
37	for	O
38	1	O
39	week	O
40	in	O
41	every	O
42	4	O
43	weeks	O
44	for	O
45	12	O
46	or	O
47	16	O
48	weeks	O
49	(	O
50	groups	O
51	I3	O
52	and	O
53	I4	O
54	).	O

1	Two	O
2	major	O
3	and	O
4	one	O
5	minor	O
6	transcription	O
7	initiation	O
8	sites	O
9	were	O
10	assigned	O
11	to	O
12	positions	O
13	+	O
14	1	O
15	and	O
16	+	O
17	24	O
18	and	O
19	position	O
20	+	O
21	14	O
22	,	O
23	respectively	O
24	,	O
25	by	O
26	a	O
27	combination	O
28	of	O
29	ribonuclease	O
30	protection	O
31	,	O
32	primer	O
33	extension	O
34	,	O
35	and	O
36	5	O
37	'	O
38	RACE	O
39	analyses	O
40	.	O

1	Hyperthyroidism	O

1	Biol	O
2	.	O

1	Drug	O
2	and	O
3	nutrient	O
4	interactions	O
5	.	O

1	However	O
2	,	O
3	little	O
4	was	O
5	understood	O
6	about	O
7	the	O
8	normal	O
9	function	O
10	of	O
11	CREB	B
12	-	I
13	2	I
14	in	O
15	mammalian	O
16	development	O
17	or	O
18	organ	O
19	physiology	O
20	.	O

1	By	O
2	negatively	O
3	regulating	O
4	GRK	B
5	-	O
6	mediated	O
7	receptor	O
8	phosphorylation	O
9	,	O
10	beta	B
11	-	I
12	arrestin	I
13	-	O
14	mediated	O
15	processes	O
16	such	O
17	as	O
18	Src	B
19	recruitment	O
20	and	O
21	clathrin	B
22	-	O
23	mediated	O
24	internalization	O
25	,	O
26	which	O
27	are	O
28	required	O
29	for	O
30	GPCR	B
31	-	O
32	mediated	O
33	ERK	B
34	activation	O
35	,	O
36	are	O
37	inhibited	O
38	,	O
39	thus	O
40	dampening	O
41	further	O
42	ERK	B
43	activation	O
44	.	O

1	Extensive	O
2	DNA	O
3	rearrangement	O
4	occurs	O
5	during	O
6	the	O
7	development	O
8	of	O
9	the	O
10	somatic	O
11	macronucleus	O
12	from	O
13	the	O
14	germ	O
15	line	O
16	micronucleus	O
17	in	O
18	ciliated	O
19	protozoans	O
20	.	O

1	Upon	O
2	analysis	O
3	of	O
4	various	O
5	deletion	O
6	and	O
7	point	O
8	-	O
9	mutated	O
10	variants	O
11	of	O
12	the	O
13	human	B
14	IL	I
15	-	I
16	6	I
17	gene	I
18	promoter	I
19	coupled	O
20	to	O
21	a	O
22	reporter	O
23	gene	O
24	,	O
25	we	O
26	screened	O
27	for	O
28	possible	O
29	cooperating	O
30	transcription	O
31	factors	O
32	.	O

1	Albumin	B
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	B
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	)	I
29	alpha	I
30	and	I
31	C	I
32	/	I
33	EBPbeta	I
34	.	O

1	However	O
2	,	O
3	expression	O
4	of	O
5	sigma	B
6	3	I
7	from	I
8	S4	I
9	(	I
10	3	I
11	'	I
12	UTR	I
13	/	I
14	S1	I
15	),	O
16	which	O
17	included	O
18	the	O
19	PKR	B
20	activator	I
21	sequence	I
22	from	I
23	S1	I
24	within	O
25	the	O
26	3	O
27	'-	O
28	UTR	O
29	of	O
30	S4	O
31	,	O
32	was	O
33	comparable	O
34	to	O
35	that	O
36	from	O
37	wild	O
38	-	O
39	type	O
40	S4	O
41	.	O

1	Twenty	O
2	-	O
3	four	O
4	hours	O
5	later	O
6	,	O
7	the	O
8	animals	O
9	were	O
10	randomized	O
11	to	O
12	subretinal	O
13	treatment	O
14	with	O
15	2	O
16	.	O
17	5	O
18	micrograms	O
19	of	O
20	tissue	B
21	plasminogen	I
22	activator	I
23	or	O
24	a	O
25	similar	O
26	volume	O
27	of	O
28	physiologic	O
29	saline	O
30	.	O

1	High	O
2	dosages	O
3	of	O
4	D	O
5	-	O
6	penicillamine	O
7	in	O
8	pulmonary	O
9	fibroses	O

1	Transcriptional	O
2	control	O
3	of	O
4	a	O
5	nuclear	O
6	gene	O
7	encoding	O
8	a	O
9	mitochondrial	O
10	fatty	O
11	acid	O
12	oxidation	O
13	enzyme	O
14	in	O
15	transgenic	O
16	mice	O
17	:	O
18	role	O
19	for	O
20	nuclear	O
21	receptors	O
22	in	O
23	cardiac	O
24	and	O
25	brown	O
26	adipose	O
27	expression	O
28	.	O

1	This	O
2	virus	O
3	is	O
4	not	O
5	merely	O
6	a	O
7	South	O
8	African	O
9	strain	O
10	of	O
11	passion	O
12	fruit	O
13	woodiness	O
14	virus	O
15	(	O
16	PWV	O
17	):	O
18	the	O
19	deduced	O
20	CP	B
21	sequence	I
22	is	O
23	only	O
24	distantly	O
25	related	O
26	to	O
27	CPs	O
28	of	O
29	other	O
30	sequenced	O
31	strains	O
32	of	O
33	PWV	B
34	,	O
35	although	O
36	it	O
37	is	O
38	part	O
39	of	O
40	a	O
41	distinct	O
42	subgroup	O
43	of	O
44	potyviruses	O
45	related	O
46	to	O
47	PWV	O
48	.	O

1	An	O
2	abnormally	O
3	high	O
4	percentage	O
5	of	O
6	hypertensive	O
7	patients	O
8	(	O
9	approximately	O
10	30	O
11	%)	O
12	undergoing	O
13	cardiac	O
14	catheterization	O
15	because	O
16	of	O
17	anginal	O
18	pain	O
19	and	O
20	/	O
21	or	O
22	exercise	O
23	-	O
24	induced	O
25	ST	O
26	-	O
27	segment	O
28	depressions	O
29	has	O
30	angiographically	O
31	normal	O
32	coronary	O
33	arteries	O
34	.	O

1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O

1	The	O
2	cell	O
3	cycle	O
4	and	O
5	transcriptional	O
6	defects	O
7	caused	O
8	by	O
9	taf17	O
10	(	O
11	slm7	B
12	-	I
13	1	I
14	)	O
15	are	O
16	consistent	O
17	with	O
18	the	O
19	role	O
20	of	O
21	TAF	B
22	(	O
23	II	O
24	)	O
25	s	O
26	as	O
27	modulators	O
28	of	O
29	transcriptional	O
30	activation	O
31	and	O
32	may	O
33	reflect	O
34	a	O
35	role	O
36	for	O
37	TAF17	O
38	in	O
39	regulating	O
40	activation	O
41	by	O
42	SBF	B
43	and	O
44	MBF	O
45	.	O

1	The	O
2	complete	O
3	response	O
4	(	O
5	CR	O
6	)	O
7	rate	O
8	was	O
9	34	O
10	%	O
11	in	O
12	the	O
13	CODE	O
14	with	O
15	rhG	B
16	-	I
17	CSF	I
18	group	O
19	and	O
20	23	O
21	%	O
22	in	O
23	the	O
24	CODE	O
25	alone	O
26	group	O
27	;	O
28	the	O
29	median	O
30	survival	O
31	was	O
32	59	O
33	and	O
34	32	O
35	weeks	O
36	,	O
37	respectively	O
38	,	O
39	in	O
40	these	O
41	groups	O
42	(	O
43	P	O
44	=	O
45	0	O
46	.	O
47	004	O
48	).	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	IRF	B
7	-	I
8	1	I
9	is	O
10	degraded	O
11	via	O
12	the	O
13	ubiquitin	B
14	-	I
15	proteasome	I
16	pathway	O
17	.	O

1	To	O
2	modulate	O
3	transcription	O
4	,	O
5	regulatory	O
6	factors	O
7	communicate	O
8	with	O
9	basal	O
10	transcription	O
11	factors	O
12	and	O
13	/	O
14	or	O
15	RNA	B
16	polymerases	I
17	in	O
18	a	O
19	variety	O
20	of	O
21	ways	O
22	.	O

1	In	O
2	cases	O
3	of	O
4	1	O
5	degrees	O
6	HPT	O
7	,	O
8	the	O
9	plasma	O
10	1	O
11	,	O
12	25	O
13	-(	O
14	OH	O
15	)	O
16	2D	O
17	level	O
18	rose	O
19	significantly	O
20	in	O
21	all	O
22	cases	O
23	(	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	05	O
30	),	O
31	although	O
32	the	O
33	pattern	O
34	of	O
35	the	O
36	increase	O
37	was	O
38	not	O
39	uniform	O
40	.	O

1	Activation	O
2	of	O
3	c	B
4	-	I
5	fos	I
6	gene	I
7	expression	O
8	by	O
9	a	O
10	kinase	O
11	-	O
12	deficient	O
13	epidermal	B
14	growth	I
15	factor	I
16	receptor	I
17	.	O

1	The	O
2	sera	O
3	and	O
4	nasal	O
5	secretions	O
6	of	O
7	142	O
8	patients	O
9	,	O
10	who	O
11	were	O
12	positive	O
13	in	O
14	HD	O
15	or	O
16	mites	O
17	skin	O
18	test	O
19	,	O
20	were	O
21	subjected	O
22	to	O
23	a	O
24	radioallergosorbent	O
25	test	O
26	(	O
27	RAST	O
28	)	O
29	for	O
30	estimating	O
31	the	O
32	specific	O
33	IgE	B
34	antibody	I
35	activity	O
36	to	O
37	mites	O
38	.	O

1	The	O
2	yeast	B
3	SSS1	I
4	gene	I
5	is	O
6	essential	O
7	for	O
8	secretory	O
9	protein	O
10	translocation	O
11	and	O
12	encodes	O
13	a	O
14	conserved	O
15	protein	O
16	of	O
17	the	O
18	endoplasmic	O
19	reticulum	O
20	.	O

1	Anesthesia	O
2	with	O
3	M	O
4	/	O
5	K	O
6	was	O
7	reversed	O
8	after	O
9	41	O
10	.	O
11	6	O
12	min	O
13	of	O
14	immobilization	O
15	with	O
16	atipamezole	O
17	.	O

1	Kf	O
2	,	O
3	c	B
4	and	O
5	CT	O
6	(	O
7	referenced	O
8	to	O
9	the	O
10	initial	O
11	lung	O
12	mass	O
13	)	O
14	decreased	O
15	linearly	O
16	with	O
17	reductions	O
18	in	O
19	lung	O
20	mass	O
21	%	O
22	delta	O
23	Kf	O
24	,	O
25	c	O
26	=	O
27	1	O
28	.	O
29	26	O
30	-	O
31	0	O
32	.	O
33	98	O
34	%	O
35	mass	O
36	removed	O
37	(	O
38	r	O
39	=	O
40	0	O
41	.	O
42	90	O
43	,	O
44	P	O
45	less	O
46	than	O
47	0	O
48	.	O
49	01	O
50	)	O
51	and	O
52	%	O
53	delta	O
54	CT	O
55	=	O
56	-	O
57	3	O
58	.	O
59	99	O
60	-	O
61	0	O
62	.	O
63	98	O
64	%	O
65	mass	O
66	removed	O
67	(	O
68	r	O
69	=	O
70	0	O
71	.	O
72	82	O
73	,	O
74	P	O
75	less	O
76	than	O
77	0	O
78	.	O
79	01	O
80	)	O
81	relationships	O
82	that	O
83	were	O
84	not	O
85	altered	O
86	by	O
87	blocker	O
88	pretreatment	O
89	.(	O
90	ABSTRACT	O
91	TRUNCATED	O
92	AT	O
93	250	O
94	WORDS	O
95	)	O

1	SAM	O
2	-	O
3	TR	O
4	-	O
5	68	O
6	-	O
7	54	O
8	.	O

1	The	O
2	R2	B
3	region	I
4	within	O
5	the	O
6	class	B
7	I	I
8	enhancer	I
9	acts	O
10	as	O
11	a	O
12	negative	O
13	element	O
14	in	O
15	Ad12	O
16	-	O
17	transformed	O
18	cells	O
19	and	O
20	exhibits	O
21	a	O
22	stronger	O
23	binding	O
24	activity	O
25	than	O
26	is	O
27	observed	O
28	in	O
29	nontumorigenic	O
30	Ad5	O
31	-	O
32	transformed	O
33	cells	O
34	,	O
35	which	O
36	are	O
37	not	O
38	reduced	O
39	in	O
40	class	O
41	I	O
42	expression	O
43	.	O

1	Strontium	O
2	nitrate	O
3	mixed	O
4	with	O
5	glycolic	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	glycolic	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	shortened	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	irritation	O
29	sensation	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	SEM	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	SEM	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	irritation	O
75	sensation	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O

1	We	O
2	have	O
3	found	O
4	that	O
5	PEA2	B
6	is	O
7	also	O
8	required	O
9	for	O
10	the	O
11	bipolar	O
12	budding	O
13	pattern	O
14	and	O
15	that	O
16	it	O
17	encodes	O
18	a	O
19	novel	O
20	protein	O
21	with	O
22	a	O
23	predicted	O
24	coiled	O
25	-	O
26	coil	O
27	domain	O
28	.	O

1	A	O
2	cdc33	O
3	-	O
4	1	O
5	strain	O
6	expressing	O
7	either	O
8	stable	O
9	Cln3p	O
10	(	O
11	Cln3	B
12	-	I
13	1p	I
14	)	O
15	or	O
16	a	O
17	hybrid	O
18	UBI4	O
19	5	O
20	'-	O
21	CLN3	B
22	mRNA	I
23	,	O
24	whose	O
25	translation	O
26	displays	O
27	decreased	O
28	dependence	O
29	on	O
30	eIF4E	B
31	,	O
32	arrested	O
33	randomly	O
34	in	O
35	the	O
36	cell	O
37	cycle	O
38	.	O

1	The	O
2	Mig1	B
3	repressor	I
4	is	O
5	a	O
6	zinc	B
7	finger	I
8	protein	I
9	that	O
10	mediates	O
11	glucose	O
12	repression	O
13	in	O
14	yeast	O
15	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	3	O
6	'-	O
7	end	O
8	-	O
9	adjacent	O
10	sequence	O
11	CA	O
12	(	O
13	N	O
14	)	O
15	3	O
16	-	O
17	10AGTNNAA	O
18	,	O
19	conserved	O
20	in	O
21	plant	O
22	Pol	B
23	II	I
24	-	I
25	specific	I
26	U	I
27	snRNA	I
28	genes	I
29	,	O
30	is	O
31	essential	O
32	for	O
33	the	O
34	3	O
35	'-	O
36	end	O
37	formation	O
38	of	O
39	U2	B
40	transcripts	I
41	and	O
42	,	O
43	similar	O
44	to	O
45	the	O
46	vertebrate	O
47	3	O
48	'	O
49	box	O
50	,	O
51	is	O
52	highly	O
53	tolerant	O
54	to	O
55	mutation	O
56	.	O

1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	O
8	individual	O
9	elements	O
10	of	O
11	secondary	O
12	structure	O
13	derived	O
14	from	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	B
23	protein	I
24	L9	I
25	have	O
26	been	O
27	synthesized	O
28	.	O

1	Serotonin	B
2	5	I
3	-	I
4	HT2	I
5	receptor	I
6	binding	O
7	on	O
8	blood	O
9	platelets	O
10	as	O
11	a	O
12	state	O
13	dependent	O
14	marker	O
15	in	O
16	major	O
17	affective	O
18	disorder	O
19	.	O

1	Prevention	O
2	by	O
3	a	O
4	heparin	O
5	-	O
6	antithrombin	B
7	III	I
8	combination	O

1	The	O
2	extraction	O
3	was	O
4	subsequently	O
5	rated	O
6	as	O
7	'	O
8	easy	O
9	'	O
10	or	O
11	'	O
12	difficult	O
13	'.	O
14	Taking	O
15	Pell	O
16	-	O
17	Gregory	O
18	class	O
19	C	O
20	as	O
21	a	O
22	predictor	O
23	of	O
24	a	O
25	'	O
26	difficult	O
27	'	O
28	extraction	O
29	,	O
30	specificity	O
31	was	O
32	88	O
33	%	O
34	but	O
35	sensitivity	O
36	was	O
37	low	O
38	at	O
39	15	O
40	%.	O

1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O

1	First	O
2	,	O
3	a	O
4	pet54	O
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	O
19	introns	O
20	aI5	B
21	alpha	I
22	and	O
23	aI5	B
24	beta	I
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	B
30	gene	I
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	B
36	mRNA	I
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O

1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Myb	I
7	regulates	O
8	the	O
9	RAG	B
10	-	I
11	2	I
12	promoter	I
13	in	O
14	T	O
15	cells	O
16	by	O
17	binding	O
18	to	O
19	this	O
20	consensus	O
21	c	B
22	-	I
23	Myb	I
24	binding	I
25	site	I
26	.	O

1	In	O
2	addition	O
3	to	O
4	restoring	O
5	checkpoint	O
6	control	O
7	,	O
8	overexpression	O
9	of	O
10	sum1	O
11	+	O
12	inhibits	O
13	the	O
14	normal	O
15	cell	O
16	cycle	O
17	response	O
18	to	O
19	osmotic	O
20	stress	O
21	.	O

1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	B
19	53	I
20	-	I
21	16	I
22	-	I
23	7	I
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	"	O
62	patch	O
63	7D	O
64	").	O

1	In	O
2	summary	O
3	,	O
4	DDC	B
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	DC	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O

1	The	O
2	3ASubE	O
3	cells	O
4	expressing	O
5	CXCR2	O
6	with	O
7	mutation	O
8	of	O
9	Ser	O
10	-	O
11	346	O
12	,	O
13	-	O
14	347	O
15	,	O
16	and	O
17	-	O
18	348	O
19	to	O
20	alanine	O
21	,	O
22	or	O
23	with	O
24	mutation	O
25	of	O
26	only	O
27	one	O
28	serine	O
29	in	O
30	this	O
31	domain	O
32	,	O
33	continue	O
34	to	O
35	be	O
36	phosphorylated	O
37	in	O
38	response	O
39	to	O
40	ligand	O
41	and	O
42	are	O
43	60	O
44	-	O
45	70	O
46	%	O
47	desensitized	O
48	following	O
49	the	O
50	initial	O
51	ligand	O
52	challenge	O
53	.	O

1	A	O
2	deletion	O
3	mutation	O
4	analysis	O
5	of	O
6	the	O
7	recombinant	B
8	protein	I
9	has	O
10	shown	O
11	that	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	region	O
17	and	O
18	the	O
19	two	O
20	leucine	O
21	zippers	O
22	are	O
23	necessary	O
24	for	O
25	the	O
26	binding	O
27	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	ORF	O
7	of	O
8	hAMPK	B
9	encodes	O
10	552	O
11	amino	O
12	acids	O
13	(	O
14	aa	O
15	)	O
16	(	O
17	62	O
18	.	O
19	250	O
20	kDa	O
21	)	O
22	and	O
23	is	O
24	highly	O
25	conserved	O
26	with	O
27	rAMPK	O
28	with	O
29	identities	O
30	of	O
31	97	O
32	.	O
33	3	O
34	and	O
35	90	O
36	%	O
37	at	O
38	the	O
39	aa	O
40	and	O
41	nt	O
42	levels	O
43	,	O
44	respectively	O
45	.	O

1	All	O
2	members	O
3	are	O
4	also	O
5	capable	O
6	of	O
7	activating	O
8	in	O
9	vivo	O
10	transcription	O
11	from	O
12	promoters	O
13	that	O
14	contain	O
15	a	O
16	C	B
17	/	I
18	EBP	I
19	-	I
20	binding	I
21	site	I
22	.	O

1	The	O
2	possibility	O
3	of	O
4	a	O
5	hereditary	O
6	disorder	O
7	leading	O
8	to	O
9	a	O
10	minor	O
11	defect	O
12	in	O
13	elastic	O
14	fibre	O
15	structure	O
16	which	O
17	could	O
18	be	O
19	responsible	O
20	for	O
21	the	O
22	spontaneous	O
23	lesions	O
24	is	O
25	discussed	O
26	.	O

1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	O
34	phosphatase	O
35	(	O
36	ACP	O
37	)	O
38	method	O
39	.	O

1	Regulatory	O
2	regions	O
3	in	O
4	the	O
5	promoter	O
6	and	O
7	third	O
8	intron	O
9	of	O
10	the	O
11	growth	B
12	hormone	I
13	gene	I
14	in	O
15	rainbow	O
16	trout	O
17	,	O
18	Oncorhynchus	O
19	mykiss	O
20	walbaum	O
21	.	O

1	By	O
2	using	O
3	a	O
4	DNA	O
5	sequence	O
6	selected	O
7	for	O
8	its	O
9	ability	O
10	to	O
11	bind	O
12	recombinant	B
13	BCL	I
14	-	I
15	6	I
16	in	O
17	vitro	O
18	,	O
19	we	O
20	show	O
21	here	O
22	that	O
23	BCL	B
24	-	I
25	6	I
26	is	O
27	present	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	complexes	O
33	in	O
34	nuclear	O
35	extracts	O
36	from	O
37	various	O
38	B	O
39	-	O
40	cell	O
41	lines	O
42	.	O

1	Another	O
2	stem	O
3	-	O
4	loop	O
5	called	O
6	structure	O
7	III	O
8	near	O
9	the	O
10	3	O
11	'-	O
12	end	O
13	of	O
14	repY	O
15	sequesters	O
16	both	O
17	the	O
18	5	O
19	'-	O
20	rCGCC	O
21	-	O
22	3	O
23	'	O
24	sequence	O
25	and	O
26	the	O
27	repZ	B
28	ribosome	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	Engagement	O
2	of	O
3	human	B
4	CD2	I
5	by	O
6	mitogenic	O
7	pairs	O
8	of	O
9	anti	B
10	-	I
11	CD2	I
12	mAb	I
13	induces	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	a	O
18	number	O
19	of	O
20	intracellular	O
21	proteins	O
22	including	O
23	a	O
24	120	O
25	kDa	O
26	phosphoprotein	O
27	that	O
28	we	O
29	identify	O
30	as	O
31	the	O
32	proto	B
33	-	I
34	oncogene	I
35	c	I
36	-	I
37	Cbl	I
38	.	O

1	Esophageal	O
2	brush	O
3	cytological	O
4	screening	O
5	was	O
6	undertaken	O
7	and	O
8	blood	O
9	concentrations	O
10	of	O
11	micronutrients	O
12	(	O
13	vitamin	O
14	A	O
15	,	O
16	E	O
17	,	O
18	B12	O
19	,	O
20	folic	O
21	acid	O
22	and	O
23	methionine	O
24	)	O
25	determined	O
26	from	O
27	adults	O
28	at	O
29	risk	O
30	for	O
31	esophageal	O
32	carcinoma	O
33	(	O
34	EC	O
35	)	O
36	in	O
37	Transkei	O
38	and	O
39	Ciskei	O
40	,	O
41	Southern	O
42	Africa	O
43	.	O

1	In	O
2	patients	O
3	who	O
4	had	O
5	received	O
6	no	O
7	previous	O
8	drug	O
9	treatment	O
10	,	O
11	log	O
12	baseline	O
13	plasma	O
14	renin	B
15	activity	O
16	and	O
17	change	O
18	in	O
19	mean	O
20	blood	O
21	pressure	O
22	after	O
23	SQ	O
24	20881	O
25	correlated	O
26	significantly	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	651	O
33	,	O
34	P	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	).	O

1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	the	O
5	amino	O
6	-	O
7	terminal	O
8	17	O
9	%	O
10	of	O
11	apoB	B
12	(	O
13	apoB17	O
14	)	O
15	was	O
16	fused	O
17	to	O
18	a	O
19	cDNA	O
20	coding	O
21	for	O
22	the	O
23	last	O
24	37	O
25	amino	O
26	acids	O
27	of	O
28	decay	O
29	-	O
30	accelerating	O
31	factor	O
32	(	O
33	DAF	B
34	),	O
35	which	O
36	contains	O
37	the	O
38	signal	O
39	for	O
40	glycosylphosphatidylinositol	O
41	anchor	O
42	attachment	O
43	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	B
28	1	I
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O

1	The	O
2	dichloromethane	O
3	is	O
4	removed	O
5	,	O
6	mobile	O
7	phase	O
8	solvent	O
9	is	O
10	added	O
11	,	O
12	and	O
13	aliquots	O
14	are	O
15	injected	O
16	onto	O
17	a	O
18	PRP	B
19	-	I
20	1	I
21	liquid	O
22	chromatographic	O
23	column	O
24	;	O
25	fluazifop	O
26	acid	O
27	is	O
28	separated	O
29	from	O
30	coextracted	O
31	compounds	O
32	and	O
33	detected	O
34	at	O
35	an	O
36	applied	O
37	potential	O
38	of	O
39	+	O
40	1	O
41	.	O
42	25	O
43	V	O
44	,	O
45	using	O
46	an	O
47	amperometric	O
48	electrochemical	O
49	detector	O
50	in	O
51	the	O
52	oxidation	O
53	mode	O
54	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	mouse	B
9	HO	I
10	-	I
11	1	I
12	gene	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	of	O
18	p32	B
19	,	O
20	initially	O
21	identified	O
22	as	O
23	a	O
24	stress	O
25	-	O
26	induced	O
27	protein	O
28	in	O
29	mouse	O
30	BALBc	B
31	/	O
32	3T3	O
33	cells	O
34	.	O

1	The	O
2	Drosophila	B
3	clathrin	I
4	heavy	I
5	chain	I
6	gene	I
7	:	O
8	clathrin	B
9	function	O
10	is	O
11	essential	O
12	in	O
13	a	O
14	multicellular	O
15	organism	O
16	.	O

1	Subjects	O
2	were	O
3	16	O
4	male	O
5	chronic	O
6	schizophrenics	O
7	consisting	O
8	of	O
9	8	O
10	DST	O
11	suppressors	O
12	and	O
13	8	O
14	nonsuppressors	O
15	.	O

1	Relations	O
2	between	O
3	cellular	O
4	electrical	O
5	activity	O
6	and	O
7	cardiac	O
8	mechanical	O
9	activity	O
10	in	O
11	man	O
12	,	O
13	the	O
14	dog	O
15	and	O
16	the	O
17	rabbit	O

1	An	O
2	ASSEMBLER	O
3	routine	O
4	for	O
5	on	O
6	-	O
7	line	O
8	graphic	O
9	display	O
10	and	O
11	averaging	O
12	of	O
13	data	O
14	acquired	O
15	on	O
16	a	O
17	personal	O
18	microcomputer	O
19	.	O

1	Modification	O
2	by	O
3	this	O
4	latter	O
5	compound	O
6	was	O
7	so	O
8	extensive	O
9	that	O
10	the	O
11	amount	O
12	of	O
13	membrane	O
14	-	O
15	associated	O
16	N	O
17	-	O
18	myristoylated	O
19	protein	O
20	was	O
21	decreased	O
22	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	DAF16	O
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	B
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	Cholinesterase	O

1	Model	O
2	IV	O
3	:	O
4	primary	O
5	abutments	O
6	with	O
7	the	O
8	lateral	O
9	incisor	O
10	and	O
11	the	O
12	second	O
13	molar	O
14	as	O
15	secondary	O
16	abutments	O
17	.	O

1	This	O
2	repression	O
3	was	O
4	reversed	O
5	agonists	O
6	of	O
7	either	O
8	receptor	O
9	demonstrating	O
10	a	O
11	functional	O
12	interaction	O
13	between	O
14	NCoR	B
15	and	O
16	PPARalpha	B
17	.	O
18	RXRalpha	B
19	heterodimeric	I
20	complexes	I
21	in	O
22	mammalian	O
23	cells	O
24	.	O

1	Regulation	O
2	of	O
3	parathyroid	B
4	hormone	I
5	-	I
6	related	I
7	protein	I
8	(	I
9	PTHrP	I
10	)	I
11	gene	I
12	expression	O
13	.	O

1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O

1	The	O
2	risk	O
3	factors	O
4	for	O
5	hematuria	O
6	in	O
7	patients	O
8	with	O
9	renal	O
10	hypouricemia	O
11	are	O
12	the	O
13	elevation	O
14	of	O
15	urinary	O
16	urate	O
17	concentration	O
18	and	O
19	the	O
20	subtypes	O
21	of	O
22	Post	O
23	and	O
24	Secretion	O
25	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	O
10	molecule	O
11	.	O

1	The	O
2	average	O
3	deviations	O
4	in	O
5	the	O
6	X	O
7	-	O
8	ray	O
9	counts	O
10	of	O
11	the	O
12	constant	O
13	elements	O
14	from	O
15	the	O
16	series	O
17	means	O
18	were	O
19	used	O
20	to	O
21	correct	O
22	the	O
23	recorded	O
24	count	O
25	of	O
26	the	O
27	variable	O
28	element	O
29	in	O
30	each	O
31	block	O
32	.	O

1	The	O
2	goal	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	determine	O
10	the	O
11	feasibility	O
12	of	O
13	retrovirus	O
14	mediated	O
15	expression	O
16	of	O
17	rp47phox	O
18	in	O
19	the	O
20	HL60	O
21	and	O
22	U937	O
23	human	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	,	O
28	and	O
29	in	O
30	an	O
31	Epstein	O
32	-	O
33	Barr	O
34	virus	O
35	transformed	O
36	B	O
37	-	O
38	lymphocyte	O
39	cell	O
40	line	O
41	(	O
42	EBV	O
43	-	O
44	BCL	O
45	)	O
46	derived	O
47	from	O
48	a	O
49	p47phox	O
50	-	O
51	deficient	O
52	CGD	O
53	patient	O
54	.	O

1	COUP	B
2	transcription	I
3	factor	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	steroid	B
10	receptor	I
11	superfamily	I
12	.	O

1	All	O
2	patients	O
3	had	O
4	the	O
5	CA	B
6	125	I
7	assay	O
8	performed	O
9	within	O
10	one	O
11	week	O
12	before	O
13	their	O
14	second	O
15	-	O
16	look	O
17	operation	O
18	.	O

1	Guiding	O
2	patients	O
3	in	O
4	the	O
5	decision	O
6	should	O
7	involve	O
8	a	O
9	multidisciplinary	O
10	team	O
11	composed	O
12	of	O
13	a	O
14	surgical	O
15	oncologist	O
16	,	O
17	geneticist	O
18	,	O
19	pathologist	O
20	,	O
21	psychotherapist	O
22	and	O
23	plastic	O
24	surgeon	O
25	.	O

1	Mutation	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	binding	I
8	sites	I
9	in	O
10	the	O
11	Rous	B
12	sarcoma	I
13	virus	I
14	long	I
15	terminal	I
16	repeat	I
17	and	O
18	gag	B
19	enhancers	O
20	.	O

1	Characterization	O
2	of	O
3	CR1	O
4	repeat	O
5	random	O
6	PCR	O
7	markers	O
8	for	O
9	mapping	O
10	the	O
11	chicken	O
12	genome	O
13	.	O

1	Since	O
2	electrical	O
3	stimulation	O
4	of	O
5	neurones	O
6	may	O
7	activate	O
8	not	O
9	only	O
10	cell	O
11	bodies	O
12	but	O
13	also	O
14	neuronal	O
15	fibres	O
16	,	O
17	this	O
18	study	O
19	aimed	O
20	to	O
21	test	O
22	a	O
23	selectively	O
24	cholinergic	O
25	neurochemical	O
26	stimulation	O
27	of	O
28	the	O
29	rat	O
30	substantia	O
31	innominata	O
32	(	O
33	SI	O
34	)	O
35	by	O
36	the	O
37	local	O
38	microinjection	O
39	of	O
40	carbachol	O
41	;	O
42	the	O
43	effects	O
44	of	O
45	this	O
46	acetylcholine	O
47	agonist	O
48	were	O
49	compared	O
50	with	O
51	glutamate	O
52	.	O

1	The	O
2	bactericidal	O
3	activity	O
4	of	O
5	six	O
6	new	O
7	rifamycin	O
8	derivatives	O
9	--	O
10	rifabutin	O
11	(	O
12	RBU	O
13	),	O
14	FCE	B
15	22250	I
16	(	O
17	F22	O
18	),	O
19	rifapentine	O
20	(	O
21	RPE	O
22	),	O
23	CGP	O
24	29861	O
25	(	O
26	C29	O
27	),	O
28	CGP	O
29	7040	O
30	(	O
31	C70	O
32	)	O
33	and	O
34	CGP	O
35	27557	O
36	(	O
37	C27	O
38	)	O
39	and	O
40	rifampicin	O
41	(	O
42	RMP	B
43	)--	I
44	have	O
45	been	O
46	measured	O
47	against	O
48	log	O
49	phase	O
50	and	O
51	,	O
52	as	O
53	a	O
54	better	O
55	test	O
56	of	O
57	sterilising	O
58	activity	O
59	,	O
60	against	O
61	stationary	O
62	phase	O
63	cultures	O
64	of	O
65	Mycobacterium	O
66	tuberculosis	O
67	,	O
68	H37Rv	O
69	.	O

1	There	O
2	are	O
3	no	O
4	introns	O
5	within	O
6	the	O
7	gene	O
8	,	O
9	which	O
10	contains	O
11	a	O
12	9360	O
13	-	O
14	bp	O
15	open	O
16	reading	O
17	frame	O
18	and	O
19	encodes	O
20	a	O
21	377	O
22	-	O
23	kDa	O
24	protein	O
25	.	O

1	Liposomal	O
2	Amphotericin	O
3	-	O
4	B	O
5	failed	O
6	in	O
7	6	O
8	/	O
9	7	O
10	patients	O
11	with	O
12	culture	O
13	-	O
14	proven	O
15	mycosis	O
16	who	O
17	died	O
18	from	O
19	infection	O
20	with	O
21	Aspergillus	O
22	(	O
23	n	O
24	=	O
25	2	O
26	)	O
27	and	O
28	Candida	O
29	(	O
30	n	O
31	=	O
32	4	O
33	),	O
34	respectively	O
35	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	cDNA	O
6	encoding	O
7	human	B
8	MEKK3	I
9	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	showed	O
7	that	O
8	OxyR	B
9	-	I
10	C199S	I
11	protected	O
12	Pmom	O
13	from	O
14	-	O
15	104	O
16	to	O
17	-	O
18	46	O
19	on	O
20	the	O
21	top	O
22	strand	O
23	and	O
24	produced	O
25	a	O
26	protection	O
27	pattern	O
28	characteristic	O
29	of	O
30	reduced	O
31	wild	B
32	-	I
33	type	I
34	OxyR	I
35	.	O

1	The	O
2	transactivation	O
3	function	O
4	of	O
5	EBNA2	B
6	was	O
7	also	O
8	observed	O
9	in	O
10	the	O
11	HeLa	O
12	epithelial	O
13	cell	O
14	line	O
15	,	O
16	which	O
17	suggests	O
18	that	O
19	EBV	O
20	and	O
21	HIV	O
22	-	O
23	1	O
24	infection	O
25	of	O
26	non	O
27	-	O
28	B	O
29	cells	O
30	may	O
31	result	O
32	in	O
33	HIV	O
34	-	O
35	1	O
36	promoter	O
37	activation	O
38	.	O

1	Beta	B
2	-	I
3	endorphin	I
4	,	O
5	ACTH	B
6	and	O
7	cortisol	O
8	secretion	O
9	were	O
10	measured	O
11	in	O
12	twelve	O
13	healthy	O
14	adult	O
15	males	O
16	after	O
17	nasal	O
18	spray	O
19	administration	O
20	200	O
21	IU	O
22	salmon	O
23	calcitonin	B
24	.	O

1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	I
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	Furthermore	O
2	,	O
3	upstream	O
4	insertion	O
5	of	O
6	the	O
7	GSTP1	B
8	silencer	I
9	element	I
10	failed	O
11	to	O
12	inhibit	O
13	activity	O
14	of	O
15	a	O
16	heterologous	O
17	promoter	O
18	in	O
19	MCF7	O
20	cells	O
21	.	O

1	Radiosensitive	O
2	nature	O
3	of	O
4	paravascular	O
5	infiltrate	O
6	-	O
7	producing	O
8	potential	O
9	of	O
10	parental	O
11	spleen	O
12	cells	O
13	.	O

1	Two	O
2	studies	O
3	on	O
4	the	O
5	relationship	O
6	between	O
7	taking	O
8	a	O
9	commercial	O
10	coaching	O
11	course	O
12	and	O
13	performance	O
14	on	O
15	the	O
16	Medical	O
17	College	O
18	Admission	O
19	Test	O
20	(	O
21	MCAT	O
22	)	O
23	are	O
24	reported	O
25	.	O

1	The	O
2	yeast	O
3	gene	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	,	O
10	designated	O
11	TIF5	B
12	,	O
13	has	O
14	been	O
15	isolated	O
16	and	O
17	expressed	O
18	in	O
19	Escherichia	O
20	coli	O
21	to	O
22	yield	O
23	a	O
24	catalytically	O
25	active	O
26	eIF	B
27	-	I
28	5	I
29	protein	I
30	.	O

1	The	O
2	hematopoietic	B
3	colony	I
4	-	I
5	stimulating	I
6	factors	I
7	(	I
8	CSF	I
9	)	O
10	have	O
11	been	O
12	introduced	O
13	into	O
14	clinical	O
15	practice	O
16	as	O
17	additional	O
18	supportive	O
19	measures	O
20	that	O
21	can	O
22	reduce	O
23	the	O
24	incidence	O
25	of	O
26	infectious	O
27	complications	O
28	in	O
29	patients	O
30	with	O
31	cancer	O
32	and	O
33	neutropenia	O
34	.	O

1	Paraneoplastic	O
2	rheumatic	O
3	syndromes	O
4	.	O

1	Counter	O
2	-	O
3	current	O
4	heat	O
5	exchange	O
6	in	O
7	the	O
8	respiratory	O
9	passages	O
10	:	O
11	effect	O
12	on	O
13	water	O
14	and	O
15	heat	O
16	balance	O
17	.	O

1	Combined	O
2	therapy	O
3	with	O
4	MK	O
5	-	O
6	801	O
7	and	O
8	nimodipine	O
9	for	O
10	protection	O
11	of	O
12	ischemic	O
13	brain	O
14	damage	O
15	.	O

1	The	O
2	gene	O
3	lac	B
4	-	I
5	1	I
6	,	O
7	encoding	O
8	the	O
9	enzyme	B
10	laccase	I
11	,	O
12	is	O
13	the	O
14	best	O
15	characterized	O
16	of	O
17	a	O
18	number	O
19	of	O
20	genes	O
21	in	O
22	the	O
23	chestnut	O
24	blight	O
25	fungus	O
26	,	O
27	Cryphonectria	O
28	parasitica	O
29	,	O
30	that	O
31	are	O
32	repressed	O
33	by	O
34	hypoviruses	O
35	,	O
36	a	O
37	group	O
38	of	O
39	virulence	O
40	-	O
41	attenuating	O
42	mycoviruses	O
43	.	O
44	lac	B
45	-	I
46	1	I
47	has	O
48	also	O
49	been	O
50	shown	O
51	to	O
52	be	O
53	transcriptionally	O
54	activated	O
55	by	O
56	low	O
57	concentrations	O
58	of	O
59	the	O
60	translational	O
61	inhibitor	O
62	cycloheximide	O
63	(	O
64	CHX	O
65	)	O
66	and	O
67	by	O
68	the	O
69	immunosuppressant	O
70	cyclosporin	O
71	A	O
72	.	O

1	A	O
2	"	O
3	Level	O
4	A	O
5	"	O
6	in	O
7	vitro	O
8	/	O
9	in	O
10	vivo	O
11	correlation	O
12	was	O
13	established	O
14	for	O
15	a	O
16	sustained	O
17	release	O
18	theophylline	O
19	(	O
20	CAS	B
21	58	O
22	-	O
23	55	O
24	-	O
25	9	O
26	)	O
27	preparation	O
28	(	O
29	Bronchoretard	O
30	)	O
31	under	O
32	investigation	O
33	.	O

1	In	O
2	eight	O
3	groups	O
4	of	O
5	subjects	O
6	operating	O
7	various	O
8	hand	O
9	-	O
10	held	O
11	vibrating	O
12	tools	O
13	and	O
14	aged	O
15	from	O
16	30	O
17	to	O
18	59	O
19	years	O
20	,	O
21	the	O
22	prevalence	O
23	rates	O
24	of	O
25	vibration	O
26	-	O
27	induced	O
28	white	O
29	finger	O
30	(	O
31	VWF	O
32	)	O
33	and	O
34	numbness	O
35	,	O
36	pain	O
37	,	O
38	or	O
39	stiffness	O
40	in	O
41	the	O
42	upper	O
43	and	O
44	lower	O
45	extremities	O
46	were	O
47	investigated	O
48	.	O

1	Both	O
2	resting	O
3	blood	O
4	flow	O
5	(	O
6	RBF	O
7	)	O
8	and	O
9	maximal	O
10	blood	O
11	flow	O
12	(	O
13	NBF	O
14	)	O
15	were	O
16	studied	O
17	by	O
18	Xenon	O
19	133	O
20	clearance	O
21	.	O

1	Overexpression	O
2	of	O
3	Trdpm1	O
4	in	O
5	a	O
6	dpm1	O
7	(+)::	O
8	his7	O
9	/	O
10	dpm1	O
11	(+)	B
12	S	I
13	.	O
14	pombe	O
15	diploid	O
16	resulted	O
17	in	O
18	a	O
19	4	O
20	-	O
21	fold	O
22	increase	O
23	in	O
24	specific	O
25	DPM	B
26	synthase	I
27	activity	O
28	.	O

1	These	O
2	results	O
3	are	O
4	very	O
5	useful	O
6	for	O
7	deciding	O
8	on	O
9	the	O
10	doses	O
11	of	O
12	hormones	O
13	and	O
14	the	O
15	expected	O
16	serum	O
17	estradiol	O
18	level	O
19	in	O
20	HRT	O
21	for	O
22	Japanese	O
23	women	O
24	.	O

1	Sequence	O
2	comparisons	O
3	have	O
4	shown	O
5	that	O
6	Aps1p	B
7	is	O
8	more	O
9	similar	O
10	to	O
11	the	O
12	sigma	O
13	subunit	O
14	of	O
15	the	O
16	Golgi	O
17	-	O
18	localized	O
19	mammalian	B
20	AP	I
21	-	I
22	1	I
23	complex	O
24	than	O
25	Aps2p	B
26	,	O
27	which	O
28	is	O
29	more	O
30	related	O
31	to	O
32	the	O
33	plasma	O
34	membrane	O
35	AP	B
36	-	I
37	2	I
38	sigma	I
39	subunit	I
40	.	O

1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	I
19	'	I
20	UTR	I
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	O
33	)	O
34	binding	O
35	proteins	O
36	of	O
37	the	O
38	alpha	O
39	-	O
40	complex	O
41	.	O

1	This	O
2	gave	O
3	rise	O
4	to	O
5	RNA	O
6	molecules	O
7	with	O
8	3	O
9	'-	O
10	untranslated	O
11	regions	O
12	of	O
13	roughly	O
14	375	O
15	,	O
16	655	O
17	,	O
18	and	O
19	945	O
20	base	O
21	pairs	O
22	.	O

1	100	O
2	of	O
3	the	O
4	patients	O
5	who	O
6	would	O
7	have	O
8	died	O
9	survive	O
10	.	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	O
16	p53	B
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	Asymptomatic	O
2	bacteriospermia	O
3	and	O
4	fertility	O

1	Rather	O
2	,	O
3	complete	O
4	skipping	O
5	of	O
6	exon	O
7	V	O
8	and	O
9	subsequent	O
10	joining	O
11	of	O
12	exon	O
13	IV	O
14	to	O
15	exon	O
16	VI	O
17	caused	O
18	a	O
19	shift	O
20	in	O
21	the	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	which	O
27	remodeled	O
28	GPHe	O
29	(	O
30	P2	O
31	)	O
32	with	O
33	an	O
34	elongated	O
35	new	O
36	hydrophobic	O
37	sequence	O
38	for	O
39	membrane	O
40	anchoring	O
41	.	O

1	Protein	O
2	cHMGI	B
3	binds	O
4	preferentially	O
5	to	O
6	AT	O
7	-	O
8	rich	O
9	DNA	O
10	with	O
11	a	O
12	half	O
13	-	O
14	saturation	O
15	value	O
16	of	O
17	1	O
18	.	O
19	1	O
20	nM	O
21	.	O

1	This	O
2	lack	O
3	of	O
4	correlation	O
5	may	O
6	be	O
7	due	O
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	She	O
2	was	O
3	able	O
4	to	O
5	stand	O
6	unaided	O
7	by	O
8	3	O
9	years	O
10	of	O
11	age	O
12	with	O
13	then	O
14	progressive	O
15	worsening	O
16	of	O
17	motor	O
18	abilities	O
19	.	O

1	Serum	O
2	lipids	O
3	and	O
4	lipoproteins	O
5	of	O
6	29	O
7	insulin	B
8	dependent	O
9	diabetic	O
10	children	O
11	have	O
12	been	O
13	determined	O
14	and	O
15	related	O
16	to	O
17	the	O
18	metabolic	O
19	status	O
20	of	O
21	the	O
22	patients	O
23	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	B
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	O
24	neuraminidases	O
25	.	O

1	A	O
2	review	O
3	of	O
4	studies	O
5	published	O
6	between	O
7	1983	O
8	and	O
9	1995	O
10	shows	O
11	that	O
12	there	O
13	are	O
14	some	O
15	common	O
16	factors	O
17	as	O
18	regards	O
19	the	O
20	psychological	O
21	distress	O
22	and	O
23	social	O
24	and	O
25	functional	O
26	limitations	O
27	this	O
28	group	O
29	of	O
30	patients	O
31	has	O
32	to	O
33	deal	O
34	with	O
35	.	O

1	In	O
2	contrast	O
3	,	O
4	similar	O
5	rates	O
6	of	O
7	B	O
8	.	O
9	sphaericus	O
10	products	O
11	,	O
12	ABG	O
13	-	O
14	6184	O
15	technical	O
16	powder	O
17	and	O
18	BSP	B
19	-	I
20	2	I
21	flowable	O
22	concentrate	O
23	,	O
24	produced	O
25	no	O
26	significant	O
27	reduction	O
28	.	O

1	Serum	O
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O

1	Furthermore	O
2	,	O
3	Rac1	B
4	activation	O
5	of	O
6	JNK	B
7	or	O
8	SRF	B
9	,	O
10	or	O
11	induction	O
12	of	O
13	lamellipodia	O
14	,	O
15	was	O
16	neither	O
17	necessary	O
18	nor	O
19	sufficient	O
20	for	O
21	Rac1	B
22	transforming	O
23	activity	O
24	.	O

1	Therefore	O
2	,	O
3	recombinant	O
4	human	O
5	Ads	O
6	that	O
7	express	O
8	noninfectious	O
9	HIV	O
10	or	O
11	other	O
12	microbial	O
13	proteins	O
14	are	O
15	attractive	O
16	vaccine	O
17	candidates	O
18	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	(	O
6	EMSAs	O
7	)	O
8	using	O
9	purified	O
10	glucocorticoid	B
11	receptor	I
12	DNA	I
13	binding	I
14	domain	I
15	(	O
16	DBD	O
17	)	O
18	demonstrated	O
19	that	O
20	both	O
21	GRE	O
22	-	O
23	2	O
24	and	O
25	-	O
26	3	O
27	motifs	O
28	interact	O
29	with	O
30	DBD	O
31	and	O
32	oligonucleotide	O
33	competition	O
34	experiments	O
35	established	O
36	that	O
37	these	O
38	have	O
39	different	O
40	affinities	O
41	for	O
42	DBD	O
43	.	O

1	In	O
2	wandering	O
3	stage	O
4	larvae	O
5	,	O
6	the	O
7	OBP	O
8	transcript	O
9	appeared	O
10	to	O
11	be	O
12	at	O
13	least	O
14	250	O
15	-	O
16	fold	O
17	less	O
18	abundant	O
19	than	O
20	ribosomal	O
21	RNA	O
22	.	O

1	In	O
2	on	O
3	-	O
4	going	O
5	screening	O
6	programmes	O
7	,	O
8	the	O
9	Haemoccult	O
10	test	O
11	consists	O
12	of	O
13	six	O
14	slides	O
15	and	O
16	a	O
17	test	O
18	is	O
19	considered	O
20	positive	O
21	if	O
22	at	O
23	least	O
24	one	O
25	slide	O
26	is	O
27	coloured	O
28	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O

1	We	O
2	determined	O
3	how	O
4	DNA	O
5	repair	O
6	is	O
7	affected	O
8	by	O
9	TFA1	O
10	conditional	O
11	mutations	O
12	.	O

1	For	O
2	example	O
3	,	O
4	introduction	O
5	of	O
6	immunogenic	O
7	and	O
8	purification	O
9	tag	O
10	sequences	O
11	into	O
12	the	O
13	C	O
14	-	O
15	terminal	O
16	coding	O
17	region	O
18	significantly	O
19	decreased	O
20	bop	O
21	gene	O
22	mRNA	O
23	and	O
24	protein	O
25	accumulation	O
26	.	O

1	Heparin	O
2	had	O
3	no	O
4	effect	O
5	on	O
6	rAC	B
7	-	I
8	st	I
9	myosin	I
10	light	I
11	chain	I
12	phosphatase	I
13	activity	O
14	,	O
15	while	O
16	the	O
17	B	O
18	subunit	O
19	-	O
20	containing	O
21	forms	O
22	were	O
23	stimulated	O
24	2	O
25	-	O
26	3	O
27	-	O
28	fold	O
29	.	O

1	Membrane	O
2	-	O
3	bound	O
4	Steel	B
5	factor	I
6	induces	O
7	more	O
8	persistent	O
9	tyrosine	B
10	kinase	I
11	activation	O
12	and	O
13	longer	O
14	life	O
15	span	O
16	of	O
17	c	B
18	-	I
19	kit	I
20	gene	I
21	-	I
22	encoded	I
23	protein	I
24	than	O
25	its	O
26	soluble	O
27	form	O
28	.	O

1	The	O
2	pharmacology	O
3	of	O
4	carnitine	O
5	.	O

1	Studies	O
2	are	O
3	necessary	O
4	to	O
5	assess	O
6	the	O
7	source	O
8	of	O
9	contamination	O
10	and	O
11	potential	O
12	role	O
13	of	O
14	MRSA	O
15	-	O
16	contaminated	O
17	milk	O
18	in	O
19	the	O
20	transmission	O
21	of	O
22	MRSA	O
23	to	O
24	neonates	O
25	.	O

1	Fourteen	O
2	patients	O
3	were	O
4	in	O
5	the	O
6	multifocal	O
7	disease	O
8	group	O
9	;	O
10	13	O
11	were	O
12	detected	O
13	by	O
14	SPECT	O
15	and	O
16	10	O
17	by	O
18	TCT	O
19	.	O

1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	O
6	promoter	O
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	I
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O

1	These	O
2	data	O
3	establish	O
4	Smd1p	B
5	as	O
6	a	O
7	required	O
8	component	O
9	of	O
10	the	O
11	cellular	O
12	splicing	O
13	apparatus	O
14	and	O
15	a	O
16	factor	O
17	in	O
18	snRNA	O
19	maturation	O
20	and	O
21	stability	O
22	.	O

1	Eight	O
2	patients	O
3	received	O
4	1	O
5	.	O
6	5	O
7	mg	O
8	of	O
9	adefovir	O
10	dipivoxil	O
11	per	O
12	kg	O
13	of	O
14	body	O
15	weight	O
16	,	O
17	and	O
18	six	O
19	patients	O
20	received	O
21	3	O
22	.	O
23	0	O
24	mg	O
25	of	O
26	adefovir	O
27	dipivoxil	O
28	per	O
29	kg	O
30	.	O

1	Calcification	O
2	of	O
3	a	O
4	cariogenic	O
5	Streptococcus	O
6	and	O
7	of	O
8	Corynebacterium	O
9	(	O
10	Bacterionema	O
11	)	O
12	matruchotii	O
13	.	O

1	Mutations	O
2	affecting	O
3	only	O
4	CD4	B
5	regulation	O
6	mapped	O
7	to	O
8	residues	O
9	previously	O
10	shown	O
11	to	O
12	mediate	O
13	the	O
14	binding	O
15	of	O
16	Nef	B
17	to	O
18	this	O
19	receptor	O
20	,	O
21	such	O
22	as	O
23	W57	O
24	and	O
25	L58	O
26	,	O
27	as	O
28	well	O
29	as	O
30	to	O
31	an	O
32	AP	O
33	-	O
34	recruiting	O
35	dileucine	O
36	motif	O
37	and	O
38	to	O
39	an	O
40	acidic	O
41	dipeptide	O
42	in	O
43	the	O
44	C	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	the	O
50	protein	O
51	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	(	I
5	TGF	I
6	)-	I
7	beta1	I
8	induces	O
9	extracellular	O
10	matrix	O
11	deposition	O
12	and	O
13	proliferation	O
14	of	O
15	mesenchymal	O
16	cells	O
17	.	O

1	Of	O
2	the	O
3	21	O
4	quadrants	O
5	positive	O
6	in	O
7	the	O
8	controls	O
9	,	O
10	17	O
11	were	O
12	correlated	O
13	with	O
14	previously	O
15	detected	O
16	jaw	O
17	pathoses	O
18	.	O

1	Routine	O
2	psychometric	O
3	screening	O
4	of	O
5	IHD	O
6	patients	O
7	may	O
8	provide	O
9	a	O
10	cost	O
11	-	O
12	effective	O
13	means	O
14	of	O
15	alerting	O
16	cardiologists	O
17	and	O
18	internists	O
19	to	O
20	the	O
21	relatively	O
22	high	O
23	levels	O
24	of	O
25	distress	O
26	among	O
27	their	O
28	patients	O
29	.	O

1	More	O
2	specific	O
3	adverse	O
4	events	O
5	,	O
6	also	O
7	frequently	O
8	considered	O
9	as	O
10	dose	O
11	-	O
12	limiting	O
13	toxicities	O
14	,	O
15	include	O
16	hypotension	O
17	with	O
18	IL	B
19	-	I
20	1	I
21	,	O
22	severe	O
23	headache	O
24	or	O
25	skin	O
26	rash	O
27	with	O
28	IL	B
29	-	I
30	3	I
31	,	O
32	and	O
33	nasal	O
34	congestion	O
35	and	O
36	gastroduodenal	O
37	lesions	O
38	with	O
39	IL	B
40	-	I
41	4	I
42	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	region	O
6	revealed	O
7	three	O
8	eight	O
9	-	O
10	bp	O
11	repetitive	O
12	elements	O
13	,	O
14	the	O
15	deletion	O
16	of	O
17	which	O
18	restored	O
19	wild	O
20	-	O
21	type	O
22	levels	O
23	of	O
24	luciferase	B
25	activity	O
26	to	O
27	the	O
28	-	O
29	916	O
30	-	O
31	bp	O
32	reporter	O
33	plasmid	O
34	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	Sp1	B
2	can	O
3	activate	O
4	transcription	O
5	through	O
6	immunoglobulin	B
7	kappa	I
8	-	I
9	chain	I
10	enhancer	I
11	or	O
12	P	B
13	-	I
14	selectin	I
15	promoter	I
16	NF	I
17	-	I
18	kappaB	I
19	sites	I
20	.	O
21	p50	B
22	homodimers	I
23	replace	I
24	Sp1	I
25	from	O
26	the	O
27	P	B
28	-	I
29	selectin	I
30	promoter	I
31	by	O
32	binding	O
33	site	O
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	O
40	Sp1	B
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	O
49	Bcl	B
50	-	I
51	3	I
52	,	O
53	stimulate	O
54	expression	O
55	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	alternative	O
7	sigma	B
8	factor	I
9	,	O
10	RpoN	B
11	,	O
12	in	O
13	Rhodobacter	O
14	capsulatus	O
15	;	O
16	physiological	O
17	relevance	O
18	of	O
19	an	O
20	autoactivated	O
21	nifU2	B
22	-	I
23	rpoN	I
24	superoperon	I
25	.	O

1	Unrecognized	O
2	amnionitis	O
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	The	O
2	obvious	O
3	functional	O
4	necessity	O
5	for	O
6	editing	O
7	in	O
8	kinetoplastid	O
9	mitochondria	O
10	is	O
11	the	O
12	formation	O
13	of	O
14	translatable	O
15	mRNAs	O
16	.	O

1	The	O
2	technique	O
3	of	O
4	the	O
5	TEE	O
6	visualization	O
7	of	O
8	the	O
9	proximal	O
10	coronary	O
11	arteries	O
12	is	O
13	described	O
14	.	O

1	IX	O
2	.	O

1	In	O
2	vitro	O
3	evaluation	O
4	of	O
5	the	O
6	mucolytic	O
7	action	O
8	of	O
9	urea	O
10	.	O

1	The	O
2	susceptibility	O
3	of	O
4	the	O
5	PPNG	O
6	strains	O
7	to	O
8	clinically	O
9	relevant	O
10	antibiotics	O
11	varied	O
12	with	O
13	the	O
14	plasmid	O
15	pattern	O
16	;	O
17	this	O
18	stresses	O
19	the	O
20	necessity	O
21	of	O
22	permanent	O
23	surveillance	O
24	of	O
25	gonococcal	O
26	infections	O
27	and	O
28	of	O
29	regular	O
30	evaluation	O
31	of	O
32	the	O
33	recommendations	O
34	for	O
35	antimicrobial	O
36	treatment	O
37	.	O

1	Precipitation	O
2	using	O
3	GST	B
4	fusion	O
5	proteins	O
6	containing	O
7	Fyn	B
8	SH2	I
9	,	O
10	SH3	B
11	,	O
12	and	O
13	SH2	B
14	/	O
15	SH3	B
16	domains	I
17	revealed	O
18	that	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	bound	O
24	principally	O
25	to	O
26	the	O
27	SH3	B
28	domain	I
29	of	O
30	Fyn	B
31	.	O

1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O

1	The	O
2	solubility	O
3	of	O
4	all	O
5	the	O
6	mutated	O
7	proteins	O
8	was	O
9	remarkably	O
10	reduced	O
11	.	O

1	Association	O
2	with	O
3	HL	O
4	-	O
5	A	O
6	W	O
7	-	O
8	27	O
9	.	O

1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O

1	Major	O
2	clinical	O
3	symptoms	O
4	of	O
5	the	O
6	disease	O
7	were	O
8	defined	O
9	in	O
10	this	O
11	group	O
12	of	O
13	patients	O
14	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	The	O
2	prescription	O
3	for	O
4	apoplexy	O
5	includes	O
6	C1	O
7	-	O
8	7	O
9	,	O
10	T1	O
11	-	O
12	9	O
13	and	O
14	L2	O
15	-	O
16	4	O
17	.	O

1	The	O
2	revertant	O
3	TATA	O
4	boxes	O
5	accelerated	O
6	the	O
7	kinetics	O
8	of	O
9	HIV	O
10	replication	O
11	when	O
12	present	O
13	in	O
14	the	O
15	context	O
16	of	O
17	an	O
18	LTR	O
19	containing	O
20	a	O
21	Sp1	B
22	mutation	I
23	(	O
24	deletion	O
25	or	O
26	site	O
27	specific	O
28	);	O
29	no	O
30	effect	O
31	was	O
32	observed	O
33	on	O
34	the	O
35	infectivity	O
36	of	O
37	wild	O
38	-	O
39	type	O
40	HIV	O
41	.	O

1	The	O
2	unexpected	O
3	presence	O
4	of	O
5	the	O
6	tRNA	O
7	(	O
8	trp	B
9	)(	I
10	CCA	I
11	)-	I
12	gene	I
13	transcript	I
14	in	O
15	mitochondria	O
16	is	O
17	also	O
18	reported	O
19	.	O

1	2	O
2	.	O

1	Release	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	cointegrate	O
17	structures	O
18	.	O

1	Comparison	O
2	of	O
3	the	O
4	genomes	O
5	of	O
6	PMTV	O
7	,	O
8	BNYVV	B
9	,	O
10	and	O
11	SBWMV	O
12	shows	O
13	that	O
14	furoviruses	O
15	exhibit	O
16	considerable	O
17	heterogeneity	O
18	in	O
19	genome	O
20	organization	O
21	.	O

1	Number	O
2	and	O
3	size	O
4	of	O
5	the	O
6	myelin	O
7	structures	O
8	in	O
9	the	O
10	pneumocytes	O
11	typ	O
12	II	O
13	increased	O
14	simultaneously	O
15	.	O

1	9	O
2	,	O
3	11	O
4	-	O
5	Seco	O
6	steroids	O
7	derived	O
8	from	O
9	estradiol	O
10	3	O
11	-	O
12	methyl	O
13	ether	O
14	.	O

1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O

1	The	O
2	mRNA	O
3	expression	O
4	of	O
5	RFX1	B
6	,	O
7	RFX2	B
8	,	O
9	and	O
10	RFX3	O
11	was	O
12	detected	O
13	ubiquitously	O
14	,	O
15	but	O
16	in	O
17	transient	O
18	-	O
19	transfection	O
20	assays	O
21	,	O
22	multimerized	O
23	RFX	B
24	binding	I
25	sites	I
26	in	O
27	front	O
28	of	O
29	a	O
30	basal	O
31	promoter	O
32	efficiently	O
33	functioned	O
34	in	O
35	a	O
36	tissue	O
37	-	O
38	and	O
39	lineage	O
40	-	O
41	specific	O
42	manner	O
43	.	O

1	Recent	O
2	work	O
3	in	O
4	this	O
5	laboratory	O
6	has	O
7	shown	O
8	that	O
9	the	O
10	gene	O
11	coding	O
12	for	O
13	acetate	B
14	kinase	I
15	(	O
16	ackA	O
17	)	O
18	in	O
19	Sinorhizobium	O
20	meliloti	O
21	is	O
22	up	O
23	-	O
24	regulated	O
25	in	O
26	response	O
27	to	O
28	phosphate	O
29	limitation	O
30	.	O

1	Genetic	O
2	and	O
3	phenotypic	O
4	analysis	O
5	indicates	O
6	that	O
7	NHP6A	B
8	and	O
9	NHP6B	B
10	function	O
11	downstream	O
12	of	O
13	SLT2	B
14	.	O

1	Such	O
2	an	O
3	interaction	O
4	could	O
5	be	O
6	detected	O
7	using	O
8	a	O
9	GST	B
10	-	O
11	POU	B
12	fusion	O
13	protein	O
14	bound	O
15	to	O
16	glutathione	O
17	-	O
18	agarose	O
19	beads	O
20	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	expression	O
6	vectors	O
7	for	O
8	CCAAT	B
9	/	I
10	enhancer	I
11	binding	I
12	protein	I
13	(	I
14	C	I
15	/	I
16	EBP	I
17	)	I
18	alpha	I
19	and	I
20	C	I
21	/	I
22	EBP	I
23	beta	I
24	trans	O
25	-	O
26	activated	O
27	the	O
28	rat	O
29	uncoupling	O
30	protein	O
31	gene	O
32	promoter	O
33	due	O
34	to	O
35	sequences	O
36	in	O
37	the	O
38	5	O
39	'	O
40	proximal	O
41	region	O
42	.	O

1	The	O
2	genomic	O
3	fragments	O
4	were	O
5	fused	O
6	upstream	O
7	of	O
8	the	O
9	luciferase	B
10	reporter	I
11	gene	I
12	.	O

1	The	O
2	4	O
3	degrees	O
4	stimuli	O
5	were	O
6	found	O
7	to	O
8	elicit	O
9	scalp	O
10	distributions	O
11	for	O
12	the	O
13	pattern	O
14	reversal	O
15	P100	O
16	and	O
17	the	O
18	pattern	O
19	onset	O
20	C1	O
21	consistent	O
22	with	O
23	striate	O
24	and	O
25	extrastriate	O
26	visual	O
27	cortical	O
28	origins	O
29	respectively	O
30	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	analyze	O
9	the	O
10	common	O
11	cause	O
12	of	O
13	asthenopia	O
14	,	O
15	mixed	O
16	astigmatism	O
17	.	O

1	It	O
2	is	O
3	also	O
4	homologous	O
5	to	O
6	other	O
7	sugar	O
8	carriers	O
9	from	O
10	human	O
11	,	O
12	mouse	O
13	and	O
14	Escherichia	O
15	coli	O
16	.	O

1	Holger	O
2	v	O
3	.	O

1	Convulsive	O
2	status	O
3	epilepticus	O
4	after	O
5	infusion	O
6	of	O
7	cisplatin	O

1	TB	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	O
23	(	O
24	p	O
25	=	O
26	0	O
27	.	O
28	03	O
29	),	O
30	and	O
31	menses	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	TB	B
41	BMC	I
42	.	O

1	axl	O
2	,	O
3	a	O
4	transforming	O
5	gene	O
6	isolated	O
7	from	O
8	primary	O
9	human	O
10	myeloid	O
11	leukemia	O
12	cells	O
13	,	O
14	encodes	O
15	a	O
16	novel	O
17	receptor	B
18	tyrosine	I
19	kinase	I
20	.	O

1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	B
16	35S	I
17	domain	I
18	B	I
19	enhancer	I
20	element	I
21	.	O

1	Naval	O
2	personnel	O
3	who	O
4	exceed	O
5	standards	O
6	for	O
7	%	O
8	BF	O
9	can	O
10	be	O
11	separated	O
12	from	O
13	active	O
14	duty	O
15	.	O

1	The	O
2	Stat5b	B
3	mRNA	I
4	has	O
5	a	O
6	size	O
7	of	O
8	5	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	786	O
18	amino	O
19	acids	O
20	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	Minor	O
2	initiation	O
3	sites	O
4	were	O
5	found	O
6	at	O
7	positions	O
8	-	O
9	128	O
10	,	O
11	-	O
12	111	O
13	,	O
14	-	O
15	91	O
16	,	O
17	and	O
18	-	O
19	74	O
20	.	O

1	In	O
2	a	O
3	heterologous	O
4	transcriptional	O
5	system	O
6	in	O
7	which	O
8	the	O
9	upstream	O
10	regions	O
11	of	O
12	oIFNtau	O
13	were	O
14	inserted	O
15	in	O
16	front	O
17	of	O
18	simian	O
19	virus	O
20	40	O
21	(	O
22	SV40	O
23	)	O
24	promoter	O
25	,	O
26	the	O
27	regions	O
28	between	O
29	bases	O
30	-	O
31	654	O
32	and	O
33	-	O
34	555	O
35	were	O
36	determined	O
37	as	O
38	being	O
39	the	O
40	enhancer	O
41	region	O
42	required	O
43	for	O
44	oIFNtau	B
45	-	O
46	SV40	O
47	-	O
48	CAT	B
49	transactivation	O
50	.	O

1	Transformed	O
2	bacterial	O
3	colonies	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	BiP	B
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O

1	Manipulation	O
2	of	O
3	the	O
4	checkpoint	O
5	regulators	O
6	involved	O
7	in	O
8	cell	O
9	cycle	O
10	arrest	O
11	and	O
12	apoptosis	O
13	may	O
14	thus	O
15	provide	O
16	a	O
17	novel	O
18	strategy	O
19	to	O
20	cancer	O
21	therapy	O
22	.	O

1	These	O
2	results	O
3	suggest	O
4	an	O
5	increased	O
6	risk	O
7	of	O
8	developing	O
9	cancer	O
10	among	O
11	polyp	O
12	patients	O
13	and	O
14	the	O
15	possibility	O
16	of	O
17	prophylactic	O
18	effect	O
19	of	O
20	polypectomy	O
21	against	O
22	subsequent	O
23	cancer	O
24	.	O

1	The	O
2	E1	O
3	nuclear	O
4	transport	O
5	motif	O
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	B
26	genes	I
27	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	O
11	-	O
12	hsp70	B
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	Nuclear	B
2	factor	I
3	kappa	I
4	B	I
5	(	O
6	NF	B
7	-	I
8	kappaB	I
9	)	O
10	is	O
11	an	O
12	important	O
13	transcription	O
14	factor	O
15	for	O
16	the	O
17	genes	O
18	of	O
19	many	O
20	pro	O
21	-	O
22	inflammatory	O
23	proteins	O
24	and	O
25	is	O
26	strongly	O
27	activated	O
28	by	O
29	the	O
30	cytokines	O
31	interleukin	B
32	-	I
33	1	I
34	and	O
35	tumor	B
36	necrosis	I
37	factor	I
38	(	O
39	TNF	B
40	)	I
41	alpha	I
42	under	O
43	various	O
44	pathological	O
45	conditions	O
46	.	O

1	Incorporation	O
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	dihydrogen	O
13	phosphate	O
14	in	O
15	the	O
16	sugar	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	shelf	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O

1	Relatively	O
2	large	O
3	DNA	O
4	rearrangements	O
5	spanning	O
6	the	O
7	region	O
8	with	O
9	tandem	O
10	direct	O
11	repeats	O
12	encoding	O
13	the	O
14	carboxy	B
15	-	I
16	terminal	I
17	histone	I
18	H1	I
19	-	O
20	like	O
21	structure	O
22	of	O
23	AlgP	O
24	were	O
25	detected	O
26	in	O
27	several	O
28	strains	O
29	upon	O
30	conversion	O
31	from	O
32	the	O
33	mucoid	O
34	to	O
35	the	O
36	nonmucoid	O
37	phenotype	O
38	.	O

1	Enzyme	O
2	histochemical	O
3	findings	O
4	in	O
5	the	O
6	ultimobranchial	O
7	body	O
8	of	O
9	the	O
10	horse	O

1	Effect	O
2	of	O
3	single	O
4	base	O
5	substitutions	O
6	at	O
7	glycine	O
8	-	O
9	870	O
10	codon	O
11	of	O
12	gramicidin	B
13	S	I
14	synthetase	I
15	2	I
16	gene	I
17	on	O
18	proline	O
19	activation	O
20	.	O

1	Since	O
2	very	O
3	recent	O
4	scanning	O
5	-	O
6	deletion	O
7	analysis	O
8	indicates	O
9	that	O
10	there	O
11	is	O
12	a	O
13	critical	O
14	region	O
15	for	O
16	activity	O
17	near	O
18	Cys	O
19	-	O
20	118	O
21	and	O
22	that	O
23	Cys	O
24	-	O
25	118	O
26	is	O
27	necessary	O
28	for	O
29	maximal	O
30	activity	O
31	,	O
32	we	O
33	conclude	O
34	that	O
35	the	O
36	Cys	O
37	-	O
38	118	O
39	residue	O
40	is	O
41	necessary	O
42	for	O
43	proper	O
44	glycosylation	O
45	and	O
46	maximal	O
47	biologic	O
48	activity	O
49	of	O
50	GM	B
51	-	I
52	CSF	I
53	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	by	O
8	S1	B
9	nuclease	I
10	mapping	O
11	.	O

1	Aluminium	O
2	resin	O
3	for	O
4	the	O
5	treatment	O
6	of	O
7	the	O
8	hyperkalamia	O
9	of	O
10	renal	O
11	failure	O
12	.	O

1	The	O
2	major	O
3	findings	O
4	of	O
5	our	O
6	studies	O
7	are	O
8	as	O
9	follows	O
10	:	O
11	1	O
12	)	O
13	There	O
14	are	O
15	no	O
16	detectable	O
17	signals	O
18	around	O
19	GDF	O
20	-	O
21	9	O
22	-	O
23	deficient	O
24	follicles	O
25	for	O
26	several	O
27	theca	O
28	cell	O
29	layer	O
30	markers	O
31	[	O
32	i	O
33	.	O
34	e	O
35	.	O

1	Ophthalmosonographic	O
2	evaluation	O
3	of	O
4	blood	O
5	flow	O
6	velocity	O
7	in	O
8	arteriocavernous	O
9	fistula	O

1	In	O
2	vitro	O
3	protein	O
4	retention	O
5	experiments	O
6	in	O
7	which	O
8	Hsp90	B
9	heterocomplexes	I
10	were	O
11	precipitated	O
12	resulted	O
13	in	O
14	coprecipitation	O
15	of	O
16	Cns1	O
17	.	O

1	Intracranial	O
2	arachnoid	O
3	cyst	O
4	of	O
5	the	O
6	middle	O
7	fossa	O
8	demonstrated	O
9	by	O
10	positive	O
11	99mTc	O
12	brainscintigraphy	O
13	.	O

1	The	O
2	mechanism	O
3	by	O
4	which	O
5	E2	B
6	-	I
7	C	I
8	represses	O
9	E2	O
10	-	O
11	dependent	O
12	enhancer	O
13	activity	O
14	most	O
15	likely	O
16	involves	O
17	competition	O
18	with	O
19	E2	O
20	for	O
21	binding	O
22	to	O
23	a	O
24	common	O
25	transcriptional	O
26	regulatory	O
27	site	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	two	O
7	treatment	O
8	groups	O
9	were	O
10	found	O
11	,	O
12	but	O
13	rapid	O
14	responders	O
15	had	O
16	a	O
17	smaller	O
18	mean	O
19	initial	O
20	platelet	O
21	-	O
22	associated	O
23	IgG	B
24	index	O
25	which	O
26	returned	O
27	more	O
28	rapidly	O
29	and	O
30	more	O
31	permanently	O
32	to	O
33	normal	O
34	than	O
35	that	O
36	of	O
37	slow	O
38	responders	O
39	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O

1	To	O
2	define	O
3	the	O
4	minimal	O
5	VDRE	O
6	binding	O
7	domain	O
8	for	O
9	human	O
10	VDR	B
11	(	O
12	hVDR	B
13	),	O
14	a	O
15	series	O
16	of	O
17	C	B
18	-	I
19	terminally	I
20	truncated	I
21	hVDR	I
22	mutants	I
23	(	O
24	Delta134	O
25	,	O
26	Delta113	O
27	,	O
28	Delta102	B
29	,	O
30	Delta90	O
31	,	O
32	Delta84	O
33	,	O
34	Delta80	O
35	,	O
36	and	O
37	Delta60	O
38	)	O
39	was	O
40	generated	O
41	and	O
42	expressed	O
43	in	O
44	bacteria	O
45	.	O

1	Although	O
2	linker	O
3	regions	O
4	in	O
5	transcription	O
6	factors	O
7	are	O
8	known	O
9	to	O
10	modulate	O
11	DNA	O
12	binding	O
13	specificity	O
14	,	O
15	our	O
16	studies	O
17	suggest	O
18	that	O
19	the	O
20	human	B
21	HSF1	I
22	linker	I
23	plays	O
24	no	O
25	role	O
26	in	O
27	determining	O
28	HSF1	B
29	binding	O
30	preferences	O
31	in	O
32	vivo	O
33	but	O
34	is	O
35	a	O
36	critical	O
37	determinant	O
38	in	O
39	regulating	O
40	the	O
41	HSF1	B
42	monomer	I
43	-	I
44	trimer	I
45	equilibrium	I
46	.	O

1	On	O
2	long	O
3	-	O
4	term	O
5	follow	O
6	-	O
7	up	O
8	,	O
9	there	O
10	was	O
11	no	O
12	significant	O
13	difference	O
14	in	O
15	the	O
16	incidence	O
17	of	O
18	hospitalizations	O
19	(	O
20	1	O
21	per	O
22	2	O
23	.	O
24	1	O
25	vs	O
26	.	O

1	We	O
2	studied	O
3	the	O
4	effect	O
5	of	O
6	skinfold	O
7	thickness	O
8	on	O
9	the	O
10	correlation	O
11	between	O
12	serum	O
13	total	O
14	bilirubin	O
15	level	O
16	and	O
17	transcutaneous	O
18	bilirubin	O
19	(	O
20	TcB	O
21	)	O
22	readings	O
23	.	O

1	A	O
2	new	O
3	set	O
4	of	O
5	cDNA	O
6	clones	O
7	spanning	O
8	approximately	O
9	3	O
10	.	O
11	2	O
12	kb	O
13	was	O
14	isolated	O
15	from	O
16	a	O
17	lambda	B
18	-	I
19	ZAP	I
20	goose	I
21	liver	I
22	cDNA	I
23	library	O
24	using	O
25	the	O
26	5	O
27	'-	O
28	most	O
29	exon	O
30	-	O
31	containing	O
32	fragment	O
33	of	O
34	the	O
35	5	O
36	'-	O
37	most	O
38	genomic	O
39	DNA	O
40	clone	O
41	.	O

1	The	O
2	prevalence	O
3	and	O
4	incidence	O
5	of	O
6	human	O
7	immunodeficiency	O
8	virus	O
9	types	O
10	1	O
11	and	O
12	2	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	,	O
18	HIV	O
19	-	O
20	2	O
21	),	O
22	human	B
23	T	I
24	-	I
25	lymphotropic	I
26	virus	I
27	types	I
28	I	I
29	and	I
30	II	I
31	(	O
32	HTLV	O
33	-	O
34	I	O
35	/	O
36	II	O
37	),	O
38	and	O
39	syphilitic	O
40	infections	O
41	and	O
42	the	O
43	association	O
44	between	O
45	these	O
46	infections	O
47	were	O
48	determined	O
49	in	O
50	a	O
51	cohort	O
52	of	O
53	police	O
54	officers	O
55	in	O
56	Guinea	O
57	-	O
58	Bissau	O
59	.	O

1	Who	O
2	says	O
3	'	O
4	National	O
5	Health	O
6	Dis	O
7	-	O
8	service	O
9	'.	O

1	A	O
2	genomic	O
3	clone	O
4	for	O
5	the	O
6	cyc07	O
7	gene	O
8	,	O
9	which	O
10	is	O
11	expressed	O
12	specifically	O
13	at	O
14	the	O
15	S	O
16	phase	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	in	O
22	synchronous	O
23	cultures	O
24	of	O
25	periwinkle	O
26	(	O
27	Catharanthus	O
28	roseus	O
29	)	O
30	cells	O
31	,	O
32	was	O
33	isolated	O
34	.	O

1	Transcription	O
2	of	O
3	the	O
4	vascular	B
5	cell	I
6	adhesion	I
7	molecule	I
8	1	I
9	(	O
10	VCAM	B
11	-	I
12	1	I
13	)	O
14	gene	O
15	in	O
16	endothelial	O
17	cells	O
18	is	O
19	induced	O
20	by	O
21	lipopolysaccharide	O
22	and	O
23	the	O
24	inflammatory	O
25	cytokines	O
26	interleukin	B
27	-	I
28	1	I
29	beta	I
30	and	O
31	tumor	B
32	necrosis	I
33	factor	I
34	alpha	I
35	(	O
36	TNF	B
37	-	I
38	alpha	I
39	).	O

1	RPA190	B
2	encodes	O
3	a	O
4	polypeptide	O
5	chain	O
6	of	O
7	186	O
8	,	O
9	270	O
10	daltons	O
11	in	O
12	a	O
13	large	O
14	uninterrupted	O
15	reading	O
16	frame	O
17	.	O

1	Lysozyme	B
2	activity	O
3	was	O
4	evidently	O
5	increased	O
6	as	O
7	well	O
8	in	O
9	undiluted	O
10	as	O
11	in	O
12	diluted	O
13	sera	O
14	in	O
15	all	O
16	our	O
17	tested	O
18	patients	O
19	.	O

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	Ig	B
2	heavy	I
3	chain	I
4	class	O
5	switching	O
6	is	O
7	directed	O
8	by	O
9	cytokines	O
10	inducing	O
11	transcription	O
12	from	O
13	unrearranged	O
14	CH	B
15	genes	I
16	.	O

1	The	O
2	COL7A1	B
3	gene	I
4	,	O
5	which	O
6	encodes	O
7	type	B
8	VII	I
9	collagen	I
10	,	O
11	has	O
12	been	O
13	implicated	O
14	as	O
15	a	O
16	candidate	O
17	gene	O
18	for	O
19	dominantly	O
20	and	O
21	recessively	O
22	inherited	O
23	forms	O
24	of	O
25	dystrophic	O
26	epidermolysis	O
27	bullosa	O
28	.	O

1	Latexin	O
2	,	O
3	a	O
4	carboxypeptidase	B
5	A	I
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O

1	All	O
2	9	O
3	untreated	O
4	patients	O
5	underwent	O
6	laparoscopy	O
7	,	O
8	which	O
9	identified	O
10	3	O
11	intra	O
12	-	O
13	abdominal	O
14	,	O
15	3	O
16	vanished	O
17	and	O
18	2	O
19	peeping	O
20	testes	O
21	,	O
22	and	O
23	1	O
24	atrophic	O
25	testis	O
26	in	O
27	the	O
28	inguinal	O
29	canal	O
30	.	O

1	We	O
2	have	O
3	overexpressed	O
4	,	O
5	purified	O
6	,	O
7	characterized	O
8	,	O
9	and	O
10	crystallized	O
11	the	O
12	BTB	B
13	/	O
14	POZ	O
15	domain	O
16	from	O
17	PLZF	B
18	(	O
19	PLZF	B
20	-	I
21	BTB	I
22	/	O
23	POZ	O
24	).	O

1	The	O
2	present	O
3	study	O
4	highlights	O
5	the	O
6	improvement	O
7	in	O
8	sputum	O
9	amoxycillin	O
10	(	O
11	amoxy	O
12	)	O
13	levels	O
14	when	O
15	a	O
16	combination	O
17	tablet	O
18	,	O
19	amoxy	O
20	500	O
21	mg	O
22	plus	O
23	bromhexeine	O
24	8	O
25	mg	O
26	,	O
27	is	O
28	administered	O
29	as	O
30	compared	O
31	to	O
32	plain	O
33	amoxy	O
34	500	O
35	mg	O
36	.	O

1	General	O
2	formulae	O
3	for	O
4	estimating	O
5	heritability	O
6	in	O
7	a	O
8	population	O
9	with	O
10	related	O
11	parents	O
12	.	O

1	Extraction	O
2	procedure	O
3	for	O
4	the	O
5	measurement	O
6	of	O
7	butyltin	O
8	compounds	O
9	in	O
10	biological	O
11	tissues	O
12	using	O
13	toluene	O
14	,	O
15	HBr	B
16	,	O
17	and	O
18	tropolone	O
19	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	had	O
6	locally	O
7	advanced	O
8	lesions	O
9	(	O
10	63	O
11	T3	O
12	-	O
13	4	O
14	:	O
15	91	O
16	.	O
17	5	O
18	%)	O
19	according	O
20	to	O
21	the	O
22	adopted	O
23	TNM	O
24	system	O
25	(	O
26	Lederman	O
27	-	O
28	Gadeberg	O
29	,	O
30	Sisson	O
31	-	O
32	Jesse	O
33	).	O

1	Sustained	O
2	activation	O
3	of	O
4	p21	B
5	expression	O
6	is	O
7	proposed	O
8	to	O
9	be	O
10	a	O
11	distinguishing	O
12	feature	O
13	of	O
14	the	O
15	activity	O
16	of	O
17	NGF	B
18	that	O
19	contributes	O
20	to	O
21	PC12	O
22	growth	O
23	arrest	O
24	during	O
25	differentiation	O

1	Natural	B
2	FL	I
3	protein	I
4	has	O
5	been	O
6	purified	O
7	from	O
8	a	O
9	stromal	O
10	cell	O
11	line	O
12	and	O
13	shown	O
14	to	O
15	be	O
16	a	O
17	65	O
18	kD	O
19	nondisulfide	O
20	-	O
21	linked	O
22	homodimeric	O
23	glycoprotein	O
24	comprised	O
25	of	O
26	30	O
27	kD	O
28	subunits	O
29	,	O
30	each	O
31	containing	O
32	12	O
33	kD	O
34	of	O
35	N	O
36	-	O
37	and	O
38	O	O
39	-	O
40	linked	O
41	sugars	O
42	.	O

1	Furthermore	O
2	,	O
3	DNA	O
4	-	O
5	bound	O
6	LAZ3	B
7	/	O
8	BCL6	B
9	recruits	O
10	SMRT	B
11	in	O
12	vivo	O
13	,	O
14	and	O
15	both	O
16	overexpressed	O
17	proteins	O
18	completely	O
19	colocalize	O
20	in	O
21	nuclear	O
22	dots	O
23	.	O

1	This	O
2	expression	O
3	assumes	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	laminar	O
10	flow	O
11	regimen	O
12	during	O
13	expiration	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O

1	The	O
2	MXR	B
3	gene	I
4	encodes	O
5	a	O
6	half	O
7	-	O
8	transporter	O
9	and	O
10	the	O
11	absence	O
12	of	O
13	cytogenetic	O
14	evidence	O
15	of	O
16	coamplification	O
17	of	O
18	other	O
19	regions	O
20	suggests	O
21	that	O
22	a	O
23	partner	O
24	may	O
25	not	O
26	be	O
27	overexpressed	O
28	,	O
29	and	O
30	instead	O
31	the	O
32	MXR	O
33	half	O
34	-	O
35	transporter	O
36	homodimerizes	O
37	to	O
38	mediate	O
39	drug	O
40	transport	O
41	.	O

1	The	O
2	MCA	O
3	and	O
4	UA	O
5	PI	O
6	values	O
7	showed	O
8	the	O
9	greatest	O
10	deviation	O
11	for	O
12	any	O
13	single	O
14	-	O
15	vessel	O
16	parameter	O
17	.	O

1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	TRH	B
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	permitted	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	thyrotropin	O
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	discriminating	O
42	.	O

1	Members	O
2	of	O
3	the	O
4	Ras	B
5	subfamily	I
6	of	O
7	small	B
8	GTP	I
9	-	I
10	binding	I
11	proteins	I
12	have	O
13	been	O
14	shown	O
15	to	O
16	be	O
17	promiscuous	O
18	towards	O
19	a	O
20	variety	O
21	of	O
22	putative	O
23	effector	O
24	molecules	O
25	such	O
26	as	O
27	the	O
28	protein	B
29	kinase	I
30	c	I
31	-	I
32	Raf	I
33	and	O
34	the	O
35	Ral	B
36	-	I
37	specific	I
38	guanine	I
39	nucleotide	I
40	exchange	I
41	factor	I
42	(	O
43	Ral	O
44	-	O
45	GEF	B
46	).	O

1	Curing	O
2	shrinkage	O
3	and	O
4	volumetric	O
5	changes	O
6	of	O
7	resin	O
8	-	O
9	modified	O
10	glass	O
11	ionomer	O
12	restorative	O
13	materials	O
14	.	O

1	Using	O
2	site	O
3	-	O
4	directed	O
5	mutagenesis	O
6	,	O
7	we	O
8	show	O
9	that	O
10	the	O
11	RAREoct	B
12	contributes	O
13	to	O
14	the	O
15	transcriptional	O
16	activation	O
17	of	O
18	Oct	B
19	-	I
20	3	I
21	/	I
22	4	I
23	promoter	I
24	in	O
25	P19	O
26	cells	O
27	and	O
28	,	O
29	most	O
30	interestingly	O
31	,	O
32	mediates	O
33	the	O
34	RA	O
35	-	O
36	induced	O
37	repression	O
38	in	O
39	RA	O
40	-	O
41	differentiated	O
42	EC	O
43	cells	O
44	.	O

1	To	O
2	establish	O
3	a	O
4	possible	O
5	association	O
6	between	O
7	familial	O
8	dysfibrinogenemia	O
9	and	O
10	thrombophilia	O
11	,	O
12	data	O
13	on	O
14	cases	O
15	with	O
16	both	O
17	affections	O
18	were	O
19	collected	O
20	in	O
21	a	O
22	study	O
23	within	O
24	the	O
25	framework	O
26	of	O
27	the	O
28	SSC	O
29	Subcommittee	O
30	on	O
31	Fibrinogen	B
32	of	O
33	the	O
34	International	O
35	Society	O
36	on	O
37	Thrombosis	O
38	and	O
39	Haemostasis	O
40	.	O

1	Efficacy	O
2	of	O
3	cervical	O
4	spine	O
5	immobilization	O
6	methods	O
7	.	O

1	This	O
2	approach	O
3	places	O
4	gHoxb	B
5	-	I
6	1	I
7	into	O
8	the	O
9	normal	O
10	embryonic	O
11	spatiotemporal	O
12	context	O
13	in	O
14	which	O
15	lab	O
16	acts	O
17	.	O

1	The	O
2	corresponding	O
3	inhibition	O
4	of	O
5	acid	O
6	phosphatase	O
7	activity	O
8	in	O
9	control	O
10	male	O
11	and	O
12	female	O
13	guinea	O
14	pigs	O
15	was	O
16	15	O
17	.	O
18	91	O
19	%	O
20	and	O
21	20	O
22	.	O
23	33	O
24	%	O
25	respectively	O
26	.	O

1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	B
16	-	I
17	1	I
18	>	O
19	fibronectin	B
20	variants	O
21	containing	O
22	CS1	O
23	>>	O
24	other	O
25	fibronectin	B
26	variants	O
27	).	O

1	ATP	O
2	by	O
3	itself	O
4	also	O
5	reduced	O
6	polypeptide	O
7	binding	O
8	to	O
9	Ssb1	B
10	/	O
11	2p	O
12	to	O
13	a	O
14	level	O
15	that	O
16	was	O
17	intermediate	O
18	between	O
19	that	O
20	observed	O
21	for	O
22	the	O
23	Ssa	B
24	Hsp70	I
25	proteins	I
26	tested	O
27	and	O
28	BiP	B
29	and	O
30	DnaK	B
31	.	O

1	Compared	O
2	to	O
3	its	O
4	counterpart	O
5	in	O
6	the	O
7	GPB	B
8	gene	I
9	,	O
10	exon	O
11	3	O
12	of	O
13	the	O
14	GPE	B
15	gene	I
16	contains	O
17	several	O
18	point	O
19	mutations	O
20	,	O
21	an	O
22	insertion	O
23	of	O
24	24	O
25	bp	O
26	,	O
27	and	O
28	a	O
29	stop	O
30	codon	O
31	which	O
32	shortens	O
33	the	O
34	reading	O
35	frame	O
36	.	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	toward	O
6	an	O
7	association	O
8	between	O
9	IENF	O
10	and	O
11	sural	O
12	nerve	O
13	unmyelinated	O
14	fiber	O
15	densities	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	32	O
22	,	O
23	p	O
24	=	O
25	0	O
26	.	O
27	054	O
28	).	O

1	However	O
2	,	O
3	a	O
4	10	O
5	--	O
6	15	O
7	%	O
8	lengthening	O
9	of	O
10	the	O
11	partial	O
12	thromboplastin	B
13	time	O
14	is	O
15	evident	O
16	after	O
17	24	O
18	hours	O
19	of	O
20	storage	O
21	.	O

1	The	O
2	gene	O
3	ccpA	B
4	encoding	O
5	the	O
6	catabolite	O
7	control	O
8	protein	O
9	CcpA	B
10	of	O
11	Staphylococcus	O
12	xylosus	O
13	has	O
14	been	O
15	cloned	O
16	and	O
17	characterized	O
18	.	O

1	Both	O
2	classes	O
3	of	O
4	MHBst	B
5	proteins	I
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O

1	By	O
2	analyzing	O
3	the	O
4	RanGAP	B
5	activity	O
6	of	O
7	a	O
8	series	O
9	of	O
10	recombinantly	O
11	expressed	O
12	rna1p	O
13	mutant	O
14	derivatives	O
15	,	O
16	we	O
17	show	O
18	that	O
19	the	O
20	highly	O
21	acidic	O
22	sequence	O
23	in	O
24	the	O
25	C	O
26	-	O
27	terminal	O
28	domain	O
29	of	O
30	both	O
31	yeast	O
32	proteins	O
33	is	O
34	indispensable	O
35	for	O
36	activating	O
37	Ran	B
38	-	O
39	mediated	O
40	GTP	O
41	hydrolysis	O
42	.	O

1	Acute	O
2	pancreatitis	O
3	is	O
4	a	O
5	rather	O
6	common	O
7	abdominal	O
8	disorder	O
9	.	O

1	JCAHO	O
2	revised	O
3	interpretation	O

1	METHODS	O
2	:	O
3	All	O
4	these	O
5	30	O
6	non	O
7	-	O
8	responders	O
9	received	O
10	an	O
11	extra	O
12	dose	O
13	of	O
14	the	O
15	same	O
16	vaccine	O
17	2	O
18	months	O
19	after	O
20	primary	O
21	immunization	O
22	and	O
23	a	O
24	booster	O
25	dose	O
26	with	O
27	a	O
28	yeast	O
29	-	O
30	derived	O
31	vaccine	O
32	6	O
33	years	O
34	later	O
35	.	O

1	Endonuclease	B
2	III	I
3	(	O
4	Nth	O
5	)	O
6	of	O
7	Escherichia	O
8	coli	O
9	is	O
10	a	O
11	DNA	O
12	glycosylase	O
13	essential	O
14	for	O
15	the	O
16	removal	O
17	of	O
18	oxidised	O
19	pyrimidine	O
20	base	O
21	residues	O
22	from	O
23	DNA	O
24	.	O

1	The	O
2	most	O
3	frequent	O
4	risk	O
5	factor	O
6	for	O
7	ischaemic	O
8	was	O
9	hypertension	O
10	.	O

1	Higher	O
2	fasting	O
3	serum	O
4	gastrin	B
5	concentration	O
6	(	O
7	102	O
8	.	O
9	0	O
10	+/-	O
11	21	O
12	.	O
13	1	O
14	vs	O
15	63	O
16	.	O
17	3	O
18	+/-	O
19	8	O
20	.	O
21	3	O
22	ng	O
23	.	O
24	l	O
25	-	O
26	1	O
27	),	O
28	and	O
29	greater	O
30	postprandial	O
31	gastrin	B
32	release	O
33	(	O
34	AUC0	O
35	-	O
36	120	O
37	:	O
38	16690	O
39	+/-	O
40	2648	O
41	vs	O
42	10654	O
43	+/-	O
44	1283	O
45	ng	O
46	.	O
47	l	O
48	-	O
49	1	O
50	min	O
51	)	O
52	were	O
53	observed	O
54	after	O
55	VTP	O
56	-	O
57	HM	O
58	than	O
59	after	O
60	VTP	O
61	-	O
62	Cas	B
63	.	O

1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O

1	These	O
2	fusion	O
3	proteins	O
4	also	O
5	allowed	O
6	the	O
7	localization	O
8	of	O
9	the	O
10	transcriptional	O
11	activation	O
12	and	O
13	DNA	O
14	binding	O
15	domains	O
16	of	O
17	the	O
18	ToxR	B
19	protein	I
20	to	O
21	its	O
22	cytoplasmically	O
23	located	O
24	N	O
25	-	O
26	terminal	O
27	portion	O
28	.	O

1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	B
32	.--	I
33	1	I
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	B
53	and	O
54	TRAUMATIS	B
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	B
83	INSOLE	I
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	B
115	(	O
116	fig	B
117	.--	I
118	6	I
119	)	O
120	(	O
121	3	O
122	).	O

1	This	O
2	enhancer	O
3	activates	O
4	both	O
5	the	O
6	K19	O
7	and	O
8	TK	B
9	basal	O
10	promoters	O
11	in	O
12	HeLa	O
13	cells	O
14	.	O

1	The	O
2	difficulties	O
3	to	O
4	analyse	O
5	prostaglandins	O
6	(	O
7	PG	O
8	)	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	are	O
15	mainly	O
16	due	O
17	to	O
18	the	O
19	lack	O
20	of	O
21	sensitivity	O
22	of	O
23	the	O
24	gas	O
25	-	O
26	chromatograph	O
27	itself	O
28	(	O
29	higher	O
30	than	O
31	200	O
32	ng	O
33	)	O
34	and	O
35	to	O
36	the	O
37	poor	O
38	resolution	O
39	of	O
40	the	O
41	packed	O
42	columns	O
43	.	O

1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	I
28	Type	I
29	Kappa	I
30	)	O
31	was	O
32	demonstrated	O
33	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	B
6	-	I
7	1	I
8	Gag	I
9	sequences	O
10	can	O
11	influence	O
12	the	O
13	viral	O
14	PR	O
15	-	O
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	B
21	TM	I
22	Env	I
23	protein	I
24	p15	I
25	(	O
26	E	O
27	).	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	nine	O
6	and	O
7	51	O
8	terminal	O
9	amino	O
10	acid	O
11	forms	O
12	already	O
13	known	O
14	,	O
15	we	O
16	identified	O
17	a	O
18	third	O
19	with	O
20	43	O
21	terminal	O
22	amino	O
23	acids	O
24	predicted	O
25	to	O
26	encode	O
27	a	O
28	novel	O
29	RET	B
30	protein	I
31	isoform	I
32	.	O

1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	O

1	In	O
2	order	O
3	to	O
4	gain	O
5	deeper	O
6	insight	O
7	into	O
8	the	O
9	role	O
10	of	O
11	the	O
12	amino	O
13	-	O
14	terminal	O
15	domain	O
16	of	O
17	the	O
18	p24	O
19	(	O
20	CA	O
21	)	O
22	protein	O
23	during	O
24	viral	O
25	replication	O
26	,	O
27	eight	O
28	highly	O
29	conserved	O
30	proline	O
31	residues	O
32	known	O
33	to	O
34	promote	O
35	turns	O
36	and	O
37	to	O
38	terminate	O
39	alpha	O
40	-	O
41	helices	O
42	within	O
43	the	O
44	p24	O
45	tertiary	O
46	structure	O
47	were	O
48	replaced	O
49	by	O
50	a	O
51	leucine	O
52	residue	O
53	(	O
54	P	O
55	-	O
56	position	O
57	-	O
58	L	O
59	).	O

1	The	O
2	PEPCK	B
3	promoter	I
4	fragment	I
5	was	O
6	introduced	O
7	either	O
8	in	O
9	the	O
10	proper	O
11	orientation	O
12	for	O
13	transcription	O
14	of	O
15	the	O
16	TK	B
17	gene	I
18	or	O
19	in	O
20	the	O
21	opposite	O
22	orientation	O
23	.	O

1	A	O
2	role	O
3	for	O
4	the	O
5	small	B
6	GTPase	I
7	Rac	I
8	in	O
9	polyomavirus	B
10	middle	I
11	-	I
12	T	I
13	antigen	I
14	-	O
15	mediated	O
16	activation	O
17	of	O
18	the	O
19	serum	O
20	response	O
21	element	O
22	and	O
23	in	O
24	cell	O
25	transformation	O
26	.	O

1	Critical	O
2	residues	O
3	required	O
4	for	O
5	repression	O
6	are	O
7	located	O
8	within	O
9	the	O
10	C	O
11	-	O
12	terminal	O
13	27	O
14	amino	O
15	acids	O
16	of	O
17	c	B
18	-	I
19	Fos	I
20	,	O
21	since	O
22	v	B
23	-	I
24	Fos	I
25	and	O
26	C	O
27	-	O
28	terminal	O
29	truncations	O
30	of	O
31	c	B
32	-	I
33	Fos	I
34	did	O
35	not	O
36	down	O
37	regulate	O
38	.	O

1	We	O
2	examined	O
3	the	O
4	binding	O
5	of	O
6	purified	O
7	T3	B
8	receptor	I
9	alpha	I
10	(	O
11	T3R	B
12	alpha	I
13	),	O
14	overexpressed	O
15	in	O
16	Escherichia	O
17	coli	O
18	,	O
19	to	O
20	wild	O
21	-	O
22	type	O
23	and	O
24	up	O
25	and	O
26	down	O
27	mutations	O
28	of	O
29	the	O
30	rGH	B
31	T3RE	I
32	to	O
33	evaluate	O
34	whether	O
35	transcriptional	O
36	potency	O
37	correlates	O
38	with	O
39	changes	O
40	in	O
41	T3R	B
42	binding	O
43	.	O

1	A	O
2	simple	O
3	analytical	O
4	method	O
5	for	O
6	l	O
7	-	O
8	menthol	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	O
17	polarized	O
18	photometric	O
19	detector	O
20	was	O
21	established	O
22	.	O

1	An	O
2	increase	O
3	in	O
4	bone	O
5	mineral	O
6	density	O
7	at	O
8	the	O
9	spine	O
10	,	O
11	total	O
12	hip	O
13	,	O
14	and	O
15	total	O
16	body	O
17	has	O
18	been	O
19	reported	O
20	with	O
21	raloxifene	O
22	but	O
23	seems	O
24	to	O
25	be	O
26	less	O
27	than	O
28	that	O
29	seen	O
30	with	O
31	estrogen	O
32	or	O
33	alendronate	O
34	therapy	O
35	.	O

1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	CIC	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	CIC	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	expiratory	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	O
39	IgG	B
40	.	O

1	Our	O
2	data	O
3	demonstrate	O
4	directly	O
5	that	O
6	Rpm1r	B
7	is	O
8	transcribed	O
9	with	O
10	its	O
11	substrates	O
12	,	O
13	tRNA	B
14	met	I
15	f	I
16	and	O
17	tRNAPro	B
18	,	O
19	from	O
20	a	O
21	promoter	O
22	located	O
23	upstream	O
24	of	O
25	the	O
26	tRNA	B
27	met	I
28	f	I
29	gene	I
30	and	O
31	suggest	O
32	that	O
33	a	O
34	portion	O
35	also	O
36	originates	O
37	from	O
38	a	O
39	second	O
40	promoter	O
41	,	O
42	located	O
43	between	O
44	the	O
45	tRNA	B
46	met	I
47	f	I
48	gene	I
49	and	O
50	RPM1	O
51	.	O

1	Two	O
2	US	O
3	commercial	O
4	cultivars	O
5	(	O
6	Tehama	O
7	and	O
8	Vina	O
9	),	O
10	three	O
11	European	O
12	commercial	O
13	cultivars	O
14	(	O
15	Esterhazy	O
16	,	O
17	139	O
18	,	O
19	G120	O
20	)	O
21	and	O
22	five	O
23	New	O
24	Zealand	O
25	selections	O
26	(	O
27	Rex	O
28	,	O
29	Dublin	B
30	'	I
31	s	I
32	Glory	I
33	,	O
34	Meyric	O
35	,	O
36	McKinster	O
37	,	O
38	Stanley	O
39	)	O
40	were	O
41	evaluated	O
42	.	O

1	We	O
2	determined	O
3	whether	O
4	a	O
5	single	O
6	injection	O
7	of	O
8	slow	O
9	-	O
10	release	O
11	estradiol	O
12	-	O
13	17beta	O
14	(	O
15	SRE2	O
16	)	O
17	would	O
18	induce	O
19	pseudopregnancy	O
20	in	O
21	gilts	O
22	and	O
23	whether	O
24	PGF2alpha	B
25	would	O
26	regress	O
27	the	O
28	corpora	O
29	lutea	O
30	(	O
31	CL	O
32	)	O
33	of	O
34	pseudopregnancy	O
35	.	O

1	After	O
2	hepatitis	O
3	B	O
4	vaccine	O
5	immunization	O
6	,	O
7	serum	O
8	antibody	O
9	response	O
10	was	O
11	of	O
12	primary	O
13	type	O
14	in	O
15	33	O
16	cases	O
17	with	O
18	anti	O
19	-	O
20	HBs	O
21	less	O
22	than	O
23	2	O
24	.	O
25	1	O
26	S	O
27	/	O
28	N	O
29	(	O
30	S	O
31	/	O
32	N	O
33	Ratio	O
34	Unit	O
35	)	O
36	at	O
37	T0	O
38	,	O
39	the	O
40	anti	B
41	-	I
42	HBs	I
43	positive	O
44	rate	O
45	was	O
46	39	O
47	.	O
48	4	O
49	%,	O
50	84	O
51	.	O
52	8	O
53	%,	O
54	96	O
55	.	O
56	7	O
57	%	O
58	and	O
59	96	O
60	.	O
61	7	O
62	%	O
63	in	O
64	T1	O
65	,	O
66	T2	O
67	,	O
68	T0	O
69	and	O
70	T12	O
71	respectively	O
72	.	O

1	Nature	O
2	398	O
3	,	O
4	828	O
5	-	O
6	830	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	alters	O
28	chromatin	O
29	structure	O
30	(	O
31	ARC	O
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	TIG	B
45	-	I
46	1	I
47	mRNA	I
48	.	O

1	Transcriptional	O
2	activity	O
3	was	O
4	measured	O
5	by	O
6	slot	O
7	-	O
8	blot	O
9	hybridization	O
10	with	O
11	steady	O
12	-	O
13	state	O
14	RNA	O
15	isolated	O
16	from	O
17	lacZ	B
18	+	I
19	M	I
20	.	O
21	smegmatis	O
22	clones	O
23	.	O

1	The	O
2	latter	O
3	domain	O
4	appears	O
5	to	O
6	be	O
7	involved	O
8	in	O
9	targeting	O
10	Num1p	O
11	to	O
12	the	O
13	mother	O
14	cell	O
15	cortex	O
16	.	O

1	The	O
2	hydrophobicity	O
3	profile	O
4	of	O
5	the	O
6	methyltransferase	B
7	reveals	O
8	the	O
9	presence	O
10	of	O
11	at	O
12	least	O
13	five	O
14	potential	O
15	transmembrane	O
16	domains	O
17	.	O

1	Three	O
2	cDNAs	O
3	encoding	O
4	basic	B
5	leucine	I
6	zipper	I
7	(	I
8	bZIP	I
9	)-	I
10	type	I
11	ABRE	I
12	-	I
13	binding	I
14	proteins	I
15	were	O
16	isolated	O
17	by	O
18	using	O
19	the	O
20	yeast	O
21	one	O
22	-	O
23	hybrid	O
24	system	O
25	and	O
26	were	O
27	designated	O
28	AREB1	B
29	,	O
30	AREB2	B
31	,	O
32	and	O
33	AREB3	B
34	(	O
35	ABA	O
36	-	O
37	responsive	O
38	element	O
39	binding	O
40	protein	O
41	).	O

1	SAECG	O
2	,	O
3	echocardiography	O
4	and	O
5	thallium	O
6	-	O
7	201	O
8	imaging	O
9	were	O
10	performed	O
11	before	O
12	and	O
13	1	O
14	month	O
15	after	O
16	attempted	O
17	angioplasty	O
18	.	O

1	After	O
2	infection	O
3	of	O
4	293	O
5	cells	O
6	(	O
7	which	O
8	provide	O
9	complementary	O
10	E1a	B
11	-	I
12	E1b	I
13	functions	O
14	),	O
15	both	O
16	viruses	O
17	directed	O
18	equal	O
19	amounts	O
20	of	O
21	P	B
22	/	I
23	C	I
24	-	I
25	specific	I
26	mRNA	I
27	transcription	O
28	.	O

1	Sibling	O
2	aggregation	O
3	of	O
4	low	O
5	-	O
6	and	O
7	high	B
8	-	I
9	density	I
10	lipoprotein	I
11	cholesterol	I
12	and	I
13	apolipoproteins	I
14	B	I
15	and	O
16	A	O
17	-	O
18	I	O
19	levels	O
20	in	O
21	black	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	Bogalusa	O
28	Heart	O
29	Study	O
30	.	O

1	Renal	O
2	response	O
3	to	O
4	captopril	O
5	in	O
6	severe	O
7	heart	O
8	failure	O
9	:	O
10	role	O
11	of	O
12	furosemide	O
13	in	O
14	natriuresis	O
15	and	O
16	reversal	O
17	of	O
18	hyponatremia	O
19	.	O

1	Middle	O
2	-	O
3	latency	O
4	auditory	O
5	evoked	O
6	potentials	O
7	(	O
8	MAEPs	O
9	)	O
10	were	O
11	recorded	O
12	in	O
13	controls	O
14	and	O
15	patients	O
16	with	O
17	focal	O
18	lesions	O
19	in	O
20	dorsolateral	O
21	prefrontal	O
22	cortex	O
23	.	O

1	Phosphorylation	O
2	analyses	O
3	indicated	O
4	that	O
5	inhibition	O
6	of	O
7	ERK	B
8	-	I
9	1	I
10	/	O
11	2	O
12	decreased	O
13	okadaic	O
14	acid	O
15	-	O
16	elevated	O
17	phosphorylation	O
18	of	O
19	JunD	B
20	and	O
21	FosB	B
22	.	O

1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	halves	O
15	of	O
16	the	O
17	nuclease	O
18	were	O
19	identified	O
20	using	O
21	different	O
22	proteases	O
23	which	O
24	cleave	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O

1	No	O
2	difference	O
3	in	O
4	the	O
5	clinical	O
6	acceptability	O
7	could	O
8	be	O
9	ascertained	O
10	between	O
11	the	O
12	two	O
13	groups	O
14	.	O

1	Functional	O
2	analysis	O
3	of	O
4	DNase	B
5	-	I
6	I	I
7	hypersensitive	O
8	sites	O
9	at	O
10	the	O
11	mouse	B
12	porphobilinogen	I
13	deaminase	I
14	gene	I
15	locus	I
16	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	Recognition	O
2	mechanisms	O
3	of	O
4	the	O
5	minus	O
6	-	O
7	strand	O
8	origin	O
9	of	O
10	phage	O
11	f1	O
12	by	O
13	Escherichia	B
14	coli	I
15	RNA	I
16	polymerase	I
17	.	O

1	The	O
2	rat	O
3	incisor	O
4	is	O
5	an	O
6	excellent	O
7	model	O
8	system	O
9	in	O
10	which	O
11	to	O
12	study	O
13	amelgenesis	O
14	.	O

1	2	O
2	.	O

1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	existed	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	BMI	O
38	.	O

1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O

1	Analysis	O
2	of	O
3	a	O
4	set	O
5	of	O
6	deletion	O
7	constructs	O
8	in	O
9	transient	O
10	transfection	O
11	assays	O
12	measuring	O
13	heterologous	O
14	reporter	O
15	gene	O
16	(	O
17	luciferase	B
18	)	O
19	activity	O
20	demonstrated	O
21	that	O
22	the	O
23	182	O
24	-	O
25	bp	O
26	5	O
27	'-	O
28	flanking	O
29	region	O
30	provides	O
31	full	O
32	promoter	O
33	activity	O
34	in	O
35	IL	B
36	-	I
37	2	I
38	-	O
39	stimulated	O
40	L2	O
41	cells	O
42	.	O

1	CREB	B
2	was	O
3	identified	O
4	as	O
5	one	O
6	of	O
7	the	O
8	protein	O
9	components	O
10	in	O
11	several	O
12	of	O
13	the	O
14	gel	O
15	shift	O
16	complexes	O
17	formed	O
18	with	O
19	the	O
20	variant	O
21	CRE	O
22	.	O

1	A	O
2	triple	O
3	-	O
4	mutant	O
5	TBP	O
6	(	O
7	R231E	O
8	+	O
9	R235E	O
10	+	O
11	R239S	O
12	)	O
13	had	O
14	greatly	O
15	reduced	O
16	activity	O
17	for	O
18	yeast	O
19	U6	B
20	snRNA	I
21	gene	I
22	transcription	O
23	while	O
24	remaining	O
25	active	O
26	for	O
27	Pol	B
28	II	I
29	basal	I
30	transcription	O
31	.	O

1	Histological	O
2	examination	O
3	revealed	O
4	a	O
5	small	O
6	simple	O
7	renal	O
8	cyst	O
9	associated	O
10	with	O
11	renal	O
12	cell	O
13	carcinoma	O
14	.	O

1	Using	O
2	an	O
3	RNase	B
4	H	I
5	-	O
6	mediated	O
7	mapping	O
8	technique	O
9	,	O
10	we	O
11	show	O
12	that	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	CstF	B
20	can	O
21	be	O
22	photo	O
23	cross	O
24	-	O
25	linked	O
26	to	O
27	pre	O
28	-	O
29	mRNAs	O
30	at	O
31	U	O
32	-	O
33	rich	O
34	regions	O
35	located	O
36	downstream	O
37	of	O
38	the	O
39	cleavage	O
40	site	O
41	of	O
42	the	O
43	simian	O
44	virus	O
45	40	O
46	late	O
47	and	O
48	adenovirus	O
49	L3	O
50	pre	O
51	-	O
52	mRNAs	O
53	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	have	O
5	already	O
6	had	O
7	an	O
8	enormous	O
9	impact	O
10	on	O
11	transfusion	O
12	practice	O
13	by	O
14	eliminating	O
15	or	O
16	reducing	O
17	the	O
18	need	O
19	for	O
20	red	O
21	blood	O
22	cell	O
23	transfusions	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	anemic	O
29	states	O
30	characterized	O
31	by	O
32	an	O
33	absolute	O
34	or	O
35	relative	O
36	decrease	O
37	in	O
38	erythropoietin	B
39	.	O

1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	B
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	B
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O

1	With	O
2	a	O
3	sample	O
4	of	O
5	mothers	O
6	of	O
7	healthy	O
8	infants	O
9	,	O
10	all	O
11	three	O
12	subscales	O
13	of	O
14	the	O
15	revised	O
16	instrument	O
17	,	O
18	WPL	B
19	-	I
20	R	I
21	,	O
22	had	O
23	acceptable	O
24	levels	O
25	of	O
26	internal	O
27	consistency	O
28	at	O
29	7	O
30	,	O
31	30	O
32	,	O
33	and	O
34	90	O
35	days	O
36	postpartum	O
37	,	O
38	and	O
39	stability	O
40	across	O
41	administrations	O
42	.	O

1	Mammalian	B
2	Ras	I
3	GTPase	I
4	-	I
5	activating	I
6	protein	I
7	(	O
8	GAP	B
9	),	O
10	p120	B
11	Ras	I
12	-	O
13	GAP	B
14	,	O
15	has	O
16	been	O
17	implicated	O
18	as	O
19	both	O
20	a	O
21	downregulator	O
22	and	O
23	effector	O
24	of	O
25	Ras	B
26	proteins	I
27	,	O
28	but	O
29	its	O
30	precise	O
31	role	O
32	in	O
33	Ras	B
34	-	O
35	mediated	O
36	signal	O
37	transduction	O
38	pathways	O
39	is	O
40	unclear	O
41	.	O

1	Groups	O
2	dicker	O
3	for	O
4	price	O
5	breaks	O
6	as	O
7	anesthetic	O
8	gas	O
9	goes	O
10	multi	O
11	-	O
12	source	O
13	.	O

1	In	O
2	TNF	B
3	-	O
4	resistant	O
5	T24	O
6	bladder	O
7	carcinoma	O
8	cells	O
9	,	O
10	TNF	B
11	failed	O
12	to	O
13	alter	O
14	EGF	B
15	-	I
16	R	I
17	tyrosine	I
18	protein	I
19	kinase	I
20	activity	O
21	although	O
22	both	O
23	EGF	B
24	and	O
25	phorbol	O
26	ester	O
27	were	O
28	shown	O
29	to	O
30	modulate	O
31	the	O
32	enzymatic	O
33	activity	O
34	of	O
35	the	O
36	receptor	O
37	in	O
38	these	O
39	cells	O
40	.	O

1	RESULTS	O
2	:	O
3	Nodular	O
4	opacities	O
5	,	O
6	mainly	O
7	centrilobular	O
8	in	O
9	distribution	O
10	,	O
11	were	O
12	the	O
13	most	O
14	common	O
15	finding	O
16	,	O
17	seen	O
18	in	O
19	21	O
20	(	O
21	72	O
22	%)	O
23	and	O
24	15	O
25	(	O
26	65	O
27	%)	O
28	of	O
29	patients	O
30	with	O
31	MTB	O
32	and	O
33	NTMB	B
34	,	O
35	respectively	O
36	.	O

1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O

1	This	O
2	construct	O
3	,	O
4	termed	O
5	pDeltaCREC	B
6	/	I
7	EBP	I
8	,	O
9	binds	O
10	C	O
11	/	O
12	EBPalpha	B
13	and	O
14	beta	O
15	but	O
16	not	O
17	CREB	B
18	,	O
19	yet	O
20	it	O
21	confers	O
22	a	O
23	nearly	O
24	complete	O
25	glucocorticoid	O
26	response	O
27	when	O
28	transiently	O
29	transfected	O
30	into	O
31	H4IIE	O
32	rat	O
33	hepatoma	O
34	cells	O
35	.	O

1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	consists	O
5	of	O
6	48	O
7	bp	O
8	of	O
9	5	O
10	'-	O
11	end	O
12	non	O
13	-	O
14	coding	O
15	region	O
16	,	O
17	1695	O
18	bp	O
19	of	O
20	coding	O
21	region	O
22	and	O
23	212	O
24	bp	O
25	of	O
26	3	O
27	'-	O
28	end	O
29	non	O
30	-	O
31	coding	O
32	region	O
33	including	O
34	a	O
35	20	O
36	bp	O
37	poly	O
38	(	O
39	A	O
40	)	O
41	tail	O
42	.	O

1	The	O
2	mechanistic	O
3	implications	O
4	of	O
5	aromatic	O
6	non	O
7	-	O
8	responsiveness	O
9	of	O
10	autonomously	O
11	expressed	O
12	A	O
13	-	O
14	domain	O
15	,	O
16	despite	O
17	its	O
18	demonstrated	O
19	ability	O
20	to	O
21	bind	O
22	phenol	O
23	,	O
24	are	O
25	discussed	O
26	.	O

1	Therefore	O
2	,	O
3	high	O
4	set	O
5	-	O
6	up	O
7	accuracy	O
8	and	O
9	reproducibility	O
10	are	O
11	mandatory	O
12	.	O

1	Pharmacokinetic	O
2	parameters	O
3	were	O
4	similar	O
5	to	O
6	values	O
7	given	O
8	in	O
9	the	O
10	literature	O
11	for	O
12	intravenous	O
13	(	O
14	IV	O
15	)	O
16	or	O
17	intraarterial	O
18	(	O
19	IA	O
20	)	O
21	bolus	O
22	MMC	O
23	injections	O
24	(	O
25	Tmax	O
26	=	O
27	7	O
28	.	O
29	0	O
30	min	O
31	following	O
32	the	O
33	beginning	O
34	of	O
35	MMC	O
36	infusion	O
37	,	O
38	Vss	O
39	=	O
40	0	O
41	.	O
42	57	O
43	1	O
44	/	O
45	kg	O
46	,	O
47	C1	O
48	=	O
49	8	O
50	.	O
51	9	O
52	ml	O
53	/	O
54	min	O
55	.	O
56	kg	O
57	,	O
58	T1	O
59	/	O
60	2	O
61	alpha	O
62	=	O
63	8	O
64	.	O
65	3	O
66	min	O
67	,	O
68	T1	O
69	/	O
70	2	O
71	beta	O
72	=	O
73	58	O
74	.	O
75	6	O
76	min	O
77	).	O

1	Tetrad	O
2	analysis	O
3	and	O
4	mitotic	O
5	recombination	O
6	experiments	O
7	localized	O
8	the	O
9	PEP4	B
10	gene	I
11	proximal	O
12	to	O
13	GAL4	B
14	on	O
15	chromosome	O
16	XVI	O
17	.	O

1	Furthermore	O
2	,	O
3	the	O
4	PH	B
5	and	O
6	PTB	B
7	domains	I
8	are	O
9	highly	O
10	homologous	O
11	(	O
12	at	O
13	least	O
14	40	O
15	%	O
16	identical	O
17	)	O
18	to	O
19	those	O
20	found	O
21	in	O
22	insulin	B
23	receptor	I
24	substrates	O
25	1	O
26	,	O
27	2	O
28	,	O
29	and	O
30	3	O
31	(	O
32	IRS	B
33	-	I
34	1	I
35	,	O
36	IRS	B
37	-	I
38	2	I
39	,	O
40	and	O
41	IRS	B
42	-	I
43	3	I
44	).	O

1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O

1	Antisense	O
2	transcription	O
3	of	O
4	a	O
5	murine	O
6	FGFR	B
7	-	I
8	3	I
9	psuedogene	I
10	during	O
11	fetal	O
12	developement	O
13	.	O

1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	distant	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	hydrogen	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O

1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O

1	The	O
2	TYAC	O
3	/	O
4	P1	O
5	resource	O
6	,	O
7	derivative	O
8	STSs	O
9	,	O
10	and	O
11	polymorphisms	O
12	constitute	O
13	an	O
14	enabling	O
15	resource	O
16	to	O
17	further	O
18	studies	O
19	of	O
20	telomere	O
21	structure	O
22	and	O
23	function	O
24	and	O
25	a	O
26	means	O
27	for	O
28	physical	O
29	and	O
30	genetic	O
31	map	O
32	integration	O
33	and	O
34	closure	O
35	.	O

1	The	O
2	most	O
3	common	O
4	grade	O
5	3	O
6	toxicity	O
7	was	O
8	neutropenia	O
9	,	O
10	thrombocytopenia	O
11	,	O
12	and	O
13	parasthesias	O
14	(	O
15	observed	O
16	in	O
17	<	O
18	10	O
19	%	O
20	of	O
21	cycles	O
22	).	O

1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	B
10	luteinizing	I
11	hormone	I
12	(	O
13	Sairam	O
14	,	O
15	M	O
16	.	O

1	Six	O
2	hours	O
3	after	O
4	the	O
5	last	O
6	administration	O
7	,	O
8	uterus	O
9	of	O
10	Gf	O
11	and	O
12	Cv	O
13	mice	O
14	were	O
15	weight	O
16	337	O
17	.	O
18	6	O
19	mg	O
20	%	O
21	and	O
22	423	O
23	.	O
24	5	O
25	mg	O
26	%	O
27	respectively	O
28	,	O
29	the	O
30	difference	O
31	was	O
32	statistically	O
33	significant	O
34	(	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	01	O
41	).	O

1	Expression	O
2	of	O
3	GlcNAc	B
4	-	I
5	TI	I
6	mRNA	I
7	in	O
8	tobacco	O
9	leaves	O
10	was	O
11	detected	O
12	using	O
13	RT	O
14	-	O
15	PCR	O
16	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	the	O
6	t	O
7	(	O
8	4	O
9	;	O
10	14	O
11	)(	O
12	p16	O
13	.	O
14	3	O
15	;	O
16	q32	O
17	)	O
18	represents	O
19	a	O
20	novel	O
21	,	O
22	recurrent	O
23	chromosomal	O
24	translocation	O
25	in	O
26	MM	O
27	,	O
28	and	O
29	suggest	O
30	that	O
31	the	O
32	FGFR3	B
33	gene	I
34	may	O
35	be	O
36	the	O
37	target	O
38	of	O
39	this	O
40	abnormality	O
41	and	O
42	thus	O
43	contribute	O
44	to	O
45	tumorigenesis	O
46	in	O
47	MM	O
48	.	O

1	Coexisting	O
2	vertical	O
3	and	O
4	horizontal	O
5	one	O
6	and	O
7	a	O
8	half	O
9	syndromes	O
10	.	O

1	Significant	O
2	immunoglobulinuria	O
3	developed	O
4	prior	O
5	to	O
6	the	O
7	development	O
8	of	O
9	azotemia	O
10	,	O
11	significantly	O
12	decreased	O
13	creatinine	O
14	clearance	O
15	,	O
16	significant	O
17	proteinuria	O
18	(	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	3	O
25	+	O
26	dipstick	O
27	or	O
28	greater	O
29	than	O
30	or	O
31	equal	O
32	to	O
33	5	O
34	gm	O
35	per	O
36	24	O
37	-	O
38	hour	O
39	urine	O
40	collection	O
41	),	O
42	or	O
43	oliguria	O
44	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	Bazett	O
5	-	O
6	corrected	O
7	QT	O
8	(	O
9	QTc	O
10	)	O
11	interval	O
12	during	O
13	exercise	O
14	has	O
15	been	O
16	used	O
17	as	O
18	a	O
19	marker	O
20	for	O
21	ischemic	O
22	disease	O
23	,	O
24	arrhythmogenic	O
25	substrate	O
26	and	O
27	the	O
28	long	O
29	QT	O
30	syndrome	O
31	.	O

1	In	O
2	untreated	O
3	mice	O
4	,	O
5	bactericidal	O
6	activity	O
7	of	O
8	peritoneal	O
9	macrophages	O
10	decreased	O
11	from	O
12	one	O
13	day	O
14	to	O
15	3	O
16	days	O
17	after	O
18	ip	O
19	injection	O
20	of	O
21	killed	O
22	L	O
23	.	O
24	monocytogenes	O
25	.	O

1	Therefore	O
2	,	O
3	in	O
4	conjunction	O
5	with	O
6	a	O
7	positive	O
8	pregnancy	O
9	test	O
10	and	O
11	the	O
12	patient	O
13	'	O
14	s	O
15	clinical	O
16	history	O
17	,	O
18	a	O
19	severely	O
20	depressed	O
21	or	O
22	absent	O
23	serum	O
24	PAPP	B
25	-	I
26	A	I
27	level	O
28	may	O
29	aid	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	extrauterine	O
35	pregnancy	O
36	.	O

1	By	O
2	screening	O
3	a	O
4	Y1	O
5	cell	O
6	cDNA	O
7	library	O
8	with	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	region	O
14	of	O
15	the	O
16	H	B
17	-	I
18	2RIIBP	I
19	nuclear	I
20	hormone	I
21	receptor	I
22	cDNA	I
23	,	O
24	we	O
25	isolated	O
26	a	O
27	cDNA	O
28	that	O
29	is	O
30	selectively	O
31	expressed	O
32	in	O
33	steroidogenic	O
34	cells	O
35	.	O

1	Survival	O
2	was	O
3	calculated	O
4	both	O
5	from	O
6	the	O
7	date	O
8	of	O
9	onset	O
10	and	O
11	from	O
12	the	O
13	date	O
14	of	O
15	diagnosis	O
16	.	O

1	Our	O
2	laboratory	O
3	and	O
4	others	O
5	have	O
6	shown	O
7	alternative	O
8	splicing	O
9	of	O
10	up	O
11	to	O
12	ten	O
13	exons	O
14	at	O
15	a	O
16	discrete	O
17	extracellular	O
18	site	O
19	to	O
20	be	O
21	primarily	O
22	responsible	O
23	for	O
24	the	O
25	generation	O
26	of	O
27	CD44	B
28	variant	I
29	(	O
30	CD44v	B
31	)	O
32	isoforms	O
33	.	O

1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O

1	RNase	B
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	O
8	-	O
9	kDa	O
10	CaM	B
11	PDE	I
12	mRNA	I
13	or	O
14	structurally	O
15	related	O
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	B
20	PDE	I
21	isoforms	I
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O

1	Epithelial	O
2	damage	O
3	was	O
4	not	O
5	observed	O
6	in	O
7	any	O
8	controls	O
9	but	O
10	was	O
11	in	O
12	all	O
13	tissues	O
14	exposed	O
15	to	O
16	SO2	O
17	.	O

1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O

1	A	O
2	recombinant	O
3	vector	O
4	,	O
5	p410	O
6	+,	O
7	was	O
8	constructed	O
9	which	O
10	carried	O
11	the	O
12	BamHI	B
13	-	I
14	K	I
15	fragment	I
16	(	O
17	nucleotides	O
18	107565	O
19	to	O
20	112625	O
21	of	O
22	the	O
23	B95	O
24	-	O
25	8	O
26	strain	O
27	,	O
28	encoding	O
29	the	O
30	EBV	B
31	-	I
32	associated	I
33	nuclear	I
34	antigen	I
35	EBNA	I
36	-	I
37	1	I
38	),	O
39	the	O
40	cis	O
41	-	O
42	acting	O
43	sequence	O
44	from	O
45	the	O
46	BamHI	B
47	-	I
48	C	I
49	fragment	I
50	,	O
51	and	O
52	a	O
53	dominant	O
54	selectable	O
55	marker	O
56	gene	O
57	encoding	O
58	G	O
59	-	O
60	418	O
61	resistance	O
62	in	O
63	animal	O
64	cells	O
65	.	O

1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O

1	During	O
2	skeletal	O
3	muscle	O
4	development	O
5	,	O
6	different	O
7	types	O
8	of	O
9	muscle	O
10	fibers	O
11	are	O
12	generated	O
13	,	O
14	which	O
15	express	O
16	different	O
17	combinations	O
18	of	O
19	muscle	O
20	-	O
21	specific	O
22	gene	O
23	products	O
24	.	O

1	The	O
2	used	O
3	expression	O
4	system	O
5	could	O
6	allow	O
7	to	O
8	produce	O
9	mutated	O
10	forms	O
11	of	O
12	SsEF	B
13	-	I
14	2	I
15	obtained	O
16	by	O
17	mutagenesis	O
18	of	O
19	the	O
20	corresponding	O
21	gene	O
22	.	O

1	Recombinant	O
2	soluble	O
3	pMCP	O
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	B
9	domains	I
10	had	I
11	factor	I
12	I	I
13	cofactor	I
14	activity	O
15	in	O
16	C3b	O
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	O
32	.	O

1	GTRE	O
2	,	O
3	TRE	O
4	,	O
5	and	O
6	CRE	O
7	oligonucleotides	O
8	all	O
9	compete	O
10	more	O
11	efficiently	O
12	for	O
13	protein	O
14	binding	O
15	to	O
16	their	O
17	labeled	O
18	congeners	O
19	than	O
20	for	O
21	protein	O
22	binding	O
23	to	O
24	either	O
25	of	O
26	the	O
27	other	O
28	labeled	O
29	oligonucleotides	O
30	,	O
31	suggesting	O
32	that	O
33	the	O
34	GTRE	O
35	,	O
36	TRE	O
37	,	O
38	and	O
39	CRE	O
40	oligonucleotides	O
41	,	O
42	suggesting	O
43	that	O
44	the	O
45	GTRE	O
46	,	O
47	TRE	O
48	,	O
49	and	O
50	CRE	O
51	oligonucleotides	O
52	each	O
53	bind	O
54	unique	O
55	as	O
56	well	O
57	as	O
58	common	O
59	proteins	O
60	,	O
61	likely	O
62	to	O
63	be	O
64	members	O
65	of	O
66	the	O
67	Jun	B
68	/	O
69	Fos	B
70	and	O
71	cAMP	B
72	-	I
73	responsive	I
74	element	I
75	-	I
76	binding	I
77	protein	I
78	/	I
79	activating	I
80	transcription	I
81	factors	I
82	(	O
83	CREB	B
84	/	O
85	ATF	B
86	)	O
87	families	O
88	of	O
89	transcription	O
90	factors	O
91	,	O
92	in	O
93	chromaffin	O
94	cells	O
95	.	O

1	In	O
2	ICE	B
3	gamma	I
4	,	O
5	most	O
6	of	O
7	the	O
8	propeptide	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	catalyst	O
28	for	O
29	ICE	B
30	autoprocessing	O
31	in	O
32	vivo	O
33	.	O

1	2	O
2	-	O
3	AP	O
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	rises	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	chromosomally	O
17	integrated	O
18	HIV	O
19	-	O
20	1	O
21	constructs	O
22	but	O
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	O
28	gene	O
29	encoding	O
30	gamma	B
31	-	I
32	actin	I
33	or	I
34	glucose	I
35	6	I
36	-	I
37	phosphate	I
38	dehydrogenase	I
39	.	O

1	Using	O
2	reference	O
3	probes	O
4	as	O
5	internal	O
6	standards	O
7	,	O
8	we	O
9	show	O
10	that	O
11	the	O
12	ost	O
13	transcription	O
14	unit	O
15	is	O
16	located	O
17	within	O
18	the	O
19	cytogenetic	O
20	band	O
21	interval	O
22	89A1	O
23	,	O
24	2	O
25	on	O
26	the	O
27	right	O
28	arm	O
29	of	O
30	the	O
31	third	O
32	chromosome	O
33	,	O
34	and	O
35	that	O
36	it	O
37	exerts	O
38	diagnostic	O
39	segmentation	O
40	gene	O
41	expression	O
42	patterns	O
43	in	O
44	the	O
45	embryo	O
46	.	O

1	In	O
2	insulin	B
3	-	O
4	responsive	O
5	cells	O
6	,	O
7	Akt	B
8	phosphorylates	O
9	and	O
10	inactivates	O
11	the	O
12	serine	B
13	/	I
14	threonine	I
15	kinase	I
16	glycogen	I
17	synthase	I
18	kinase	I
19	-	I
20	3	I
21	(	O
22	GSK	B
23	-	I
24	3	I
25	).	O

1	Northern	O
2	blot	O
3	analyses	O
4	demonstrate	O
5	that	O
6	3	O
7	.	O
8	9	O
9	-	O
10	and	O
11	5	O
12	-	O
13	kilobase	O
14	mRNAs	O
15	corresponding	O
16	to	O
17	the	O
18	cDNA	O
19	were	O
20	present	O
21	in	O
22	all	O
23	tissues	O
24	examined	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	protein	O
30	it	O
31	encodes	O
32	performs	O
33	a	O
34	housekeeping	O
35	function	O
36	.	O

1	In	O
2	memory	O
3	of	O
4	Magdelaine	O
5	Comtesse	O

1	RU486	O
2	and	O
3	ONO	O
4	802	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	O
16	-	O
17	specific	O
18	GTPase	B
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	I
25	alpha	I
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	O
32	-	O
33	specific	O
34	GTPase	B
35	-	I
36	activating	I
37	protein	I
38	for	O
39	p21rac	O
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	Effects	O
2	of	O
3	repeated	O
4	exposures	O
5	of	O
6	hydrogen	O
7	sulphide	O
8	on	O
9	rat	O
10	hippocampal	O
11	EEG	O
12	.	O

1	Exon	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	HSL	B
13	translation	I
14	start	I
15	site	I
16	.	O

1	Emergency	O
2	treatment	O
3	of	O
4	facial	O
5	and	O
6	maxillary	O
7	/	O
8	mandibular	O
9	injuries	O

1	The	O
2	spleen	O
3	rate	O
4	of	O
5	about	O
6	600	O
7	villagers	O
8	of	O
9	RK	O
10	I	O
11	examined	O
12	was	O
13	54	O
14	.	O
15	3	O
16	%	O
17	and	O
18	the	O
19	parasite	O
20	rate	O
21	13	O
22	.	O
23	2	O
24	%	O
25	before	O
26	the	O
27	drug	O
28	intervention	O
29	.	O

1	Artificial	O
2	ventilation	O
3	was	O
4	conducted	O
5	using	O
6	a	O
7	tidal	O
8	volume	O
9	of	O
10	10	O
11	ml	O
12	X	O
13	kg	O
14	-	O
15	1	O
16	and	O
17	a	O
18	rate	O
19	of	O
20	10	O
21	to	O
22	12	O
23	c	O
24	X	O
25	min	O
26	-	O
27	1	O
28	.	O

1	Cell	O
2	lines	O
3	derived	O
4	from	O
5	the	O
6	tumors	O
7	were	O
8	examined	O
9	by	O
10	fluorescent	O
11	in	O
12	situ	O
13	hybridization	O
14	for	O
15	the	O
16	status	O
17	of	O
18	the	O
19	transferred	O
20	human	O
21	chromosome	O
22	and	O
23	by	O
24	PCR	O
25	for	O
26	marker	O
27	loss	O
28	.	O

1	The	O
2	Arabidopsis	B
3	FAD7	I
4	gene	I
5	encodes	O
6	a	O
7	chloroplast	O
8	omega	B
9	-	I
10	3	I
11	fatty	I
12	acid	I
13	desaturase	I
14	that	O
15	catalyzes	O
16	the	O
17	desaturation	O
18	of	O
19	lipid	O
20	-	O
21	linked	O
22	dienoic	O
23	fatty	O
24	acids	O
25	(	O
26	18	O
27	:	O
28	2	O
29	and	O
30	16	O
31	:	O
32	2	O
33	).	O

1	RESULTS	O
2	:	O
3	Basal	O
4	plasma	O
5	IGF	B
6	-	I
7	I	I
8	levels	O
9	as	O
10	well	O
11	as	O
12	body	O
13	mass	O
14	index	O
15	(	O
16	BMI	O
17	)	O
18	were	O
19	lower	O
20	in	O
21	amenorrheic	O
22	patients	O
23	than	O
24	in	O
25	healthy	O
26	controls	O
27	.	O

1	Benztropine	O
2	for	O
3	venlafaxine	O
4	-	O
5	induced	O
6	night	O
7	sweats	O
8	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	This	O
2	result	O
3	suggested	O
4	that	O
5	mutant	O
6	I299	O
7	has	O
8	diminished	O
9	cap	O
10	-	O
11	binding	O
12	activity	O
13	.	O

1	Induction	O
2	of	O
3	the	O
4	CINC	B
5	promoter	I
6	by	O
7	IL	B
8	-	I
9	17	I
10	in	O
11	IEC	O
12	-	O
13	6	O
14	cells	O
15	was	O
16	TNF	B
17	receptor	I
18	-	I
19	associated	I
20	factor	I
21	-	I
22	6	I
23	(	O
24	TRAF6	O
25	),	O
26	but	O
27	not	O
28	TRAF2	B
29	,	O
30	dependent	O
31	.	O

1	Either	O
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	O
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O

1	A	O
2	bacteriological	O
3	relapse	O
4	requiring	O
5	treatment	O
6	occurred	O
7	by	O
8	5	O
9	years	O
10	in	O
11	16	O
12	.	O
13	8	O
14	%	O
15	of	O
16	113	O
17	R3	O
18	,	O
19	5	O
20	.	O
21	2	O
22	%	O
23	of	O
24	97	O
25	R5	O
26	,	O
27	and	O
28	20	O
29	.	O
30	0	O
31	%	O
32	of	O
33	115	O
34	Z5	O
35	patients	O
36	with	O
37	organisms	O
38	sensitive	O
39	to	O
40	streptomycin	O
41	and	O
42	isoniazid	O
43	initially	O
44	.	O

1	Regulation	O
2	of	O
3	the	O
4	Raf	B
5	kinase	I
6	in	O
7	T	O
8	cells	O
9	differs	O
10	from	O
11	findings	O
12	with	O
13	a	O
14	variety	O
15	of	O
16	cell	O
17	lines	O
18	that	O
19	the	O
20	catalytic	O
21	domain	O
22	of	O
23	Raf	B
24	(	O
25	Raf	B
26	(	O
27	delta26	O
28	-	O
29	303	O
30	))	O
31	shows	O
32	no	O
33	activity	O
34	.	O

1	Consanguinity	O
2	and	O
3	migration	O
4	in	O
5	the	O
6	marriages	O
7	of	O
8	the	O
9	region	O
10	of	O
11	Nunoa	O
12	,	O
13	Santiago	O
14	,	O
15	1850	O
16	-	O
17	1960	O

1	To	O
2	understand	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	increased	O
8	cell	O
9	surface	O
10	stability	O
11	compared	O
12	with	O
13	wild	O
14	-	O
15	type	O
16	peptide	O
17	and	O
18	to	O
19	understand	O
20	the	O
21	differences	O
22	in	O
23	T	O
24	cell	O
25	recognition	O
26	between	O
27	I1Y	O
28	and	O
29	I1F	O
30	,	O
31	we	O
32	determined	O
33	the	O
34	x	O
35	-	O
36	ray	O
37	crystal	O
38	structures	O
39	of	O
40	the	O
41	two	O
42	class	O
43	I	O
44	MHC	B
45	-	I
46	peptide	I
47	complexes	O
48	.	O

1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	O
13	to	O
14	3	O
15	),	O
16	apocytochrome	O
17	b	O
18	(	O
19	cob	B
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	O
30	to	O
31	6	O
32	,	O
33	nad4L	B
34	),	O
35	two	O
36	ATPase	B
37	subunits	I
38	(	O
39	atp6	B
40	and	O
41	atp9	O
42	),	O
43	three	O
44	ribosomal	B
45	RNAs	I
46	(	O
47	rrn5	O
48	,	O
49	srn	O
50	and	O
51	lrn	O
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	B
58	proteins	I
59	(	O
60	rps3	O
61	,	O
62	rps11	O
63	,	O
64	rps12	O
65	and	O
66	rpl16	O
67	).	O

1	The	O
2	single	O
3	strandedness	O
4	is	O
5	manifested	O
6	as	O
7	a	O
8	terminal	O
9	extension	O
10	of	O
11	the	O
12	G	O
13	-	O
14	rich	O
15	strand	O
16	(	O
17	G	O
18	tails	O
19	)	O
20	that	O
21	can	O
22	occur	O
23	independently	O
24	of	O
25	telomerase	B
26	,	O
27	suggesting	O
28	that	O
29	cdc17	O
30	/	O
31	pol1	O
32	mutants	O
33	exhibit	O
34	defects	O
35	in	O
36	telomeric	O
37	lagging	O
38	-	O
39	strand	O
40	synthesis	O
41	.	O

1	To	O
2	avoid	O
3	complications	O
4	,	O
5	accurate	O
6	quantitative	O
7	analysis	O
8	of	O
9	NO	O
10	and	O
11	NO2	B
12	is	O
13	necessary	O
14	during	O
15	this	O
16	therapy	O
17	.	O

1	At	O
2	temperatures	O
3	permissive	O
4	for	O
5	transformation	O
6	,	O
7	6m2	O
8	cells	O
9	contain	O
10	P58gag	B
11	produced	O
12	from	O
13	the	O
14	4	O
15	.	O
16	0	O
17	-	O
18	kilobase	O
19	(	O
20	kb	O
21	)	O
22	viral	O
23	RNA	O
24	genome	O
25	and	O
26	P85gag	B
27	-	I
28	mos	I
29	translated	O
30	from	O
31	a	O
32	3	O
33	.	O
34	5	O
35	-	O
36	kb	O
37	spliced	O
38	mRNA	O
39	.	O

1	Ras	B
2	-	O
3	and	O
4	ultra	O
5	-	O
6	violet	O
7	-	O
8	responsive	O
9	protein	O
10	kinases	O
11	that	O
12	phosphorylate	O
13	c	B
14	-	I
15	Jun	I
16	on	O
17	serine	O
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	Lung	O
7	elastance	O
8	(	O
9	EL	O
10	)	O
11	and	O
12	resistance	O
13	(	O
14	RL	O
15	)	O
16	were	O
17	calculated	O
18	from	O
19	measurements	O
20	of	O
21	airway	O
22	pressure	O
23	,	O
24	esophageal	O
25	pressure	O
26	,	O
27	and	O
28	airway	O
29	flow	O
30	in	O
31	five	O
32	anesthetized	O
33	,	O
34	paralyzed	O
35	dogs	O
36	during	O
37	sinusoidal	O
38	forcing	O
39	at	O
40	a	O
41	constant	O
42	mean	O
43	airway	O
44	pressure	O
45	of	O
46	10	O
47	cmH2O	O
48	in	O
49	a	O
50	wide	O
51	range	O
52	of	O
53	breathing	O
54	frequencies	O
55	(	O
56	0	O
57	.	O
58	2	O
59	to	O
60	1	O
61	.	O
62	0	O
63	Hz	O
64	in	O
65	intervals	O
66	of	O
67	0	O
68	.	O
69	2	O
70	)	O
71	and	O
72	tidal	O
73	volumes	O
74	(	O
75	50	O
76	,	O
77	100	O
78	,	O
79	200	O
80	,	O
81	and	O
82	to	O
83	300	O
84	mL	O
85	).	O

1	Dual	O
2	innervation	O
3	of	O
4	fast	O
5	fibers	O
6	in	O
7	trunk	O
8	muscles	O
9	of	O
10	lamprey	O
11	larvae	O

1	The	O
2	intercistronic	O
3	gene	O
4	junctions	O
5	of	O
6	vesicular	O
7	stomatitis	O
8	virus	O
9	(	O
10	VSV	O
11	)	O
12	contain	O
13	conserved	O
14	sequence	O
15	elements	O
16	that	O
17	are	O
18	important	O
19	for	O
20	polyadenylation	O
21	and	O
22	transcription	O
23	termination	O
24	of	O
25	upstream	O
26	transcript	O
27	as	O
28	well	O
29	as	O
30	reinitiation	O
31	of	O
32	transcription	O
33	of	O
34	downstream	O
35	transcript	O
36	.	O

1	Its	O
2	application	O
3	in	O
4	Madagascar	O
5	:	O
6	advantages	O
7	and	O
8	disadvantages	O

1	BACKGROUND	O
2	:	O
3	Chemicals	O
4	vary	O
5	considerably	O
6	in	O
7	their	O
8	intrinsic	O
9	ability	O
10	to	O
11	cause	O
12	allergic	O
13	contact	O
14	dermatitis	O
15	.	O

1	All	O
2	patients	O
3	in	O
4	the	O
5	control	O
6	group	O
7	showed	O
8	a	O
9	significant	O
10	improvement	O
11	in	O
12	their	O
13	PEFR	O
14	while	O
15	only	O
16	3	O
17	patients	O
18	in	O
19	the	O
20	treated	O
21	group	O
22	showed	O
23	an	O
24	improvement	O
25	.	O

1	Small	B
2	Maf	I
3	proteins	I
4	interact	O
5	with	O
6	the	O
7	human	B
8	transcription	I
9	factor	I
10	TCF11	I
11	/	O
12	Nrf1	B
13	/	O
14	LCR	O
15	-	O
16	F1	O
17	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	for	O
7	the	O
8	HML	B
9	ARS	I
10	cluster	I
11	(	O
12	ARS303	O
13	,	O
14	ARS320	B
15	,	O
16	and	O
17	ARS302	O
18	),	O
19	inactivity	O
20	of	O
21	origins	O
22	is	O
23	independent	O
24	of	O
25	local	O
26	transcriptional	O
27	silencing	O
28	,	O
29	even	O
30	though	O
31	origins	O
32	and	O
33	silencers	O
34	share	O
35	key	O
36	cis	O
37	-	O
38	and	O
39	trans	O
40	-	O
41	acting	O
42	components	O
43	.	O

1	Two	O
2	scintigraphic	O
3	methods	O
4	,	O
5	resting	O
6	dipyridamole	O
7	and	O
8	exercise	O
9	thallium	O
10	-	O
11	201	O
12	myocardial	O
13	perfusion	O
14	imaging	O
15	,	O
16	to	O
17	detect	O
18	and	O
19	localize	O
20	coronary	O
21	artery	O
22	stenosis	O
23	were	O
24	compared	O
25	in	O
26	32	O
27	patients	O
28	suffering	O
29	from	O
30	coronary	O
31	artery	O
32	disease	O
33	.	O

1	Muscular	O
2	pathology	O

1	Previous	O
2	work	O
3	has	O
4	shown	O
5	that	O
6	spleen	B
7	necrosis	I
8	virus	I
9	(	I
10	SNV	I
11	)	I
12	long	I
13	terminal	I
14	repeats	I
15	(	O
16	LTRs	O
17	)	O
18	are	O
19	associated	O
20	with	O
21	Rex	B
22	/	O
23	Rex	O
24	-	O
25	responsive	O
26	element	O
27	-	O
28	independent	O
29	expression	O
30	of	O
31	bovine	O
32	leukemia	O
33	virus	O
34	RNA	O
35	and	O
36	supports	O
37	the	O
38	hypothesis	O
39	that	O
40	SNV	B
41	RNA	I
42	contains	O
43	a	O
44	cis	O
45	-	O
46	acting	O
47	element	O
48	that	O
49	interacts	O
50	with	O
51	cellular	O
52	Rex	O
53	-	O
54	like	O
55	proteins	O
56	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	polypeptide	O
7	sequence	O
8	of	O
9	the	O
10	Drosophila	O
11	protein	O
12	with	O
13	the	O
14	equivalent	O
15	subunits	O
16	from	O
17	mouse	O
18	and	O
19	yeast	O
20	suggests	O
21	that	O
22	they	O
23	are	O
24	closely	O
25	related	O
26	and	O
27	defines	O
28	three	O
29	conserved	O
30	regions	O
31	which	O
32	are	O
33	likely	O
34	to	O
35	be	O
36	important	O
37	for	O
38	enzyme	O
39	activity	O
40	.	O

1	The	O
2	actuarial	O
3	local	O
4	control	O
5	rates	O
6	at	O
7	10	O
8	years	O
9	for	O
10	the	O
11	three	O
12	treatment	O
13	groups	O
14	were	O
15	as	O
16	follows	O
17	:	O
18	subtotal	O
19	excision	O
20	alone	O
21	,	O
22	18	O
23	%;	O
24	subtotal	O
25	excision	O
26	plus	O
27	postoperative	O
28	radiation	O
29	therapy	O
30	,	O
31	82	O
32	%;	O
33	and	O
34	total	O
35	excision	O
36	alone	O
37	,	O
38	77	O
39	%.	O

1	Mono	O
2	-	O
3	ADP	O
4	-	O
5	ribosylation	O
6	is	O
7	a	O
8	reversible	O
9	modification	O
10	of	O
11	proteins	O
12	,	O
13	with	O
14	NAD	O
15	:	O
16	arginine	O
17	ADP	O
18	-	O
19	ribosyltransferases	O
20	(	O
21	EC	B
22	2	I
23	.	I
24	4	I
25	.	I
26	2	I
27	.	O
28	31	O
29	)	O
30	and	O
31	ADP	B
32	-	I
33	ribosylarginine	I
34	hydrolases	I
35	(	O
36	EC	B
37	3	I
38	.	I
39	2	I
40	.	I
41	2	I
42	.	O
43	19	O
44	)	O
45	catalyzing	O
46	the	O
47	opposing	O
48	reactions	O
49	in	O
50	an	O
51	ADP	O
52	-	O
53	ribosylation	O
54	cycle	O
55	.	O

1	Schedule	O
2	2	O
3	,	O
4	in	O
5	which	O
6	2	O
7	.	O
8	4	O
9	mg	O
10	/	O
11	kg	O
12	c	O
13	-	O
14	DDP	O
15	was	O
16	administered	O
17	immediately	O
18	before	O
19	X	O
20	-	O
21	ray	O
22	on	O
23	5	O
24	consecutive	O
25	days	O
26	produced	O
27	the	O
28	highest	O
29	degree	O
30	of	O
31	enhancement	O
32	of	O
33	radiation	O
34	effect	O
35	(	O
36	expressed	O
37	as	O
38	dose	O
39	-	O
40	effect	O
41	factor	O
42	);	O
43	and	O
44	the	O
45	next	O
46	greatest	O
47	enhancement	O
48	was	O
49	produced	O
50	by	O
51	12	O
52	mg	O
53	/	O
54	kg	O
55	c	O
56	-	O
57	DDP	O
58	administered	O
59	24	O
60	h	O
61	before	O
62	the	O
63	start	O
64	of	O
65	fractionated	O
66	daily	O
67	radiotherapy	O
68	.	O

1	The	O
2	growth	O
3	defect	O
4	of	O
5	a	O
6	reg1	O
7	reg2	O
8	double	O
9	mutant	O
10	is	O
11	alleviated	O
12	by	O
13	a	O
14	loss	O
15	-	O
16	of	O
17	-	O
18	function	O
19	mutation	O
20	in	O
21	the	O
22	SNF1	B
23	-	I
24	encoded	I
25	protein	I
26	kinase	I
27	.	O

1	The	O
2	mechanism	B
3	whereby	I
4	zeta	I
5	PKC	I
6	regulates	O
7	NF	B
8	-	I
9	kappa	I
10	B	I
11	most	O
12	probably	O
13	involves	O
14	the	O
15	activation	O
16	of	O
17	a	O
18	putative	O
19	I	B
20	kappa	I
21	B	I
22	kinase	I
23	of	O
24	molecular	O
25	mass	O
26	approximately	O
27	50	O
28	kDa	O
29	,	O
30	which	O
31	phosphorylates	O
32	and	O
33	inactivates	O
34	I	B
35	kappa	I
36	B	I
37	.	O

1	Recently	O
2	we	O
3	have	O
4	performed	O
5	a	O
6	detailed	O
7	analysis	O
8	of	O
9	specific	O
10	neuronal	O
11	populations	O
12	affected	O
13	by	O
14	the	O
15	mutation	O
16	which	O
17	shed	O
18	new	O
19	light	O
20	on	O
21	the	O
22	role	O
23	of	O
24	Krox	B
25	-	I
26	20	I
27	in	O
28	the	O
29	segmentation	O
30	and	O
31	on	O
32	the	O
33	physiological	O
34	consequences	O
35	of	O
36	its	O
37	inactivation	O
38	.	O

1	The	O
2	human	O
3	T	O
4	cell	O
5	lymphotropic	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	O
25	-	O
26	domain	O
27	/	O
28	leucine	B
29	-	I
30	zipper	I
31	(	I
32	bZip	I
33	)	I
34	protein	I
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	O
48	Tax	O
49	-	O
50	responsive	O
51	element	O
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O

1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	A	O
2	survey	O
3	is	O
4	given	O
5	of	O
6	the	O
7	pharmacological	O
8	backgrounds	O
9	that	O
10	are	O
11	relevant	O
12	for	O
13	the	O
14	drug	O
15	treatment	O
16	of	O
17	essential	O
18	hypertension	O
19	in	O
20	the	O
21	elderly	O
22	.	O

1	The	O
2	assembly	O
3	of	O
4	sequence	O
5	ready	O
6	,	O
7	high	O
8	-	O
9	resolution	O
10	physical	O
11	maps	O
12	and	O
13	construction	O
14	of	O
15	minimally	O
16	overlapping	O
17	contigs	O
18	for	O
19	the	O
20	human	O
21	as	O
22	well	O
23	as	O
24	model	O
25	genomes	O
26	requires	O
27	accurate	O
28	determination	O
29	of	O
30	the	O
31	extent	O
32	of	O
33	overlap	O
34	between	O
35	adjacent	O
36	clones	O
37	as	O
38	well	O
39	as	O
40	their	O
41	relative	O
42	orientation	O
43	.	O

1	Absorption	O
2	was	O
3	rapid	O
4	,	O
5	with	O
6	a	O
7	mean	O
8	time	O
9	to	O
10	peak	O
11	of	O
12	39	O
13	min	O
14	.	O

1	Subsequent	O
2	experiments	O
3	showed	O
4	that	O
5	motoric	O
6	tasks	O
7	rather	O
8	than	O
9	cognitive	O
10	aspects	O
11	of	O
12	the	O
13	COWA	O
14	task	O
15	were	O
16	critical	O
17	in	O
18	potentiating	O
19	finger	O
20	-	O
21	tapping	O
22	performance	O
23	.	O

1	Genesis	O
2	of	O
3	foam	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	Cloforex	O
13	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	O
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	We	O
2	estimate	O
3	that	O
4	the	O
5	protease	O
6	activity	O
7	is	O
8	at	O
9	least	O
10	35	O
11	-	O
12	fold	O
13	greater	O
14	in	O
15	mature	O
16	B	O
17	cells	O
18	than	O
19	in	O
20	pre	O
21	-	O
22	B	O
23	cells	O
24	.	O

1	The	O
2	atp	O
3	1	O
4	and	O
5	atp	O
6	2	O
7	types	O
8	of	O
9	cDNA	O
10	sequences	O
11	were	O
12	the	O
13	most	O
14	redundant	O
15	among	O
16	the	O
17	28	O
18	different	O
19	isoperoxidases	O
20	identified	O
21	among	O
22	about	O
23	200	O
24	peroxidase	B
25	encoding	O
26	ESTs	O
27	.	O

1	It	O
2	also	O
3	suggests	O
4	that	O
5	there	O
6	is	O
7	another	O
8	pathway	O
9	which	O
10	can	O
11	activate	O
12	SWI4	B
13	transcription	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	SWI6	B
19	.	O

1	The	O
2	FFA	O
3	levels	O
4	were	O
5	not	O
6	affected	O
7	(	O
8	P	O
9	greater	O
10	than	O
11	.	O
12	1	O
13	)	O
14	by	O
15	meal	O
16	interval	O
17	.	O

1	Unlike	O
2	the	O
3	mammalian	B
4	proteins	I
5	,	O
6	XFGF3	B
7	is	O
8	efficiently	O
9	secreted	O
10	as	O
11	a	O
12	Mr	B
13	31	I
14	,	I
15	000	I
16	glycoprotein	I
17	,	O
18	gp31	O
19	,	O
20	which	O
21	undergoes	O
22	proteolytic	O
23	cleavage	O
24	to	O
25	produce	O
26	an	O
27	NH2	B
28	-	I
29	terminally	I
30	truncated	I
31	product	I
32	,	O
33	gp27	B
34	.	O

1	(	O
2	1992	O
3	)	O
4	J	O
5	.	O

1	Malonate	O
2	decarboxylation	O
3	in	O
4	Malonomonas	O
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	O
11	-	O
12	S	O
13	-[	O
14	acyl	O
15	-	O
16	carrier	O
17	protein	O
18	]	O
19	from	O
20	acetyl	B
21	-	I
22	S	I
23	-[	I
24	acyl	I
25	-	I
26	carrier	I
27	protein	I
28	]	I
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	B
36	protein	I
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	O
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O

1	Statistically	O
2	significant	O
3	effects	O
4	were	O
5	noted	O
6	at	O
7	doses	O
8	which	O
9	did	O
10	not	O
11	appear	O
12	to	O
13	be	O
14	maternally	O
15	toxic	O
16	.	O

1	A	O
2	genetic	O
3	screen	O
4	in	O
5	yeast	O
6	has	O
7	allowed	O
8	us	O
9	to	O
10	identify	O
11	a	O
12	novel	O
13	transcriptional	O
14	factor	O
15	binding	O
16	to	O
17	the	O
18	GlRE	B
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	chicken	B
26	ovalbumin	I
27	upstream	I
28	promoter	I
29	-	I
30	transcription	I
31	factor	I
32	II	I
33	(	O
34	COUP	B
35	-	I
36	TFII	I
37	).	O

1	SCL	O
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O

1	Thus	O
2	,	O
3	the	O
4	human	O
5	D1A	O
6	gene	O
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O

1	For	O
2	this	O
3	,	O
4	cDNAs	O
5	containing	O
6	the	O
7	60K	O
8	,	O
9	87K	O
10	,	O
11	110K	O
12	and	O
13	170K	O
14	protein	O
15	coding	O
16	sequences	O
17	were	O
18	each	O
19	provided	O
20	with	O
21	an	O
22	ATG	O
23	start	O
24	codon	O
25	and	O
26	the	O
27	cDNA	O
28	containing	O
29	the	O
30	60K	O
31	coding	O
32	sequence	O
33	with	O
34	a	O
35	TAA	O
36	stop	O
37	codon	O
38	immediately	O
39	downstream	O
40	of	O
41	the	O
42	coding	O
43	sequence	O
44	.	O

1	Platelet	O
2	counts	O
3	and	O
4	function	O
5	as	O
6	well	O
7	as	O
8	fibrinogen	B
9	and	O
10	von	B
11	Willebrand	I
12	factor	I
13	(	O
14	vWF	B
15	)	O
16	levels	O
17	were	O
18	determined	O
19	in	O
20	each	O
21	sample	O
22	.	O

1	E	O
2	50	O
3	,	O
4	843	O
5	(	O
6	1994	O
7	)].	O

1	A	O
2	total	O
3	of	O
4	194	O
5	STSs	O
6	map	O
7	to	O
8	this	O
9	interval	O
10	of	O
11	3	O
12	Mb	O
13	,	O
14	giving	O
15	an	O
16	average	O
17	marker	O
18	resolution	O
19	of	O
20	approximately	O
21	one	O
22	per	O
23	15	O
24	kb	O
25	.	O

1	In	O
2	controls	O
3	,	O
4	only	O
5	modest	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	spindle	O
5	pole	O
6	body	O
7	duplication	O
8	gene	O
9	MPS1	O
10	is	O
11	part	O
12	of	O
13	a	O
14	mitotic	O
15	checkpoint	O
16	.	O

1	Full	O
2	thyroid	O
3	function	O
4	testing	O
5	was	O
6	performed	O
7	on	O
8	600	O
9	randomly	O
10	selected	O
11	samples	O
12	with	O
13	normal	O
14	TSH	B
15	values	O
16	and	O
17	also	O
18	on	O
19	subjects	O
20	with	O
21	abnormal	O
22	TSH	B
23	levels	O
24	.	O

1	Analyses	O
2	of	O
3	hGMR	B
4	beta	I
5	subunit	I
6	mutants	I
7	revealed	O
8	two	O
9	cytoplasmic	O
10	regions	O
11	involved	O
12	in	O
13	activation	O
14	of	O
15	the	O
16	c	B
17	-	I
18	myc	I
19	promoter	I
20	,	O
21	one	O
22	is	O
23	essential	O
24	and	O
25	the	O
26	other	O
27	is	O
28	dispensable	O
29	but	O
30	enhances	O
31	the	O
32	activity	O
33	.	O

1	Coexpression	O
2	studies	O
3	indicate	O
4	that	O
5	insulin	B
6	and	O
7	PKB	B
8	suppress	O
9	transactivation	O
10	by	O
11	C	B
12	/	I
13	EBPbeta	I
14	,	O
15	but	O
16	not	O
17	C	O
18	/	O
19	EBPalpha	B
20	,	O
21	and	O
22	that	O
23	N	O
24	-	O
25	terminal	O
26	transactivation	O
27	domains	O
28	in	O
29	C	B
30	/	I
31	EBPbeta	I
32	are	O
33	required	O
34	.	O

1	Purified	O
2	P7	O
3	could	O
4	be	O
5	assembled	O
6	onto	O
7	particles	O
8	lacking	O
9	P7	O
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	O
15	(	O
16	RNA	B
17	polymerase	I
18	)	O
19	and	O
20	P7	O
21	.	O

1	Mechanism	O
2	of	O
3	immunogenesis	O
4	in	O
5	vaccination	O
6	with	O
7	streptomycin	O
8	-	O
9	dependent	O
10	mutants	O
11	of	O
12	salmonellae	O
13	and	O
14	shigellae	O
15	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	putative	O
10	adhesive	O
11	molecule	O
12	from	O
13	P	O
14	.	O
15	falciparum	O
16	that	O
17	shares	O
18	both	O
19	sequence	O
20	and	O
21	structural	O
22	similarities	O
23	with	O
24	a	O
25	sporozoite	O
26	surface	O
27	molecule	O
28	from	O
29	Plasmodium	O
30	termed	O
31	the	O
32	thrombospondin	B
33	-	I
34	related	I
35	anonymous	I
36	protein	I
37	(	O
38	TRAP	B
39	)	O
40	and	O
41	,	O
42	to	O
43	a	O
44	lesser	O
45	extent	O
46	,	O
47	with	O
48	the	O
49	circumsporozoite	O
50	(	O
51	CS	O
52	)	O
53	protein	O
54	.	O

1	cDNA	O
2	and	O
3	structural	O
4	organization	O
5	of	O
6	the	O
7	gene	O
8	Pole1	O
9	for	O
10	the	O
11	mouse	B
12	DNA	I
13	polymerase	I
14	epsilon	I
15	catalytic	O
16	subunit	O
17	.	O

1	In	O
2	the	O
3	eight	O
4	patients	O
5	with	O
6	persistent	O
7	generalized	O
8	lymph	O
9	-	O
10	adenopathy	O
11	(	O
12	PGL	O
13	)	O
14	and	O
15	nontender	O
16	,	O
17	nonenlarging	O
18	nodes	O
19	,	O
20	pathologic	O
21	analysis	O
22	revealed	O
23	lymphoid	O
24	hyperplasia	O
25	.	O

1	The	O
2	double	B
3	-	I
4	stranded	I
5	RNA	I
6	binding	I
7	domain	I
8	(	O
9	dsRBD	O
10	)	O
11	is	O
12	an	O
13	approximately	O
14	65	O
15	amino	O
16	acid	O
17	motif	O
18	that	O
19	is	O
20	found	O
21	in	O
22	a	O
23	variety	O
24	of	O
25	proteins	O
26	that	O
27	interact	O
28	with	O
29	double	O
30	-	O
31	stranded	O
32	(	O
33	ds	O
34	)	O
35	RNA	O
36	,	O
37	such	O
38	as	O
39	Escherichia	B
40	coli	I
41	RNase	I
42	III	I
43	and	O
44	the	O
45	dsRNA	B
46	-	I
47	dependent	I
48	kinase	I
49	,	O
50	PKR	B
51	.	O

1	Leukemia	O
2	in	O
3	twins	O
4	:	O
5	world	O
6	-	O
7	wide	O
8	review	O
9	of	O
10	clinical	O
11	cases	O
12	.	O

1	In	O
2	the	O
3	Oct	B
4	-	I
5	1	I
6	crystal	O
7	,	O
8	the	O
9	POU	B
10	-	O
11	specific	O
12	domain	O
13	recognizes	O
14	a	O
15	GCAT	O
16	half	O
17	-	O
18	site	O
19	,	O
20	while	O
21	the	O
22	corresponding	O
23	sequence	O
24	recognized	O
25	by	O
26	the	O
27	Pit	B
28	-	I
29	1	I
30	POU	I
31	-	I
32	specific	I
33	domain	I
34	,	O
35	GTAT	B
36	,	O
37	is	O
38	on	O
39	the	O
40	opposing	O
41	strand	O
42	.	O

1	Deletion	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	essential	O
7	domain	O
8	of	O
9	this	O
10	promoter	O
11	,	O
12	termed	O
13	the	O
14	ORF5	O
15	/	O
16	deltaX	B
17	transcript	I
18	promoter	I
19	,	O
20	mapped	O
21	to	O
22	nucleotides	O
23	1525	O
24	-	O
25	1625	O
26	.	O

1	The	O
2	geometric	O
3	mean	O
4	hemagglutination	O
5	-	O
6	inhibition	O
7	antibody	O
8	titers	O
9	(	O
10	GMT	O
11	)	O
12	of	O
13	non	O
14	-	O
15	immunized	O
16	,	O
17	once	O
18	-	O
19	immunized	O
20	,	O
21	and	O
22	twice	O
23	-	O
24	immunized	O
25	chickens	O
26	were	O
27	compared	O
28	at	O
29	2	O
30	-	O
31	week	O
32	intervals	O
33	following	O
34	primary	O
35	immunization	O
36	,	O
37	secondary	O
38	immunization	O
39	,	O
40	and	O
41	challenge	O
42	.	O

1	It	O
2	is	O
3	exclusively	O
4	observed	O
5	in	O
6	smooth	O
7	muscle	O
8	cells	O
9	by	O
10	Northern	O
11	blotting	O
12	and	O
13	immunohistochemical	O
14	analysis	O
15	and	O
16	therefore	O
17	designated	O
18	"	B
19	smoothelin	I
20	."	I
21	A	I
22	human	I
23	smooth	I
24	muscle	I
25	cDNA	I
26	library	O
27	was	O
28	screened	O
29	with	O
30	the	O
31	monoclonal	O
32	antibody	O
33	R4A	O
34	,	O
35	and	O
36	a	O
37	full	O
38	-	O
39	size	O
40	cDNA	O
41	of	O
42	the	O
43	protein	O
44	was	O
45	selected	O
46	.	O

1	The	O
2	secondary	O
3	,	O
4	but	O
5	not	O
6	the	O
7	primary	O
8	,	O
9	antibody	O
10	responses	O
11	of	O
12	male	O
13	C57Bl	O
14	/	O
15	6	O
16	mice	O
17	were	O
18	higher	O
19	among	O
20	mice	O
21	housed	O
22	alone	O
23	compared	O
24	to	O
25	mice	O
26	housed	O
27	in	O
28	groups	O
29	;	O
30	differences	O
31	were	O
32	observed	O
33	for	O
34	both	O
35	IgM	B
36	and	O
37	IgG	B
38	anti	I
39	-	I
40	KLH	I
41	antibodies	I
42	.	O

1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O

1	Interestingly	O
2	,	O
3	an	O
4	antibody	O
5	against	O
6	N	B
7	-	I
8	SMase	I
9	can	O
10	abrogate	O
11	Ox	O
12	-	O
13	LDL	B
14	-	O
15	and	O
16	TNF	B
17	-	I
18	alpha	I
19	-	O
20	induced	O
21	apoptosis	O
22	and	O
23	therefore	O
24	may	O
25	be	O
26	useful	O
27	for	O
28	in	O
29	vivo	O
30	studies	O
31	of	O
32	apoptosis	O
33	in	O
34	experimental	O
35	animals	O
36	.	O

1	Antithrombin	B
2	III	I
3	prevents	O
4	60	O
5	min	O
6	warm	O
7	intestinal	O
8	ischemia	O
9	reperfusion	O
10	injury	O
11	in	O
12	rats	O
13	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	O
20	-	O
21	kDa	O
22	component	O
23	of	O
24	cleavage	O
25	stimulation	O
26	factor	O
27	(	O
28	CstF	O
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	O
53	.	O

1	HLA	B
2	-	I
3	A	I
4	and	O
5	B	O
6	phenotypes	O
7	of	O
8	105	O
9	patients	O
10	suffering	O
11	from	O
12	malignant	O
13	melanomas	O
14	were	O
15	determined	O
16	,	O
17	with	O
18	special	O
19	regard	O
20	for	O
21	metastatic	O
22	form	O
23	or	O
24	relapse	O
25	.	O

1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	O
11	of	O
12	anastomotic	O
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	O
19	Billroth	O
20	'	O
21	s	O
22	type	O
23	II	O
24	reconstruction	O
25	varied	O
26	from	O
27	a	O
28	few	O
29	days	O
30	to	O
31	19	O
32	years	O
33	,	O
34	with	O
35	an	O
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	O
7	reversible	O
8	change	O
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	B
25	-	I
26	1	I
27	C	I
28	-	I
29	terminal	I
30	region	I
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	O
38	kd	O
39	cellular	O
40	Elk	B
41	-	I
42	1	I
43	kinase	I
44	.	O

1	Mycotoxins	O
2	in	O
3	feeds	O
4	and	O
5	foods	O
6	.	O

1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	I
23	beta	I
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	O
35	therapy	O
36	.	O

1	The	O
2	leader	O
3	sequence	O
4	of	O
5	the	O
6	isolated	O
7	cDNA	O
8	clone	O
9	contains	O
10	several	O
11	small	O
12	open	O
13	reading	O
14	frames	O
15	upstream	O
16	of	O
17	the	O
18	initiation	O
19	codon	O
20	of	O
21	the	O
22	largest	O
23	open	O
24	reading	O
25	frame	O
26	coding	O
27	for	O
28	the	O
29	homeodomain	B
30	protein	I
31	.	O

1	These	O
2	changes	O
3	in	O
4	virus	O
5	entry	O
6	features	O
7	may	O
8	result	O
9	in	O
10	coronaviruses	O
11	with	O
12	novel	O
13	pathogenic	O
14	properties	O
15	.	O

1	In	O
2	experiment	O
3	2	O
4	the	O
5	rats	O
6	had	O
7	free	O
8	access	O
9	to	O
10	two	O
11	bottles	O
12	,	O
13	one	O
14	of	O
15	which	O
16	contained	O
17	tap	O
18	water	O
19	,	O
20	and	O
21	the	O
22	other	O
23	contained	O
24	either	O
25	an	O
26	ethanol	O
27	(	O
28	6	O
29	%)	O
30	or	O
31	a	O
32	sucrose	O
33	(	O
34	5	O
35	%)	O
36	solution	O
37	.	O

1	Both	O
2	can	O
3	be	O
4	elevated	O
5	on	O
6	a	O
7	single	O
8	vascular	O
9	pedicle	O
10	based	O
11	on	O
12	the	O
13	superficial	O
14	temporal	O
15	artery	O
16	,	O
17	the	O
18	double	O
19	-	O
20	layered	O
21	temporal	O
22	fascia	O
23	flap	O
24	.	O

1	Chronic	O
2	thyroiditis	O
3	as	O
4	a	O
5	risk	O
6	factor	O
7	of	O
8	B	O
9	-	O
10	cell	O
11	lymphoma	O
12	in	O
13	the	O
14	thyroid	O
15	gland	O
16	.	O

1	The	O
2	RPO1	O
3	of	O
4	LCDV	B
5	shows	O
6	the	O
7	highest	O
8	similarity	O
9	to	O
10	the	O
11	RPO1	O
12	of	O
13	IIV6	B
14	and	O
15	significant	O
16	lower	O
17	similarity	O
18	to	O
19	the	O
20	eukaryotic	B
21	polymerases	I
22	II	I
23	and	I
24	III	I
25	as	O
26	well	O
27	as	O
28	to	O
29	the	O
30	archaebacteral	O
31	subunit	O
32	.	O

1	None	O
2	of	O
3	the	O
4	measured	O
5	parameters	O
6	(	O
7	heart	O
8	contents	O
9	of	O
10	neutral	O
11	lipids	O
12	,	O
13	total	O
14	phospholipids	O
15	,	O
16	phosphatidylcholine	O
17	,	O
18	phosphatidylethanolamine	O
19	,	O
20	diphosphatidylglycerol	O
21	,	O
22	sphingomyelin	B
23	and	O
24	fatty	O
25	acid	O
26	composition	O
27	of	O
28	each	O
29	phospholipid	O
30	class	O
31	)	O
32	appeared	O
33	to	O
34	be	O
35	related	O
36	with	O
37	the	O
38	grading	O
39	of	O
40	the	O
41	lesions	O
42	.	O

1	Application	O
2	of	O
3	the	O
4	method	O
5	to	O
6	a	O
7	representative	O
8	set	O
9	of	O
10	50	O
11	known	O
12	genes	O
13	from	O
14	Arabidopsis	O
15	thaliana	O
16	showed	O
17	significant	O
18	improvement	O
19	in	O
20	prediction	O
21	accuracy	O
22	compared	O
23	to	O
24	previous	O
25	spliced	O
26	alignment	O
27	methods	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	constant	O
6	magnetic	O
7	field	O
8	on	O
9	the	O
10	phagocytic	O
11	activity	O
12	of	O
13	Paramecia	O

1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O

1	OBJECTIVE	O
2	:	O
3	The	O
4	purpose	O
5	of	O
6	this	O
7	article	O
8	is	O
9	to	O
10	review	O
11	balance	O
12	instruments	O
13	developed	O
14	within	O
15	the	O
16	past	O
17	10	O
18	years	O
19	that	O
20	can	O
21	be	O
22	used	O
23	in	O
24	the	O
25	clinic	O
26	or	O
27	home	O
28	environment	O
29	.	O

1	Effects	O
2	of	O
3	cortisone	O
4	,	O
5	starvation	O
6	,	O
7	and	O
8	rickets	O
9	on	O
10	oxidative	O
11	enzyme	O
12	activities	O
13	of	O
14	epiphyseal	O
15	cartilage	O
16	from	O
17	rats	O
18	.	O

1	To	O
2	examine	O
3	the	O
4	biochemical	O
5	basis	O
6	of	O
7	the	O
8	end	O
9	joining	O
10	,	O
11	nuclear	O
12	extracts	O
13	were	O
14	prepared	O
15	from	O
16	a	O
17	wide	O
18	variety	O
19	of	O
20	mammalian	O
21	cell	O
22	lines	O
23	and	O
24	tested	O
25	for	O
26	their	O
27	ability	O
28	to	O
29	join	O
30	test	O
31	plasmid	O
32	substrates	O
33	.	O

1	Androgens	O
2	and	O
3	growth	O
4	.	O

1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	constructs	O
28	.	O

1	The	O
2	Psc2	O
3	cDNA	O
4	contained	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	homologous	O
10	to	O
11	CP2	B
12	family	I
13	proteins	I
14	.	O

1	The	O
2	tumor	B
3	-	I
4	suppressor	I
5	protein	I
6	p53	I
7	is	O
8	involved	O
9	in	O
10	maintaining	O
11	genomic	O
12	stability	O
13	.	O

1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	B
6	-	O
7	specific	O
8	and	O
9	MAP2	B
10	-	O
11	specific	O
12	mRNAs	O
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	B
24	-	I
25	specific	I
26	mRNA	I
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	O

1	Endorphins	B
2	and	O
3	legal	O
4	issues	O
5	.	O

1	Normal	O
2	rates	O
3	of	O
4	weight	O
5	gain	O
6	were	O
7	seen	O
8	once	O
9	absorbed	O
10	energy	O
11	intakes	O
12	reached	O
13	100	O
14	-	O
15	110	O
16	%	O
17	of	O
18	requirements	O
19	.	O

1	Compensative	O
2	justice	O
3	and	O
4	moral	O
5	investment	O
6	among	O
7	Japanese	O
8	,	O
9	Chinese	O
10	,	O
11	and	O
12	Koreans	O
13	.	O

1	Radiotherapy	O
2	and	O
3	early	O
4	orchiectomy	O
5	in	O
6	stage	O
7	D1	O
8	prostatic	O
9	carcinoma	O

1	This	O
2	5	O
3	'	O
4	splice	O
5	site	O
6	sequence	O
7	was	O
8	required	O
9	for	O
10	enhanced	O
11	polyadenylation	O
12	and	O
13	was	O
14	recognized	O
15	by	O
16	both	O
17	U1	B
18	small	I
19	nuclear	I
20	ribonucleoproteins	I
21	(	O
22	snRNPs	O
23	)	O
24	and	O
25	alternative	O
26	splicing	O
27	factor	B
28	/	I
29	splicing	I
30	factor	I
31	2	I
32	(	O
33	ASF	B
34	/	O
35	SF2	B
36	).	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	Comparison	O
2	with	O
3	the	O
4	crystal	O
5	structure	O
6	of	O
7	Desulfovibrio	O
8	gigas	O
9	,	O
10	Dg	O
11	,	O
12	Fd	O
13	(	O
14	Kissinger	O
15	et	O
16	al	O
17	.,	O
18	1991	O
19	)	O
20	reveals	O
21	a	O
22	very	O
23	similar	O
24	folding	O
25	topology	O
26	,	O
27	although	O
28	several	O
29	secondary	O
30	structural	O
31	elements	O
32	are	O
33	extended	O
34	in	O
35	Pf	O
36	relative	O
37	to	O
38	Dg	O
39	Fd	O
40	.	O

1	There	O
2	was	O
3	no	O
4	apparent	O
5	effect	O
6	of	O
7	growth	O
8	temperature	O
9	on	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	fad7	B
17	mRNA	I
18	in	O
19	wild	O
20	type	O
21	plants	O
22	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	patients	O
6	with	O
7	acute	O
8	respiratory	O
9	failure	O
10	requiring	O
11	artificial	O
12	ventilation	O
13	have	O
14	two	O
15	componenents	O
16	of	O
17	the	O
18	pulmonary	O
19	shunt	O
20	,	O
21	one	O
22	parallel	O
23	with	O
24	and	O
25	the	O
26	other	O
27	inversely	O
28	related	O
29	with	O
30	the	O
31	PAO2	O
32	.	O

1	Moreover	O
2	,	O
3	the	O
4	Rho	B
5	family	I
6	protein	I
7	Cdc42	I
8	,	O
9	a	O
10	conserved	O
11	morphogenetic	O
12	G	O
13	protein	O
14	,	O
15	is	O
16	also	O
17	a	O
18	potent	O
19	regulator	O
20	of	O
21	filamentous	O
22	growth	O
23	and	O
24	FG	B
25	(	O
26	TyA	B
27	)::	O
28	lacZ	B
29	expression	O
30	in	O
31	S	O
32	.	O
33	cerevisiae	O
34	.	O

1	Green	O
2	pepper	O
3	significantly	O
4	inhibited	O
5	N	O
6	-	O
7	nitrosothiazolidine	O
8	-	O
9	carboxylic	O
10	acid	O
11	formation	O
12	relative	O
13	to	O
14	ascorbic	O
15	acid	O
16	alone	O
17	.	O

1	The	O
2	Epstein	B
3	-	I
4	Barr	I
5	virus	I
6	transactivator	I
7	Zta	I
8	triggers	I
9	lytic	I
10	gene	I
11	expression	O
12	and	O
13	is	O
14	essential	O
15	for	O
16	replication	O
17	of	O
18	the	O
19	lytic	O
20	origin	O
21	,	O
22	oriLyt	B
23	.	O

1	Hyperthyroidism	O
2	is	O
3	one	O
4	of	O
5	the	O
6	numerous	O
7	causes	O
8	of	O
9	infertility	O
10	and	O
11	recurrent	O
12	abortion	O
13	.	O

1	The	O
2	sequences	O
3	showed	O
4	extensive	O
5	homologies	O
6	with	O
7	squalene	B
8	synthase	I
9	genes	I
10	and	O
11	enzymes	O
12	from	O
13	a	O
14	number	O
15	of	O
16	other	O
17	organisms	O
18	and	O
19	extreme	O
20	amino	O
21	acid	O
22	conservation	O
23	within	O
24	the	O
25	binding	O
26	and	O
27	catalytic	O
28	domains	O
29	.	O

1	Administration	O
2	of	O
3	the	O
4	dopamine	O
5	agonist	O
6	bromocriptine	O
7	(	O
8	2	O
9	.	O
10	5	O
11	mg	O
12	three	O
13	times	O
14	a	O
15	day	O
16	for	O
17	4	O
18	days	O
19	)	O
20	suppressed	O
21	(	O
22	P	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	)	O
29	mean	O
30	24	O
31	-	O
32	h	O
33	plasma	O
34	18	O
35	-	O
36	OHB	O
37	levels	O
38	from	O
39	21	O
40	.	O
41	9	O
42	+/-	O
43	2	O
44	.	O
45	0	O
46	to	O
47	14	O
48	.	O
49	8	O
50	+/-	O
51	1	O
52	.	O
53	4	O
54	ng	O
55	/	O
56	dl	O
57	.	O

1	Stylohyoid	O
2	chain	O
3	ossification	O
4	:	O
5	choice	O
6	of	O
7	the	O
8	surgical	O
9	approach	O
10	.	O

1	Effect	O
2	of	O
3	acute	O
4	and	O
5	chronic	O
6	psychogenic	O
7	stress	O
8	on	O
9	corticoadrenal	O
10	and	O
11	pituitary	O
12	-	O
13	thyroid	O
14	hormones	O
15	in	O
16	male	O
17	rats	O
18	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	(	I
8	snRNP	I
9	)	O
10	to	O
11	the	O
12	pre	O
13	-	O
14	mRNA	O
15	is	O
16	an	O
17	early	O
18	and	O
19	important	O
20	step	O
21	in	O
22	spliceosome	O
23	assembly	O
24	.	O

1	Wnt	B
2	-	I
3	1	I
4	(	O
5	int	B
6	-	I
7	1	I
8	)	O
9	is	O
10	a	O
11	cellular	O
12	oncogene	O
13	often	O
14	activated	O
15	by	O
16	insertion	O
17	of	O
18	proviral	O
19	DNA	O
20	of	O
21	the	O
22	mouse	O
23	mammary	O
24	tumor	O
25	virus	O
26	.	O

1	Distal	O
2	lower	O
3	motor	O
4	neuron	O
5	syndrome	O
6	with	O
7	high	O
8	-	O
9	titer	O
10	serum	B
11	IgM	I
12	anti	I
13	-	I
14	GM1	I
15	antibodies	I
16	:	O
17	improvement	O
18	following	O
19	immunotherapy	O
20	with	O
21	monthly	O
22	plasma	O
23	exchange	O
24	and	O
25	intravenous	O
26	cyclophosphamide	O
27	.	O

1	Additional	O
2	studies	O
3	with	O
4	new	O
5	and	O
6	reprocessed	O
7	regenerated	O
8	cellulose	O
9	dialyzers	O
10	comparing	O
11	450	O
12	and	O
13	220	O
14	mL	O
15	/	O
16	min	O
17	blood	O
18	flow	O
19	rates	O
20	at	O
21	10	O
22	minutes	O
23	showed	O
24	no	O
25	change	O
26	in	O
27	BTG	O
28	.	O

1	Since	O
2	one	O
3	group	O
4	of	O
5	adolescents	O
6	more	O
7	difficult	O
8	to	O
9	influence	O
10	are	O
11	those	O
12	whose	O
13	parents	O
14	smoke	O
15	,	O
16	parental	O
17	involvement	O
18	in	O
19	smoking	O
20	prevention	O
21	may	O
22	be	O
23	a	O
24	powerful	O
25	enhancer	O
26	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	deletion	O
6	promoter	O
7	-	O
8	reporter	O
9	constructs	O
10	found	O
11	that	O
12	the	O
13	basal	O
14	activity	O
15	of	O
16	P2	O
17	resided	O
18	in	O
19	the	O
20	proximal	O
21	region	O
22	of	O
23	P2	O
24	.	O

1	Immediately	O
2	after	O
3	surgery	O
4	,	O
5	dialysate	O
6	PGE2	O
7	and	O
8	adenosine	O
9	concentrations	O
10	were	O
11	3	O
12	.	O
13	7	O
14	+/-	O
15	0	O
16	.	O
17	7	O
18	and	O
19	296	O
20	+/-	O
21	127	O
22	nM	O
23	,	O
24	respectively	O
25	.	O

1	The	O
2	dopamine	B
3	D4	I
4	receptor	I
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	catecholaminergic	O
11	receptors	O
12	contain	O
13	several	O
14	putative	O
15	SH3	B
16	binding	O
17	domains	O
18	.	O

1	Thus	O
2	,	O
3	the	O
4	CCAAT	O
5	box	O
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	assist	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	O
19	alpha	B
20	-	I
21	subunit	I
22	gene	I
23	to	O
24	trophoblasts	O
25	.	O

1	We	O
2	studied	O
3	the	O
4	role	O
5	of	O
6	prostaglandins	O
7	in	O
8	acid	O
9	-	O
10	induced	O
11	esophagitis	O
12	and	O
13	the	O
14	associated	O
15	LES	O
16	hypotension	O
17	by	O
18	simultaneous	O
19	treatment	O
20	of	O
21	some	O
22	animals	O
23	with	O
24	indomethacin	O
25	(	O
26	150	O
27	micrograms	O
28	/	O
29	kg	O
30	intravenous	O
31	),	O
32	a	O
33	specific	O
34	inhibitor	O
35	of	O
36	prostaglandin	O
37	synthesis	O
38	,	O
39	either	O
40	during	O
41	production	O
42	of	O
43	esophagitis	O
44	or	O
45	during	O
46	recovery	O
47	.	O

1	Mechanism	O
2	of	O
3	the	O
4	t	O
5	(	O
6	14	O
7	;	O
8	18	O
9	)	O
10	chromosomal	O
11	translocation	O
12	:	O
13	structural	O
14	analysis	O
15	of	O
16	both	O
17	derivative	O
18	14	O
19	and	O
20	18	O
21	reciprocal	O
22	partners	O
23	.	O

1	False	O
2	positive	O
3	PET	O
4	FDG	O
5	corresponded	O
6	to	O
7	lung	O
8	infection	O
9	,	O
10	degenerative	O
11	bone	O
12	disease	O
13	,	O
14	and	O
15	reconstruction	O
16	artifact	O
17	.	O

1	In	O
2	support	O
3	of	O
4	clinical	O
5	antianginal	O
6	studies	O
7	,	O
8	the	O
9	vasodilator	O
10	nicorandil	O
11	(	O
12	NIC	O
13	)	O
14	was	O
15	combined	O
16	with	O
17	the	O
18	beta	B
19	-	I
20	adrenergic	I
21	receptor	I
22	antagonists	O
23	propranolol	O
24	(	O
25	PRO	O
26	)	O
27	and	O
28	atenolol	O
29	(	O
30	ATN	O
31	)	O
32	and	O
33	with	O
34	the	O
35	calcium	O
36	channel	O
37	blocker	O
38	diltiazem	O
39	(	O
40	DTZ	O
41	)	O
42	to	O
43	determine	O
44	their	O
45	cardiovascular	O
46	and	O
47	pharmacokinetic	O
48	interactions	O
49	.	O

1	With	O
2	this	O
3	GH	B
4	and	O
5	estrogen	O
6	treatment	O
7	regimen	O
8	,	O
9	most	O
10	girls	O
11	with	O
12	TS	O
13	can	O
14	grow	O
15	and	O
16	develop	O
17	much	O
18	more	O
19	in	O
20	conformity	O
21	with	O
22	their	O
23	healthy	O
24	peers	O
25	.	O

1	However	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	SF	B
9	levels	O
10	of	O
11	IL	B
12	-	I
13	8	I
14	with	O
15	those	O
16	of	O
17	lactate	O
18	,	O
19	LDH	B
20	,	O
21	beta	B
22	2	I
23	-	I
24	microglobulin	I
25	and	O
26	glucose	O
27	.	O

1	All	O
2	patients	O
3	were	O
4	evaluable	O
5	for	O
6	toxicity	O
7	and	O
8	9	O
9	for	O
10	response	O
11	.	O

1	Characterization	O
2	of	O
3	the	O
4	alpha	B
5	4	I
6	integrin	I
7	gene	I
8	promoter	I
9	.	O

1	The	O
2	two	O
3	mouse	O
4	lines	O
5	carrying	O
6	the	O
7	unfragmented	O
8	Hnf3g	O
9	-	O
10	lacZ	B
11	YAC	O
12	showed	O
13	tissue	O
14	-	O
15	specific	O
16	,	O
17	copy	O
18	number	O
19	-	O
20	dependent	O
21	and	O
22	position	O
23	-	O
24	independent	O
25	expression	O
26	,	O
27	proving	O
28	that	O
29	170	O
30	kb	O
31	of	O
32	the	O
33	Hnf3g	B
34	locus	I
35	contain	O
36	all	O
37	elements	O
38	important	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	Hnf3g	B
44	.	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	O
6	results	O
7	of	O
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	O
25	T1	O
26	-	O
27	3	O
28	N0	O
29	-	O
30	1	O
31	M0	O
32	)	O
33	esophageal	O
34	squamous	O
35	cell	O
36	carcinoma	O
37	(	O
38	SCC	O
39	)	O
40	or	O
41	esophageal	O
42	adenocarcinoma	O
43	.	O

1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	the	O
6	ubiquitous	O
7	expression	O
8	of	O
9	2	O
10	.	O
11	9	O
12	kb	O
13	and	O
14	3	O
15	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	O
21	functional	O
22	antithrombin	B
23	III	I
24	(	O
25	AT	O
26	III	O
27	)	O
28	activity	O
29	.	O

1	These	O
2	regions	O
3	contain	O
4	inverted	O
5	E	O
6	-	O
7	box	O
8	palindromic	O
9	or	O
10	direct	O
11	repeat	O
12	motifs	O
13	and	O
14	bind	O
15	SREBP	B
16	-	I
17	1	I
18	with	O
19	different	O
20	affinities	O
21	.	O

1	Of	O
2	these	O
3	carriers	O
4	149	O
5	were	O
6	diagnosed	O
7	to	O
8	be	O
9	asymptomatic	O
10	clinically	O
11	,	O
12	biochemically	O
13	and	O
14	echographically	O
15	.	O

1	DNA	B
2	polymerase	I
3	E	I
4	,	O
5	DNA	B
6	ligase	I
7	III	I
8	and	O
9	a	O
10	DNA	O
11	structure	O
12	-	O
13	specific	O
14	endonuclease	O
15	co	O
16	-	O
17	purify	O
18	with	O
19	the	O
20	five	O
21	polypeptide	O
22	complex	O
23	.	O

1	We	O
2	have	O
3	obtained	O
4	the	O
5	human	B
6	EP4	I
7	receptor	I
8	gene	I
9	sequence	I
10	and	O
11	determined	O
12	its	O
13	structure	O
14	relative	O
15	to	O
16	EP4R	O
17	cDNA	O
18	synthesized	O
19	from	O
20	peripheral	O
21	blood	O
22	lymphocytes	O
23	.	O

1	CONCLUSION	O
2	(	O
3	S	O
4	):	O
5	Measuring	O
6	urinary	O
7	LH	B
8	levels	O
9	is	O
10	an	O
11	excellent	O
12	method	O
13	for	O
14	determining	O
15	ovulation	O
16	.	O

1	Following	O
2	2	O
3	.	O
4	5	O
5	Gy	O
6	,	O
7	HbO2	B
8	changes	O
9	were	O
10	minimal	O
11	.	O

1	In	O
2	the	O
3	DNA	O
4	recognition	O
5	helix	O
6	of	O
7	finger	O
8	II	O
9	,	O
10	the	O
11	conserved	O
12	Arg	O
13	at	O
14	position	O
15	62	O
16	(	O
17	N	O
18	-	O
19	terminal	O
20	side	O
21	of	O
22	the	O
23	first	O
24	zinc	O
25	-	O
26	coordinating	O
27	histidine	O
28	)	O
29	was	O
30	changed	O
31	to	O
32	a	O
33	Leu	O
34	or	O
35	Gln	O
36	.	O

1	The	O
2	model	O
3	captures	O
4	the	O
5	essence	O
6	of	O
7	predator	O
8	-	O
9	prey	O
10	dynamics	O
11	to	O
12	provide	O
13	reasonable	O
14	predictions	O
15	of	O
16	population	O
17	patterns	O
18	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	pilin	B
6	gene	I
7	,	O
8	tcpA	B
9	,	O
10	is	O
11	dependent	O
12	upon	O
13	ToxR	B
14	and	O
15	upon	O
16	ToxT	B
17	.	O

1	A	O
2	given	O
3	standard	O
4	input	O
5	function	O
6	and	O
7	a	O
8	given	O
9	value	O
10	of	O
11	distribution	O
12	volume	O
13	(	O
14	Vd	O
15	)	O
16	used	O
17	for	O
18	the	O
19	rCBF	O
20	measurement	O
21	of	O
22	this	O
23	method	O
24	were	O
25	calculated	O
26	from	O
27	the	O
28	dynamic	O
29	study	O
30	by	O
31	six	O
32	normal	O
33	volunteers	O
34	.	O

1	Although	O
2	p48	B
3	gene	I
4	induction	O
5	is	O
6	dependent	O
7	on	O
8	STAT1	B
9	and	O
10	JAK1	B
11	,	O
12	activated	O
13	STAT1	B
14	does	O
15	not	O
16	bind	O
17	to	O
18	GATE	O
19	.	O

1	A	O
2	suspected	O
3	new	O
4	storage	O
5	disease	O
6	in	O
7	cattle	O
8	.	O

1	Simultaneous	O
2	right	O
3	and	O
4	left	O
5	adrenal	O
6	and	O
7	peripheral	O
8	blood	O
9	samples	O
10	were	O
11	collected	O
12	for	O
13	determination	O
14	of	O
15	oestrone	O
16	(	O
17	E1	O
18	)	O
19	and	O
20	oestradiol	O
21	(	O
22	E2	O
23	).	O

1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	rev3	O
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	O
14	-->	O
15	T	O
16	.	O
17	A	O
18	transversions	O
19	by	O
20	the	O
21	rad18	B
22	mutator	I
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	rad6	O
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	O
41	-->	O
42	T	O
43	.	O
44	A	O
45	transversion	O
46	.	O

1	When	O
2	given	O
3	the	O
4	choice	O
5	between	O
6	an	O
7	estrous	O
8	female	O
9	and	O
10	a	O
11	sexually	O
12	active	O
13	male	O
14	in	O
15	the	O
16	AOF	O
17	,	O
18	flutamide	O
19	females	O
20	,	O
21	as	O
22	well	O
23	as	O
24	controls	O
25	,	O
26	preferred	O
27	the	O
28	male	O
29	partner	O
30	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Systemic	O
6	and	O
7	pulmonary	O
8	hemodynamics	O
9	,	O
10	arterial	O
11	blood	O
12	gas	O
13	determination	O
14	,	O
15	bronchoalveolar	O
16	lavage	O
17	protein	O
18	and	O
19	neutrophil	O
20	content	O
21	,	O
22	neutrophil	O
23	oxidant	O
24	burst	O
25	,	O
26	lung	O
27	myeloperoxidase	O
28	content	O
29	,	O
30	and	O
31	scanning	O
32	electron	O
33	micrographic	O
34	studies	O
35	.	O

1	Residual	O
2	amphotericin	O
3	B	O
4	was	O
5	detected	O
6	in	O
7	the	O
8	feces	O
9	of	O
10	the	O
11	mice	O
12	only	O
13	while	O
14	they	O
15	were	O
16	receiving	O
17	the	O
18	0	O
19	.	O
20	3	O
21	mg	O
22	/	O
23	ml	O
24	dose	O
25	level	O
26	.	O

1	In	O
2	gel	O
3	retardation	O
4	assays	O
5	,	O
6	an	O
7	RCS	B
8	cell	I
9	-	I
10	specific	I
11	protein	I
12	and	O
13	another	O
14	closely	O
15	related	O
16	protein	O
17	expressed	O
18	only	O
19	in	O
20	RCS	O
21	cells	O
22	and	O
23	primary	O
24	chondrocytes	O
25	bound	O
26	to	O
27	a	O
28	10	O
29	-	O
30	bp	O
31	sequence	O
32	within	O
33	the	O
34	18	O
35	-	O
36	mer	O
37	.	O

1	This	O
2	result	O
3	supports	O
4	the	O
5	argument	O
6	that	O
7	the	O
8	beta	O
9	'	O
10	subunit	O
11	plays	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	determining	O
17	the	O
18	progress	O
19	of	O
20	transcription	O
21	elongation	O
22	.	O

1	In	O
2	mitogen	O
3	-	O
4	stimulated	O
5	splenocytes	O
6	,	O
7	Gfi	B
8	-	I
9	1	I
10	expression	O
11	begins	O
12	to	O
13	rise	O
14	at	O
15	12	O
16	h	O
17	after	O
18	stimulation	O
19	and	O
20	reaches	O
21	very	O
22	high	O
23	levels	O
24	after	O
25	50	O
26	h	O
27	,	O
28	suggesting	O
29	that	O
30	it	O
31	may	O
32	be	O
33	functionally	O
34	involved	O
35	in	O
36	events	O
37	occurring	O
38	after	O
39	the	O
40	interaction	O
41	of	O
42	IL	B
43	-	I
44	2	I
45	with	O
46	its	O
47	receptor	O
48	,	O
49	perhaps	O
50	during	O
51	the	O
52	transition	O
53	from	O
54	the	O
55	G1	O
56	to	O
57	the	O
58	S	O
59	phase	O
60	of	O
61	the	O
62	cell	O
63	cycle	O
64	.	O

1	For	O
2	steers	O
3	the	O
4	urinary	O
5	N	O
6	values	O
7	were	O
8	403	O
9	and	O
10	295	O
11	mg	O
12	/	O
13	kg	O
14	W0	O
15	.	O
16	75	O
17	at	O
18	200	O
19	and	O
20	350	O
21	kg	O
22	live	O
23	weight	O
24	respectively	O
25	and	O
26	total	O
27	N	O
28	excretion	O
29	including	O
30	faecal	O
31	N	O
32	was	O
33	408	O
34	and	O
35	320	O
36	mg	O
37	/	O
38	kg	O
39	W0	O
40	.	O
41	75	O
42	.	O

1	Upon	O
2	differentiation	O
3	with	O
4	retinoic	O
5	acid	O
6	(	O
7	RA	O
8	),	O
9	transcription	O
10	of	O
11	the	O
12	Rex	B
13	-	I
14	1	I
15	gene	I
16	decreases	O
17	rapidly	O
18	.	O

1	PRH75	O
2	,	O
3	a	O
4	new	O
5	nucleus	O
6	-	O
7	localized	O
8	member	O
9	of	O
10	the	O
11	DEAD	B
12	-	I
13	box	I
14	protein	I
15	family	I
16	from	O
17	higher	O
18	plants	O
19	.	O

1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	O
12	glutamic	B
13	acid	I
14	decarboxylase	I
15	gene	I
16	.	O

1	The	O
2	gene	O
3	encoding	O
4	the	O
5	105	B
6	-	I
7	kDa	I
8	protein	I
9	(	O
10	p105	B
11	)	O
12	precursor	O
13	of	O
14	the	O
15	p50	B
16	subunit	I
17	of	I
18	transcription	I
19	factor	I
20	NF	I
21	-	I
22	kappa	I
23	B	I
24	also	O
25	encodes	O
26	a	O
27	p70	B
28	I	I
29	kappa	I
30	B	I
31	protein	I
32	,	O
33	I	B
34	kappa	I
35	B	I
36	gamma	I
37	,	O
38	which	O
39	is	O
40	identical	O
41	to	O
42	the	O
43	C	O
44	-	O
45	terminal	O
46	607	O
47	amino	O
48	acids	O
49	of	O
50	p105	B
51	.	O

1	These	O
2	human	O
3	IFN	B
4	-	I
5	beta	I
6	-	O
7	transformed	O
8	cell	O
9	populations	O
10	have	O
11	acquired	O
12	a	O
13	low	O
14	,	O
15	constitutive	O
16	production	O
17	of	O
18	human	B
19	IFN	I
20	,	O
21	while	O
22	replicating	O
23	at	O
24	a	O
25	rate	O
26	similar	O
27	to	O
28	that	O
29	of	O
30	untransformed	O
31	cells	O
32	and	O
33	of	O
34	cells	O
35	transformed	O
36	with	O
37	the	O
38	control	O
39	vector	O
40	carrying	O
41	a	O
42	human	O
43	IFN	B
44	-	I
45	beta	I
46	sequence	I
47	encoding	O
48	an	O
49	inactive	O
50	,	O
51	mutated	O
52	protein	O
53	.	O

1	Freezing	O
2	of	O
3	plasma	O
4	to	O
5	obtain	O
6	better	O
7	yield	O
8	of	O
9	factor	B
10	VIII	I
11	:	O
12	C	O
13	.	O

1	Polyglactin	B
2	910	O
3	suture	O
4	absorption	O
5	and	O
6	the	O
7	role	O
8	of	O
9	cellular	O
10	enzymes	O
11	.	O

1	An	O
2	increase	O
3	in	O
4	the	O
5	level	O
6	of	O
7	serum	O
8	enzymes	O
9	,	O
10	such	O
11	as	O
12	aspartate	B
13	transaminase	I
14	,	O
15	alkaline	B
16	phosphatase	I
17	,	I
18	creatine	I
19	phosphokinase	I
20	,	O
21	lactate	B
22	dehydrogenase	I
23	after	O
24	D	O
25	.	O
26	russelli	O
27	venom	O
28	injection	O
29	in	O
30	albino	O
31	rats	O
32	is	O
33	indicative	O
34	of	O
35	cell	O
36	or	O
37	tissue	O
38	damage	O
39	.	O

1	Studies	O
2	on	O
3	the	O
4	method	O
5	of	O
6	size	O
7	reduction	O
8	of	O
9	medicinal	O
10	compounds	O
11	.	O

1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O

1	KEY	O
2	WORDS	O
3	:	O
4	Melaleuca	O
5	;	O
6	Lake	O
7	Okeechobee	O
8	;	O
9	Littoral	O
10	zone	O
11	;	O
12	Water	O
13	level	O
14	;	O
15	Regulation	O
16	schedule	O

1	Induction	O
2	of	O
3	both	O
4	potential	O
5	transcripts	O
6	follows	O
7	heat	O
8	shock	O
9	in	O
10	vivo	O
11	.	O

1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	O
21	)/	O
22	tretinoin	O
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	these	O
6	synthetic	O
7	binding	O
8	sites	O
9	have	O
10	a	O
11	more	O
12	restricted	O
13	and	O
14	specific	O
15	ability	O
16	to	O
17	enhance	O
18	transcription	O
19	when	O
20	assayed	O
21	in	O
22	transformed	O
23	embryos	O
24	.	O

1	Immunofluorescence	O
2	microscopy	O
3	revealed	O
4	extensive	O
5	deposition	O
6	of	O
7	such	O
8	extracellular	O
9	matrices	O
10	as	O
11	type	B
12	IV	I
13	collagen	I
14	and	O
15	laminin	B
16	in	O
17	the	O
18	vascular	O
19	wall	O
20	.	O

1	By	O
2	using	O
3	lacZ	B
4	fusions	O
5	,	O
6	it	O
7	was	O
8	possible	O
9	to	O
10	localize	O
11	the	O
12	DNA	O
13	sequences	O
14	required	O
15	to	O
16	mediate	O
17	nitrate	O
18	repression	O
19	to	O
20	the	O
21	pfl	O
22	promoter	O
23	-	O
24	regulatory	O
25	region	O
26	.	O

1	Lyn	B
2	kinase	I
3	immunoprecipitated	O
4	from	O
5	lysates	O
6	of	O
7	irradiated	O
8	BCP	O
9	as	O
10	well	O
11	as	O
12	a	O
13	full	O
14	-	O
15	length	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	(	O
21	GST	B
22	)-	O
23	Lyn	B
24	fusion	O
25	protein	O
26	-	O
27	phosphorylated	O
28	recombinant	O
29	human	O
30	p34cdc2	O
31	on	O
32	tyrosine	O
33	15	O
34	.	O

1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	Ritchie	O
12	-	O
13	Index	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	ESR	O
19	and	O
20	CRP	B
21	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	of	O
6	ADH5	B
7	contains	O
8	consensus	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	transcriptional	O
14	regulatory	O
15	proteins	O
16	,	O
17	Sp1	B
18	,	O
19	AP2	B
20	,	O
21	LF	B
22	-	I
23	A1	I
24	,	O
25	NF	B
26	-	I
27	1	I
28	,	O
29	NF	B
30	-	I
31	A2	I
32	,	O
33	and	O
34	NF	B
35	-	I
36	E1	I
37	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	combined	O
7	treatment	O
8	with	O
9	a	O
10	thromboxane	B
11	synthetase	I
12	inhibitor	O
13	and	O
14	a	O
15	thromboxane	O
16	receptor	O
17	antagonist	O
18	provides	O
19	a	O
20	better	O
21	protection	O
22	against	O
23	digoxin	O
24	intoxication	O
25	than	O
26	with	O
27	either	O
28	agent	O
29	alone	O
30	.	O

1	Much	O
2	evidence	O
3	indicates	O
4	that	O
5	p38	B
6	is	O
7	an	O
8	activator	O
9	of	O
10	MyoD	B
11	:	O
12	(	O
13	i	O
14	)	O
15	p38	B
16	kinase	I
17	activity	O
18	is	O
19	required	O
20	for	O
21	the	O
22	expression	O
23	of	O
24	MyoD	B
25	-	I
26	responsive	I
27	genes	I
28	,	O
29	(	O
30	ii	O
31	)	O
32	enforced	O
33	induction	O
34	of	O
35	p38	B
36	stimulates	O
37	the	O
38	transcriptional	O
39	activity	O
40	of	O
41	a	O
42	Gal4	B
43	-	O
44	MyoD	B
45	fusion	O
46	protein	O
47	and	O
48	allows	O
49	efficient	O
50	activation	O
51	of	O
52	chromatin	O
53	-	O
54	integrated	O
55	reporters	O
56	by	O
57	MyoD	B
58	,	O
59	and	O
60	(	O
61	iii	O
62	)	O
63	MyoD	B
64	-	O
65	dependent	O
66	myogenic	O
67	conversion	O
68	is	O
69	reduced	O
70	in	O
71	mouse	O
72	embryonic	O
73	fibroblasts	O
74	derived	O
75	from	O
76	p38alpha	B
77	(-/-)	I
78	embryos	O
79	.	O

1	Further	O
2	,	O
3	they	O
4	are	O
5	consistent	O
6	with	O
7	the	O
8	suggestion	O
9	that	O
10	sites	O
11	homologous	O
12	to	O
13	the	O
14	CAR1	B
15	URS	I
16	may	O
17	be	O
18	situated	O
19	in	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	regions	O
25	of	O
26	multiple	O
27	unrelated	O
28	yeast	O
29	genes	O
30	.	O

1	Resistance	O
2	to	O
3	thyroid	O
4	hormone	O
5	:	O
6	implications	O
7	for	O
8	neurodevelopmental	O
9	research	O
10	on	O
11	the	O
12	effects	O
13	of	O
14	thyroid	O
15	hormone	O
16	disruptors	O
17	.	O

1	Most	O
2	patients	O
3	preferred	O
4	tablets	O
5	to	O
6	injection	O
7	both	O
8	on	O
9	day	O
10	1	O
11	(	O
12	313	O
13	v	O
14	200	O
15	)	O
16	and	O
17	at	O
18	follow	O
19	up	O
20	(	O
21	373	O
22	v	O
23	104	O
24	).	O

1	Digestion	O
2	of	O
3	NF	B
4	-	I
5	IL6	I
6	with	O
7	endoprotease	O
8	Asp	O
9	-	O
10	N	O
11	produced	O
12	a	O
13	domain	O
14	smaller	O
15	than	O
16	the	O
17	TCD	B
18	(	O
19	NF	B
20	-	I
21	IL6	I
22	bZIP	I
23	domains	I
24	(	O
25	NFBD	O
26	)	O
27	(	O
28	272	O
29	-	O
30	345	O
31	)),	O
32	a	O
33	domain	O
34	identified	O
35	either	O
36	in	O
37	the	O
38	absence	O
39	or	O
40	the	O
41	presence	O
42	of	O
43	DNA	O
44	.	O

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	O
9	recall	O
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	O

1	Epithelial	O
2	and	O
3	corneal	O
4	thickness	O
5	measurements	O
6	by	O
7	in	O
8	vivo	O
9	confocal	O
10	microscopy	O
11	through	O
12	focusing	O
13	(	O
14	CMTF	O
15	).	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	in	O
6	all	O
7	studies	O
8	favouring	O
9	PVI	O
10	.	O

1	The	O
2	previously	O
3	described	O
4	enhanced	O
5	translation	O
6	of	O
7	spinach	O
8	L12	O
9	mRNA	O
10	from	O
11	its	O
12	two	O
13	tandem	O
14	AUG	O
15	codons	O
16	and	O
17	the	O
18	two	O
19	functional	O
20	rpl12	O
21	genes	O
22	in	O
23	Arabidopsis	O
24	probably	O
25	provide	O
26	two	O
27	mechanisms	O
28	for	O
29	generating	O
30	the	O
31	four	O
32	copies	O
33	of	O
34	L12	B
35	/	O
36	chloroplast	O
37	ribosome	O
38	,	O
39	qualitatively	O
40	different	O
41	from	O
42	those	O
43	attempted	O
44	in	O
45	eubacteria	O
46	.	O

1	Measurement	O
2	of	O
3	magnesium	O
4	absorption	O
5	in	O
6	man	O
7	using	O
8	stable	O
9	26Mg	O
10	as	O
11	a	O
12	tracer	O
13	.	O

1	The	O
2	plant	O
3	hormone	O
4	auxin	O
5	transcriptionally	O
6	activates	O
7	early	O
8	genes	O
9	.	O

1	The	O
2	pet56	O
3	and	O
4	his3	B
5	genes	I
6	are	O
7	transcribed	O
8	divergently	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	192	O
18	bp	O
19	.	O

1	Convulsive	O
2	seizure	O
3	during	O
4	a	O
5	treatment	O
6	with	O
7	interferon	B
8	alpha	I
9	for	O
10	chronic	O
11	viral	O
12	hepatitis	O
13	C	O

1	These	O
2	women	O
3	should	O
4	not	O
5	be	O
6	given	O
7	the	O
8	current	O
9	estrogen	O
10	PPI	O
11	,	O
12	which	O
13	was	O
14	designed	O
15	to	O
16	warn	O
17	women	O
18	of	O
19	the	O
20	risks	O
21	of	O
22	long	O
23	-	O
24	term	O
25	estrogen	O
26	use	O
27	;	O
28	a	O
29	PPI	O
30	should	O
31	be	O
32	written	O
33	specifically	O
34	for	O
35	patients	O
36	receiving	O
37	short	O
38	courses	O
39	.	O

1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	claim	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O

1	Amyloid	B
2	beta	I
3	-	I
4	protein	I
5	(	I
6	Abeta	I
7	)	O
8	is	O
9	the	O
10	main	O
11	constituent	O
12	of	O
13	amyloid	O
14	fibrils	O
15	found	O
16	in	O
17	senile	O
18	plaques	O
19	and	O
20	cerebral	O
21	vessels	O
22	in	O
23	Alzheimer	O
24	'	O
25	s	O
26	disease	O
27	(	O
28	AD	O
29	)	O
30	and	O
31	is	O
32	derived	O
33	by	O
34	proteolysis	O
35	from	O
36	the	O
37	beta	B
38	-	I
39	amyloid	I
40	precursor	I
41	protein	I
42	(	O
43	APP	B
44	).	O

1	The	O
2	alterations	O
3	in	O
4	differentiation	O
5	of	O
6	osteoprogenitor	O
7	cells	O
8	,	O
9	together	O
10	with	O
11	the	O
12	failure	O
13	of	O
14	mineralization	O
15	,	O
16	resulted	O
17	in	O
18	significantly	O
19	lower	O
20	rates	O
21	of	O
22	bone	O
23	formation	O
24	(	O
25	as	O
26	measured	O
27	by	O
28	fluorochrome	O
29	labeling	O
30	)	O
31	in	O
32	the	O
33	magnesium	O
34	-	O
35	deficient	O
36	rats	O
37	.	O

1	Mnt	O
2	:	O
3	Max	B
4	complexes	I
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	B
9	-	O
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O

1	SUP46	O
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	B
11	protein	I
12	S13	I
13	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	B
8	splicing	I
9	suppressor	I
10	1	I
11	(	O
12	ESS1	O
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O

1	Self	O
2	-	O
3	heating	O
4	after	O
5	deep	O
6	hypothermia	O
7	(	O
8	20	O
9	degrees	O
10	C	O
11	)	O
12	causes	O
13	a	O
14	considerable	O
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	glutaminase	O
21	activity	O
22	at	O
23	all	O
24	studied	O
25	incubation	O
26	temperatures	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	O
45	under	O
46	hypothermia	O
47	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	the	O
5	0	O
6	.	O
7	38	O
8	kb	O
9	promoter	O
10	sequence	O
11	with	O
12	the	O
13	promoters	O
14	of	O
15	the	O
16	Sm	B
17	-	I
18	E	I
19	gene	I
20	and	I
21	U1	I
22	snRNA	I
23	genes	I
24	revealed	O
25	several	O
26	homologous	O
27	motifs	O
28	,	O
29	suggesting	O
30	that	O
31	genes	O
32	encoding	O
33	the	O
34	snRNP	O
35	components	O
36	may	O
37	be	O
38	coordinately	O
39	regulated	O
40	.	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	dosage	O
6	radiation	O
7	on	O
8	metabolism	O
9	and	O
10	function	O
11	of	O
12	the	O
13	rat	O
14	kidney	O
15	damaged	O
16	by	O
17	ischemia	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	successfully	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	metronidazole	O
11	(	O
12	a	O
13	tissue	O
14	amoebicide	O
15	)	O
16	and	O
17	diloxanide	O
18	(	O
19	a	O
20	lumenal	O
21	amoebicide	O
22	).	O

1	Marine	O
2	oils	O
3	and	O
4	cardiovascular	O
5	reactivity	O
6	.	O

1	Automatic	O
2	view	O
3	box	O
4	.	O

1	Fourteen	O
2	healthy	O
3	male	O
4	volunteers	O
5	completed	O
6	the	O
7	study	O
8	.	O

1	CNS	O
2	effects	O
3	of	O
4	local	O
5	anesthetics	O
6	only	O
7	partially	O
8	dependent	O
9	on	O
10	biogenic	O
11	amine	O
12	mechanisms	O
13	.	O

1	The	O
2	P	O
3	-	O
4	wr	O
5	and	O
6	P	O
7	-	O
8	rr	O
9	cDNA	O
10	sequences	O
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	O
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	O
15	-	O
16	lacZ	B
17	expression	O
18	.	O

1	Hb	B
2	levels	O
3	remained	O
4	adequate	O
5	(	O
6	Hb	O
7	=	O
8	10	O
9	.	O
10	68	O
11	+/-	O
12	0	O
13	.	O
14	77	O
15	g	O
16	/	O
17	dl	O
18	)	O
19	after	O
20	14	O
21	.	O
22	6	O
23	+/-	O
24	7	O
25	.	O
26	64	O
27	months	O
28	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	I
15	C	I
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	O
29	element	O
30	called	O
31	the	O
32	gamma	O
33	-	O
34	IFN	B
35	-	O
36	activated	O
37	transcriptional	O
38	element	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	foreign	O
6	gene	O
7	was	O
8	confirmed	O
9	by	O
10	Southern	O
11	analysis	O
12	.	O

1	The	O
2	conservation	O
3	of	O
4	both	O
5	the	O
6	G	O
7	-	O
8	box	O
9	and	O
10	H	O
11	-	O
12	box	O
13	in	O
14	different	O
15	CHS	O
16	promoters	O
17	emphasizes	O
18	their	O
19	importance	O
20	as	O
21	regulatory	O
22	motifs	O
23	.	O

1	Decreased	O
2	levels	O
3	of	O
4	alpha2	B
5	-	I
6	antiplasmin	I
7	were	O
8	also	O
9	observed	O
10	in	O
11	the	O
12	mediastinum	O
13	(	O
14	0	O
15	.	O
16	50	O
17	versus	O
18	0	O
19	.	O
20	61	O
21	U	O
22	/	O
23	mL	O
24	;	O
25	p	O
26	<	O
27	0	O
28	.	O
29	05	O
30	).	O

1	Cbf3	O
2	contains	O
3	three	O
4	proteins	O
5	,	O
6	Cbf3a	B
7	,	O
8	Cbf3b	B
9	and	O
10	Cbf3c	B
11	.	O

1	Thirty	O
2	-	O
3	five	O
4	patients	O
5	were	O
6	included	O
7	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	analyzed	O
6	human	B
7	CTCF	I
8	cDNA	I
9	clones	O
10	and	O
11	show	O
12	here	O
13	that	O
14	the	O
15	ubiquitously	O
16	expressed	O
17	11	O
18	-	O
19	zinc	B
20	-	I
21	finger	I
22	factor	I
23	CTCF	I
24	is	O
25	an	O
26	exceptionally	O
27	highly	O
28	conserved	O
29	protein	O
30	displaying	O
31	93	O
32	%	O
33	identity	O
34	between	O
35	avian	O
36	and	O
37	human	O
38	amino	O
39	acid	O
40	sequences	O
41	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	mouse	O
6	and	O
7	human	O
8	cDNAs	O
9	encoding	O
10	UNC	B
11	-	I
12	51	I
13	-	I
14	like	I
15	kinase	I
16	(	O
17	ULK1	O
18	).	O

1	PBSX	O
2	is	O
3	induced	O
4	by	O
5	agents	O
6	which	O
7	elicit	O
8	the	O
9	SOS	O
10	response	O
11	.	O

1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	residues	O
7	are	O
8	conserved	O
9	among	O
10	all	O
11	three	O
12	sequences	O
13	,	O
14	yet	O
15	all	O
16	three	O
17	viruses	O
18	have	O
19	retained	O
20	response	O
21	elements	O
22	for	O
23	glucocorticoids	O
24	,	O
25	two	O
26	positionally	O
27	conserved	O
28	CCAAT	O
29	boxes	O
30	,	O
31	and	O
32	positionally	O
33	conserved	O
34	TATA	O
35	boxes	O
36	.	O

1	We	O
2	describe	O
3	49	O
4	cases	O
5	with	O
6	papillary	O
7	tumor	O
8	<	O
9	1	O
10	cm	O
11	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	substituted	O
7	and	O
8	wild	O
9	type	O
10	peptides	O
11	were	O
12	observed	O
13	,	O
14	suggesting	O
15	that	O
16	this	O
17	substitution	O
18	in	O
19	the	O
20	intact	O
21	protein	O
22	may	O
23	cause	O
24	disruption	O
25	of	O
26	global	O
27	rather	O
28	than	O
29	local	O
30	structures	O
31	.	O

1	This	O
2	motif	O
3	,	O
4	first	O
5	described	O
6	for	O
7	the	O
8	Drosophila	B
9	homeobox	I
10	activator	I
11	DEAF	I
12	-	I
13	1	I
14	,	O
15	identifies	O
16	an	O
17	emerging	O
18	group	O
19	of	O
20	metazoan	O
21	transcriptional	O
22	modulators	O
23	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	of	O
6	6493	O
7	nucleotides	O
8	encompassing	O
9	the	O
10	bet	O
11	genes	O
12	of	O
13	Escherichia	O
14	coli	O
15	which	O
16	encode	O
17	the	O
18	osmoregulatory	O
19	choline	O
20	-	O
21	glycine	O
22	betaine	O
23	pathway	O
24	.	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	High	O
2	concentrations	O
3	of	O
4	tumor	B
5	-	I
6	associated	I
7	trypsin	I
8	inhibitor	O
9	in	O
10	hemodialyzed	O
11	patients	O
12	.	O

1	The	O
2	low	O
3	molecular	O
4	mass	O
5	polypeptide	O
6	complex	O
7	is	O
8	assumed	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	antigen	O
14	presentation	O
15	,	O
16	generating	O
17	peptides	O
18	from	O
19	cytosolic	B
20	protein	I
21	antigens	I
22	,	O
23	which	O
24	are	O
25	subsequently	O
26	presented	O
27	to	O
28	cytotoxic	O
29	T	O
30	-	O
31	lymphocytes	O
32	on	O
33	the	O
34	cell	O
35	surface	O
36	.	O

1	HCV	O
2	infection	O
3	acquired	O
4	during	O
5	or	O
6	after	O
7	BMT	O
8	caused	O
9	only	O
10	mild	O
11	acute	O
12	hepatitis	O
13	C	O
14	,	O
15	which	O
16	progressed	O
17	to	O
18	chronic	O
19	hepatitis	O
20	C	O
21	in	O
22	one	O
23	patient	O
24	surviving	O
25	10	O
26	years	O
27	after	O
28	BMT	O
29	.	O

1	Recombinant	B
2	HRMT1L2	I
3	protein	I
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	B
14	activity	O
15	in	O
16	vitro	O
17	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	-	I
8	derived	I
9	construct	I
10	(	O
11	a	O
12	-	O
13	Src	B
14	),	O
15	that	O
16	was	O
17	excluded	O
18	from	O
19	detergent	O
20	-	O
21	resistant	O
22	membranes	O
23	,	O
24	could	O
25	not	O
26	restore	O
27	the	O
28	series	O
29	of	O
30	phagocytosis	O
31	signaling	O
32	.	O

1	Adult	O
2	Amblyomma	O
3	lepidum	O
4	ticks	O
5	fed	O
6	as	O
7	nymphs	O
8	on	O
9	this	O
10	goat	O
11	transmitted	O
12	heartwater	O
13	to	O
14	a	O
15	Friesian	O
16	(	O
17	Bos	O
18	taurus	O
19	)	O
20	calf	O
21	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	O
5	C	O
6	virus	O
7	(	O
8	HCV	O
9	)	O
10	infection	O
11	is	O
12	relatively	O
13	low	O
14	in	O
15	childhood	O
16	,	O
17	with	O
18	anti	O
19	-	O
20	HCV	O
21	prevalence	O
22	rates	O
23	of	O
24	0	O
25	.	O
26	1	O
27	-	O
28	0	O
29	.	O
30	4	O
31	%	O
32	in	O
33	the	O
34	Western	O
35	world	O
36	.	O

1	Stems	O
2	contain	O
3	distinctly	O
4	less	O
5	P	B
6	protein	I
7	mRNA	I
8	and	O
9	the	O
10	relative	O
11	level	O
12	in	O
13	roots	O
14	is	O
15	very	O
16	low	O
17	but	O
18	still	O
19	clearly	O
20	detectable	O
21	.	O

1	Lac	B
2	operators	I
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	B
11	promoter	I
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O

1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O

1	Mutational	O
2	analysis	O
3	of	O
4	mammalian	B
5	translation	I
6	initiation	I
7	factor	I
8	5	I
9	(	O
10	eIF5	B
11	):	O
12	role	O
13	of	O
14	interaction	O
15	between	O
16	the	O
17	beta	O
18	subunit	O
19	of	O
20	eIF2	B
21	and	O
22	eIF5	B
23	in	O
24	eIF5	O
25	function	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	the	O
6	same	O
7	males	O
8	,	O
9	breeding	O
10	in	O
11	different	O
12	years	O
13	on	O
14	the	O
15	same	O
16	territories	O
17	,	O
18	had	O
19	significantly	O
20	larger	O
21	harems	O
22	in	O
23	the	O
24	years	O
25	they	O
26	had	O
27	familiar	O
28	neighbors	O
29	.	O

1	The	O
2	likelihood	O
3	that	O
4	a	O
5	common	O
6	region	O
7	of	O
8	deletions	O
9	would	O
10	contain	O
11	a	O
12	tumor	O
13	suppressor	O
14	is	O
15	strongly	O
16	enhanced	O
17	by	O
18	coincidence	O
19	of	O
20	that	O
21	region	O
22	with	O
23	a	O
24	chromosome	O
25	fragment	O
26	suppressing	O
27	tumorigenicity	O
28	upon	O
29	introduction	O
30	in	O
31	tumor	O
32	cells	O
33	.	O

1	Pseudocontact	O
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O

1	Promoter	O
2	recognition	O
3	algorithms	O
4	identified	O
5	divergent	O
6	promoter	O
7	elements	O
8	within	O
9	the	O
10	CpG	O
11	island	O
12	,	O
13	which	O
14	lies	O
15	between	O
16	the	O
17	ATM	O
18	and	O
19	E14	O
20	/	O
21	NPAT	B
22	genes	I
23	,	O
24	and	O
25	provide	O
26	evidence	O
27	for	O
28	a	O
29	putative	O
30	second	O
31	ATM	B
32	promoter	I
33	located	O
34	within	O
35	intron	O
36	3	O
37	,	O
38	immediately	O
39	upstream	O
40	of	O
41	the	O
42	first	O
43	coding	O
44	exon	O
45	.	O

1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	databanks	O
6	show	O
7	that	O
8	Tactile	O
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	B
15	gene	I
16	superfamily	I
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	O
22	amalgam	O
23	,	O
24	the	O
25	melanoma	B
26	Ag	I
27	MUC	I
28	-	I
29	18	I
30	,	O
31	members	O
32	of	O
33	the	O
34	carcinoembryonic	B
35	Ag	I
36	family	I
37	,	O
38	the	O
39	poliovirus	B
40	receptor	I
41	,	O
42	and	O
43	the	O
44	neural	O
45	cell	O
46	adhesion	O
47	molecule	O
48	.	O

1	The	O
2	majority	O
3	of	O
4	the	O
5	cases	O
6	with	O
7	0	O
8	-	O
9	I	O
10	or	O
11	0	O
12	-	O
13	III	O
14	components	O
15	were	O
16	sm	O
17	.	O
18	cancer	O
19	.	O

1	Resistance	O
2	to	O
3	the	O
4	simulated	O
5	physiologic	O
6	environment	O
7	was	O
8	tested	O
9	by	O
10	measured	O
11	retention	O
12	of	O
13	mechanical	O
14	properties	O
15	after	O
16	immersion	O
17	times	O
18	in	O
19	pseudo	O
20	-	O
21	extracellular	O
22	fluid	O
23	(	O
24	PECF	O
25	)	O
26	at	O
27	37	O
28	degrees	O
29	C	O
30	for	O
31	as	O
32	long	O
33	as	O
34	three	O
35	years	O
36	.	O

1	One	O
2	possible	O
3	solution	O
4	is	O
5	a	O
6	thin	O
7	radial	O
8	forearm	O
9	free	O
10	flap	O
11	.	O

1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	explanation	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	NBS	O
18	.	O

1	Ten	O
2	selenocysteine	O
3	residues	O
4	(	O
5	deduced	O
6	)	O
7	are	O
8	present	O
9	.	O

1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	B
38	delta	I
39	mutation	I
40	.	O

1	Replicating	O
2	simian	O
3	virus	O
4	40	O
5	(	O
6	SV40	O
7	)	O
8	chromosomes	O
9	were	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	to	O
15	other	O
16	eukaryotic	O
17	chromosomes	O
18	in	O
19	that	O
20	the	O
21	rate	O
22	and	O
23	extent	O
24	of	O
25	micrococcal	B
26	nuclease	I
27	(	I
28	MNase	I
29	)	O
30	digestion	O
31	were	O
32	greater	O
33	with	O
34	replicating	O
35	than	O
36	with	O
37	nonreplicating	O
38	mature	O
39	SV40	O
40	chromatin	O
41	.	O

1	Far	O
2	-	O
3	infrared	O
4	hopping	O
5	conductivity	O
6	in	O
7	the	O
8	CuO	B
9	chains	I
10	of	O
11	a	O
12	single	O
13	-	O
14	domain	O
15	YBa2Cu3O7	B
16	-	I
17	delta	I
18	crystal	O
19	.	O

1	Mutants	O
2	lacking	O
3	any	O
4	tyrosine	O
5	residues	O
6	in	O
7	the	O
8	cytoplasmic	O
9	domain	O
10	maintain	O
11	their	O
12	ability	O
13	to	O
14	activate	O
15	STAT5	B
16	and	O
17	STAT1	B
18	but	O
19	cannot	O
20	activate	O
21	STAT3	B
22	,	O
23	implying	O
24	that	O
25	STAT5	B
26	and	O
27	STAT1	B
28	activation	O
29	does	O
30	not	O
31	require	O
32	receptor	O
33	tyrosine	O
34	phosphorylation	O
35	.	O

1	Interleukin	B
2	-	I
3	1	I
4	levels	O
5	remained	O
6	low	O
7	throughout	O
8	the	O
9	course	O
10	.	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	Nitrofurazone	O
2	significantly	O
3	reduced	O
4	the	O
5	rise	O
6	in	O
7	LH	B
8	induced	O
9	by	O
10	LHRH	B
11	.	O

1	We	O
2	have	O
3	earlier	O
4	evolved	O
5	an	O
6	experimental	O
7	model	O
8	by	O
9	means	O
10	of	O
11	which	O
12	changes	O
13	identical	O
14	to	O
15	the	O
16	microembolism	O
17	syndrome	O
18	can	O
19	be	O
20	induced	O
21	from	O
22	a	O
23	reproducible	O
24	musculo	O
25	-	O
26	skeletal	O
27	trauma	O
28	in	O
29	pigs	O
30	observed	O
31	under	O
32	long	O
33	-	O
34	term	O
35	anesthesia	O
36	under	O
37	standardized	O
38	conditions	O
39	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	functional	O
6	elements	O
7	,	O
8	both	O
9	located	O
10	downstream	O
11	from	O
12	the	O
13	TATA	O
14	motif	O
15	,	O
16	that	O
17	control	O
18	Id4	B
19	promoter	I
20	activity	O
21	.	O

1	A	O
2	point	O
3	mutation	O
4	in	O
5	Galphao	O
6	and	O
7	Galphai1	O
8	blocks	O
9	interaction	O
10	with	O
11	regulator	O
12	of	O
13	G	B
14	protein	I
15	signaling	O
16	proteins	O
17	.	O

1	Null	O
2	alleles	O
3	of	O
4	SAS4	B
5	and	O
6	SAS5	O
7	bypassed	O
8	the	O
9	role	O
10	of	O
11	the	O
12	Abf1p	B
13	binding	I
14	site	I
15	of	O
16	the	O
17	HMR	B
18	-	I
19	E	I
20	silencer	I
21	but	O
22	not	O
23	the	O
24	role	O
25	of	O
26	the	O
27	ACS	O
28	or	O
29	Rap1p	B
30	binding	I
31	site	I
32	.	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	O
27	lit	O
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	Isolation	O
2	of	O
3	a	O
4	temperature	O
5	-	O
6	sensitive	O
7	mutant	O
8	with	O
9	an	O
10	altered	B
11	tRNA	I
12	nucleotidyltransferase	I
13	and	O
14	cloning	O
15	of	O
16	the	O
17	gene	O
18	encoding	O
19	tRNA	B
20	nucleotidyltransferase	I
21	in	O
22	the	O
23	yeast	O
24	Saccharomyces	O
25	cerevisiae	O
26	.	O

1	The	O
2	Cr	O
3	.	O
4	psbA	B
5	-	I
6	4	I
7	ORF	I
8	contains	O
9	an	O
10	H	O
11	-	O
12	N	O
13	-	O
14	H	O
15	motif	O
16	,	O
17	and	O
18	possibly	O
19	a	O
20	GIY	O
21	-	O
22	YIG	O
23	motif	O
24	.	O

1	Whereas	O
2	a	O
3	PR55	B
4	beta	I
5	transcript	I
6	of	O
7	about	O
8	2	O
9	.	O
10	3	O
11	kb	O
12	was	O
13	detected	O
14	at	O
15	high	O
16	levels	O
17	in	O
18	the	O
19	neuroblastoma	O
20	derived	O
21	cell	O
22	line	O
23	LA	O
24	-	O
25	N	O
26	-	O
27	1	O
28	,	O
29	the	O
30	level	O
31	of	O
32	the	O
33	mRNA	O
34	was	O
35	very	O
36	low	O
37	in	O
38	the	O
39	other	O
40	human	O
41	cell	O
42	lines	O
43	analyzed	O
44	.	O

1	Antenatal	O
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O

1	Furthermore	O
2	,	O
3	addition	O
4	of	O
5	B	B
6	-	I
7	Myb	I
8	-	I
9	glutathionine	I
10	S	I
11	-	I
12	transferase	I
13	fusion	I
14	protein	I
15	inhibited	O
16	complex	O
17	formation	O
18	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	segments	O
6	of	O
7	C3	O
8	represented	O
9	by	O
10	amino	O
11	acid	O
12	residues	O
13	1082	O
14	-	O
15	1118	O
16	,	O
17	1117	O
18	-	O
19	1155	O
20	,	O
21	1234	O
22	-	O
23	1294	O
24	and	O
25	1312	O
26	-	O
27	1404	O
28	accommodate	O
29	C3	O
30	(	O
31	D	O
32	)	O
33	epitopes	O
34	that	O
35	are	O
36	expressed	O
37	by	O
38	erythrocyte	O
39	-	O
40	bound	O
41	C3	B
42	fragments	I
43	,	O
44	but	O
45	not	O
46	by	O
47	the	O
48	corresponding	O
49	fluid	O
50	-	O
51	phase	O
52	fragment	O
53	,	O
54	whereas	O
55	the	O
56	segments	O
57	spanning	O
58	residues	O
59	973	O
60	-	O
61	1026	O
62	and	O
63	1477	O
64	-	O
65	1510	O
66	contain	O
67	C3	O
68	(	O
69	D	O
70	)	O
71	epitopes	O
72	that	O
73	are	O
74	exposed	O
75	exclusively	O
76	in	O
77	denatured	O
78	C3	O
79	and	O
80	therefore	O
81	hidden	O
82	in	O
83	physiological	O
84	fragments	O
85	of	O
86	the	O
87	protein	O
88	.	O

1	The	O
2	primary	O
3	structure	O
4	and	O
5	cotranscription	O
6	of	O
7	the	O
8	petCA	B
9	genes	I
10	encoding	O
11	the	O
12	Rieske	B
13	-	I
14	FeS	I
15	(	O
16	nuclear	O
17	encoded	O
18	in	O
19	plants	O
20	)	O
21	and	O
22	apocytochrome	B
23	f	I
24	proteins	I
25	has	O
26	been	O
27	described	O
28	previously	O
29	(	O
30	Kallas	O
31	,	O
32	T	O
33	.,	O
34	Spiller	O
35	,	O
36	S	O
37	.,	O
38	and	O
39	Malkin	B
40	,	O
41	R	O
42	.	O

1	This	O
2	experimental	O
3	design	O
4	was	O
5	used	O
6	to	O
7	determine	O
8	the	O
9	effect	O
10	of	O
11	displacement	O
12	of	O
13	the	O
14	alpha	B
15	4	I
16	-	I
17	2	I
18	binding	I
19	site	I
20	on	O
21	the	O
22	repression	O
23	of	O
24	alpha	B
25	4	I
26	gene	I
27	transcription	O
28	by	O
29	ICP4	B
30	.	O

1	RESULTS	O
2	:	O
3	Significant	O
4	changes	O
5	from	O
6	pretreatment	O
7	to	O
8	posttreatment	O
9	were	O
10	observed	O
11	(	O
12	p	O
13	<	O
14	0	O
15	.	O
16	001	O
17	).	O

1	Recently	O
2	,	O
3	roles	O
4	also	O
5	have	O
6	been	O
7	suggested	O
8	for	O
9	the	O
10	nuclear	B
11	trans	I
12	-	I
13	factor	I
14	GATA	I
15	-	I
16	1	I
17	in	O
18	regulating	O
19	progenitor	O
20	cell	O
21	proliferation	O
22	.	O

1	We	O
2	detected	O
3	mos	B
4	transcripts	I
5	by	O
6	Northern	O
7	(	O
8	RNA	O
9	)	O
10	analyses	O
11	in	O
12	RNA	O
13	prepared	O
14	from	O
15	chicken	O
16	and	O
17	quail	O
18	ovaries	O
19	and	O
20	testes	O
21	.	O

1	In	O
2	the	O
3	work	O
4	reported	O
5	here	O
6	,	O
7	we	O
8	used	O
9	peptide	O
10	mapping	O
11	,	O
12	mass	O
13	spectrometry	O
14	,	O
15	and	O
16	site	O
17	-	O
18	directed	O
19	mutagenesis	O
20	to	O
21	identify	O
22	two	O
23	sets	O
24	of	O
25	pAP	B
26	phosphorylation	O
27	sites	O
28	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	B
13	L	I
14	-	I
15	CAM	I
16	gene	I
17	.	O

1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	well	O
8	established	O
9	polarity	O
10	of	O
11	RXR	B
12	heterodimer	O
13	binding	O
14	to	O
15	bipartite	O
16	hormone	O
17	response	O
18	elements	O
19	,	O
20	with	O
21	the	O
22	VDR	B
23	recognizing	O
24	the	O
25	3	O
26	'-	O
27	half	O
28	-	O
29	element	O
30	.	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	B
18	factor	I
19	.	O

1	The	O
2	transcripts	O
3	were	O
4	equally	O
5	active	O
6	with	O
7	or	O
8	without	O
9	a	O
10	5	O
11	'	O
12	methylated	O
13	capstructure	O
14	as	O
15	expected	O
16	,	O
17	since	O
18	EMCV	B
19	-	I
20	RNA	I
21	is	O
22	one	O
23	of	O
24	the	O
25	mRNAs	O
26	capable	O
27	of	O
28	internal	O
29	initiation	O
30	.	O

1	Cardiovascular	O
2	and	O
3	adrenal	O
4	medullo	O
5	-	O
6	sympathetic	O
7	reactions	O
8	to	O
9	acute	O
10	tobacco	O
11	poisoning	O

1	The	O
2	specific	O
3	interaction	O
4	between	O
5	a	O
6	defined	O
7	structural	O
8	element	O
9	of	O
10	the	O
11	human	B
12	immunodeficiency	I
13	virus	I
14	mRNA	I
15	(	O
16	RRE	O
17	,	O
18	the	O
19	Rev	B
20	response	I
21	element	I
22	)	O
23	and	O
24	the	O
25	virus	B
26	-	I
27	encoded	I
28	protein	I
29	Rev	I
30	has	O
31	been	O
32	implicated	O
33	in	O
34	the	O
35	regulation	O
36	of	O
37	the	O
38	export	O
39	of	O
40	unspliced	O
41	or	O
42	singly	O
43	spliced	O
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	O
50	cytoplasm	O
51	.	O

1	The	O
2	p34	B
3	.	I
4	8	I
5	gene	I
6	has	O
7	a	O
8	strong	O
9	codon	O
10	usage	O
11	bias	O
12	which	O
13	is	O
14	strikingly	O
15	different	O
16	from	O
17	that	O
18	of	O
19	the	O
20	polyhedrin	B
21	gene	I
22	.	O

1	Deflunia	O
2	was	O
3	well	O
4	tolerated	O
5	by	O
6	25	O
7	patients	O
8	,	O
9	very	O
10	well	O
11	tolerated	O
12	by	O
13	2	O
14	.	O

1	When	O
2	differentiated	O
3	G0	O
4	-	O
5	arrested	O
6	leaf	O
7	cells	O
8	were	O
9	induced	O
10	to	O
11	resume	O
12	cell	O
13	division	O
14	by	O
15	treatment	O
16	with	O
17	plant	O
18	hormones	O
19	,	O
20	cycMs4	B
21	transcription	O
22	was	O
23	induced	O
24	before	O
25	the	O
26	onset	O
27	of	O
28	DNA	O
29	synthesis	O
30	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O

1	As	O
2	demonstrated	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	analysis	O
8	and	O
9	supershift	O
10	experiments	O
11	,	O
12	FIRE1	O
13	,	O
14	located	O
15	between	O
16	-	O
17	516	O
18	and	O
19	-	O
20	498	O
21	,	O
22	is	O
23	responsible	O
24	for	O
25	binding	O
26	NF	B
27	-	I
28	Y	I
29	.	O

1	Leukemia	B
2	-	I
3	inhibitory	I
4	factor	I
5	(	O
6	LIF	O
7	)	O
8	is	O
9	a	O
10	neuropoietin	O
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	Five	O
2	concensus	O
3	poly	O
4	A	O
5	addition	O
6	sites	O
7	are	O
8	located	O
9	in	O
10	the	O
11	350	O
12	base	O
13	pairs	O
14	immediately	O
15	following	O
16	the	O
17	protein	B
18	IX	I
19	coding	I
20	region	I
21	.	O

1	The	O
2	respiratory	O
3	rate	O
4	was	O
5	13	O
6	+/-	O
7	1	O
8	breaths	O
9	/	O
10	min	O
11	with	O
12	52	O
13	+/-	O
14	4	O
15	%	O
16	of	O
17	the	O
18	respiratory	O
19	cycle	O
20	spent	O
21	in	O
22	inspiration	O
23	;	O
24	end	O
25	-	O
26	tidal	O
27	CO2	O
28	pressure	O
29	increased	O
30	by	O
31	3	O
32	.	O
33	3	O
34	+/-	O
35	1	O
36	.	O
37	0	O
38	Torr	O
39	during	O
40	runs	O
41	at	O
42	SIP	O
43	.	O

1	Actins	O
2	show	O
3	two	O
4	different	O
5	forms	O
6	of	O
7	N	O
8	-	O
9	terminal	O
10	processing	O
11	dependent	O
12	on	O
13	their	O
14	N	O
15	-	O
16	terminal	O
17	sequence	O
18	.	O

1	Muscle	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	Tests	O
2	showed	O
3	that	O
4	an	O
5	overall	O
6	impression	O
7	of	O
8	the	O
9	force	O
10	applied	O
11	could	O
12	be	O
13	obtained	O
14	from	O
15	a	O
16	laboratory	O
17	simulation	O
18	,	O
19	but	O
20	that	O
21	clearing	O
22	cement	O
23	and	O
24	testing	O
25	cement	O
26	were	O
27	not	O
28	modelled	O
29	by	O
30	this	O
31	method	O
32	.	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	O
21	DNA	B
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O

1	In	O
2	all	O
3	experimental	O
4	eyes	O
5	,	O
6	there	O
7	was	O
8	a	O
9	marked	O
10	reduction	O
11	,	O
12	but	O
13	never	O
14	a	O
15	complete	O
16	absence	O
17	of	O
18	adrenergic	O
19	nerves	O
20	in	O
21	the	O
22	iris	O
23	.	O

1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	O
14	ANA	O
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	O
29	.	O

1	Psychological	O
2	disturbance	O
3	was	O
4	greater	O
5	in	O
6	the	O
7	high	O
8	life	O
9	stress	O
10	group	O
11	as	O
12	indicated	O
13	by	O
14	significant	O
15	elevations	O
16	on	O
17	the	O
18	global	O
19	severity	O
20	index	O
21	of	O
22	the	O
23	Symptom	O
24	Checklist	O
25	-	O
26	90	O
27	and	O
28	elevations	O
29	on	O
30	somatization	O
31	,	O
32	obsessive	O
33	compulsive	O
34	,	O
35	interpersonal	O
36	sensitivity	O
37	,	O
38	depression	O
39	,	O
40	anxiety	O
41	and	O
42	psychoticism	O
43	subscales	O
44	.	O

1	Patterns	O
2	of	O
3	connections	O
4	underlying	O
5	cross	O
6	-	O
7	modality	O
8	integration	O
9	were	O
10	studied	O
11	by	O
12	injecting	O
13	distinguishable	O
14	,	O
15	retrograde	O
16	tracers	O
17	(	O
18	Fluoro	O
19	-	O
20	Gold	O
21	and	O
22	diamidino	O
23	yellow	O
24	)	O
25	in	O
26	pairwise	O
27	manner	O
28	into	O
29	different	O
30	sensory	O
31	representations	O
32	(	O
33	visual	O
34	,	O
35	somatosensory	O
36	,	O
37	and	O
38	auditory	O
39	)	O
40	in	O
41	the	O
42	cerebral	O
43	cortex	O
44	of	O
45	the	O
46	rat	O
47	.	O

1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	five	O
6	tyrosine	O
7	residues	O
8	in	O
9	the	O
10	cytoplasmic	O
11	domain	O
12	of	O
13	the	O
14	receptor	O
15	were	O
16	subsequently	O
17	used	O
18	to	O
19	confirm	O
20	our	O
21	conclusions	O
22	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	B
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O

1	Selection	O
2	of	O
3	the	O
4	22	O
5	items	O
6	of	O
7	the	O
8	Clinical	O
9	Institute	O
10	Withdrawal	O
11	Assessment	O
12	-	O
13	Benzodiazepines	O
14	(	O
15	CIWA	B
16	-	I
17	B	I
18	)	O
19	was	O
20	based	O
21	on	O
22	statistically	O
23	significant	O
24	differences	O
25	between	O
26	baseline	O
27	and	O
28	critical	O
29	withdrawal	O
30	periods	O
31	in	O
32	high	O
33	-	O
34	dose	O
35	subjects	O
36	and	O
37	between	O
38	symptoms	O
39	associated	O
40	with	O
41	placebo	O
42	and	O
43	diazepam	O
44	in	O
45	low	O
46	-	O
47	dose	O
48	subjects	O
49	,	O
50	using	O
51	contingency	O
52	tables	O
53	and	O
54	logistic	O
55	regression	O
56	analysis	O
57	.	O

1	These	O
2	animals	O
3	were	O
4	viable	O
5	and	O
6	fertile	O
7	.	O

1	Biol	O
2	.	O

1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	polyhedrin	B
9	gene	I
10	of	O
11	Spodoptera	O
12	exigua	O
13	nuclear	O
14	polyhedrosis	O
15	virus	O
16	.	O

1	Influence	O
2	of	O
3	neural	O
4	regulation	O
5	on	O
6	anti	O
7	-	O
8	arrhythmic	O
9	effects	O
10	of	O
11	GABA	O
12	in	O
13	rats	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O

1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O

1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	O
11	studied	O
12	using	O
13	fragments	O
14	containing	O
15	CIRs	B
16	(	O
17	CIR3	B
18	-	I
19	CIR6	I
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	B
30	I	I
31	footprinting	O
32	.	O

1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	B
13	-	I
14	2	I
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	Thus	O
2	,	O
3	TRAF2	B
4	initiates	O
5	SAPK	B
6	and	O
7	p38	B
8	activation	O
9	by	O
10	binding	O
11	two	O
12	proximal	O
13	protein	O
14	kinases	O
15	:	O
16	GCK	O
17	and	O
18	RIP	O
19	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	(	O
2	1986	O
3	)	O
4	method	O
5	of	O
6	separation	O
7	of	O
8	Cryptosporidium	O
9	spp	O
10	.	O
11	oocysts	O
12	from	O
13	feces	O
14	by	O
15	using	O
16	a	O
17	percoll	O
18	discontinuous	O
19	density	O
20	gradient	O
21	appeared	O
22	a	O
23	method	O
24	of	O
25	choice	O
26	for	O
27	obtaining	O
28	large	O
29	numbers	O
30	of	O
31	oocysts	O
32	of	O
33	C	O
34	.	O
35	parvum	O
36	free	O
37	of	O
38	fecal	O
39	contamination	O
40	.	O

1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	O
8	CDKN2A	B
9	and	O
10	CDKN2B	O
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	Hantaan	O
2	virus	O
3	.	O

1	The	O
2	ligand	O
3	for	O
4	RXR	B
5	,	O
6	9	O
7	-	O
8	cis	O
9	retinoic	O
10	acid	O
11	,	O
12	has	O
13	the	O
14	opposite	O
15	effect	O
16	of	O
17	destabilizing	O
18	the	O
19	heterodimeric	O
20	-	O
21	DNA	O
22	complex	O
23	.	O

1	Furthermore	O
2	,	O
3	this	O
4	element	O
5	confers	O
6	p53	B
7	induction	O
8	to	O
9	the	O
10	otherwise	O
11	nonresponsive	O
12	adenovirus	O
13	major	O
14	late	O
15	promoter	O
16	.	O

1	GLUT5	B
2	mRNA	I
3	is	O
4	expressed	O
5	at	O
6	highest	O
7	levels	O
8	in	O
9	small	O
10	intestine	O
11	and	O
12	at	O
13	much	O
14	lower	O
15	levels	O
16	in	O
17	kidney	O
18	,	O
19	skeletal	O
20	muscle	O
21	,	O
22	and	O
23	adipose	O
24	tissue	O
25	.	O

1	During	O
2	chronic	O
3	treatment	O
4	,	O
5	when	O
6	plasma	O
7	concentrations	O
8	fluctuated	O
9	between	O
10	23	O
11	.	O
12	5	O
13	ng	O
14	.	O
15	ml	O
16	-	O
17	1	O
18	at	O
19	8	O
20	h	O
21	and	O
22	14	O
23	ng	O
24	.	O
25	ml	O
26	-	O
27	1	O
28	at	O
29	24	O
30	h	O
31	post	O
32	-	O
33	dosing	O
34	,	O
35	ST	O
36	segment	O
37	depression	O
38	at	O
39	an	O
40	individually	O
41	comparable	O
42	workload	O
43	was	O
44	significantly	O
45	decreased	O
46	by	O
47	28	O
48	%	O
49	compared	O
50	with	O
51	placebo	O
52	(	O
53	P	O
54	<	O
55	0	O
56	.	O
57	005	O
58	)	O
59	at	O
60	both	O
61	points	O
62	in	O
63	time	O
64	.	O

1	In	O
2	slightly	O
3	older	O
4	embryos	O
5	,	O
6	the	O
7	expression	O
8	was	O
9	skewed	O
10	to	O
11	one	O
12	side	O
13	of	O
14	the	O
15	embryo	O
16	and	O
17	by	O
18	E6	B
19	.	O
20	5	O
21	,	O
22	at	O
23	the	O
24	onset	O
25	of	O
26	gastrulation	O
27	,	O
28	expression	O
29	was	O
30	seen	O
31	in	O
32	the	O
33	epiblast	O
34	,	O
35	visceral	O
36	endoderm	O
37	,	O
38	nascent	O
39	mesoderm	O
40	,	O
41	and	O
42	the	O
43	primitive	O
44	streak	O
45	.	O

1	The	O
2	somatoform	O
3	conundrum	O
4	:	O
5	a	O
6	question	O
7	of	O
8	nosological	O
9	valves	O
10	.	O

1	Sequence	O
2	conservation	O
3	is	O
4	greatest	O
5	for	O
6	residues	O
7	located	O
8	near	O
9	the	O
10	active	O
11	centers	O
12	of	O
13	the	O
14	exo	O
15	and	O
16	pol	B
17	domains	I
18	of	O
19	the	O
20	E	B
21	.	I
22	coli	I
23	DNA	I
24	polymerase	I
25	I	I
26	structure	I
27	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	alignment	O
6	of	O
7	TC	O
8	II	O
9	with	O
10	that	O
11	of	O
12	other	O
13	Cbl	B
14	binding	I
15	proteins	I
16	(	O
17	rat	O
18	intrinsic	O
19	factor	O
20	,	O
21	human	B
22	transcobalamin	I
23	I	I
24	and	I
25	porcine	I
26	haptocorrin	I
27	)	O
28	revealed	O
29	only	O
30	33	O
31	%	O
32	overall	O
33	homology	O
34	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	AIDS	O
7	patients	O
8	with	O
9	cryptococcosis	O
10	,	O
11	tolerance	O
12	to	O
13	ILd	B
14	-	I
15	AmB	I
16	was	O
17	acceptable	O
18	when	O
19	the	O
20	daily	O
21	dosage	O
22	did	O
23	not	O
24	exceed	O
25	1	O
26	mg	O
27	/	O
28	kg	O
29	,	O
30	but	O
31	the	O
32	higher	O
33	1	O
34	.	O
35	5	O
36	mg	O
37	/	O
38	kg	O
39	daily	O
40	dosage	O
41	was	O
42	associated	O
43	with	O
44	an	O
45	unacceptable	O
46	rate	O
47	of	O
48	nephrotoxicity	O
49	.	O

1	Nucleotide	O
2	sequence	O
3	,	O
4	genome	O
5	organization	O
6	and	O
7	phylogenetic	O
8	analysis	O
9	of	O
10	pineapple	O
11	mealybug	O
12	wilt	O
13	-	O
14	associated	O
15	virus	O
16	-	O
17	2	O
18	.	O

1	To	O
2	evaluate	O
3	the	O
4	cost	O
5	and	O
6	benefits	O
7	of	O
8	screening	O
9	tests	O
10	for	O
11	Chlamydia	O
12	trachomatis	O
13	in	O
14	adolescent	O
15	males	O
16	,	O
17	we	O
18	developed	O
19	a	O
20	decision	O
21	analysis	O
22	model	O
23	and	O
24	compared	O
25	the	O
26	leukocyte	B
27	esterase	I
28	urine	O
29	dipstick	O
30	test	O
31	with	O
32	culture	O
33	,	O
34	with	O
35	direct	O
36	-	O
37	smear	O
38	fluorescent	O
39	antibody	O
40	(	O
41	DFA	O
42	),	O
43	and	O
44	with	O
45	the	O
46	option	O
47	of	O
48	no	O
49	screening	O
50	(	O
51	no	O
52	treatment	O
53	).	O

1	Endoscopic	O
2	examinations	O
3	,	O
4	peripheral	O
5	white	O
6	blood	O
7	cell	O
8	(	O
9	WBC	O
10	)	O
11	counts	O
12	,	O
13	and	O
14	assays	O
15	of	O
16	myeloperoxidase	B
17	activity	O
18	(	O
19	MPO	B
20	)	O
21	in	O
22	homogenates	O
23	of	O
24	colon	O
25	mucosa	O
26	were	O
27	performed	O
28	after	O
29	one	O
30	week	O
31	(	O
32	4	O
33	%	O
34	DSS	O
35	model	O
36	)	O
37	and	O
38	eight	O
39	weeks	O
40	(	O
41	1	O
42	%	O
43	DSS	O
44	model	O
45	).	O

1	Purified	O
2	PLB	B
3	showed	I
4	optimal	I
5	lyase	I
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O

1	Pharmacology	O
2	studies	O
3	with	O
4	potassium	O
5	chloride	O
6	and	O
7	acetylcholine	O
8	suggest	O
9	that	O
10	raveron	O
11	acts	O
12	as	O
13	a	O
14	calcium	O
15	antagonist	O
16	by	O
17	blocking	O
18	the	O
19	influx	O
20	of	O
21	extracellular	O
22	calcium	O
23	.	O

1	V	O
2	.	O

1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O

1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	O
7	-	O
8	1	O
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	O
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	O
29	templates	O
30	.	O

1	Heat	O
2	-	O
3	labile	O
4	-	O
5	like	O
6	enterotoxin	O
7	(	O
8	LT	O
9	)	O
10	was	O
11	produced	O
12	by	O
13	26	O
14	of	O
15	42	O
16	stool	O
17	isolates	O
18	(	O
19	62	O
20	%),	O
21	while	O
22	only	O
23	1	O
24	of	O
25	the	O
26	42	O
27	isolates	O
28	(	O
29	2	O
30	%)	O
31	produced	O
32	enterotoxinlike	O
33	activity	O
34	in	O
35	suckling	O
36	mice	O
37	;	O
38	65	O
39	%	O
40	of	O
41	the	O
42	cytotoxin	O
43	-	O
44	producing	O
45	strains	O
46	also	O
47	produced	O
48	an	O
49	LT	O
50	-	O
51	like	O
52	material	O
53	.	O

1	No	O
2	specific	O
3	subgroup	O
4	of	O
5	clients	O
6	benefited	O
7	more	O
8	from	O
9	URD	O
10	,	O
11	although	O
12	a	O
13	prospective	O
14	study	O
15	employing	O
16	random	O
17	assignment	O
18	might	O
19	be	O
20	more	O
21	successful	O
22	in	O
23	identifying	O
24	such	O
25	a	O
26	group	O
27	.	O

1	Concordantly	O
2	,	O
3	it	O
4	was	O
5	shown	O
6	that	O
7	the	O
8	dnHLH	B
9	protein	I
10	Id1	I
11	inhibits	O
12	differentiation	O
13	of	O
14	muscle	O
15	and	O
16	myeloid	O
17	cells	O
18	in	O
19	vitro	O
20	.	O

1	The	O
2	combination	O
3	of	O
4	Pitx2	O
5	and	O
6	another	O
7	homeodomain	B
8	protein	I
9	,	O
10	Pit	B
11	-	I
12	1	I
13	,	O
14	yielded	O
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	B
24	promoter	I
25	in	O
26	transfection	O
27	assays	O
28	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	insulin	B
6	effect	O
7	to	O
8	increase	O
9	ras	B
10	GTP	O
11	formation	O
12	and	O
13	MAP	B
14	kinase	I
15	activity	O
16	was	O
17	negligible	O
18	in	O
19	A	O
20	/	O
21	K1018	O
22	cells	O
23	but	O
24	normal	O
25	,	O
26	or	O
27	supernormal	O
28	,	O
29	in	O
30	Y	O
31	/	O
32	F2	O
33	cells	O
34	.	O

1	Conjugated	O
2	and	O
3	unconjugated	O
4	phenylacetic	O
5	acid	O
6	and	O
7	m	O
8	-	O
9	and	O
10	p	O
11	-	O
12	hydroxyphenylacetic	O
13	acid	O
14	have	O
15	been	O
16	determined	O
17	in	O
18	the	O
19	plasma	O
20	of	O
21	normal	O
22	,	O
23	healthy	O
24	subjects	O
25	after	O
26	fasting	O
27	,	O
28	consumption	O
29	of	O
30	a	O
31	meal	O
32	and	O
33	ingestion	O
34	of	O
35	deuterium	O
36	labelled	O
37	amine	O
38	precursors	O
39	,	O
40	by	O
41	high	O
42	-	O
43	resolution	O
44	gas	O
45	chromatography	O
46	--	O
47	high	O
48	resolution	O
49	mass	O
50	spectrometry	O
51	with	O
52	selected	O
53	ion	O
54	monitoring	O
55	of	O
56	their	O
57	trifluoroethyl	O
58	-	O
59	pentafluoropropionyl	O
60	derivatives	O
61	.	O

1	Hypotension	O
2	was	O
3	produced	O
4	by	O
5	head	O
6	up	O
7	tilt	O
8	.	O

1	The	O
2	altered	O
3	amino	O
4	acid	O
5	residues	O
6	of	O
7	the	O
8	seven	O
9	mutant	O
10	9ORF1	O
11	polypeptides	O
12	clustered	O
13	within	O
14	three	O
15	separate	O
16	regions	O
17	referred	O
18	to	O
19	as	O
20	region	O
21	I	O
22	(	O
23	residues	O
24	34	O
25	to	O
26	41	O
27	),	O
28	region	O
29	II	O
30	(	O
31	residues	O
32	89	O
33	to	O
34	91	O
35	),	O
36	and	O
37	C	B
38	-	I
39	terminal	I
40	region	I
41	III	I
42	(	O
43	residues	O
44	122	O
45	to	O
46	125	O
47	).	O

1	Its	O
2	expression	O
3	pattern	O
4	is	O
5	representative	O
6	of	O
7	many	O
8	B	O
9	cell	O
10	-	O
11	specific	O
12	proteins	O
13	,	O
14	which	O
15	are	O
16	essential	O
17	for	O
18	B	O
19	cell	O
20	development	O
21	and	O
22	activation	O
23	but	O
24	are	O
25	down	O
26	-	O
27	regulated	O
28	after	O
29	B	O
30	cells	O
31	become	O
32	terminally	O
33	differentiated	O
34	plasma	O
35	cells	O
36	.	O

1	Differential	O
2	expression	O
3	of	O
4	AP	B
5	-	I
6	2alpha	I
7	and	O
8	AP	B
9	-	I
10	2beta	I
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	B
20	-	I
21	FABP	I
22	promoter	I
23	activity	O
24	by	O
25	AP	B
26	-	I
27	2	I
28	.	O

1	AGO1	O
2	is	O
3	similar	O
4	to	O
5	QDE	B
6	-	I
7	2	I
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	B
13	-	I
14	1	I
15	required	O
16	for	O
17	RNAi	B
18	.	O

1	Amplification	O
2	and	O
3	overexpression	O
4	of	O
5	the	O
6	c	B
7	-	I
8	erbB	I
9	-	I
10	2	I
11	gene	I
12	in	O
13	21MT	B
14	-	I
15	2	I
16	and	O
17	21MT	B
18	-	I
19	1	I
20	human	O
21	breast	O
22	carcinoma	O
23	cells	O
24	results	O
25	in	O
26	progressively	O
27	elevated	O
28	levels	O
29	of	O
30	constitutively	O
31	tyrosine	O
32	-	O
33	phosphorylated	O
34	p185erbB	B
35	-	I
36	2	I
37	and	O
38	is	O
39	associated	O
40	with	O
41	progressive	O
42	insulin	B
43	-	I
44	like	I
45	growth	I
46	factor	I
47	(	O
48	IGF	B
49	)	O
50	and	O
51	combined	O
52	IGF	B
53	/	O
54	epidermal	B
55	growth	I
56	factor	I
57	(	O
58	EGF	B
59	)	O
60	independence	O
61	in	O
62	culture	O
63	.	O

1	The	O
2	applicability	O
3	of	O
4	laparoscopic	O
5	donor	O
6	nephrectomy	O
7	(	O
8	LDN	O
9	)	O
10	has	O
11	not	O
12	been	O
13	assessed	O
14	in	O
15	the	O
16	obese	O
17	donor	O
18	.	O

1	Short	O
2	therapy	O
3	with	O
4	omeprazole	O
5	20	O
6	mg	O
7	/	O
8	b	O
9	.	O
10	i	O
11	.	O
12	d	O
13	.,	O
14	clarithromycin	O
15	500	O
16	mg	O
17	/	O
18	b	O
19	.	O
20	i	O
21	.	O
22	d	O
23	.,	O
24	and	O
25	CBS	O
26	120	O
27	mg	O
28	/	O
29	q	O
30	.	O
31	i	O
32	.	O
33	d	O
34	.	O
35	is	O
36	a	O
37	safe	O
38	,	O
39	well	O
40	tolerated	O
41	combination	O
42	that	O
43	achieves	O
44	a	O
45	80	O
46	.	O
47	6	O
48	%	O
49	eradication	O
50	rate	O
51	of	O
52	H	O
53	.	O
54	pylori	O
55	and	O
56	duodenal	O
57	ulcer	O
58	healing	O
59	rates	O
60	as	O
61	good	O
62	as	O
63	those	O
64	achieved	O
65	by	O
66	omeprazole	O
67	20	O
68	mg	O
69	/	O
70	d	O
71	when	O
72	given	O
73	for	O
74	4	O
75	wk	O
76	.	O

1	Recently	O
2	,	O
3	cell	O
4	-	O
5	surface	O
6	TRAIL	O
7	has	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	expressed	O
13	by	O
14	activated	O
15	human	O
16	and	O
17	mouse	O
18	T	O
19	lymphocytes	O
20	,	O
21	raising	O
22	the	O
23	possibility	O
24	that	O
25	TRAIL	B
26	might	O
27	be	O
28	involved	O
29	in	O
30	T	O
31	cell	O
32	-	O
33	mediated	O
34	cytotoxicity	O
35	and	O
36	/	O
37	or	O
38	immune	O
39	regulation	O
40	.	O

1	In	O
2	addition	O
3	,	O
4	double	O
5	mutants	O
6	with	O
7	either	O
8	dim1	B
9	-	I
10	delta	I
11	or	O
12	dim2	B
13	-	I
14	1	I
15	and	O
16	the	O
17	endocytosis	O
18	mutants	O
19	end4	O
20	-	O
21	1	O
22	or	O
23	act1	B
24	-	I
25	1	I
26	displayed	O
27	synthetic	O
28	growth	O
29	defects	O
30	,	O
31	indicating	O
32	that	O
33	the	O
34	DIM	B
35	gene	I
36	products	I
37	function	O
38	in	O
39	a	O
40	common	O
41	or	O
42	parallel	O
43	endocytic	O
44	pathway	O
45	.	O

1	Acetoin	O
2	-	O
3	dependent	O
4	expression	O
5	of	O
6	the	O
7	acoABCD	B
8	operon	I
9	could	O
10	be	O
11	restored	O
12	in	O
13	the	O
14	E	B
15	.	I
16	coli	I
17	acoK	I
18	mutants	I
19	by	O
20	supplying	O
21	a	O
22	plasmid	O
23	carrying	O
24	an	O
25	intact	O
26	acoK	O
27	,	O
28	suggesting	O
29	a	O
30	transactivating	O
31	function	O
32	of	O
33	the	O
34	gene	O
35	product	O
36	.	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	APRE	B
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	B
13	necrosis	I
14	factor	I
15	-	I
16	alpha	I
17	(	O
18	TNFalpha	B
19	)]-	O
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	B
26	nuclear	I
27	factor	I
28	-	I
29	kappaB	I
30	(	O
31	NF	B
32	-	I
33	kappaB	I
34	)	O
35	complex	O
36	Rel	B
37	A	I
38	x	I
39	NF	I
40	-	I
41	kappaB1	I
42	.	O

1	No	O
2	patient	O
3	in	O
4	group	O
5	2	O
6	developed	O
7	HAT	B
8	(	O
9	P	O
10	=	O
11	0	O
12	.	O
13	006	O
14	versus	O
15	group	O
16	1	O
17	).	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	B
5	-	I
6	III	I
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	B
13	tissue	I
14	inhibitor	I
15	of	I
16	metalloproteinases	I
17	-	I
18	1	I
19	(	O
20	TIMP	B
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	We	O
2	also	O
3	present	O
4	evidence	O
5	that	O
6	human	B
7	HYAL1	I
8	is	O
9	identical	O
10	to	O
11	an	O
12	uncharacterized	O
13	gene	O
14	positionally	O
15	cloned	O
16	by	O
17	others	O
18	from	O
19	chromosome	O
20	3p21	O
21	.	O
22	3	O
23	that	O
24	is	O
25	homozygously	O
26	deleted	O
27	in	O
28	several	O
29	small	O
30	-	O
31	cell	O
32	lung	O
33	carcinoma	O
34	cell	O
35	lines	O
36	.	O

1	The	O
2	MRS	O
3	II	O
4	meets	O
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	The	O
2	effects	O
3	of	O
4	several	O
5	opioid	O
6	agonists	O
7	and	O
8	the	O
9	opioid	O
10	antagonist	O
11	naloxone	O
12	were	O
13	examined	O
14	in	O
15	rats	O
16	responding	O
17	under	O
18	a	O
19	fixed	O
20	-	O
21	consecutive	O
22	-	O
23	number	O
24	(	O
25	FCN	O
26	)	O
27	schedule	O
28	.	O

1	The	O
2	pseudolymphoma	O
3	syndrome	O
4	is	O
5	a	O
6	reversible	O
7	reactive	O
8	condition	O
9	consisting	O
10	of	O
11	fever	O
12	,	O
13	lymphadenopathy	O
14	and	O
15	generalized	O
16	rash	O
17	.	O

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	B
12	influenza	I
13	virus	I
14	protein	I
15	among	O
16	cellular	O
17	translation	O
18	factors	O
19	.	O

1	The	O
2	RS447	O
3	human	O
4	megasatellite	O
5	tandem	O
6	repetitive	O
7	sequence	O
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	Hyperprolactinaemia	O
2	,	O
3	moderate	O
4	hypogonadism	O
5	,	O
6	infraclinical	O
7	neuropathies	O
8	,	O
9	arterial	O
10	stenoses	O
11	and	O
12	moderate	O
13	venous	O
14	leakages	O
15	seem	O
16	to	O
17	play	O
18	a	O
19	partial	O
20	role	O
21	of	O
22	organic	O
23	starter	O
24	or	O
25	cofactor	O
26	,	O
27	the	O
28	sexual	O
29	consequences	O
30	of	O
31	which	O
32	are	O
33	amplified	O
34	by	O
35	psychological	O
36	factors	O
37	,	O
38	partly	O
39	secondary	O
40	to	O
41	the	O
42	initial	O
43	sexual	O
44	failures	O
45	.	O

1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	O
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O

1	The	O
2	program	O
3	has	O
4	been	O
5	written	O
6	in	O
7	a	O
8	generic	O
9	BASIC	O
10	in	O
11	order	O
12	to	O
13	make	O
14	the	O
15	procedure	O
16	user	O
17	-	O
18	friendly	O
19	.	O

1	Since	O
2	the	O
3	morphology	O
4	of	O
5	the	O
6	lesions	O
7	can	O
8	mimic	O
9	that	O
10	of	O
11	other	O
12	cutaneous	O
13	disorders	O
14	,	O
15	Bowen	O
16	'	O
17	s	O
18	disease	O
19	is	O
20	often	O
21	not	O
22	recognized	O
23	initially	O
24	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	thermophilus	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	B
19	coli	I
20	enzyme	I
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	B
50	.	I
51	coli	I
52	enzyme	I
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	141	O
68	extra	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	thermophilus	O
79	enzyme	O
80	.	O

1	Experiments	O
2	were	O
3	performed	O
4	in	O
5	which	O
6	brain	O
7	-	O
8	stem	O
9	auditory	O
10	-	O
11	evoked	O
12	responses	O
13	(	O
14	BAERs	O
15	)	O
16	were	O
17	elicited	O
18	by	O
19	two	O
20	types	O
21	of	O
22	pseudorandom	O
23	pulse	O
24	trains	O
25	:	O
26	maximum	O
27	length	O
28	sequences	O
29	(	O
30	MLS	O
31	)	O
32	and	O
33	Legendre	O
34	sequences	O
35	(	O
36	LGS	O
37	).	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Update	O
2	on	O
3	maternal	O
4	-	O
5	fetal	O
6	infections	O
7	by	O
8	hepatitis	O
9	C	O
10	,	O
11	HIV	O
12	and	O
13	cytomegalovirus	O

1	Compound	O
2	1	O
3	is	O
4	either	O
5	21	O
6	-	O
7	O	O
8	-	O
9	angeloyl	O
10	,	O
11	22	O
12	-	O
13	O	O
14	-	O
15	tigloyl	O
16	R1	O
17	-	O
18	barrigenol	O
19	,	O
20	or	O
21	21	O
22	-	O
23	O	O
24	-	O
25	tigloyl	O
26	,	O
27	22	O
28	-	O
29	O	O
30	-	O
31	angeloyl	O
32	R1	O
33	-	O
34	barrigenol	O
35	.	O

1	The	O
2	dnaQ	B
3	-	I
4	lacZ	I
5	and	O
6	the	O
7	rnh	O
8	-	O
9	lacZ	B
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	I
20	galactosidase	I
21	activity	O
22	were	O
23	produced	O
24	.	O

1	In	O
2	Rat	O
3	1a	O
4	cells	O
5	,	O
6	m1R	B
7	stimulation	O
8	of	O
9	phospholipase	B
10	C	I
11	beta	I
12	and	O
13	the	O
14	marked	O
15	rise	O
16	in	O
17	intracellular	O
18	calcium	O
19	stimulated	O
20	cyclic	O
21	AMP	O
22	(	O
23	cAMP	O
24	)	O
25	synthesis	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	activation	O
31	of	O
32	protein	B
33	kinase	I
34	A	I
35	.	O

1	Mg	B
2	-	I
3	chelatase	I
4	of	I
5	tobacco	I
6	:	O
7	identification	O
8	of	O
9	a	O
10	Chl	B
11	D	I
12	cDNA	I
13	sequence	I
14	encoding	O
15	a	O
16	third	O
17	subunit	O
18	,	O
19	analysis	O
20	of	O
21	the	O
22	interaction	O
23	of	O
24	the	O
25	three	O
26	subunits	O
27	with	O
28	the	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	system	O
34	,	O
35	and	O
36	reconstitution	O
37	of	O
38	the	O
39	enzyme	O
40	activity	O
41	by	O
42	co	O
43	-	O
44	expression	O
45	of	O
46	recombinant	B
47	CHL	I
48	D	I
49	,	O
50	CHL	O
51	H	O
52	and	O
53	CHL	O
54	I	O
55	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	global	O
7	assessment	O
8	patients	O
9	showed	O
10	a	O
11	highly	O
12	significant	O
13	preference	O
14	for	O
15	imipramine	O
16	compared	O
17	with	O
18	placebo	O
19	as	O
20	adjunctive	O
21	therapy	O
22	.	O

1	In	O
2	vitro	O
3	precipitation	O
4	with	O
5	a	O
6	glutathione	B
7	-	I
8	S	I
9	-	I
10	transferase	I
11	-	I
12	fusion	I
13	protein	I
14	containing	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	transactivation	O
20	domain	O
21	of	O
22	STAT5a	B
23	showed	O
24	GH	B
25	-	O
26	regulated	O
27	association	O
28	of	O
29	ERK1	B
30	/	O
31	2	O
32	with	O
33	the	O
34	fusion	O
35	protein	O
36	,	O
37	while	O
38	this	O
39	was	O
40	not	O
41	seen	O
42	when	O
43	serine	O
44	780	O
45	in	O
46	STAT5a	B
47	was	O
48	changed	O
49	to	O
50	alanine	O
51	.	O

1	Similar	O
2	results	O
3	were	O
4	obtained	O
5	with	O
6	xylitol	O
7	,	O
8	an	O
9	activator	O
10	of	O
11	the	O
12	pentose	O
13	phosphate	O
14	pathway	O
15	.	O

1	The	O
2	promoter	O
3	mutation	O
4	is	O
5	complemented	O
6	in	O
7	trans	O
8	by	O
9	E1A	B
10	products	O
11	of	O
12	the	O
13	heterologous	O
14	helper	O
15	adenovirus	O
16	type	O
17	5	O
18	(	O
19	Ad5	O
20	).	O

1	Molecular	O
2	mimicry	O
3	of	O
4	human	O
5	cytokine	O
6	and	O
7	cytokine	O
8	response	O
9	pathway	O
10	genes	O
11	by	O
12	KSHV	O
13	.	O

1	It	O
2	is	O
3	thus	O
4	one	O
5	of	O
6	the	O
7	key	O
8	enzymes	O
9	involved	O
10	in	O
11	the	O
12	triiodothyronine	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	growth	O
18	,	O
19	differentiation	O
20	and	O
21	basal	O
22	metabolism	O
23	in	O
24	vertebrates	O
25	.	O

1	The	O
2	gene	O
3	encoding	O
4	IFN	B
5	-	I
6	gamma	I
7	was	O
8	previously	O
9	found	O
10	to	O
11	contain	O
12	an	O
13	intronic	O
14	enhancer	O
15	element	O
16	that	O
17	was	O
18	not	O
19	tissue	O
20	-	O
21	specific	O
22	in	O
23	its	O
24	activity	O
25	,	O
26	despite	O
27	the	O
28	restricted	O
29	expression	O
30	of	O
31	the	O
32	intact	O
33	IFN	B
34	-	I
35	gamma	I
36	-	I
37	encoding	I
38	gene	I
39	.	O

1	CyIIa	B
2	transcription	O
3	follows	O
4	,	O
5	and	O
6	is	O
7	therefore	O
8	downstream	O
9	of	O
10	,	O
11	the	O
12	initial	O
13	specification	O
14	of	O
15	these	O
16	embryonic	O
17	domains	O
18	.	O

1	The	O
2	AtERF	B
3	genes	I
4	were	O
5	differentially	O
6	regulated	O
7	by	O
8	ethylene	O
9	and	O
10	by	O
11	abiotic	O
12	stress	O
13	conditions	O
14	,	O
15	such	O
16	as	O
17	wounding	O
18	,	O
19	cold	O
20	,	O
21	high	O
22	salinity	O
23	,	O
24	or	O
25	drought	O
26	,	O
27	via	O
28	ETHYLENE	O
29	-	O
30	INSENSITIVE2	O
31	(	O
32	EIN2	O
33	)-	O
34	dependent	O
35	or	O
36	-	O
37	independent	O
38	pathways	O
39	.	O

1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	transactivation	O
6	domain	O
7	of	O
8	heat	B
9	shock	I
10	factor	I
11	1	I
12	is	O
13	negatively	O
14	regulated	O
15	and	O
16	stress	O
17	responsive	O
18	.	O

1	This	O
2	cohort	O
3	of	O
4	patients	O
5	was	O
6	selected	O
7	on	O
8	the	O
9	basis	O
10	of	O
11	clinical	O
12	stage	O
13	.	O

1	Both	O
2	mutations	O
3	confer	O
4	amino	O
5	acid	O
6	substitutions	O
7	in	O
8	the	O
9	viral	B
10	coat	I
11	protein	I
12	but	O
13	differ	O
14	in	O
15	their	O
16	relative	O
17	abilities	O
18	to	O
19	utilize	O
20	the	O
21	foreign	O
22	scaffolding	O
23	protein	O
24	.	O

1	An	O
2	ASIC	O
3	-	O
4	chip	O
5	for	O
6	stereoscopic	O
7	depth	O
8	analysis	O
9	in	O
10	video	O
11	-	O
12	real	O
13	-	O
14	time	O
15	based	O
16	on	O
17	visual	O
18	cortical	O
19	cell	O
20	behavior	O
21	.	O

1	A	O
2	MEK	B
3	-	O
4	specific	O
5	inhibitor	O
6	(	O
7	PD098059	O
8	)	O
9	(	O
10	Dudley	O
11	,	O
12	D	O
13	.	O

1	Merlie	O
2	,	O
3	Cold	O
4	Spring	O
5	Harbor	O
6	Symp	O
7	.	O

1	Here	O
2	we	O
3	report	O
4	on	O
5	the	O
6	isolation	O
7	of	O
8	ICK2	B
9	,	O
10	and	O
11	show	O
12	that	O
13	it	O
14	interacts	O
15	with	O
16	Cdc2aAt	B
17	,	O
18	but	O
19	not	O
20	with	O
21	a	O
22	second	O
23	CDK	B
24	from	O
25	Arabidopsis	O
26	,	O
27	Cdc2bAt	B
28	.	O

1	This	O
2	mutant	O
3	was	O
4	identified	O
5	by	O
6	screening	O
7	with	O
8	a	O
9	TGF	B
10	-	I
11	beta	I
12	-	O
13	inducible	O
14	vector	O
15	a	O
16	series	O
17	of	O
18	mink	O
19	lung	O
20	epithelial	O
21	cell	O
22	clones	O
23	that	O
24	have	O
25	normal	O
26	TGF	B
27	-	I
28	beta	I
29	binding	O
30	activity	O
31	but	O
32	have	O
33	lost	O
34	antiproliferative	O
35	and	O
36	transcriptional	O
37	responses	O
38	to	O
39	TGF	B
40	-	I
41	beta	I
42	.	O

1	Blood	O
2	flow	O
3	velocity	O
4	waveforms	O
5	were	O
6	recorded	O
7	by	O
8	pulsed	O
9	Doppler	O
10	examination	O
11	of	O
12	the	O
13	fetal	O
14	internal	O
15	carotid	O
16	and	O
17	middle	O
18	cerebral	O
19	arteries	O
20	using	O
21	the	O
22	established	O
23	transabdominal	O
24	route	O
25	as	O
26	well	O
27	as	O
28	a	O
29	new	O
30	transvaginal	O
31	approach	O
32	.	O

1	Laboratory	O
2	pyrolyses	O
3	have	O
4	indeed	O
5	shown	O
6	that	O
7	PCBs	O
8	give	O
9	significant	O
10	yields	O
11	of	O
12	PCDFs	O
13	,	O
14	and	O
15	chlorobenzenes	O
16	give	O
17	both	O
18	PCDFs	O
19	and	O
20	PCDDs	O
21	.	O

1	Examination	O
2	of	O
3	the	O
4	immediate	O
5	sequence	O
6	5	O
7	'	O
8	to	O
9	the	O
10	mRNA	O
11	start	O
12	site	O
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	O
20	enhancer	O
21	sequences	O
22	.	O

1	We	O
2	specially	O
3	devised	O
4	3	O
5	types	O
6	of	O
7	turbo	O
8	pumps	O
9	,	O
10	a	O
11	centrifugal	O
12	pump	O
13	(	O
14	CFP	O
15	),	O
16	a	O
17	mixed	O
18	flow	O
19	pump	O
20	(	O
21	MFP	O
22	),	O
23	and	O
24	an	O
25	axial	O
26	flow	O
27	pump	O
28	(	O
29	AFP	B
30	),	O
31	and	O
32	analyzed	O
33	their	O
34	in	O
35	vitro	O
36	performance	O
37	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	efficacies	O
6	of	O
7	adjuvant	O
8	carboplatin	O
9	and	O
10	of	O
11	abdominal	O
12	radiotherapy	O
13	seem	O
14	to	O
15	be	O
16	identical	O
17	.	O

1	Thus	O
2	,	O
3	the	O
4	PCE	B
5	binds	O
6	a	O
7	Pbx	O
8	dimer	O
9	partner	O
10	that	O
11	behaves	O
12	unlike	O
13	Class	B
14	I	I
15	Hox	I
16	proteins	I
17	.	O

1	Framingham	O
2	Type	O
3	A	O
4	behavior	O
5	was	O
6	positively	O
7	associated	O
8	with	O
9	diastolic	O
10	blood	O
11	pressure	O
12	(	O
13	r	O
14	=	O
15	0	O
16	.	O
17	17	O
18	,	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	05	O
25	)	O
26	among	O
27	the	O
28	women	O
29	.	O

1	High	O
2	plasma	O
3	concentrations	O
4	of	O
5	soluble	O
6	E	B
7	-	I
8	selectin	I
9	were	O
10	closely	O
11	associated	O
12	with	O
13	multiple	O
14	-	O
15	organ	O
16	dysfunction	O
17	and	O
18	death	O
19	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	B
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O

1	RESULTS	O
2	:	O
3	Acetabular	O
4	index	O
5	returned	O
6	to	O
7	normal	O
8	gradually	O
9	as	O
10	the	O
11	time	O
12	went	O
13	by	O
14	and	O
15	significantly	O
16	within	O
17	one	O
18	year	O
19	after	O
20	the	O
21	reduction	O
22	of	O
23	developmental	O
24	dislocation	O
25	of	O
26	the	O
27	hip	O
28	.	O

1	One	O
2	such	O
3	element	O
4	,	O
5	1P	O
6	,	O
7	was	O
8	employed	O
9	to	O
10	clone	O
11	from	O
12	a	O
13	rat	B
14	pituitary	I
15	cDNA	I
16	expression	O
17	library	O
18	a	O
19	novel	O
20	417	O
21	-	O
22	amino	O
23	acid	O
24	WD	O
25	protein	O
26	,	O
27	designated	O
28	PREB	B
29	(	O
30	PRL	B
31	regulatory	I
32	element	I
33	binding	I
34	)	I
35	protein	I
36	.	O

1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O

1	The	O
2	alpha	O
3	-	O
4	subunit	O
5	by	O
6	itself	O
7	binds	O
8	to	O
9	telomeric	O
10	DNA	O
11	.	O

1	Characterization	O
2	of	O
3	the	O
4	regulon	O
5	controlled	O
6	by	O
7	the	O
8	leucine	O
9	-	O
10	responsive	O
11	regulatory	O
12	protein	O
13	in	O
14	Escherichia	O
15	coli	O
16	.	O

1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O

1	We	O
2	report	O
3	two	O
4	patients	O
5	receiving	O
6	maintenance	O
7	valproate	O
8	,	O
9	one	O
10	with	O
11	resolving	O
12	acute	O
13	hepatitis	O
14	C	O
15	and	O
16	the	O
17	other	O
18	with	O
19	chronic	O
20	persistent	O
21	hepatitis	O
22	C	O
23	,	O
24	with	O
25	incidental	O
26	microvesicular	O
27	steatosis	O
28	demonstrated	O
29	on	O
30	oil	O
31	-	O
32	red	O
33	O	O
34	stains	O
35	.	O

1	The	O
2	pia	O
3	mater	O
4	at	O
5	the	O
6	site	O
7	of	O
8	the	O
9	entry	O
10	of	O
11	blood	O
12	vessels	O
13	into	O
14	the	O
15	central	O
16	nervous	O
17	system	O
18	.	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	Both	O
2	alleles	O
3	are	O
4	functionally	O
5	expressed	O
6	and	O
7	are	O
8	distributed	O
9	within	O
10	CD4	B
11	+/	O
12	CD8	B
13	+	I
14	T	I
15	cell	I
16	subsets	I
17	.	O

1	Furthermore	O
2	,	O
3	the	O
4	insertion	O
5	of	O
6	the	O
7	ColE1	B
8	cer	I
9	site	I
10	into	O
11	the	O
12	RK2	O
13	plasmid	O
14	deleted	O
15	for	O
16	the	O
17	par	O
18	region	O
19	failed	O
20	to	O
21	stabilize	O
22	the	O
23	plasmid	O
24	in	O
25	the	O
26	MC1061K	O
27	strain	O
28	,	O
29	indicating	O
30	that	O
31	the	O
32	multimer	O
33	resolution	O
34	activity	O
35	encoded	O
36	by	O
37	parCBA	B
38	is	O
39	not	O
40	by	O
41	itself	O
42	responsible	O
43	for	O
44	the	O
45	stabilization	O
46	activity	O
47	observed	O
48	for	O
49	this	O
50	operon	O
51	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	),	O
10	a	O
11	proinflammatory	O
12	cytokine	O
13	,	O
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	testosterone	O
19	production	O
20	in	O
21	mouse	O
22	Leydig	O
23	cells	O
24	.	O

1	Practical	O
2	use	O
3	and	O
4	interpretation	O
5	of	O
6	viral	O
7	hepatitis	O
8	B	O
9	markers	O
10	and	O
11	hepatic	O
12	biopsy	O
13	in	O
14	HBs	B
15	Ag	I
16	carriers	O
17	and	O
18	at	O
19	the	O
20	chronic	O
21	hepatitis	O
22	stage	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	Following	O
2	the	O
3	injection	O
4	of	O
5	PGF2	O
6	alpha	O
7	,	O
8	heifers	O
9	were	O
10	observed	O
11	visually	O
12	for	O
13	signs	O
14	of	O
15	estrus	O
16	at	O
17	0730	O
18	and	O
19	1630	O
20	(	O
21	45	O
22	min	O
23	each	O
24	).	O

1	Overlapping	O
2	cDNA	O
3	clones	O
4	were	O
5	isolated	O
6	and	O
7	sequenced	O
8	.	O

1	Sequence	O
2	analysis	O
3	and	O
4	identification	O
5	of	O
6	two	O
7	hyp	O
8	regulatory	O
9	mutants	O
10	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	/	O
6	TGF	B
7	-	I
8	alpha	I
9	HCCs	I
10	were	O
11	also	O
12	characterized	O
13	by	O
14	a	O
15	particularly	O
16	strong	O
17	expression	O
18	of	O
19	TGF	B
20	-	I
21	alpha	I
22	and	O
23	very	O
24	low	O
25	apoptotic	O
26	index	O
27	in	O
28	contrast	O
29	to	O
30	high	O
31	levels	O
32	of	O
33	apoptosis	O
34	in	O
35	peritumorous	O
36	tissues	O
37	and	O
38	c	B
39	-	I
40	myc	I
41	HCCs	I
42	.	O

1	A	O
2	follow	O
3	-	O
4	up	O
5	study	O
6	of	O
7	22	O
8	patients	O
9	with	O
10	Ebstein	O
11	'	O
12	s	O
13	anomaly	O
14	has	O
15	been	O
16	performed	O
17	.	O

1	Therefore	O
2	,	O
3	both	O
4	the	O
5	Chilean	O
6	and	O
7	the	O
8	Japanese	O
9	samples	O
10	collected	O
11	in	O
12	high	O
13	-	O
14	risk	O
15	areas	O
16	showed	O
17	higher	O
18	mutagenic	O
19	rates	O
20	than	O
21	the	O
22	Japanese	O
23	ones	O
24	in	O
25	a	O
26	low	O
27	-	O
28	risk	O
29	area	O
30	,	O
31	with	O
32	a	O
33	statistical	O
34	significance	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	chi	O
43	-	O
44	square	O
45	test	O
46	).	O

1	Histological	O
2	slides	O
3	of	O
4	one	O
5	biopsy	O
6	of	O
7	each	O
8	patient	O
9	(	O
10	formalin	O
11	-	O
12	fixed	O
13	and	O
14	paraffin	O
15	-	O
16	embedded	O
17	)	O
18	were	O
19	stained	O
20	with	O
21	a	O
22	Modified	O
23	Giemsa	O
24	(	O
25	MG	O
26	),	O
27	the	O
28	Warthin	B
29	-	I
30	Starry	I
31	(	O
32	WS	O
33	),	O
34	and	O
35	an	O
36	immunohistochemical	O
37	method	O
38	(	O
39	IMM	O
40	)	O
41	using	O
42	purified	O
43	polyclonal	O
44	H	O
45	.	O
46	pylori	O
47	antiserum	O
48	(	O
49	DAKO	O
50	B471	O
51	).	O

1	Alternative	O
2	splicing	O
3	of	O
4	fibroblast	B
5	growth	I
6	factor	I
7	receptor	I
8	2	I
9	(	O
10	FGF	B
11	-	I
12	R2	I
13	)	I
14	is	O
15	an	O
16	example	O
17	of	O
18	highly	O
19	regulated	O
20	alternative	O
21	splicing	O
22	in	O
23	which	O
24	exons	O
25	IIIb	O
26	and	O
27	IIIc	B
28	are	O
29	utilized	O
30	in	O
31	a	O
32	mutually	O
33	exclusive	O
34	manner	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O

1	The	O
2	present	O
3	results	O
4	demonstrate	O
5	that	O
6	rats	O
7	with	O
8	relatively	O
9	small	O
10	remnants	O
11	of	O
12	one	O
13	olfactory	O
14	bulb	O
15	can	O
16	perform	O
17	a	O
18	variety	O
19	of	O
20	odor	O
21	detection	O
22	and	O
23	discrimination	O
24	tasks	O
25	as	O
26	well	O
27	or	O
28	nearly	O
29	as	O
30	well	O
31	as	O
32	controls	O
33	.	O

1	The	O
2	bovine	O
3	papillomavirus	O
4	E2	O
5	protein	O
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	O
17	p53	B
18	-	O
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	O
27	papillomavirus	O
28	type	O
29	30	O
30	DNA	O
31	.	O

1	Movement	O
2	programming	O
3	depends	O
4	on	O
5	understanding	O
6	of	O
7	behavioral	O
8	requirements	O
9	.	O

1	Host	O
2	lipids	O
3	in	O
4	tuberculous	O
5	infection	O
6	.	O

1	Demispan	O
2	is	O
3	a	O
4	reliable	O
5	and	O
6	reproducible	O
7	measure	O
8	of	O
9	stature	O
10	in	O
11	the	O
12	elderly	O
13	.	O

1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O

1	This	O
2	report	O
3	substantiates	O
4	that	O
5	at	O
6	least	O
7	two	O
8	of	O
9	the	O
10	18	O
11	kDa	O
12	hsps	O
13	in	O
14	maize	O
15	are	O
16	products	O
17	of	O
18	different	O
19	but	O
20	related	O
21	genes	O
22	.	O

1	When	O
2	voltage	O
3	-	O
4	operated	O
5	Ca2	O
6	+	O
7	channels	O
8	(	O
9	VOC	O
10	)	O
11	were	O
12	blocked	O
13	by	O
14	nifedipine	O
15	,	O
16	midazolam	O
17	,	O
18	in	O
19	concentrations	O
20	more	O
21	than	O
22	1	O
23	microM	O
24	,	O
25	attenuated	O
26	both	O
27	phasic	O
28	and	O
29	tonic	O
30	responses	O
31	.	O

1	The	O
2	role	O
3	of	O
4	ascorbic	O
5	acid	O
6	in	O
7	the	O
8	prevention	O
9	of	O
10	bladder	O
11	tumor	O
12	formation	O
13	.	O

1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O

1	15	O
2	,	O
3	2500	O
4	-	O
5	2508	O
6	;	O
7	O	O
8	'	O
9	Neill	O
10	,	O
11	T	O
12	.	O

1	Direct	O
2	binding	O
3	and	O
4	competition	O
5	assays	O
6	using	O
7	30	O
8	-	O
9	mer	O
10	oligonucleotide	O
11	probes	O
12	representing	O
13	the	O
14	individual	O
15	CBF1	B
16	binding	I
17	sites	I
18	indicated	O
19	that	O
20	CBF1	B
21	bound	O
22	less	O
23	efficiently	O
24	to	O
25	the	O
26	CD23	B
27	promoter	I
28	and	O
29	the	O
30	EBV	O
31	LMP	B
32	-	I
33	1	I
34	promoter	I
35	sites	I
36	than	O
37	to	O
38	the	O
39	Cp	B
40	site	I
41	.	O

1	The	O
2	sequencing	O
3	of	O
4	the	O
5	conditional	O
6	lethal	O
7	mutation	B
8	ts	I
9	-	I
10	A13	I
11	,	O
12	localized	O
13	in	O
14	the	O
15	nrdE	O
16	cistron	O
17	,	O
18	and	O
19	the	O
20	lethality	O
21	of	O
22	insertional	O
23	mutations	O
24	targeted	O
25	in	O
26	the	O
27	internal	O
28	region	O
29	of	O
30	nrdE	B
31	and	O
32	nrdF	B
33	,	O
34	demonstrated	O
35	the	O
36	essential	O
37	role	O
38	of	O
39	this	O
40	locus	O
41	.	O

1	Under	O
2	these	O
3	schedules	O
4	,	O
5	a	O
6	reinforced	O
7	response	O
8	run	O
9	consisted	O
10	of	O
11	responding	O
12	between	O
13	eight	O
14	and	O
15	12	O
16	times	O
17	on	O
18	one	O
19	response	O
20	key	O
21	(	O
22	work	O
23	key	O
24	)	O
25	and	O
26	then	O
27	responding	O
28	once	O
29	on	O
30	a	O
31	second	O
32	response	O
33	key	O
34	(	O
35	reinforced	O
36	key	O
37	).	O

1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	B
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O

1	So	O
2	far	O
3	no	O
4	problems	O
5	with	O
6	multiply	O
7	resistant	O
8	strains	O
9	have	O
10	developed	O
11	.	O

1	An	O
2	evolutionary	O
3	conserved	O
4	element	O
5	is	O
6	essential	O
7	for	O
8	somite	O
9	and	O
10	adjacent	O
11	mesenchymal	O
12	expression	O
13	of	O
14	the	O
15	Hoxa1	B
16	gene	I
17	.	O

1	At	O
2	least	O
3	one	O
4	clone	O
5	,	O
6	lambda	B
7	HHG	I
8	41	I
9	,	O
10	contains	O
11	,	O
12	in	O
13	addition	O
14	to	O
15	the	O
16	histone	B
17	genes	I
18	,	O
19	a	O
20	region	O
21	that	O
22	hybridizes	O
23	with	O
24	a	O
25	cytoplasmic	O
26	RNA	O
27	approximately	O
28	330	O
29	nucleotides	O
30	in	O
31	length	O
32	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	The	O
2	effects	O
3	of	O
4	diltiazem	O
5	were	O
6	stereoselective	O
7	,	O
8	thus	O
9	the	O
10	potentiation	O
11	induced	O
12	by	O
13	d	O
14	-	O
15	cis	O
16	diltiazem	O
17	was	O
18	significantly	O
19	greater	O
20	in	O
21	all	O
22	cases	O
23	than	O
24	that	O
25	induced	O
26	by	O
27	l	O
28	-	O
29	cis	O
30	diltiazem	O
31	,	O
32	which	O
33	suggests	O
34	that	O
35	calcium	O
36	channel	O
37	blockade	O
38	plays	O
39	a	O
40	role	O
41	in	O
42	these	O
43	interactions	O
44	.	O

1	The	O
2	method	O
3	described	O
4	may	O
5	prove	O
6	useful	O
7	in	O
8	studying	O
9	the	O
10	physiology	O
11	of	O
12	the	O
13	nasal	O
14	cycle	O
15	.	O

1	There	O
2	was	O
3	no	O
4	clear	O
5	correlation	O
6	between	O
7	the	O
8	MFA	O
9	and	O
10	the	O
11	severity	O
12	of	O
13	the	O
14	UTS	O
15	phenotype	O
16	.	O

1	Specific	O
2	clotting	O
3	factor	O
4	assays	O
5	showed	O
6	an	O
7	isolated	O
8	deficiency	O
9	of	O
10	factor	O
11	X	O
12	ranging	O
13	from	O
14	7	O
15	to	O
16	12	O
17	per	O
18	cent	O
19	on	O
20	three	O
21	determinations	O
22	.	O

1	The	O
2	inspiratory	O
3	oxygen	O
4	concentration	O
5	needed	O
6	(	O
7	FiO2	O
8	)	O
9	and	O
10	the	O
11	Horowitz	O
12	quotient	O
13	differed	O
14	in	O
15	a	O
16	highly	O
17	significant	O
18	manner	O
19	beginning	O
20	on	O
21	the	O
22	1st	O
23	day	O
24	after	O
25	trauma	O
26	.	O

1	Suppressors	O
2	of	O
3	defective	O
4	silencing	O
5	in	O
6	yeast	O
7	:	O
8	effects	O
9	on	O
10	transcriptional	O
11	repression	O
12	at	O
13	the	O
14	HMR	B
15	locus	I
16	,	O
17	cell	O
18	growth	O
19	and	O
20	telomere	O
21	structure	O
22	.	O

1	A	O
2	DNA	O
3	fragment	O
4	carrying	O
5	1	O
6	,	O
7	100	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	UGT1A1	B
19	gene	I
20	was	O
21	enough	O
22	for	O
23	MC	O
24	induction	O
25	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	has	O
5	confirmed	O
6	that	O
7	this	O
8	mutation	O
9	affects	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	region	O
15	of	O
16	the	O
17	alpha	O
18	subunit	O
19	,	O
20	changing	O
21	a	O
22	leucine	O
23	residue	O
24	at	O
25	position	O
26	290	O
27	to	O
28	a	O
29	histidine	O
30	(	O
31	rpoAL290H	O
32	).	O

1	These	O
2	results	O
3	confirmed	O
4	that	O
5	cleavage	O
6	of	O
7	the	O
8	leader	O
9	peptide	O
10	is	O
11	the	O
12	last	O
13	step	O
14	in	O
15	nisin	O
16	maturation	O
17	and	O
18	is	O
19	necessary	O
20	to	O
21	generate	O
22	a	O
23	biologically	O
24	active	O
25	peptide	O
26	.	O

1	These	O
2	are	O
3	the	O
4	long	O
5	terminal	O
6	repeat	O
7	(	O
8	LTR	O
9	)	O
10	promoter	O
11	,	O
12	which	O
13	regulates	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	structural	O
19	proteins	O
20	,	O
21	and	O
22	a	O
23	second	O
24	internal	O
25	promoter	O
26	,	O
27	located	O
28	towards	O
29	the	O
30	3	O
31	'	O
32	end	O
33	of	O
34	the	O
35	env	B
36	gene	I
37	,	O
38	that	O
39	directs	O
40	expression	O
41	of	O
42	the	O
43	viral	O
44	auxiliary	O
45	proteins	O
46	.	O

1	The	O
2	neuroleptic	O
3	-	O
4	induced	O
5	increase	O
6	in	O
7	central	O
8	DA	O
9	turnover	O
10	(	O
11	an	O
12	indicator	O
13	for	O
14	the	O
15	degree	O
16	of	O
17	DA	B
18	receptor	I
19	blocking	O
20	)	O
21	was	O
22	found	O
23	to	O
24	be	O
25	positively	O
26	correlated	O
27	with	O
28	the	O
29	therapeutic	O
30	effect	O
31	of	O
32	neuroleptics	O
33	and	O
34	the	O
35	development	O
36	of	O
37	hypokinetic	O
38	-	O
39	rigid	O
40	symptoms	O
41	.	O

1	Supplementing	O
2	a	O
3	soybean	B
4	protein	I
5	and	O
6	sucrose	O
7	-	O
8	based	O
9	diet	O
10	with	O
11	levels	O
12	of	O
13	2	O
14	.	O
15	2	O
16	,	O
17	11	O
18	,	O
19	and	O
20	55	O
21	ppm	O
22	of	O
23	the	O
24	antibiotic	O
25	,	O
26	from	O
27	the	O
28	two	O
29	sources	O
30	each	O
31	with	O
32	two	O
33	different	O
34	purities	O
35	,	O
36	improved	O
37	weight	O
38	gain	O
39	of	O
40	chicks	O
41	an	O
42	average	O
43	of	O
44	23	O
45	%	O
46	and	O
47	improved	O
48	feed	O
49	efficiency	O
50	an	O
51	average	O
52	of	O
53	13	O
54	%	O
55	at	O
56	the	O
57	higher	O
58	levels	O
59	(	O
60	all	O
61	P	O
62	less	O
63	than	O
64	.	O
65	01	O
66	).	O

1	Validation	O
2	of	O
3	the	O
4	survey	O
5	of	O
6	work	O
7	styles	O
8	:	O
9	a	O
10	profile	O
11	measure	O
12	of	O
13	the	O
14	type	O
15	A	O
16	behaviour	O
17	pattern	O
18	.	O

1	Serum	O
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O

1	Because	B
2	L	I
3	-	I
4	plastin	I
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	B
52	L	I
53	-	I
54	plastin	I
55	gene	I
56	promoters	I
57	.	O

1	5	O
2	microU	B
3	/	I
4	l	I
5	thyrotropin	I
6	:	O
7	75	O
8	%	O
9	(	O
10	1974	O
11	),	O
12	45	O
13	%	O
14	(	O
15	1977	O
16	)	O
17	and	O
18	20	O
19	%	O
20	(	O
21	1980	O
22	).	O

1	The	O
2	effects	O
3	of	O
4	high	O
5	intensity	O
6	light	O
7	emissions	O
8	,	O
9	produced	O
10	by	O
11	a	O
12	novel	O
13	pulsed	O
14	power	O
15	energization	O
16	technique	O
17	(	O
18	PPET	O
19	),	O
20	on	O
21	the	O
22	survival	O
23	of	O
24	bacterial	O
25	populations	O
26	of	O
27	verocytotoxigenic	O
28	Escherichia	O
29	coli	O
30	(	O
31	serotype	O
32	0157	O
33	:	O
34	H7	O
35	)	O
36	and	O
37	Listeria	O
38	monocytogenes	O
39	(	O
40	serotype	O
41	4b	O
42	)	O
43	were	O
44	investigated	O
45	.	O

1	A	O
2	series	O
3	of	O
4	amino	O
5	terminal	O
6	deletion	O
7	mutants	O
8	(	O
9	d10	O
10	,	O
11	d20	O
12	,	O
13	d27	O
14	,	O
15	d31	O
16	,	O
17	d40	O
18	,	O
19	d44	O
20	,	O
21	and	O
22	d73	O
23	)	O
24	were	O
25	compared	O
26	for	O
27	processing	O
28	,	O
29	cell	O
30	surface	O
31	expression	O
32	,	O
33	and	O
34	maintenance	O
35	of	O
36	their	O
37	biological	O
38	attributes	O
39	by	O
40	recombinant	O
41	expression	O
42	of	O
43	mutant	O
44	genes	O
45	using	O
46	a	O
47	plasmid	O
48	vector	O
49	(	O
50	pcDL	B
51	-	I
52	SR	I
53	alpha	I
54	-	I
55	296	I
56	)	O
57	in	O
58	CV	B
59	-	I
60	1	I
61	and	O
62	HeLa	O
63	cells	O
64	.	O

1	The	O
2	mechanism	O
3	involves	O
4	Gbetagamma	O
5	subunit	O
6	-	O
7	mediated	O
8	increases	O
9	in	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	Shc	B
15	adapter	I
16	protein	I
17	,	O
18	Shc	B
19	*	I
20	Grb2	I
21	complex	I
22	formation	O
23	,	O
24	and	O
25	recruitment	O
26	of	O
27	Ras	B
28	guanine	I
29	nucleotide	I
30	exchange	I
31	factor	I
32	activity	O
33	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	evaluate	O
11	the	O
12	bony	O
13	anchorage	O
14	of	O
15	a	O
16	new	O
17	implant	O
18	(	O
19	orderly	O
20	wired	O
21	surface	O
22	effect	O
23	with	O
24	alloy	O
25	Ti	O
26	Al	O
27	Va	O
28	and	O
29	ordered	O
30	pores	O
31	of	O
32	488	O
33	mu	O
34	).	O

1	Thigh	O
2	girth	O
3	correlated	O
4	positively	O
5	with	O
6	HDL	B
7	and	O
8	HDL2	B
9	-	I
10	C	I
11	and	O
12	mass	O
13	,	O
14	and	O
15	with	O
16	LDL	B
17	particle	O
18	size	O
19	among	O
20	women	O
21	.	O

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	O
17	unit	O
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	Regulatory	O
2	motifs	O
3	for	O
4	gene	O
5	expression	O
6	such	O
7	as	O
8	nuclear	B
9	-	I
10	factor	I
11	-	I
12	kappaB	I
13	-	I
14	binding	I
15	-	I
16	site	I
17	-	I
18	like	I
19	sequence	I
20	(	O
21	kappaB	B
22	site	I
23	)	O
24	and	O
25	nuclear	B
26	-	I
27	factor	I
28	-	I
29	interleukin	I
30	-	I
31	6	I
32	-	I
33	binding	I
34	-	I
35	site	I
36	-	I
37	like	I
38	sequence	I
39	(	O
40	NF	B
41	-	I
42	IL	I
43	-	I
44	6	I
45	site	I
46	)	O
47	were	O
48	found	O
49	in	O
50	the	O
51	5	O
52	'-	O
53	upstream	O
54	regulatory	O
55	region	O
56	.	O

1	Although	O
2	Pho85	B
3	is	O
4	not	O
5	essential	O
6	for	O
7	viability	O
8	,	O
9	Pcl1	O
10	,	O
11	2	O
12	-	O
13	Pho85	B
14	kinase	I
15	complexes	O
16	become	O
17	essential	O
18	for	O
19	Start	O
20	in	O
21	the	O
22	absence	O
23	of	O
24	Cln1	B
25	,	O
26	2	O
27	-	O
28	Cdc28	B
29	kinases	I
30	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	I
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	Secondary	O
2	cleavage	O
3	of	O
4	RT	O
5	at	O
6	Trp	O
7	-	O
8	595	O
9	-	O
10	Tyr	O
11	-	O
12	596	O
13	of	O
14	Pol	B
15	yields	O
16	a	O
17	truncated	O
18	form	O
19	lacking	O
20	the	O
21	C	B
22	-	I
23	terminal	I
24	RNase	I
25	H	I
26	domain	I
27	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	O
5	IIDR	O
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	However	O
2	,	O
3	mean	O
4	food	O
5	intake	O
6	in	O
7	the	O
8	40	O
9	%	O
10	group	O
11	was	O
12	half	O
13	that	O
14	of	O
15	the	O
16	ACT	O
17	group	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	001	O
24	)	O
25	and	O
26	significantly	O
27	less	O
28	(	O
29	p	O
30	<	O
31	0	O
32	.	O
33	01	O
34	)	O
35	than	O
36	the	O
37	SEP	O
38	group	O
39	,	O
40	which	O
41	consumed	O
42	amounts	O
43	equivalent	O
44	to	O
45	65	O
46	%	O
47	of	O
48	daily	O
49	requirement	O
50	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	a	O
6	nuclear	O
7	gene	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	that	O
12	specifies	O
13	MRP13	O
14	,	O
15	a	O
16	protein	O
17	of	O
18	the	O
19	small	O
20	subunit	O
21	of	O
22	the	O
23	mitochondrial	O
24	ribosome	O
25	.	O

1	Erythrocyte	O
2	AA	O
3	in	O
4	FO	O
5	+	O
6	EPO	B
7	-	O
8	supplemented	O
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	formula	O
19	-	O
20	fed	O
21	levels	O
22	.	O

1	ORFA	O
2	and	O
3	ccdA	O
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	Insulin	B
2	regulation	O
3	of	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	kinase	I
9	kinase	I
10	(	O
11	MEK	B
12	),	O
13	mitogen	B
14	-	I
15	activated	I
16	protein	I
17	kinase	I
18	and	O
19	casein	B
20	kinase	I
21	in	O
22	the	O
23	cell	O
24	nucleus	O
25	:	O
26	a	O
27	possible	O
28	role	O
29	in	O
30	the	O
31	regulation	O
32	of	O
33	gene	O
34	expression	O
35	.	O

1	We	O
2	have	O
3	isolated	O
4	three	O
5	mutant	O
6	alleles	O
7	of	O
8	CDC4	B
9	(	O
10	cdc4	O
11	-	O
12	10	O
13	,	O
14	cdc4	O
15	-	O
16	11	O
17	,	O
18	and	O
19	cdc4	B
20	-	I
21	16	I
22	)	O
23	which	O
24	suppress	O
25	the	O
26	nuclear	O
27	division	O
28	defect	O
29	of	O
30	cdc20	O
31	-	O
32	1	O
33	cells	O
34	.	O

1	All	O
2	patients	O
3	had	O
4	elevated	O
5	levels	O
6	of	O
7	serum	B
8	IgE	I
9	antibodies	I
10	to	O
11	the	O
12	crude	O
13	soybean	O
14	extract	O
15	;	O
16	binding	O
17	values	O
18	ranged	O
19	from	O
20	2	O
21	.	O
22	3	O
23	to	O
24	28	O
25	.	O
26	1	O
27	times	O
28	that	O
29	of	O
30	a	O
31	negative	O
32	control	O
33	serum	O
34	.	O

1	Previously	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	51	O
7	-	O
8	bp	O
9	promoter	O
10	fragment	O
11	,	O
12	oligo31	O
13	/	O
14	32	O
15	,	O
16	which	O
17	conferred	O
18	heat	O
19	shock	O
20	inducibility	O
21	on	O
22	the	O
23	heterologous	O
24	CYC1	O
25	-	O
26	lacZ	B
27	reporter	I
28	gene	I
29	in	O
30	S	O
31	.	O
32	cerevisiae	O
33	(	O
34	N	O
35	.	O

1	IgE	B
2	levels	O
3	showed	O
4	higher	O
5	values	O
6	compared	O
7	to	O
8	normal	O
9	individuals	O
10	and	O
11	IgE	B
12	levels	O
13	were	O
14	higher	O
15	in	O
16	children	O
17	groups	O
18	than	O
19	in	O
20	adults	O
21	regardless	O
22	of	O
23	the	O
24	intensity	O
25	of	O
26	infection	O
27	.	O

1	Eighteen	O
2	patients	O
3	were	O
4	untreated	O
5	,	O
6	and	O
7	8	O
8	had	O
9	been	O
10	given	O
11	previous	O
12	treatment	O
13	with	O
14	depot	O
15	testosterone	O
16	100	O
17	mg	O
18	intramuscularly	O
19	every	O
20	2	O
21	-	O
22	3	O
23	weeks	O
24	for	O
25	an	O
26	average	O
27	duration	O
28	of	O
29	4	O
30	.	O
31	7	O
32	years	O
33	.	O

1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O

1	Serum	O
2	relaxin	O
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O

1	Instead	O
2	,	O
3	mRNA	O
4	of	O
5	2	O
6	.	O
7	0	O
8	and	O
9	2	O
10	.	O
11	8	O
12	kb	O
13	are	O
14	detected	O
15	in	O
16	varying	O
17	abundance	O
18	.	O

1	Identification	O
2	of	O
3	dynein	B
4	heavy	I
5	chain	I
6	genes	I
7	expressed	O
8	in	O
9	human	O
10	and	O
11	mouse	O
12	testis	O
13	:	O
14	chromosomal	O
15	localization	O
16	of	O
17	an	O
18	axonemal	O
19	dynein	O
20	gene	O
21	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	murine	O
9	p44	B
10	MAP	I
11	kinase	I
12	(	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	1	I
19	)	I
20	gene	I
21	,	O
22	the	O
23	determination	O
24	of	O
25	its	O
26	intron	O
27	/	O
28	exon	O
29	boundaries	O
30	,	O
31	and	O
32	the	O
33	characterization	O
34	of	O
35	its	O
36	promoter	O
37	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	O
8	jun	B
9	activation	O
10	by	O
11	TCDD	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	tetradecanoyl	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	aromatic	O
54	hydrocarbons	O
55	(	O
56	AhRE	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	O
62	jun	B
63	genes	I
64	fused	O
65	to	O
66	the	O
67	firefly	B
68	luciferase	I
69	gene	I
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	B
76	minimal	I
77	promoter	I
78	.	O

1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	B
6	albumin	I
7	,	O
8	BUN	O
9	and	O
10	SCr	B
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O

1	She	O
2	improved	O
3	with	O
4	a	O
5	combination	O
6	of	O
7	benzodiazepines	O
8	and	O
9	the	O
10	acetylcholinesterase	B
11	inhibitor	O
12	physostigmine	O
13	.	O

1	Evaluation	O
2	of	O
3	antiepileptic	O
4	drug	O
5	effect	O
6	on	O
7	membrane	O
8	fluidity	O
9	.	O

1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O

1	Stringent	O
2	hybridization	O
3	of	O
4	EHS	B
5	-	I
6	1	I
7	back	O
8	to	O
9	primate	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	EHS	B
16	-	I
17	1	I
18	loci	I
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	chimpanzee	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	rhesus	O
38	monkey	O
39	DNA	O
40	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	opiate	O
6	antagonist	O
7	naloxone	O
8	was	O
9	evaluated	O
10	in	O
11	11	O
12	unselected	O
13	patients	O
14	with	O
15	cerebral	O
16	ischemia	O
17	.	O

1	A	O
2	chicken	O
3	paxillin	B
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	B
21	paxil	I
22	-	I
23	lin	I
24	.	O

1	USA	O
2	80	O
3	,	O
4	802	O
5	-	O
6	806	O
7	]	O
8	was	O
9	used	O
10	to	O
11	isolate	O
12	a	O
13	genomic	O
14	clone	O
15	lambda	O
16	PGK	B
17	-	I
18	1	I
19	containing	O
20	a	O
21	portion	O
22	of	O
23	an	O
24	autosomal	O
25	locus	O
26	for	O
27	phosphoglycerate	B
28	kinase	I
29	(	O
30	PGK	B
31	).	O

1	Dopamine	O
2	neurons	O
3	in	O
4	subjects	O
5	that	O
6	received	O
7	6	O
8	-	O
9	OHDA	O
10	were	O
11	protected	O
12	by	O
13	pre	O
14	-	O
15	treatment	O
16	with	O
17	GBR	O
18	-	O
19	12909	O
20	.	O

1	IFN	B
2	alpha	I
3	and	O
4	IFN	B
5	gamma	I
6	inducibility	O
7	is	O
8	mediated	O
9	by	O
10	a	O
11	single	O
12	element	O
13	:	O
14	a	O
15	high	O
16	affinity	O
17	,	O
18	nearly	O
19	palindromic	O
20	version	O
21	of	O
22	the	O
23	IFN	B
24	gamma	I
25	activation	I
26	site	I
27	(	O
28	GAS	B
29	).	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	Seven	O
2	patients	O
3	(	O
4	8	O
5	.	O
6	3	O
7	percent	O
8	)	O
9	had	O
10	latent	O
11	hypothyroidism	O
12	only	O
13	discovered	O
14	by	O
15	hormonal	O
16	determinations	O
17	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	these	O
6	genes	O
7	differ	O
8	at	O
9	only	O
10	nine	O
11	positions	O
12	,	O
13	resulting	O
14	in	O
15	three	O
16	amino	O
17	acid	O
18	differences	O
19	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	bacteriophage	O
10	-	O
11	type	O
12	RNA	O
13	polymerase	O
14	from	O
15	the	O
16	higher	O
17	plant	O
18	Chenopodium	O
19	album	O
20	.	O

1	Further	O
2	,	O
3	the	O
4	ability	O
5	of	O
6	recombinant	B
7	beta	I
8	and	I
9	/	I
10	or	I
11	gamma	I
12	chains	I
13	to	O
14	function	O
15	in	O
16	defined	O
17	biochemical	O
18	assays	O
19	of	O
20	beta	B
21	gamma	I
22	activity	O
23	was	O
24	assessed	O
25	for	O
26	membrane	O
27	extracts	O
28	and	O
29	supernatant	O
30	fractions	O
31	from	O
32	infected	O
33	Sf9	O
34	cells	O
35	.	O

1	A	O
2	chimeric	O
3	VP16	B
4	-	I
5	Tat	I
6	construct	I
7	containing	O
8	the	O
9	leucine	O
10	mutations	O
11	showed	O
12	no	O
13	increased	O
14	AP	B
15	-	I
16	1	I
17	responsiveness	O
18	in	O
19	comparison	O
20	with	O
21	that	O
22	of	O
23	the	O
24	VP16	B
25	activation	O
26	domain	O
27	alone	O
28	.	O

1	In	O
2	subjects	O
3	(	O
4	n	O
5	=	O
6	5	O
7	)	O
8	with	O
9	quadriplegia	O
10	and	O
11	reduced	O
12	sympathetic	O
13	tone	O
14	secondary	O
15	to	O
16	cervical	O
17	cord	O
18	trauma	O
19	,	O
20	TcpO2	O
21	at	O
22	42	O
23	degrees	O
24	C	O
25	and	O
26	vasodilation	O
27	index	O
28	were	O
29	increased	O
30	(	O
31	45	O
32	.	O
33	0	O
34	mmHg	O
35	and	O
36	0	O
37	.	O
38	61	O
39	);	O
40	TcpO2	O
41	at	O
42	45	O
43	degrees	O
44	C	O
45	did	O
46	not	O
47	change	O
48	.	O

1	Experience	O
2	with	O
3	the	O
4	tensor	O
5	fasciae	O
6	latae	O
7	free	O
8	flap	O
9	.	O

1	This	O
2	study	O
3	determined	O
4	the	O
5	arthritogenic	O
6	potential	O
7	of	O
8	silicone	O
9	gel	O
10	by	O
11	either	O
12	mixing	O
13	it	O
14	with	O
15	bovine	B
16	collagen	I
17	II	I
18	(	O
19	BII	O
20	)	O
21	or	O
22	by	O
23	injecting	O
24	silicone	O
25	gel	O
26	alone	O
27	in	O
28	DA	O
29	rats	O
30	.	O

1	Because	O
2	of	O
3	a	O
4	rapid	O
5	development	O
6	of	O
7	the	O
8	connective	O
9	tissue	O
10	scars	O
11	,	O
12	however	O
13	,	O
14	at	O
15	the	O
16	place	O
17	of	O
18	the	O
19	destroyed	O
20	glandular	O
21	parenchyma	O
22	areas	O
23	,	O
24	there	O
25	is	O
26	no	O
27	normalization	O
28	of	O
29	the	O
30	organ	O
31	'	O
32	s	O
33	structure	O
34	and	O
35	function	O
36	by	O
37	the	O
38	42d	O
39	day	O
40	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Semen	O
6	analyses	O
7	were	O
8	performed	O
9	on	O
10	58	O
11	patients	O
12	with	O
13	stages	O
14	I	O
15	-	O
16	III	O
17	HD	O
18	before	O
19	,	O
20	during	O
21	,	O
22	and	O
23	after	O
24	chemotherapy	O
25	and	O
26	after	O
27	the	O
28	sperm	O
29	count	O
30	recovered	O
31	from	O
32	the	O
33	effects	O
34	of	O
35	abdominal	O
36	radiotherapy	O
37	that	O
38	was	O
39	given	O
40	after	O
41	chemotherapy	O
42	.	O

1	The	O
2	mobility	O
3	shift	O
4	assay	O
5	of	O
6	the	O
7	65	O
8	bp	O
9	(-	O
10	318	O
11	/	O
12	-	O
13	254	O
14	)	O
15	fragment	O
16	with	O
17	nuclear	O
18	extract	O
19	from	O
20	the	O
21	dark	O
22	-	O
23	adapted	O
24	sample	O
25	showed	O
26	an	O
27	additional	O
28	band	O
29	,	O
30	not	O
31	seen	O
32	with	O
33	the	O
34	light	O
35	-	O
36	grown	O
37	sample	O
38	.	O

1	The	O
2	translation	O
3	products	O
4	of	O
5	both	O
6	clones	O
7	are	O
8	highly	O
9	homologous	O
10	to	O
11	APS1	B
12	(	O
13	66	O
14	and	O
15	86	O
16	%	O
17	identity	O
18	,	O
19	respectively	O
20	)	O
21	over	O
22	their	O
23	entire	O
24	lengths	O
25	,	O
26	including	O
27	amino	O
28	terminal	O
29	sequences	O
30	resembling	O
31	transit	O
32	peptides	O
33	for	O
34	plastid	O
35	localization	O
36	.	O

1	Molecular	O
2	dissection	O
3	of	O
4	the	O
5	multimeric	O
6	CD3	B
7	-	I
8	TCR	I
9	complex	I
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	O
17	,	O
18	CD3	B
19	zeta	I
20	and	O
21	CD3	B
22	epsilon	I
23	,	O
24	autonomously	O
25	couple	O
26	antigenic	O
27	recognition	O
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	intracytoplasmic	O
37	activation	O
38	cascade	O
39	.	O

1	Thus	O
2	,	O
3	Pet111p	B
4	could	O
5	play	O
6	dual	O
7	roles	O
8	in	O
9	both	O
10	membrane	O
11	localization	O
12	and	O
13	regulation	O
14	of	O
15	Cox2p	B
16	synthesis	O
17	within	O
18	mitochondria	O
19	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	suggest	O
7	that	O
8	the	O
9	Mif2	B
10	protein	I
11	interacts	O
12	with	O
13	Cep1p	B
14	at	O
15	the	O
16	centromere	O
17	and	O
18	that	O
19	the	O
20	yeast	O
21	centromere	O
22	indeed	O
23	exists	O
24	as	O
25	a	O
26	higher	O
27	order	O
28	protein	O
29	-	O
30	DNA	O
31	complex	O
32	.	O

1	Sex	O
2	ratio	O
3	at	O
4	birth	O
5	.	O

1	Records	O
2	of	O
3	31	O
4	children	O
5	with	O
6	AIDS	O
7	or	O
8	AIDS	O
9	-	O
10	related	O
11	complex	O
12	admitted	O
13	to	O
14	the	O
15	pediatric	O
16	intensive	O
17	care	O
18	unit	O
19	for	O
20	acute	O
21	respiratory	O
22	failure	O
23	throughout	O
24	a	O
25	46	O
26	-	O
27	month	O
28	period	O
29	were	O
30	reviewed	O
31	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	Patulin	B
2	is	O
3	extracted	O
4	from	O
5	apple	O
6	butter	O
7	samples	O
8	with	O
9	ethyl	O
10	acetate	O
11	and	O
12	the	O
13	extract	O
14	is	O
15	cleaned	O
16	up	O
17	on	O
18	a	O
19	silica	O
20	gel	O
21	column	O
22	,	O
23	using	O
24	benzene	O
25	-	O
26	ethyl	O
27	acetate	O
28	(	O
29	75	O
30	+	O
31	25	O
32	)	O
33	as	O
34	the	O
35	eluant	O
36	.	O

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	B
11	gene	I
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	B
20	gene	I
21	regulator	I
22	,	O
23	the	O
24	leucine	B
25	zipper	I
26	transcription	I
27	factor	I
28	MafB	I
29	/	I
30	Kr	I
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	loss	O
6	of	O
7	MAD2	O
8	staining	O
9	in	O
10	meiosis	O
11	was	O
12	not	O
13	correlated	O
14	with	O
15	initial	O
16	microtubule	O
17	attachment	O
18	but	O
19	was	O
20	correlated	O
21	with	O
22	a	O
23	measure	O
24	of	O
25	tension	O
26	:	O
27	the	O
28	distance	O
29	between	O
30	homologous	O
31	or	O
32	sister	O
33	kinetochores	O
34	(	O
35	in	O
36	meiosis	O
37	I	O
38	and	O
39	II	O
40	,	O
41	respectively	O
42	).	O

1	The	O
2	relationship	O
3	between	O
4	the	O
5	rare	O
6	complications	O
7	mentioned	O
8	above	O
9	and	O
10	the	O
11	pathophysiology	O
12	of	O
13	Bartter	O
14	'	O
15	s	O
16	syndrome	O
17	is	O
18	still	O
19	obscure	O
20	.	O

1	Echinostomiasis	O
2	is	O
3	aggravated	O
4	by	O
5	socioeconomic	O
6	factors	O
7	such	O
8	as	O
9	poverty	O
10	,	O
11	malnutrition	O
12	,	O
13	an	O
14	explosively	O
15	growing	O
16	free	O
17	-	O
18	food	O
19	market	O
20	,	O
21	a	O
22	lack	O
23	of	O
24	supervised	O
25	food	O
26	inspection	O
27	,	O
28	poor	O
29	or	O
30	insufficient	O
31	sanitation	O
32	,	O
33	other	O
34	helminthiases	O
35	,	O
36	and	O
37	declining	O
38	economic	O
39	conditions	O
40	.	O

1	Concomitant	O
2	chronic	O
3	lymphocytic	O
4	leukemia	O
5	,	O
6	acute	O
7	myeloid	O
8	leukemia	O
9	,	O
10	and	O
11	thrombosis	O
12	with	O
13	protein	B
14	C	I
15	deficiency	O
16	.	O

1	Paracrine	O
2	activation	O
3	of	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	LTR	I
9	promoter	I
10	by	O
11	the	O
12	viral	B
13	Tat	I
14	protein	I
15	is	O
16	mechanistically	O
17	similar	O
18	to	O
19	trans	O
20	-	O
21	activation	O
22	within	O
23	a	O
24	cell	O
25	.	O

1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O

1	The	O
2	effects	O
3	of	O
4	systemic	O
5	glucose	O
6	concentration	O
7	on	O
8	brain	O
9	metabolism	O
10	following	O
11	repeated	O
12	brain	O
13	ischemia	O
14	.	O

1	Conditions	O
2	influencing	O
3	inhibitors	O
4	of	O
5	the	O
6	colony	B
7	-	I
8	stimulating	I
9	factor	I
10	(	I
11	CSF	I
12	).	O

1	To	O
2	determine	O
3	the	O
4	effects	O
5	on	O
6	the	O
7	pulmonary	O
8	barrier	O
9	of	O
10	several	O
11	surface	O
12	active	O
13	agents	O
14	,	O
15	a	O
16	series	O
17	of	O
18	metered	O
19	dose	O
20	inhalers	O
21	(	O
22	MDIs	O
23	)	O
24	was	O
25	prepared	O
26	and	O
27	used	O
28	to	O
29	dose	O
30	aerosolized	O
31	surfactant	O
32	to	O
33	the	O
34	airways	O
35	of	O
36	isolated	O
37	perfused	O
38	rat	O
39	lungs	O
40	.	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	The	O
2	RAS	B
3	-	I
4	cyclic	I
5	AMP	I
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	cAPK	I
11	pathway	O
12	prevents	O
13	the	O
14	UAS	O
15	activity	O
16	of	O
17	IREu	B
18	in	O
19	the	O
20	presence	O
21	of	O
22	glucose	O
23	as	O
24	the	O
25	sole	O
26	carbon	O
27	source	O
28	,	O
29	while	O
30	the	O
31	transcriptional	O
32	activators	O
33	Msn2p	B
34	and	O
35	Msn4p	B
36	promote	O
37	the	O
38	UAS	O
39	activity	O
40	of	O
41	this	O
42	repeat	O
43	in	O
44	the	O
45	presence	O
46	of	O
47	acetate	O
48	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	rose	O
5	and	O
6	the	O
7	plasma	O
8	aldosterone	O
9	level	O
10	fell	O
11	after	O
12	taking	O
13	lisinopril	O
14	.	O

1	Tissue	B
2	plasminogen	I
3	activator	I
4	,	O
5	its	O
6	inhibitor	O
7	and	O
8	other	O
9	parameters	O
10	of	O
11	fibrinolysis	O
12	in	O
13	blood	O
14	of	O
15	patients	O
16	operated	O
17	for	O
18	mild	O
19	hypertrophy	O
20	of	O
21	the	O
22	prostate	O

1	Selected	O
2	topics	O
3	in	O
4	pediatric	O
5	ultrasonography	O
6	--	O
7	1992	O
8	.	O

1	The	O
2	introduction	O
3	of	O
4	hARF4	O
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	Sec7p	O
18	pools	O
19	.	O

1	Leukocyte	O
2	enzyme	O
3	activity	O
4	and	O
5	blood	O
6	lymphocyte	O
7	blast	O
8	transformation	O
9	in	O
10	chronic	O
11	bronchitis	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	SAGA	O
10	inhibits	O
11	TBP	B
12	binding	O
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	O
22	lacking	O
23	Spt3	B
24	or	O
25	Spt8	O
26	is	O
27	not	O
28	inhibitory	O
29	.	O

1	An	O
2	intralobar	O
3	change	O
4	in	O
5	temperature	O
6	above	O
7	or	O
8	below	O
9	36	O
10	degrees	O
11	C	O
12	decreases	O
13	only	O
14	the	O
15	lobar	O
16	bronchial	O
17	blood	O
18	flow	O
19	and	O
20	does	O
21	not	O
22	influence	O
23	blood	O
24	flow	O
25	to	O
26	other	O
27	nearby	O
28	tissues	O
29	including	O
30	those	O
31	vascularized	O
32	by	O
33	the	O
34	bronchial	O
35	circulation	O
36	.	O

1	PAI	B
2	-	I
3	1	I
4	levels	O
5	increased	O
6	significantly	O
7	in	O
8	patients	O
9	who	O
10	received	O
11	iohexol	O
12	but	O
13	not	O
14	in	O
15	those	O
16	who	O
17	received	O
18	ioxaglate	O
19	.	O

1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	O

1	They	O
2	contrast	O
3	trends	O
4	in	O
5	fertility	O
6	,	O
7	life	O
8	expectancy	O
9	ratios	O
10	,	O
11	and	O
12	gender	O
13	differences	O
14	in	O
15	these	O
16	countries	O
17	with	O
18	the	O
19	Hispanic	O
20	population	O
21	of	O
22	the	O
23	United	O
24	States	O
25	.	O

1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	I
6	of	O
7	pp60src	O
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	B
16	and	O
17	p110	B
18	.	O

1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	O
8	provides	O
9	an	O
10	easy	O
11	and	O
12	accurate	O
13	P0	O
14	.	O
15	1	O
16	measurement	O
17	using	O
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O

1	In	O
2	accordance	O
3	with	O
4	clinical	O
5	improvement	O
6	we	O
7	found	O
8	a	O
9	decrease	O
10	of	O
11	laboratory	O
12	indicators	O
13	of	O
14	inflammation	O
15	(	O
16	C	B
17	-	I
18	reactive	I
19	protein	I
20	,	O
21	alpha	O
22	2	O
23	-	O
24	globuline	O
25	,	O
26	prostaglandin	O
27	E2	O
28	).	O

1	Petrous	O
2	meningioma	O
3	en	O
4	plaque	O
5	presenting	O
6	as	O
7	a	O
8	right	O
9	middle	O
10	ear	O
11	tumor	O
12	.	O

1	Notice	O
2	of	O
3	retraction	O
4	.	O

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	O
15	SNFs	O
16	.	O

1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	I
24	3	I
25	beta	I
26	protein	I
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	sequence	O
7	of	O
8	the	O
9	p54	B
10	gene	I
11	carried	O
12	by	O
13	two	O
14	virulent	O
15	ASFV	O
16	strains	O
17	(	O
18	E70	O
19	and	O
20	E75	O
21	)	O
22	with	O
23	that	O
24	obtained	O
25	from	O
26	virus	O
27	Ba71V	O
28	showed	O
29	100	O
30	%	O
31	similarity	O
32	.	O

1	Dual	O
2	radionuclide	O
3	subtraction	O
4	imaging	O
5	of	O
6	the	O
7	spleen	O
8	using	O
9	67Ga	O
10	citrate	O
11	and	O
12	99mTc	O
13	is	O
14	useful	O
15	in	O
16	further	O
17	delineating	O
18	lesions	O
19	that	O
20	are	O
21	identified	O
22	on	O
23	either	O
24	a	O
25	routine	O
26	radiogallium	O
27	survey	O
28	or	O
29	on	O
30	a	O
31	conventional	O
32	sulfur	O
33	colloid	O
34	liver	O
35	-	O
36	spleen	O
37	image	O
38	.	O

1	Oxfendazole	O
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	Because	O
2	of	O
3	serious	O
4	infections	O
5	(	O
6	fever	O
7	larger	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	101	O
13	degrees	O
14	F	O
15	.	O
16	granulocytes	O
17	less	O
18	than	O
19	1	O
20	,	O
21	000	O
22	/	O
23	mm	O
24	,	O
25	3	O
26	and	O
27	hospitalization	O
28	)	O
29	and	O
30	1	O
31	drug	O
32	death	O
33	in	O
34	the	O
35	first	O
36	4	O
37	patients	O
38	,	O
39	oral	O
40	calcium	O
41	leucovorin	O
42	,	O
43	20	O
44	to	O
45	30	O
46	mg	O
47	/	O
48	m2	O
49	orally	O
50	,	O
51	was	O
52	given	O
53	2	O
54	days	O
55	after	O
56	methotrexate	O
57	in	O
58	subsequent	O
59	treatment	O
60	cycles	O
61	.	O

1	Inactivation	O
2	of	O
3	p53	B
4	but	O
5	not	O
6	p73	O
7	by	O
8	adenovirus	O
9	type	O
10	5	O
11	E1B	O
12	55	O
13	-	O
14	kilodalton	O
15	and	O
16	E4	B
17	34	I
18	-	I
19	kilodalton	I
20	oncoproteins	I
21	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	selective	O
6	expression	O
7	of	O
8	the	O
9	receptor	O
10	,	O
11	FL	B
12	expression	O
13	was	O
14	detected	O
15	in	O
16	90	O
17	-	O
18	100	O
19	%	O
20	of	O
21	the	O
22	various	O
23	cell	O
24	types	O
25	of	O
26	leukemia	O
27	cell	O
28	lines	O
29	from	O
30	all	O
31	hematopoietic	O
32	cell	O
33	lineages	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	B
14	cyclooxygenase	I
15	product	I
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	O
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O

1	The	O
2	use	O
3	of	O
4	the	O
5	PLCgamma	B
6	inhibitory	I
7	peptide	I
8	,	O
9	neomycin	O
10	and	O
11	the	O
12	calcium	O
13	chelator	O
14	BAPTA	O
15	-	O
16	AM	O
17	on	O
18	oocytes	O
19	expressing	O
20	FGFR1	O
21	or	O
22	the	O
23	stimulation	O
24	by	O
25	PDGF	B
26	-	I
27	BB	I
28	of	O
29	oocytes	O
30	expressing	O
31	PDGFR	B
32	-	I
33	FGFR1	I
34	mutated	O
35	on	O
36	the	O
37	PLCgamma	B
38	binding	I
39	site	I
40	,	O
41	prevented	O
42	GVBD	O
43	and	O
44	ERK2	B
45	phosphorylation	O
46	.	O

1	The	O
2	DNA	O
3	binding	O
4	and	O
5	multimerization	O
6	activities	O
7	of	O
8	c	B
9	-	I
10	Myb	I
11	appear	O
12	to	O
13	be	O
14	unaffected	O
15	by	O
16	the	O
17	S528A	O
18	substitution	O
19	,	O
20	suggesting	O
21	that	O
22	phosphorylation	O
23	of	O
24	serine	O
25	528	O
26	may	O
27	mediate	O
28	its	O
29	effect	O
30	on	O
31	the	O
32	transcription	O
33	transactivating	O
34	activity	O
35	of	O
36	c	B
37	-	I
38	Myb	I
39	by	O
40	regulating	O
41	interactions	O
42	with	O
43	other	O
44	proteins	O
45	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	molecular	O
6	lesions	O
7	of	O
8	nine	O
9	Scm	B
10	mutant	I
11	alleles	I
12	,	O
13	which	O
14	identify	O
15	functional	O
16	requirements	O
17	for	O
18	specific	O
19	domains	O
20	.	O

1	An	O
2	experiment	O
3	was	O
4	carried	O
5	on	O
6	133	O
7	grown	O
8	up	O
9	fowls	O
10	and	O
11	broilers	O
12	from	O
13	4	O
14	industrial	O
15	farms	O
16	,	O
17	vaccinated	O
18	with	O
19	spray	O
20	lento	O
21	and	O
22	mesogenic	O
23	vaccines	O
24	for	O
25	straining	O
26	the	O
27	immunity	O
28	against	O
29	pseodopest	O
30	through	O
31	RIHA	O
32	and	O
33	provoking	O
34	pseudoplague	O
35	with	O
36	a	O
37	pathogenic	O
38	virus	O
39	.	O

1	METHODS	O
2	:	O
3	A	O
4	total	O
5	of	O
6	15	O
7	pigs	O
8	were	O
9	randomised	O
10	to	O
11	ligation	O
12	of	O
13	left	O
14	marginal	O
15	arteries	O
16	(	O
17	infarction	O
18	group	O
19	,	O
20	n	O
21	=	O
22	5	O
23	),	O
24	to	O
25	TMLR	O
26	of	O
27	the	O
28	left	O
29	lateral	O
30	wall	O
31	using	O
32	a	O
33	holmium	O
34	:	O
35	yttrium	O
36	-	O
37	aluminium	O
38	garnet	O
39	(	O
40	Ho	O
41	:	O
42	YAG	O
43	)	O
44	laser	O
45	(	O
46	laser	O
47	group	O
48	,	O
49	n	O
50	=	O
51	5	O
52	),	O
53	and	O
54	to	O
55	both	O
56	(	O
57	laser	O
58	-	O
59	infarction	O
60	group	O
61	,	O
62	n	O
63	=	O
64	5	O
65	).	O

1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	nylon	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	suture	O
24	lysis	O
25	following	O
26	a	O
27	single	O
28	shot	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	Dacron	O
35	or	O
36	10	O
37	/	O
38	0	O
39	prolene	O
40	.	O

1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O

1	Topics	O
2	reviewed	O
3	here	O
4	include	O
5	:	O
6	data	O
7	supporting	O
8	the	O
9	association	O
10	of	O
11	myositis	O
12	with	O
13	cancer	O
14	and	O
15	the	O
16	appropriate	O
17	evaluations	O
18	for	O
19	malignancy	O
20	in	O
21	a	O
22	myositis	O
23	patient	O
24	;	O
25	an	O
26	approach	O
27	to	O
28	the	O
29	assessment	O
30	of	O
31	patients	O
32	with	O
33	dermatomyositis	O
34	sine	O
35	myositis	O
36	;	O
37	the	O
38	usefulness	O
39	of	O
40	the	O
41	clinicopathological	O
42	and	O
43	serological	O
44	classifications	O
45	;	O
46	a	O
47	discussion	O
48	of	O
49	whether	O
50	childhood	O
51	and	O
52	adult	O
53	myositis	O
54	are	O
55	the	O
56	same	O
57	or	O
58	different	O
59	entities	O
60	;	O
61	a	O
62	review	O
63	of	O
64	those	O
65	prognostic	O
66	factors	O
67	to	O
68	consider	O
69	in	O
70	the	O
71	clinical	O
72	management	O
73	of	O
74	myositis	O
75	patients	O
76	;	O
77	current	O
78	approaches	O
79	and	O
80	their	O
81	limitations	O
82	for	O
83	assessing	O
84	disease	O
85	activity	O
86	and	O
87	damage	O
88	.	O

1	Spontaneous	O
2	recovery	O
3	occurs	O
4	within	O
5	30	O
6	min	O
7	to	O
8	2	O
9	hrs	O
10	.	O

1	Cerebral	O
2	vasculitis	O
3	secondary	O
4	to	O
5	Crohn	O
6	'	O
7	s	O
8	disease	O
9	seems	O
10	to	O
11	be	O
12	a	O
13	very	O
14	rare	O
15	phenomenon	O
16	.	O

1	Specifically	O
2	,	O
3	they	O
4	were	O
5	performed	O
6	to	O
7	determine	O
8	whether	O
9	detection	O
10	of	O
11	envelope	O
12	phase	O
13	disparity	O
14	was	O
15	consistent	O
16	with	O
17	processing	O
18	within	O
19	a	O
20	single	O
21	channel	O
22	in	O
23	which	O
24	the	O
25	AM	O
26	tones	O
27	were	O
28	simply	O
29	added	O
30	.	O

1	Homodimers	O
2	of	O
3	the	O
4	three	O
5	proteins	O
6	specifically	O
7	recognize	O
8	the	O
9	G	O
10	-	O
11	box	O
12	motif	O
13	,	O
14	with	O
15	GBF1	B
16	and	O
17	GBF3	B
18	binding	O
19	symmetrically	O
20	to	O
21	this	O
22	palindromic	O
23	sequence	O
24	.	O

1	Probable	O
2	progressive	O
3	multifocal	O
4	leukoencephalopathy	O
5	(	O
6	PML	B
7	)	O
8	was	O
9	diagnosed	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	clinical	O
15	picture	O
16	and	O
17	magnetic	O
18	resonance	O
19	imaging	O
20	in	O
21	a	O
22	63	O
23	-	O
24	year	O
25	-	O
26	old	O
27	man	O
28	with	O
29	a	O
30	complete	O
31	remission	O
32	of	O
33	a	O
34	non	O
35	-	O
36	Hodgkin	O
37	'	O
38	s	O
39	lymphoma	O
40	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	CRE	O
6	of	O
7	the	O
8	human	B
9	c	I
10	-	I
11	fos	I
12	promoter	I
13	located	O
14	at	O
15	-	O
16	60	O
17	was	O
18	weakly	O
19	induced	O
20	by	O
21	cAMP	O
22	and	O
23	E1a	B
24	in	O
25	both	O
26	HeLa	O
27	and	O
28	PC12	O
29	cells	O
30	.	O

1	The	O
2	dominant	O
3	negative	O
4	mutant	O
5	of	O
6	SHP	B
7	-	I
8	2	I
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	the	O
14	induction	O
15	of	O
16	tyrosine	O
17	phosphorylation	O
18	and	O
19	DNA	O
20	-	O
21	binding	O
22	activity	O
23	of	O
24	m	O
25	-	O
26	Stat5a	B
27	,	O
28	m	O
29	-	O
30	Stat5b	B
31	,	O
32	and	O
33	the	O
34	carboxyl	O
35	-	O
36	terminal	O
37	deletion	O
38	variant	O
39	m	O
40	-	O
41	Stat5adelta749	O
42	,	O
43	as	O
44	well	O
45	as	O
46	the	O
47	transactivation	O
48	potential	O
49	of	O
50	m	O
51	-	O
52	Stat5a	B
53	and	O
54	m	O
55	-	O
56	Stat5b	O
57	.	O

1	Some	O
2	studies	O
3	of	O
4	exercise	O
5	have	O
6	associated	O
7	beta	B
8	-	I
9	endorphin	I
10	release	O
11	with	O
12	increased	O
13	exertion	O
14	levels	O
15	,	O
16	but	O
17	other	O
18	evidence	O
19	suggests	O
20	that	O
21	acidosis	O
22	may	O
23	stimulate	O
24	the	O
25	release	O
26	of	O
27	beta	B
28	-	I
29	endorphin	I
30	.	O

1	Therefore	O
2	,	O
3	we	O
4	studied	O
5	ninety	O
6	coagulopathic	O
7	patients	O
8	with	O
9	the	O
10	aim	O
11	of	O
12	determining	O
13	the	O
14	prevalence	O
15	of	O
16	hepatitis	O
17	C	O
18	virus	O
19	(	O
20	HCV	O
21	)	O
22	antibodies	O
23	using	O
24	the	O
25	ELISA	O
26	and	O
27	RIBA	O
28	methods	O
29	.	O

1	A	O
2	low	O
3	aspirin	B
4	esterase	I
5	activity	O
6	may	O
7	be	O
8	a	O
9	contributory	O
10	factor	O
11	in	O
12	precipitating	O
13	these	O
14	aspirin	O
15	sensitive	O
16	reactions	O
17	.	O

1	We	O
2	have	O
3	identified	O
4	a	O
5	strong	O
6	Tas	O
7	-	O
8	responsive	O
9	element	O
10	,	O
11	designated	O
12	TRE	O
13	(	O
14	GP	O
15	),	O
16	near	O
17	the	O
18	3	O
19	'	O
20	end	O
21	of	O
22	the	O
23	gag	B
24	gene	O
25	and	O
26	preceding	O
27	the	O
28	pol	B
29	gene	I
30	of	I
31	SFV	I
32	-	I
33	1	I
34	.	O

1	A	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	of	O
7	amphotericin	O
8	B	O
9	(	O
10	5	O
11	mg	O
12	/	O
13	kg	O
14	/	O
15	day	O
16	i	O
17	.	O
18	p	O
19	.)	O
20	significantly	O
21	reduced	O
22	the	O
23	glomerular	O
24	filtration	O
25	rate	O
26	(	O
27	GFR	O
28	)	O
29	measured	O
30	as	O
31	inuline	O
32	clearance	O
33	and	O
34	creatinine	O
35	clearance	O
36	(	O
37	0	O
38	.	O
39	74	O
40	+/-	O
41	0	O
42	.	O
43	29	O
44	and	O
45	0	O
46	.	O
47	16	O
48	+/-	O
49	0	O
50	.	O
51	04	O
52	ml	O
53	/	O
54	min	O
55	,	O
56	respectively	O
57	)	O
58	in	O
59	comparison	O
60	to	O
61	vehicle	O
62	-	O
63	treated	O
64	rats	O
65	(	O
66	2	O
67	.	O
68	04	O
69	+/-	O
70	0	O
71	.	O
72	23	O
73	and	O
74	1	O
75	.	O
76	29	O
77	+/-	O
78	0	O
79	.	O
80	19	O
81	ml	O
82	/	O
83	min	O
84	,	O
85	respectively	O
86	).	O

1	The	O
2	FCMS	O
3	conditions	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	2	O
9	kW	O
10	maximum	O
11	electrical	O
12	power	O
13	consumption	O
14	,	O
15	800	O
16	V	O
17	maximum	O
18	capacitor	O
19	voltage	O
20	,	O
21	720	O
22	microseconds	O
23	pulsewidth	O
24	(	O
25	180	O
26	microseconds	O
27	rise	O
28	time	O
29	),	O
30	and	O
31	5	O
32	-	O
33	30	O
34	Hz	O
35	frequency	O
36	.	O

1	Standard	O
2	reference	O
3	sources	O
4	indicate	O
5	that	O
6	an	O
7	able	O
8	-	O
9	bodied	O
10	11	O
11	-	O
12	year	O
13	-	O
14	old	O
15	child	O
16	of	O
17	comparable	O
18	height	O
19	requires	O
20	1	O
21	,	O
22	493	O
23	kcal	O
24	/	O
25	d	O
26	for	O
27	support	O
28	of	O
29	basal	O
30	metabolic	O
31	functions	O
32	.	O

1	Heterozygous	O
2	mutation	O
3	in	O
4	the	O
5	G	O
6	+	O
7	5	O
8	position	O
9	of	O
10	intron	O
11	33	O
12	of	O
13	the	O
14	pro	B
15	-	I
16	alpha	I
17	2	I
18	(	I
19	I	I
20	)	I
21	gene	I
22	(	O
23	COL1A2	O
24	)	O
25	that	O
26	causes	O
27	aberrant	O
28	RNA	O
29	splicing	O
30	and	O
31	lethal	O
32	osteogenesis	O
33	imperfecta	O
34	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	I
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	I
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	B
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	found	O
6	between	O
7	the	O
8	TS	O
9	and	O
10	the	O
11	PTS	O
12	.	O

1	A	O
2	single	O
3	protease	O
4	-	O
5	resistant	O
6	structure	O
7	formed	O
8	by	O
9	the	O
10	entirety	O
11	of	O
12	both	O
13	PDZ	B
14	repeats	I
15	1	I
16	and	O
17	2	O
18	(	O
19	PDZ1	B
20	-	I
21	2	I
22	)	O
23	contains	O
24	the	O
25	protein	B
26	4	I
27	.	I
28	1	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	3874	O
6	bp	O
7	of	O
8	cloned	O
9	R	O
10	.	O
11	sphaeroides	O
12	chromosomal	O
13	DNA	O
14	,	O
15	including	O
16	the	O
17	three	O
18	structural	O
19	genes	O
20	fbcF	B
21	,	O
22	fbcB	B
23	and	O
24	fbcC	B
25	has	O
26	been	O
27	determined	O
28	.	O

1	These	O
2	residues	O
3	,	O
4	Ile244	O
5	at	O
6	the	O
7	extracellular	O
8	end	O
9	of	O
10	transmembrane	B
11	helix	I
12	3	I
13	,	O
14	and	O
15	Tyr318	O
16	at	O
17	the	O
18	COOH	O
19	-	O
20	terminal	O
21	portion	O
22	of	O
23	extracellular	O
24	loop	O
25	2	O
26	,	O
27	are	O
28	replaced	O
29	by	O
30	Leu	O
31	and	O
32	Ile	O
33	in	O
34	the	O
35	PTH	B
36	-	I
37	1	I
38	receptor	I
39	,	O
40	respectively	O
41	.	O

1	Studies	O
2	using	O
3	HLA	B
4	-	I
5	DR	I
6	-	I
7	B7	I
8	-	I
9	1	I
10	-	I
11	LFA	I
12	-	I
13	3	I
14	triple	O
15	transfectants	O
16	showed	O
17	that	O
18	the	O
19	LFA	O
20	-	O
21	3	O
22	-	O
23	induced	O
24	NF	O
25	-	O
26	AT	O
27	DNA	O
28	binding	O
29	activity	O
30	was	O
31	negatively	O
32	regulated	O
33	by	O
34	B7	B
35	-	I
36	1	I
37	costimulation	O
38	.	O

1	The	O
2	repetitive	O
3	ETn	O
4	(	O
5	early	O
6	transposon	O
7	)	O
8	family	O
9	of	O
10	sequences	O
11	represents	O
12	an	O
13	active	O
14	"	O
15	mobile	O
16	mutagen	O
17	"	O
18	in	O
19	the	O
20	mouse	O
21	genome	O
22	.	O

1	Intracellular	O
2	pH	O
3	,	O
4	H	O
5	ion	O
6	flux	O
7	and	O
8	H	O
9	ion	O
10	permeability	O
11	coefficient	O
12	in	O
13	bullfrog	O
14	toe	O
15	muscle	O
16	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	relative	O
6	strengths	O
7	of	O
8	the	O
9	promoters	O
10	were	O
11	similar	O
12	in	O
13	different	O
14	contexts	O
15	.	O

1	Purification	O
2	of	O
3	MvaT	O
4	enriched	O
5	for	O
6	two	O
7	polypeptides	O
8	of	O
9	approximate	O
10	molecular	O
11	mass	O
12	15	O
13	kDa	O
14	and	O
15	16	O
16	kDa	O
17	,	O
18	designated	O
19	P15	B
20	and	O
21	P16	B
22	.	O

1	BSE	O
2	and	O
3	farmworkers	O
4	.	O

1	Using	O
2	an	O
3	opsonophagocytic	O
4	bacterial	O
5	assay	O
6	and	O
7	a	O
8	suckling	O
9	rat	O
10	model	O
11	of	O
12	GBS	O
13	sepsis	O
14	,	O
15	we	O
16	analyzed	O
17	a	O
18	modified	O
19	human	B
20	immunoglobulin	I
21	for	O
22	opsonic	O
23	and	O
24	protective	O
25	antibody	O
26	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	upstream	O
6	of	O
7	this	O
8	initiation	O
9	codon	O
10	reveals	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	promotor	O
16	sequence	O
17	.	O

1	Yeast	O
2	Gal11	B
3	protein	I
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	B
16	and	O
17	general	B
18	regulatory	I
19	factor	I
20	I	I
21	/	I
22	repressor	I
23	/	I
24	activator	I
25	site	I
26	binding	I
27	protein	I
28	1	I
29	/	I
30	translation	I
31	upstream	I
32	factor	I
33	.	O

1	An	O
2	apparent	O
3	ufo	O
4	mRNA	O
5	overexpression	O
6	was	O
7	not	O
8	found	O
9	in	O
10	any	O
11	of	O
12	the	O
13	positive	O
14	leukemia	O
15	cell	O
16	lines	O
17	,	O
18	but	O
19	was	O
20	identified	O
21	in	O
22	the	O
23	drug	O
24	-	O
25	resistant	O
26	subclones	O
27	of	O
28	the	O
29	cervix	O
30	carcinoma	O
31	cell	O
32	line	O
33	HeLa	O
34	.	O

1	The	O
2	authors	O
3	found	O
4	that	O
5	except	O
6	for	O
7	fear	O
8	and	O
9	pugnacity	O
10	all	O
11	husband	O
12	-	O
13	wife	O
14	trait	O
15	correlations	O
16	were	O
17	positive	O
18	,	O
19	in	O
20	contrast	O
21	to	O
22	Winch	O
23	'	O
24	s	O
25	principle	O
26	of	O
27	type	O
28	I	O
29	complementarity	O
30	.	O

1	The	O
2	LMW	B
3	FGF	I
4	-	I
5	2	I
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	I
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	O
24	isoform	O
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	I
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	MBF	O
6	on	O
7	incisors	O
8	and	O
9	its	O
10	direction	O
11	in	O
12	three	O
13	dimensions	O
14	for	O
15	different	O
16	jaw	O
17	openings	O
18	in	O
19	ten	O
20	subjects	O
21	.	O

1	The	O
2	corticosterone	O
3	synthesis	O
4	inhibitor	O
5	metyrapone	O
6	(	O
7	75	O
8	mg	O
9	/	O
10	kg	O
11	i	O
12	.	O
13	p	O
14	.)	O
15	was	O
16	given	O
17	to	O
18	attenuate	O
19	the	O
20	rise	O
21	of	O
22	corticosterone	O
23	to	O
24	a	O
25	level	O
26	typical	O
27	of	O
28	stressed	O
29	males	O
30	.	O

1	No	O
2	drop	O
3	in	O
4	oxygen	O
5	saturation	O
6	(	O
7	SaO2	O
8	)	O
9	or	O
10	visual	O
11	evidence	O
12	of	O
13	transient	O
14	electroencephalographic	O
15	(	O
16	EEG	O
17	)	O
18	arousals	O
19	can	O
20	be	O
21	found	O
22	at	O
23	repeat	O
24	polysomnography	O
25	.	O

1	The	O
2	domains	O
3	involved	O
4	in	O
5	superactivation	O
6	appear	O
7	to	O
8	be	O
9	a	O
10	subset	O
11	of	O
12	those	O
13	necessary	O
14	to	O
15	achieve	O
16	synergistic	O
17	activation	O
18	.	O

1	Transitory	O
2	subclinical	O
3	and	O
4	permanent	O
5	hypothyroidism	O
6	in	O
7	the	O
8	course	O
9	of	O
10	subacute	O
11	thyroiditis	O
12	(	O
13	de	O
14	Quervain	O
15	).	O

1	Sestamibi	O
2	scintigraphy	O
3	,	O
4	performed	O
5	in	O
6	70	O
7	patients	O
8	,	O
9	was	O
10	less	O
11	sensitive	O
12	than	O
13	ultrasonography	O
14	(	O
15	80	O
16	%).	O

1	Differential	O
2	drawing	O
3	size	O
4	associated	O
5	with	O
6	unilateral	O
7	brain	O
8	damage	O
9	.	O

1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O

1	To	O
2	assess	O
3	the	O
4	functional	O
5	importance	O
6	of	O
7	these	O
8	NBS	O
9	in	O
10	the	O
11	overall	O
12	drug	O
13	resistance	O
14	phenotype	O
15	conferred	O
16	by	O
17	mdr1	B
18	,	O
19	we	O
20	introduced	O
21	amino	O
22	acid	O
23	substitutions	O
24	in	O
25	the	O
26	core	O
27	consensus	O
28	sequence	O
29	for	O
30	nucleotide	O
31	binding	O
32	,	O
33	GXGKST	O
34	.	O

1	The	O
2	csbA	B
3	fusion	O
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	isolated	O
9	and	O
10	sequenced	O
11	several	O
12	p15E	B
13	cDNA	I
14	gene	I
15	fragments	I
16	amplified	O
17	by	O
18	means	O
19	of	O
20	polymerase	O
21	chain	O
22	reaction	O
23	(	O
24	PCR	O
25	)	O
26	from	O
27	parental	O
28	(	O
29	P815	O
30	)	O
31	and	O
32	xenogenized	O
33	(	O
34	P815	O
35	/	O
36	DTIC	B
37	)	O
38	tumour	O
39	cells	O
40	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Dupuytren	O
5	'	O
6	s	O
7	contracture	O

1	Aneurysmectomy	O
2	and	O
3	the	O
4	performance	O
5	of	O
6	CABG	O
7	were	O
8	not	O
9	significantly	O
10	associated	O
11	with	O
12	postoperative	O
13	ECG	O
14	changes	O
15	,	O
16	but	O
17	more	O
18	bypass	O
19	grafts	O
20	per	O
21	patient	O
22	grafted	O
23	appeared	O
24	in	O
25	the	O
26	group	O
27	with	O
28	postoperative	O
29	ECG	O
30	changes	O
31	,	O
32	suggesting	O
33	that	O
34	coronary	O
35	artery	O
36	disease	O
37	may	O
38	be	O
39	more	O
40	severe	O
41	in	O
42	that	O
43	group	O
44	.	O

1	POU	B
2	-	I
3	domain	I
4	proteins	I
5	,	O
6	such	O
7	as	O
8	the	O
9	pituitary	B
10	-	I
11	specific	I
12	factor	I
13	Pit	I
14	-	I
15	1	I
16	,	O
17	are	O
18	members	O
19	of	O
20	the	O
21	homeodomain	B
22	family	I
23	of	O
24	proteins	O
25	which	O
26	are	O
27	important	O
28	in	O
29	development	O
30	and	O
31	homeostasis	O
32	,	O
33	acting	O
34	constitutively	O
35	or	O
36	in	O
37	response	O
38	to	O
39	signal	O
40	-	O
41	transduction	O
42	pathways	O
43	to	O
44	either	O
45	repress	O
46	or	O
47	activate	O
48	the	O
49	expression	O
50	of	O
51	specific	O
52	genes	O
53	.	O

1	Vac1p	O
2	was	O
3	found	O
4	to	O
5	bind	O
6	the	O
7	Sec1p	B
8	homologue	I
9	Vps45p	I
10	.	O

1	A	O
2	fine	O
3	-	O
4	structure	O
5	deletion	O
6	map	O
7	of	O
8	human	O
9	chromosome	O
10	11p	O
11	:	O
12	analysis	O
13	of	O
14	J1	O
15	series	O
16	hybrids	O
17	.	O

1	Exposure	O
2	of	O
3	endothelium	O
4	to	O
5	pulsatile	O
6	shear	O
7	stresses	O
8	that	O
9	followed	O
10	a	O
11	tape	O
12	recording	O
13	of	O
14	physiological	O
15	flow	O
16	waveforms	O
17	(	O
18	electromagnetic	O
19	flowmeter	O
20	)	O
21	did	O
22	not	O
23	cause	O
24	gross	O
25	injury	O
26	or	O
27	denudation	O
28	even	O
29	when	O
30	peak	O
31	shear	O
32	exceeded	O
33	1500	O
34	dyne	O
35	/	O
36	cm2	O
37	.	O

1	Transcriptional	O
2	regulators	O
3	utilizing	O
4	the	O
5	POU	B
6	domain	O
7	DNA	O
8	-	O
9	binding	O
10	motif	O
11	have	O
12	been	O
13	shown	O
14	to	O
15	form	O
16	multi	O
17	-	O
18	protein	O
19	complexes	O
20	dependent	O
21	on	O
22	the	O
23	POU	B
24	domain	I
25	itself	O
26	and	O
27	its	O
28	flexible	O
29	recognition	O
30	of	O
31	various	O
32	octamer	O
33	sequence	O
34	elements	O
35	.	O

1	Role	O
2	of	O
3	c	B
4	-	I
5	myc	I
6	in	I
7	simian	I
8	virus	I
9	40	I
10	large	I
11	tumor	I
12	antigen	I
13	-	O
14	induced	O
15	DNA	O
16	synthesis	O
17	in	O
18	quiescent	O
19	3T3	O
20	-	O
21	L1	O
22	mouse	O
23	fibroblasts	O
24	.	O

1	ENV	B
2	also	O
3	was	O
4	secreted	O
5	from	O
6	P	O
7	.	O
8	pastoris	O
9	using	O
10	the	O
11	S	B
12	.	I
13	cerevisiae	I
14	alpha	I
15	-	I
16	factor	I
17	prepro	I
18	secretion	O
19	leader	O
20	and	O
21	the	O
22	S	B
23	.	I
24	cerevisiae	I
25	invertase	I
26	signal	O
27	sequence	O
28	.	O

1	In	O
2	the	O
3	tissues	O
4	tested	O
5	,	O
6	except	O
7	brain	O
8	,	O
9	the	O
10	message	O
11	for	O
12	CLIP	O
13	-	O
14	170	O
15	was	O
16	more	O
17	abundant	O
18	than	O
19	that	O
20	for	O
21	Restin	B
22	.	O

1	The	O
2	data	O
3	provide	O
4	evidence	O
5	both	O
6	for	O
7	a	O
8	signal	O
9	transduction	O
10	pathway	O
11	independent	O
12	of	O
13	JNK	B
14	,	O
15	ERK	B
16	,	O
17	and	O
18	p38	B
19	MAP	I
20	kinase	I
21	to	O
22	be	O
23	involved	O
24	in	O
25	the	O
26	induction	O
27	of	O
28	rhoB	B
29	by	O
30	genotoxic	O
31	stress	O
32	,	O
33	and	O
34	furthermore	O
35	,	O
36	indicate	O
37	autoregulation	O
38	of	O
39	rhoB	B
40	.	O

1	Nuclear	B
2	beta	I
3	II	I
4	PKC	I
5	,	O
6	like	O
7	p34cdc2	B
8	kinase	I
9	,	O
10	may	O
11	function	O
12	to	O
13	regulate	O
14	nuclear	O
15	lamina	O
16	structural	O
17	stability	O
18	during	O
19	cell	O
20	cycle	O
21	.	O

1	This	O
2	complex	O
3	interacts	O
4	at	O
5	the	O
6	GTPase	B
7	domain	O
8	in	O
9	the	O
10	large	O
11	subunit	O
12	rRNA	O
13	,	O
14	overlapping	O
15	the	O
16	binding	O
17	site	O
18	of	O
19	the	O
20	protein	O
21	L11	O
22	-	O
23	like	O
24	eukaryotic	O
25	counterpart	O
26	(	O
27	Saccharomyces	B
28	cerevisiae	I
29	protein	I
30	L15	I
31	and	O
32	mammalian	B
33	protein	I
34	L12	I
35	).	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	various	O
6	repeats	O
7	suggests	O
8	its	O
9	organization	O
10	is	O
11	similar	O
12	to	O
13	the	O
14	beta	O
15	-	O
16	heterochromatic	O
17	regions	O
18	near	O
19	the	O
20	base	O
21	of	O
22	the	O
23	major	O
24	chromosome	O
25	arms	O
26	.	O

1	HANYS	O
2	criticizes	O
3	laparoscopic	O
4	gall	O
5	bladder	O
6	guidelines	O
7	.	O

1	Signaling	O
2	from	O
3	the	O
4	small	B
5	GTP	I
6	-	I
7	binding	I
8	proteins	I
9	Rac1	I
10	and	O
11	Cdc42	B
12	to	O
13	the	O
14	c	B
15	-	I
16	Jun	I
17	N	I
18	-	I
19	terminal	I
20	kinase	I
21	/	O
22	stress	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	pathway	O
28	.	O

1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	I
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O

1	To	O
2	our	O
3	knowledge	O
4	,	O
5	type	O
6	IV	O
7	renal	O
8	tubular	O
9	acidosis	O
10	has	O
11	not	O
12	been	O
13	reported	O
14	previously	O
15	in	O
16	association	O
17	with	O
18	Alport	O
19	'	O
20	s	O
21	syndrome	O
22	in	O
23	an	O
24	adult	O
25	patient	O
26	.	O

1	The	O
2	RAD18	B
3	gene	I
4	open	I
5	reading	I
6	frame	I
7	encodes	O
8	a	O
9	protein	O
10	of	O
11	487	O
12	amino	O
13	acids	O
14	,	O
15	with	O
16	a	O
17	calculated	O
18	molecular	O
19	weight	O
20	of	O
21	55	O
22	,	O
23	512	O
24	.	O

1	Multiple	O
2	chemical	O
3	sensitivity	O
4	(	O
5	MCS	O
6	)	O
7	is	O
8	a	O
9	syndrome	O
10	in	O
11	which	O
12	multiple	O
13	symptoms	O
14	reportedly	O
15	occur	O
16	with	O
17	low	O
18	-	O
19	level	O
20	chemical	O
21	exposure	O
22	.	O

1	From	O
2	the	O
3	15	O
4	-	O
5	kb	O
6	clone	O
7	a	O
8	4	O
9	-	O
10	kb	O
11	EcoRI	B
12	fragment	I
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	O
32	gene	O
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	The	O
2	possible	O
3	roles	O
4	of	O
5	HRMT1L1	B
6	and	O
7	HRMT1L2	B
8	in	O
9	human	O
10	disease	O
11	are	O
12	currently	O
13	unknown	O
14	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	SRFDelta5	B
2	acts	O
3	as	O
4	a	O
5	naturally	O
6	occurring	O
7	dominant	O
8	negative	O
9	regulatory	O
10	mutant	O
11	that	O
12	blocks	O
13	SRF	B
14	-	I
15	dependent	I
16	skeletal	I
17	alpha	I
18	-	I
19	actin	I
20	,	O
21	cardiac	B
22	alpha	I
23	-	I
24	actin	I
25	,	O
26	smooth	B
27	alpha	I
28	-	I
29	actin	I
30	,	O
31	SM22alpha	B
32	,	O
33	and	O
34	SRF	B
35	promoter	I
36	-	O
37	luciferase	B
38	reporter	I
39	activities	O
40	.	O

1	If	O
2	this	O
3	is	O
4	present	O
5	,	O
6	such	O
7	patients	O
8	should	O
9	be	O
10	closely	O
11	monitored	O
12	,	O
13	and	O
14	any	O
15	atypical	O
16	lesions	O
17	biopsied	O
18	.	O

1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O

1	Western	O
2	analyses	O
3	with	O
4	antisera	O
5	raised	O
6	against	O
7	Lu	B
8	-	I
9	ECAM	I
10	-	I
11	1	I
12	peptides	I
13	show	O
14	that	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	predicted	O
23	open	O
24	reading	O
25	frame	O
26	is	O
27	present	O
28	only	O
29	in	O
30	the	O
31	larger	O
32	size	O
33	proteins	O
34	(	O
35	i	O
36	.	O
37	e	O
38	.	O

1	ID	B
2	-	I
3	PaGIA	I
4	diphtheria	I
5	toxin	I
6	polymer	I
7	particle	O
8	diagnostic	O
9	agent	O
10	manufactured	O
11	by	O
12	DiaMed	B
13	AG	I
14	,	O
15	Switzerland	O
16	,	O
17	was	O
18	tried	O
19	at	O
20	bacteriological	O
21	laboratory	O
22	of	O
23	Institute	O
24	of	O
25	Childhood	O
26	Infections	O
27	in	O
28	St	O
29	.	O

1	However	O
2	,	O
3	as	O
4	determined	O
5	by	O
6	PCR	O
7	with	O
8	primers	O
9	specific	O
10	for	O
11	the	O
12	26	O
13	-	O
14	kDa	O
15	product	O
16	,	O
17	the	O
18	majority	O
19	of	O
20	cats	O
21	at	O
22	2	O
23	and	O
24	4	O
25	weeks	O
26	p	O
27	.	O
28	t	O
29	.	O
30	had	O
31	gastric	O
32	fluid	O
33	samples	O
34	which	O
35	were	O
36	positive	O
37	for	O
38	H	O
39	.	O
40	pylori	O
41	and	O
42	three	O
43	of	O
44	three	O
45	cats	O
46	at	O
47	2	O
48	weeks	O
49	p	O
50	.	O
51	t	O
52	.	O
53	had	O
54	dental	O
55	plaque	O
56	which	O
57	was	O
58	positive	O
59	for	O
60	H	O
61	.	O
62	pylori	O
63	.	O

1	Strain	O
2	CFN037	O
3	is	O
4	an	O
5	R	O
6	.	O
7	etli	O
8	mutant	O
9	induced	O
10	by	O
11	a	O
12	single	O
13	Tn5mob	O
14	insertion	O
15	in	O
16	the	O
17	promoter	O
18	region	O
19	of	O
20	the	O
21	thiCOGE	B
22	gene	I
23	cluster	I
24	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	Engrailed	O
10	and	O
11	Pbx1	B
12	sites	I
13	indicated	O
14	that	O
15	other	O
16	unidentified	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	intronic	O
28	fragment	O
29	.	O

1	We	O
2	also	O
3	show	O
4	by	O
5	immunogold	O
6	electron	O
7	microscopy	O
8	immunocytochemistry	O
9	that	O
10	amphiphysin	B
11	I	I
12	is	O
13	localized	O
14	in	O
15	the	O
16	nerve	O
17	terminal	O
18	cytomatrix	O
19	and	O
20	is	O
21	partially	O
22	associated	O
23	with	O
24	endocytic	O
25	intermediates	O
26	.	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	B
15	-	I
16	specific	I
17	regulatory	I
18	factor	I
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	B
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	Initial	O
2	control	O
3	of	O
4	bleeding	O
5	is	O
6	similar	O
7	,	O
8	but	O
9	eradication	O
10	is	O
11	achieved	O
12	in	O
13	fewer	O
14	sessions	O
15	with	O
16	EVL	O
17	.	O

1	Furthermore	O
2	,	O
3	heparin	B
4	lyase	I
5	treatment	O
6	of	O
7	extracts	O
8	of	O
9	cells	O
10	expressing	O
11	recombinant	B
12	YD	I
13	-	I
14	repeat	I
15	protein	I
16	releases	O
17	this	O
18	protein	O
19	from	O
20	high	O
21	molecular	O
22	mass	O
23	aggregates	O
24	.	O

1	Ca2	B
2	+/	I
3	calmodulin	I
4	-	I
5	dependent	I
6	protein	I
7	kinase	I
8	II	I
9	(	O
10	CaMK	B
11	II	I
12	)	O
13	is	O
14	a	O
15	multifunctional	B
16	serine	I
17	/	I
18	threonine	I
19	protein	I
20	kinase	I
21	that	O
22	regulates	O
23	ion	O
24	channels	O
25	,	O
26	metabolic	O
27	enzymes	O
28	,	O
29	cytoskeletal	O
30	proteins	O
31	,	O
32	and	O
33	possibly	O
34	transcription	O
35	factors	O
36	.	O

1	Light	O
2	microscopical	O
3	and	O
4	routine	O
5	immunohistochemical	O
6	studies	O
7	of	O
8	a	O
9	cervical	O
10	neoplasm	O
11	in	O
12	a	O
13	32	O
14	year	O
15	old	O
16	woman	O
17	initially	O
18	suggested	O
19	a	O
20	histiocytic	O
21	lymphoma	O
22	,	O
23	but	O
24	histochemical	O
25	staining	O
26	for	O
27	chloroacetate	B
28	esterase	I
29	established	O
30	the	O
31	correct	O
32	diagnosis	O
33	.	O

1	Feline	O
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O

1	Several	O
2	authors	O
3	have	O
4	recently	O
5	reported	O
6	interference	O
7	in	O
8	theophylline	O
9	analysis	O
10	by	O
11	paraxanthine	O
12	(	O
13	1	O
14	,	O
15	7	O
16	-	O
17	dimethylxanthine	O
18	),	O
19	an	O
20	important	O
21	metabolite	O
22	of	O
23	caffeine	O
24	.	O

1	All	O
2	patients	O
3	received	O
4	VCR	O
5	1	O
6	.	O
7	0	O
8	mg	O
9	/	O
10	m2	O
11	weekly	O
12	for	O
13	6	O
14	weeks	O
15	with	O
16	dose	O
17	modification	O
18	for	O
19	neurotoxicity	O
20	.	O

1	Although	O
2	the	O
3	mechanism	O
4	of	O
5	action	O
6	of	O
7	ICRF	B
8	-	I
9	159	I
10	and	O
11	187	O
12	has	O
13	not	O
14	been	O
15	clearly	O
16	defined	O
17	,	O
18	it	O
19	is	O
20	evident	O
21	from	O
22	both	O
23	preclinical	O
24	and	O
25	early	O
26	clinical	O
27	studies	O
28	that	O
29	these	O
30	compounds	O
31	are	O
32	of	O
33	interest	O
34	.	O

1	HA	O
2	resulted	O
3	in	O
4	decreased	O
5	(	O
6	p	O
7	less	O
8	than	O
9	0	O
10	.	O
11	05	O
12	)	O
13	Tre	O
14	(	O
15	0	O
16	.	O
17	4	O
18	degrees	O
19	C	O
20	)	O
21	and	O
22	HR	O
23	(	O
24	17	O
25	b	O
26	X	O
27	min	O
28	-	O
29	1	O
30	),	O
31	and	O
32	increased	O
33	(	O
34	p	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	)	O
41	Msw	O
42	(	O
43	16	O
44	g	O
45	X	O
46	m	O
47	-	O
48	2	O
49	X	O
50	h	O
51	-	O
52	1	O
53	)	O
54	during	O
55	the	O
56	saline	O
57	experiments	O
58	.	O

1	Effect	O
2	of	O
3	aging	O
4	on	O
5	respiratory	O
6	skeletal	O
7	muscles	O
8	.	O

1	3	O
2	)	O
3	and	O
4	one	O
5	distal	O
6	(-	O
7	11	O
8	.	O
9	8	O
10	/-	O
11	10	O
12	.	O
13	9	O
14	),	O
15	presented	O
16	an	O
17	enhancer	O
18	activity	O
19	in	O
20	pituitary	O
21	cells	O
22	when	O
23	placed	O
24	upstream	O
25	of	O
26	the	O
27	SV40	B
28	promoter	I
29	.	O

1	Results	O
2	of	O
3	this	O
4	study	O
5	indicate	O
6	that	O
7	GLC	O
8	of	O
9	short	O
10	chain	O
11	fatty	O
12	acids	O
13	produced	O
14	on	O
15	agar	O
16	medium	O
17	by	O
18	anaerobes	O
19	,	O
20	combined	O
21	with	O
22	simple	O
23	tests	O
24	such	O
25	as	O
26	Gram	O
27	'	O
28	s	O
29	stain	O
30	and	O
31	colonial	O
32	morphology	O
33	,	O
34	may	O
35	allow	O
36	fir	O
37	direct	O
38	presumptive	O
39	genus	O
40	identification	O
41	from	O
42	an	O
43	initial	O
44	pure	O
45	agar	O
46	culture	O
47	.	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	B
19	chalcone	I
20	synthase	I
21	promoter	I
22	.	O

1	Disability	O
2	insurance	O
3	under	O
4	social	O
5	security	O
6	.	O

1	The	O
2	value	O
3	of	O
4	different	O
5	sources	O
6	of	O
7	nitrogen	O
8	in	O
9	diets	O
10	for	O
11	the	O
12	early	O
13	-	O
14	weaned	O
15	calf	O
16	.	O

1	Biol	O
2	.	O

1	Mutation	O
2	of	O
3	TTF	B
4	-	I
5	1	I
6	-	I
7	binding	I
8	sites	I
9	(	O
10	TBE	O
11	)	O
12	1	O
13	,	O
14	3	O
15	,	O
16	and	O
17	4	O
18	in	O
19	combination	O
20	markedly	O
21	decreased	O
22	transcriptional	O
23	activity	O
24	of	O
25	SP	B
26	-	I
27	A	I
28	promoter	I
29	-	I
30	chloramphenicol	I
31	acetyltransferase	I
32	constructs	I
33	containing	O
34	SP	B
35	-	I
36	A	I
37	gene	I
38	sequences	I
39	from	O
40	-	O
41	256	O
42	to	O
43	+	O
44	45	O
45	.	O

1	The	O
2	following	O
3	aspects	O
4	were	O
5	assessed	O
6	:	O
7	(	O
8	1	O
9	)	O
10	The	O
11	effect	O
12	on	O
13	the	O
14	cardiovascular	O
15	system	O
16	in	O
17	terms	O
18	of	O
19	brachial	O
20	arterial	O
21	pressure	O
22	,	O
23	pulse	O
24	rate	O
25	,	O
26	and	O
27	oxygen	O
28	consumption	O
29	(	O
30	VO2	O
31	)	O
32	during	O
33	exercise	O
34	in	O
35	5	O
36	health	O
37	volunteers	O
38	;	O
39	(	O
40	2	O
41	)	O
42	emg	O
43	activity	O
44	of	O
45	the	O
46	tibialis	O
47	anterior	O
48	and	O
49	gastrocnemius	O
50	muscles	O
51	during	O
52	exercise	O
53	in	O
54	the	O
55	same	O
56	5	O
57	volunteers	O
58	;	O
59	and	O
60	(	O
61	3	O
62	)	O
63	postexercise	O
64	ankle	O
65	pressure	O
66	changes	O
67	in	O
68	10	O
69	subjects	O
70	with	O
71	angiographically	O
72	proven	O
73	occlusive	O
74	arterial	O
75	diseases	O
76	of	O
77	the	O
78	lower	O
79	extremities	O
80	.	O

1	A	O
2	novel	O
3	cDNA	O
4	clone	O
5	termed	O
6	R2	B
7	was	O
8	isolated	O
9	by	O
10	subtractive	O
11	hybridization	O
12	of	O
13	a	O
14	cDNA	O
15	library	O
16	of	O
17	phytohemagglutinin	B
18	(	O
19	PHA	B
20	)/	O
21	phorbol	O
22	myristate	O
23	acetate	O
24	-	O
25	stimulated	O
26	Jurkat	O
27	cells	O
28	and	O
29	by	O
30	rescreening	O
31	a	O
32	cDNA	O
33	library	O
34	of	O
35	PHA	B
36	-	O
37	stimulated	O
38	peripheral	O
39	blood	O
40	lymphocytes	O
41	.	O

1	The	O
2	mature	O
3	AP	B
4	-	I
5	2	I
6	mRNA	I
7	is	O
8	spliced	O
9	from	O
10	7	O
11	exons	O
12	distributed	O
13	over	O
14	a	O
15	region	O
16	of	O
17	18	O
18	kb	O
19	genomic	O
20	DNA	O
21	.	O

1	This	O
2	may	O
3	explain	O
4	in	O
5	part	O
6	a	O
7	secular	O
8	trend	O
9	towards	O
10	reduced	O
11	birthweight	O
12	for	O
13	gestation	O
14	in	O
15	preterm	O
16	infants	O
17	.	O

1	This	O
2	distribution	O
3	implies	O
4	that	O
5	the	O
6	polycistronic	O
7	precursor	O
8	is	O
9	imported	O
10	into	O
11	the	O
12	nucleolus	O
13	for	O
14	processing	O
15	to	O
16	the	O
17	mature	O
18	snoRNAs	O
19	,	O
20	and	O
21	that	O
22	the	O
23	import	O
24	or	O
25	processing	O
26	pathway	O
27	involves	O
28	coiled	O
29	bodies	O
30	.	O

1	Charcoal	O
2	-	O
3	facilitated	O
4	dialysis	O
5	.	O

1	This	O
2	suggested	O
3	that	O
4	delta	O
5	6	O
6	and	O
7	delta	O
8	5	O
9	desaturation	O
10	activities	O
11	are	O
12	normal	O
13	in	O
14	these	O
15	conditions	O
16	with	O
17	this	O
18	C18	O
19	:	O
20	2w6	O
21	supply	O
22	.	O

1	Tobacco	O
2	mosaic	O
3	virus	O
4	-	O
5	infected	O
6	tobacco	O
7	(	O
8	Nicotiana	O
9	tabacum	O
10	var	O
11	.	O

1	The	O
2	murine	O
3	mutation	O
4	dominant	O
5	white	O
6	spotting	O
7	(	O
8	W	O
9	)	O
10	is	O
11	in	O
12	the	O
13	proto	B
14	-	I
15	oncogene	I
16	,	O
17	c	B
18	-	I
19	kit	I
20	.	O

1	In	O
2	rlf2	O
3	mutants	O
4	,	O
5	telomeric	O
6	chromatin	O
7	is	O
8	perturbed	O
9	:	O
10	Telomeric	O
11	silencing	O
12	is	O
13	reduced	O
14	and	O
15	Rap1p	B
16	localization	O
17	is	O
18	altered	O
19	.	O

1	Results	O
2	from	O
3	in	O
4	vitro	O
5	transcription	O
6	-	O
7	translation	O
8	analysis	O
9	and	O
10	maxicell	O
11	experiments	O
12	suggested	O
13	that	O
14	the	O
15	447	O
16	-	O
17	bp	O
18	ORF	O
19	was	O
20	the	O
21	one	O
22	being	O
23	actively	O
24	expressed	O
25	.	O

1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O

1	One	O
2	missense	O
3	allele	O
4	(	O
5	P236S	O
6	)	O
7	with	O
8	complete	O
9	loss	O
10	of	O
11	function	O
12	at	O
13	30	O
14	degreesC	O
15	and	O
16	four	O
17	missense	O
18	alleles	O
19	(	O
20	L173F	O
21	,	O
22	E225K	O
23	,	O
24	S269L	O
25	and	O
26	E274K	O
27	)	O
28	that	O
29	conferred	O
30	a	O
31	temperature	O
32	sensitive	O
33	phenotype	O
34	were	O
35	identified	O
36	.	O

1	The	O
2	cDNA	O
3	was	O
4	expressed	O
5	in	O
6	Saccharomyces	O
7	cerevisiae	O
8	under	O
9	the	O
10	control	O
11	of	O
12	the	O
13	yeast	B
14	triose	I
15	phosphate	I
16	isomerase	I
17	promoter	I
18	.	O

1	Intrathecal	O
2	acetyl	B
3	cholinesterase	I
4	inhibitors	O
5	produce	O
6	analgesia	O
7	that	O
8	is	O
9	synergistic	O
10	with	O
11	morphine	O
12	and	O
13	clonidine	O
14	in	O
15	rats	O
16	.	O

1	Binding	O
2	of	O
3	SSP	O
4	to	O
5	the	O
6	stage	O
7	selector	O
8	element	O
9	(	O
10	SSE	O
11	)	O
12	in	O
13	the	O
14	proximal	B
15	gamma	I
16	-	I
17	globin	I
18	promoter	I
19	is	O
20	integral	O
21	to	O
22	the	O
23	competitive	O
24	silencing	O
25	of	O
26	a	O
27	linked	O
28	beta	B
29	-	I
30	promoter	I
31	in	O
32	embryonic	O
33	/	O
34	fetal	O
35	stage	O
36	erythroleukemia	O
37	(	O
38	K562	O
39	)	O
40	cells	O
41	.	O

1	The	O
2	mean	O
3	change	O
4	in	O
5	HbA1	O
6	,	O
7	adjusted	O
8	for	O
9	the	O
10	initial	O
11	value	O
12	,	O
13	was	O
14	-	O
15	0	O
16	.	O
17	4	O
18	%	O
19	in	O
20	the	O
21	experimental	O
22	and	O
23	+	O
24	0	O
25	.	O
26	5	O
27	%	O
28	in	O
29	the	O
30	control	O
31	group	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O

1	III	O
2	.	O

1	A	O
2	false	O
3	positive	O
4	marker	O
5	screen	O
6	was	O
7	associated	O
8	with	O
9	the	O
10	occurrence	O
11	of	O
12	hand	O
13	-	O
14	foot	O
15	syndrome	O
16	even	O
17	when	O
18	the	O
19	effect	O
20	of	O
21	regimen	O
22	was	O
23	accounted	O
24	for	O
25	by	O
26	stratification	O
27	(	O
28	p	O
29	=	O
30	.	O
31	01	O
32	).	O

1	In	O
2	addition	O
3	,	O
4	media	O
5	containing	O
6	F	B
7	beta	I
8	alpha	I
9	/	I
10	CG	I
11	beta	I
12	displayed	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	to	O
18	both	O
19	CG	O
20	and	O
21	FSH	B
22	receptors	I
23	.	O

1	Nuclear	B
2	-	I
3	encoded	I
4	chloroplast	I
5	ribosomal	I
6	protein	I
7	L12	I
8	of	O
9	Nicotiana	O
10	tabacum	O
11	:	O
12	characterization	O
13	of	O
14	mature	O
15	protein	O
16	and	O
17	isolation	O
18	and	O
19	sequence	O
20	analysis	O
21	of	O
22	cDNA	O
23	clones	O
24	encoding	O
25	its	O
26	cytoplasmic	O
27	precursor	O
28	.	O

1	LA	O
2	-	O
3	3848	O
4	-	O
5	MS	O
6	.	O

1	Cloning	O
2	and	O
3	primary	O
4	structure	O
5	of	O
6	neurocan	O
7	,	O
8	a	O
9	developmentally	O
10	regulated	O
11	,	O
12	aggregating	O
13	chondroitin	O
14	sulfate	O
15	proteoglycan	O
16	of	O
17	brain	O
18	.	O

1	c	B
2	-	I
3	Fos	I
4	transcriptional	O
5	activity	O
6	stimulated	O
7	by	O
8	H	B
9	-	I
10	Ras	I
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	distinct	O
16	from	O
17	JNK	B
18	and	O
19	ERK	B
20	.	O

1	The	O
2	RFLP	O
3	patterns	O
4	of	O
5	the	O
6	isolates	O
7	from	O
8	six	O
9	of	O
10	these	O
11	patients	O
12	remained	O
13	essentially	O
14	unchanged	O
15	(	O
16	two	O
17	strains	O
18	showed	O
19	one	O
20	additional	O
21	band	O
22	)	O
23	despite	O
24	the	O
25	development	O
26	of	O
27	drug	O
28	resistance	O
29	.	O

1	The	O
2	fragments	O
3	of	O
4	each	O
5	region	O
6	were	O
7	amplified	O
8	by	O
9	polymerase	O
10	chain	O
11	reaction	O
12	and	O
13	analyzed	O
14	by	O
15	gel	O
16	electrophoresis	O
17	to	O
18	detect	O
19	single	O
20	-	O
21	strand	O
22	conformation	O
23	polymorphism	O
24	.	O

1	Cat	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	O
12	for	O
13	the	O
14	beta	B
15	-	I
16	adrenergic	I
17	receptor	I
18	kinase	I
19	(	O
20	betaARK	O
21	or	O
22	GRK	B
23	-	I
24	2	I
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	O
32	-	O
33	GAP	B
34	activity	O
35	.	O

1	To	O
2	understand	O
3	whether	O
4	Shc	B
5	localization	O
6	in	O
7	membrane	O
8	rafts	O
9	is	O
10	sufficient	O
11	to	O
12	regulate	O
13	Shc	B
14	function	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	Shc	B
20	chimera	O
21	containing	O
22	the	O
23	Ras	B
24	membrane	O
25	localization	O
26	motif	O
27	at	O
28	the	O
29	C	O
30	-	O
31	terminus	O
32	.	O

1	Similarity	O
2	is	O
3	most	O
4	striking	O
5	in	O
6	the	O
7	zinc	O
8	knuckle	O
9	region	O
10	,	O
11	a	O
12	region	O
13	characteristic	O
14	of	O
15	gag	B
16	genes	O
17	of	O
18	most	O
19	replication	O
20	-	O
21	competent	O
22	retroelements	O
23	.	O

1	Both	O
2	genes	O
3	comprise	O
4	three	O
5	exons	O
6	,	O
7	two	O
8	introns	O
9	and	O
10	an	O
11	unusually	O
12	long	O
13	3	O
14	'-	O
15	untranslated	O
16	region	O
17	(	O
18	3	O
19	.	O
20	2	O
21	kilobase	O
22	pairs	O
23	),	O
24	specificying	O
25	a	O
26	mRNA	O
27	of	O
28	approximately	O
29	4	O
30	.	O
31	1	O
32	kilobases	O
33	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	the	O
6	p72syk	B
7	protein	I
8	tyrosine	I
9	kinase	I
10	is	O
11	physically	O
12	associated	O
13	with	O
14	the	O
15	TCR	B
16	/	O
17	CD3	B
18	complex	O
19	and	O
20	is	O
21	rapidly	O
22	tyrosine	O
23	phosphorylated	O
24	and	O
25	activated	O
26	by	O
27	receptor	O
28	triggering	O
29	also	O
30	in	O
31	T	O
32	cells	O
33	lacking	O
34	p56lck	O
35	.	O

1	The	O
2	PRB	B
3	-	I
4	1b	I
5	gene	I
6	encodes	O
7	for	O
8	a	O
9	basic	O
10	-	O
11	type	O
12	component	O
13	of	O
14	the	O
15	pathogenesis	O
16	-	O
17	related	O
18	PR	B
19	-	I
20	1	I
21	protein	I
22	family	I
23	.	O

1	The	O
2	Spo0F	O
3	residues	O
4	making	O
5	up	O
6	the	O
7	hydrophobic	O
8	patch	O
9	are	O
10	very	O
11	similar	O
12	in	O
13	all	O
14	response	O
15	regulators	O
16	suggesting	O
17	that	O
18	the	O
19	binding	O
20	is	O
21	initiated	O
22	through	O
23	the	O
24	same	O
25	residues	O
26	in	O
27	all	O
28	interacting	O
29	response	O
30	regulator	O
31	-	O
32	kinase	O
33	pairs	O
34	.	O

1	Pb	O
2	foil	O
3	(	O
4	0	O
5	.	O
6	55	O
7	gcm	O
8	-	O
9	2	O
10	)	O
11	provided	O
12	the	O
13	best	O
14	overall	O
15	improvement	O
16	.	O

1	NH3	O
2	and	O
3	NO	O
4	interaction	O
5	with	O
6	Si	O
7	(	O
8	100	O
9	)-(	O
10	2	O
11	x	O
12	1	O
13	)	O
14	surfaces	O
15	.	O

1	Choice	O
2	of	O
3	vessel	O
4	.	O

1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	O
5	fusions	O
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O

1	A	O
2	decanucleotide	O
3	promoter	O
4	sequence	O
5	homologous	O
6	to	O
7	those	O
8	found	O
9	in	O
10	humans	O
11	and	O
12	mice	O
13	was	O
14	located	O
15	in	O
16	the	O
17	5	O
18	'	O
19	untranslated	O
20	region	O
21	of	O
22	one	O
23	horse	B
24	gene	I
25	.	O

1	Disruption	O
2	of	O
3	any	O
4	one	O
5	of	O
6	the	O
7	four	O
8	genes	O
9	encoding	O
10	the	O
11	newly	O
12	identified	O
13	SRP	B
14	proteins	I
15	results	O
16	in	O
17	slow	O
18	cell	O
19	growth	O
20	and	O
21	inefficient	O
22	protein	O
23	translocation	O
24	across	O
25	the	O
26	ER	O
27	membrane	O
28	.	O

1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	B
11	ICS	I
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	B
22	-	I
23	IV	I
24	gene	I
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	B
40	TK	I
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	O
50	gene	O
51	(	O
52	pBLCAT2	O
53	).	O

1	The	O
2	risk	O
3	for	O
4	these	O
5	complications	O
6	is	O
7	increased	O
8	by	O
9	the	O
10	following	O
11	factors	O
12	:	O
13	multiple	O
14	gestation	O
15	,	O
16	the	O
17	combination	O
18	of	O
19	magnesium	O
20	sulfate	O
21	and	O
22	beta	O
23	-	O
24	adrenergic	O
25	agonist	O
26	,	O
27	and	O
28	the	O
29	use	O
30	of	O
31	adrenocortico	O
32	-	O
33	steroids	O
34	to	O
35	hasten	O
36	fetal	O
37	pulmonary	O
38	maturity	O
39	.	O

1	The	O
2	isolated	O
3	POT1	B
4	clones	O
5	hybridized	O
6	to	O
7	a	O
8	1	O
9	.	O
10	4	O
11	kb	O
12	RNA	O
13	species	O
14	,	O
15	which	O
16	was	O
17	induced	O
18	approximately	O
19	30	O
20	-	O
21	fold	O
22	when	O
23	oleate	O
24	was	O
25	the	O
26	carbon	O
27	source	O
28	.	O

1	Role	O
2	of	O
3	NH	B
4	(	O
5	2	O
6	)-	O
7	and	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	of	O
13	the	O
14	P	B
15	protein	I
16	of	O
17	human	O
18	parainfluenza	O
19	virus	O
20	type	O
21	3	O
22	in	O
23	transcription	O
24	and	O
25	replication	O
26	.	O

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	B
7	-	I
8	3	I
9	/	O
10	EGFP	B
11	fusion	I
12	protein	I
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	B
22	-	I
23	3	I
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	The	O
2	peroxisome	O
3	biogenesis	O
4	disorders	O
5	(	O
6	PBDs	B
7	)	O
8	are	O
9	a	O
10	set	O
11	of	O
12	lethal	O
13	genetic	O
14	diseases	O
15	characterized	O
16	by	O
17	peroxisomal	O
18	metabolic	O
19	deficiencies	O
20	,	O
21	multisystem	O
22	abnormalities	O
23	,	O
24	mental	O
25	retardation	O
26	,	O
27	and	O
28	premature	O
29	death	O
30	.	O

1	Tissue	O
2	pressure	O
3	,	O
4	rCBF	O
5	,	O
6	and	O
7	water	O
8	content	O
9	were	O
10	measured	O
11	from	O
12	gray	O
13	matter	O
14	in	O
15	the	O
16	central	O
17	core	O
18	and	O
19	the	O
20	peripheral	O
21	margin	O
22	of	O
23	the	O
24	MCA	O
25	territory	O
26	over	O
27	6	O
28	h	O
29	after	O
30	MCAO	O
31	.	O

1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	B
14	julibrissin	I
15	DURAZZ	I
16	..	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	The	O
2	average	O
3	values	O
4	were	O
5	199	O
6	and	O
7	424	O
8	revertants	O
9	/	O
10	g	O
11	for	O
12	the	O
13	hamburgers	O
14	and	O
15	hot	O
16	dogs	O
17	,	O
18	respectively	O
19	.	O

1	The	O
2	remaining	O
3	RAD	O
4	+	O
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	O
18	cells	O
19	.	O

1	The	O
2	upstream	B
3	delta	I
4	-	I
5	alpha	I
6	breakpoint	I
7	is	O
8	flanked	O
9	by	O
10	the	O
11	direct	O
12	repeats	O
13	of	O
14	the	O
15	acceptor	O
16	splice	O
17	site	O
18	,	O
19	whereas	O
20	the	O
21	down	O
22	-	O
23	stream	O
24	alpha	B
25	-	I
26	delta	I
27	breakpoint	I
28	is	O
29	located	O
30	in	O
31	the	O
32	adjacent	O
33	intron	O
34	.	O

1	Rinit	O
2	reflects	O
3	the	O
4	Newtonian	O
5	resistances	O
6	and	O
7	Rdiff	O
8	represents	O
9	the	O
10	viscoelastic	O
11	/	O
12	inhomogeneous	O
13	pressure	O
14	dissipations	O
15	in	O
16	the	O
17	system	O
18	.	O

1	The	O
2	genomic	O
3	and	O
4	transcriptional	O
5	complexity	O
6	of	O
7	the	O
8	Crry	B
9	and	O
10	Crry	B
11	-	I
12	ps	I
13	genes	I
14	.	O

1	A	O
2	stable	O
3	heterologous	O
4	cell	O
5	line	O
6	containing	O
7	the	O
8	mouse	B
9	TRH	I
10	receptor	I
11	was	O
12	constructed	O
13	by	O
14	transfection	O
15	of	O
16	nonexcitable	O
17	293	O
18	cells	O
19	,	O
20	which	O
21	lack	O
22	L	O
23	channel	O
24	activity	O
25	.	O

1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	B
9	-	I
10	phosphoglycerate	I
11	kinase	I
12	gene	I
13	of	O
14	Pyrococcus	O
15	woesei	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O

1	The	O
2	frequency	O
3	of	O
4	integrations	O
5	that	O
6	led	O
7	to	O
8	transcription	O
9	of	O
10	the	O
11	lacZ	B
12	gene	I
13	was	O
14	estimated	O
15	to	O
16	be	O
17	0	O
18	.	O
19	5	O
20	%	O
21	of	O
22	all	O
23	integrations	O
24	,	O
25	of	O
26	which	O
27	14	O
28	%	O
29	were	O
30	downregulated	O
31	on	O
32	differentiation	O
33	of	O
34	32D	O
35	cells	O
36	towards	O
37	neutrophils	O
38	.	O

1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	B
9	and	O
10	TRAF2	B
11	in	O
12	JNK	B
13	activation	O
14	and	O
15	confirm	O
16	that	O
17	LMP1	B
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	O
24	TNF	B
25	receptor	I
26	/	O
27	CD40	B
28	family	I
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O

1	Among	O
2	38	O
3	patients	O
4	with	O
5	inducible	O
6	reentrant	O
7	VTs	O
8	who	O
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	Sensing	O
2	with	O
3	chemically	O
4	and	O
5	biologically	O
6	modified	O
7	carbon	O
8	electrodes	O
9	.	O

1	Moreover	O
2	,	O
3	expression	O
4	of	O
5	antisense	O
6	Ha	B
7	-	I
8	Ras	I
9	or	O
10	dominant	B
11	negative	I
12	Raf	I
13	-	I
14	1	I
15	abrogated	O
16	the	O
17	mitogenic	O
18	effect	O
19	of	O
20	TGF	B
21	-	I
22	beta1	I
23	in	O
24	TSU	O
25	-	O
26	Pr1	O
27	,	O
28	and	O
29	the	O
30	TGF	B
31	-	I
32	beta1	I
33	inhibition	O
34	of	O
35	DU145	B
36	was	O
37	switched	O
38	to	O
39	stimulation	O
40	by	O
41	V12Ha	B
42	-	I
43	Ras	I
44	transfection	O
45	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	MHC	B
6	class	I
7	II	I
8	,	O
9	purified	O
10	soluble	O
11	D10	O
12	TCR	B
13	bound	O
14	to	O
15	Staphylococcus	B
16	aureus	I
17	enterotoxin	I
18	C2	I
19	with	O
20	an	O
21	association	O
22	rate	O
23	of	O
24	1	O
25	.	O
26	69	O
27	+/-	O
28	0	O
29	.	O
30	12	O
31	x	O
32	10	O
33	(	O
34	4	O
35	)	O
36	M	O
37	(-	O
38	1	O
39	)	O
40	sec	O
41	(-	O
42	1	O
43	)	O
44	and	O
45	a	O
46	dissociation	O
47	rate	O
48	of	O
49	1	O
50	.	O
51	9	O
52	+/-	O
53	0	O
54	.	O
55	47	O
56	x	O
57	10	O
58	(-	O
59	2	O
60	)	O
61	sec	O
62	(-	O
63	1	O
64	),	O
65	giving	O
66	a	O
67	dissociation	O
68	constant	O
69	of	O
70	1	O
71	.	O
72	1	O
73	microM	O
74	.	O

1	Less	O
2	antibacterial	O
3	activity	O
4	was	O
5	shown	O
6	toward	O
7	the	O
8	Gram	O
9	-	O
10	negative	O
11	bacilli	O
12	,	O
13	i	O
14	.	O
15	e	O
16	.,	O
17	Pseudomonas	O
18	,	O
19	Klebsiella	B
20	-	I
21	Enterobacter	I
22	,	O
23	Shigella	O
24	,	O
25	Escherichia	O
26	coli	O
27	,	O
28	Serratia	O
29	marcescens	O
30	and	O
31	Proteus	O
32	.	O

1	Antibodies	O
2	specific	O
3	to	O
4	rE12	B
5	and	O
6	rNFIL	B
7	-	I
8	6	I
9	disrupt	O
10	nucleoprotein	O
11	complexes	O
12	with	O
13	these	O
14	DNA	O
15	-	O
16	binding	O
17	sites	O
18	,	O
19	confirming	O
20	the	O
21	interaction	O
22	of	O
23	native	O
24	in	O
25	vivo	O
26	factors	O
27	.	O

1	Cloning	O
2	of	O
3	higher	O
4	plant	O
5	omega	O
6	-	O
7	3	O
8	fatty	O
9	acid	O
10	desaturases	O
11	.	O

1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O

1	Five	O
2	control	O
3	subjects	O
4	with	O
5	COPD	O
6	,	O
7	who	O
8	performed	O
9	the	O
10	same	O
11	sequence	O
12	of	O
13	tests	O
14	without	O
15	breathing	O
16	30	O
17	%	O
18	O2	O
19	,	O
20	showed	O
21	no	O
22	change	O
23	in	O
24	flow	O
25	rates	O
26	or	O
27	density	O
28	dependence	O
29	.	O

1	Effects	O
2	of	O
3	temperature	O
4	and	O
5	moulting	O
6	cycle	O
7	on	O
8	melanin	B
9	synthesis	O
10	in	O
11	the	O
12	newt	O
13	,	O
14	Triturus	O
15	cristatus	O
16	.	O

1	The	O
2	patients	O
3	undergoing	O
4	VTLB	O
5	had	O
6	significantly	O
7	shorter	O
8	operative	O
9	times	O
10	(	O
11	VTLB	O
12	,	O
13	100	O
14	.	O
15	2	O
16	+/-	O
17	27	O
18	.	O
19	2	O
20	min	O
21	.	O
22	vs	O
23	OLB	B
24	,	O
25	119	O
26	.	O
27	8	O
28	+/-	O
29	42	O
30	.	O
31	6	O
32	min	O
33	;	O
34	p	O
35	<	O
36	0	O
37	.	O
38	01	O
39	)	O
40	and	O
41	less	O
42	blood	O
43	loss	O
44	(	O
45	VTLB	O
46	,	O
47	4	O
48	.	O
49	7	O
50	+/-	O
51	14	O
52	.	O
53	6	O
54	ml	O
55	vs	O
56	OLB	B
57	,	O
58	65	O
59	.	O
60	7	O
61	+/-	O
62	77	O
63	.	O
64	0	O
65	ml	O
66	;	O
67	p	O
68	<	O
69	0	O
70	.	O
71	001	O
72	).	O

1	Plasma	O
2	CCK	B
3	levels	O
4	were	O
5	determined	O
6	at	O
7	regular	O
8	intervals	O
9	.	O

1	Suppression	O
2	of	O
3	food	O
4	intake	O
5	in	O
6	the	O
7	rat	O
8	by	O
9	tung	O
10	oil	O
11	.	O

1	A	O
2	single	O
3	case	O
4	of	O
5	an	O
6	adenocarcinoma	O
7	,	O
8	arising	O
9	in	O
10	a	O
11	retroperitoneal	O
12	enterogenous	O
13	cyst	O
14	and	O
15	which	O
16	presented	O
17	as	O
18	a	O
19	left	O
20	renal	O
21	cyst	O
22	,	O
23	is	O
24	reported	O
25	.	O

